AANS/CNS SECTION ON DISORDERS OF THE SPINE AND PERIPHERAL NERVES



CHAIRPERSON

American Association of Neurological Surgeons

A Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons



Agenda for Spine Section Executive Committee Meeting

Charles L. Branch , Jr. MD WFU Baptist Medicul Center		
Phone. (336)716-4083 Fax. (336)716-3065	1. Secretary's report	D. Resnick
Email: cbranch@wfubme.edu	Review and approval of minutes	
SECRETARY	Review and approval of contact inf	formation and EC membership roster
Daniel K. Resnick , MD University of Wiscousin - Madison	2. Treasurer's Report	C. Wolfla
Phone (698)263-9651 Fax (608)263-1728	3. Committee Reports	
E-mail. resnick@neurosurg.wise edu	a) Annual Meeting	J. Hurlbert/M. McLaughlin
TREASURER	b) CPT	R. Johnson
Christopher E. Wolfla , MD Medical College of Wiscousin	c) Exhibits	J. Knightly
Phone: (414)805-5400 Fax. (414)258-6266	d) Future sites	I. Kalfas
E-mail evoillage neuroscience mew edu	e) World Spine	
CHAIRPERSON-ELECT	f) Research and Awards	P. Gerszten
Joseph T. Alexander , MD Wake Forest University	g) Education	C. Kuntz
Phone (336)716-6437 Fox. (336)716-3065	h) Guidelines	P. Matz
E-mail jtalexan@wfubme.edu	i) Outcomes	M. Kaiser
IMMEDIATE PAST CHAIRPERSON	j) Peripheral nerve TF	E. Zager
Robert F. Heary , MD UMDNJ-New Jersey Med. Sch	k) Publications	M. Wang
Phone (973)972-2334 Fax (973)972-2333	1) Public Relations	T. Choudhri
E-mail heary@undnj.edu	m) Membership	Z. Gokaslan
2007 ANNUAL MEETING	n) Washington Committee	R. Heary/C. Branch
CHAIRPERSON	o) Fellowships	P. Mummaneni
Mark R. McLaughlin , MD Princeton Brain	p) PAC	S. Ondra
Phone: (609)468-4146 Fax (215)741-3143	q) Web Site	C. Wolfla/ J. Cheng
E-mail m melaughlin <i>gi</i> princetonbrainandspine com	r) CME	E. Mendel
2007 SCIENTIFIC PROGRAM	s) Nominating Committee	R. Heary
CHAIRPERSON	t) Rules and Regs	T. Choudhri
R. Joha Hurlbert, MD PhD Foothills Med. Ctr./Clinical Neurosci	u) Newsletter	M. Groff
E-mail jhurlber@ucalgary.ca	4. Old Business	
MEMBERS-AT-LARGE	1) NREF	
Daniel II-Kim, MD E-mail neurokim@stanford.edu	5. New Business	
Kevin T. Foley, MD	1) Outcomes Project	Z. Gokowala
E-mail. kfolcy@usit.net	2) SANS	G. Rodts
Gregory R Trost, MD E-mail: trost@neurosurg.wisc.edu	3) Mailing List	J. Alexander
	4) SRS Curriculum	S. Ondra
	+) SNS Currentum	5. Ondra

Minutes of Spine Section Executive Committee Meeting April 24, 2006

Members Present: Chris Wolfla, Peter Gerszten, Mike Wang, Ehud Mendel, Greg Trost, Joseph Alexander, Charlie Kuntz, William Mitchell, Mike Kaiser, Mike Groff, Steve Ondra, Daniel Resnick, Charlie Branch, Eric Zager, Ian Kalfas, Ziya Gokoslan, Tanvir Choudhri, Chris Shaffrey

Guests: Don Quest, Ron Engelbreit

Secretary's report: given by Dr. Resnick. Minutes from March meeting were reviewed and approved.

Dr. Quest visited the section meeting and expressed the welcome of the AANS and support of the AANS for section activities.

Treasurer's report: Dr. Wolfla gave the treasurer's report – see page 10 of agenda book. As of March 31, 1.2 million dollars are in the long term investment fund. Overall, we are ahead of budget in terms of the annual meeting- registration fees were less than budgeted but exhibitor fees were increased. The AANSPAC donation was discussed. As it turns out, we cannot contribute due to tax laws. Several alternatives for directed contributions were discussed. Discussion on this issue was tabled. Discussion of annual meeting revenue also ensued. The report was reviewed and approved.

Annual Meeting: Drs. Groff and Mclaughlin (written report)

Highlights of the annual meeting were presented. A discussion of what to do with the data derived from the interactive surveys occurred. It was suggested that Dr. McLaughlin collate the collected data and report it at the October executive committee meeting. A decision will be made at that time as to whether or not further dispersal is warranted and in what form.

Motion:

The AANS/CNS Joint Section on Spinal Disorders and Peripheral Nerves policy on withdrawn abstracts:

FIRST AUTHORS OF ABSTRACTS (ORAL) ACCEPTED AND ACKNOWLEDGED WHO SUBSEQUENTLY WITHDRAW WILL INCUR A ONE YEAR SUSPENSION OF PRIVILEGES FROM ORAL PRESENTATION AT THE SUBSEQUENT JOINT SPINE ANNUAL MEETING.

A STATEMENT REGARDING THIS POLICY WILL BE INCLUDED ON THE AUTHOR ACKNOWLEDGMENT FORM SIGNED BY THE AUTHOR.

THE MOTION MADE, SECONDED, DISCUSSED, AND APPROVED.

It was noted that registration was significantly decreased compared to last year and previous Orlando meetings. Discussion regarding the cause of the lower numbers centered on difficulties with meeting management.

Exhibits: no report

Education: Dr. Kuntz has been appointed as the new chairman of education. Dr. Groff and Dr. Mendel reported on upcoming activities at the CNS meeting in October. Dr. Groff reported that a paper on hypertonic saline in mouse SCI will receive the Synthes spine award.

Future Sites: Dr. Kalfas reported that we are under contract for the next three years. Subsequent negotiations for 2010 and beyond will depend on meeting services arrangements.

Nominations Committee: The slate of officers was elected at the annual business meeting on the Friday following the last executive committee meeting. President elect: Joe Alexander, Treasurer: Chris Wolfla, Member at Large: Greg Trost.

Fellowships: Dr. Wolfla – nothing new to report.

Awards: Dr. Gerszten will be taking over the committee leadership. Drs. Trost, Hurlbert, Kuntz, and Mummanneni volunteered to serve as fellowship reviewers. Dr. Michael Levi will also be asked to participate.

Website: Dr. Wolfla – the website has been updated since the meeting. Any new ideas or content should be forwarded to Dr. Wolfla.

Guidelines: Dr. Matz- no report.

Outcomes: Dr. Kaiser gave a summary report. Dr. Gowhala's proposal was tabled for the present time as he was not available to present.

Rules and Regs: Dr. Kuntz – see enclosed addendum. The officers will review the committee grid to determine which committees will be permanent and which are ad hoc. Committee chairman will submit to Dr. Kuntz brief descriptions of their committees for inclusion in the bylaws. Following this process, updating of the voting membership will be proposed.

A motion was made to change item 6.03 B such that emailing is offered as an alternative to mailing. This was discussed, reviewed, and approved. It was further moved that email was an acceptable alternative to mailing in most circumstances. This was discussed and approved.

Washington Committee: Dr. Alexander discussed participation of section members on the FDA orthopedic devices committee. Dr. Branch encouraged all members to contribute individually to the PAC.

A motion was made to direct the chairman to investigate the mechanism and merits of a directed contribution to support the Washington Committee.

The motion was discussed and approved.

Peripheral Nerve Taskforce: Dr. Zager provided an update on CPT nerve repair survey (see below) and activities at national meetings.

Public Relations: Dr. Choudhri reported that the logo contest is underway.

CPT: Dr. Mitchell gave an update on code changes for wound infection, TDA, and proposed new codes for the Xstop device. Dr. Zager provided an update on Brachial plexus codes. Dr. Mitchell reminded us that the membership of the section needs to participate in the valuation surveys and to encourage our membership to participate in order to provide data to the coding and reimbursement committee. Dr. Mitchell was asked to communicate directly with the executive committee and to publish announcements in our newsletter and our website in order to notify spinal neurosurgeons about the importance of the surveys. He will also communicate with Dr. Johnson who will be taking over leadership of this committee.

Membership Committee: Dr. Gokoslan- eblast scheduled to go out to all residents shortly after the AANS meeting to notify residents about membership policies and to encourage registration.

Newsletter: Dr. Groff will be the newsletter chair.

CME Liason: Dr. Mendel – no new business.

Publications: Dr. Wang – Spine, The Spine Journal, J Neurosurgery, and Neurosurgery have all offered to consider publishing proceedings from our meeting. A decision as to which arrangement best suits the section will be made over the next six months.

QIW: Dr. Resnick – no report given

Meeting Services: Dr. Branch presented the proposals from Broadwater and the CNS. It was emphasized that the change in meeting services was not a plan to distance ourselves from either of our parent organizations. The change is meant to improve our ability to provide a top quality meeting to our members.

Discussion of the proposals occurred.

A motion was made to accept the proposal tendered by the Congress of Neurological Surgeons.

This motion was approved following discussion. Four voting members present voted to approve the motion. One voting member voted against. One member present and two proxy voted to abstain.

Following further discussion, a motion was made to direct the chairman to pursue further negotiations with the Congress with regard to meeting services.

This motion was discussed and unanimously approved.

New Business:

A motion was made to investigate a spine directed NREF contribution to allow funding of spinal research fellowships. An initial dollar amount of \$500,000.00 for research fellowships directed by the spine section.

This motion was discussed and approved.

Announcements: Dates of the next EC meeting will be distributed once they are available.

Respectfully submitted by Daniel Resnick

Executive Committee Officers and Committee Chairs JOINT SECTION ON DISORDERS OF THE SPINE & PERIPHERAL NERVES October, 2006

Position	2003-04	2004-05	2005-06	2006-07
Chair	R.Haid	G. Rodts	R. Heary	C. Branch
Chair Elect	G.Rodts	R. Heary	C. Branch	J. Alexander
Immediate Past Chair	N.Baldwin	R. Haid	G. Rodts	R. Heary
Secretary	C.Branch	C. Branch	D.Resnick	D. Resnick
Treasurer	T.Ryken	T. Ryken	T. Ryken	C. Wolfla
Members at Large Ex-Officio Members	R.Heary R. Apfelbaum J. Alexander	D. Kim R. Apfelbaum J. Alexander Z. Gokaslan	J. Alexander D. Kim K. Foley Z. Gokaslan	D. Kim K. Foley G. Trost C. Shaffrey
	R. Heary Z. Gokaslan			G. Rodts
Annual Meeting Chair	D.Resnick	C. Shaffrey	M. Groff	M. McLaughlin
Scientific Program Chair	C. Shaffrey	M. Groff	M. McLaughlin	J. Hurlbert
Exhibit Chair	M.McLaughlin/Knig htly	M.McLaughlin	J. Knightley	J. Knightly
Future Sites	J. Alexander	J. Alexander	J. Alexander	I. Kalfas
Education Committee Chair	J.Hurlbert	J. Hurlbert	J. Hurlbert	C. Kuntz
CME Representative	T.Ryken	T. Ryken	T. Ryken	E. Mendal
Newsletter	Hurlbert/Khoo	L. Khoo	J. York	M. Groff
Rules and Regulations Chair	D.DiRisio	D. DiRisio	D. DiRisio	T. Choudhri
Nominating Committee Chair	N.Baldwin	R. Haid	R. Rodts	R. Heary
Research and Awards Committee Chair		J.Guest	C. Wolfla	P. Gerszten
Publications Committee Chair	V.Traynelis	C. Dickman	C. Dickman	M. Wang
Web Site Committee Chair	Levi/Wolfla	C. Wolfla	C. Wolfla	C. Wolfla
Guidelines Committee Chair	D.Resnick	D. Resnick	P. Matz	P. Matz
Membership Committee	G.Trost	G. Trost	G. Trost	Z. Gokoslan
Outcomes Committee Chair	P.Gerszten	P. Gerszten	M. Kaiser T. Choudhri	M. Kaiser
CPT Committee	W.Mitchell G. Przybylski	W. Mitchell	W. Mitchell R. Johnson	R. Johnson
Peripheral Nerve Task Force Chair	R.Midha	R. Midha	E. Zager	E. Zager
Washington/FDA	Fessler/McCormick	P. McCormick	R. Rodts	R. Heary
Section Rep.,P.A.C.	S.Ondra	S. Ondra	S. Ondra	S. Ondra
Public Relations	G. Pait	C. Kuntz T.Choudhri	C. Kuntz T. Choudhri	T. Choudhri
Fellowships			J. Alexander	P. Mummaneni

NREF Advisory Board		J. Guest
AANS PDP		M. Groff
Representative		

JOINT SECTION ON DISORDERS OF THE SPINE & PERIPHERAL NERVES Committee Membership March 10, 2005

	2002-03	2003-04	2004-05	2005-06	2006-07
Nominating Committee Men	N.Epstein	R.Fessler	J. Campbell	V. Traynelis	R. Apfelbaum
	R.Fessler	J.Campbell	V. Traynelis	R. Apfelbaum	R. Midha
	J.Campbell	V.Traynelis	R. Apfelbau	R. Midha	G. Trost
Strategic Planning Committe	N.Baldwin	R.Haid	R. Rodts	R. Heary	C. Branch
	P.McCormick	C.Branch	R. Heary	C. Branch	J. Alexander
	R.Rodts	R.Rodts	C. Branch	T. Ryken	D. Resnick
	C.Branch	T.Ryken	T. Ryken	G. Rodts	C. Wolfla
	R.Haid	N. Baldwin	R. Haid		R. Heary
Research and Awards Comr	C.Wolfla	C.Wolfla	J. Guest	C. Wolfla	
	P.Sawin	P.Sawin	C. Wolfla	J. Guest	
		G.Trost	G. Trost	G. Trost	
			C. Shaffrey	C. Shaffrey	
Fellowships				J. Alexander S. Ondra C. Shaffrey Z. Gokaslan C. Kuntz	

heary@umdnj.edu; Cbranch@wfubmc.edu; Resnick@neurosurg.wisc.edu; kfoley@semmes-murphey.com; zgokasl1@jhmi.edu; mgroff@iupui.edu; mclaughlin@princetonbrainandspine.com; jknightly@atlanticneurosurgical.com; jhurlber@ucalgary.ca; cwolfla@neuroscience.mcw.edu; matzpg@yahoo.com; trost@neurosurg.wisc.edu; mgk7@columbia.edu; tanvir.choudhri@msnyuhealth.org; zagere@uphs.upenn.edu; sondra@nmff.org; Charleskuntz@yahoo.com; Kalfas@neus.ccf.org; Rjohnson@neurosurgery.wayne.edu; myw@usc.edu; gersztenpc@upmc.edu; neurokimdaniel@yahoo.com; joseph.cheng@vanderbilt.edu; vmum@aol.com; jtalexan59@yahoo.com CIS8Z@hscmail.mcc.virginia.edu; Gerald_Rodts@emoryhealthcare.org; zoher.ghogawala@yale.edu; ehud.mendel@osumc.edu; neurokimdaniel@yahoo.com



Association of Neurological Surgeons

5550 Meadowbrook Drive Rolling Meadows, IL 60008

member services: 888.566.AANS phone: 847.378.0500 fax: 847.378.0600 web: www.NeurosurgeryToday.org web: www.AANS.org

September 5, 2006

Christopher Wolfla, MD Department of Neurosurgery 9200 W. Wisconsin Ave. Milwaukee, WI 53226

Dear Doctor Wolfla:

The enclosed financial statements for the AANS/CNS Section on Disorder of the Spine & Peripheral Nerves are for the Year Ended June 30, 2006, and comparative information for the Year Ended June 30, 2005.

The financials statements have been audited by the auditing firm of RSM McGladrey. Until their final report and opinion are presented, changes to Fiscal Year 2006 are a small possibility. After your review of the financial statements and commentary, if you have any questions, please do not hesitate to contact me at 847-378-0509 or rwe@aans.org.

Sincerely,

Ronald W. Engelbreit, CPA Deputy Executive Director

Enclosures

Cc: Charles L. Branch, MD Donald O. Quest, MD Richard G. Ellenbogen, MD James R. Bean, MD Joel D. MacDonald, MD Laurie Behncke

AANS/CNS Section on Disorders of the Spine Statement of Financial Position As of June 30, 2006

	Current Year 06/30/06	Prior Year 06/30/05
ASSETS		
Checking & Short Term Investments	\$854,910	\$703,221
Accounts Receivable, net of Allowance for Uncollectible Accounts	32,800	9,762
Prepaid Expenses	12,548	17,398
Long-Term Investment Pool, at Market	1,211,422	940,545
TOTAL ASSETS	\$2,111,680	\$1,670,927
LIABILITIES AND NET ASSETS		
Liabilities Accounts Payable and Current Liabilities Deferred Contribution Revenue Deferred Dues	\$46,250 41,000 32,450	\$25,000 27,850
Total Liabilities	\$119,700	\$52,850
Net Assets Unrestricted	\$1,618,077	\$1,250,199
Net Revenue (Expense)	373,903	367,878
Total Net Assets	\$1,991,980	\$1,618,077
TOTAL LIABILITIES AND NET ASSETS	\$2,111,680	\$1,670,927

3,500 136,500 51,250 130,000 8,920 533,570 1,000 75,000 6,000 2,000 2,000 5,000 1,000 9,170 40,000 723,740 504,576 784,996 FY '06 Budget 49,488 1,500 203,000 1,936 89,491 2,979 504 1,182 36 8.672 25,000 5,134 8,781 730,042 992,702 297 ട്ട 538 27 568,396 521 704,911 ЧТD FY '06 2,769 131,156 8,421 (100,000) 50,000 829,923 632 55,650 1,100 8,363 906 426 25,000 271 950 1,745 324 1,576 714,810 ω 526,214 452,030 YTD FY'05 For the Twelve Months Ending June 30, 2006 8,421 (100,000) Statement of Activities 55,650 1,100 50,000 906 426 2,769 8,363 714,810 25,000 324 1,576 632 829,923 131,156 950 ,745 452,030 526,214 271 FY '05 Final 3,327 131,246 45,000 12,398 7,679 560,306 52,125 850 678,408 888 352 125,000 219 4,425 105 1,421 13,649 399,405 50 266 ,666 80 690,496 116 8,351 FΥ '04 Final Cervical Degenerative Spine Guidelines P Contributions for Operating Expenses Lumbar Fusion Guidelines Project Fellowship/Award Sponsorship TOTAL REVENUES & SUPPORT Publications Sales Revenue Contributions & Affiliations Annual Meeting Revenue Annual Meeting Expense **Miscellaneous Revenue** Marketing & Advertising Uncollectable Accounts Office & other Supplies Postage & Distribution Printing/Typesetting Professional Services Femporary Personnel Speaker Expenses Membership Dues Staff Coordination Mailing List Sales Food & Beverage Gifts & Gratuties TOTAL EXPENSES Legal Services Miscellaneous Audio Visual Fellowships Decorating Telephone Photocopy Bank Fee EXPENSES REVENUES Facility Grants Signs

AANS/CNS Section on Disorders of the Spine

250

400

08/31/06 03:25 PM

S 4B New Spine

(9,356)

51,900

86,112

64,169

64,169

95,637

Investment Earnings

NET REVENUE

373,903

367,878

=

367,878

83,549

AANS/CNS Section on Disorders of the Spine Statement of Activities Annual Meeting For the Twelve Months Ending June 30. 2006

	For the Twelve Months Ending June 30, 2006	ths Ending June 3	0, 2006		
	FY '04 Final	FY '05 Final	YTD FY'05	ΥТD FY '06	FY '06 Budget
REVENUES					
Registration Fees	200,465	195,820 II	195,820	149,680 II	193,050
	205,275	269,725	269,725	261,900 11	198,400
Contributions/sponsorsnips	134,762 5 065	229,500 II	229,500	282,000 II	118,600
bailiquet reveilue Miscellaneous Revenue	07'202 14.539	6,303 II 11.200 II	8,303 11,200	24,284 II 12 178 II	12,620
TOTAL REVENUES & SUPPORT	560,306	714.810 II	714,810	730.042 11	533,570
EXPENSES			an a		
Audio Visual	35,991	42,928 II	42,928	67.522	69.700
Bank Fee	9,661	9,718 II	9,718	7,459 11	10,000
Computer Programing & Supplies		=		=	
Decorating	12,548	12,031	12,031	13,531	12,200
Entertainment	13,944	7,516 II	7,516	9,958 II	9,550
Facility	1,575	1,034	1,034		4,500
Food & Beverage	146,808	191,901	191,901	203,201	185,611
Freight & Snipping	2,003	1/3 11	1/3	1,000,1	7,500
Honoraria & Awards	36	320 II 18 II	320 18	300 II 1 173 II	420
Insurance	5.606	2.688 II	2.688	2.754	2,800
Marketing & Advertising	1.347	500 II	500	150 11	2,250
Outside Labor	576	-		=	450
Office & other Supplies	245	443 II	443	232	600
Photocopy	404	149	149	986 II	450
Postage & Distribution	7,814	5,229 II	5,229	6,499 II	6,675
Printing/ I ypesetting	38,637	41,914	41,914	43,627	38,350
Protessional Services	9,561	13,466	13,466	14,620	16,500
Signo	1,801	0,094 II 1,064 II	5,094	2,039 1	4,500
Organia Concelor Economico		1,001 11	1,001	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3,200 25,000
opeaner Experises Staff Travel	11 531)	8 610 II	20,100 R 610	41,231 11	10 578
Telephone	4.338	10.599	10.599	6.371	9,500
Temporary Personnel	1,978	2,406	2,406	1,887	2.500
Tours & Transportation	1,014	=		633 11	2,500
Volunteer Travel		9,824 II	9,824	21,488	9,792
Uncollectable Accounts		=		=:	4
Starr Coordination Miscellaneous	000,68	II 240,000	26,042	45,971	062,80
TOTA! EXDENSES	200 405	452 030 11	452 030	468 306	ENA R78
	2011/2020		0001201	H 020'000	
NET REVENUE	160,902	262,780 II	262,780	161,646 11	28,994

08/31/06 03:24 PM


S 4A

AANS/CNS Section on Disorders of the Spine Statement of Activities For the Twelve Months Ending June 30, 2006

	FY '04 Final	FY '05 Final		FY '06 Final		FY '06 Budget	FY '07 Budget
REVENUES							
Membership Dues	52,125	55,650	II	49,488	П	51,250	50,750
Mailing List Sales	850	1,100		1,500		01,200	0,700
Publications Sales Revenue	50	0		0	ii	0	0
Fellowship/Award Sponsorship	45,000	50,000		203,000		130,000	136,000
Miscellaneous Revenue	12,398	00,000	II	_00,000 0		0	0
Contributions for Operating Expenses	7,679	8,363		8,672		8,920	9,368
Annual Meeting Revenue	560,306	714,810		730,042	II	533,570	792,376
TOTAL REVENUES & SUPPORT	678,408	829,923	II	992,702	II	723,740	988,494
EXPENSES							
Audio Visual	888	906	Ш	2,979	Ш	1,000	1,000
Bank Fee	352	426		297		400	460
Contributions & Affiliations	125,000	25,000		25,000	II	75,000	75,000
Decorating	219	271		504		250	250
Facility	0	0	II	0	1	0	0
Food & Beverage	3,327	2,769	II	1,936		3,500	3,500
Fellowships	131,246	131,156	II	89,491	П	136,500	140,800
Grants	0	0	II	0	II	0	500,000
Gifts & Gratuties	0	0	П	0	II	0	0
Marketing & Advertising	4,425	0	П	0	П	6,000	6,000
Legal Services	, 0	0	П	0	П	0	0
Office & other Supplies	266	950	П	521	Ш	400	600
Photocopy	116	8	П	90	Ш	200	200
Postage & Distribution	1,666	1,745	Ш	1,182	П	2,000	2,000
Printing/Typesetting	105	324	П	36	Ш	0	0
Professional Services	1,421	1,576	Ш	538	П	5,000	1,000
Signs	0	0	Ш	0	Ш	0	0
Speaker Expenses	0	0	Ш	5,134	П	0	0
Telephone	60	632	Ш	27	Ш	1,000	800
Temporary Personnel	0	0	П	0	П	0	0
Uncollectable Accounts	0	0	Ш	0	Ш	0	0
Staff Coordination	8,351	8,421	П	8,781	П	9,170	9,618
Miscellaneous	0	(100,000)	Ш	0	Ш	0	0
Cervical Degenerative Spine Guidelines	0	0	П	0	Ш	40,000	40,000
Lumbar Fusion Guidelines Project	13,649	0	Ш	0	Ш	0	0
Annual Meeting Expense	399,405	452,030	<u> </u>	568,396	Ш	504,576	616,053
TOTAL EXPENSES	690,496	526,214	II	704,911	II	784,996	1,397,281
Investment Earnings	95,637	64,169	11	86,112	II	51,900	65,000
NET REVENUE	83,549	367,878		373,903	II	(9,356)	(343,787)

Long-term Investments of the AANS\CNS Section

on Disorder of the Spine & Peripheral Nerves



UBS Financial Services Inc. 257 EAST MAIN STREET BARRINGTON, IL 60010 Your Financial Advisor BODOLAY, JOHN L 847-277-2129 847-277-2100/800-824-2521

Investment Account

Account Number: GS 08240 25

PP3A032335-X246 0051517 - 000002

PP3A032335-X246 - 0606 - GS - 0

June 2006


Asset allocation

This graph provides values and/or percentages by asset class. Insurance products, 529 Plans, Private investments, accrued interest and pending return of principal are not included in the asset classification

Alternative strategies	 .00	0.00 %
Fixed income Balanced	362,067.23 .00	29.89 % 0.00 %
Equities	715,091.18	59.03 %
Cash	\$.00 134,275.83	0.00 % 11.08 %
	Total asset value	% of total

Total value comparison

This graph includes credits, debits and changes in market value. It does not include Insurance products, 529 Plans, Private investments, accrued interest and pending return of principal.



AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS CNS SECTION ON DISORDERS OF THE SPINE 5500 MEADOWBROOK INDSTRL CT ROLLING MEADOWS IL 60008-3800

Account instructions

The account record was signed by your Financial Advisor and approved by a Principal of the Firm.

Bulletin board

ACCESS THE BORROWING POWER OF YOUR PORTFOLIO. READ THE ENCLOSED NEWSLETTER FOR INFORMATION ON SECURITIES-BASED LENDING AS A POTENTIAL SOLUTION FOR YOUR LENDING NEEDS. PREFERRED CLIENT PRIORITY SERVICES 1-877-352-3592.

VISIT OUR WEB SITE AT WWW.UBS.COM.

Member SIPC

Page 1 of 8

June 06/ GS 08240 25

UBS Financial Services Inc. 257 EAST MAIN STREET BARRINGTON, IL 60010 Your Financial Advisor BODOLAY, JOHN L 847-277-2129 847-277-2100/800-824-2521

Investment Account

PP3A032174-X6 - 000008S

Account Number: GS 08240 25

0004235 02 AT 0.545 027PP3A AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS CNS SECTION ON DISORDERS OF THE SPINE 5500 MEADOWBROOK INDSTRL CT ROLLING MEADOWS IL 60008-3800

Bulletin board

CONSIDER A 529 PLAN FOR YOUR COLLEGE SAVINGS STRATEGY. 529 PLANS OFFER BENEFITS THAT MAY NOT BE AVAILABLE IN OTHER EDUCATION SAVINGS PLANS.

PREFERRED CLIENT PRIORITY SERVICES 1-877-352-3592. VISIT OUR WEB SITE AT WWW.UBS.COM.

PP3A032174-X6 - 0806 - GS - 0

August 2006


Asset allocation

This graph provides values and/or percentages by asset class. Insurance products, 529 Plans, Private Investments, accrued interest and pending return of principal are not included in the asset classification

 Cash Cash alternatives Equities Fixed income Balanced Alternative strategies Other 	\$ Total asset value .00 134,410.36 727,523.84 372,947.11 .00 .00	% of total 0.00 % 10.88 % 58.91 % 30.21 % 0.00 % 0.00 % 0.00 %
Total	\$.00 1,234,881.31	<u> </u>

Total value comparison


This graph includes credits, debits and changes in market value. It does not include Insurance products, 529 Plans, Private investments, accrued interest and pending return of principal.



Member SIPC

August 06/ GS 08240 25


Annual Meeting Analysis of the AANS\CNS Section on Disorder of the Spine & Peripheral Nerves



In 000's

Income Statement Analysis of the AANS\CNS Section

on Disorder of the Spine & Peripheral Nerves



In 000's



5550 Meadowbrook Drive Rolling Meadows, IL 60008

member services: 888.566.AANS **phone:** 847.378.0500 **fax:** 847.378.0600 **web:** www.AANS.org www.NeurosurgeryToday.org

2006-2007 Board of Directors

President Donald O. Quest <u>doq1@columbia.edu</u>

President-Elect Jon H. Robertson jrobertson@semmes-murphey.com

> Vice-President Arthur L. Day aday1@partners.org

Secretary James T. Rutka james.rutka@sickkids.ca

> Treasurer James R. Bean jbeanlex@aol.com

Past President Fremont P. Wirth

Directors-at-Large William T. Couldwell Robert E. Harbaugh Christopher M. Loftus Warren R. Selman Troy M. Tippett

Regional Directors NE: Stephen T. Onesti NW: Jeffrey W. Cozzens SE: R. Patrick Jacob SW: Edie E. Zusman

> Historian Eugene S. Flamm

Executive Director Thomas A. Marshall <u>tam@aans.org</u>



August 21, 2006

Charles L. Branch Jr., MD WFU Baptist Medical Center Medical Center Blvd/Neurosurgery Winston Salem, NC 27157

Dear Dr. Branch,

At the recent AANS Executive Committee Meeting, the AANS Annual Meeting dates for 2008 in Chicago were changed from March 29 – April 3 to April 26 – May 1. There was a conflict with another large medical association holding their Annual Meeting over the exact dates as the AANS. Moving the date has the additional beneficial effect of increasing the separation between the AANS Annual Meeting and the Spine Section Meeting.

Should you have any questions, please feel free to contact Patty Anderson, AANS Director of Meetings.

Sincerely,

Donald O. Quest, MD AANS President

Cc: Joseph T. Alexander, MD Robert F. Heary, MD Daniel K. Resnick, MD Christopher E. Wolfla, MD

RESEARCH AND AWARDS COMMITTEE

Spine Section Executive Committee Meeting CNS Chicago October 9th, 2007

1. Current Awards:

Award	Vendor Support	Amount
Larson Award	Depuy Spine	\$30,000
Kline Award	Integra	\$15,000
Apfelbaum Award	Aesculap	\$15,000
Cloward Fellowship	Medtronic	\$30,000
Cahill Fellowship	Synthes	\$30,000
Sonntag Fellowship	Medtronic	\$5,000
Crockard Fellowship	Depuy Spine	\$5,000
Outcomes Committee Award	Wallace Fund	\$3,000
Mayfield Award (Basic)	Spine Section	\$3,000
Mayfield Award (Clinical)	Spine Section	\$3,000

2. Deadline will be December 1st, 2006.

3. Awards Reviewers:

Peter C. Gerszten, MD R. John Hurlbert, MD Gregory R. Trost, MD Charles Kuntz, IV, MD Praveen V. Mummaneni, MD Allan D. Levi, MD, Ph D

4. Reviewers for Mayfield Awards?

5. 2007 Spine Section Meeting

15 minutes to announce the 2007 award winners45 minutes will be allotted to have the 2006 award winners present their work

6. Other business

Current status of 1500 word manuscript for the Mayfield Awards



5550 Meadowbrook Drive Rolling Meadows, IL 60008

member services: 888.566.AANS phone: 847.378.0500 fax: 847.378.0600 web: www.NeurosurgeryToday.org web: www.AANS.org

July 12, 2006

Daniel K. Resnick, MD University of Wisconsin-Madison 600 Highland Ave. K4/834 CSC Madison, WI 53792-0001

Dear Dr. Resnick:

I am writing to the chairs and secretaries of each section to ask for your support of the AANS Case Studies project. This is a new project at the AANS which contains an online repository of neurosurgical case material submitted and reviewed by neurosurgeons for education within our community.

As you may recall, at any stage in practice one encounters cases which differ from the "classic" textbook cases that are often portrayed in our textbooks. In short, there is a great deal to be learned by coming to understand the nuances of how disease presentation and treatment may vary, even within the same diagnosis, when one has seen a large body of case material.

Recognizing this, we set out to create a system whereby neurosurgeons in practice could easily submit cases to an online repository. The system allows one to upload PowerPoint, images, audio, video, word documents and other text files to describe case material that you have seen in practice. The fully searchable database is now available online at MyAANS.org and is organized by disease sections.

You can read more about the features of the index at <u>http://www.aans.org/library/Article.aspx?ArticleId=38185</u> in our spring 2006 AANS *Bulletin;* or you can view a test drive of the system by logging into MyAANS.org and pointing your browser to <u>https://www.myaans.org/Default.aspx?tabid=131</u>, the online help area for the index.

We are asking if each of the Joint Sections would help us to identify a section member to serve as a reviewer for cases in their subspecialty area. To further your understanding of the initiative, we would very much like to present the Case Studies Project to your executive committee either by conference call or a 10 minute review in person (perhaps at the CNS meeting in Chicago). If you prefer that your volunteer view the demonstration instead, that can be arranged.

We do think this will be a valuable service to your section members. Please contact me at bcarter@partners.org or 617-726-3360 with your thoughts and if it would be possible to present to your committee.

Thank you and best regards,

Bob S. Carter MD PhD AANS Case Studies Project Leader

cc: Shelley D. Timmons, Chair AANS Information Technology Committee

AANS 2007 – Joint Section Spine and Peripheral Nerve Afternoon Sessions

Tuesday

2:45-5:30 Peripheral Nerve

2:45-3:15 (30 minutes) Guest Lecturer: Treatment Strategies for Upper Extremity Peripheral Nerve Injuries Christopher Oberlin, M.D.@ Moderator: Robert J. Spinner, M.D.@

3:15-4:30 (75 minutes – 15 minutes each speaker) Symposium: Peripheral Nerve Debates Moderator Rajiv Midha, M.D. and John E. McGillicuddy, M.D.@

- 1) Endoscopic vs Open Carpal and Cubital Tunnel Decompression Kartik G. Krishnan, MD vs. Eric L. Zager, M.D.@
- 2) Lumbar Radiculopathy vs. Lower Extremity Neuropathy Allen H. Maniker, M.D. vs. Allan J. Belzberg, M.D.@
- 3) Questions and Panel Discussion

4:30-5:30 (60 minutes – 10 minutes each abstract) Oral Abstract Presentations – 6

Wednesday

2:45-5:30 Spine

2:45-4:10 (85 minutes – 15 minutes each speaker) Symposium: Moderator: Charles Kuntz, IV, M.D. and Michael W. Groff, M.D.

Option 1 Motion Preservation

- 1) Cervical Arthroplasty: New Horizon Regis W. Haid, Jr., M.D.@
- 2) Lumbar Arthroplasty: Success or Failure? Richard G. Fessler, M.D., Ph.D.
- 3) Posterior Interspinous Process Distraction/Facet Replacement Larry T. Khoo, M.D.
- 4) Posterior Dynamic Stabilization: Preliminary Data Joseph T. Alexander, M.D.@
- 5) Minimally Invasive Decompression RCT- Claudius F. C. Thomé. M.D.@
- 6) Questions and Panel Discussion

Option 2 Spondylolisthesis or Other

- 1) Primary Repair of Pars Defects
- 2) Posterolateral Fusion for Degenerative Spondylolisthesis
- 3) Fusion and Fixation for Degenerative Spondylolisthesis
- 4) Reduction for High Grade Spondylolisthesis
- 5) Fusion in Situ for High Grade Spondylolisthesis
- 6) Questions and Panel Discussion

4:10-5:30 (80 minutes – 10 minutes each abstract) Oral Abstract Presentations – 8 Dan Here is a response from the ACP people to Paul's communication. CB

From: Jayne Schablaske [mailto:schablas@ohsu.edu]
Sent: Thu 7/20/2006 2:40 PM
To: pmatz@uabmc.edu
Cc: Roger Chou; timothy-ryken@uiowa.edu; Charles Branch
Subject: Re: Evidence-based Clinical Practice Guidelines for Low back
Pain

Dear. Dr. Matz -

Thanks very much for your participation in the peer review - we appreciate your expertise and input.

At the end of July I will send the draft evidence review and peer review form via email, unless you would prefer a hard copy send in the mail.

We will need to have review comments within 3-4 weeks upon receipt. We are making every effort to make the systematic evidence review as concise as possible, but given the scope of the project we anticipate that peer review will require several hours of time. We can provide the evidence electronically or as a hard copy. We anticipate that it will take about 3 months after the systematic evidence review has undergone the peer review process to complete the draft Clinical Practice Guidelines, which would be sent out for peer review in the fall.

If you have any questions, please feel free to ask me or Dr. Chou.

Jayne

Jayne Schablaske Senior Research Assistant

Oregon Evidence-based Practice Center OHSU - Department of Medical Informatics & Clinical Epidemiology Mailcode: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239-3098 503.418.3347 | Fax: 503.494.4551

>>> "Paul Matz" <pmatz@uabmc.edu> 07/17/06 11:14 AM >>>

Dr. Chou,

In reference to your email below, I am volunteering to act as a neurosurgery peer-reviewer in your development of Evidenced-based guidelines for low back pain. I will check with Dr. Ryken on his status. Please let me know the details and the time frame.

Paul Matz

Gentlemen It is difficult to know how to process this but we should investigate this. I will appoint Paul Matz, current Guidelines Committee Chair for the Section and Tim Ryken, former Section Treasurer/Outcomes expert to understand this intiative and to serve as reviewers. By way of this email stream, I will ask Paul to communicate with Roger Chou and express our interest and offer to serve as a resource. He will report to the Section on this initiative and its potential impact and what resources we need to direct toward that program and similars ones that will undoubtedly pop up in the future.More to follow. Charlie Branch **Peer Review**

August 3, 2006

Dear Peer Reviewer:

Thank you for agreeing to serve as a peer reviewer for the evidence review for the American Pain Society/American College of Physicians Clinical Guidelines for the Management of Low Back Pain. Included is a brief Peer Review Form to use for your evaluation of the evidence.

As communicated in the invitation sent to you, part of the evidence-based clinical guideline development process is to seek review of the material by external experts and potential users of the guidelines. We plan a 2-stage peer review process for this Guidelines project. The first stage is to review the evidence report, to help insure that the recommendations are based on accurate evidence. The second stage will be to review the actual draft guidelines and recommendations, which we expect to be send out for peer review later this year.

Because of the large volume of evidence to cover for low back pain the evidence report is quite lengthy. We realized that peer reviewers might not have time to provide feedback on every part of the report. Please feel free to focus your comments on those parts of the report where you feel you have the most expertise in. We are particularly interested in knowing if there are important clinical trials that are missing.

Sincerely,

Roger Chou, MD Director, American Pain Society Clinical Guidelines Development Oregon Evidence-based Practice Center Oregon Health & Science University Portland, OR 503-494-5367 <u>chour@ohsu.edu</u>

Name of Re	Reviewer: Paul Matz, MD						
Address:	Idress: Suite 1034 FOT, 510 20 th Street South						
City:	Birmingha	am	Im State: AL Zip code: 35294				
Phone:	205 975 8	3872	72 Fax: 205 975 8337				
Email:	pmatz@u	iabmc.edu	J				

Instructions:

Please read and review this Draft evidence review with particular focus on your area of expertise. Your responses are confidential and will be used only to assess the validity, clarity and accuracy of the interpretation of the evidence data. If applicable, please specify the draft page and line numbers in your comments.

Given the length of the evidence report, we realize that it would be difficult to provide detailed comments on every part of the report. Please feel free to focus your comments on your particular specialty area/area of expertise as well as on the overall structure and content of the report. We are also particularly interested in knowing of important trials that are missing from the report.

If you need more space than is provided, please attach additional pages.

Return this completed form via email (or mail, if that is the method you received it) by **August 29, 2006** to:

Jayne Schablaske Oregon Evidence-based Practice Center Mail code: BICC Oregon Health Sciences University 3181 SW Sam Jackson Park Road Portland, OR 97239

For questions, you may contact via email: <u>schablas@ohsu.edu</u>, or phone: 503-418-3347.

Specialty Area:	Neurological Surgery					
		r	1			
 Are the methods for identifying relevant systematic reviews and studies adequate? 		YES	x	No	Not Clear	
2. Are the methods for exclusion of studies appropriate?		YES	x	No	Not Clear	x
3. Are the methods for grading the quality of systematic reviews and individual studies appropriate?		YES	x	No	Not Clear	
4. Is any critical literature, or work in progress, missing?		YES	x	No	Not Clear	

	In the development of these guidelines, the authors undertook a standard review process. For any given question, systematic reviews were obtained along with any RCTs that related to the subject matter. In addition, any case-control studies dealing with the relevant topic were often reviewed. The main drawback of the search process was the shear volume of articles to be found regarding low back pain. Because the subject field was so broad, it appeared difficult to include and review smaller studies. Therefore, emphasis was given to systematic reviews. This approach is acceptable if the original trials and studies contained in a systematic					
Comments:	 review are re-evaluated. It appeared that sometimes this did not occur. Case in point: lines 954-955 state that MRI and CT have similar accuracy in diagnosing herniated discs. This conclusion was drawn from the manuscript: Jarvik J and Deyo R: <i>Ann Intern Med 2002;137:586-597</i>. However, these authors also state that "Computed tomography can accurately depict the foraminal and extraforaminal nerve root because surrounding fat provides natural contrast computed tomography is less effective for evaluating the intrathecal nerve root." This statement is important since most imaging should be undertaken to evaluate nerve root impingement. 					
	question 8: surgery and low back pain) did not include any analyses contained in the "Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine." These are included in <i>J Neurosurg:Spine 2:636-759, 2005</i> . These guidelines review the utility of surgery for lower back pain.					

American Pain Society DRAFT Evidence Review Peer Review Form American College of Physicians Clinical Practice Guidelines for Low Back Pain August 3, 2006

Format

1. Is the material organized appropriately and systematically?	YES		No	Not Clear	x
2. Are the terms adequately defined?	YES	x	No		
3. Is the writing style appropriate for health care professionals and patients?	YES	x	No		
4. Is the format and structure satisfacotry?	YES		No	Not Clear	x

Comments:	The material was organized systematically. However, the scope of the project was so broad that it appeared detail was missing in the analyses of complex reviews and clinical studies. One might consider two sets of guidelines. One dealing with non-invasive therapy for lower back pain (questions 1-5, 10) and one dealing with invasive therapy (including surgery) for lower back pain (questions 6-9).
-----------	--

Overall content

The Draft evidence review:					
 Has relevant and important Key Questions in the area of LBP 		x	NO	Not Clear	
2. Comprehensively covers the Key Questions	YES	x	NO	Not Clear	
 Is applicable to my patients or area of specialty 	YES	x	NO	Not Clear	
4. Has an adequate level of detail	YES		NO	Not Clear	х
Is useful overall to determine LBP recommendations			NO	Not Clear	x

Comments:	 Because of the broad scope of the project, it appeared that detail was lacking, especially with regard to in-depth analysis of the appropriate RCTs. In question 1, the authors review the arsenal of diagnostic tests available. The conclusions were sound except for the accuracy of CT and MRI which should be clarified (discussed above). Questions 2-5 address non-invasive management of lower back pain. These cover a broad array of topics in appropriate fashion. Question 6: lines 4362 to 4366 review a study comparing fusion for isthmic listhesis to fusion for discogenic back pain. Surgery for the latter was 44% as successful. This is essentially not interpretable since one is comparing "apples to oranges." Accordingly, one should expound about the weaknesses of this study. Question 7: deals primarily with injections and seems to show mixed results for different types of injections over the short- and long-term. Question 8 addresses the effectiveness of surgery for lower back pain. This question does not review of the analyses undertaken in the "Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine." These are included in <i>J Neurosurg:Spine 2:636-759, 2005.</i>
	Lines 5487 to 5491: The authors state conflicting results regarding fusion for chronic lower back pain with two higher quality trials

American College of Physicians Clinical Practice Guidelines for Low Back Pain August 3, 2006

Feel Review For	n August 3, 2006
	stating surgery was no better and one supporting surgery. Although Fairbank et al. demonstrated improvement with surgery (n=349 study group, p<0.05), the authors of this study downplayed these results (<i>BMJ 2005;330(7502):1233</i>) for uncertain reasons. Furthermore, in this trial, 48 of 173 patients in the rehabilitation arm crossed over to surgery (28%). Consequently, it is the opinion of this reviewer that few conclusions can be made regarding the efficacy of intensive rehabilitation of 28% of the group has opted to cross over to the alternate therapy. The Fritzell study, though, was a well-controlled trial of 294 patients that supported surgery over a 2-year interval. The Brox studies only included 60-64 patients; in the lumbar fusion guidelines, the small sample size and large confidence intervals noted in the Brox study indicated that the sample size was too small. <i>J Neurosurg: Spine 2:670-672, 2005.</i>
	The authors of these guidelines conclude that the better results observed in the non-surgical group in the Brox and Fairbank studies may be due to improvements from intensive rehabilitation (a result which might be questioned given the small size of the Brox study, Lines 5254 to 5260).
	The authors state that the efficacy of instrumented to non- instrumented fusion is inconsistent though clinical outcomes are similar after excluding two lower-quality trials reporting better outcomes (lines 5492-5495) The authors may be better served undertaking a true meta-analysis and defining inclusion criteria and outcome measure rather than randomly excluding trials as this seemingly introduces bias. The lumbar fusion guidelines <i>J</i> <i>Neurosurg: Spine 2:700-706, 2005</i> conclude that pedicle screw fixation may be an option for high-risk patients who may have a malunion but that the utilization of pedicle screws does increase cost and complications.
	Lines 5515-5519, "Trials of surgery versus non-surgical management generally included patients who did not have clear indications for surgery, failed to improve after 6 months to 2 years conservative management, and had disease localized to L4-5 or L5- S1. It is my opinion that failure to improve could be construed as a
	reason to undertake surgery and that there is not an issue with surgery at L4-5 or L5-S1. These points should be clarified.
	Spinal Stenosis: Lines 5520-5526 indicated that standard initial surgical therapy (decompression and/or diskectomy) is associated with improved outcomes after one year compared to initial non-surgical therapy with differences attenuated after 4 years. This

American College of Physicians Clinical Practice Guidelines for Low Back Pain August 3, 2006

h August 3, 2006
reviewer concurs. Lines 5532-33 concluded diskectomy superior to chemonucleolysis, a result with which this reviewer concurs.
Lines 5537-5540 conclude no difference between laminectomy and multiple laminotomy and no difference between decompression with and without posterolateral fusion; this result is in agreement with the lumbar fusion guidelines (<i>J Neurosurg: Spine 2:686-691</i> , <i>2005</i>) which state that fusion is not generally indicated if overt instability is not evident.
Lines 5541-5543, conclude that no difference exists between patients undergoing fusion alone versus fusion with decompression in the setting of L5-S1 isthmic spondylolisthesis. This conclusion was referenced from the study by E Carragee <i>in J Bone Joint Surg</i> <i>Am</i> 79:1175-1180, 1997. A small group of patients were divided into smokers and nonsmokers. In the nonsmokers, patients underwent non-instrumented PLF \pm decompression. In the smokers, patients underwent instrumented PLF \pm decompression. It appeared that decompression increased the pseudoarthrosis and pain rates. However, numbers were small and patients were not randomized at all. This author does not believe this represents a "good quality" randomized trial. I would put the strength of data as "poor" not "fair" as these guidelines authors have listed. In addition, the statement should be qualified that this does not extend to patients with neurological deficit (as is stated in the conclusion of the Carragee paper).
Question 9 addresses the effectiveness of other modalities for treatment of back pain and sciatica. The authors of these guidelines review spinal cord stimulators. They conclude that spinal cord stimulation is beneficial in half of the patients with chronic back/leg pain or failed back surgery syndrome. They report a return-to-work rate of 40%. It is my opinion that they are correct in assessing the quality of supporting data is poor. There do not exist any high quality, randomized controlled trials to support a stronger position.

GUIDELINE FOR THE MANAGEMENT OF

Low Back Pain

Draft Evidence Review Executive Summary

Roger Chou, MD Laurie Hoyt Huffman, MS

Sponsored by:

The American Pain Society & The American College of Physicians



1 EXECUTIVE SUMMARY

2 **Purpose of this report**

This evidence review focuses on evaluation and management of low back pain in adults. The American Pain Society (APS), which commissioned this report, will use it in partnership with the American College of Physicians (ACP) to develop evidence-based recommendations for low back pain.

7 Background

Low back pain is an extremely common problem, with a point prevalence in
developed countries of up to 33%, one-year prevalence up to 65%, and lifetime
prevalence up to 84%, though estimates vary widely. In the US, nonspecific mechanical
low back pain is the fifth most common reason for all physician visits, and the second
most common symptomatic reason.

Low back pain is costly, with estimates of total annual cost in the U.S. ranging from \$20 to \$50 billion. In the U.S., low back pain is the most common cause for chronic or permanent impairment in persons under the age of 65, and the most common cause of activity limitations in persons under the age of 45. It has been estimated that between 2% and 8% of the U.S. work force is disabled or compensated for back injuries each year.

19 Many patients with acute episodes of low back pain do not seek care because 20 symptoms are often brief and self-limited. Among those who do seek medical care, 21 rapid improvements in pain (average improvement of 58% of initial score), disability 22 (average improvement of 58%), and return to work (82% of those initially off work return 23 to work) are seen in the first month. Further improvement generally continues until 24 approximately three months, after which levels for pain, disability, and return to work 25 appear to remain relatively constant. Up to one-third of patients report persistent back 26 pain of at least moderate intensity one year after an acute episode requiring care, and 27 one in five report substantial activity limitations. Recurrences of pain also are common, 28 with 60% to three-quarters of patients experiencing at least one relapse within 12 29 months. Prolonged disability may be more frequent than previously suspected: in one 30 systematic review of 36 studies on the course of low back pain in the general

1

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

population, 16% (range 3% to 40%) of patients were sick-listed 6 months after entry into
the study. Factors associated with the development of chronic disability due to low back
pain include pre-existing psychological distress, presence of other types of chronic pain,
job dissatisfaction or stress, and disputes over compensation issues.

35 Many options are available for the evaluation and management of acute or 36 chronic low back pain. However, there has been little consensus, either within or 37 between specialties, on appropriate uses of diagnostic tests and interventions. Despite 38 wide variations in practice, several studies have shown that patients experience broadly 39 similar outcomes, though costs of care can differ substantially both between and within 40 specialties. In addition to unexplained practice variations, another historical feature of 41 low back pain management has been the widespread uptake and use of unproven (and 42 sometimes invasive and costly) interventions, some of which have later been shown to 43 be ineffective, or even harmful. Other interventions are widely used despite studies showing only marginal benefits. 44

45 Scope

46 Target populations for this review are adults (>18 years old), pregnant women, 47 persons with hyperacute, acute, subacute or chronic low back pain, persons with 48 nonspecific low back pain (including discogenic pain, facet joint pain, spondylosis, 49 degenerative disc disease, sacroiliac joint pain, etc.), radicular low back pain (including 50 lumbar disc prolapse), spinal stenosis, and failed back surgery syndrome. Treatment of 51 infection, cauda equina syndrome, cancer, spondyloarthropathies, systemic 52 inflammatory disease, fibromyalgia syndrome, and vertebral compression fracture was 53 excluded from the scope of this review, though evaluation to rule out such conditions 54 was considered within the scope. Evaluation and management of osteoporosis without 55 clear fracture and acute major trauma was also outside our scope. Children and 56 adolescents were excluded because diagnostic and therapeutic considerations are 57 substantially different than in adults. We reviewed evidence on low back pain of any 58 duration.

59 Target interventions for this review include the following non-invasive
60 interventions: medications, systemic corticosteroids, herbal therapy, brief interventions,
61 back schools, exercise, hydrotherapy, spa therapy, acupuncture, acupressure,

2

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- 62 neuroreflexotherapy, spinal manipulation, massage, short wave diathermy, interferential 63 therapy, ultrasound, behavioral intervention, multidisciplinary rehabilitation, physical 64 conditioning programs, traction, and low level laser. Invasive, non-surgical interventions 65 include: epidural steroid injections, intradiscal steroid injections, chemonucleolysis, local 66 injections, facet (zygapophysial) joint injections, prolotherapy, botulinum toxin, 67 adhesiolysis, radiofrequency denervation, intradiscal electrothermal therapy (IDET) and 68 percutaneous intradiscal radiofrequency thermocoagulation. Surgical interventions 69 include: degenerative conditions of the lumbar spine, spinal stenosis, isthmic 70 spondylolisthesis and lumbar disc prolapse.
- Target outcomes addressed one of the five core domains for low back pain as
 suggested in recent recommendations: back specific function, generic health status,
- 73 pain, work disability, and patient satisfaction.

74 **Conclusions**

- 75 Key Question 1.
- 76 What features of the history and physical exam are predictive of specific serious
- 77 underlying conditions ("red flags"), other specific conditions that may be
- responsive to specific therapies in patients with LBP (such as nerve root
- 79 compression or spinal stenosis), or high risk for persistent low back pain and
- 80 associated disability ("yellow flags")?

81 *Features of history and physical exam predictive of serious underlying conditions*

- 82 ("red flags"), compression fracture, ankylosing spondylitis, nerve root
- 83 compression, and spinal stenosis
- Previous history of cancer (positive likelihood ratio 14.7), unexplained weight loss
 (positive likelihood ratio 2.7), and failure to improve after 1 month of therapy (positive
 likelihood ratio 3.0) were associated with a specificity for diagnosing cancer of >0.90
 in patients with acute low back pain presenting to primary care in one higher-quality
 study (level of evidence: fair).
- The presence of any of the following was associated with a high sensitivity (1.00) and moderate specificity (0.60) for diagnosing cancer in one higher-quality study: age >50 years, history of cancer, unexplained weight loss, or failure of conservative therapy (positive likelihood ratio 2.5, negative likelihood ratio 0.0) (level of evidence: fair).

- Few studies have evaluated the accuracy of history and physical exam for diagnosing
 infection, though history of intravenous drug use, skin infection, or urinary tract
 infection only had modest sensitivity in one study (level of evidence: poor).
- Older age and history of corticosteroid use were the best predictors of vertebral compression fractures (level of evidence: fair).
- Younger age of onset was sensitive but not specific for diagnosing ankylosing
 spondylitis. Physical exam findings were generally associated with poor sensitivity
 and relatively high specificities (level of evidence: fair).
- Describing typical symptoms of sciatica has a relatively high sensitivity but
 inconsistent specificity for diagnosing radiculopathy. A positive straight leg raise (th
- inconsistent specificity for diagnosing radiculopathy. A positive straight leg raise (the
 best-studied physical exam maneuver) was associated with a pooled sensitivity of
- 104 0.91 and specificity of 0.26 in one higher-guality systematic review. A positive
- 105 crossed straight leg raise was associated with a pooled sensitivity of 0.29 and a
- 106 specificity of 0.88. The specificity of neurologic deficits consistent with nerve root
- 107 compression ranges from modest to high (level of evidence: fair).
- In one study, spinal stenosis was less likely in patients younger than 65 years old. A
 wide-based gait and absence of pain when seated were associated with higher
 likelihoods of spinal stenosis (level of evidence: fair).
- 111 Features of the history and physical exam associated with development of

112 chronic and disabling low back pain

- There is consistent evidence from multiple systematic reviews that psychologic distress, job dissatisfaction, high levels of "fear avoidance" beliefs, disputed compensation claims, and somatization are associated with worse low back pain outcomes (level of evidence: good).
- Increased duration or severity of pain and presence of leg pain are modestly associated with poorer outcomes (level of evidence: fair).
- Physical exam findings were inconsistently associated with outcomes and were
 weaker predictors than psychosocial factors (level of evidence: fair).
- Validated tools or scales for identifying patients likely to have poorer outcomes are
 lacking, though one study found the Vermont disability questionnaire promising (level
 of evidence: poor).
- 124 Key Question 1a.
- 125 **Does identification of 'yellow flags' lead to improved outcomes in patients**
- 126 with LBP?

- Two higher-quality trials found no benefits after 12 months from brief interventions identified at identifying and treating 'yellow flags' relative to usual care or standard physical therapy in unselected patients with acute or subacute back pain (level of evidence: good).
- One lower-quality trial found that an intensive multidisciplinary functional restoration program was more effective than usual care after 12 months in patients with back pain for less than 8 weeks who were identified as being at higher risk for chronic disability using a screening tool (level of evidence: poor).
- One lower-quality trial found fear-avoidance based therapy superior to usual care for back specific functional status after 24 months in patients with persistent activity limitations, though beneficial effects on pain were only short-lived (level of evidence: poor).
- One higher-quality trial found no difference between fear-avoidance therapy and standard physical therapy after 6 months, though fear-avoidance beliefs were
 degraged in the intervention group (level of evidence; feir)
- 141 decreased in the intervention group (level of evidence: fair).

142 Key Question 2.

- 143 What diagnostic tests should be ordered, and under what circumstances, for
- 144 patients with LBP?

145 Key Question 2a.

- 146 What is the diagnostic accuracy of different diagnostic tests for identifying
- 147 serious underlying conditions (e.g., tumor, infection, compression fracture)?
- MRI and radionuclide scanning are more sensitive than plain radiography for
 diagnosing vertebral cancer, though plain radiography is associated with high
 specificity (level of evidence: good).
- MRI is more accurate than either plain radiography or radionuclide scanning for diagnosing vertebral infection (level of evidence: fair).
- Plain radiography appears sensitive for diagnosing vertebral compression fracture,
 but is unable to provide information about acuity (level of evidence: fair).
- An elevated erythrocyte sedimentation was associated with moderate sensitivity and specificity for diagnosing vertebral cancer in one higher-quality study (level of evidence: fair).

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- 158 Key Question 2b.
- 159 What is the diagnostic accuracy of different diagnostic tests for identifying other
- 160 conditions (e.g. nerve root compression, herniated disc, spinal stenosis) that may
- 161 respond to specific therapies?
- MRI and CT scan are associated with similar diagnostic accuracy for diagnosing
 herniated disc or spinal stenosis (level of evidence: good).
- Evidence on the diagnostic accuracy of different imaging methods for diagnosing ankylosing spondylitis is sparse. Plain radiography may have high specificity, but higher-quality studies are needed (level of evidence: fair).
- An elevated ESR was associated with moderate sensitivity and specificity for
 diagnosing ankylosing spondylitis in patients suspected of having the disease (level of
 evidence: fair).
- There is no evidence supporting the use of thermography or surface
- 171 electromyography for diagnosis of low back pain (level of evidence: fair).

172 Key Question 2c.

- 173 In patients with 'red flags,' how does the choice of diagnostic testing affect
- 174 clinical outcomes
- There is no direct evidence on the efficacy of diagnostic testing in patients with 'red
- 176 flags,' though all guidelines recommend prompt and appropriate work-up (including
- 177 advanced imaging) because delayed diagnosis and treatment can be associated with
- 178 poorer outcomes

179 Key Question 2d.

180 In patients without 'red flags,' how does the choice of diagnostic testing (or no

181 testing) affect clinical outcomes?

- Routine plain radiography did not identify any additional serious diseases compared to usual care and did not improve outcomes including pain and functional status,
 though there appeared to be modest beneficial effects on patient satisfaction and psychologic well-being (two trials, one higher-quality) (level of evidence: fair).
- In one lower-quality trial, the combination of delayed selective imaging with a brief
 educational intervention was not associated with differences in any outcomes relative
 to routine plain radiography, including patient satisfaction and psychologic distress
 (level of evidence: poor).

- Routine MRI was associated with only minor benefits on pain and functional status
 outcomes compared to selective imaging in one higher-quality trial. A lower-quality
- trial found that in patients who had undergone MRI, disclosure of results was not
 associated with improved outcomes compared to non-disclosure unless clinically
- 194 necessary (level of evidence: fair).
- In two higher-quality trials, rapid MRI was not associated with any significant benefits
 compared to plain radiography in patients in whom imaging was thought indicated
 (level of evidence: good).
- 198 Key Question 3.
- 199 What is the effectiveness of different non-invasive interventions for non-specific
- 200 low back pain, radicular LBP, or spinal stenosis, and under what circumstances?

201 Medications

202 Acetaminophen

- There is conflicting evidence from lower quality trials regarding the efficacy of
 acetaminophen versus NSAIDs for acute low back pain, with most showing no
 difference in outcomes (level of evidence: fair).
- For chronic low back pain, one higher quality trial found acetaminophen inferior to an
 NSAID on an overall assessment of efficacy (level of evidence: fair).
- Multiple trials of patients with osteoarthritis consistently found acetaminophen inferior
 to NSAIDs for pain relief (level of evidence: good).
- There is insufficient evidence from single, lower quality trials comparing
 acetaminophen to other interventions (such as physical therapy, a corset, or spinal
 manipulation) to accurately judge relative efficacy (level of evidence: poor).
- Acetaminophen is associated with a lower risk of serious GI side effects compared to
 NSAIDs based primarily on observational data (level of
 evidence: fair).
- Acetaminophen is better tolerated than NSAIDs (level of evidence: good).
- Additional studies are required to evaluate whether high-dose acetaminophen is
 associated with increased cardiovascular risk (single observational study) (level of
 evidence: poor).

220 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

- 221 Non-selective, non-steroidal anti-inflammatory drugs
- There is evidence from multiple trials that NSAIDs are associated with modest shortterm pain relief compared to placebo in patients with acute low back pain (level of evidence: good).

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- A single higher quality trial found that NSAIDs are effective in patients with chronic low back pain (level of evidence: fair).
- NSAIDs have not been shown to be more effective than other medications (opioids, skeletal muscle relaxants) or non-invasive interventions (spinal manipulation, physical therapy, bed rest) (level of evidence: fair).
- There is no evidence that any NSAID is more effective than any other (level of evidence: good).
- NSAIDs are associated with an increased risk of serious GI complications compared to non-use (level of evidence: good).
- NSAIDs other than naproxen were associated with a modest increase in risk of cardiovascular complications relative to non-use in one recent meta-analysis of randomized controlled trials (level of evidence: good).
- 237 COX-2 selective NSAIDs
- Systematic reviews of COX-2-selective NSAIDs given for a variety of indications
 found no clear differences in efficacy (pain relief) relative to non-selective NSAIDs
 (level of evidence: good).
- Celecoxib is associated with a lower risk of GI complications compared to non selective NSAIDs, but most of the evidence comes from short-term trials (level of
 evidence: good).
- Celecoxib appears to be associated with an increased risk of myocardial infarction compared to placebo (level of evidence: good).

246 **Aspirin**

- There is insufficient evidence to judge the efficacy of aspirin in patients with low back
 pain (level of evidence: poor).
- Aspirin is associated with an increased risk of GI bleeding even at low doses (level of evidence: good).
- Aspirin is effective in the primary and secondary prevention of cardiovascular events
 (level of evidence: good).

253 Other medications

254 Antidepressants

- Tricyclic antidepressants are consistently more effective than placebo for pain relief
 and other outcomes in higher-quality trials of patients with chronic low back pain, but
 do not appear to improve functional outcomes (level of evidence: good).
- Several trials suggest that paroxetine and trazodone not effective or marginally effective compared to placebo (level of evidence: fair).

- There is insufficient evidence from head-to-head trials (one lower-quality trial) to
 judge the relative effectiveness of tricyclic antidepressants and selective serotonin
 reuptake inhibitors (level of evidence: poor).
- There are no trials on the effectiveness of other antidepressants (such as venlafaxine or duloxetine), and insufficient evidence to judge the efficacy of antidepressants for acute low back pain (level of evidence: poor).
- Although serious adverse events were not reported in the trials, the selected
 populations evaluated in clinical trials may make it difficult to extrapolate results to
 general practice (level of evidence: poor).

269 **Benzodiazepenes**

- There is insufficient evidence to judge the efficacy of benzodiazepines (1 low-quality trial) for acute low back pain (level of evidence: poor).
- Two higher quality trials indicate that benzodiazepines are effective for short-term outcomes in patients with chronic low back pain (level of evidence: fair).
- Diazepam was inferior to carisoprodol (a drug metabolized to meprobamate) in one
 higher quality trial, but no different than other skeletal muscle relaxants in two other
 trials (level of evidence: fair).
- Benzodiazepines are associated with increased short-term central nervous system
 adverse events (level of evidence: good). Risks of addiction, abuse, development of
 tolerance, and overdose, particularly with long-term use, are unknown.

280 Gabapentin

- Limited evidence from two trials (one higher quality) suggests that gabapentin is
 associated with modest short-term benefits for pain relief in patients with
 radiculopathy (level of evidence: fair).
- There are no trials evaluating the efficacy of gabapentin in patients with non-radicular low back pain.

286 *Muscle relaxants*

- Skeletal muscle relaxants are consistently more effective than placebo for short-term (less than one week) pain relief and global response in patients with acute low back pain (level of evidence: good).
- There is insufficient evidence to judge the efficacy of skeletal muscle relaxants in patients with chronic low back pain or those with sciatica (level of evidence: poor).
- Although there is no evidence proving that one skeletal muscle relaxant is superior to others (level of evidence: fair), the efficacy of cyclobenzaprine is supported by the most evidence.

- Skeletal muscle relaxants are associated with an increased rate of adverse events
 compared to placebo, though they are usually mild and self-limited (level of
 evidence: fair).
- Specific safety issues are associated with carisoprodol (metabolism to meprobamate), dantrolene (potentially fatal hepatotoxicity), chlorzoxazone and tizanidine (usually reversible and mild hepatotoxicity).

301 *Opioid analgesics*

- Multiple trials of patients with various non-cancer pain conditions consistently indicate that opioids are superior to placebo for pain relief in primarily short-term trials (level of evidence: good), though evidence in patients specifically with either acute or chronic low back pain (one higher quality demonstrating benefit) is sparse (level of evidence: fair).
- There is insufficient evidence from single, lower quality trials to judge the efficacy of opioids versus acetaminophen or in addition to NSAIDs (level of evidence: poor).
- Consistent evidence from lower-quality trials found no differences between long- and short-acting opioids on a variety of outcomes in patients with chronic low back pain (level of evidence: fair).
- There were no clear differences between long-acting opioids in two head-to-head
 trials evaluating different comparisons (level of evidence: fair).
- Although adverse events are common with opioids (level of evidence: fair), there are
 no reliable estimates for rates of abuse or addiction, overdose, or other serious
 adverse events (level of evidence: poor).

317 Tramadol

- Tramadol was moderately more effective than placebo for short-term pain and
 assessment of functional status in one higher-quality trial of patients with chronic low
 back pain (level of evidence: fair).
- Tramadol was no better than the combination of paracetamol plus codeine in one lowquality trial of patients with chronic low back pain (level of evidence: poor).
- There is insufficient evidence to judge the efficacy of tramadol compared to
 acetaminophen or opioid analgesics alone or to NSAIDs available in the U.S. (no
 trials).
- In single trials, tramadol was associated with similar rates of withdrawal due to
 adverse events (a marker for intolerable or severe adverse events) compared to
 placebo or the combination of paracetamol + codeine (level of evidence: fair).

329 Systemic corticosteroids

- Systemic corticosteroids are consistently not associated with a clinically significant
 benefit in patients with acute sciatica when given parenterally (single injection) or as a
 short oral taper (three higher-quality trials) (level of evidence: good).
- One trial found no benefit from a single intramuscular injection of corticosteroids in
 patients with acute non-radicular low back pain, but the level of evidence can't be
 adequately assessed because it is only available as a conference abstract.
- Serious adverse events after a single large bolus were not reported in one trial (level of evidence: fair). However, systemic corticosteroids are associated with hyperglycemia, systemic infections, bleeding, and osteoporosis, and psychosis, particularly with higher doses and longer courses.

340 Herbal therapy

- Several higher-quality trials found devil's claw superior to placebo for short-term pain relief in patients with acute exacerbations of chronic low back pain. However all of the trials were led by the same investigator, raising concerns about reproducibility of findings in other settings (level of evidence: fair).
- One higher-quality trial found willow bark superior to placebo for short-term pain relief in patients with acute exacerbations of chronic low back pain (level of evidence: fair)
- Evidence on the efficacy of cayenne was mixed, with three lower-quality trials suggesting short-term benefits compared to placebo for pain relief and other outcomes in patients with acute low back pain or acute exacerbations of chronic low back pain, but one other lower-quality trial showing no benefit compared to a homeopathic gel (level of evidence: fair).
- Serious adverse reactions with herbal therapy appear uncommon (level of evidence: fair).
- No trials evaluated long-term outcomes.

355 Acupuncture and related interventions

356 Acupuncture

- There is consistent evidence from multiple trials that acupuncture is effective for
 short-term pain relief compared to no treatment or sham acupuncture in patients with
 chronic low back pain for pain, and superior to no treatment (but not sham) for
 functional outcomes (level of evidence: good)
- Evidence on longer-term (>6 weeks) outcomes is sparse but suggests that
 acupuncture is more effective than sham TENs and no treatment in patients with
 chronic low back pain. One recent, higher-quality trial found that beneficial effects on
 pain persist for up to 24 months (level of evidence: fair).

- Acupuncture was inferior to spinal manipulation in two trials (one higher quality) (level of evidence: fair)
- There is no evidence that acupuncture is more effective than other active
- interventions in patients with chronic low back pain (each comparison only evaluatedin a small number of trials) (level of evidence: poor to fair).
- There is insufficient evidence to judge the efficacy of acupuncture (small numbers of primarily lower-quality trials) in patients with acute low back pain (level of evidence: poor).
- Dry needling alone was not effective compared to trigger point injections or acupuncture in one trial of patients with acute low back pain (level of evidence: poor), but was more effective than placebo or when added to other interventions in two trials of patients with chronic low back pain (level of evidence: fair).
- Serious adverse events with acupuncture appeared rare in trials and prospective
 studies, though they were often poorly reported (level of evidence: fair).

379 Acupressure

- There is evidence from two trials (one higher quality) that acupressure is more effective than standard therapy in patients with chronic low back pain for pain and functional outcomes. However, it is not clear if these results can be generalized to other settings because both trials were conducted in Taiwan by the same investigators (level of evidence: fair)
- Acupressure does not appear associated with serious adverse events, but harms
 were only reported by one trial (level of evidence: fair).
- There is no evidence in patients with acute low back pain

388 *Neuroreflexotherapy*

- There is consistent evidence (three trials, two higher-quality) that neuroreflexotherapy is superior to sham therapy or usual care for short-term pain relief in patients with chronic low back pain. However, all of the trials were conducted in Spain by the same principal investigator at a specialized center, raising questions about the applicability of results to other settings (level of evidence: fair).
- Evidence on beneficial effects of neuroreflexotherapy relative to sham treatment on
 functional outcomes is mixed (level of evidence: fair).
- The single lower-quality trial assessing one-year outcomes found lower self-reported
 sick leave and consumption of health care resources with neuroreflexotherapy
 relative to usual care (level of evidence: fair).

399 Educational interventions

400 Back schools

- Back schools were superior to placebo in a single lower-quality trial of patients with
 acute or subacute low back pain for short-term recovery and return to work, but not
 for pain or long-term recurrences (level of evidence: poor).
- Evidence on the effects of back schools versus placebo or wait list controls for
 chronic low back pain is inconsistent, though most studies found no beneficial effects
 (level of evidence: fair).
- There was also mixed evidence on the efficacy of back schools relative to other active interventions in patients with acute low back pain (one higher quality trial finding benefit on sick leave but three other trials finding no benefit), but consistent evidence for modest benefits in patients with chronic low back pain (level of evidence: fair).
- More intensive back school programs based on the original Swedish program and
 programs in occupational settings appeared more effective (level of evidence: fair).

413 Brief educational interventions

- In three higher-quality trials, a brief educational intervention was associated with
 beneficial effects on sick leave in workers with subacute low back pain, though most
 of the benefits were observed in the first year after the intervention. There were no
 clear effects on pain or functional status (level of evidence: good).
- A brief intervention was only modestly inferior to the brief intervention plus exercise
 and manipulation in patients with chronic low back pain (one higher-quality trial) (level
 of evidence: fair).

421 **Exercise and related interventions**

422 Exercise

- Exercise is modestly superior to placebo in multiple trials of patients with chronic low
 back pain for pain relief and work-related outcomes, though the pain relief benefits do
 not appear to reach pre-defined levels of minimal clinically important differences (level
 of evidence: good).
- Exercise regimens incorporating features such as individual tailoring, supervision,
 stretching, and strengthening are associated with the best outcomes in metaregression analyses (level of evidence: fair).
- Evidence on the efficacy of exercise relative to placebo or no treatment in patients
 with acute low back pain is somewhat inconsistent, though most trials found no
 benefit (level of evidence: fair).

- One recent, higher-quality trial found a standardized exercise regimen inferior to
 physical therapy tailored according to patient signs and symptoms (level of evidence:
 fair).
- Evidence from numerous trials suggests no clinically significant difference between
 exercise and other non-invasive interventions for either acute or chronic low back
 pain (level of evidence: good).

439 Hydrotherapy

- There is insufficient evidence (one poor-quality trial) to judge the efficacy of
 hydrotherapy versus delayed hydrotherapy (level of evidence: poor).
- There is consistent evidence from two lower-quality trials that hydrotherapy and landbased therapy are associated with similar outcomes in patients with chronic low back
 pain (level of evidence: fair).
- There is no evidence on the effects of hydrotherapy in patients with acute low
 back pain.

447 **Yoga**

- Viniyoga was superior to traditional exercises and a self-care education book for
 back-specific functional status and use of medications in one higher-quality trial (level
 of evidence: fair).
- There is insufficient evidence to judge the effectiveness of other types of yoga (two
 small, low quality trials of Hatha yoga) (level of evidence: poor).

453 Multidisciplinary interventions

454 *Multidisciplinary rehabilitation*

- In two lower-quality trials, multidisciplinary rehabilitation (particularly with a work site visit) in patients with subacute low back pain was associated with quicker return to work, reduced sick leave, and improved disability relative to usual care (level of evidence: fair).
- Intensive multidisciplinary rehabilitation with functional restoration is more effective than usual care or non-multidisciplinary rehabilitation for reducing pain and improving function in patients with chronic low back pain, though effects on work-related outcomes are mixed (four trials, three higher-quality) (level of evidence: good).
- Less intensive (<100 hours) multidisciplinary rehabilitation was not more effective
 than usual care or non-multidisciplinary rehabilitation (five trials) (level of evidence:
 good).

There is insufficient evidence from one, lower-quality RCT to determine the efficacy of
 multidisciplinary rehabilitation in patients with acute low back pain (level of evidence:
 poor).

Physical conditioning programs (work conditioning, work hardening, and functional restoration)

- Evidence of benefits from six heterogeneous trials of physical conditioning programs
 in patients with acute low back pain is inconsistent, with the majority of studies
 showing no benefit (level of evidence: fair).
- Physical conditioning programs with a cognitive-behavioral approach are effective for reducing sick leave relative to usual care in two trials (one higher quality) of patients with chronic low back pain (level of evidence: fair). There is no clear benefit from physical conditioning programs without a cognitive-behavioral approach.
- Physical conditioning programs were effective for reducing days lost from work
 relative to passive physical therapy in patients with chronic low back pain (two high
 quality trials) (level of evidence: good).

481 **Physical modalities**

482 Interferential therapy

- One higher-quality trial found no difference between interferential therapy and
 manipulation in patients with subacute low back pain (level of evidence: fair).
- One lower-quality trial found no difference between interferential therapy and traction
 in patients with primarily chronic low back pain (level of evidence: poor).
- One lower-quality trial found no clear differences between interferential therapy with
 electrodes applied in the paraspinal area or to the painful area plus a self-care book
 versus a self-care book alone (level of evidence: poor).

490 Low-level laser

- There is conflicting evidence from five trials (four higher quality) on the effectiveness of low-level laser compared to placebo or sham laser in patients with chronic low back pain. Four trials (three higher quality) found laser therapy superior to sham for pain or functional status up to one year following treatment, but one higher-quality trial found no difference between laser and sham in patients also receiving exercise. In addition, interpretation of results is compromised by the use of heterogeneous and non-standardized outcome measures in some studies (level of evidence: fair).
- 498 Low-level laser was equivalent to exercise or the combination of laser plus exercise in one lower-quality trial (level of evidence: poor).
- There is no reliable evidence (one lower-quality trial) on low-level laser therapy in patients with acute low back pain (level of evidence: poor).

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- Additional research is needed on optimal doses of low-level laser therapy, number of
 sessions, and type of laser in patients with chronic low back pain.
- Publication bias from non-English language studies could affect these conclusions.

505 Short-wave diathermy

- One higher-quality trial found no difference between short-wave diathermy and sham diathermy on pain after 12 weeks in patients with low back pain for at least 2 months (level of evidence: fair).
- In patients with back pain of varying duration, one higher-quality trial found no
 difference between short-wave diathermy, sham diathermy, exercise, or traction using
 an unvalidated measure of global effect after 2 weeks (level of evidence: fair).
- One higher-quality trial found no difference between short-wave diathermy and spinal
 manipulation on pain after 12 weeks in patients with low back pain for at least 2
 months (level of evidence: fair).
- In patients with acute low back pain, one small, lower-quality trial found a lower
 proportion of patients reporting pain relief after 2 weeks in patients randomized to
 short-wave diathermy compared to spinal manipulation (level of evidence: poor).

518 **Traction**

- There is consistent evidence from multiple trials that continuous or intermittent traction are not associated with superior outcomes compared to placebo, sham, or other treatments for patients with low back pain of varying duration, either with or without sciatica (level of evidence: good).
- There is evidence from two lower quality trials that autotraction is superior to placebo
 or sham therapies and one lower quality trial that autotraction is superior to
 mechanical traction (level of evidence: fair).
- Adverse events reported in the trials included aggravation of signs and symptoms and
 subsequent surgery, but were inconsistently and poorly reported (level of
 evidence: poor).

529 Ultrasound

• There is insufficient evidence (single low-quality studies) to judge the efficacy of ultrasound for low back pain (level of insufficient: poor).

532 Other non-invasive interventions

533 Behavioral interventions

• There is consistent evidence from four RCTs (one higher quality) that cognitivebehavioral therapy is moderately more effective than wait list control for short-term

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- 536 pain intensity in patients with chronic low back pain, though there were no significant 537 differences on functional status and other outcomes (level of evidence: good).
- Two lower-quality trials found progressive relaxation associated with large positive
 benefits relative to wait list control for pain intensity and behavioral outcomes in
 patients with chronic low back pain (level of evidence: fair).
- Evidence on benefits associated with EMG biofeedback relative to wait list control is
 mixed, though three out of four trials demonstrated a moderate benefit on pain
 intensity in patients with chronic low back pain (level of evidence: fair).
- Operant therapy was not associated with any benefits relative to wait list controls in three trials of patients with chronic low back pain (level of evidence: good).
- Behavioral interventions have not clearly been shown to be superior to other active
 interventions for most outcomes, though one systematic review found moderate
 benefits for short- and long-term disability (level of evidence: fair).
- There is no clear evidence from head-to-head comparisons that one behavioral intervention is superior to any other (level of evidence: fair to good).

551 Massage

- Massage was superior to sham therapy in one higher quality trial of patients with subacute or chronic non-specific low back pain (level of evidence: fair).
- Massage was consistently inferior to spinal manipulation in three trials (one higher quality) up to one year after a course of treatment in patients with chronic low back pain (level of evidence: fair).
- In single trials comparing massage to other interventions, massage was inferior to transcutaneous electrical stimulation, similar to exercise and corsets, and moderately superior to relaxation, acupuncture, and a self-care education book (level of evidence for each comparison: fair).
- A single trial found acupuncture massage superior to classical (Swedish) massage
 (level of evidence: fair).
- There is insufficient evidence to judge the efficacy of massage in patients with acute
 low back pain (one lower-quality trial) or in patients with sciatica (no trials specifically
 in this population) (level of evidence: poor).

566 Modified work

• There is consistent evidence from one lower-quality trial and observational studies that modified work can decrease time lost from work (level of evidence: fair).

569 Spa therapy

- Spa therapy was consistently and substantially superior to no spa therapy for pain in
 three lower-quality trials of patients (all conducted in Europe) with chronic low back
 pain up to nine months after a three-week course of treatment (level of evidence: fair).
- Spa therapy was no better than no spa therapy for pain in one lower-quality RCT of
 patients with subacute or chronic low back pain, but associated with decreased
 analgesic use (level of evidence: poor).
- Spa therapy was no better than underwater massage or underwater traction or when
 added to exercise therapy in patients with subacute or chronic low back pain in two
 lower-quality trials (level of evidence: poor).
- There is no evidence for spa therapy in patients with acute low back pain.

580 Spinal manipulation

- Pooled evidence from many trials indicates that spinal manipulation is modestly
 superior to sham, no treatment, or therapies thought to be ineffective or harmful, in
 patients with either acute or chronic low back pain (level of evidence: good).
- There is also consistent evidence from multiple trials that spinal manipulation is no more effective than other standard conservative interventions (level of evidence: good).
- In patients without severe or progressive neurologic deficits, serious adverse events
 such as cauda equina syndrome or worsening lumbar disc herniation following lumbar
 spinal manipulation are very rare (level of evidence: good).
- 590 Key Question 3a.

591 Can decision tools predict which patients are more likely to respond to specific

- 592 therapies like physical therapy or chiropractic?
- A decision tool for identifying patients likely to benefit from spinal manipulation has been prospectively validated as highly predictive in a randomized trial. However, evidence of beneficial effects on clinical outcomes from applying the decision tool is not yet available. In addition, the tool may not be practical for use in many primary care settings, and a more pragmatic version has not yet been prospectively validated (level of evidence: fair).
- A decision tool for identifying patients likely to benefit from stabilization exercise has
 not yet been validated (level of evidence: poor).

601

- 601 Key Question 4.
- 602 What is the value of different patient education or patient self-care methods for
- 603 improving patient outcomes?

604 Self-care advice or education

605 Bed rest

- In two higher quality trials, advice to rest in bed was consistently associated with
 small but statistically inferior outcomes compared to advice to remain active in
 patients with acute nonspecific low back pain (level of evidence: good).
- Advice to rest in bed was consistently associated with similar outcomes compared to
 physiotherapy/exercise in two higher quality trials of patients with acute nonspecific
 low back pain (level of evidence: good).
- There is insufficient evidence to accurately judge the efficacy of advice to rest in bed relative to interventions other than exercise (level of evidence: poor).
- In patients with sciatica, one higher quality trial found that physiotherapy was
 associated with modestly superior functional status outcomes at 3 weeks compared
 to advice to rest in bed, but this effect was no longer present after 12 weeks (level of
 evidence: good).
- Longer duration of bed rest was not associated with better outcomes compared to
 shorter duration, and increased the number of days off work in one higher-quality trial
 (level of evidence: fair).
- There is no evidence to judge the efficacy of advice to rest in bed in patients with chronic low back pain.

623 Advice for activity

- Advice to remain active was associated with similar effects on functional status or pain compared to exercise therapy in one higher-quality trial of patients with acute non-specific low back pain and one higher-quality trial of patients with symptoms for more than six weeks, but with slower return from sick leave and more back pain recurrences in one older, lower-quality trial (level of evidence: fair).
- Advice to remain active was not associated with clear benefits in a single, higher quality trial of patients with acute low back pain with sciatica (level of evidence: fair).
- Advice to exercise was superior to usual care in one lower-quality trial of patients with
 low back pain for less than 90 days. There were no differences between advice to
 exercise and a self-care book, and the combination did not improve outcomes (level
 of evidence: poor).
- See section on bed rest for summary of bed rest versus advice to remain active.

636 Self-care books

• Four trials (one higher-quality) found no difference between a self-care book and usual care in pain or symptom bothersomeness scores (level of evidence: fair).

In three higher-quality trials comparing a self-care book to other active interventions (yoga, acupuncture, exercise, massage, or manipulation), there were either no significant differences or the self-care book was modestly inferior on symptom bothersomeness scores and functional status. The largest differences were seen in single trials comparing a self-care book to yoga and a self-care book to massage (level of evidence: good).

- There was no difference between a self-care book and advice to exercise in one lower-quality trial (level of evidence: poor).
- Different methods for providing information in a self-care book were not associated
 with significant differences in pain or functional status, though a brief nurse education
 visit increased the proportion of patients who exercised in one higher-quality trial
 compared to providing the self-care book alone, and an experimental self-care book
 targeted at changing beliefs and behaviors reduced fear avoidance beliefs more than
- 652 a traditional self-care book in another higher-quality trial (level of evidence: fair).

653 *E-mail discussion groups*

One lower-quality trial found an e-mail discussion group intervention plus a self-care
 book and videotape superior to usual care for pain, disability, role function and health
 distress after one year in patients with chronic low back pain (level of evidence: poor).

657 Self-care exercise videotape

 One lower quality trial found no differences in functional status between videotaped exercise advice and face-to-face advice through 4 to 6 weeks in patients with back pain of unspecified duration, but videotaped advice was superior for short-term pain (level of evidence: poor).

662 Advice to restrict early morning flexion

 One lower-quality trial found that patients with chronic low back pain who were given advice to restrict early morning flexion reported better outcomes related to pain intensity and disability compared to those given sham exercise advice, but marked baseline differences make these findings unreliable (level of evidence: poor).

667 Lay-facilitated groups for self-care

- A four-session lay-led self-care group was associated with greater improvements in
 functional status (but not pain intensity) compared to usual care after 6 to 12 months
 in one lower-quality trial of patients with subacute low back pain (level of evidence:
- 671 poor).

672 Self-help tools for back surgery decisions

- One higher-quality trial found no differences in function between an interactive video
- 674 plus self-care book versus a self-care book alone for informing back surgery
- decisions even though a lower proportion of patients with herniated disc underwent
- 676 surgery. The video was associated with a lower proportion of patients with severe
- pain at one year, though there was no difference in rates of resolution of back or leg
- 678 pain (level of evidence: fair).

679 Self-care interventions

680 *Lumbar supports*

- There is insufficient evidence from one lower quality trial to determine whether lumbar
 supports are effective compared to no intervention (level of evidence: poor).
- There is conflicting evidence regarding the effectiveness of lumbar supports compared to other interventions (soft tissue massage, spinal manipulation, advice on lifestyle and bedrest, physiotherapy, acetaminophen, TENS, or usual care). Most comparisons were evaluated in only one lower-quality trial. The trials were mainly conducted in subjects with non-specific low back pain of varying or unspecified duration (level of evidence: poor).
- One higher-quality trial found that a lumbar support with a rigid insert was associated
 with superior global assessment of outcomes compared to a support without a rigid
 insert (level of evidence: fair).

692 *Mattresses*

- One higher-quality trial found that a firm mattress was less likely to lead to
 improvement in pain related disability and worsen pain while in bed compared to a
 medium-firm mattress in patients with chronic low back pain. There were no
 differences in other pain outcomes (level of evidence: fair).
- There was insufficient evidence to judge the relative effectiveness of other mattress
 types (level of evidence: poor).

699 Superficial heat or cold

- There is consistent evidence from three higher-quality trials that heat wrap therapy or a heated blanket is modestly superior to placebo or a non-heated blanket for shortterm pain relief and back-specific functional status in patients with acute or subacute low back pain (level of evidence: good).
- Heat wrap therapy was also modestly superior to analgesic medications for short term pain relief in one higher-quality trial of patients with acute low back pain (level of
 evidence: fair).

- Heat wrap therapy was superior to a self-care booklet, but not to exercise, in one
 higher-quality trial of patients with a mix of acute and subacute low back pain (level of
 evidence: fair).
- There is insufficient evidence (one lower-quality trial) to determine the efficacy of
- 711 superficial cold (level of evidence: poor).

712 Key Question 5.

- 713 Does referral from primary care providers to back specialty providers affect
- 714 patient outcomes? What are the outcomes for patients who are managed by
- 715 different types of care providers or by multidisciplinary or interdisciplinary
- 716 clinics?
- There is no direct evidence on the effects of referral from primary care to back
 specialty providers on patient outcomes, though evidence on the effects of certain
 interventions offered by specialty providers is reviewed elsewhere.
- One recent large, high-quality trial found medical care and chiropractic care associated with similar patient outcomes. Observational data also suggests no significant differences for back pain episodes managed by different provider types, though patterns of care varied (level of evidence: fair).
- 724 Key Question 6.
- 725 What is the diagnostic accuracy and potential harms associated with diagnostic
- 726 tests for identifying patients who will benefit from invasive procedures such as
- 727 provocative discography, diagnostic nerve blocks, or other similar tests? Does
- 728 prior use of these tests improve outcomes from invasive procedures?

729 **Provocative discography**

- Positive responses to provocative discography were uncommon in small series of healthy, asymptomatic volunteers (level of evidence: fair).
- In patients without significant back pain, provocative discography was frequently associated with positive pain responses in small series of patients with chronic pain at other sites, those with somatization, those with previous disc surgery, and those disabled or seeking monetary compensation (level of evidence: fair).
- Incorporating pressure criteria into the definition for a positive response did not
 eliminate positive results in high-risk sub-groups of patients without significant low
 back pain in one small study (level of evidence: fair).

- Previous back surgery, chronic pain, and abnormal psychometric testing were also
 associated with increased rates of positive discography in small series of patients with
 chronic back pain (level of evidence: fair).
- One higher-quality cohort study found that relative to the rate of successful surgery
 for single-level isthmic spondylolisthesis, the rate of successful surgery for presumed
 discogenic back pain (based on provocative discography) was 43-44% in a highly
 selected population of patients without comorbidities (level of evidence: fair).
- In one lower-quality observational study, surgery outcomes were similar with or
 without the use of provocative discography to select patients (level of evidence: poor).
- Discitis appears rare with or without antibiotics. Other serious adverse events also appear rare. In one study, persistent pain was reported in patients with somatization or chronic pain at other sites (level of evidence: fair).

751 Diagnostic selective nerve root blocks

There are no studies evaluating the impact of diagnostic selective nerve root blocks
 on clinical outcomes relative to non-invasive methods alone for evaluating suspected
 nerve root compression.

755 **Diagnostic facet joint blocks**

- There are no studies evaluating the impact of facet joint blocks on clinical outcomes
 in patients with prolonged non-specific low back pain.
- Evidence on interventions targeted at facet joint pain is outlined in key question 7. In
 all trials of facet joint interventions, patients were enrolled based on positive
 diagnostic facet joint blocks.

761 Key Question 7.

- 762 What is the effectiveness of injections (and different injection interventions) for
- 763 non-specific low back pain, radicular low back pain, or spinal stenosis, and under
- 764 what circumstances?

765 Injections

766 *Chemonucleolysis*

- Chemonucleolysis with chymopapain was consistently superior to placebo in five
 higher-quality trials of patients with prolapsed lumbar disc (level of evidence: good).
- There is insufficient evidence to accurately judge the efficacy of chemonucleolysis
- with collagenase relative to placebo (one lower-quality trial) (level of evidence: poor).

- Chemonucleolysis was consistently associated with trends towards worse outcomes
 relative to standard discectomy in five lower-quality trials, and led to subsequent
 surgery in about 30% of cases (level of evidence: fair).
- Chemonucleolysis with chymopapain and intradiscal steroid injections were
 consistently associated with similar outcomes in three lower-quality trials (level of
 evidence: fair).
- One lower-quality trial found no differences between chemonucleolysis with
 chymopapain and spinal manipulation after one year, though manipulation was
 superior at short-term (through 6 weeks) follow-up (level of evidence: poor).
- Chemonucleolysis with chymopapain and collagenase were associated with similar pain outcomes in two lower-quality trials (one with five year follow-up), but chymopapain was associated with a trend towards reduced rate of subsequent surgery in one trial (level of evidence: fair).
- Chemonucleolysis with chymopapain is associated with mild allergic reactions in up to
 12% of patients, though reporting of allergic reactions was suboptimal. Serious
 complications appear uncommon (level of evidence: poor).

787 Epidural steroid injections

- Evidence of beneficial effects following epidural steroid injections by interlaminar or caudal approaches in patients with sciatica is mixed, with some studies showing short-term benefits, but most trials (including two larger, high-quality trials) reporting no longer-term benefits. Most evidence is in patients with symptoms of at least one month's duration (level of evidence: fair).
- There is insufficient evidence (one lower-quality trial showing no benefit) to accurately
 judge the efficacy of epidural steroids in patients with low back pain without sciatica
 (level of evidence: fair).
- One higher-quality trial found that epidural steroids have no sustained effects on
 walking distance relative to a placebo injection in patients with spinal stenosis (level
 of evidence: fair).
- In one higher-quality randomized trial, epidural steroid injection was no better than trigger point injections at one month for overall outcomes, though modestly superior at three months. Other trials comparing epidural steroids and local injections were either not randomized or did not clearly inject tender points (level of evidence: fair).
- Epidural steroid injections were not clearly superior to intramuscular steroids for longterm outcomes (level of evidence: fair).
- One higher-quality trial reported inferior outcomes with epidural steroid injection alone versus epidural adhesiolysis in patients with chronic back pain who previously failed an epidural injection, but reported high rates of response in the adhesiolysis group and unusually low rates in the epidural arm (0%) (level of evidence: fair).

- There is insufficient evidence (one lower-quality trial for each comparison) to
 accurately judge the relative efficacy of epidural steroids compared to dry-needling or
 discectomy (level of evidence: poor).
- Several trials have found no clear differences between transforaminal and other
 approaches for administering epidural steroids, but lack of radiologic confirmation of
 epidural placement for the other approaches limits their interpretation (level of
 evidence: poor).
- One higher-quality trial found no differences between caudal epidural steroid and targeted steroid placement during spinal endoscopy, with needle placement confirmed by fluoroscopy for both methods (level of evidence: fair).

819 Facet (zygapophysial) joint injections

- Evidence from two randomized trials indicates that facet joint injections are not beneficial for short-term pain relief in patients with chronic low back pain, though there was a trend towards modestly superior sustained pain relief in the single higherguality trial of patients with chronic low back pain (level of evidence: fair).
- Two trials (one higher-quality) found no difference between facet joint injections and medial branch block.
- There is no evidence on efficacy of facet joint injections for acute low back pain.

827 Intradiscal steroid injections

- There is consistent evidence from three low quality trials that intradiscal steroids are not associated with improved outcomes compared to control injections in patients with chronic low back pain with positive results on provocative discography (level of evidence: fair).
- One low quality trial found that intradiscal steroids are superior to discography alone
 in a selected subgroup of patients that failed epidural steroid injections and had
 inflammatory changes on MRI (level of evidence: poor).
- Three lower-quality trials found no differences between intradiscal steroid injection
 and chemonucleolysis in patients with prolapsed lumbar disc or sciatica (level of
 evidence: fair).
- None of the trials reported safety outcomes.

839 Local injections

- There is consistent evidence from three lower quality trials that trigger point injection
 with a local anesthetic is superior to saline injection for short-term pain relief in
 patients with subacute or chronic low back pain (level of evidence: fair).
- There is no evidence on long-term pain relief.
- One low-quality trial found trigger point injection inferior to a dry needle acupuncture stick (level of evidence: poor).
- Using a steroid in place of a local anesthetic or adding a steroid to a local anesthetic did not result in superior outcomes in one higher-quality trial (level of evidence: fair).

See section on epidural steroids for comparison between local injections and trigger
 point injections.

850 **Prolotherapy**

- There is conflicting evidence on the efficacy of prolotherapy versus control injections for chronic low back pain from three higher-quality trials (level of evidence: fair).
- There is no evidence in patients with acute low back pain.
- Serious adverse events have not been reported following prolotherapy treatments,
- though nearly all patients report increases in back pain (level of evidence: fair).

856 Sacroiliac joint injection

One higher-quality but very small trial found sacroiliac joint steroid injection superior
 to local anesthetic injection for short-term pain relief in patients thought to have non spondylarthropathic sacroiliac pain (level of evidence: poor).

860 Botulinum toxin

- A single, small, higher-quality trial found botulinum toxin injection superior to saline
 injection for short-term pain relief and improvement in functional status in patients
 with chronic low back pain who failed to respond to standard treatments (level of
 evidence: fair).
- There is no evidence comparing botulinum toxin injection to other interventions.
- There is no evidence on effectiveness of botulinum toxin injection in patients with
 acute low back pain.
- There is insufficient evidence to judge safety of botulinum toxin in patients with low
 back pain, though one case of fatal anaphylaxis has been reported.

Radiofrequency denervation, intradiscal electrothermal therapy, and precutaneous intradiscal radiofrequency thermocoagulation

872 *Radiofrequency denervation*

- The evidence on the efficacy of radiofrequency denervation of the medial branch of the primary dorsal ramus in patients with a positive facet joint block is mixed, with two of three higher quality trials showing no benefits compared to sham or control injection, even in highly selected populations (level of evidence: fair).
- Radiofrequency denervation was not effective in one higher quality trial of highly
 selected patients with chronic radicular pain and a positive nerve block (level of
 evidence: fair).
- Radiofrequency denervation of the ramus communicans nerve was superior to sham
 in patients with positive discography in one lower-quality trial (level of evidence: poor).
- Adverse events were poorly reported, but serious adverse events have not yet been observed following radiofrequency denervation.

884 Intradiscal electrothermal therapy (IDET)

- There is conflicting evidence from two higher-quality trials on the efficacy of IDET relative to sham in patients with chronic low back pain with positive provocative discography. In the one trial reporting benefits from IDET, benefits were modest despite the evaluation of a highly selected population (level of evidence: fair).
- Complications associated with IDET were poorly reported but generally appeared
 mild or transient, though there are case reports of cauda equina syndrome and
 vertebral osteonecrosis after IDET (level of evidence: poor).

892 *Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)*

- One small, low-quality trial found no differences between percutaneous intradiscal
 radiofrequency thermocoagulation and sham in patients with a positive response to
 analgesic discography (level of evidence: poor).
- There is insufficient data to judge the safety of PIRFT.

897 Key Question 8.

- 898 What is the effectiveness of surgery (and different surgical interventions) for non-
- 899 specific low back pain, radicular low back pain, or spinal stenosis, and under
- 900 what circumstances?
- 901 Efficacy of surgery versus non-surgical management

902 Non-specific, degenerative low back pain

- In patients with chronic low back pain due to other degenerative conditions, two highquality trials indicate that spinal fusion surgery is no better than intensive
 rehabilitation plus a cognitive intervention, but a third trial found surgery superior to
 conventional physical therapy (level of evidence: fair).
- Evidence regarding the efficacy of instrumented versus non-instrumented fusion is inconsistent, though clinical outcomes are similar after excluding two lower-quality trials reporting better outcomes and pooling data from the remaining five trials (level of evidence: fair).
- Evidence regarding the efficacy of anterior, posterior, or combined fusion from four trials is inconsistent and does not permit reliable judgments about relative efficacy (level of evidence: fair).
- Electrical stimulation may improve fusion rates in non-instrumented (but not instrumented) fusion, but didn't have a clear effect on clinical outcomes in three trials (level of evidence: fair).
- Artificial disc replacement with the Charite artificial disc was equivalent to anterior
 interbody fusion with a stand-alone cage for a combined measure of success at 24

- months in the only completed (higher-quality) trial. There were no differences in pain
 relief, functional status, of employment status at 24 months, though earlier results
- 921 favored artificial disc replacement (level of evidence: fair).
- Early complications following spine surgery occur in up to about 20% of patients. Inhospitality mortality after spine surgery occurs in about 0.2%, deep wound infection in
 1.5%, deep vein thrombosis in 1.6%, pulmonary embolus in 2.2%, and nerve injury in
 2.8% for nerve injury (level of evidence: fair).
- Complications from spinal fusion were higher with more technically difficult methods
 in one trial (level of evidence: fair).
- Rates of complications were similar after artificial disk replacement and fusion in one
 higher-quality trial (level of evidence: fair).
- Trials of surgery versus non-surgical management generally included patients who did not have clear indications for surgery (such as progressive or severe neurologic deficits or severe, intractable pain), failed to improve after 6 months to 2 years of conservative management, and had disease localized to L4-L5 and/or L5-S1.
- 934 Spinal stenosis, lumbar disc prolapse, and isthmic spondylolisthesis
- In patients with spinal stenosis and lumbar disc prolapse, consistent evidence from single RCTs and good-quality observational studies indicates that standard initial surgical therapy (decompression or discectomy, respectively) is associated with improved outcomes after one year compared to initial non-surgical therapy (or delayed surgery), but differences in outcomes are attenuated after 4 to 10 years of follow-up (level of evidence: fair).
- There is insufficient evidence from single low quality trials to judge the efficacy of
 surgery versus non-surgical management for mild isthmic spondylolisthesis (level of
 evidence: poor).
- There is insufficient evidence from one lower-quality trial to judge the efficacy of an interspinous spacer device for spinal stenosis (level of evidence: poor).
- Standard discectomy was consistently superior to chemonucleolysis in five lowerquality trials (level of evidence: fair).
- There is insufficient evidence (one lower-quality trial) to accurately judge the relative
 efficacy of epidural steroids compared to discectomy (level of evidence: poor).
- In patients with spinal stenosis, one lower-quality trial found no differences between
 laminectomy versus multiple laminotomy and three trials found no difference between
 postero-lateral fusion (with or without instrumentation) versus decompression alone
 (level of evidence: poor to fair).

- In patients with isthmic L5/S1 spondylolisthesis, one trial found no difference between
 patients undergoing fusion alone versus fusion plus laminectomy and decompression
 (level of evidence: fair).
- In patients with lumbar prolapse, there are no clear differences between standard discectomy and microdiscectomy or discectomy using different interposition
 membranes (level of evidence: fair).
- There is mixed evidence from two trials on the efficacy of automated percutaneous
 discectomy versus microdiscectomy, with one trial reporting similar outcomes and the
 other (using different techniques) poorer outcomes (level of evidence: poor).
- There is insufficient evidence to judge the efficacy of laser discectomy relative to other surgical methods (level of evidence: poor).
- 965 Key Question 9.
- 966 What is the effectiveness of other modalities (such as TENS or spinal cord
- 967 stimulation) for non-specific low back pain, radicular low back pain, or spinal
- 968 stenosis, and under what circumstances?

969 Transcutaneous electrical nerve stimulation (TENS)

- There is conflicting evidence regarding the efficacy of TENS versus sham TENS for
 patients with non-specific chronic low back pain, though the sole higher-quality trial
 found no benefit (level of evidence: fair).
- There is consistent evidence from four trials that TENS is not superior to acupuncture
 in patients with chronic low back pain (level of evidence: fair).
- Evidence regarding the efficacy of TENS to other interventions in patients with
 chronic low back pain is limited to single trials of traction (traction superior), massage
 (TENS superior), and ice massage (no differences) (level of evidence: poor).
- TENS was no better than sham TENS and inferior to spinal manipulation in two lowerquality trials of patients with subacute low back pain (level of evidence: fair).
- TENS is associated with skin irritation that is usually minor (level of evidence: fair).

981 **Percutaneous electrical nerve stimulation**

- PENS was superior to sham PENS in two lower-quality trials of patients with chronic
 low back pain for pain outcomes. In the only trial assessing outcomes after the end of
 treatment, pain benefits were present after two months, but there was no effect on
 functional outcomes (level of evidence: fair).
- PENS was superior to TENS and a minimal exercise intervention for pain and functional outcomes in one lower-quality trial of patients with chronic low back pain at the end of treatment, but in the only trial evaluating longer-term outcomes, no benefits were present after two months (level of evidence: poor).

- PENS was superior to sham PENS and TENS for pain and functional outcomes in one lower-quality trial of patients with sciatica, but outcomes were only assessed immediately after a two-week course of treatment (level of evidence: poor).
- There is insufficient evidence to accurately judge the safety of PENS.

994 Spinal cord stimulation

- Low-quality evidence from multiple case series found that approximately half of patients with chronic back and leg pain or failed back surgery syndrome had decreased pain after spinal cord stimulator implantation, and 40% were returned to work. However, the lack of higher-quality evidence severely limits confidence in these estimates (level of evidence: poor).
- Spinal cord stimulation is associated with frequent complications, especially related to electrode or lead problems. Although most complications appear minor, infections (6% of complications) and cerebrospinal fluid leak (7%) have been reported (level of evidence: poor).
- 1004 Key Question 10.
- 1005 Which combinations of therapies are effective for acute low back pain? Chronic
- 1006 low back pain?

1007 **Combinations of medications**

- There is consistent evidence from three higher-quality trials that tizanidine combined with acetaminophen or an NSAID is associated with greater short-term pain relief and decrease of muscle spasm in patients with acute low back pain (level of evidence: good).
- One higher-quality trial found no benefits from adding orphenadrine to acetaminophen
 in patients with acute low back pain, though the combination was associated with
 fewer disability days (level of evidence: fair).
- One lower-quality trial found no benefits from adding cyclobenzaprine to an NSAID in patients with acute low back pain (level of evidence: poor).
- There is insufficient evidence from one trial (doses unclear) to judge the efficacy of opioids plus an NSAID versus an NSAID alone (level of evidence: poor).
- Adding a muscle relaxant to acetaminophen or an NSAID was associated with an increased risk of central nervous system adverse effects (level of evidence: good).
- 1021 Self-care advice combined with other interventions
- Two trials (one higher-quality) found that a self-care book plus advice plus exercise therapy was superior to the self-care book and advice alone. One trial was in patients with back pain for less than 6 weeks and the other in patients off work for less than one year due to back pain (level of evidence: fair).

- Two trials (one higher-quality) found that adding face-to-face advice to a self-care
 book did not improve patient outcomes, though one of the trials found that self reported exercise and patient satisfaction was higher (level of evidence: fair).
- There is insufficient evidence to judge the efficacy of a self-care book plus
 interferential therapy relative to a self-care book alone (one lower-quality trial) (level
 of evidence: poor).

1032 Exercise combined with other interventions

The addition of exercise to other non-invasive interventions is associated with modest improvements in pain (about 5 points on a 100 point scale) and function (about 2 points on a 100 point scale) in a large meta-regression (level of evidence: good).

1036 Acupuncture combined with other non-invasive interventions

- In four higher-quality trials, acupuncture was associated with moderate beneficial
 effects on pain and function through 12 months when combined with a variety of other
 non-invasive intervention compared to the other intervention alone (level of
 evidence: good).
- There is insufficient evidence to judge the effects of acupuncture added to other
 interventions in patients with acute low back pain (one lower-quality trial) (level of
 evidence: poor).

1044 Spinal manipulation combined with other interventions

- Compared to exercise therapy alone, the addition of spinal manipulation was not associated with significant benefits in a recent, large, lower-quality trial (level of evidence: fair).
- The combination of spinal manipulation plus exercise and a brief intervention (physician consultation) was associated with modest long-term differences in pain but not function relative to physician consultation alone in one higher-quality trial (level of evidence: fair).

1052 Massage combined with other interventions

Compared to exercise and education alone, the addition of massage therapy was
 associated with moderate short-term benefits for pain and disability in patients with
 subacute low back pain.

1056 Behavioral therapy combined with other interventions

- Behavioral interventions were consistently ineffective for improving outcomes when
 added to a variety of other interventions in six lower-quality trials of patients with
 chronic low back pain. Diversity in both the behavioral and non-behavioral
- 1060 interventions may limit the generalizability of these findings (level of evidence: fair).

- Behavioral interventions were consistently ineffective for improving outcomes when
 added to a variety of other interventions in six lower-quality trials of patients with
- 1063 chronic low back pain. Diversity in both the behavioral and non-behavioral
- 1064 interventions may limit the generalizability of these findings (level of evidence: fair).

1065 Traction combined with other interventions

Traction plus physical therapy was no better than physical therapy alone in one small,
 lower-quality trial (level of evidence: poor).

1068 Key Question 11.

1069 What are effective strategies for failed back surgery syndrome?

1070 Adhesiolysis

- Although one higher-quality trial found adhesiolysis markedly superior to epidural steroids for pain relief in patients with refractory back pain who failed a previous epidural steroid injection, confirmation of results by other trials is necessary because of the extremely low (0%) response rate in the epidural steroid group (level of evidence: fair).
- There is no clear evidence that use of hypertonic saline or hyaluronidase improves outcomes from adhesiolysis compared to using isotonic saline alone (level of evidence: fair).
- Adverse events were infrequent and usually minor in the trials, but were more
 common and included suspected infection, subarachnoid puncture, and post-dural
 headache in up to 9-14% of patients in observational studies (level of evidence: fair).

1082 Intrathecal therapy

- There is insufficient data to judge the efficacy of intrathecal therapy in patients with
 failed back surgery syndrome (limited observational studies only) (level of
 evidence: poor).
- Adverse events with intrathecal therapy appear to be frequent and often require surgery (level of evidence: poor).

1088 Non-invasive interventions

One lower-quality trial found no significant differences in immediate post-treatment
 ODI scores between exercise, physical agents, manipulation, and no treatment in
 patients with chronic low back pain following L5 laminectomy (level of evidence:
 poor).

1093 Spinal cord stimulation

- One small RCT found that spinal cord stimulation was associated with a higher
 likelihood of pain relief and lower likelihood of increase in opioid use in patients with
 failed back surgery syndrome, but results are difficult to interpret because of a high
 rate of crossovers (level of evidence: fair).
- Other evidence (low-quality observational data) is inadequate to make reliable judgments about efficacy.
- Long-term complications after spinal cord stimulation have not been well-studied, but
 include infection and generator or lead-associated problems.

1102 Key Question 12.

1103 How effective are different methods of integrating and coordinating care in

1104 improving outcomes?

- Coordination of care was superior to usual care for improving functional status and pain after 6 months while reducing use of specialized imaging tests in workers
 receiving short-term (4 to 8 weeks) compensation for low back pain in one lower quality trial (level of evidence: poor).
- There is insufficient evidence to judge the efficacy of coordination or integration of care in other (primary care) settings (one low quality trial) (level of evidence: poor).

1111 Key Question 13.

- 1112 What interventions are effective for secondary prevention of LBP in patients who
- 1113 have had an episode of acute LBP, or prevention of flares of LBP in patients with
- 1114 chronic LBP?

1115 Back schools

Evidence on the efficacy of back schools for preventing recurrent episodes of low back pain is mixed, which may be due in part to diversity between populations and interventions evaluated. One higher-quality trial found that an intensive back school intervention decreased recurrent episodes of low back pain more than no back school through three years of follow-up, but another evaluating a 'mini' back school found no clear effect. Three shorter-term (1 year) trials (one higher-quality) also found no effect (level of evidence: fair).

One lower-quality trial found back school inferior to calisthenic exercises for reducing
low back pain episodes through 12 months (level of evidence: poor).

1125

1126 **Exercise**

- There is consistent evidence from two lower-quality trials that an exercise program is
 superior to education only for reducing long-term low back pain recurrences (level of
 evidence: fair).
- There is insufficient evidence (one very low-quality trial) to judge the efficacy of an ongoing exercise program for reducing future episodes of low back pain (level of evidence: poor).

1133 Lumbar supports

• No trials have evaluated the efficacy of lumbar supports for secondary prevention.

1135 Advice to stay active

- One higher-quality trial found no difference in long-term (through 3 years) recurrences
- in patients on sick leave for low back pain randomized to a single spine clinic examand advice to stay active versus usual care (level of evidence: fair).

1139 Early occupational medicine intervention

An early occupational medicine intervention was associated with a greater likelihood
 of lower back pain recurrences in one higher-quality trial (level of evidence: fair).

1142 Behavioral interventions, multidisciplinary rehabilitation, spinal

1143 manipulation, acupuncture, patient information or education

- There is no evidence on the effects of behavioral interventions, multidisciplinary disciplinary rehabilitation, spinal manipulation, and acupuncture on recurrent back pain episodes
- 1147

1148 Key Question 14.

- 1149 What is/are safe and effective strategies for managing low back pain during
- 1150 pregnancy and post-partum?

1151 Acupuncture during pregnancy

- Three lower-quality trials found acupuncture more effective than usual care (2 trials)
 or exercise (1 trial) for improving pain and function in pregnant women with low back
 pain (level of evidence: fair).
- 1155 **Physical therapy during pregnancy**
- One higher-quality trial found water gymnastics superior to usual care for treating
 back pain in pregnant women (level of evidence: fair).
- Individualized physiotherapy was superior to usual care in two lower-quality trials
 (level of evidence: fair).

- Evidence on efficacy of group education and exercise was mixed, with one of three lower-quality trials finding group education and exercise superior to usual care in only one of three lower-quality trials (level of evidence: poor).
- A pelvic tilt exercise was associated with decreased pain in one lower-quality trial of
 pregnant women with low back pain, but also lower birthweight and earlier (full-term)
 onset of labor (level of evidence: poor).

1166 Massage during pregnancy

- Although two lower-quality trials found that massage therapy decreased pain scores in pregnant women, effects appeared modest and it was not clear if the differences were significant relative to usual care or progressive relaxation (level of evidence: poor).
- 1171 Supportive devices during pregnancy
- There is insufficient evidence from one lower-quality trial to determine the efficacy of
 the Ozzlo pillow versus standard pillows in pregnant women with low back pain (level
- 1174 of evidence: poor).
- 1175 Key Question 15.
- 1176 What is the cost-effectiveness associated with different interventions or
- 1177 management strategies (such as care provided by different types of providers) for
- 1178 managing low back pain?
- We identified four recent systematic reviews on cost-effectiveness of different
- 1180 interventions or management strategies in patients with low back pain. All concluded
- 1181 that current economic analyses are insufficient for determining the most cost-effective
- 1182 interventions. Individual cost studies are summarized separately elsewhere for each
- 1183 of the interventions reviewed in this report.

GUIDELINE FOR THE MANAGEMENT OF

Low Back Pain

Draft Evidence Review

Roger Chou, MD Laurie Hoyt Huffman, MS

Sponsored by:

The American Pain Society & The American College of Physicians



TABLE OF CONTENTS

Introduction	1
Purpose	1
Background	1
Previous Guidelines	2
Scope of Evidence Review	5
Key Questions	5
Populations	6
Interventions	7
Outcomes	9
Conflict of Interest	10
Methods	10
Literature Search and Strategy	10
Inclusion/Exclusion Criteria	11
Data Extraction and Synthesis	11
Assessing Research Applicability	13
Rating a Body of Evidence	13
Size of Literature Reviewed	14
Results	15
Key Question 1 - What features of the history and physical exam are predictive of specific serious underlying conditions ("red flags"), other specific conditions that may be responsive to specific therapies in patients with LBP (such as nerve root compression or spinal stenosis), or high risk for persistent low back pain and associated disability ("yellow flags")?	15
Key Question 2 - What diagnostic tests should be ordered, and under what circumstances, for patients with LBP?	27
Key Question 3 - What is the effectiveness of different non-invasive interventions for non-specific low back pain, radicular LBP, or spinal stenosis, and under what circumstances?	40
Key Question 4 - What is the value of different patient education or patient self-care methods for improving patient outcomes?	124

D
2
3
1
5
1
1
3
)
7
3
3
5

APPENDICES

Appendix 1:	Search Strategies – Systematic Reviews	280
Appendix 2:	Search Strategies – Primary Studies	281
Appendix 3:	Criteria for Assessing Scientific Quality of Research	
	Reviews	286
Appendix 4:	Criteria List for the Methodological Quality Assessment	288
Appendix 5:	List of Relevant Systematic Reviews	290

1 TECHNICAL REPORT – EVIDENCE REVIEW

2 Introduction

3 **Purpose of this report**

This evidence review focuses on evaluation and management of low back pain in adults. The American Pain Society (APS), which commissioned this report, will use it in partnership with the American College of Physicians (ACP) to develop evidence-based recommendations for low back pain.

8 Background

9 Low back pain is an extremely common problem, with a point prevalence in 10 developed countries of up to 33%, one-year prevalence up to 65%, and lifetime 11 prevalence up to 84%, though estimates vary widely [1]. In the U.S., nonspecific 12 mechanical low back pain is the fifth most common reason for all physician visits, and 13 the second most common symptomatic reason [2]. In one study, 7.6% of U.S. adults 14 randomly surveyed by telephone had at least one occurrence of severe acute low back 15 pain during a one-year period, with 39% of those seeking medical care for the 16 episode [3].

17 Low back pain is also very costly, with estimates of total annual cost in the U.S. 18 ranging from \$20 to \$50 billion [4]. Much of the cost is associated with days lost from 19 work. In the U.S., low back pain is the most common cause for chronic or permanent 20 impairment in persons under the age of 65, and the most common cause of activity 21 limitations in persons under the age of 45 [5]. It has been estimated that between 2% 22 and 8% of the U.S. work force is disabled or compensated for back injuries each year 23 [5, 6]. Treatments costs are also large and growing. Medical treatment for chronic low 24 back pain is estimated to cost \$9000 to \$19,000 per patient annually, and interventional 25 treatments cost a minimum of \$13 billion in 1990 [6].

Many patients with acute episodes of low back pain do not seek care because symptoms are often brief and self-limited. Among those who do seek medical care, rapid improvements in pain (average improvement of 58% of initial score), disability (average improvement of 58%), and return to work (82% of those initially off work return to work) are seen in the first month [7]. Further improvement generally continues until

31 approximately three months, after which levels for pain, disability, and return to work 32 appear to remain relatively constant. Up to one-third of patients report persistent back 33 pain of at least moderate intensity one year after an acute episode requiring care, and 34 one in five report substantial activity limitations [8]. Recurrences of pain also are 35 common, with 60% to three-quarters of patients experiencing at least one relapse within 36 12 months [7, 9]. Prolonged disability may be more frequent than previously suspected: 37 in one systematic review of 36 studies on the course of low back pain in the general 38 population, 16% (range 3% to 40%) of patients were sick-listed 6 months after entry into 39 the study [9]. Factors associated with the development of chronic disability due to low 40 back pain include pre-existing psychological distress, presence of other types of chronic 41 pain, job dissatisfaction or stress, and disputes over compensation issues [10].

42 Many options are available for the evaluation and management of acute or 43 chronic low back pain. However, there has been little consensus, either within or 44 between specialties, on appropriate uses of diagnostic tests [11] and interventions [12]. 45 This is demonstrated by numerous studies showing unexplained variations in use of 46 diagnostic tests and treatment. In an international comparison, for example, the rate of 47 back surgery in the U.S. was over five times higher than the rate in the U.K. [13]. Within 48 Washington State, rates of back surgery varied up to 15-fold among different counties 49 [14]. Despite wide variations in practice, several studies have shown that patients 50 experience broadly similar outcomes, though costs of care can differ substantially both 51 between and within specialties [15, 16]. In addition to unexplained practice variations, 52 another historical feature of low back pain management has been the widespread 53 uptake and use of unproven (and sometimes invasive and costly) interventions, some of 54 which have later been shown to be ineffective, or even harmful [17]. Other interventions 55 are widely used despite studies showing only marginal benefits [18].

56 Previous guidelines

57 The Quebec Task Force on Spinal Disorders published one of the first evidence-58 based clinical practice guidelines for management of low back pain in 1987 [19]. This 59 early attempt at using an explicit scientific basis for issuing management 60 recommendations found insufficient evidence to support the use of most common 61 diagnostic procedures and treatment modalities. In 1994, a multidisciplinary expert 62 panel convened by the U.S. Agency for Health Care and Policy Research (AHCPR)

63 issued its recommendations on management of acute low back pain [20]. The 64 approach recommended by the AHCPR guidelines emphasize history taking and 65 physical examination to exclude 'red flag' symptoms suggestive of serious underlying pathology; targeted physical examination focusing on neurologic screening; diagnostic 66 67 triage into broad categories including nonspecific low back pain, radicular syndrome, or 68 specific pathology (which were felt to be diagnosable in only a small minority of cases); 69 judicious use of diagnostic imaging; and consideration of psychosocial factors when 70 there is no improvement. Despite an exhaustive literature search and review, none of 71 the 40 recommendations made for clinical care were viewed as supported by strong 72 research evidence, and only six were judged as having at least a moderate evidence 73 base. At the time, the AHCPR guidelines were subject to intense criticism and scrutiny, 74 in part because they recommended more conservative initial management for most 75 acute low back problems [21]. Nonetheless, nearly all multidisciplinary guidelines published since 1994 have recommended an approach similar to the AHCPR guidelines 76 77 [22].

78 There are now at least 11 international guidelines for management of low back 79 pain. Most of their diagnostic and therapeutic recommendations are similar [22]. 80 However, there are some discrepancies, particularly with regard to recommendations 81 for exercise therapy, spinal manipulation, use of muscle relaxants, and provision of 82 patient information. These differences may in part reflect contextual differences 83 between countries that can affect interpretations of the evidence and how the trade-offs 84 between benefits, side effects, and costs are weighted [23]. In addition, a systematic 85 review of 17 primary care guidelines found areas in which the overall quality of 86 guidelines could be improved, including better descriptions of how the evidence was 87 identified, selected and summarized; more attention to patient preferences; increased 88 consideration of how guidelines could be implemented; better use of external peer 89 review; and more transparent descriptions of editorial oversight and potential conflicts of 90 interests [24].

The effects of evidence-based clinical practice guidelines on outcomes in
patients with low back pain are difficult to assess. However, several trials evaluating
outcomes associated with the selective imaging approach recommended in nearly all
guidelines are now available (see Results, Key Question 2d). In addition, an

95 observational study from Australia found that back care based on guidelines and 96 provided in multidisciplinary clinics was associated with improved pain scores after 12 97 months, decreased use of imaging and opioid medications, greater patient satisfaction, 98 and decreased health care costs compared to usual care provided in general practice 99 clinics, though one problem interpreting this study is that the multidisciplinary clinic itself 100 may have had an effect [25]. Another observational study found that a mass-media 101 campaign in the state of Victoria, Australia based on evidence-based guidelines 102 (encouraging normal activities and exercising, remaining at work, and providing positive 103 messages about likelihood of recovery) and aimed at altering back pain beliefs was 104 associated with a decline in the number of claims for back pain, rates of days 105 compensated, and medical payments for low back pain claims compared to a 106 neighboring state without such a campaign [26]. A U.S. trial found that randomization of 107 communities to an educational intervention regarding an evidence-based approach to 108 low back pain as recommended in national guidelines resulted in a decline in the rate of 109 surgery by about 9% compared to usual care [27].

110 The American Pain Society, in partnership with this American College of 111 Physicians, initiated this project to systematically review the current state of evidence 112 and develop updated recommendations for management of acute and chronic low back 113 pain using an evidence-based, balanced, and multidisciplinary approach. Throughout 114 this evidence report, we highlight previous recommendations and findings from the 115 AHCPR guidelines. We also summarize recommendations from two more recent 116 guidelines from the U.S. and the U.K.: A federally funded U.S. guideline issued by the 117 Veterans Affairs/Department of Defense (VA/DoD) in 1999 [28] and the U.K. Royal 118 College of General Practitioners (RCGP) [29] guideline, which was initially released in 119 1996 and updated in 1999. The AHCPR, VA/DoD, and UK RCGP guidelines primarily 120 focus on acute low back pain, though some recommendations for evaluation and 121 treatment of persistent low back pain are included. A recent, multinational guideline 122 from Europe issued in 2004 (the European COST B13 guidelines) addresses both acute 123 and chronic low back pain, as well as prevention of back pain [30-32]. Both the AHCPR 124 and VA/DoD guidelines use a letter rating system to grade the strength of evidence for 125 recommendations, ranging from A (strong) to D (no adequate scientific studies). The UK RCGP guidelines use a star rating system, ranging from *** (generally consistent 126

- 127 finding in a majority of multiple acceptable studies) to * (no acceptable studies). The
- 128 European COST guidelines adopted the AHCPR method for grading evidence, but do
- 129 not explicitly grade the strength of recommendations.

130 Scope of evidence review

131 Key Questions

- 132 The Key Questions used to guide this evidence review were developed in
- 133 conjunction with a multidisciplinary expert panel convened by the American Pain
- 134 Society:
- 135 1. What features of the history and physical exam are predictive of specific serious 136 underlying conditions ("red flags"), other specific conditions that may be 137 responsive to specific therapies in patients with LBP (such as nerve root 138 compression or spinal stenosis), or high risk for persistent low back pain and 139 associated disability ("yellow flags")? 140 Does identification of 'yellow flags' lead to improved outcomes in patients with 141 LBP? 142 2. What diagnostic tests should be ordered, and under what circumstances, for 143 patients with LBP? 144 What is the diagnostic accuracy of different diagnostic tests for identifying 145 serious underlying conditions (e.g., tumor, infection, compression fracture)? 146 What is the diagnostic accuracy of different diagnostic tests for identifying 147 other conditions (e.g. nerve root compression, herniated disc, spinal stenosis) 148 that may respond to specific therapies? 149 • In patients with 'red flags,' how does the choice of diagnostic testing affect 150 clinical outcomes? 151 • In patients without 'red flags,' how does the choice of diagnostic testing (or no 152 testing) affect clinical outcomes? 153 3. What is the effectiveness of different non-invasive interventions for non-specific 154 low back pain, radicular LBP, or spinal stenosis, and under what circumstances? 155 Can decision tools predict which patients are more likely to respond to 156 specific therapies like physical therapy or chiropractic? 157 4. What is the value of different patient education or patient self-care methods for 158 improving patient outcomes?

159 160	5.	Does referral from primary care providers to specialty providers affect patient outcomes?
161 162		 What are the outcomes for patients who are managed by different types of care providers or by multidisciplinary or interdisciplinary clinics?
163 164 165 166	6.	What is the diagnostic accuracy and potential harms associated with diagnostic tests for identifying patients who will benefit from invasive procedures such as provocative discography and discogram, diagnostic nerve blocks, or other similar tests?
167		• Does prior use of these tests improve outcomes from invasive procedures?
168 169 170	7.	What is the effectiveness of injections (and different injection interventions) for non-specific low back pain, radicular low back pain, or spinal stenosis, and under what circumstances?
171 172 173	8.	What is the effectiveness of surgery (and different surgical interventions) for non- specific low back pain, radicular low back pain, or spinal stenosis, and under what circumstances?
174 175 176	9.	What is the effectiveness of other modalities (such as TENS or spinal cord stimulation) for non-specific low back pain, radicular low back pain, or spinal stenosis, and under what circumstances?
177 178	10.	Which combinations of therapies are effective for acute low back pain? Chronic low back pain?
179	11.	What are effective strategies for failed back surgery syndrome?
180 181	12.	How effective are different methods of integrating and coordinating care in improving outcomes?
182 183 184	13.	What interventions are effective for secondary prevention of LBP in patients who have had an episode of acute LBP, or prevention of flares of LBP in patients with chronic LBP?
185 186	14.	What is/are safe and effective strategies for managing low back pain during pregnancy and post-partum?
187 188 189	15.	What is the cost-effectiveness associated with different interventions or management strategies (such as care provided by different types of providers) for managing low back pain?
190	Popu	lations
191	Targe	t populations for this review are:
192	•	Adults (>18 years old)
193	•	Pregnant women

- Persons with hyperacute (defined as less than 1 week of symptoms), acute (less than 4 to 6 weeks), subacute (between 4 weeks and 3 months) or chronic (greater than 3 months) low back pain
- Persons with nonspecific low back pain (including discogenic pain, facet joint pain, spondylosis, degenerative disc disease, sacroiliac joint pain, etc.), radicular low back pain (including lumbar disc prolapse), spinal stenosis, and failed back surgery syndrome
- 201 Treatment of certain specific conditions (such as infection, cauda equina 202 syndrome, cancer, spondyloarthropathies, systemic inflammatory disease, fibromyalgia 203 syndrome, and vertebral compression fracture) was excluded from the scope of this 204 review, though evaluation to rule out such conditions was considered within the scope. 205 Evaluation and management of osteoporosis without clear fracture and acute major 206 trauma was also outside our scope. Children and adolescents were excluded because 207 diagnostic and therapeutic considerations are substantially different than in adults [33, 208 34].
- Low back pain presents as a continuum ranging from acute (often defined as less than 4 weeks in duration) to chronic (often defined as greater than three months in duration). Patients may present to providers at any stage on this continuum, have mixed presentation (e.g., chronic low back pain with an acute exacerbation), or unclear date of onset. In addition, many trials evaluate mixed populations of patients with different durations of symptoms. Therefore, we reviewed evidence on low back pain of any duration.
- 216 Interventions
- 217 Target interventions for this review are:
- 218 Non-invasive interventions
- 219 Medications
- 220 Acetaminophen
- 221 Non-selective non-steroidal anti-inflammatory drugs (NSAIDs)
- 222 Cyclo-oxygenase-2 selective NSAIDs
- 223 Aspirin
- 224 Skeletal muscle relaxants
- 225 Antidepressants

- 226 Opioid analgesics
- 227 Tramadol
- 228 Gabapentin
- 229 Systemic corticosteroids

230 Other non-invasive interventions

- 231 Herbal therapy
- 232 Brief educational interventions
- 233 Back schools
- 234 Exercise
- 235 Hydrotherapy
- 236 Spa therapy
- 237 Acupuncture
- 238 Acupressure
- 239 Neuroreflexotherapy
- 240 Spinal manipulation
- 241 Massage
- 242 Short wave diathermy
- 243 Interferential therapy
- 244 Ultrasound
- 245 Behavioral interventions
- 246 Multidisciplinary rehabilitation
- 247 Physical conditioning programs
- 248 Traction
- 249 Low-level laser
- 250 Self-care interventions (including advice for bed rest or on remaining active and self-251 care books)

252 Invasive, non-surgical interventions

- 253 Epidural steroid injections
- 254 Intradiscal steroid injections
- 255 Chemonucleolysis
- 256 Local injections
- 257 Facet (zygapophysial) joint injections

- 258 Prolotherapy (sclerosant injections)
- 259 Botulinum toxin
- 260 Adhesiolysis
- 261 Radiofrequency denervation
- 262 Intradiscal electrothermal therapy (IDET)
- 263 Percutaneous intradiscal radiofrequency thermocoagulation
- 264 Surgical interventions
- Fusion and vertebral disc replacement for degenerative conditions of the lumbarspine
- 267 Surgery for spinal stenosis and lumbar isthmic spondylolisthesis
- 268 Discectomy for lumbar disc prolapse

269 Outcomes

We selected target outcomes based on the five core domains for low back pain suggested in recent recommendations: back specific function, generic health status, pain, work disability, and patient satisfaction [35, 36]. The two most commonly used measures of back-specific function are the Roland Morris Disability Questionnaire (RDQ) and the Oswestry Disability Index (ODI) [37]. The RDQ is reported on a 0 to 24 scale and the ODI on a 0 to 100 scale. Improvements of 2-3 points on the RDQ and 10 points on the ODI have been proposed as minimal clinically important differences [38].

Studies usually evaluate generic health status with the Medical Outcomes Study
Short Form-36 (SF-36) or other multi-question assessments. These questionnaires
measure how well an individual functions physically, socially, cognitively, and
psychologically. The SF-36 measures 8 dimensions, each on a 0 to 100 scale [39].
The individual dimensions can also be combined into several commonly reported
subscales (such as the Physical Component Summary and Mental Component
Summary).

Most studies measure pain intensity using either visual analogue or categorical pain scales (using either numbers or a list of adjectives describing different levels of pain intensity) [40]. Visual analogue scales (VAS) usually consist of a line on a piece of paper labeled 0 at one end, indicating no pain, and a maximum number (commonly 10

288 or 100) at the other, indicating excruciating pain. Patients designate their current pain 289 level on the line. Categorical pain scales, on the other hand, consist of several pain 290 category options from which a patient must choose (e.g., no pain, mild, moderate, or 291 severe for a verbal rating scale, 0 to 10 for a numerical rating scale such as the Brief 292 Pain Inventory). Many studies also report the proportion of patients with "significant" 293 improvement in pain, often defined as at least a 20-point (or 20%) improvement on a 294 VAS[41]. The SF-36 bodily pain scale has been recommended as a preferred method 295 for reporting pain outcomes because it measures both pain intensity and interference 296 with activities [35].

Work status is often measured by employment status, days off work, or time
before returning to work. Patient satisfaction is usually assessed using a generic global
scale, though more formal methods have been developed. Some studies also report
effects of interventions on mood or the preference for one medication over another.
Whenever available, we reviewed evidence on adverse events and safety as well as
direct and indirect costs.

303 Conflict of Interest

The evidence review was conducted at the Oregon Evidence-based Practice Center with funding from APS. None of the investigators conducting this review (RC and LHH) had any known or potential conflicts of interest to disclose.

307 Methods

308 Literature Search and Strategy

309 We searched the topic of low back pain using multiple electronic databases. 310 Most searches were conducted from 1966 (the start date of MEDLINE) through July 311 2005. Periodic updates on the electronic searches were performed through March 312 2006. Because of the large body of evidence on low back pain, our strategy was to first 313 identify relevant systematic reviews for each Key Question. In addition to MEDLINE, we 314 searched the Cochrane Database of Systematic Reviews and the websites of the 315 Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 316 Bandolier, and the NHA Health Technology Assessment Programme. The detailed 317 search strategy for low back pain systematic reviews is presented in Appendix 1.

318 When high-quality systematic reviews for a particular topic were lacking or 319 required updating, we conducted targeted searches for primary studies using MEDLINE, 320 the Cochrane Central Register of Controlled Trials, EMBASE, Psycholnfo, CINAHL, and 321 PEDro (the latter three for appropriate topics). Examples of detailed search strategies 322 for primary studies are shown in Appendix 2.

Periodic hand searching of relevant medical journals, reviews of reference lists (particularly of relevant guidelines and systematic reviews), and expert suggestions supplemented the electronic searches. Abstracts were not included in systematic searches. Reviews, policy statements, and other papers with contextual value were also obtained.

328 Inclusion/exclusion Criteria

All identified citations were imported into an electronic database (EndNote® 9.0) and considered for inclusion. Papers were selected for full review if they were about low back pain, were relevant to a Key Question, evaluated a target population and intervention, and reported at least one relevant outcome (pain, back-specific functional status, generic health status, work status, patient satisfaction, or harms).

334 When a systematic review was not available for a particular topic, we included all 335 relevant randomized controlled trials and controlled clinical trials. We also included 336 recently published randomized trials to supplement older systematic reviews for 337 selected topics. We only reviewed controlled observational studies for topics where 338 sufficient clinical trials evidence is not available. Other observational studies (such as 339 uncontrolled case series) were excluded. Studies of cost were included if they were 340 conducted alongside a randomized trial or were a full economic analysis. Foreign 341 language papers were considered if they were clinical trials and an abstract was 342 available in English. Studies of non-human subjects and those without original data 343 were excluded.

344 Data Extraction and Synthesis

We used predefined criteria to assess the internal validity of included systematic reviews and trials. For each systematic review, we abstracted the following information: (1) purpose of the review, (2) databases searched, (3) dates of the searches, (4)

348 language restrictions, if any, (5) number of studies included, (6) criteria used to include 349 studies, (7) limitations of the included studies, (8) methods for rating the quality of 350 included studies, (9) methods for synthesizing the evidence, (10) the interventions 351 evaluated, (11) main efficacy outcomes, and (12) adverse events. We assessed the 352 internal validity (quality) of systematic reviews using the methods developed by Oxman 353 and Guyatt (Appendix 3) [42]. Each study was scored between 1 and 7 based on the 354 following criteria: comprehensiveness of search strategy; application of pre-defined 355 inclusion criteria to select studies; appropriate assessment of validity; and use of 356 appropriate methods to synthesize the evidence. Using this system, systematic reviews 357 with a score of four or less are considered to have potential major flaws and we 358 classified these as 'lower quality'. Systematic reviews with major flaws have been 359 shown to be more likely to produce positive conclusions about the effectiveness of 360 interventions [43, 44]. Systematic reviews with scores of five or higher were considered 361 'higher quality'.

362 For each clinical trial, we abstracted the following information: (1) study design, 363 (2) purpose of study, (3) inclusion and exclusion criteria, (4) number of patients 364 approached, eligible, and randomized, (5) demographics and baseline characteristics, 365 (6) setting, (7) funding source, (8) interventions evaluated, (9) main efficacy results, (10) 366 adverse events (including withdrawal due to adverse events), (11) duration of follow-up, 367 (12) loss to follow-up, and (13) compliance to treatment. We assessed the internal 368 validity of randomized clinical trials using the eleven predefined criteria proposed by the 369 Cochrane Back Review Group (see Appendix 4 for details on how we operationalized 370 the criteria) [45]. We rated the internal validity of each trial based on the methods used 371 for randomization, allocation concealment, and blinding; the similarity of compared 372 groups at baseline; the use of co-interventions; compliance to allocated therapy; 373 adequate reporting of dropouts; loss to follow-up; non-differential timing of outcome 374 assessment; and the use of intention-to-treat analysis. Trials were scored between zero 375 and eleven, according to the number of criteria were met. For certain interventions for 376 which blinding was unfeasible (such as surgery), we removed blinding of patient and 377 providers as quality criteria, so the maximum score was nine. Consistent with most 378 reviews conducted by the Cochrane Back Group [46, 47], we considered trials receiving

more than half of the total possible score 'higher-quality' and those receiving less thanhalf 'lower-quality'.

381 Several studies evaluating the rate of positive pain responses with discography in 382 patients without serious back pain (see Key Question 6) differed from typical studies of 383 diagnostic test accuracy because they did not compare results of one test to a reference 384 standard (no reference standard is available). We assessed the quality of these studies 385 using nine criteria adapted from methods developed by the U.S. Preventive Services 386 Task Force [48] or based on empiric studies [49, 50] of sources of variation and bias in 387 studies of diagnostic tests. We determined whether each study evaluated a 388 consecutive series of patients or a random subset, was prospective, evaluated patients 389 with a spectrum of symptoms, adequately described the discography technique, used 390 current discography techniques, adequately described criteria for a positive test, used 391 an appropriate definition for a positive test, performed statistical analysis on potential 392 predictors of positive tests, and performed blinded testing. Studies that met at least five 393 of the nine criteria were considered higher-quality.

Two reviewers independently rated the quality of each systematic review and primary study. Any discrepancy was resolved via a consensus process.

396 Assessing Research Applicability and Clinical Relevance

Factors that we considered when assessing the applicability of trials include whether the publication adequately described the study population and interventions, whether the setting or population is so different from typical U.S. settings that the results might not be applicable, whether the differences are clinically (as well as statistically) significant, and whether the treatment received by the control group was reasonably representative of standard practice [51]. We also recorded the funding source and role of the sponsor.

404 Rating a Body of Evidence

We assessed the overall strength of evidence for a body of literature about a
particular Key Question using methods adapted from the U.S. Preventive Services Task
Force [48]. To assign an overall strength of evidence (good, fair, or poor), we examined
the type, number and quality of studies; the strength of association; the consistency of

results within and between study designs; and the possibility for publication bias. For
this report, we defined minimum criteria for a body of literature to meet an overall 'good'
or 'fair' rating:

412 Good quality: Multiple consistent higher quality RCTs, or 1 definitive RCT
413 Fair quality: 1 higher quality RCT; multiple consistent lower quality RCTs, or

- 414 multiple consistent higher-quality controlled observational studies
- 415 **Poor quality:** Does not meet criteria for fair or good
- 416

417 Consistent results from good-quality studies across a broad range of populations 418 suggest a high degree of certainty that the results of the studies are true (that is, the 419 entire body of evidence would be considered "good-guality"). For a body of fair-guality 420 studies, however, consistent results could indicate that similar biases are operating in all 421 of the studies. For a poor quality body of evidence, reliable conclusions are not 422 possible because of insufficient evidence, of there is low certainty that the results are 423 not due to bias or other methodologic shortcomings in the studies. Inconsistent results 424 from high-quality studies may lower confidence that the results of any particular study 425 are true, or reflect diversity between studies in the populations or interventions 426 evaluated. Large effect sizes on important, patient-centered outcomes can increase the 427 confidence in study findings, particularly when they are reported by higher-quality 428 studies. On the other hand, unvalidated assessment techniques or heterogeneous 429 reporting methods for important outcomes may weaken or downgrade the overall body 430 of evidence for that particular outcome or make it difficult to accurately estimate the true 431 magnitude of benefit or harm.

432 Size of literature reviewed

Investigators reviewed 1312 abstracts identified by searches for systematic
reviews. From the searches, 243 full-text articles were reviewed. A list of relevant
systematic reviews identified for this report is shown in Appendix 5. A total of 7635
citations were identified in 27 searches for primary studies of selected topics.

437 **Results**

438 Key Question 1.

- 439 What features of the history and physical exam are predictive of specific serious
- 440 underlying conditions ("red flags"), other specific conditions that may be
- responsive to specific therapies in patients with LBP (such as nerve root
- 442 compression or spinal stenosis), or high risk for persistent low back pain and
- 443 associated disability ("yellow flags")?
- 444 *Features of history and physical exam predictive of serious underlying conditions*
- 445 ("red flags"), compression fracture, ankylosing spondylitis, nerve root
- 446 compression, and spinal stenosis

447 In primary care, about 0.7% of patients will have spinal malignancy (primary or 448 metastatic), 3% ankylosing spondylitis, 4% compression fractures, 0.3% ankylosing 449 spondylitis, and 0.01% spinal infection [52]. Spinal stenosis and symptomatic herniated 450 disc are present in about 3% and 4%, respectively [53]. Up to 90% of patients have 451 non-specific low back pain, for which there is imprecise or no correlation with any 452 specific pathology [53]. Features of history and physical exam that can identify patients 453 more likely to have serious conditions such as cancer or infection ("red flags") or other 454 conditions that may respond to specific treatments (such as nerve root compression 455 from lumbar disc prolapse, spinal stenosis, ankylosing spondylitis, and vertebral 456 compression fracture) are important for guiding diagnosis and therapy.

- 457 Results of search: systematic reviews
- 458 We identified four systematic reviews (three higher-quality [53, 54, 55], one lower-
- 459 quality [53]) on the accuracy of history and physical exam for diagnosing various
- 460 conditions associated with low back pain. We excluded three other reviews that were
- 461 outdated [56], did not clearly describe systematic methods for identifying or synthesizing
- the literature [56], did not report diagnostic accuracy [57], or reported duplicate
- 463 information from another published review [58].
- 464 The most recent systematic review was published in 2002 (searches conducted through
- 465 September 2001) [58]. All of the systematic reviews noted important methodological
- shortcomings in the primary literature. These included spectrum bias (for example, only

467 evaluating patients who underwent surgery, patients from referral settings, or those with

468 more severe disease), little attention to inter- or intra-rater reliability, verification bias,

- 469 non-blinded assessment of the index or reference tests, poor description of the index
- 470 test, and lack of attention to reproducibility of findings over time. These deficiencies
- 471 could explain some of the observed variation between studies in reported diagnostic
- 472 accuracy. Another limitation of the literature is that the specific features of history and
- 473 physical exam that were assessed varied, and for several features only a single or few
- 474 studies are available. Only one systematic review (rated higher-quality), on the
- 475 accuracy of the straight leg raise test for disc herniation, pooled data quantitatively [54].
- 476 Results of search: additional studies
- 477 We did not search for additional studies.

478 Accuracy of history and physical exam features for identifying specific diagnoses479 associated with low back pain

- 480
- 481 Cancer

482 Two systematic reviews evaluated the diagnostic accuracy of history for identifying 483 patients with cancer [55, 58]. Based on one higher-quality study [52], both systematic 484 reviews found that failure to improve after 1 month of therapy, unexplained weight loss, 485 and previous history of cancer were each associated with high specificity (>0.90). 486 Previous history of cancer was associated with the highest positive likelihood ratio at 487 14.7. Only age >50 years and no relief with bed rest were associated with sensitivities 488 greater than 0.50 (0.77 and >0.90, respectively). Having any of the following was 489 associated with a sensitivity of 1.0 and specificity of 0.60 for diagnosing vertebral 490 cancer: age >50, history of cancer, unexplained weight loss, or failure of conservative 491 therapy (positive likelihood ratio 2.5). For physical exam findings, one systematic 492 review found that the sensitivity of spinal tenderness for diagnosing vertebral cancer 493 varied widely across four studies (range 0.15 to 0.80), though specificity was relatively 494 consistent (0.60 to 0.78) [55]. Other physical exam findings had poor sensitivity, though 495 certain neuromuscular (weakness, atrophy, reflex changes) or sensory deficits were 496 associated with high specificity in some studies.

497 Infection

- 498 Few studies evaluated the accuracy of history in diagnosing spinal osteomyelitis or
- 499 other infections causing low back pain. One systematic review found a sensitivity of
- 500 0.40 for a history of intravenous drug abuse, urinary tract infection, or skin infection
- 501 (specificity not reported) [58].
- 502 Compression fracture
- 503 For diagnosis of compression fracture, one systematic review included one unpublished
- 504 study that found that corticosteroid use had a higher predictive value (positive likelihood
- 505 ratio 12.0) than age or history of trauma [58]. Age >50 years was associated with a
- 506 sensitivity of 0.84 and specificity of 0.61 (positive likelihood ratio 2.2 and negative
- 507 likelihood ratio 0.26) and age >70 years was associated with a sensitivity of 0.22 and
- 508 specificity of 0.96 (positive likelihood ratio 5.5 and negative likelihood ratio 0.81).

509 Ankylosing spondylitis

- 510 Two systematic reviews evaluated the diagnostic accuracy of history for identifying
- 511 patients with ankylosing spondylitis [53, 55]. Both found younger age of onset
- 512 associated with high sensitivity but poor specificity (sensitivity and specificity 0.92 and
- 513 0.30 for onset <35 years, 1.00 and 0.07 for onset <40 years). Most other historical
- 514 features had only modest predictive value or gave inconsistent results. For example,
- 515 the specificity of a history of sacral pressure varied from 0.68 to 0.92 in three studies.
- 516 Combining historical findings (positive response to 4 of 5 screening questions: onset
- 517 before age 40, chronic onset, duration >3 months, morning stiffness, and improvement
- 518 with exercise) did not improve diagnostic accuracy (positive likelihood ratio of 1.3 and
- 519 negative likelihood ratio of 0.94). All physical exam findings (including Schober's test,
- 520 degree of chest expansion, reduced lateral mobility, sacral or lumbar pressure) were
- 521 associated with poor sensitivity. In single studies, chest expansion <=2.5 cm, Schober's
- 522 sign <4 cm, and restricted anteroposterior compression, lateral compression, or hip
- 523 extension were associated with relatively high specificities (>0.80).

524 Herniated disc or radiculopathy

- 525 For diagnosing a herniated disc or radiculopathy, three systematic reviews found that a
- 526 history of sciatica had a fairly high (79% to 99%) sensitivity and widely varying
- 527 specificity (14% to 88%) [59]. One systematic review also found that a typical
- 528 distribution for radiculopathy on a pain drawing had modest sensitivity (46%) but high

529 specificity (84%) in one higher-quality study [59]. The best-evaluated physical exam 530 findings for herniated disc are the straight leg raise (Laseague's test) and the crossed 531 straight leg raise tests. In a higher-guality, recent systematic review of 17 studies, the 532 pooled sensitivity and specificity of the straight leg raise test for diagnosing herniated 533 disc were 0.91 (95% CI 0.82 to 0.94) and 0.26 (95% CI 0.16 to 0.38) [54]. The pooled 534 diagnostic odds ratio was 3.74 (95% Cl 1.2 to 11.4). For the crossed straight leg raise 535 test, the pooled sensitivity and specificity were 0.29 (95% CI 0.24 to 0.34) and 0.88 536 (95% CI 0.86 to 0.90), with a pooled diagnostic odds ratio of 4.39 (95% CI 0.74 to 25.9). 537 Three other systematic reviews were consistent with these results [53, 55, 59]. Other 538 physical exam findings (such as decreased reflexes, strength, muscle atrophy, or 539 sensory deficits) have been less well studied. In general, the presence of such 540 neurological deficits is an insensitive finding for diagnosing radiculopathy or herniated 541 disc [53, 55, 59]. Isolated studies found that iliopsoas or tibialis anterior weakness have 542 high (97% and 89%) specificity [59]. The specificity of gastrocnemius weakness, calf 543 atrophy, and depressed ankle or knee jerks for diagnosing herniated disc ranged from 544 modest to high [53, 55, 59].

- The accuracy of combined history and physical examination findings for diagnosing herniated disc varied across studies, in part because of inconsistencies in how the clinical findings were defined across studies [59]. For example, the sensitivity and specificity were 27% and 97% in one study that defined a positive "cluster" as two or more positive findings [60], but 98% and 7% in another that defined a positive cluster as "probable diagnosis" based on clinical exam and history [61].
- 551 Spinal stenosis
- 552 One systematic review found that lack of pain when seated and a wide-based gait had 553 the highest positive predictive value for spinal stenosis (6.6 and 14.3 in one study, 554 respectively) [53]. Age greater than 65 years was associated with a negative likelihood 555 ratio of 0.33.
- 556 Summary of evidence
- Previous history of cancer (positive likelihood ratio 14.7), unexplained weight loss
 (positive likelihood ratio 2.7), and failure to improve after 1 month of therapy
 (positive likelihood ratio 3.0) were associated with a specificity for diagnosing

560 561	cancer of >0.90 in patients with acute low back pain presenting to primary care in one higher-quality study (level of evidence: fair).
562 563 564 565 566	 The presence of any of the following was associated with a high sensitivity (1.00) and moderate specificity (0.60) for diagnosing cancer in one higher-quality study: age >50 years, history of cancer, unexplained weight loss, or failure of conservative therapy (positive likelihood ratio 2.5, negative likelihood ratio 0.0) (level of evidence: fair).
567	 Few studies have evaluated the accuracy of history and physical exam for
568	diagnosing infection, though history of intravenous drug use, skin infection, or
569	urinary tract infection only had modest sensitivity in one study (level of evidence:
570	poor).
571	 Older age and history of corticosteroid use were the best predictors of vertebral
572	compression fractures (level of evidence: fair).
573	 Younger age of onset was sensitive but not specific for diagnosing ankylosing
574	spondylitis. Physical exam findings were generally associated with poor
575	sensitivity and relatively high specificities (level of evidence: fair).
576	 Describing typical symptoms of sciatica has a relatively high sensitivity but
577	inconsistent specificity for diagnosing radiculopathy. A positive straight leg raise
578	(the best-studied physical exam maneuver) was associated with a pooled
579	sensitivity of 0.91 and specificity of 0.26 in one higher-quality systematic review.
580	A positive crossed straight leg raise was associated with a pooled sensitivity of
581	0.29 and a specificity of 0.88. The specificity of neurologic deficits consistent
582	with nerve root compression ranges from modest to high (level of evidence: fair).
583	 In one study, spinal stenosis was less likely in patients younger than 65 years
584	old. A wide-based gait and absence of pain when seated were associated with
585	higher likelihoods of spinal stenosis (level of evidence: fair).
586	Recommendations and findings from other guidelines
587 588 589 590	• The AHCPR guidelines recommend inquiring about features of the history and clinical exam suggestive of cancer or infection (history of cancer, unexplained weight loss, intravenous drug use, history of urinary infection, pain increased by rest, fever), particularly in patients over the age of 50 (strength of evidence: B).
591	 The AHCPR guidelines recommend inquiring about features suggestive of cauda
592	equina syndrome such as bladder dysfunction, saddle anesthesia, and major
593	limb motor weakness (strength of evidence: C).
594	 The AHCPR guidelines recommend inquiring about significant trauma or minor
595	fall or heavy lift in potentially osteoporotic or older patients to avoid delays in
596	diagnosing fractures (strength of evidence: C).

- 597 The AHCPR guidelines recommend straight leg raise testing to assess sciatica in young adults, but notes that it may be normal in older patients with spinal stenosis (strength of evidence: B).
- The AHCPR guidelines recommend a focused neurologic exam emphasizing
 ankle and knee reflexes, ankle and great toe dorsiflection strength, and
 distribution of sensory complaints to document the presence of neurologic
 deficits (strength of evidence: B).
- The VA/DoD and UK RCGP guidelines adopted an approach nearly identical to
 the one suggested by the AHCPR guidelines (history and physical with focus on
 identifying red flags and focussed neurologic examination).
- The European COST guidelines also recommend diagnostic triage in patients
 with acute low back pain as recommended by other guidelines. In patients with
 chronic low back pain, diagnostic triage is recommended at the first assessment
 and at reassessment to exclude specific spinal pathology and nerve root pain.

611 Features of the history and physical exam associated with development of

- 612 chronic and disabling low back pain
- 613 Rapid improvements in low back pain typically occur in the first month after 614 presentation. However, a small proportion of patients develop chronic and disabling 615 back pain. One systematic review found that 82% of those initially off work returned to 616 work within one month, and 93% had returned to work by three to six months, with little 617 subsequent improvement [7]. "Yellow flags" describe features of the history or physical 618 examination that could help identify patients more likely to develop chronic and 619 disabling low back pain in order to provide interventions that might help retain or 620 improve functionality.
- 621 Results of search: systematic reviews
- 622 We identified nine systematic reviews evaluating features of the history predictive of a
- high risk for persistent low back pain and related disability [7, 62-69]. Three were rated
- 624 higher quality [7, 64, 66]. Three lower-quality systematic reviews evaluated features of
- 625 the physical exam predictive of persistent and disabling low back pain [62, 69, 70]. All
- 626 of the systematic reviews reported important methodological shortcomings in the
- 627 primary literature including lack of blinding, small sample sizes, inadequate analyses of
- 628 confounders, and incomplete follow-up of patients. In addition, the populations and

- 629 settings were heterogeneous. Because of these limitations, all of the systematic
- 630 reviews only qualitatively synthesized the evidence.
- 631 Results of search: additional studies
- 632 We did not search for additional studies

Accuracy of history and physical exam features for identifying patients more likely to develop chronic and disabling low back pain

635 The most recent, higher-quality systematic review (based on 54 higher-quality studies) 636 found strong evidence that each of the following was a predictor of persistent low back 637 pain, non-return to work, or disability: low back pain associated with increased pain 638 severity, longer duration, associated disability, or leg pain; low back pain-related 639 sickness leave; history of spinal surgery; low job satisfaction; and poor general health 640 [64]. There was moderate evidence that work-related and psychological factors (such 641 as employment status, amount of wages, workers' compensation, and depression) and 642 physical factors (such as time spent lifting per day and work postures) were also 643 associated with worse outcomes. Findings of other systematic reviews were generally 644 concordant. A second higher-quality systematic review of 18 prospective cohort studies 645 (six rated high or acceptable quality), for example, also found increased psychologic 646 distress, somatization, and poorer coping strategies associated with unfavorable 647 outcomes [66]. Several systematic reviews found receipt of benefits or worker's 648 compensation associated with poorer outcomes [62, 65, 69]. Other systematic reviews 649 also found modest evidence for an association between more severe pain [65, 69] or 650 presence of radiating [62, 67] or continuous pain [67] and poorer outcomes. Evidence 651 regarding an association between age or gender and poorer outcomes was mixed and 652 inconsistent [62, 65, 67].

653 Only a handful of studies assessed the usefulness of specific scales to predict poorer 654 outcomes. One recent higher-quality systematic review found that the Vermont disability 655 prediction questionnaire appeared promising [7]. In one higher quality study, higher 656 scores (>0.48) were associated with a positive likelihood ratio for return to work at 3 657 months of 5.7 (95% CI 3.9 to 8.5) and a negative likelihood ratio of 0.07 (95% CI 0.01 to 658 0.50). Fear avoidance (avoidance of activity because of fears that it will worsen 659 symptoms or outcomes) predicted worse outcomes in two [62, 67] of three [66] 660 systematic reviews.

- 661 Evidence regarding the prognostic value of physical exam findings for predicting poorer 662 outcomes associated with low back pain is sparser than evidence regarding 663 psychosocial factors. Presence of positive sham tests for pain (such as Waddell's 664 nonorganic signs) consistently predicted disability in one systematic review [67]. Other 665 physical exam findings such as positive straight leg raise tests, absence of neurological 666 signs, and intact range of motion were inconsistently associated with poorer outcomes 667 [62, 70]. One systematic review found that physical exam findings were weaker 668 predictors of outcomes than psychosocial factors [69]. 669 Summary of evidence 670 • There is consistent evidence from multiple systematic reviews that psychologic 671 distress, job dissatisfaction, high levels of "fear avoidance" beliefs, disputed 672 compensation claims, and somatization are associated with worse low back pain 673 outcomes (level of evidence: good). 674 • Increased duration or severity of pain and presence of leg pain are modestly 675 associated with poorer outcomes (level of evidence: fair). 676 Physical exam findings were inconsistently associated with outcomes and were 677 weaker predictors than psychosocial factors (level of evidence: fair). 678 Validated tools or scales for identifying patients likely to have poorer outcomes 679 are lacking, though one study found the Vermont disability questionnaire 680 promising (level of evidence: poor). 681 Recommendations and findings from other guidelines 682 The AHCPR guidelines recommend inquiring about psychological and • 683 socioeconomic problems as nonphysical factors can complicate assessment and treatment (strength of evidence: C). 684 685 • The AHCPR guidelines found that social, economic, and psychological factors 686 can significantly alter a patient's response to back symptoms and to treatment of 687 those symptoms (strength of evidence: D). 688 The VA/DoD, UK RCGP and European COST guidelines also recommend • 689 assessing psychological and socioeconomic factors and reviewing them if there 690 is no improvement. 691 Key Question 1a. 692 693 Does identification of 'vellow flags' lead to improved outcomes in patients with
- 694 LBP?

- 695 Results of search: systematic reviews
- 696 We found no systematic review evaluating the effects of interventions targeted at
- 697 identification and treatment of yellow flags in patients with acute or subacute low back
- 698 pain. Although several systematic reviews evaluate interventions addressing
- 699 psychosocial issues in patients with subacute or mixed duration low back pain,
- identification and treatment of yellow flags was usually not the main goal of therapy or
- 701 was included as part of a multidisciplinary biopsychosocial approach [71-75]. See
- discussions of behavioral interventions, multidisciplinary interventions, and functional
- restoration/physical conditioning under Key Question 3.
- 704 Results of search: trials

705 We identified two higher-quality trials evaluating brief interventions for identifying and

treating 'yellow flags' [76, 77]. A third, lower-quality trial evaluated an intensive,

707 multidisciplinary intervention [78]. Two other trials (one higher-quality [79]) evaluated

the efficacy of fear-avoidance based therapy [79, 80]. All were conducted in patients

- 709 with acute or subacute low back pain.
- 710 Efficacy of interventions for identifying and treating 'yellow flags'
- 711 Although several recent trials have assessed interventions for identifying and treating
- 712 'yellow flags,' it is difficult to draw general conclusions about their effectiveness because
- of differences in the treatments (ranging from brief interventions administered by a
- 714 primary care clinician to intensive, multidisciplinary interventions) and populations
- studied. Two higher-quality trials found that brief interventions were no more effective
- than standard practice or conventional physical therapy in patients with back pain of
- 717 less than 12 weeks' duration (Table 1) [76, 77]. One trial (N=314) found no differences
- through 12 months between usual care and a minimal (20 minute) intervention aimed at
- 719 identifying, providing information about, and promoting self-care of psychosocial risk
- factors for any outcome including back-specific functional status (RDQ score), pain, sick
- 121 leave, perceived general health (SF-36), or general practitioner visits [77]. The minimal
- intervention also failed to show a benefit in higher-risk subgroups of patients with
- 723 increased baseline psychologic distress or recurrent back pain. The second trial
- 724 (N=402) found no differences on back-specific functional status (ODI score), pain, time
- off work, depression scores, use of health care resources, or satisfaction with care at
- either 3 or 12 months among patients randomized to a brief pain management program

- 727 (aimed at identifying psychosocial risk factors, emphasizing return to normal activity
- 728 through functional goal setting, and using educational strategies to overcome
- psychosocial barriers to recovery as well as a tailored exercise program) versus
- standard physical therapy (with an emphasis on spinal manipulation), though the
- number of physical therapy sessions was slightly lower with the brief intervention [76].
- 732 In both trials, patients improved regardless of which intervention they were randomized
- 733 to.
- 734

Table1. Trials of brief interventions for identifying and treating 'yellow flags'

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hay, 2005[76]	N=402	Brief pain intervention vs. manual physical therapy (results at	
	12 months	12 months unless otherwise noted) ODI score, mean change from baseline: 7.8 vs. 8.1 at 3 months, p=0.755; 8.8 vs. 8.8 at 12 months, p=0.994	
		Overall assessment 'much better' or 'completely better' at 12 months: 68% vs. 69%	8/11
		Back pain (0 to 100 scale): 78 vs. 70, p=0.401 Took time off work in last 12 months: 54% vs. 58%, p=0.45 Satisfaction with treatment (0 to 100 scale), median: 03 va. 03	
Jellema,	N=314	Satisfaction with treatment (0 to 100 scale), median: 93 vs. 93 Minimal intervention vs. usual care	
2005[77]	12 months	(results at 12 months unless otherwise noted) RDQ score (0 to 24 scale): 1 vs. 1, mean difference 0.25 (-0.77 to 1.28)	
		No recovery (rated recovery as slightly improved, no change, slightly worse, much worse, or very much worse): 42/132 (32%) vs. 43/156 (28%), odds ratio 1.16 (0.63 to 2.17) Sick leave due to low back pain: 8/107 (8%) vs. 9/128 (7%), odds	6/11
		ratio 0.69 (0.43 to 1.13) Pain severity: mean difference 0.015 (-0.41 to 0.44)	

735

736 Several factors could explain the lack of an effect in these two trials. In one study,

737 patients receiving the intervention were not permitted to receive physical therapy for the

first six weeks [77]. In addition, the general practitioners randomized to the minimal

intervention arm in that trial were only moderately successful in identifying psychosocial

- 740 factors, and were no more effective than usual care in improving outcomes measured
- by psychosocial scales [81]. It's possible that additional training or a more intense
- 742 intervention could result in more effective treatment. In addition, targeting the
- 743 intervention to high-risk patients could improve outcomes compared to treating a less
- selected group of patients [82]. These hypotheses are supported in part by a third,
- small (N=70), lower-quality trial which found that a more intense (including 3 physician
- evaluations and a total of 45 physical therapy, biofeedback/pain management, group

- 747 didactic, and case manager/occupational therapy sessions), multidisciplinary functional
- restoration intervention was associated with improved pain, and decreased disability
- 749 after 12 months (Table 2) compared to usual care in patients with acute (<8 weeks) low
- back pain identified as higher risk for chronic disability using a screening tool [78].
- 751 752

Table 2. Trial of intensive multidisciplinary functional restoration in patients at higher riskfor chronic disability

Author, year	Number of patients Duration of follow-up	Main results	Quality
Gatchel, 2003[78]	12 months	Multidisciplinary functional restoration vs. usual care Return to work at 12 months: 91% vs. 69% (p=0.027) Average number of healthcare visits: 26 vs. 29 (p=0.004) Average number of healthcare visits related to low back pain: 17 vs. 27, p=0.004 Average number of disability days due to back pain: 38 vs. 102, p=0.001	2/11
		Average most 'intense pain" at 12 month follow-up: 46 vs. 67, p=0.001 Average self-rated pain over last 3 months: 27 vs. 43, p=0.001 Taking opioid analgesics: 27% vs. 44%, p=0.020	

753

754 Two other trials evaluated interventions for reducing fear avoidance (Table 3). In one 755 lower-quality trial, 240 patients with persistent low back pain and activity limitations 8 to 756 10 weeks after the initial visit were randomized to a four-session individualized fear 757 avoidance intervention with a psychologist and physical therapists versus usual care 758 [79]. The intervention was superior for disability outcomes, with the proportion of 759 patients with greater than one-third reduction in RDQ score 28% vs. 13% at 2 months 760 (p=0.0007) and 49% vs. 37% at 24 months (p=0.08). Average pain intensity was 761 slightly better with the intervention at 2 months, though the difference was no longer 762 significant at 24 months. There was no difference in SF-36 scores or ability to work. 763 though a lower proportion of patients randomized to the fear avoidance intervention 764 reported activity limitation due to back pain for 30 or more days after 24 months (8.5% 765 vs. 14.3%, p=0.04). The patients randomized to the fear avoidance intervention also 766 reported lower scores on fear-avoidance and worry rating scales through 24 months. 767 The second, smaller (N=67), higher-quality trial found no differences on the ODI scale 768 or pain intensity after 6 months between low back pain (less than 8 weeks duration)

- 769 patients randomized to fear avoidance-based physical therapy (encouraging patient to
- take an active role in treatment and to view back pain as common, along with a self-
- care booklet and graded exercise) and usual physical therapy [80]. The fear avoidance
- intervention was associated with lower fear avoidance beliefs in the subgroup of
- 773 patients with high baseline fear avoidance scores.
- 774

Table3. Trials of fear-avoidance based interventions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Von Korff, 2005[79]	N=240 24 months	Fear avoidance intervention vs. usual careRDQ score (0 to 24): 10.2 vs. 11.5 at 2 months,p=0.0002; 8.1 vs. 9.1 at 24 months, p=0.0078Proportion of patients with greater than one-thirdreduction in RDQ score: 28% vs. 13% at 2 months,p=0.0007; 49% vs. 37% at 24 months, p=0.08Fear-avoidance (17-68): 36.4 vs. 39.9 at 2 months,p<0.0001; 34.3 vs. 38.4 at 24 months, p=0.0001	
George, 2003[80]	N=67 6 months	Fear avoidance vs. standard physical therapy ODI Score (0 to 100), mean change: 18.0 vs. 17.1 at 4 weeks, (NS), 23.9 vs. 23.0 at 6 months (NS) Present pain intensity (0 to 10), mean change: 2.4 vs. 2.0 at 4 weeks (NS), 2.6 vs. 3.0 at 6 months (NS) Fear Avoidance Beliefs Questionnaire, Physical Activity Scale (0 to 24), mean change: 5.0 vs. 1.8 at 6 months, p=0.037 Fear Avoidance Beliefs Questionnaire, Work Scale (0 to 42), mean change: 3.1 vs. 1.9 at 6 months, p=0.352	7/11

775

776 Safety

- Adverse events were not reported in any of the trials.
- 778

779 Costs

- A cost-benefit analysis of the trial comparing an intensive, early multidisciplinary
- 781 intervention in patients identified as higher risk for chronic disability calculated a net
- gain of \$9122, mostly related to a reduction in lost wages in the intervention group [78].

783 Summary of evidence

- Two higher-quality trials found no benefits after 12 months from brief
- 785 interventions identified at identifying and treating 'yellow flags' relative to usual

786 care or standard physical therapy in unselected patients with acute or subacute 787 back pain (level of evidence: good). 788 One lower-quality trial found that an intensive multidisciplinary functional 789 restoration program was more effective than usual care after 12 months in 790 patients with back pain for less than 8 weeks who were identified as being at 791 higher risk for chronic disability using a screening tool (level of evidence: poor). 792 • One lower-quality trial found fear-avoidance based therapy superior to usual care 793 for back specific functional status after 24 months in patients with persistent 794 activity limitations, though beneficial effects on pain were only short-lived (level of 795 evidence: poor). 796 One higher-guality trial found no difference between fear-avoidance therapy and 797 standard physical therapy after 6 months, though fear-avoidance beliefs were 798 decreased in the intervention group (level of evidence: fair). 799 **Recommendations from other guidelines** 800 No guidelines make specific recommendations about interventions in patients • 801 identified as having 'yellow flags'.

802 Key Question 2.

803 What diagnostic tests should be ordered, and under what circumstances, for 804 patients with LBP?

805 Because many anatomic abnormalities are guite common in healthy persons. 806 diagnostic imaging often identifies radiographic abnormalities that are only loosely 807 associated with symptoms. In one systematic review of findings from plain radiography, 808 degenerative changes (disc space narrowing, osteophytes, and sclerosis) were only 809 modestly associated with low back pain (OR 1.2 to 3.3) [83]. Other findings, such as 810 spondylolysis, spondylolisthesis, spina bifida, transitional vertebrae, spondylosis, and 811 Scheuermann's disease did not appear to be associated with symptoms. Another 812 systematic review found that more sophisticated imaging methods were more likely to 813 identify radiologic abnormalities in asymptomatic patients than plain radiography [53]. 814 The proportion of asymptomatic patients with herniated disc on MRI, for example, 815 ranged from 9% to 76%, degenerative disc from 46% to 93%, and stenosis from 1% to 816 21%. Greater use of advanced diagnostic imaging could lead to additional testing and 817 interventions. For example, a significant proportion of the geographic variation in spinal 818 surgery rates across the U.S. appears correlated with differential rates of obtaining MRI

- 819 [84]. On the other hand, patients and providers may be reassured by obtaining imaging
- 820 tests, even if the findings don't necessarily alter management.

821 Key Question 2a.

822 What is the diagnostic accuracy of different diagnostic tests for identifying

- 823 serious underlying conditions (e.g., tumor, infection, compression fracture)?
- 824 Results of search: systematic reviews
- 825 We identified one recent higher-quality systematic review that evaluated the diagnostic
- 826 accuracy of plain radiography, magnetic resonance imaging (MRI), computed
- 827 tomography (CT), or radionuclide scanning for diagnosing serious underlying conditions
- 828 associated with low back pain [53]. We excluded six other systematic reviews because
- they were outdated [56, 85-88] or reported duplicate information [58].
- 830 The systematic review found numerous flaws in diagnostic studies, with the most
- common being failure to apply a single reference test to all patients, test review bias
- 832 (study test was reviewed with knowledge of the final diagnosis), diagnosis review bias
- 833 (determination of the final diagnosis was affected by the study test), and spectrum bias
- 834 (only severe cases of disease were evaluated) [53]. Additional limitations of primary
- 835 studies include heterogeneous populations, small sample sizes, and small numbers of
- 836 studies. Estimates of diagnostic accuracy were therefore considered imprecise, and
- 837 ranges rather than pooled estimates were reported.
- 838 We also identified one higher-quality systematic review on the accuracy of erythrocyte
- 839 sedimentation rate testing in patients with low back pain [55], one higher-quality
- 840 systematic review on the accuracy of thermography for diagnosing lumbar radiculopathy
- [89], and one lower-quality systematic review on the accuracy of surface
- 842 electromyogram [90]. One other systematic review of surface electromyogram was
- 843 excluded because it primarily evaluated whether the test could distinguish patients with
- low back pain from those without low back pain [91].
- 845 Accuracy of imaging for diagnosing cancer
- 846 The accuracy of diagnostic imaging for diagnosing vertebral cancer is summarized in
- 847 Table 4. Plain radiography was associated with lower sensitivity for metastatic cancer
- 848 than MRI or radionuclide scanning (with planar imaging or SPECT), though it was

- 849 associated with high specificity [53]. Magnetic resonance imaging and SPECT were
- 850 associated with similar diagnostic accuracy. Planar imaging was less accurate than
- 851 SPECT.
- 852

854

Table 4. Estimated accuracy of different imaging techniques for diagnosing cancer (ranges)

Technique	Sensitivi <i>t</i> y	Specificity	Positive likelihood ratio	Negative likelihood ratio
Plain radiography	0.6	0.95-0.995	12-120	0.40-0.42
MRI	0.83-0.93	0.90-0.97	8.3-31	0.07-0.19
Radionuclide scanning with planar imaging	0.74-0.98	0.64-0.81	3.9	0.32
SPECT	0.87-0.93	0.91-0.93	9.7	0.14

Source: Jarvik and Deyo, 2002[53]

855 Accuracy of imaging for diagnosing vertebral infection

856 For diagnosing vertebral infection, plain radiography was less accurate than MRI or

radionuclide scanning (Table 5) [53]. MRI was more accurate than either plain

858 radiography or radionuclide scanning.

859Table 5. Estimated accuracy of different imaging techniques for diagnosing vertebral860infection (ranges)

Technique	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Plain radiography	0.82	0.57	1.9	0.32
MRI	0.96	0.92	12	0.04
Radionuclide scanning	0.90	0.78	4.1	0.13

Source: Jarvik and Deyo, 2002[53]

861

862 Accuracy of imaging for diagnosing vertebral compression fracture

863 For vertebral compression fracture, plain radiography appears sensitive, but its ability to

864 distinguish acute from chronic fracture is poor, and asymptomatic fractures are

865 frequently identified [53]. Although radionuclide scanning is insensitive for diagnosing

866 fractures, it can help distinguish recent from old fractures. MRI can also provide

additional information about the acuity of compression fractures.

868 Accuracy of elevated erythrocyte sedimentation rate for diagnosing cancer

869 One systematic review [55] included a higher-quality study [52] that found that an ESR

- 870 >=20 mm/hr was associated with a sensitivity of 0.78 and specificity of 0.67 for
- 871 diagnosing vertebral cancer.

- 872 Costs
- 873 A decision analysis found that for diagnosing cancer in patients with low back pain, a
- 874 strategy of selectively imaging patients with a positive clinical finding (history of cancer,
- age >=50 years, weight loss, or failure to improve with conservative therapy) in
- 876 combination with either an elevated ESR (>=50 mm/hr) or a positive x-ray was
- 877 associated with the lowest cost-effectiveness ratio (\$5283 per case found) [92]. Using a
- similar strategy but directly imaging patients with a history of cancer resulted in similar
- 879 estimates of cost-effectiveness. A decision analysis of diagnostic strategies for
- 880 excluding cancer found that rapid MRI was associated with an incremental cost-
- effectiveness of nearly \$300,000/QALY relative to routine x-ray imaging [93].
- 882 Summary of evidence
- MRI and radionuclide scanning are more sensitive than plain radiography for
 diagnosing vertebral cancer, though plain radiography is associated with high
 specificity (level of evidence: good).
- MRI is more accurate than either plain radiography or radionuclide scanning for
 diagnosing vertebral infection (level of evidence: fair).
- Plain radiography appears sensitive for diagnosing vertebral compression
 fracture, but is unable to provide information about acuity (level of evidence: fair).
- An elevated erythrocyte sedimentation was associated with moderate sensitivity and specificity for diagnosing vertebral cancer in one higher-quality study (level of evidence: fair).
- 893 **Recommendations and findings from other guidelines**
- The AHCPR guidelines state that plain x-rays in combination with CBC and ESR may be useful for ruling out tumor or infection in patients with acute low back problems when any of the following are present: prior cancer or recent infection, fever over 100 degrees F, IV drug abuse, prolonged steroid use, low back pain worse with rest, unexplained weight loss (strength of evidence: C).
- The AHCPR guidelines recommend prompt CT or MRI in the presence of red flags suggesting cauda equina syndrome or progressive motor weakness, preferably in consultation with a surgeon (level of evidence: C).
- 902 The AHCPR guidelines recommend CT or MRI when clinical findings strongly
 903 suggest tumor, infection, fracture, or other space-occupying lesions of the spine
 904 (strength of evidence: C).
- 905 The AHCPR guidelines state that in the presence of red flags, especially for
 906 tumor or infection, the use of other imaging studies such as bone scan, CT, or

- 907 MRI may be clinically indicated even in plain x-rays are negative (strength of 908 evidence: C).
- The AHCPR guidelines recommend against CT-myelography and myelography
 because they are invasive and have an increased risk of complications, except in
 special situations for preoperative planning (strength of evidence: D).
- 912 The European COST guidelines recommend MRI in patients with chronic low
 913 back pain with serious red flags.

914 Key Question 2b.

- 915 What is the diagnostic accuracy of different diagnostic tests for identifying other
- 916 conditions (e.g. nerve root compression, herniated disc, spinal stenosis) that may
- 917 respond to specific therapies?
- 918 Results of search: systematic reviews
- 919 We identified the same systematic reviews described for Key Question 2a.
- 920 Results of search: trials
- 921 We did not search for additional trials
- 922 Accuracy of imaging for diagnosing nerve root compression, herniated disc, and spinal
 923 stenosis
- 924 Plain radiography cannot directly visualize intervertebral discs and is therefore
- 925 insensitive for diagnosing disc herniation [53]. Similarly, facet osteophytes or severe
- 926 spondylolisthesis on plain radiography can suggest nerve root impingement, but
- 927 additional imaging is required to confirm the diagnosis. Plain radiography is also unable
- 928 to detect compromise of the vertebral canal caused by soft tissue.
- 929 One recent systematic review evaluated the accuracy of CT and MRI for diagnosing
- 930 herniated disc and spinal stenosis [53]. It found that magnetic resonance imaging and
- 931 computed tomography were associated with similar accuracy for diagnosing either
- 932 condition (Table 6).

933 Table 6. Estimated accuracy of different imaging techniques for diagnosing disc herniation and 934 spinal stenosis (ranges reported)

Technique	Sensitivity	Specificity	Positive likelihood ratio	Negative likelihood ratio
Herniated disc				
MRI	0.6-1.0	0.43-0.97	1.1-33	0-0.93
СТ	0.62-0.9	0.7-0.87	2.1-6.9	0.11-0.54
Spinal stenosis				
MRI	0.9	0.72-1.0	3.2-not defined	0.10-0.14
СТ	0.9	0.8-0.96	4.5-22	0.10-0.22

Source: Jarvik and Deyo, 2002[]

935

936 Accuracy of imaging for diagnosing ankylosing spondylitis

937 Evidence on the diagnostic accuracy of different imaging methods for diagnosing

938 ankylosing spondylitis is sparse. Plain radiography was associated with a sensitivity of

939 0.26 to 0.45 and specificity of 1, but spectrum bias could have inflated these estimates

940 [53]. Radionuclide scanning with planar imaging was associated with low sensitivity but

941 high specificity in two studies (sensitivity 0.25 and 0.26, specificity 0.95 to 1.0) [94, 95].

942 In one other study, SPECT increased sensitivity to 0.85 but decreased specificity to

943 0.90 [94]. MRI was associated with a sensitivity of 0.45 for diagnosing ankylosing

944 spondylitis in one study, but specificity could not be calculated [95].

945 Diagnostic accuracy of other (non-imaging) tests

946 One higher-guality study found an elevated ESR associated with a sensitivity of 0.69

947 and specificity of 0.68 for diagnosing ankylosing spondylitis in patients suspected of

948 having the disease [55]. A systematic review on the diagnostic accuracy of

949 thermography found major methodological flaws, inconsistent results, and no clear

950 evidence supporting its use in diagnosis of radiculopathy [89]. Another systematic

951 review found inconclusive and inadequate evidence to support the use of surface

952 electromyography for diagnosis of low back pain [90].

953

Summary of evidence

- 954 MRI and CT scan are associated with similar diagnostic accuracy for diagnosing 955 herniated disc or spinal stenosis (level of evidence: good).
- 956 Evidence on the diagnostic accuracy of different imaging methods for diagnosing 957 ankylosing spondylitis is sparse. Plain radiography may have high specificity, but higher-quality studies are needed (level of evidence: fair). 958

- 959 An elevated ESR was associated with moderate sensitivity and specificity for 960 diagnosing ankylosing spondylitis in patients suspected of having the disease (level of evidence: fair). 961 962 There is no evidence supporting the use of thermography or surface 963 electromyography for diagnosis of low back pain (level of evidence: fair). 964 **Recommendations from other guidelines** 965 The AHCPR guidelines recommend against thermography for assessing acute • 966 low back problems (strength of evidence: C). 967 The AHCPR guidelines recommend against electrophysiologic testing when the • diagnosis of radiculopathy is obvious and specific on clinical examination 968 969 (strength of evidence: D). 970 The AHCPR guidelines recommend against surface EMG and F-wave tests in 971 patients with acute low back symptoms (strength of evidence: C). 972 The AHCPR guidelines found that needle EMG and H-reflex tests of the lower • 973 limb may be useful in assessing questionable nerve root dysfunction in patients 974 with leg symptoms for longer than 4 weeks (regardless of presence of back pain) (strength of evidence: C). 975 976 The AHCPR guidelines found that SEPs may be useful in assessing suspected 977 spinal stenosis and spinal cord myelopathy (strength of evidence: C). 978 The VA/DoD recommendations for diagnostic imaging are essentially identical to 979 the AHCPR recommendations. 980 The European COST guidelines do not recommend electromyography for chronic • 981 nonspecific low back pain. 982 The European COST guidelines recommend MRI for evaluation of radicular • 983 symptoms, and plain radiography for evaluation of structural deformities. They 984 recommend against MRI or CT for the diagnosis of facet joint pain. 985 Key Question 2c. 986 In patients with 'red flags,' how does the choice of diagnostic testing affect 987 clinical outcomes? 988 Results of search: systematic reviews
- 989 We found no systematic reviews addressing this question.
- 990 Results of search: trials
- 991 No trials are available.

DRAFT – for Peer Review only

APS Clinical Guidelines for the Management of Low Back Pain

- 992 Efficacy of diagnostic testing in patients with 'red flags'
- 993 We found no studies comparing outcomes associated with the use of different
- 994 diagnostic tests in patients with low back pain and associated cancer, vertebral
- 995 infection, or cauda equina syndrome. All guidelines recommend prompt and
- appropriate work-up (including advanced imaging techniques) and management of
- 997 patients suspected of having these conditions or with a history of significant vertebral
- trauma, because delayed diagnosis and treatment can be associated with poorer
- 999 outcomes [20, 28, 29, 32].
- 1000 Summary of evidence
- There is no direct evidence on the efficacy of diagnostic testing in patients with 'red flags,' though all guidelines recommend prompt and appropriate work-up (including advanced imaging) because delayed diagnosis and treatment can be associated with poorer outcomes.

1005 **Recommendations from other guidelines**

- The AHCPR, VA/DoD, UK RCGP, and European COST guidelines all
 recommend prompt work-up and immediate action in patients with low back pain
 suspected of having a red flag condition.
- The European COST guidelines recommend MRI in patients with chronic low back pain with serious red flags.
- 1011 Key Question 2d.

1012 In patients without 'red flags,' how does the choice of diagnostic testing (or no

- 1013 testing) affect clinical outcomes?
- 1014 Results of search: systematic reviews
- 1015 We found no systematic reviews addressing this question.
- 1016 Results of search: trials
- 1017 We identified three randomized controlled trials (one higher-quality [96]) evaluating
- 1018 routine, early plain radiography versus imaging only if clinically necessary (or without
- 1019 improvement) in patients presenting for initial evaluation of low back pain without 'red
- 1020 flags' [96-98]. Routine radiography was compared to usual care in two trials [96, 98]
- 1021 and to a brief educational intervention in the third.[97]. Four other trials evaluated
- 1022 different strategies for using MRI in patients with low back pain. One higher-quality trial
- 1023 (N=782) compared early routine versus delayed selective MRI or CT in patients

1024 presenting to surgical clinics for evaluation of low back pain [99]. A lower-guality trial 1025 performed MRI in all patients, and compared results in patients in whom results were 1026 routinely given versus those in whom results were disclosed only if clinically indicated 1027 [100]. Two higher-guality trials (conducted by the same investigators and using the 1028 same study design) evaluated the effects of rapid MRI versus plain radiography in patients with low back pain in whom imaging was clinically felt appropriate [101. 102]. 1029 1030 Efficacy of routine, early plain radiography versus usual care or imaging only if clinically 1031 necessary (or without improvement) 1032 Delayed imaging resulted in no serious missed diagnoses in any of the three trials

Delayed imaging resulted in no senous missed diagnoses in any of the time time times

1033 comparing routine plain radiography to imaging only if clinically necessary (or without

- 1034 improvement) [96-98]. Routine radiography also was not associated with improved
- 1035 patient functioning, time off work, severity of pain, or overall health status in any of the
- trials (Table 7). The only higher-quality trial (N=153) found routine radiography
- 1037 modestly superior for psychological well-being [96]. In a large (N=421), lower-quality
- trial, routine radiography was associated with increased physician visits in the 3 months
- 1039 after imaging and a trend towards a higher likelihood of pain at 6 months, but also
- 1040 increased patient satisfaction, though differences were modest [98]. Results of a third,
- 1041 lower-quality trial suggests that patient education might ameliorate any negative effects
- 1042 of delayed imaging, as delayed imaging paired with a brief educational intervention was
- 1043 not associated with increased anxiety, dissatisfaction, or dysfunction or differences in
- 1044 subsequent clinical treatments compared to early routine imaging [97].

1045

1045

Table 7. Trials of early plain radiography versus imaging only if clinically necessary

	Number of		
	patients		
	Duration of		
Author, year	follow-up	Main results	Quality
Kerry, 2002[96]	N=153	Routine plain radiography vs. usual care (1 year data)	quanty
Keny, 2002[90]	1 year	SF-36, adjusted difference (not referred - referred): no subscale significant except for mental health -8, p<0.05 EuroQol, adjusted difference: 1 (NS) RDQ score (0 to 24), adjusted difference: -0.3 (NS) Consulted for back pain 6 weeks to 1 year: 32% vs. 39%, AOR 0.7 (0.3 to 1.4) Referred to other health professional 6 weeks to 1 year: 45% vs. 46%, AOR 1.1 (0.5 to 2.3) Very satisfied at 6 weeks: 33% vs. 28%, AOR 1.3 (0.6 to 3.0) Days off work, 0-12 months: 8.46 vs. 6.16 GP consultations: 1.6 vs. 1.1, p=0.06	5/11
		Other consultations: 5.9 vs. 2.9, p=0.003	
Kendrick, 2001[98]	N=421 9 month	Routine plain radiography vs. usual care (9 month data) Still has pain at 6 months: 65% vs. 57% (p=0.11) Taken time off work: 13% vs. 13% (p=0.87) Median days off work: 11.5 vs. 8.5 (p=0.84) Median RDQ score: 3 vs. 2 (p=0.06) Median pain score: 1 vs. 1 (p=0.17) Median health status score: 80 vs. 80 (p=0.30) Median satisfaction with consultation: 21 vs. 19 (p<0.01, favors routine radiography) >=3 visits to doctor: 5% vs. 5% Visited provider within 3 months: 53% vs. 30% (RR 1.62, 95% Cl 1.33 to 1.97)	6/11
Deyo, 1987[97]	N=101 3 months	Routine plain radiography vs. selective imaging + brief educational intervention Sickness Impact Profile (0 to 100, higher indicating worse function): 16.6 vs 13.6 at 3 weeks (NS), 12.3 vs. 10.3 at 3 months (NS) Days of work absenteeism: 4.1 vs. 4.4 at 3 weeks (NS) Additional days of work loss: 0.28 vs. 0.05 at 3 months (NS) Self-rated improvement (1 to 6 scale): 2.7 vs. 2.7 at 3 weeks, 2.6 vs. 2.6 at 3 months Duration of pain: 9.4 vs. 10.8 days at 3 weeks (NS), 13.3 vs. 18.4 additional days of pain at 3 months (NS) Total physician visits: 1.07 vs. 0.42 at 3 months Overall satisfaction score (9 to 27 scale): 23.7 vs. 24.0 No differences for other measures of patient perceptions and attitudes (including worry that pain is due to serious illness)	4/11

1046

1047 Efficacy of routine MRI versus MRI only if clinically necessary (or without improvement)

1048 One higher-quality trial (N=782) found that in patients with low back pain of varying

1049 duration (40% with symptoms for >1 year) referred to surgeons with uncertain need for

advanced imaging, routine early MRI or CT was associated with statistically significant

1051 but modest differences in the Aberdeen Low Back Pain Score, SF-36 Bodily Pain Scale,

- 1052 and Euro-Qol after 8 and 24 months relative to delayed, selective imaging (Table 8) 1053 [99]. Differences on pain scales averaged about 3 points on 0 to100 scales. There 1054 were no differences in the proportion of patients undergoing surgery, receiving 1055 injections, or other measures of health care use. A lower-quality trial that obtained MRI 1056 in all patients with acute low back pain or radiculopathy found that routine disclosure of 1057 MRI findings was not associated with greater improvements in RDQ function scores 1058 compared to withholding MRI results unless clinically necessary [100]. There were also 1059 no differences on any of the SF-36 subscales other than general health, which favored 1060 the blinded arm (6.0 vs. 4.2 point improvement at 6 weeks, p=0.008).
- 1061

Table 8. Trials of early MRI versus imaging only if clinically necessary

Author, year	Number of patients Duration of follow-up	Main results	Quality
Modic, 2005[100]	N=246 6 weeks	Unblinded vs. blinded MR results >50% improvement in RDQ function: 60% vs. 67% (p=0.397) Proportion 'satsified' with condition: 23% vs. 31% (p=0.207) Self-efficacy, fear-avoidance beliefs, and SF-36: similar between arms except for general health subscale of SF- 36, mean improvement 4.2 vs. 6.0 at 6 weeks (p=0.008)	2/11
Gilbert, 2004[99]	N=782 2 years	Early imaging (90% had MRI or CT) vs. delayed (30% had MRI or CT) (24 month data) Subsequent outpatient appointment: 84% vs. 68%, p<0.001 Total number of consultations: 1.91 vs. 1.88 (NS) Hospital admissions: 7.9% vs. 6.7% (NS) Surgical operation: 6.9% vs. 5.1% (NS) Injections: 17.8% vs. 19.3 % (NS) Aberdeen Low Back Pain score (0 to 100 scale), adjusted mean difference: -3.62, p=0.002 EQ-5D score (-0.59 to +1 scale), adjusted mean difference: 0.057, p=0.01 SF-36, bodily pain (0 to 100 scale), adjusted mean difference: 5.14, p=0.004 No differences on other SF-36 subscales	6/11

1062

1063 Efficacy of rapid MRI versus plain radiography in patients with low back pain referred for 1064 imaging

1065 In the larger (N=380) of two higher-quality trials comparing rapid MRI to plain

1066 radiography in patients with low back pain referred for imaging, there was no difference

1067 in any outcomes including functional status, pain intensity, or rate of spinal surgery

- 1068 (Table 9) [101]. The smaller (N=62) trial (conducted by the same investigators) reported 1069 similar findings [102].
- 1070

Table 9. Trials of rapid MRI versus plain radiography in patients referred for imaging

Author, year	Number of patients Duration of follow-up	Main results	Quality
Jarvik, 2003[101]	N=380 6 weeks	MRI vs. plain radiograph RDQ Scale score, adjusted (12 month): 9.34 vs. 8.75 (NS) (score better for MRI at 3 months) SF-36: No differences at 12 months for bodily pain, physical functioning, role-physical Pain-bothersomeness: 9.68 vs. 9.75, NS Pain-frequency: 10.09 vs. 10.21, NS Lost work, days past 4 weeks: 1.57 vs. 1.26, NS Patient satisfaction: 7.04 vs. 7.34, NS Patient reassurance score: 3.18 vs. 2.50, p<0.05 favoring MRI Proportion reporting reassurance from imaging: 74% vs. 58% (p=0.002) Lumbar spine surgery: 6% vs. 2%	8/11
Jarvik, 1997[102]	N=62 3 months	Rapid MRI vs. plain radiography (3 month data)Modified RDQ score: 12.5 vs. 12.1 (p=0.40)SF-36: No differencesPain bothersomeness (0 to 24): 9.7 vs. 10.0 (p=0.79)Pain frequency (0 to 24): 10.1 vs. 9.9 (p=0.35)Disability days: No differences for number of home days,limited activity days, or bed daysPatient satisfaction: Only differences among 12 questionsabout patient satisfaction were proportion who thoughtclinicians were concerned (75% vs. 100%, p=0.01) andproportion who felt reassured (72% vs. 37%, p=0.03)Proportion of patients referred to back specialists: 32% vs.36%	6/11

- 1071
- 1072 Costs

1073 Several recent RCTs of routine versus selective imaging also conducted cost-

1074 effectiveness analysis. In one trial, the cost-effectiveness of routine plain radiography

1075 was estimated at £20 per point on a patient satisfaction scale (scored between 9 and

1076 27), the only outcome for which there was a difference in efficacy [103]. The increased

- 1077 cost was mostly related to the direct costs of the imaging procedure itself. In another
- trial, early MRI or CT imaging was associated with a mean additional QALY of 0.041
- 1079 during 24 months relative to selective imaging, with an incremental cost-effectiveness of
- 1080 \$2,124/QALY [99]. These results are consistent with an older decision analysis that
- 1081 found that the costs associated with routine lumbar radiography in patients with acute
- 1082 low back pain did not appear to justify the small benefits (\$2,072 to avert one day of

physical suffering) [104]. Finally, rapid MRI imaging was associated with additional
costs of about \$300 relative to plain radiography in patients with low back pain referred
for imaging, with nearly identical clinical outcomes (essentially a cost-minimization
analysis) [101].

Summary of evidence

1087

- Routine plain radiography did not identify any additional serious diseases
 compared to usual care and did not improve outcomes including pain and
 functional status, though there appeared to be modest beneficial effects on
 patient satisfaction and psychologic well-being (two trials, one higher-quality)
 (level of evidence: fair).
- In one lower-quality trial, the combination of delayed selective imaging with a brief educational intervention was not associated with differences in any outcomes relative to routine plain radiography, including patient satisfaction and psychologic distress (level of evidence: poor).
- Routine MRI was associated with only minor benefits on pain and functional status outcomes compared to selective imaging in one higher-quality trial. A lower-quality trial found that in patients who had undergone MRI, disclosure of results was not associated with improved outcomes compared to non-disclosure unless clinically necessary (level of evidence: fair).
- In two higher-quality trials, rapid MRI was not associated with any significant
 benefits compared to plain radiography in patients in whom imaging was thought
 indicated (level of evidence: good).
- 1105 **Recommendations and findings from other guidelines**
- The AHCPR guidelines recommend against plain radiography for routine evaluation of patients with acute low back problems within the first month of symptoms, unless a red flag is noted on clinical examination (strength of evidence: B).
- The AHCPR guidelines state that in patients without red flags, after 1 month of symptoms, an imaging test is acceptable when surgery is being considered (or to rule out a suspected serious condition) (strength of evidence: B).
- The UK RCGP guidelines recommend avoidance of unnecessary or repeated x-rays, noting that lumbar spine x-rays involve 150 times the radiation of a chest x-ray (strength of evidence: ***).
- The European COST guidelines recommend against routine diagnostic imaging for acute or chronic nonspecific low back pain.

1118

- 1119 Key Question 3.
- 1120 What is the effectiveness of different non-invasive interventions for non-specific
- 1121 low back pain, radicular LBP, or spinal stenosis, and under what circumstances?

1122 Medications

1123 Acetaminophen

- 1124 Search results: systematic reviews
- 1125 We identified one recent, lower-quality systematic review of medications for low back
- pain that included trials of acetaminophen [105]. In addition, a higher-quality Cochrane
- 1127 review of NSAIDs for low back pain included trials comparing acetaminophen to
- 1128 NSAIDs [106, 107]. The systematic reviews included three to five short-term (five week
- or less in duration) trials, only one of which was rated high quality [108]. We excluded
- 1130 two relevant but older systematic reviews [109, 110].
- 1131 Search results: trials
- 1132 We identified two lower-quality trials of acetaminophen not included in the systematic
- 1133 reviews [111, 112]. Both compared acetaminophen to other active interventions.
- 1134 Efficacy of acetaminophen versus placebo
- 1135 We found no trials comparing acetaminophen to placebo in patients with low back pain.
- 1136 Efficacy of acetaminophen versus NSAIDs
- 1137 The Cochrane review included three lower-quality trials with conflicting evidence on the
- 1138 efficacy of acetaminophen relative to NSAIDs for acute low back pain [106, 107]. Two
- trials [113, 114] reported no difference in outcomes between acetaminophen and
- 1140 NSAIDs, but a third found that two of four evaluated NSAIDs were superior to
- acetaminophen [115]. Another trial of patients with back pain of mixed acute and
- 1142 chronic duration found no differences between acetaminophen and flurbiprofen [116].
- 1143 In patients with chronic low back pain, one higher-quality trial (included in both
- 1144 systematic reviews) found acetaminophen inferior to diflunisal for the proportion of
- 1145 patients reporting good or excellent efficacy after four weeks (10 of 16 vs. 4 of 12,
- 1146 p=0.01), though the proportion reporting no or mild low back pain was similar (13 of 16
- 1147 vs. 7 of 12) [108]. Although there are no other trials of acetaminophen versus NSAID
- 1148 for chronic low back pain, there is consistent evidence from good-quality systematic

- 1149 reviews of patients with osteoarthritis that acetaminophen is modestly inferior for pain
- 1150 relief [117-120].
- 1151 Efficacy of acetaminophen versus other interventions
- 1152 In single, lower-quality trials, acetaminophen was inferior to amitriptyline [121] and
- 1153 electroacupuncture [112]. Other trials found no difference between acetaminophen,
- 1154 codeine, phenylbutazone, or the combination of aspirin plus oxycodone for rates of
- 1155 'return to work' [114] or between acetaminophen and either physical therapy, a corset,
- 1156 or spinal manipulation for pain or other assessed outcomes [111].
- 1157 Safety
- 1158 Adverse events associated with acetaminophen were poorly reported in trials of patients
- 1159 with low back pain. In two higher-quality systematic reviews of osteoarthritis patients,
- 1160 acetaminophen was superior to NSAIDs for gastrointestinal tolerability and other GI side
- 1161 effects [118, 120]. However, despite the perceived safety advantages of
- acetaminophen, data from clinical trials on serious side effects like bleeding,
- 1163 hypertension, and myocardial infarction are sparse. Observational data suggest that
- acetaminophen is associated with a lower rate of GI bleeding compared to NSAIDs
- 1165 [122, 123], but may be associated with modest increases in blood pressure [124-126]
- and renal dysfunction [127]. Although requiring further study, one recent analysis from
- 1167 the Nurses' Health Study also suggests that heavy use of acetaminophen may be
- 1168 associated with an increased risk of cardiovascular events similar in magnitude to heavy
- 1169 use of NSAIDs [128]. Although acetaminophen is associated with potentially fatal
- 1170 overdose, use at approved levels does not appear to increase the risk of hepatotoxicity
- 1171 in patients without liver problems.
- 1172 Costs
- 1173 We found no studies evaluating costs.
- 1174 Summary of evidence
- There is conflicting evidence from lower quality trials regarding the efficacy of acetaminophen versus NSAIDs for acute low back pain, with most showing no difference in outcomes (level of evidence: fair).
- For chronic low back pain, one higher quality trial found acetaminophen inferior
 to an NSAID on an overall assessment of efficacy (level of evidence: fair).

1180 1181	 Multiple trials of patients with osteoarthritis consistently found acetaminophen inferior to NSAIDs for pain relief (level of evidence: good).
1182 1183 1184	 There is insufficient evidence from single, lower quality trials comparing acetaminophen to other interventions (such as physical therapy, a corset, or spinal manipulation) to accurately judge relative efficacy (level of evidence: poor).
1185 1186 1187	 Acetaminophen is associated with a lower risk of serious GI side effects compared to NSAIDs based primarily on observational data (level of evidence: fair).
1188	 Acetaminophen is better tolerated than NSAIDs (level of evidence: good).
1189 1190 1191	 Additional studies are required to evaluate whether high-dose acetaminophen is associated with increased cardiovascular risk (single observational study) (level of evidence: poor).
1192	Recommendations and findings from other guidelines
1193 1194	 The AHCPR guidelines found acetaminophen reasonably safe and acceptable for treating patients with acute low back problems (strength of evidence: C).
1195	 The VA/DoD guideline recommendations are identical to AHCPR's.
1196 1197	 The UK RCGP guideline found that comparisons of effectiveness between acetaminophen and NSAIDs are inconsistent (strength of evidence: **).
1198 1199	 The European COST guidelines recommend acetaminophen as first choice when needed for pain relief in patients with acute low back pain.
1200	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
1201	Non-selective, non-steroidal anti-inflammatory drugs
1202 1203	Results of search: systematic reviews We identified two systematic reviews [105-107] evaluating the efficacy of non-selective
1203	NSAIDs in patients with non-specific low back pain. One is a higher-quality Cochrane
1204	review of 51 trials (16 rated high quality) [106, 107]. A third, fair quality systematic
1206	review evaluated the efficacy of NSAIDs in patients with sciatica [129]. We excluded
1207	four older systematic reviews [110, 130-132].
1208	Results of search: trials
1209	We did not search for additional trials.
1210	Efficacy of NSAIDs versus placebo
1211	The Cochrane review estimated a pooled relative risk (3 trials) for global improvement in
1212	patients with acute low back pain of 1.24 (95% CI 1.10 to 1.41) after one week of

- 1213 NSAID relative to placebo and 1.29 (95% CI 1.05 to 1.57) for not requiring additional
- 1214 analgesics [106, 107]. Qualitatively, two of four higher quality trials included in the
- 1215 Cochrane review reported better pain relief with NSAIDs compared to placebo and two
- 1216 found no differences. In a single trial of patients with chronic low back pain (rated
- 1217 higher-quality), an NSAID (ibuprofen) was superior to placebo [133].
- 1218 The second, lower-quality systematic review was not as comprehensive (21 trials) as
- 1219 the Cochrane review [105]. It also concluded that NSAIDs are effective for acute low
- 1220 back pain The third systematic review, which focused on a subset of trials evaluating
- 1221 patients with sciatica, found no difference between NSAIDs and placebo (3 trials, OR
- 1222 0.99, 95% CI 0.6 to 1.7) [129].
- 1223 Efficacy of NSAIDs versus other interventions
- 1224 The Cochrane review found moderate evidence that NSAIDs are not more effective
- than opioid analgesics or muscle relaxants (6 trials, 1 higher-quality) [106, 107].
- 1226 However, small sample sizes (N=19 to 44) could have reduced the ability of some trials
- 1227 to detect differences. The Cochrane review also included two trials that found that
- 1228 NSAIDs are not more effective than physiotherapy or spinal manipulation and two trials
- 1229 that reached discordant conclusions about the efficacy of NSAIDs relative to bed rest in
- 1230 patients with acute low back pain.
- 1231 Efficacy of different NSAIDs
- 1232 The Cochrane review included multiple (24) trials that provided no evidence suggesting
- 1233 that any one NSAID is superior to others for pain relief [106, 107].
- 1234 Safety
- The Cochrane review found that NSAIDs were associated with similar risk of adverse
 events compared to placebo (RR 0.83, 95% CI 0.64 to 1.08) [106, 107]. However, the
 trials included in the systematic reviews were not designed to evaluate risks of serious
 harms such as GI bleeds and CV events. When taken for a variety of indications,
- 1239 NSAIDs are associated with an increased risk for serious GI complications such as
- 1240 bleeding and perforation that increases with age [134, 135]. In a recent, meta-analysis
- 1241 evaluating the cardiovascular safety of NSAIDs, all non-selective NSAIDs other than
- 1242 naproxen were associated with an increased rate of myocardial infarction (about 1
- 1243 additional myocardial infarction for every 300 patients treated for one year with an

- 1244 NSAID versus non-use) [136]. Because of concerns about potential cardiovascular
- 1245 risks, the FDA recently required labeling revisions stating additional warnings for all
- 1246 non-selective NSAIDs [137].
- 1247 Costs
- 1248 We found no studies evaluating costs.

1249 Summary of evidence

- There is evidence from multiple trials that NSAIDs are associated with modest short-term pain relief compared to placebo in patients with acute low back pain (level of evidence: good).
- A single higher quality trial found that NSAIDs are effective in patients with chronic low back pain (level of evidence: fair).
- NSAIDs have not been shown to be more effective than other medications
 (opioids, skeletal muscle relaxants) or non-invasive interventions (spinal
 manipulation, physical therapy, bed rest) (level of evidence: fair).
- There is no evidence that any NSAID is more effective than any other (level of evidence: good).
- NSAIDs are associated with an increased risk of serious GI complications compared to non-use (level of evidence: good).
- NSAIDs other than naproxen were associated with a modest increase in risk of cardiovascular complications relative to non-use in one recent meta-analysis of randomized controlled trials (level of evidence: good).
- 1265 **Recommendations and findings from other guidelines**
- The AHCPR guidelines found NSAIDs acceptable for treating patients with acute
 low back problems (strength of evidence: B).
- The AHCPR guidelines found that NSAIDs have a number of potential side
 effects, with the most frequent gastrointestinal irritation. They recommend the
 decision to use these medications to be guided by comorbidity, side effects, cost,
 and patient and provider preference (strength of evidence: C).
- The VA/DoD and UK RCGP guidelines for NSAIDs are similar to the AHCPR
 recommendations.
- Both the VA/DoD (strength of evidence: B) and UK RCGP (strength of evidence:
 ***) guidelines found that various NSAIDs are equally effective for low back pain.
- The UK RCGP guidelines also found that NSAIDs are less effective for the reduction of nerve root pain (strength of evidence: **).

The European COST guidelines recommend NSAIDs as second choice (after paracetamol) when needed for pain relief in patients with acute low back pain.
 They also recommend NSAIDs for pain relief in patients with chronic low back pain, but only for exacerbations or short-term periods (up to 3 months).

1282 COX-2 selective NSAIDs

- 1283 COX-2 selective NSAIDs have a theoretical advantage over non-selective
- 1284 NSAIDs for causing fewer GI complications because they don't block the cyclo-
- 1285 oxygenase-1 enzyme, which helps protect the stomach lining. However, rofecoxib and
- 1286 valdecoxib were both voluntarily withdrawn from the market after the publication of trials
- 1287 indicating an increased risk of myocardial infarction [138, 139]. Celecoxib is currently
- 1288 the only COX-2 selective NSAID available in the U.S.
- 1289 Results of search: systematic reviews
- 1290 No trials of COX-2 inhibitors were included in the Cochrane review of NSAIDs [106,
- 1291 107]. We identified no other systematic reviews evaluating COX-2 inhibitors in patients
- 1292 with low back pain.
- 1293 Results of search: trials
- 1294 Although we identified eight trials of COX-2 inhibitors in patients with low back pain
- 1295 [140-147], none evaluated celecoxib, the only drug in this class currently available in the
- 1296 U.S. We did not review these trials further.
- 1297 Efficacy of COX-2 inhibitors
- 1298 In trials of patients with osteoarthritis and rheumatoid arthritis, there was no clear
- 1299 difference in efficacy or tolerability between celecoxib and non-selective NSAIDs for
- 1300 pain relief, functional outcomes, or other measures of clinical efficacy [148, 149].
- 1301 Safety
- 1302 Celecoxib was associated with a lower rate of GI complications compared to non-
- 1303 selective NSAIDs in a meta-analysis of primarily short-term randomized trials [149]. In
- 1304 the only long-term study designed to assess ulcer complications (the CLASS trials),
- 1305 celecoxib was associated with fewer gastrointestinal complications after 6 months
- 1306 compared to diclofenac, but not compared to ibuprofen [150]. However, this benefit was
- no longer present after longer follow-up, in part due to high loss to follow-up [151]. No
- 1308 GI safety advantage was seen with celecoxib in the subgroup of patients taking aspirin.

- 1309 An increased risk of myocardial infarction in patients randomized to celecoxib compared
- 1310 to placebo was observed in a recently published long-term polyp prevention trial [152].
- 1311 The most comprehensive meta-analysis also reported an increased risk of myocardial
- 1312 infarction with celecoxib compared to placebo when given for a variety of indications
- 1313 [136]. Other than naproxen, which was associated with a lower risk of myocardial
- 1314 infarction, the risk of MI with selective and non-selective NSAIDs in this meta-analysis
- 1315 was similar.
- 1316 Costs
- 1317 We found no studies evaluating costs.
- 1318 Summary of evidence
- Systematic reviews of COX-2-selective NSAIDs given for a variety of indications found no clear differences in efficacy (pain relief) relative to non-selective NSAIDs (level of evidence: good).
- Celecoxib is associated with a lower risk of GI complications compared to non selective NSAIDs, but most of the evidence comes from short-term trials (level of
 evidence: good).
- Celecoxib appears to be associated with an increased risk of myocardial infarction compared to placebo (level of evidence: good).
- 1327 Aspirin
- 1328 Like the non-aspirin NSAIDs, aspirin (acetylsalicylic acid) has anti-inflammatory
- 1329 and analgesic effects. An important distinction between aspirin and non-aspirin
- 1330 NSAIDs, however, is that aspirin also induces long-lasting functional defects in platelets,
- 1331 and is therefore also used for primary and secondary prevention of thrombotic events,
- 1332 though usually in lower doses than those used for pain relief.
- 1333 Results of search: systematic reviews
- 1334 We identified no systematic reviews evaluating the efficacy of aspirin for low back pain.
- 1335 Results of search: trials
- 1336 We identified one lower-quality trial evaluating the efficacy of aspirin versus multiple
- 1337 comparator drugs in patients with acute low back pain [115].

- 1338 Efficacy of aspirin versus other analgesics
- 1339 The single relevant trial found that aspirin at 3600 mg/day was associated with a lower
- 1340 mean daily pain index scores (3 point scale, 1.425 vs. 1.713, p<0.05) compared to the
- 1341 combination of dextropropoxyphene + acetaminophen, but was not significantly different
- 1342 than indomethacin, mefenamic acid, acetaminophen alone, or phenylbutazone [115].
- 1343 Aspirin also received the highest patient preference rating, though the difference was
- 1344 only significant compared to mefenamic acid and phenylbutazone (2.37 vs. 1.75 and
- 1345 1.68, respectively, on a 3-point scale).
- 1346 Safety
- 1347 Most trials evaluating gastrointestinal bleeding risk and cardioprotective effects with
- 1348 aspirin have been conducted in patients receiving it for prophylaxis and at lower doses
- 1349 (50 mg to 1500 mg/day) than considered effective for full analgesic and anti-
- 1350 inflammatory effects. In a good-quality meta-analysis of 24 such randomized trials with
- nearly 66,000 participants, the risk of gastrointestinal hemorrhage was 2.47% with
- 1352 aspirin compared with 1.42% with placebo (OR 1.68, 95% CI 1.51 to 1.88), based on an
- 1353 average of 28 months therapy [153]. There was no relation between gastrointestinal
- 1354 hemorrhage and dose, and modified release formulations did not attenuate the risk for
- 1355 bleeding.
- 1356 Costs
- 1357 We found no studies evaluating costs.
- 1358 Summary of evidence
- There is insufficient evidence to judge the efficacy of aspirin in patients with low back pain (level of evidence: poor).
- Aspirin is associated with an increased risk of GI bleeding even at low doses
 (level of evidence: good).
- Aspirin is effective in the primary and secondary prevention of cardiovascular
 events (level of evidence: good).
- 1365 **Recommendations and findings from other guidelines**
- The AHCPR guidelines do not consider aspirin separately from other NSAIDs.

1367 Other Medications

1368 Antidepressants

1369 Certain antidepressants (particularly those that inhibit norepinephrine uptake) are 1370 thought to have potential pain-modulating properties independent from their effects on 1371 depression. However, two earlier systematic reviews concluded that in patients with low 1372 back pain, there was either insufficient evidence to recommend their use [154] or 1373 moderate evidence that they were not effective [110].

- 1374 Results of search: systematic reviews
- 1375 We identified four recent systematic reviews evaluating the efficacy of antidepressants
- 1376 for low back pain [105, 155-157]. The two higher-quality systematic reviews included
- 1377 seven [157] and nine [156] placebo-controlled trials ranging from 6 to 16 weeks in
- 1378 duration. One of the other systematic reviews [105] also included one head-to-head
- trial [158] of antidepressants and one trial [121] comparing an antidepressant to
- 1380 acetaminophen. We excluded four older systematic reviews [110, 154, 159, 160].
- 1381 Results of search: trials
- 1382 We did not search for additional trials.
- 1383 Efficacy of antidepressants versus placebo

1384 The overall conclusions of the two higher-quality systematic reviews appeared 1385 concordant [156, 157]. One found tricyclic or tetracyclic antidepressants superior to 1386 placebo for at least one pain-related outcome measure in four of five trials of patients 1387 with chronic low back pain (analgesic effect size 0.43 [161] and 0.69 [162] in the 2 1388 highest quality studies) [157]. Effects on functional outcomes were inconsistently 1389 reported and did not suggest a clear benefit. The only tetracyclic antidepressant 1390 evaluated was maprotiline, a drug not available in the U.S. [161]. None of the trials 1391 evaluated norepinephrine-serotonin reuptake inhibitors such as duloxetine or 1392 venlafaxine. There were no beneficial effects seen in three trials of antidepressants 1393 without inhibitory effects on norepinephrine uptake (paroxetine and trazodone)

1394 compared to placebo.

1395 The second higher-quality systematic review found that all antidepressants pooled

- 1396 together are effective for improving pain severity (standardized mean difference 0.41,
- 1397 95% CI 0.22 to 0.61), though not for activities of daily living (standardized mean

difference 0.25, 95% CI –0.21 to 0.69) [156]. Although the conclusions were reported
as insensitive to antidepressant class (statistics not reported), the point estimates from
individual studies suggests that paroxetine and trazodone were associated with the
least benefit.

- 1402 The other two systematic reviews came to similar conclusions regarding the efficacy of
- 1403 antidepressants relative to placebo for chronic low back pain [105, 155]. No trials
- 1404 evaluated the efficacy of antidepressants versus placebo for acute low back pain.
- 1405 *Efficacy of one antidepressant versus another antidepressant*
- 1406 Two head-to-head trials provided somewhat conflicting evidence on the relative efficacy
- 1407 of different antidepressant classes: one higher quality trial [162] found maprotiline
- 1408 superior to paroxetine for pain relief in patients with chronic low back pain (-45% vs. –
- 1409 27%, p=0.013), but one lower quality trial [158] found that similar proportions of patients
- 1410 randomized to amitriptyline and fluoxetine reported at least moderate pain relief (82%
- 1411 vs. 77%).
- 1412 Efficacy of antidepressants versus other interventions
- 1413 There is little evidence regarding the efficacy of antidepressants relative to other
- 1414 medications for low back pain. A single, small (N=39), lower-quality trial included in one
- 1415 of the systematic reviews [105] found amitriptyline superior to acetaminophen for pain
- relief (p=0.045) in patients with acute low back pain [121].
- 1417 Safety
- 1418 One systematic review found antidepressants associated with a higher risk for any
- 1419 adverse event compared to placebo (22% vs. 14%, p=0.01), though adverse events
- 1420 were generally not well reported [156]. Drowsiness (7%), dry mouth (9%), dizziness
- 1421 (7%) and constipation (4%) were the most commonly reported events. The trials were
- 1422 not designed to assess the risk of serious adverse events such as overdose, increased
- 1423 suicidality, and arrhythmias associated with antidepressant use.
- 1424 Costs
- 1425 We found no studies evaluating costs.

1426	Summary of evidence
1427 1428 1429	 Tricyclic antidepressants are consistently more effective than placebo for pain relief and other outcomes in higher-quality trials of patients with chronic low back pain, but do not appear to improve functional outcomes (level of evidence: good).
1430 1431	 Several trials suggest that paroxetine and trazodone not effective or marginally effective compared to placebo (level of evidence: fair).
1432 1433 1434	 There is insufficient evidence from head-to-head trials (one lower-quality trial) to judge the relative effectiveness of tricyclic antidepressants and selective serotonin reuptake inhibitors (level of evidence: poor).
1435 1436 1437	 There are no trials on the effectiveness of other antidepressants (such as venlafaxine or duloxetine), and insufficient evidence to judge the efficacy of antidepressants for acute low back pain (level of evidence: poor).
1438 1439 1440	 Although serious adverse events were not reported in the trials, the selected populations evaluated in clinical trials may make it difficult to extrapolate results to general practice (level of evidence: poor).
1441	
1442	Recommendations and findings from other guidelines
1443 1444	 The AHCPR guidelines recommend against use of antidepressant medications for acute low back problems (strength of evidence: C).
1445 1446 1447	 The VA/DoD guidelines do not address antidepressant medications, and the UK RCGP guidelines found little evidence on their effectiveness for chronic low back pain, and none for acute low back pain (strength of evidence: *).
1448 1449 1450 1451	• The European COST guidelines recommend consideration of noradrenergic or noradrenergic-serotoninergic antidepressants as co-medications for pain relief in patients with chronic low back pain without renal disease, glaucoma, pregnancy, chronic obstructive pulmonary disease, or heart failure.
1452	Benzodiazepenes
1453	Results of search: systematic reviews
1454	We identified two systematic reviews evaluating benzodiazepenes for low back pain
1455	[105, 163, 164]. Of these, a recent higher-quality Cochrane review was the most
1456	comprehensive (8 trials of benzodiazepenes) [163, 164]. We excluded two relevant but

- 1457 older systematic reviews [109, 110].
- 1458 Results of search: trials
- 1459 We did not search for additional trials

- 1460 *Efficacy of benzodiazepines versus placebo*
- 1461 The Cochrane review included a single, lower-quality placebo-controlled trial of
- 1462 benzodiazepines in patients with acute low back pain. It found diazepam associated
- 1463 with better short-term pain relief and overall improvement [165]. Of three trials in
- 1464 patients with chronic low back pain, two higher-quality trials found that tetrazepam (not
- 1465 available in the U.S.) was associated with better short-term pain relief (RR 0.71, 95% CI
- 1466 0.54 to 0.93) and overall improvement (RR 0.63, 95% CI 0.42 to 0.97) after 10-14 days
- 1467 [166, 167]. On the other hand, a lower-quality placebo-controlled trial of diazepam
- 1468 found no benefit [168]. Results of a second systematic review were consistent with the
- 1469 Cochrane review [105].
- 1470 Efficacy of benzodiazepine versus skeletal muscle relaxant
- 1471 There were no differences between diazepam and either tizanidine [169] or
- 1472 cyclobenzaprine [168] in two trials included in the Cochrane review. In a third, high
- 1473 quality trial, diazepam was inferior to carisoprodol for muscle spasm, global efficacy
- 1474 (excellent or very good 70% vs. 45%), and functional status [170].
- 1475 Safety
- 1476 Central nervous system events such as somnolence, fatigue, and lightheadedness were
- 1477 reported more frequently with benzodiazepines compared to placebo [163, 164]. No
- 1478 trial evaluated risks with long-term use such as addiction, abuse, overdose, or
- 1479 development of tolerance in patients with low back pain.
- 1480 Costs
- 1481 We found no studies evaluating costs.
- 1482Summary of evidence
- There is insufficient evidence to judge the efficacy of benzodiazepines (1 lowerquality trial) for acute low back pain (level of evidence: poor).
- Two higher quality trials indicate that benzodiazepines are effective for short-term outcomes in patients with chronic low back pain (level of evidence: fair).
- Diazepam was inferior to carisoprodol (a drug metabolized to meprobamate) in
 one higher quality trial, but no different than other skeletal muscle relaxants in
 two other trials (level of evidence: fair).
- Benzodiazepines are associated with increased short-term central nervous system adverse events (level of evidence: good). Risks of addiction, abuse,

development of tolerance, and overdose, particularly with long-term use, areunknown.

1494 **Recommendations and findings from other guidelines**

- The UK RCGP guidelines note that benzodiazepines for more than two weeks carry a significant risk of habituation and dependency (strength of evidence: **)
- The European COST guidelines recommendations for muscle relaxants and benzodiazepines are the same.

1499 Gabapentin

1500 Gabapentin is an anticonvulsant shown to be effective in patients with

neuropathic pain [171, 172]. One advantage of gabapentin over older anticonvulsants

- 1502 is its superior safety profile. However, the efficacy of gabapentin in patients with
- 1503 radicular (or non-radicular) low back pain has not been well studied.
- 1504 Results of search: systematic reviews
- 1505 We identified no systematic reviews evaluating the efficacy of gabapentin in patients
- 1506 with low back pain.
- 1507 Results of search: trials
- 1508 We identified two short-term (six to eight weeks), randomized, placebo-controlled trials
- 1509 evaluating the efficacy of gabapentin in patients with radiculopathy [173, 174]. One was
- 1510 rated higher quality [173].
- 1511 Efficacy of gabapentin versus placebo
- 1512 In the higher-quality trial, neither gabapentin nor placebo was associated with an
- 1513 improvement in resting back pain compared to baseline after six weeks (Table 10)
- 1514 [173]. However, gabapentin (but not placebo) was associated with small improvements
- 1515 compared to baseline on assessments of back pain with movement and of leg pain,
- 1516 though it was not clear if between-group differences were significant. In the other,
- 1517 lower-quality trial, patients with radiculopathy had greater improvement in pain at rest
- 1518 with gabapentin versus placebo at the end of treatment [174]

1519

1519

Table 10. Trials of gabapentin versus placebo in patients with radicular low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Yildirim, 2003[174]	N=50 8 weeks	Gabapentin titrated to 3600 mg/day versus placebo Back pain at rest (mean change from baseline on 0-3 scale): -1.04 vs0.32, p<0.01	3/11
McCleane, 2001[173]	N=80 6 weeks	Gabapentin titrated to 1200 mg/day versus placebo Back pain at rest (mean change from baseline on 0-10 VAS): -0.51 (NS) vs. 0.1 (NS) Back pain with movement (mean change from baseline on 0-10 VAS): -0.47 (p<0.05) vs. +0.01 (NS) Leg pain (mean change from baseline on 0-10 VAS): - 0.45 (p<0.05) vs0.24 (NS)	8/11

- 1520
- 1521 Safety
- 1522 Withdrawal due to adverse events occurred in 2 of 25 patients randomized to
- 1523 gabapentin versus none of 25 randomized to placebo in one trial [174]. No withdrawals
- 1524 due to adverse events occurred in the other trial [173]. However, drowsiness (6%), loss
- 1525 of energy (6%), and dizziness (6%) were reported with gabapentin [173].
- 1526 Cost-effectiveness
- 1527 We found no studies evaluating cost-effectiveness.
- 1528 Summary of evidence 1529 Limited evidence from two trials (one higher quality) suggests that gabapentin is • 1530 associated with modest short-term benefits for pain relief in patients with radiculopathy (level of evidence: fair). 1531 1532 There are no trials evaluating the efficacy of gabapentin in patients with non-1533 radicular low back pain. 1534 Recommendations and findings from other guidelines 1535 The European COST guidelines found insufficient evidence to recommend • 1536 gabapentin in patients with chronic nonspecific low back pain. 1537 **Muscle relaxants** 1538 Skeletal muscle relaxants are a heterogeneous group of medications used to 1539 treat two distinct underlying conditions: spasticity from the upper motor neuron 1540 syndrome and pain or spasms from musculoskeletal conditions such as non-specific low 1541 back pain. The muscle relaxants carisoprodol, chlorzoxazone, cyclobenzaprine,
 - 1542 metaxalone, methocarbamol, and orphenadrine carry FDA-approved indications for

- 1543 treatment of musculoskeletal conditions. Although the other drugs in this class
- 1544 (baclofen, dantrolene, and tizanidine) are approved only for the treatment of spasticity,
- 1545 there is some overlap in clinical usage. In particular, tizanidine has also been studied in
- 1546 patients with musculoskeletal conditions such as low back pain. Benzodiazepines are
- 1547 commonly used as muscle relaxants, though they are not FDA-approved for this
- 1548 indication (see section on benzodiazepenes).
- 1549 Results of search: systematic reviews
- 1550 We identified four systematic reviews evaluating the efficacy and safety of muscle
- relaxants for low back pain [105, 129, 163, 164, 175]. Of these, a recent higher-quality
- 1552 Cochrane review was the most comprehensive (25 trials of skeletal muscle relaxants)
- 1553 [163, 164]. We excluded two older systematic reviews [109, 110].
- 1554 Results of search: trials
- 1555 We found no trials comparing the efficacy of muscle relaxants to acetaminophen or1556 NSAIDs.
- 1557 Efficacy of skeletal muscle relaxants versus placebo
- 1558 The Cochrane review included eight trials that found skeletal muscle relaxants muscle 1559 relaxants superior to placebo for short-term (2 to 4 days) pain relief (at least a two-point 1560 or 30% improvement on an 11 point pain rating scale) and global efficacy in patients 1561 with acute low back pain [163, 164]. From 3 higher quality trials and one lower quality 1562 trial that could be pooled, the relative risk for pain relief was 0.80 (0.71 to 0.89) after 2 to 1563 4 days and 0.58 (0.45 to 0.76) after 5 to 7 days. The relative risk for greater global 1564 efficacy was 0.49 (0.25 to 0.95) after 2 to 4 days and 0.68 (0.41 to 1.13) after 5 to 7 1565 davs.
- 1566 The Cochrane review also included three trials of patients with chronic low back pain.
- 1567 Only one—a lower-quality trial of cyclobenzaprine that did not report pain intensity or
- 1568 global efficacy outcomes—evaluated a skeletal muscle relaxant available in the U.S.
- 1569 [168].
- 1570 Results from three other systematic reviews were concordant with the Cochrane review.
- 1571 A less comprehensive, qualitative systematic review reached similar overall conclusions
- 1572 [105]. Another systematic review focusing on one skeletal muscle relaxant found

1573 cyclobenzaprine modestly superior to placebo (effect size 0.38 to 0.58) for pain, muscle

- 1574 spasm, tenderness to palpation, range of motion, and activities of daily living, with the
- 1575 greatest benefit seen within the first few days of treatment [175]. The third systematic
- 1576 review, focussing on treatments for sciatica, included one trial demonstrating no
- 1577 benefits from tizanidine over placebo [129].

1578 *Efficacy of different muscle relaxants*

- 1579 The Cochrane review found no clear evidence that any muscle relaxant was superior to
- 1580 others for efficacy or safety in patients with low back pain [163, 164]. A systematic
- review of muscle relaxants for broader indications came to similar conclusions [176].
- 1582 However, the amount of supporting evidence for different skeletal muscle relaxants
- 1583 varies widely. Cyclobenzaprine is by far the best-studied drug. One the other hand,
- 1584 there is sparse evidence (two trials) on the effectiveness of the antispasticity drugs
- 1585 dantrolene and baclofen for either chronic or acute low back pain [163, 164].

1586 Safety

- 1587 The Cochrane review found that skeletal muscle relaxants are associated with more
- 1588 total adverse events and central nervous system adverse effects than placebo (RR
- 1589 1.50, 95% CI 1.14 to 1.98 and 2.04, 95% CI 1.123 to 3.37, respectively), though most
- are self-limited and serious complications appear rare [163, 164]. Certain skeletal
- 1591 muscle relaxants are associated with specific safety issues. Because of its metabolism
- 1592 in part to meprobamate, a drug removed from the market due to addiction and overdose
- 1593 potential, carisoprodol is a controlled substance in some states (though not federally
- 1594 controlled). Dantrolene carries a black box warning on its label about potentially fatal
- 1595 hepatotoxicity. Chlorzoxazone and tizanidine are also associated with usually self-
- 1596 limited and mild hepatotoxicity [176].
- 1597 Costs
- 1598 We found no studies evaluating costs.

1599 Summary of evidence

 Skeletal muscle relaxants are consistently more effective than placebo for shortterm (less than one week) pain relief and global response in patients with acute low back pain (level of evidence: good).

1603 1604 1605	• There is insufficient evidence to judge the efficacy of skeletal muscle relaxants in patients with chronic low back pain or those with sciatica (level of evidence: poor).
1606	 Although there is no evidence proving that one skeletal muscle relaxant is
1607	superior to others (level of evidence: fair), the efficacy of cyclobenzaprine is
1608	supported by the most evidence.
1609	 Skeletal muscle relaxants are associated with an increased rate of adverse
1610	events compared to placebo, though they are usually mild and self-limited (level
1611	of evidence: fair).
1612	 Specific safety issues are associated with carisoprodol (metabolism to
1613	meprobamate), dantrolene (potentially fatal hepatotoxicity), chlorzoxazone and
1614	tizanidine (usually reversible and mild hepatotoxicity).
1615	Recommendations and findings from other guidelines
1616	 The AHCPR guidelines recommend muscle relaxants as an option in the
1617	treatment of low back pain problems. While they found muscle relaxants
1618	probably more effective than placebo, they also found that muscle relaxants had
1619	not been shown to be more effective than NSAIDs (strength of evidence: C).
1620	 The AHCPR guidelines recommend balancing potential side effects (particularly
1621	drowsiness) associated with muscle relaxants against a patient's intolerance for
1622	other agents when considering the optional use of muscle relaxants (strength of
1623	evidence: C).
1624	 The VA/DoD guidelines are identical to the AHCPR guidelines.
1625	 The UK RCGP guidelines are similar to the AHCPR recommendations, but rated
1626	evidence on the effectiveness of muscle relaxants for acute back pain more
1627	highly (strength of evidence: ***).
1628	 The European COST guidelines recommend adding a short course of muscle
1629	relaxants on its own or added to NSAIDs in patients with acute low back pain, if
1630	acetaminophen or NSAIDs failed to reduce pain.
1631 1632 1633 1634	• The European COST guidelines recommend considering muscle relaxants for short-term pain relief in chronic low back pain, but to use them cautiously because of side effects and use other pain relieving drugs with fewer side effects first.
1635	Opioid analgesics
1636	Opioid analgesics are a class of medications that act on common receptors and
1637	are natural derivatives of morphine. They are available in immediate-release and

1638 sustained-release formulations, and can be administered via a variety of routes (most

- 1639 commonly oral or transdermal). Opioids are the most potent medications available for
- 1640 treatment of most types of severe pain. However, they are also associated with a
- 1641 variety of adverse events, including nausea, somnolence, respiratory depression,
- 1642 overdose, abuse, and addiction.
- 1643 Results of search: systematic reviews
- 1644 We identified two systematic reviews evaluating the efficacy of medications for low back
- 1645 pain that included trials of opioids [105, 110]. One only included two trials evaluating
- 1646 opioids in combination with another analgesic [105]. The other systematic review [110]
- 1647 included one additional trial [114]. We excluded two other reviews that did not clearly
- 1648 use systematic methods [177, 178] and one older systematic review [109]. None
- 1649 included additional relevant trials. One other recent systematic review evaluated the
- 1650 efficacy and safety of opioids in 15 double-blind, placebo-controlled trials of patients
- 1651 with non-cancer pain, but none specifically evaluated patients with low back pain [179].
- 1652 Results of search: trials
- 1653 We identified nine trials (one higher-quality [180]) evaluating the efficacy of opioids in
- 1654 patients with low back pain. Two were placebo-controlled [180, 181]. Two trials
- 1655 compared opioids to either NSAIDs or acetaminophen [114, 182]. The remainder
- 1656 compared different opioid drugs or formulations (long versus short-acting). All of the
- trials were less than 3 weeks in duration except for two (one 16 weeks [182], the other
- 1658 13 months [183]).

1659 Efficacy of opioids versus placebo

- 1660 One higher-quality, placebo-controlled trial (N=235) found that long-acting oxymorphone 1661 and long-acting oxycodone were both superior to placebo for pain relief after 18 days in 1662 patients with chronic low back pain (difference in pain relief about 18 points on a 100 1663 point scale) [180]. The active treatments were also superior to placebo for several 1664 outcomes assessing functional status (Table 11). A problem with interpreting these 1665 results is that all patients were titrated to stable doses of opioids prior to randomization, 1666 so differences between the active treatments and placebo could have been due in part 1667 to cessation of opioids and withdrawal.
- 1668 The other, lower-quality placebo-controlled trial found that in patients with acute or 1669 chronic low back pain, the weak opioid propoxyphene was no better than placebo for

- 1670 improvement in pain scores or assessments of global improvement [181]. In addition,
- 1671 patients on proposyphene reported greater improvements than placebo in only one of
- 1672 three sleep parameters (difficulty falling asleep).
- 1673

Table 11. Trials of an opioid versus placebo in patients with low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hale, 2005[180]	N=235 18 days	Long-acting morphine versus long-acting oxycodone versus placebo Pain intensity (100 point VAS), mean differences versus placebo: -18.21 vs18.55 (p=0.0001 for each comparison) Global assessment at least 'good': 59% vs. 63% vs. 27%	7/11
Barratta, 1976[181]	N=61 14 days	Propoxyphene versus placebo Pain on active improvement (mean improvement from baseline): 0.8 vs. 0.4, NS Global improvement at least 'satisfactory': 22% vs. 14% (NS)	4/11

1674

1675 A systematic review of 15 double-blind, placebo-controlled trials of opioids versus

1676 placebo for any non-cancer pain condition (most commonly osteoarthritis and

1677 neuropathic pain) found that the mean decrease in pain intensity in most trials was at

1678 least 30% with opioids and similar for neuropathic and musculoskeletal pain [179].

1679 Efficacy of opioids versus NSAIDs or acetaminophen

- 1680 The relative or added benefits of opioids compared to NSAIDs or acetaminophen have
- 1681 only been evaluated in two lower-quality trials (Table 12). One small trial or patients
- 1682 with chronic low back pain found that adding an opioid to naproxen alone was
- 1683 associated with superior outcomes for average pain, current pain, and anxiety or
- 1684 depression scores after 16 weeks [182]. Differences in pain relief were fairly modest,
- 1685 however, ranging between 5 and 10 points on a 100-point scale. In addition, results are
- 1686 difficult to interpret because doses of naproxen weren't clearly reported. Another trial
- 1687 (N=50) found that the mean number of days before return to work was similar in patients
- with acute low back pain randomized to codeine or acetaminophen (10.7 vs. 13.0 days)[114].

1690

1690

Table 12. Trials of an opioid versus an NSAID or acetaminophen

Author, year	Number of patients Duration of follow-up	Main results	Quality
Jamison, 1998[182]	N=36 16 weeks	Long-acting morphine + short-acting oxycodone (titrated dose) + naproxen versus short-acting oxycodone (set dose) + naproxen versus naproxen alone Pain intensity (100 point VAS), mean differences versus placebo: -18.21 vs18.55 (p=0.0001 for each comparison) Global assessment at least 'good': 59% vs. 63% vs. 27%	3/11
Wiesel, 1980[114]	N=50 14 days	Codeine versus acetaminophen Mean number of days before return to work: 10.7 vs. 13.0 (NS)	1/11

1691

1692 Efficacy of different opioids and opioid formulations

1693 There was no evidence from five lower-quality trials that long-acting opioid formulations

are superior to short-acting formulations in patients with low back pain (Table 13) [182,

- 1695 184-187].
- 1696

Table 13. Trials of a long-acting opioid versus a short-acting opioid

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hale, 1999[186]	N=57 4-7 days followed by crossover	Long-acting versus short-acting oxycodone No differences for overall pain intensity, mean pain intensity, or rescue drug use	4/11
Salzman, 1998[187]	N=57 10 days	Long-acting versus short-acting oxycodone No differences for pain intensity, time to stable pain control, mean number of dose adjustements	3/11
Jamison, 1998[182]	N=36 16 weeks	Long-acting morphine + short-acting oxycodone (titrated dose) + naproxen versus short-acting oxycodone (set dose) + naproxen Pain intensity (100 point VAS), mean differences versus placebo: -18.21 vs. –18.55 (NS) Global assessment at least 'good': 59% vs. 63%	3/11
Hale, 1997[185]	N=104 5 days	Long-acting codeine plus acetaminophen versus short-acting codeine plus acetaminophen Long-acting codeine superior for pain intensity, but non- equivalent codeine use (200 mg vs. 71 mg)	5/11
Gostick, 1989[184]	N=61 2 weeks followed by crossover	Long-acting versus short-acting dihydrocodeine No differences for pain intensity, rescue drug use, global efficacy, patient preference	5/11

1697

1698 In two head to head trials (Table 14), there was no difference in efficacy between long-

1699 acting oxymorphone and long-acting oxycodone [180] or transdermal fentanyl and long-

- acting morphine [183]. The latter study is the longest (13 months) and largest (N=683)
- 1701 trial available.
- 1702

Table 14.	Head-to-head trials of long-acting opioids
-----------	--

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hale, 2005[180]	N=235 18 days	Long-acting morphine versus long-acting oxycodone No differences for pain intensity, pain relief, pain interference with activities, global assessment	7/11
Allan, 2005[183]	N=683 13 months	Transdermal fentanyl versus long-acting oral morphine No differences for pain scores, rescue medication use, quality of life, loss of working days	4/11

1703

1704 A systematic review of opioids for all non-cancer pain conditions concluded that no

1705 differences have been shown between long- and short-acting opioids or different long-

1706 acting opioids [188].

1707 Safety

1708 In the single higher quality trial, a large proportion of patients on opioids had adverse

1709 events (85%), with constipation and sedation the most commonly reported symptoms

1710 [180]. Few "serious" adverse events were reported, and withdrawal due to adverse

1711 events was low in all groups, probably due in part to the use of a titration phase. In

1712 trials comparing opioids to other analgesics (NSAIDs or acetaminophen), constipation,

1713 dry mouth, somnolence, and nausea were all more common in the opioid arms [114,

1714 182]. One lower-quality trial reported a higher rate of constipation with long-acting

1715 morphine compared to transdermal fentanyl (52% vs. 65%) [183]. However, long-acting

1716 morphine was also associated with a trend towards a lower rate of withdrawal due to

1717 adverse events (37% vs. 31%).

1718 In a systematic review of opioids for various non-cancer pain conditions, about 80% of

1719 patients experienced at least one adverse event, with constipation (41%), nausea

1720 (32%), and somnolence (29%) most common [179]. Opioids were also associated with

a higher risk of discontinuation due to adverse events (24% vs. 15%, RR 1.4, 95% CI

1722 1.1 to 1.9). Abuse and addiction were rarely reported, but because of short follow-up

1723 and enrollment of highly selected patients, reliable conclusions about risks for these

- 1724 outcomes was not possible. In trials with longer-term (longer than seven months) open-
- 1725 label follow-up, less than half of patients remained on opioids.

1726 Costs

1727 We found no studies evaluating costs.

1728 Summary of evidence

- Multiple trials of patients with various non-cancer pain conditions consistently
 indicate that opioids are superior to placebo for pain relief in primarily short-term
 trials (level of evidence: good), though evidence in patients specifically with either
 acute or chronic low back pain (one higher quality demonstrating benefit) is
 sparse (level of evidence: fair).
- There is insufficient evidence from single, lower quality trials to judge the efficacy
 of opioids versus acetaminophen or in addition to NSAIDs (level of evidence:
 poor).
- Consistent evidence from lower-quality trials found no differences between longand short-acting opioids on a variety of outcomes in patients with chronic low
 back pain (level of evidence: fair).
- There were no clear differences between long-acting opioids in two head-to-head
 trials evaluating different comparisons (level of evidence: fair).
- Although adverse events are common with opioids (level of evidence: fair), there are no reliable estimates for rates of abuse or addiction, overdose, or other serious adverse events (level of evidence: poor).

1745 **Recommendations and findings from other guidelines**

- The AHCPR guidelines recommend opioids as an option for a time-limited course
 in patients with acute low back problems, with the decision guided by
 consideration of potential complications (which can lead to discontinuation in as
 many of 35% of patients) relative to other options (strength of evidence: C).
- The AHCPR guidelines found opioids no more effective in relieving low back
 symptoms than safer analgesics such as acetaminophen, aspirin, or other
 NSAIDs (strength of evidence: C).
- The AHCPR guidelines recommend warning patients about potential physical dependence and the danger associated with the use of opioids while operating heavy equipment or driving (strength of evidence: C).
- The VA/DoD and UK RCGP guideline recommendations are essentially identical to the AHCPR recommendations.

- The UK RCGP guidelines also suggest that pain of such severity that it requires opioids for longer than two weeks requires further investigation and assistance with management (strength of evidence: *).
- The UK RCGP guidelines suggest paracetamol-weak opioid combinations as an alterative when paracetamol or NSAIDs alone do not give adequate pain control, though adverse effects include constipation and drowsiness (strength of evidence: **).
- The European COST guidelines recommend weak opioids in patients with
 nonspecific chronic low back pain who do not respond to other treatment
 modalities. Due to the risk of addiction, they recommend slow-release over
 immediate-release formulations and scheduled rather than as needed dosing.

1769 Tramadol

- 1770 Results of search: systematic reviews
- 1771 We identified one higher-quality systematic review [105] that included three short-term
- 1772 (1 to 4 week) trials (N=55, 127, and 96) [189-191] of tramadol (a synthetic opioid
- analogue) for low back pain. Two of the trials were rated higher-quality [189, 191].
- 1774 Results of search: trials
- 1775 We identified no trials of tramadol in patients with low back pain that met inclusion
- 1776 criteria. Five trials were excluded because they evaluated the efficacy of tramadol in
- 1777 combination with acetaminophen or a long-acting formulation not available in the U.S.
- 1778 (Peloso 2004; Ruoff 2003; Mullican 2001; Raber 1999) [192]. One other trial was
- 1779 excluded because it was only published as an abstract [193].
- 1780 Efficacy of tramadol versus placebo
- 1781 The systematic review [105] included one higher-quality trial [191] that found tramadol
- more effective than placebo for mean pain scores at 4 weeks (3.5 vs. 5.1 on 10 point
- scale, p<=0.001) and also superior on the McGill Pain Questionnaire (p=0.0007) and
- 1784 the RDQ Questionnaire (p=0.0001).
- 1785 *Efficacy of tramadol versus other interventions*
- 1786 No trial compared tramadol to opioid analgesics in patients with low back pain. The
- 1787 systematic review included two trials comparing tramadol to other drugs [105]. In one
- 1788 higher-quality trial, tramadol was inferior to dextroprofen-trometamol (an NSAID not
- available in the U.S.) for pain (p=0.044) and need for rescue medication (p=0.011) in
- 1790 patients with acute low back pain [189]. In a lower-quality trial, tramadol was associated

- 1791 with similar outcomes compared to the combination of paracetamol + codeine in
- 1792 patients with chronic low back pain [190].
- 1793 Safety
- 1794 In two trials included in the systematic review [105], tramadol was associated with
- 1795 similar rates of withdrawal due to adverse events compared to placebo [191] or the
- 1796 combination of paracetamol plus codeine [189].
- 1797 Costs
- 1798 We found no studies evaluating costs.
- 1799 Summary of evidence
- Tramadol was moderately more effective than placebo for short-term pain and assessment of functional status in one higher-quality trial of patients with chronic low back pain (level of evidence: fair).
- Tramadol was no better than the combination of paracetamol plus codeine in one
 low-quality trial of patients with chronic low back pain (level of evidence: poor).
- There is insufficient evidence to judge the efficacy of tramadol compared to
 acetaminophen or opioid analgesics alone or to NSAIDs available in the U.S. (no
 trials).
- In single trials, tramadol was associated with similar rates of withdrawal due to adverse events (a marker for intolerable or severe adverse events) compared to placebo or the combination of paracetamol + codeine (level of evidence: fair).
- 1811
 Recommendations and findings from other guidelines
- The European COST guidelines recommend weak opioids (including tramadol) in patients with nonspecific chronic low back pain who do not respond to other treatment modalities. Due to the risk of addiction, they recommend slow-release over immediate-release formulations and scheduled rather than as needed dosing.

1817 Systemic corticosteroids

- 1818 Results of search: systematic reviews
- 1819 We identified no systematic reviews evaluating the efficacy of systemic corticosteroids
- 1820 in patients with low back pain.
- 1821 Results of search: trials
- 1822 We identified three small (N=33 to 65), higher-quality trials evaluating the efficacy of
- 1823 systemic corticosteroids for discogenic sciatica of acute or unspecified duration [194-

- 1824 196]. One other trial evaluated the efficacy of systematic corticosteroids in patients with
- 1825 acute non-specific low back pain, but is only available as a conference abstract [194-
- 1826 197]. We also excluded one German-language trial [198].

1827 Efficacy of systemic corticosteroids versus placebo

- 1828 In the highest quality trial, a single large (500 mg) bolus of intravenous
- 1829 methylprednisolone was associated with a small (average 6 mm on a 100 mm scale)
- 1830 early improvement in short-term leg pain compared to placebo in patients with acute
- 1831 sciatica, but the benefit was no longer present after the first 3 days (Table 15) [194].
- 1832 There were no differences in degree of pain relief, improvements in functional disability,
- 1833 the proportion requiring spine surgery within the first month, or medication use. In the
- 1834 two other trials, seven day courses of either oral [195] or intramuscular [196]
- 1835 dexamethasone were not associated with any differences in any outcomes including
- 1836 overall effect (either early or after up to 4 years of follow-up), hospitalization length, or
- 1837 subsequent surgery.

1838 Table 15. Trials of systemic corticosteroids versus placebo in patients with chronic low back pain

	Number of patients Duration of		
Author, year	follow-up	Main results	Quality
Finckh, 2006[194]	N=65 (acute sciatica) 30 days	Methylprednisolone 500 mg bolus versus placebo Leg pain, difference between interventions in VAS pain scores (0 to 100 scale): 5.7 (favors methylprednisolone) at day 3, (p=0.04), not significant after 3 days (p=0.22) Proportion with >20 mm improvement in VAS pain score after 1 day: 48% vs. 28% (p=0.097)	10/11
Haimovic, 1986[195]	N=33 (duration of symptoms unclear) 1 to 4 years	Dexamethasone 1 week oral taper versus placebo Early improvement: 33% (7/21) vs. 33% (4/12) Sustained improvement (1 to 4 years): 50% (8/16) vs. 64% (7/11)	6/11
Porsman, 1979[196]	N=52 (duration of symptoms unclear) 9 days or longer	Dexamethasone 1 week intramuscular taper versus placebo 'Positive effect': 52% (13/25) vs. 58% (14/24) Subsequent surgery: 32% (8/25) vs. 25% (6/24)	6/11

1839

- 1840 The excluded German-language trial also reported no significant difference between a
- 1841 10-day course of intramuscular steroids and placebo in patients with sciatica (OR for
- 1842 successful outcome 2.0, 95% CI 0.8 to 4.9) [198]. In the only trial of systemic
- 1843 corticosteroids in patients with acute non-specific low back pain (only available as an

- abstract), there were no differences in pain relief through one month after a single
- 1845 intramuscular injection of 160 mg of methylprednisolone [197].
- 1846 Safety
- 1847 A large intravenous methylprednisolone bolus was associated with two cases of
- 1848 transient hyperglycemia and one case of facial flushing in one trial [194]. Adverse
- 1849 events were poorly reported in the other trials.
- 1850 *Costs*
- 1851 We found no studies evaluating cost-effectiveness.
- 1852 Summary of evidence
- Systemic corticosteroids are consistently not associated with a clinically significant benefit in patients with acute sciatica when given parenterally (single injection) or as a short oral taper (three higher-quality trials) (level of evidence: good).
- One trial found no benefit from a single intramuscular injection of corticosteroids
 in patients with acute non-radicular low back pain, but the level of evidence can't
 be adequately assessed because it is only available as a conference abstract.
- Serious adverse events after a single large bolus were not reported in one trial (level of evidence: fair). However, systemic corticosteroids are associated with hyperglycemia, systemic infections, bleeding, and osteoporosis, and psychosis, particularly with higher doses and longer courses.
- 1864Recommendations and findings from other guidelines
- The AHCPR guidelines recommend against systemic steroids for acute low back
 problems (strength of evidence: C).
- The AHCPR guidelines found a potential for severe side effects with extended
 use of oral steroids or short-term use of high-dose steroids (strength of evidence:
 D).
- The UK RCGP guidelines on systemic steroids are similar.

1871 Herbal therapy

- 1872 Results of search: systematic reviews
- 1873 We identified two systematic reviews evaluating the efficacy of herbal therapies for low
- 1874 back pain [105, 199]. The more comprehensive study was a recent, higher-quality
- 1875 Cochrane review of 10 trials evaluating devil's claw, white willow bark, or topical
- 1876 cayenne [199]. Although eight of the ten included trials were rated high quality, they

- 1877 only assessed short-term (<6 weeks) outcomes and more than half either had authors
- 1878 with potential conflicts of interest or did not report potential conflicts. In addition, the
- 1879 same investigator led half of the trials. The other systematic review was less
- 1880 comprehensive and only included one trial each of willow bark and devil's claw (both
- 1881 included in the Cochrane review) [105]. The Cochrane review was an update of a
- 1882 previous (non-Cochrane) systematic review [200].
- 1883 Results of search: trials
- 1884 We did not search for additional trials
- 1885 Efficacy of harpagoside (devil's claw) versus placebo
- 1886 The Cochrane review included two higher quality trials [201, 202] that found devil's claw
- 1887 (harpagoside) superior to placebo for 'proportion pain-free' (9% to 17% in the active
- 1888 treatment groups versus 2% to 5% with placebo) in patients with acute episodes of
- 1889 chronic non-specific low back pain [199]. However, significant differences were not
- 1890 seen for Arhus Index scores (a measure of physical impairment, disability, and pain) or
- 1891 concomitant analgesic (tramadol) use.
- 1892 Efficacy of salix alba (white willow bark) versus placebo
- 1893 One higher-quality trial of patients with chronic low back pain found white willow bark
- 1894 superior to placebo for 'proportion pain-free' with a significant dose trend (5.7% with
- 1895 placebo, 21% with low dose willow bark, 39% with high dose) as well as for
- 1896 improvements in Arhus Index scores [203].
- 1897 Efficacy of capsicum frutescens (cayenne) versus placebo
- 1898 Capsaicin is the main active ingredient in cayenne. In one lower-quality trial of patients 1899 with acute low back pain, topical cayenne (in combination with topical salicylate) was 1900 superior to placebo cream in one lower-quality trial (improvement of about 3.79 cm on 1901 10 cm VAS after 14 days) [204]. Two other studies of chronic low back pain (both just 1902 meeting criteria for classification as higher-quality trials) found that cayenne was associated with a higher likelihood of at least 50% improvement in pain compared to 1903 1904 placebo (35% versus 17% in one trial [205] and 45% versus 24% in the other [206]). 1905 Arhus Index scores also decreased more in the cayenne groups (33% vs. 22% in one 1906 trial [205] and 42% vs. 31% in the other [206]). However, a fourth, lower-quality trial of 1907 cayenne versus homeopathic treatment (Spiroflor SLR homeopathic gel) in patients with
 - 66

- 1908 back pain of mixed duration found no differences for pain relief, proportion using
- acetaminophen, proportion unable to work, or assessments of overall efficacy [207].
- 1910 Efficacy of herbal therapy versus other interventions
- 1911 Two higher-quality trials included in the Cochrane review compared either devil's claw
- 1912 [142] or willow bark [141] to low-dose (12.5 mg) rofecoxib, a COX-2 inhibitor no longer
- 1913 on the market. Both found no statistically or clinically significant differences between
- 1914 herbal therapy and rofecoxib for pain, Arhus Index scores, or other outcomes.
- 1915 Safety
- 1916 Devil's claw was not consistently associated with a higher rate of adverse events
- 1917 compared to placebo in one systematic review [200]. Serious adverse events were rare
- 1918 in the included trials, though a severe allergic reaction was reported in a study
- 1919 evaluating willow bark [203]. Cayenne is associated with burning or itching upon initial
- 1920 administration that decreases after repeated applications.
- 1921 Costs
- 1922 We found no studies evaluating cost-effectiveness.
- 1923 Summary of evidence
- Several higher-quality trials found devil's claw superior to placebo for short-term pain relief in patients with acute exacerbations of chronic low back pain.
 However all of the trials were led by the same investigator, raising concerns about reproducibility of findings in other settings (level of evidence: fair).
- One higher-quality trial found willow bark superior to placebo for short-term pain
 relief in patients with acute exacerbations of chronic low back pain (level of
 evidence: fair)
- Evidence on the efficacy of cayenne was mixed, with three lower-quality trials suggesting short-term benefits compared to placebo for pain relief and other outcomes in patients with acute low back pain or acute exacerbations of chronic low back pain, but one other lower-quality trial showing no benefit compared to a homeopathic gel (level of evidence: fair).
- Serious adverse reactions with herbal therapy appear uncommon (level of evidence: fair).
- No trials evaluated long-term outcomes.

1939 **Recommendations and findings from other guidelines**

- The European COST guidelines make no recommendation for herbal therapy for acute low back pain, but note that most of the available trials came from the same research group and primarily involved patients with acute exacerbations of chronic low back pain.
- The European COST guidelines recommend consideration of capsicum pain
 plasters for short-term symptomatic pain relief in chronic low back pain.

1946 Acupuncture and related interventions

1947 Acupuncture

1948 Results of search: systematic reviews

1949 We identified two recent, good-quality systematic reviews (33 and 35 trials) evaluating

- 1950 the efficacy of acupuncture (including electroacupuncture) in patients with primarily
- 1951 chronic low back pain [208-210]. One of these reviews [209, 210] (an update of a
- 1952 previous Cochrane review [211]) also evaluated the efficacy of dry needling (a
- 1953 technique involving the insertion of needles into trigger points). Both reviews found
- 1954 significant methodological shortcomings in the acupuncture literature (10 of 33 and 14
- 1955 of 35 studies rated as higher quality). In addition, about one third of the trials were
- 1956 conducted in Asian settings, which could limit the generalizability of findings to the U.S.
- 1957 We identified one systematic review on safety of acupuncture in patients with low back
- 1958 pain [212]. We excluded six older systematic reviews [213-220] and one review that
- 1959 didn't clearly use systematic methods [221].
- 1960 Results of search: trials
- 1961 We identified one additional recent, higher-quality trial evaluating longer-term (two
- 1962 years) outcomes associated with acupuncture in patients with low back pain [222].
- 1963 *Efficacy of acupuncture versus placebo or sham treatment*
- 1964 Both systematic reviews found sparse evidence on the effectiveness of acupuncture in
- 1965 patients with acute low back pain relative to placebo, sham, or no treatment (three
- 1966 RCTs in one systematic review and four in the other) [208-210]. The available evidence
- 1967 was inconclusive because of small sample sizes, methodologic shortcomings, short
- 1968 duration of follow-up, and inconsistent results, with some trials showing no differences.
- 1969For chronic low back pain, both systematic reviews found acupuncture more effective1970than no treatment (SMD 0.69, 95% CI 0.40 to 0.98 [208] and 0.73, 95% CI 0.28 to 1.19

[209, 210]) or sham treatments (acupuncture or TENS) (standardized mean difference 1971 1972 0.54, 95% CI 0.35 to 0.73 and weighted mean difference -17.79, 95% CI -25.5 to -1973 10.7, respectively) for short-term (defined as <6 weeks or <3 months, respectively) pain 1974 relief. Both systematic reviews also found acupuncture associated with short-term 1975 improvements in functional status compared to no treatment (SMD 0.62, 95% CI 0.30 to 1976 0.95 [208] and 0.63, 95% CI 0.19 to 1.08 [209, 210]), but there were no differences 1977 compared to sham therapies. For short- and long-term assessments of "overall" 1978 improvement, acupuncture was superior to sham treatments and no treatment. 1979 The systematic reviews found sparse evidence on longer-term (defined as longer than 6 1980 weeks after treatment) benefits. Acupuncture was associated with better long-term pain 1981 relief compared to sham TENS in two trials (SMD 0.62, 95% CI 0.03 to 1.22) and to no 1982 additional treatment in five trials (SMD 0.74, 95% CI 0.02 to 1.47), though there were no 1983 significant differences compared to sham acupuncture (two trials, SMD 0.59, 95% CI -1984 0.10 to 1.29) [208]. One higher-quality trial included in the systematic reviews 1985 evaluated outcomes one year after treatment, finding no differences in pain compared 1986 to no treatment (SMD 0.35, 95% CI –0.51 to 0.09) [223]. However, a recent high-quality 1987 trial not included in the systematic reviews suggests that benefits from acupuncture may

1988 extend beyond a year (Table 16) [222]. It found that routinely offering acupuncture1989 (94% of patients offered acupuncture received it) was associated with sustained

1990 benefits on SF-36 pain scores after 24 months (mean adjusted difference at 24 months,

1991 p=0.032) and use of low back pain medications in the last 4 weeks (60% vs. 41%,

1992 p=0.03) compared to usual general practitioner care. However, there were no

1993 differences in ODI scores, McGill Present Pain Intensity scores, or other SF-36

1994 dimension scores.

1995

Table 16. Long-term trial of acupuncture versus usual care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Thomas, 2005[222]	N=241 24 months	Routinely offering acupuncture versus usual care SF-36 Pain score, mean adjusted difference between interventions: +5.6 at 12 months (p=0.11), +8.0 at 24 months (p=0.03) (favors acupuncture) McGill Present Pain Intensity: No difference at 12 or 24 months ODI Score: No difference at 12 or 24 months Pain-free in last 12 months: 18% vs. 8% (p=0.06) Use of low back pain medication in last 4 weeks: 60% vs. 41% (p=0.03)	7/11

1996

- 1997 Efficacy of acupuncture versus other active interventions
- 1998 Both systematic reviews found acupuncture inferior to spinal manipulation for short-term
- 1999 pain relief [208-210]. One of the systematic reviews calculated a standardized mean
- 2000 difference of -1.32 (95% CI -1.87 to -0.77) from two trials [208]. Neither found any
- 2001 evidence that acupuncture is more effective than other active therapies (massage,
- analgesic medication, or TENS, each comparison evaluated in one to four trials).
- 2003 *Efficacy of different acupuncture techniques*

2004 The Cochrane review compared the effectiveness of different acupuncture techniques 2005 (8 trials, 2 high quality) [209, 210]. In one higher-quality trial, deep stimulation was 2006 superior to superficial stimulation immediately after the sessions and at short-term follow-up [224]. In the other high-quality trial, there was no difference between manual 2007 2008 acupuncture and electroacupuncture [225]. There was insufficient evidence to judge 2009 the comparative efficacy of other acupuncture techniques (single comparisons from 2010 flawed trials). There was no difference between manual and electroacupuncture in one 2011 trial [225].

2012 Efficacy of dry needling

The Cochrane review [209, 210] included one lower-quality trial of patients with acute low back pain that found no difference between one session of dry needling versus trigger point injection with lidocaine and steroid, trigger point injection with lidocaine only, or cooling spray over the trigger point area followed by acupuncture [226]. In patients with chronic low back pain, one higher quality trial found that superficial needling of trigger points was superior to placebo TENS for immediate pain relief [227]

and one lower-quality trial found that dry needling added to a regimen of physiotherapy,

- 2020 occupational therapy, and industrial assessments was superior to the regimen without 2021 dry needling [228] for short- and intermediate-term functional status.
- 2022 Safety
- 2023 The Cochrane review found that only 14 of 35 trials reported any complications or side
- 2024 effects [209, 210]. Minor complications occurred in 5% (13/245) patients receiving
- acupuncture, 0% (0 of 156) receiving sham, and 10% (21/205) receiving other
- 2026 interventions. None of the complications were fatal or required hospitalization.
- 2027 Another systematic review of prospective (randomized and non-randomized) studies of 2028 acupuncture (over 250,000 acupuncture treatments analyzed) in patients with various 2029 conditions found wide variation in rates of adverse events, ranging from 1% to 45% for 2030 needle pain, and 0.03% to 38% for bleeding [212]. The wide range in estimates is 2031 probably due in part to differences in methods for defining, identifying, and reporting 2032 adverse events. Feelings of faintness and syncope were uncommon, with an incidence 2033 of 0% to 0.3%. Serious adverse events, which may be more likely to be reported, were 2034 rare. Pneumothorax was reported in two patients, and there were no cases of
- 2035 infections.
- 2036 Costs
- 2037 Only two trials estimated cost-effectiveness for acupuncture. It found that routinely
- 2038 offering acupuncture was associated with an incremental cost-effectiveness of
- 2039 £4241/QALY (95% CI £191 to £28,026) relative to usual care [222]. Another trial found
- 2040 no significant differences in back pain-related HMO costs between patients randomized
- to acupuncture, massage, and self-care (with massage the most effective therapy)
- 2042 [223].
- 2043 Summary of evidence
- There is consistent evidence from multiple trials that acupuncture is effective for short-term pain relief compared to no treatment or sham acupuncture in patients with chronic low back pain for pain, and superior to no treatment (but not sham)
 for functional outcomes (level of evidence: good).
- Evidence on longer-term (>6 weeks) outcomes is sparse but suggests that
 acupuncture is more effective than sham TENs and no treatment in patients with

2050 2051	chronic low back pain. One recent, higher-quality trial found that beneficial effects on pain persist for up to 24 months (level of evidence: fair).
2052 2053	 Acupuncture was inferior to spinal manipulation in two trials (one higher quality) (level of evidence: fair)
2054 2055 2056	 There is no evidence that acupuncture is more effective than other active interventions in patients with chronic low back pain (each comparison only evaluated in a small number of trials) (level of evidence: poor to fair).
2057 2058 2059	 There is insufficient evidence to judge the efficacy of acupuncture (small numbers of primarily lower-quality trials) in patients with acute low back pain (level of evidence: poor).
2060 2061 2062 2063	 Dry needling alone was not effective compared to trigger point injections or acupuncture in one trial of patients with acute low back pain (level of evidence: poor), but was more effective than placebo or when added to other interventions in two trials of patients with chronic low back pain (level of evidence: fair).
2064 2065	 Serious adverse events with acupuncture appeared rare in trials and prospective studies, though they were often poorly reported (level of evidence: fair).
2066	Recommendations and findings from other guidelines
2067 2068 2069	• The AHCPR guidelines recommend against invasive needle acupuncture and other dry needling techniques for patients with acute low back problems (strength of evidence: D).
2070 2071	 The VA/DoD and UK RCGP guidelines on acupuncture for acute low back pain are similar.
2072 2073 2074	 The European COST guidelines make no recommendations on acupuncture for acute low back pain, and found insufficient evidence to recommend acupuncture for chronic low back pain.
2075	Acupressure
2076	Acupressure is a non-invasive method that involves manipulation with the fingers
2077	instead of needles on acupuncture points. It has been less well studied than
2078	acupuncture.
2079	Results of search: systematic reviews
2080	We found no systematic review evaluating its efficacy.
2081	Results of search: trials
2082	We identified two recent open-label RCTs (one rated higher quality [229]) of
2083	acupressure, both conducted in Taiwan by the same group of investigators [229, 230].

2084 *Efficacy of acupressure versus physical therapy*

2085 Both trials found that acupressure was more effective than physical therapy (consisting 2086 of multiple techniques at the discretion of the physical therapist) in patients with chronic 2087 low back pain (Table 17)[229, 230]. In the one trial reporting functional outcomes, there 2088 were modest differences in changes in the RDQ and ODI scores that persisted through 2089 the end of follow-up six months (-5.36, 95% CI -7.21 to -3.52 and -7.99, 95% CI -10.8 2090 to -5.17, respectively) [229]. Days off from work/school also improved more in the 2091 acupressure group (mean difference compared to baseline -2.79, p<0.0001). In both 2092 trials, acupressure was superior to physical therapy for measures of pain relief. The 2093 mean difference in changes from baseline pain scores were -27.2 on a 100 point VAS 2094 (p<0.0001) and -4.46 on the 0 to 45 Short-form Pain Questionnaire (p=0.0001) after 6 2095 months. The effects on pain relief were about twice as high as seen with most other 2096 conventional interventions or acupuncture.

2097

Table 17. Trials of acupressure versus physical therapy

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hsieh, 2006[229]	N=158 6 months	Acupressure versus physical therapy RDQ score, difference in mean change from baseline: - 5.36, 95% CI –7.21 to –3.52 (p<0.0001) Modified ODI score, difference in mean change from baseline: -7/99, 95% CI –10.8 to –5.17 (p<0.0001) Pain (VAS, 0 to 100), difference in mean change from baseline between interventions: -27.12 (p<0.0001)	5/11
Hsieh, 2004[230]	N=146 6 months	Acupressure versus physical therapy Short-form Pain questionnaire, mean change from baseline: -8.69 vs4.23 (p=0.0001)	6/11

2098

2099 Safety

- 2100 One of the trials reported no adverse events in the acupressure group [230]. The other
- 2101 trial did not report adverse events.
- 2102
- 2103 Costs
- 2104 We found no studies evaluating costs.

2105 Summary of evidence

There is evidence from two trials (one higher quality) that acupressure is more
 effective than standard therapy in patients with chronic low back pain for pain
 and functional outcomes. However, it is not clear if these results can be

- 2109 generalized to other settings because both trials were conducted in Taiwan by 2110 the same investigators (level of evidence: fair)
- Acupressure does not appear associated with serious adverse events, but harms
 were only reported by one trial (level of evidence: fair).
- There is no evidence in patients with acute low back pain.
- 2114 **Recommendations and findings from other guidelines**
- None of the guidelines address acupressure.
- 2116 Neuroreflexotherapy
- 2117 Neuroreflexotherapy is a technique from Spain characterized by the temporary
- 2118 implantation of staples superficially into the skin over trigger points in the back and
- 2119 referred tender points in the ear. Like acupuncture, it involves the use of puncture
- 2120 devices in the skin. However, neuroreflexotherapy is believed to stimulate different
- 2121 zones of the skin.
- 2122 Results of search: systematic reviews
- 2123 We identified one recent, higher-quality Cochrane review (three trials, two rated higher-
- 2124 quality (Kovacs 1993 and Kovacs 1997) evaluating the effectiveness of
- 2125 neuroreflexotherpay in patients with chronic low back pain [231]. The same principal
- 2126 investigator conducted all three trials in Spain (total number of patients 273).
- 2127 Results of search: trials
- 2128 We did not search for additional trials.
- 2129 Efficacy of neuroreflexotherapy versus sham neuroreflexotherapy
- 2130 The two higher-quality trials [232, 233] found neuroreflexotherapy markedly superior to
- sham therapy for short-term (up to 45 days) pain relief. In one trial, the proportion of
- 2132 patients with pain relief was 96% with neuroreflexotherapy vs. 2.3% with sham
- 2133 (p<0.0001) [232]. In the other, neuroreflexotherapy was associated with an average
- 2134 improvement in spontaneous pain of 3.09 (on a 45 point scale) compared to 0.34 with
- sham treatment [233]. One [232] of the two trials also found neuroreflexotherapy
- 2136 superior for a variety of functional and work-related outcomes.
- 2137 Efficacy of neuroreflexotherapy versus usual care
- 2138 The third, lower-quality trial compared neuroreflexotherapy to usual care [234]. It found
- 2139 neuroreflexotherapy superior for short-term (60 days) pain relief (average improvement

- 5.50 on a 60 point scale versus 1.92, p<0.0005) and functional status (average
- 2141 improvement 8.67 on RDQ scale versus 2.05, p=0.007). Number of days on sick leave
- and duration of sick leave (average 3.2 vs. 105.2 days, p=0.001) and use of health care
- 2143 services were also lower in the neuroreflexotherapy group after one year. There were
- 2144 no differences in quality of life.
- 2145 Costs
- 2146 One trial that included a cost-effectiveness analysis found that neuroreflexotherapy
- 2147 dominated (total costs lower and clinical outcomes superior) [234]. Neuroreflexotherapy
- 2148 was associated with median costs of \$800 compared to \$3800 with usual care, and
- superior by an average of 5.5 points on the RDQ Scale (0 to 24).
- 2150 Safety
- 2151 One trial found a higher incidence of adverse effects in the control group (65% vs. 9%),
- 2152 primarily due to gastric discomfort associated with NSAID use [232]. Skin tightness was
- associated with implantation of staples, but did not require early extraction in any
- 2154 patient. Scarring was not specifically reported in any trial, but is not believed to be an
- 2155 important problem because of the superficial nature of the staple implantations.
- 2156 Summary of evidence
- There is consistent evidence (three trials, two higher-quality) that
 neuroreflexotherapy is superior to sham therapy or usual care for short-term pain
 relief in patients with chronic low back pain. However, all of the trials were
 conducted in Spain by the same principal investigator at a specialized center,
 raising questions about the applicability of results to other settings (level of
 evidence: fair).
- Evidence on beneficial effects of neuroreflexotherapy relative to sham treatment
 on functional outcomes is mixed (level of evidence: fair).
- The single lower-quality trial assessing one-year outcomes found lower self reported sick leave and consumption of health care resources with
 neuroreflexotherapy relative to usual care (level of evidence: fair).
- 2168 **Recommendations and findings from other guidelines**
- The European COST guidelines recommend consideration of
 neuroreflexotherapy for patients with moderate or severe (>3/10 on VAS),
 chronic low back pain.

2172 Educational Interventions

2173 Back schools

The original Swedish back school was introduced in 1969 [235, 236]. The basic elements of back schools consist of an educational and skills program, including exercises, in which all lessons are given to groups of patients and supervised by a therapist or medical specialist. However, the content and intensity of back schools meeting this basic definition can vary widely.

- 2179 Results of search: systematic reviews
- 2180 We identified one recent, higher-quality Cochrane review of 19 trials (6 rated higher-
- 2181 quality) of back schools for acute or chronic low back pain [237, 238]. It updated a
- 2182 previous Cochrane review [239]. We also included three other recent systematic
- 2183 reviews, though all were rated lower-quality [240-242]. Another recent, higher-quality
- 2184 systematic review evaluated factors that could predict better outcomes from back
- 2185 schools and multidisciplinary rehabilitation (results not clearly separated for the two
- 2186 interventions) [243]. We excluded ten older systematic reviews [132, 244-252].
- 2187 Results of search: trials
- 2188 We did not search for additional trials.
- 2189 Efficacy of back schools versus placebo
- 2190 The Cochrane review included one lower-quality trial [253] that found back school 2191 superior to placebo (short-wave therapy at the lowest intensity) in patients with acute or 2192 subacute low back pain for short-term recovery and return to work, but not for short-2193 term pain or long-term recurrences [237, 238]. There was conflicting evidence from 2194 eight trials (2 higher-quality [254, 255]) on the effectiveness of back schools versus 2195 placebo or wait list controls for chronic low back pain. For short-term outcomes, seven 2196 RCTs found no benefit from back schools. For long-term outcomes, one high-quality 2197 study [255] found positive effects on functional status and return to work, though two 2198 other lower-quality trials [256, 257] found no long-term benefits. Results of back 2199 schools were generally more promising in trials conducted in an occupational setting 2200 (moderate evidence for improved short- and intermediate-term pain and return to work) 2201 and for more intensive (three to five-week stays in specialized centers) programs

consisting of modifications of the original Swedish back school. In general, however,benefits associated with back schools appeared modest.

The systematic review evaluating factors associated with better outcomes after back
school or multidisciplinary rehabilitation found consistent evidence that higher baseline

- pain level was associated with worse outcomes, and that several work-related
- 2207 parameters (such as high satisfaction) and low levels of active coping skills at baseline
- 2208 were associated with better outcomes [243]. Other variables lacked consistent
- predictive value, in part due to flaws in the studies and because many predictors wereonly evaluated in one study.
- 2211 Conclusions of three other recent (lower-quality) systematic reviews were generally
- 2212 consistent with the Cochrane review [240-242].
- 2213 Efficacy of back schools versus other interventions
- The Cochrane review [237, 238] included four trials (two higher quality [258-260]) on the
- 2215 effectiveness of back school versus other treatments (physical therapy, usual care, or
- advice) in patients with acute low back pain. Although one higher-quality trial reported
- decreased sickness leave after 200 days (30% vs. 60%) and 5 years (19% vs. 34%)
- [258, 259], the other three trials reported no significant differences [253, 260, 261]. In
- 2219 patients with chronic low back pain, the Cochrane review included 6 trials (four in
- 2220 occupational settings) and found that back schools are superior to other conservative
- treatments (exercises, spinal manipulation, myofascial therapy, or some kind of advice)
- 2222 for short and intermediate-term pain relief and improvement in functional status, but not
- 2223 for long-term outcomes [237, 238].
- 2224 Safety
- 2225 No studies assessed safety.
- 2226 Cost-effectiveness
- 2227 We found no studies evaluating cost-effectiveness.
- 2228
- 2229Summary of evidence
- Back schools were superior to placebo in a single lower-quality trial of patients
 with acute or subacute low back pain for short-term recovery and return to work,
 but not for pain or long-term recurrences (level of evidence: poor).

- 2233 Evidence on the effects of back schools versus placebo or wait list controls for 2234 chronic low back pain is inconsistent, though most studies found no beneficial effects (level of evidence: fair). 2235 2236 There was also mixed evidence on the efficacy of back schools relative to other 2237 active interventions in patients with acute low back pain (one higher quality trial 2238 finding benefit on sick leave but three other trials finding no benefit), but consistent evidence for modest benefits in patients with chronic low back pain 2239 2240 (level of evidence: fair). 2241 More intensive back school programs based on the original Swedish program 2242 and programs in occupational settings appeared more effective (level of 2243 evidence: fair). 2244 Recommendations and findings from other guidelines 2245 The AHCPR guidelines found that in the workplace, back schools with worksite-• 2246 specific education may be effective adjuncts to individual education efforts by the 2247 clinician the treatment of patients with acute low back problems (strength of 2248 evidence: C). 2249 The AHCPR guidelines found that the efficacy of back schools in • 2250 nonoccupational settings had not been proven (strength of evidence: C). 2251 The European COST guidelines recommend considering back schools where • 2252 information given is consistent with evidence-based recommendations for short-2253 term (<6 weeks) pain relief and improvements in functional status. They do not 2254 recommend back schools as a treatment for chronic low back pain when aiming 2255 at long-term effects (>12 months).
- 2256 Brief educational interventions
- 2257 We defined brief interventions as a detailed clinical examination by a physician
- and/or physiotherapist followed by individualized back education and advice. As we
- defined them, brief interventions typically require several hours and are usually
- 2260 completed in one or two sessions. Brief interventions differ from back schools because
- they don't involve group education and exercises. They also are distinct from
- 2262 multidisciplinary rehabilitation, which generally includes a specific psychologic
- 2263 component as well as a supervised rehabilitation program.
- 2264 Results of search: systematic reviews
- 2265 We found no systematic reviews of brief interventions.

2266 Results of search: trials

- 2267 We identified three higher-quality trials (all in workers with low back pain for less than
- three months) that evaluated brief interventions in workers with subacute low back pain
- (Table 18) [258, 259, 262-264]. A third higher-quality trial evaluated a brief intervention
- in patients with chronic low back pain [265, 266].
- 2271 Efficacy of brief educational interventions versus usual care
- 2272 One trial of patients on sick leave for 8 to 12 weeks due to low back pain found that a
- single visit to a spine clinic with a detailed examination by a physiatrist and physical
- therapist and advice to remain active was associated with no differences in the
- proportion of patients who continued to report low back pain at 6 months or 1 year or
- the proportion off sick leave at 3 years, though patients randomized to the intervention
- 2277 were more likely to be off sick leave at 1 year (OR 1.60, 95% CI 1.08 to 2.39) [262,
- 2278 267]. In another trial, which evaluated patients with bothersome low back pain for up to
- 2279 3 months, the brief intervention was associated with fewer sick days after 1 year (19
- 2280 versus 41 days, p=0.02) [264] and 2 years (30 versus 62 days, p=0.03) [263]. There
- were no differences in pain or ODI scores at any time. A smaller proportion of patients
- reported severe symptoms at 3 months, but not with longer duration of follow-up. The
- third trial found that compared to usual care, workers with back pain for four to twelve
- 2284 weeks who received a detailed examination and three hours of advice for light activity
- were less likely to be on sick leave (19% versus 34%, p<0.001) and on permanent
- 2286 disability (49% vs 69%, p<0.03) after five years [258, 259].

Table 18. Trials of brief educational interventions versus usual care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Molde Hagen, 2000 and 2003[262, 267]	N=510 3 years	Brief intervention versus usual care LBP still present at 1 year: 47% vs. 52% (NS) Off sick leave at 1 year: 69% vs. 57% (p<0.05) Off sick leave at 3 years: 64% vs. 62% (NS) New episodes of sick leave due to LBP (through 3 years): 62% (147/237) vs. 61% (135/220) (NS)	6/11
Karjalainen, 2003[264]	N=170 2 years	Brief intervention versus mini intervention plus work site visit versus usual care Pain intensity: 3.5 vs. 3.2 vs. 3.4 at 24 months (NS) Very or extremely bothersome symptoms during the past week: 29% vs. 35% vs. 48% at 3 months, 23% vs. 20% vs. 29% at 24 months (p=0.048 for A vs. C at 3 months, NS for B vs. C) ODI: 19 vs. 18 vs. 18 at 24 months (NS) Days on sick leave: 30 vs. 45 vs. 62 (p=0.030 for A vs. C, NS for B vs. C)	8/11
Indahl, 1995 and 1998[258, 259]	N=489 5 years	Brief intervention vs usual care On sick leave: 30% vs. 60% at 200 days, 19% vs 34% at 5 years (p<0.001) Long term or permanent disability status after 5 years: 19% vs 34% (p<0.001) Sick listed > 2 x: 49% vs 69% (p<0.03)	6/11

2288

2289 Efficacy of brief educational interventions versus brief educational interventions plus 2290 manipulation and exercise

2291 One higher-quality trial found a brief intervention (consisting of a physician consultation

and individualized reassurance, education, and back advice with a repeat visit at 5

2293 months) modestly inferior to the brief intervention plus manipulation and exercise for

pain relief at 12 and 24 months (difference of about 6 points on a 100 point pain scale at

12 months and about 3 points at 24 months) (Table 19) [265, 266]. Effects on disability,

health-related quality of life and number of days of sick leave through 1 year (20 vs. 14

days) were similar.

Table 19. Trial of brief educational intervention versus brief intervention plus exerciseand manipulation

Author, year	Number of patients Duration of follow-up	Main results	Quality
Niemisto, 2003 and 2005[265, 266]	N=204 2 years	Brief intervention versus brief intervention plus manipulation plus exercise Pain (0 to 100): 32.2 vs. 25.7 at 12 months (p=0.01), 33.1 vs. 30.7 at 24 months ODI: 16.5 vs. 13.7 at 12 months (p=0.20), 14.0 vs. 12.0 at 24 months Health-related Quality of Life (15D): No differences Number of days of work absence through 1 year: 20 vs. 14	7/11

2300

2301 Safety

2302 Neither trial evaluated safety.

2303 Cost-effectiveness

- The two trials of workers with subacute low back pain found the brief intervention superior to usual care by an average of \$3,497 [262] and 4839 Euros [263], largely due to the decreased sick leave in the first year after the intervention (cost-benefit analysis).
- 2307 The third trial estimated an incremental cost-effectiveness of \$512 per additional point
- 2308 of improvement on a 100-point pain scale for combined manipulation and exercise plus
- a brief intervention, versus the brief intervention alone [266].

2310 Summary of evidence

- In three higher-quality trials, a brief educational intervention was associated with beneficial effects on sick leave in workers with subacute low back pain, though most of the benefits were observed in the first year after the intervention. There were no clear effects on pain or functional status (level of evidence: good).
- A brief intervention was only modestly inferior to the brief intervention plus
 exercise and manipulation in patients with chronic low back pain (one higherquality trial) (level of evidence: fair).
- 2318 **Recommendations and findings from other guidelines**
- The European COST guidelines recommend brief educational interventions that
 encourage a return to normal activity to reduce sickness absence and disability
 associated with chronic low back pain.

2322 Exercise and Related Interventions

2323 Exercise

- 2324 Results of search: systematic reviews
- 2325 We identified a recent, good-quality Cochrane review (61 trials) evaluating the
- effectiveness of exercise therapy for nonspecific low back pain [268, 269]. Most of the
- evidence was in patients with chronic low back pain (43 trials). Only eight of the 61
- trials were rated high quality (met all four quality rating criteria). We included four other
- recent systematic reviews of exercise therapy; each with a less comprehensive scope
- than the Cochrane review [270-273]. One was rated higher-quality [270]. We excluded
- an outdated Cochrane review [274] and 13 other older systematic reviews [110, 132,
- 2332 249, 250, 275-283].
- 2333 Results of search: trials

We identified a recent, large, lower-quality trial comparing manipulation, exercise, or both to usual care [284]. We also included a recent, higher-quality trial comparing a standard exercise regimen to an individualized approach using a patient classification

2337 scheme [285].

2338 Efficacy of exercise therapy versus placebo or usual care

2339 The Cochrane review [268, 269] found that exercise therapy was superior to usual care 2340 or no treatment in only two of eleven trials (one higher quality [286] and one lower-2341 quality [287]). Among trials with data that could be pooled, there was no difference 2342 between exercise therapy and no exercise for pain relief (3 trials) or functional 2343 outcomes (3 trials) at any time period. The Cochrane review also included five trials 2344 comparing exercise to usual care or no treatment in patients with subacute low back 2345 pain. Although two trials [288, 289] (one higher-guality [289]) found reduced 2346 absenteeism with a graded-activity intervention in the workplace compared with usual 2347 care and one low-quality trial [290] found improved functioning over usual care with an 2348 exercise program combined with behavioral therapy, pooled results suggested no 2349 difference on pain scores (5 trials, weighted mean difference 1.89 on a 100 point scale, 2350 95% CI –1.13 to 4.91) or functional outcomes (4 trials, weighted mean difference 1.07, 2351 95% CI -3.18 to 5.32).

2352 By contrast, in patients with chronic low back pain, exercise was modestly superior 2353 relative to no treatment for pain relief at the earliest follow-up period (weighted mean 2354 improvement 10 points on a 0 to 100 scale, 95% CI 1.31 to 19.09), though not for 2355 functional outcomes (weighted mean improvement 3.00, 95% CI -0.53 to 6.48) [268, 2356 269]. Results were similar at later follow-up. The differences were somewhat greater in 2357 health care settings (mean improvement 13.3 points on pain, 95% CI 5.5 to 21.1 and 2358 6.9 on function, 95% CI 2.2 to 11.77) than in occupational or general population 2359 settings, but still did not meet pre-defined criteria for minimal clinically important 2360 differences (20 point improvement for pain and 10 points for function).

Another higher-quality systematic review focusing on work outcomes (14 trials) found that exercise (including exercise as part of a multidisciplinary intervention) reduced sick leave during the first year (effect size -0.24, 95% CI -0.36 to -0.11) and improved the proportion returned to work (RR 0.75 at 1 year, p<0.05), though there was no benefit in the severely disabled subgroup (>90 days sick leave under usual care) or in patients receiving disability payments [270].

A lower-quality systematic review [271] focusing on patients with spondylolysis and
spondylolisthesis included only two trials (one higher quality [291]), both of which found
exercise superior relative to usual care [291] or sham exercise [292].

The recently published, large (N=1334) UK BEAM Trial was consistent with the results of the systematic reviews (Table 21) [284]. In patients with low back pain for at least 28 days, exercise only had small beneficial effects on pain and disability relative to usual care.

Table 21. Results of the UK BEAM trial

Author, year	Number of patients Duration of follow-up	Main results	Quality
UK BEAM Trial, 2004[284]	N=1334 12 months	Manipulation + exercise versus manipulation versus exercise (all results are absolute net benefit relative to usual care at 12 months) RDQ Questionnaire (0 to 24 scale): 1.30 (95% CI 0.54 to 2.07) vs. 1.01 (95% CI 0.22 to 1.81) vs. 0.39 (95% CI - 0.41 to 1.19) Modified Von Korff pain score (0 to 100 scale): 6.71 (95% CI 2.47 to 10.95) vs. 5.87 (95% CI 1.58 to 10.17) vs. 4.90 (95% CI 0.30 to 9.50)	2 or 3/11
		Modified Von Korff disability score (0 to 100 scale): 6.71 (95% CI 2.62 to 10.80) vs. 5.65 (95% CI 1.57 to 9.72) vs. 4.56 (95% CI 0.34 to 8.78)	

2375

2376 Efficacy of exercise therapy versus other interventions

2377 The Cochrane review included seven trials of patients with acute low back pain that

2378 found no difference between exercise therapy and other conservative treatments

2379 (difference in pain relief 0.31 point, 95% CI –0.10 to 0.72) or functional outcomes [268,

2380 269]. In patients with chronic low back pain, exercise was associated with statistically

significant but only marginal benefits on pain (5.93 points, 95% CI 2.21 to 9.65) and

function (2.37 points, 95% CI 0.74 to 4.0) relative to other conservative interventions.

Another, fair-quality systematic review found that McKenzie exercise therapy (5 trials) was associated with modest short-term improvements in short-term pain and disability compared to other conservative interventions in patients with back pain of mixed duration (pooled effect –8.6, 95% CI –13.7 to –3.5 for pain and –5.4, 95% CI –8.4 to –

2387 2.4 for function), but no better for intermediate term disability or work absence [273].

2388 Like the Cochrane review, the UK BEAM Trial [284] found no clear differences between 2389 exercise therapy and manipulation (see Table 21 above). Another trial not included in 2390 the Cochrane review compared a standardized exercise regimen (low-stress aerobic 2391 exercise, general muscle reconditioning, and advice to stay active) with an approach 2392 using a classification scheme to match patient signs and symptoms to specific exercises 2393 or other treatments (such as manipulation, mobilization, or traction) in workers with back 2394 pain for less than three weeks (Table 22) [285]. It found that patients receiving physical 2395 therapy according to the classification scheme had greater improvements in ODI scores 2396 at 4 weeks (between-group difference 10.9, 95% CI 1.9 to 19.9) and at one year (9.0,

- 2397 95% CI 0.30 to 17.7), and were less likely to have continued work restrictions (42% vs.
- 2398 17%, p=0.017). One difficulty in interpreting these results, however, is that the intensity
- 2399 of the standardized exercise regimen was unclear.

2400Table 22. Trial comparing standardized exercise therapy to individualized treatment based on2401a classification scheme

Author, year	Number of patients Duration of follow-up	Main results	Quality
Fritz, 2003[285]	N=78	Standard exercise vs. classification-based therapy	
	1 year	(mean differences between groups relative to baseline) ODI: 10.9 (95% CI 1.9 to 19.9) at 4 weeks, 9.0 (0.30 to 17.7) at 1 year SF-36 physical component summary: 5.6 (0.6 to 10.7) at 4 weeks, 3.6 (-2.1 to 9.3) at 1 year SF-36 mental component summary: 5.7 (1.8 to 9.5) at 4 weeks, 3.6 (-1.4 to 8.7) at 1 year Continued work restrictions after four weeks: 42% (15/36) vs. 17% (7/41)	7/11

2402

2403 Efficacy of different types of exercise regimens

2404 The authors of the Cochrane review also conducted a meta-regression analysis to 2405 evaluated specific features of exercise interventions associated with improved 2406 outcomes in patients with chronic low back pain [293]. Compared to home exercises 2407 only, improved pain scores were seen with individually designed programs (5.4 point 2408 improvement in pain scores, 95% credible interval 1.3 to 9.5), supervised home 2409 exercise (6.1 points, credible interval –0.2 to 12.4), group (4.8 points, 95% credible 2410 interval 0.2 to 9.4 points), and individually supervised programs (5.9 points, 95% 2411 credible interval 2.1 to 9.8 points). High-dose exercise programs (20 or more hours of 2412 intervention time) were not superior to low-dose programs. Interventions that included 2413 additional conservative care were better (5.1 points, 95% credible interval 1.8 to 8.4 2414 points) than those without additional conservative care. The exercise regimens that 2415 were most effective used stretching and strengthening, though there was some overlap 2416 with other types (aerobic, mobilizing, or other specific exercise methods). Modelling 2417 suggested that an intervention incorporating all of the features of an effective exercise 2418 intervention would improve pain scores by 18.1 points (95% credible interval 11.1 to 2419 25.0 points) compared to no treatment and 13.0 points (95% credible interval 6.0 to 19.9 2420 points) compared to other conservative treatment and function by 5.5 points (95%

credible interval 0.5 to 10.5) compared to no treatment and by 2.7 points (95% credible

- interval –1.7 to 7.1) compared to other conservative interventions, though no trials ofsuch an intervention are available.
- 2424 Safety

2425 None of the systematic reviews assessed adverse events associated with exercise

- therapy, which were poorly reported in the trials.
- 2427 Costs

2428 Two trials calculated cost-effectiveness ratios for exercise therapies. The UK BEAM

2429 trial found the addition of exercise associated with an incremental cost-effectiveness of

2430 £8300/QALY relative to best care, though exercise was dominated by the combination

- of exercise and manipulation (more costly and less effective) [284]. Another British trial
- estimated an incremental cost-effectiveness of £3010/QALY for physiotherapy relative
- to physiotherapy advice alone, but a high likelihood of no significant differences
- between interventions [294].

2435 Two trials compared costs between exercise programs and usual care. One found no

significant cost differences related to health services, equipment, and days off work

2437 between a progressive exercise program and usual primary care [290]. A cost-

2438 minimization analysis from another trial found no differences in total costs (direct and

2439 indirect) between either a standard or intensive physical therapy program and usual

2440 care [295].

2441 Three other trials included cost-benefit analyses of exercise therapy versus other

2442 interventions. One trial found no significant difference between exercise and either bed

rest or usual activities in patients with acute low back pain (usual activities associated

with more rapid recovery in this trial) [286]. Another trial found exercise associated with

greater costs compared to providing a self-care education book (\$437 versus \$153),

- and only marginally better outcomes [296]. The trial comparing standardized exercise
- therapy to classification-based treatment found higher total median costs with the
- former (\$1004 versus \$774), though the difference was not significant (p=0.13) [285].

2449 Studies comparing costs between exercise therapy and spinal manipulation are 2450 discussed in the spinal manipulation section.

2451	Summary of evidence
2452 2453 2454 2455	• Exercise is modestly superior to placebo in multiple trials of patients with chronic low back pain for pain relief and work-related outcomes, though the pain relief benefits do not appear to reach pre-defined levels of minimal clinically important differences (level of evidence: good).
2456 2457 2458	• Exercise regimens incorporating features such as individual tailoring, supervision, stretching, and strengthening are associated with the best outcomes in meta-regression analyses (level of evidence: fair).
2459 2460 2461	• Evidence on the efficacy of exercise relative to placebo or no treatment in patients with acute low back pain is somewhat inconsistent, though most trials found no benefit (level of evidence: fair).
2462 2463 2464	• One recent, higher-quality trial found a standardized exercise regimen inferior to physical therapy tailored according to patient signs and symptoms (level of evidence: fair).
2465 2466 2467	• Evidence from numerous trials suggests no clinically significant difference between exercise and other non-invasive interventions for either acute or chronic low back pain (level of evidence: good).
2468	Recommendations and findings from other guidelines
2469 2470 2471 2472	• The AHCPR guidelines found that low-stress aerobic exercise can prevent debilitation due to inactivity during the first month of symptoms and help patients with acute low back problems return to usual functioning (strength of evidence: C).
2473 2474 2475	• The AHCPR guidelines suggest that low-stress aerobic exercise programs can be started during the first 2 weeks for most patients with acute low back problems (strength of evidence: D).
2476 2477 2478 2479	• The AHCPR guidelines suggest that conditioning exercises for trunk muscles are helpful for patients with acute low back problems, particularly if symptoms persist, but may aggravate symptoms more than aerobic exercise in the first 2 weeks (strength of evidence: C).
2480 2481	• The AHCPR guidelines found no evidence that back-specific exercise machines provide benefit over traditional exercise (strength of evidence: D).
2482 2483	 The AHCPR guidelines found no evidence to support stretching of the back muscles for acute low back problems (strength of evidence: D).
2484 2485 2486	• The AHCPR guidelines suggest that gradually increasing exercise quotas result in better outcomes than telling patients to stop exercising if pain occurs (strength of evidence: C).

2487 2488	•	The VA/DoD guideline recommendations for exercise are similar to the AHCPR recommendations.
2489 2490 2491	•	The UK RCGP guidelines found that it is doubtful that specific back exercises produce significant improvement in acute low back pain, or that it is possible to select which patients will respond to which exercises (strength of evidence: ***).
2492 2493 2494	•	The UK RCGP guidelines found some evidence that exercise programs and physical reconditioning can improve pain and function in patients with chronic low back pain (strength of evidence: **).
2495 2496	•	The UK RCGP guidelines found theoretical arguments for starting exercise programs at around 6 weeks after start of symptoms (strength of evidence: *).
2497 2498	•	The European COST guidelines recommend against advising specific exercises for acute low back pain.
2499 2500 2501 2502 2503 2504	•	The European COST guidelines recommend supervised exercise as a first-line treatment for chronic low back pain. They suggest exercise programs not requiring expensive training machines, the use of a cognitive-behavioral approach with graded exercises, and quotas. Group exercises are considered a low-cost option. The guidelines provide no recommendations on specific types of exercise, and suggest that the patient and therapist could best determine that.

2505 Hydrotherapy

- 2506 Results of search: systematic reviews
- 2507 We found no systematic reviews evaluating the efficacy of hydrotherapy (water-based
- 2508 exercise) in patients with low back pain.
- 2509 Results of search: trials
- 2510 We identified three lower-quality trials of hydrotherapy, all in patients with chronic low
- 2511 back pain [297-299].
- 2512 Efficacy of hydrotherapy versus delayed hydrotherapy
- 2513 One lower-quality trial (N=109) found hydrotherapy superior to delayed hydrotherapy in
- 2514 patients with chronic low back pain for back-specific functional status, but not for pain
- 2515 (Table 23) [297]. Incomplete and inconsistent reporting of results data makes this trial
- 2516 difficult to interpret.

Table 23. Trial of hydrotherapy versus delayed hydrotherapy

Author, year	Number of patients Duration of follow-up	Main results	Quality
McIlveen, 1998[297]	N=109 4 weeks	Hydrotherapy versus delayed hydrotherapy ODI, percent improved: 27% vs. 8% (p=0.05) Pain rating index of McGill Pain Questionnaire, percent improved >10 points: 11% vs. 8% (NS) Present pain intensity of McGill Pain Questionnaire, percent improved by >1 point: 33% vs. 22% (NS)	3/11

2518

- 2519 Efficacy of hydrotherapy versus land-based therapy
- 2520 Two trials (N=60 and N=30) each found no differences between hydrotherapy and land-
- 2521 based therapy for short-term pain or functional status in patients with chronic low back
- 2522 pain (Table 24) [298, 299].
- 2523

Table 24. Trials of hydrotherapy versus land-based therapy

Author, year	Number of patients Duration of follow-up	Main results	Quality
Yozbatiran, 2004[299]	N=30 4 weeks	Hydrotherapy vs. land-based therapy Pain, mean improvement in VAS (0-10 scale): 3.53 vs. 2.53 (NS)	2/11
		ODI, mean improvement: 19.34 vs. 17.34 (NS)	
Sjogren, 1997[298]	N=60 4 weeks	Hydrotherapy vs. land-based therapy Pain, mean improvement in VAS (0-10 scale): 1.35 vs. 0.79 (NS) ODI, mean improvement: 3.25 vs. 2.40 (NS)	3/11

2524

2525 Safety

Adverse events were not reported in any of the trials.

2527 Costs

- 2528 We found no studies on costs.
- 2529 Summary of evidence
- There is insufficient evidence (one poor-quality trial) to judge the efficacy of hydrotherapy versus delayed hydrotherapy (level of evidence: poor).
- There is consistent evidence from two lower-quality trials that hydrotherapy and
 land-based therapy are associated with similar outcomes in patients with chronic
 low back pain (level of evidence: fair).
- There is no evidence on the effects of hydrotherapy in patients with acute low back pain.

- 2537 **Recommendations and findings from other guidelines**
- 2538 None of the guidelines address hydrotherapy.
- 2539 Yoga

Yoga can typically be distinguished from traditional exercise by its utilization of specific body positions, breathing techniques, and emphasis on mental focus. One challenge in evaluating the efficacy of yoga is that many styles are practiced, each with different emphases and postures.

- 2544 Results of search: systematic reviews
- 2545 We identified no systematic reviews evaluating the efficacy of yoga in patients with low
- 2546 back pain.
- 2547 Results of search: trials
- 2548 We identified three trials (one higher quality [300]) evaluating the efficacy of yoga in
- 2549 patients with chronic low back pain (Table 25) [300-302].
- 2550 Efficacy of yoga

2551 In the higher-quality trial (N=101), six weeks of viniyoga (a therapeutically oriented style) 2552 was modestly superior to both conventional exercise and a self-care education book for 2553 back related function at twelve weeks (mean difference on RDQ score -1.8, 95% DCI -2554 3.5 to -0.1 and mean difference -3.4, 95% CI -5.1 to -1.6, respectively), but only 2555 superior to the self-care book at 26 weeks (mean difference -3.6, 95% CI -5.4 to -1.8) 2556 [300]. Effects on symptom bothersomeness scores were similar at 12 weeks for all 2557 three interventions, though yoga was superior to the self-care book at 26 weeks (mean 2558 difference -2.2, 95% CI -3.2 to -1.2). Yoga was also associated with decreased 2559 medication use at week 26 (21% vs. 50% vs. 59%, p<0.05 for yoga versus either 2560 comparator), though there was no significant difference in the proportion of patients 2561 visiting health care providers for low back pain.

Two lower-quality, smaller trials (N=60 and 22) evaluated lyengar yoga, a commonly practiced style of Hatha yoga that makes frequent use of props. The larger trial found yoga more effective than exercise instruction (from a weekly newsletter) for reducing disability [301]. The benefits were sustained for 3 months after the end of a 16-week course of treatment (-8.5 vs. –10.4 on a 70 point scale, p=0.009). Differences on pain outcomes were modest and only significant when adjusted for baseline differences in

- the intervention groups. In addition, interpreting the results is difficult because nearly a
- third of the patients did not complete the study or were lost to follow-up. The other trial
- 2570 found no significant differences on measures of back-specific function or depression
- 2571 [302]. Pain outcomes were not assessed.
- 2572

Table 25. Trials of yoga versus exercis

	Number of patients Duration of		
Author, year	follow-up	Main results	Quality
Sherman, 2006[300]	N=101 26 weeks	Viniyoga versus exercise RDQ Score (0 to 24 scale), mean difference between groups relative to baseline: -1.8 (-3.5 to -0.1) at 12 weeks (p=0.034) and -1.5 (-3.2 to 0.2) at 26 weeks (p=0.092)	8/11
		Viniyoga versus self-care book RDQ Score, mean difference between groups relative to baseline: -3.4 (-5.1 to -1.6) at 12 weeks (p=0.0002) and - 3.6 (-5.4 to -1.8) at 26 weeks (p<0.001)	
Williams, 2005[301]	N=60 7 months	Iyengar yoga versus exercise education Present Pain Index, mean change at 7 months (0 to 5 scale): -0.5 vs0.9, p=0.140 Pain Disability Index, mean change at 7 months (7 to 70 scale): -8.5 vs10.4, p=0.009 Pain, VAS, mean change at 7 months (0 to 10 scale): 1.2 vs1.6, p=0.398	4/11
Galantino, 2004[302]	N=22 6 weeks	Iyengar yoga versus usual activities Oswestry Disabilty Index (change from baseline): 3.83 vs. 2.18 Proportion with lower scores on Oswestry: 46% vs. 40%	3/11

- 2574 Safety
- 2575 No study reported safety outcomes.
- 2576 Costs
- 2577 We found no studies on costs.
- 2578 Summary of evidence
- Viniyoga was superior to traditional exercises and a self-care education book for
 back-specific functional status and use of medications in one higher-quality trial
 (level of evidence: fair).
- There is insufficient evidence to judge the effectiveness of other types of yoga (two small, low quality trials of Hatha yoga) (level of evidence: poor).
- 2584 **Recommendations and findings from other guidelines**
- 2585 None of the guidelines address yoga.

2586 *Multidisciplinary Interventions*

2587 Multidisciplinary rehabilitation

2588 Results of search: systematic reviews

We identified higher-quality Cochrane reviews evaluating the efficacy of multidisciplinary rehabilitation in patients with chronic (>3 months) [303, 304] and subacute (defined as >4 weeks and <3 months in duration) [71, 72] low back pain. They included ten (three higher quality) and two (both lower quality) trials, respectively. No systematic review evaluated the effectiveness of multidisciplinary rehabilitation in patients with acute low back pain. We included one other recent systematic review evaluating multidisciplinary rehabilitation and behavioral interventions [305]. Another recent systematic review was

- excluded because it only included one relevant trial that was already included in the
- 2597 Cochrane review [306]. We also excluded one older systematic review [242].
- 2598 Results of search: trials
- 2599 We identified one recent (lower-quality) trial of intensive multidisciplinary rehabilitation in
- high-risk patients with acute low back pain[78].
- 2601 Efficacy of multidisciplinary rehabilitation versus usual care or non-multidisciplinary 2602 rehabilitation
- 2603 One of the Cochrane reviews found that in patients with subacute low back pain (two 2604 lower-guality RCTs, N=103 and 104), multidisciplinary rehabilitation (defined as an 2605 intervention consisting of a physician's consultation plus a psychological, social, or 2606 vocational intervention, or a combination of these) with a workplace visit is more 2607 effective than usual care [71, 72]. In one of the trials, return to work averaged 10 weeks 2608 (SD=12.7) with multidisciplinary rehabilitation (including measurement of functional 2609 capacity, a work-place visit, back school, and graded exercise with an operant-2610 conditioning approach) versus 15 weeks (SD=15.6) with traditional care (p=0.03 for 2611 difference), and there was less sick leave in the multidisciplinary rehabilitation group in 2612 the following year (mean difference -7.5 days, 95% CI=-15.06 to 0.06) [289]. 2613 Subjective disability was also modestly superior in the intervention group. In the second 2614 trial, the duration of absence from work was lower with a combined occupational and 2615 clinical intervention (occupational physician consultation and work place visit) and 2616 clinical intervention (back school, visit to back specialist, and multidisciplinary work
- 2617 rehabilitation including functional rehabilitation therapy if needed) compared to the

occupational or clinical interventions alone or to usual care (median days off work 60 vs.
67 vs. 131 vs. 120 days, p<0.05) [307]. Return to work was 2.4 times faster in the
combined intervention group compared to the usual care group (95% CI 1.19 to 4.89)
and 1.91 times faster with any occupational intervention compared to the two groups
without the occupational intervention (95% CI 1.18 to 3.1). The combined intervention
group also was associated with greater improvements in Oswestry scores after one

2624 year compared to usual care (mean difference 10.7, p=0.02).

2625 The other Cochrane review (10 trials) included three trials (two higher quality) [308-310] 2626 of patients with chronic low back pain that found intensive (>100 hours), daily 2627 multidisciplinary biopsychosocial rehabilitation (defined by the reviewers as an 2628 intervention with a physical component plus a psychological and/or social/occupational 2629 component meeting pre-defined criteria) with functional restoration superior to non-2630 multidisciplinary rehabilitation or usual care for improving functional status (standardized 2631 mean difference -0.40 to -0.90 at 3-4 months and -0.56 to -1.07 at 60 months), and 2632 two trials (both higher quality) [308, 309] showing superiority for pain outcomes 2633 (standardized mean difference -0.56 and -0.74 at 3-4 months and -0.51 and 0.00 at 60 2634 months) [303, 304]. There was inconsistent evidence regarding vocational outcomes, 2635 with one higher-quality trial [309] showing improvements in 'work-readiness' but two 2636 other higher-quality trials [310, 311] showing no benefits on sickness leave. In contrast 2637 to the intensive interventions, less intensive multidisciplinary rehabilitation was not 2638 associated with improvements in pain, function, or vocational outcomes compared to 2639 non-multidisciplinary outpatient rehabilitation or usual care (five trials, three higher 2640 quality).

The non-Cochrane systematic review found multidisciplinary rehabilitation modestly superior to usual care or non-multidisciplinary rehabilitation for the proportion returned to work (effect size 0.53, 95% CI 0.19 to 0.86 at long-term follow-up), but not for pain intensity [305]. However, it included fewer (five) trials than the Cochrane review, and appeared to combine results of trials evaluating intensive and less intensive multidisciplinary rehabilitation.

2647 One recent, small (N=70) trial found that an intensive multidisciplinary intervention
2648 (including 3 physician evaluations and a total of 45 physical therapy, biofeedback/pain

management, group didactic, and case manager/occupational therapy sessions) was
associated with improved pain, decreased disability, and decreased costs (mainly
related to lost wages) compared to usual care in patients with low back pain of less than
8 weeks duration at higher risk for chronic disability based on a screening tool (Table
2653 26) [78].

2654Table 26. Trial of intensive multidisciplinary rehabilitation in patients with low back pain2655for <8 weeks</td>

Author, year	Number of patients Duration of follow-up	Main results	Quality
Gatchel, 2005[78]	N=70 12 months	Functional restoration vs. usual care Return to work at 12 months: 91% vs. 69% (p=0.027 Average number of disability days due to back pain: 38 vs. 102, p=0.001 Average self-rated pain over last 3 months: 27 vs. 43, p=0.001 Taking opioid analgesics: 27% vs. 44%, p=0.020	2 or 3/11

- 2656
- 2657 Safety
- 2658 No study evaluated safety.
- 2659 Costs

2660 In one trial of workers disabled due to low back pain, multidisciplinary rehabilitation with 2661 physical conditioning was associated with an average cost-benefit of \$18,585 after 6.4 2662 years of follow-up, though the difference was not statistically significant, in part because 2663 of skewed distributions [312]. Another trial found a light multidisciplinary intervention 2664 associated with an average cost-benefit of about \$15,000 after 2 years relative to usual 2665 care in workers with chronic low back pain [313]. A cost-benefit analysis of the trial 2666 comparing an intensive, early multidisciplinary intervention in patients with acute low 2667 back pain identified as higher risk for chronic disability estimated a net gain of \$9122, 2668 mostly related to a reduction in lost wages in the intervention group [78].

2669

Summary of evidence

In two lower-quality trials, multidisciplinary rehabilitation (particularly with a work site visit) in patients with subacute low back pain was associated with quicker return to work, reduced sick leave, and improved disability relative to usual care (level of evidence: fair).

- 2674 Intensive multidisciplinary rehabilitation with functional restoration is more 2675 effective than usual care or non-multidisciplinary rehabilitation for reducing pain 2676 and improving function in patients with chronic low back pain, though effects on work-related outcomes are mixed (four trials, three higher-quality) (level of 2677 2678 evidence: good). 2679 Less intensive (<100 hours) multidisciplinary rehabilitation was not more effective 2680 than usual care or non-multidisciplinary rehabilitation (five trials) (level of evidence: good). 2681 2682 There is insufficient evidence from one, lower-guality RCT to determine the 2683 efficacy of multidisciplinary rehabilitation in patients with acute low back pain 2684 (level of evidence: poor). 2685 Recommendations and findings from other guidelines 2686 The European COST guidelines recommend considering multidisciplinary • 2687 treatment programs in occupational settings for workers on sick leave for more 2688 than 4-8 weeks and multidisciplinary intervention with functional restoration in 2689 patients with chronic low back pain who have failed monodisciplinary treatment 2690 options. 2691 Physical conditioning programs (work conditioning, work hardening, and 2692 functional restoration)
- 2693 Physical conditioning programs (variously referred to as work conditioning, work 2694 hardening, and functional restoration/exercise programs) involve simulated or actual 2695 work tasks in a supervised environment in order to enhance job performance skills and 2696 improve strength, endurance, flexilibility, and cardiovascular fitness in injured workers 2697 [314]. The goal of such programs is to improve functional and work outcomes. One 2698 important challenge in assessing the efficacy of physical conditioning programs, 2699 however, is the wide variation in the content (such as the use of behavioral therapy or 2700 the type of exercise) and intensity of treatments.
- 2701 Results of search: systematic reviews
- 2702 We identified one good-quality Cochrane review (19 trials, 10 rated higher quality) on
- the efficacy of physical conditioning programs in patients with acute or chronic low back
- pain [74, 75]. Several of the trials evaluated in this Cochrane review were also included
- in the Cochrane reviews of multidisciplinary rehabilitation for subacute (2 of 2 trials) [71,
- 2706 72] and chronic (3 of 10 trials) [303, 304] low back pain. We excluded one older
- 2707 systematic review [314].

- 2708 Results of search: trials
- 2709 We identified one additional trial of an intensive multidisciplinary functional restoration
- 2710 intervention in patients with low back pain for less than eight weeks (see discussion in
- 2711 multidisciplinary rehabilitation section) [78].
- 2712 Efficacy of physical conditioning programs versus usual care
- 2713 In patients with acute low back pain, the Cochrane review found that only one [315] of
- five included trials (three rated higher quality [286, 315, 316]) found a positive treatment
- 2715 effect from physical conditioning programs on time lost from work, proportion of subjects
- 2716 off work, or functional status [74, 75]. A recent trial not included in the Cochrane review
- found an intensive, multidisciplinary functional restoration intervention superior to usual
 care for several outcomes in high-risk patients with acute low back pain (see section on
- 2718 care for several outcomes in high-lisk patients with acute low back pain (see section of
- 2719 multidisciplinary rehabilitation) [78].
- 2720 In patients with chronic low back pain (14 trials), physical conditioning programs that
- 2721 included a cognitive-behavioral approach generally appeared effective for reducing time
- off work. In two relatively homogeneous trials [289, 307] (one higher quality [307]) of
- 2723 physical conditioning programs versus usual care, the number of sick days lost at 12
- 2724 months follow-up compared to usual care or advice averaged 45 days (95% CI 3 to 88).
- 2725 There was little evidence for or against the efficacy of specific exercises not
- accompanied by a cognitive behavioral approach.
- 2727 Efficacy of physical conditioning programs versus other interventions
- 2728 The Cochrane review [74, 75] included two higher-quality trials [317, 318] that found
- that physical conditioning programs were associated with an average of 112 and 243
- 2730 fewer lost work days compared to passive physiotherapy in patients with chronic low
- 2731 back pain.
- 2732 Safety
- 2733 No study evaluated safety.
- 2734 Costs
- 2735 See the section on multidisciplinary rehabilitation.

2736	Summary of evidence
2737	 Evidence of benefits from six heterogeneous trials of physical conditioning
2738	programs in patients with acute low back pain is inconsistent, with the majority of
2739	studies showing no benefit (level of evidence: fair).
2740	 Physical conditioning programs with a cognitive-behavioral approach are
2741	effective for reducing sick leave relative to usual care in two trials (one higher
2742	quality) of patients with chronic low back pain (level of evidence: fair). There is
2743	no clear benefit from physical conditioning programs without a cognitive-
2744	behavioral approach.
2745	 Physical conditioning programs were effective for reducing days lost from work
2746	relative to passive physical therapy in patients with chronic low back pain (two

- relative to passive physical therapy in patients with chronic low back pain (two 2746 2747 high quality trials) (level of evidence: good).
- Recommendations and findings from other guidelines 2748
- 2749 • The European COST guidelines recommend considering multidisciplinary 2750 treatment programs in occupational settings for workers on sick leave for more 2751 than 4-8 weeks and multidisciplinary intervention with functional restoration in 2752 patients with chronic low back pain who have failed monodisciplinary treatment 2753 options.
- 2754 **Physical Modalities**

2755 Interferential therapy

- 2756 Interferential therapy involves the application of a medium frequency alternating
- current modulated to produce low frequencies up to 150 Hz. It is thought to increase 2757
- 2758 blood flow to tissues and provide pain relief, and is more comfortable for patients than
- 2759 transcutaneous electrical nerve stimulation.
- 2760 Results of search: systematic reviews
- 2761 We found no systematic reviews of interferential therapy.
- Results of search: trials 2762
- 2763 We identified three trials (one higher-quality [319]) of interferential therapy [319-321].
- 2764 Two trials evaluated patients with subacute (>4 weeks) back pain and the other
- 2765 evaluated patients with back pain of mixed duration (mainly chronic). Interferential
- 2766 therapy was compared to spinal manipulation, traction, and a back self-care book in one
- 2767 trial each.

- 2768 Efficacy of interferential therapy versus spinal manipulation or traction
- 2769 One higher-quality trial (N=240) found no difference between an 8-week course of
- 2770 interferential therapy versus spinal manipulation for pain, functional disability, quality of
- 2771 life, work status, or other outcomes after 6 to 12 months in patients with subacute (>4
- weeks) low back pain (Table 27) [319]. A lower-quality trial (N=152) also found no
- 2773 difference between spinal manipulation and traction on pain or the ODI after 3 months in
- 2774 patients with back pain of unspecified duration (primarily >5 years) [320].
- 2775

Table 27. Trials of inteferential therapy versus other interventions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hurley, 2004[319]	N=240 12 months	Interferential therapy versus manipulative therapy versus combination (mean improvement at 12 months) Pain (0 to 100 VAS): -26.5 vs18.2 vs25.7 (NS) McGill Pain Questionnaire Pain Rating Index (0 to 78): - 8.3 vs6.4 vs9.2 (NS) RDQ score (0 to 24): -4.9 vs4.7 vs6.5 (NS) SF-36: No differences Recurrent low back pain: 69% vs. 77% vs. 64% (NS) Absent from work >30 days: 8% vs. 12% vs. 12%	7/11
Werners, 1999[320]	N=152 3 months	Interferential therapy versus traction (mean difference from baseline to 3 months) Pain (0 to 100): -9.8 vs14.6 (NS) Oswestry (0 to 100): -7.7 vs7.4	4/11

2776

2777 Efficacy of interferential therapy plus a back self-care book versus a back self-care book2778 alone

2779 One small (N=60), lower-quality trial in patients with subacute back pain (>4 weeks)

2780 found that interferential therapy applied to the paraspinal area (near the target spinal

2781 nerve) plus a back self-care book was superior to the back self-care book alone on the

2782 RDQ Questionnaire after 3 months, but not on the Pain Rating Index or EQ-5D (Table

2783 28) [321]. However, baseline RDQ Questionnaire scores were higher in the

2784 interferential therapy group (median 9.0 vs. 5.0). In fact, median RDQ scores were

- identical at 3 months in the two groups (1.0 vs. 1.0). This trial also found no differences
- between interferential therapy applied to the painful area plus a self-care book and the
- 2787 self-care book alone.

Table 28. Trial of inteferential therapy + self-care book versus a self-care book alone

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hurley, 2001[321]	N=60 3 months	Interferential therapy applied to painful area + self- care book versus interferential therapy applied to area of spinal nerve + self-care book versus self-care book alone (difference in median scores from baseline to 3 months) McGill Pain Questionnaire Pain Rating Index (0 to 78): +2.2 vs2.5 vs9.7 RDQ Score (0 to 24): -3.5 vs8.0 vs4.0 EQ-5D: No difference RDQ Score, median score at 3 months: 2.0 vs. 1.0 vs. 1.0	5/11

2789

- 2790 Safety
- 2791 One trial reported no adverse events with interferential therapy or manipulation [319].
- 2792 The other two trials reported no information on adverse events.
- 2793 Costs
- 2794 We found no studies evaluating costs.

2795 Summary of evidence

- One higher-quality trial found no difference between interferential therapy and 2797 manipulation in patients with subacute low back pain (level of evidence: fair).
- One lower-quality trial found no difference between interferential therapy and traction in patients with primarily chronic low back pain (level of evidence: poor).
- One lower-quality trial found no clear differences between interferential therapy
 with electrodes applied in the paraspinal area or to the painful area plus a self-care book versus a self-care book alone (level of evidence: poor).

2803 **Recommendations and findings from other guidelines**

- The AHCPR guidelines found physical agents and modalities (including electrical stimulation) of insufficiently proven benefit to justify their cost in patients with acute low back pain (strength of evidence: C).
- The VA/DoD and UK RCGP guidelines reached similar conclusions.
- The European COST guideline made no recommendation for interferential
 therapy in acute low back pain, and found insufficient evidence to recommend
 interferential therapy for chronic low back pain.

2811 Low-level laser

- 2812 Low-level laser therapy involves the application of laser at wavelengths varying 2813 from 632 to 904 nm to the skin in order to apply electromagnetic energy to soft tissues.
- 2814 Results of search: systematic reviews
- 2815 We identified no systematic reviews evaluating the efficacy of low-level laser in patients
- 2816 with low back pain. One recent systematic review of low-level laser therapy for various
- 2817 musculoskeletal conditions included four trials [322-325] of patients with low back pain
- 2818 [326]. Two older systematic reviews of low-level laser for various musculoskeletal
- 2819 conditions included only one [327] or two [328] trials of patients with low back pain.
- 2820 Results of search: trials

We identified seven trials (four higher-quality [322-325]) of low-level laser therapy in patients with low back pain [322-325, 329-331]. Four evaluated patients with chronic low back pain, one evaluated patients with acute low back pain, and two did not specify the duration of back pain. Although low-level laser is frequently used in Russia and

- Asia, we found no non-English language trials. However, studies in those languages
- are frequently not indexed in English-language electronic databases.
- 2827 Effectiveness of low-level laser therapy versus sham therapy or placebo

2828 Results of six trials evaluating low-level laser in patients with chronic low back pain or 2829 low back pain of unspecified duration are difficult to interpret because they used 2830 heterogeneous outcome measures and different types of lasers at varying doses. Two 2831 [322, 324] of the three [323] higher-quality trials found that laser was superior to placebo 2832 or sham laser at the end of treatment for back-specific function (Oswestry score). 2833 proportion with pain relief, and ratings of overall response (Table 29). In one trial, these 2834 benefits persisted for one month following treatment [322], and in another, relapse of 2835 back pain was less likely 6 months following the end of treatment [324]. One other 2836 higher-quality trial found laser more 'effective' than sham, but used a poorly described 2837 and unvalidated outcome measure [325]. One lower-quality trial of patients with back 2838 pain of unspecified duration reported similar findings, with decreased relapse through 2839 one year following treatment [330]. In the single higher quality trial that found no 2840 difference between laser and sham laser, each group also received a standardized 2841 home exercise regimen [323].

Table 29. Trials of low-level laser therapy versus sham laser

Author, year	Number of patients Duration of follow-up	Main results	Quality
Basford, 1999[322]	N=61 1 month after end of treatment	Nd:YAG laser versus sham (mean change from baseline) ODI score: -6.3 vs2.1 Maximal pain in the last 24 hours (0 to 100 VAS): -16.1 vs2.3	8/11
Soriano, 1998[324]	N=85 6 months after end of treatment	GaAS laser versus sham Proportion with >60% pain relief at end of treatment: 71% (27/38) vs. 36% (12/33), p<0.007	6/11
Toya, 1994[325]	N=41 1 day after treatment	GaAS laser versus sham Treatment 'effective': 94% (15/16) vs. 48% (12/25)	10/11
Klein, 1990[323]	N=20 1 month after treatment	GaAS laser + exercise versus sham + exercise (mean change from baseline) Pain (0 to 7.5 VAS): -1.3 vs1.2 RDQ Disability score: -1.8 vs3.0	6/11
Longo, 1988[330]	N=120 1 year after treatment	904 nm laser vs. 10600 nm laser vs. sham Complete disappearance of pain 1 month after treatment: 95% vs. 82.5% vs. 2.5% Relapse 1 year after treatment: 65% vs. 70% vs. 95%	5/11

2843

A recent systematic review found low level laser effective for a variety of

2845 musculoskeletal conditions when the subgroup of trials evaluating higher doses were

analyzed [326]. The criteria for adequate doses were pre-defined for various locations

2847 in an *a priori* matter. There were too few trials (four) to assess the effects of dose in

2848 patients specifically with low back pain.

2849 Effectiveness of low-level laser therapy versus other interventions: trials

2850 One trial of low-level laser for acute low back pain was uninterpretable because of poor

2851 methodologic quality, unclear reporting of outcomes, and comparison to mesotherapy

2852 (an unproven technique involving injections of various substances into fat) (Table 30)

2853 [331]. Another lower-quality trial found that laser, exercise, and the combination of laser

2854 plus exercise resulted in similar pain and back-specific functional status outcomes in

2855 patients with chronic low back pain [329].

Table 30. Trials of low-level laser therapy versus other interventions

Author, year Monticone, 2004[331]	Number of patients Duration of follow-up N=22 Up to 12 months after treatment	Main results Laser versus stabilization (exercise, lumbar therapy, and mesotherapy) Pain at rest (VAS 0 to 10), mean change from baseline and 12 months following end of treatment: 0 vs. –5; -1 vs. –6 Pain with movement (VAS 0 to 10), mean change from baseline and 12 months following end of treatment: -4 vs. –7, -2 vs. –8	Quality 1/11
Gur, 2003[329]	N=75 1 month after treatment	Laser versus exercise versus laser + exercise (mean change from baseline) Pain (0 to 10 VAS): -4.2 vs3.6 vs4.4 (p>0.05) RDQ Score: -9.7 vs9.6 vs11.5 (p>0.05) Modified ODI: -16.4 vs16.9 vs17.6 (p>0.05)	3/11

2857

2858 Safety

2859 In a systematic review of low-level laser therapy for various musculoskeletal conditions,

six of the 11 trials evaluating higher doses reported no adverse events [326]. One other

trial reported one transient adverse event in both the laser and sham groups [322].

2862 Costs

2863 We found no studies evaluating costs.

2864 Summary of evidence

- 2865 There is conflicting evidence from five trials (four higher quality) on the • 2866 effectiveness of low-level laser compared to placebo or sham laser in patients 2867 with chronic low back pain. Four trials (three higher quality) found laser therapy 2868 superior to sham for pain or functional status up to one year following treatment, 2869 but one higher-guality trial found no difference between laser and sham in patients also receiving exercise. In addition, interpretation of results is 2870 2871 compromised by the use of heterogeneous and non-standardized outcome 2872 measures in some studies (level of evidence: fair).
- Low-level laser was equivalent to exercise or the combination of laser plus
 exercise in one lower-quality trial (level of evidence: poor).
- There is no reliable evidence (one lower-quality trial) on low-level laser therapy in patients with acute low back pain (level of evidence: poor).
- Additional research is needed on optimal doses of low-level laser therapy,
 number of sessions, and type of laser in patients with chronic low back pain.

2879 2880	 Publication bias from non-English language studies could affect these conclusions.
2881 2882 2883 2884	 Recommendations and findings from other guidelines The AHCPR guidelines found physical agents and modalities (including low-level laser) of insufficiently proven benefit to justify their cost for acute low back pain (strength of evidence: C).
2885	 The VA/DoD guidelines reached similar conclusions.
2886	 The UK RCGP guidelines don't mention low-level laser.
2887 2888	 The European COST guidelines found insufficient evidence to recommend low- level laser for chronic low back pain.
2889	Short-wave diathermy
2890 2891	Short wave diathermy involves the application of short wave electromagnetic radiation with a frequency range from 10 to 100 MHz in order to heat the tissues.
2892 2893 2894 2895	Results of search: systematic reviews We identified no systematic review of short-wave diathermy. However, a good-quality Cochrane review of spinal manipulation [332, 333] included two trials (one higher-quality [334]) comparing short-wave diathermy to sham diathermy or manipulation.
2896 2897 2898	Results of search: trials We identified one additional higher-quality trial comparing short wave diathermy to exercises, traction, and sham in patients with back pain for longer than one week [335].
2899 2900 2901 2902 2903 2904 2905 2906	<i>Efficacy of short-wave diathermy versus sham diathermy</i> One higher-quality trial included in the Cochrane review found no significant differences in median pain scores after 12 weeks in patients with low back pain for at least two months randomized to short-wave diathermy versus sham diathermy [334]. Another higher-quality trial (not included in the Cochrane review) found no differences in global response (other outcomes not reported) between short-wave diathermy and sham diathermy after 2 weeks in patients with back pain for longer than one week (widely varying durations) (Table 31) [335].
2907	

Table 31. Additional trial of short-wave diathermy in patients with back pain of at leastone week in duration

Author, year	Number of patients Duration of follow-up	Main results	Quality
Sweetman, 1993[335]	N=400	Short wave diathermy versus extension exercises versus traction versus sham diathermy Global effect "better" at 2 weeks: 39% (39/100) vs. 45% (45/100) vs. 49% (49/100) vs. 37% (37/100) (NS)	6/11

2909

- 2910 Efficacy of short-wave diathermy versus other interventions
- 2911 One higher-quality trial in the Cochrane review of spinal manipulation found no
- 2912 significant differences between short-wave diathermy and spinal manipulation on
- 2913 median pain scores or requirement for analgesics after 12 weeks in patients with low
- back pain for at least two months [334]. In a small, lower-quality trial (also included in
- the Cochrane review), the proportion of patients with acute low back pain with continued
- 2916 pain was higher after two weeks with short-wave diathermy (9 of 12) compared to spinal
- 2917 manipulation (1 of 12) [336]. However, no details about the short wave diathermy
- 2918 intervention were provided.
- 2919 The higher-quality trial not included in the Cochrane review found no difference between
- short-wave diathermy and either extension exercises or traction after two weeks in
- 2921 patients with low back pain for longer than one week [335].
- 2922 Safety
- 2923 No studies assessed safety.
- 2924 Cost
- 2925 We found no studies evaluating costs.

2926 Summary of evidence

- One higher-quality trial found no difference between short-wave diathermy and sham diathermy on pain after 12 weeks in patients with low back pain for at least 2029 2 months (level of evidence: fair).
- In patients with back pain of varying duration, one higher-quality trial found no difference between short-wave diathermy, sham diathermy, exercise, or traction using an unvalidated measure of global effect after 2 weeks (level of evidence: fair).

- 2934 One higher-guality trial found no difference between short-wave diathermy and 2935 spinal manipulation on pain after 12 weeks in patients with low back pain for at 2936 least 2 months (level of evidence: fair). 2937 In patients with acute low back pain, one small, lower-quality trial found a lower • proportion of patients reporting pain relief after 2 weeks in patients randomized to 2938 2939 short-wave diathermy compared to spinal manipulation (level of evidence: poor). 2940 Recommendations and findings from other guidelines 2941 The AHCPR guidelines found physical agents and modalities (including short • 2942 wave diathermy) of insufficiently proven benefit to justify their cost in patients with 2943 acute low back pain (strength of evidence: C). 2944 The VA/DoD and UK RCGP guidelines reached similar conclusions. • 2945 The European COST guidelines found insufficient evidence to recommend short-• wave diathermy for chronic low back pain. 2946 2947 Traction 2948 Results of search: systematic reviews 2949 We identified one higher-quality Cochrane review (24 RCTs, 5 rated high-quality) of 2950 traction for low back pain [337, 338]. All of the trials evaluated patients with low back 2951 pain and sciatica, though seven also included patients without sciatica. We also 2952 included three other recent systematic reviews [129, 283, 339]. We excluded three 2953 older systematic reviews [110, 277, 340]. 2954 Results of search: trials 2955 We did not search for additional trials. 2956 Efficacy of traction versus placebo, sham, or no treatment 2957 The Cochrane review [337, 338] included two higher-guality trials [341-343] of patients
- with low back pain of varying duration (with or without sciatica) that found that tractionwas no more effective than placebo, sham, or no treatment, for pain, functional status,
- 2960 overall improvement, or work absenteeism. In patients with sciatica of mixed duration,
- two lower quality trials [344, 345] found autotraction more effective than placebo, sham,
- 2962 or no treatment for pain, global improvement, or work absenteeism, but other forms of
- 2963 traction (continuous or intermittent traction) were not associated with beneficial effects
- 2964 (8 trials, 1 higher-quality [346]).

Three other systematic reviews did not include any trials not in the Cochrane review and either concluded that there is no evidence that traction is effective for low back pain (with [129] or without [283] sciatica), or found insufficient evidence to draw reliable

- 2968 conclusions [339].
- 2969 Efficacy of traction versus other active interventions

2970 Six RCTs (five rated lower-quality) compared various types of traction to other active 2971 treatments in patients with sciatica of varying duration. In the lone higher-quality trial, 2972 autotraction was superior to abdominal and pelvic floor muscle isometric exercises at 2973 the end of treatment [347]. However, the benefits were no longer present after one 2974 month. In another trial, intermittent traction was superior to physiotherapy for global 2975 well-being after three to five weeks, though no better than patients receiving hot packs 2976 only [348]. In the other four trials, no statistically significant differences were seen when 2977 traction was compared to spinal manipulation and a corset [349], an infra-red lamp [350, 2978 351], exercise and shortwave diathermy [335], or strengthening and range of motion 2979 exercises [352]. In patients with chronic low back pain and sciatica, traction was no 2980 more effective than isometric exercise in two trials [352, 353], and superior to TENS in

the third [354] (none rated high quality).

In one higher-quality trial of patients with low back pain of varying duration without
sciatica, there were no differences on pain or function at three months after treatment in
patients randomized to intermittent traction versus interferential treatment [320].

2985 *Efficacy of different types of traction*

One small (N=44) trial found autotraction more effective than mechanical traction for global improvement (but not pain or function) in chronic LBP patients with or without sciatica [355]. In two other small trials, there were no differences between static and intermittent traction [356] or between autotraction and manual traction [357]. One trial found no differences in effects of intermittent or continuous traction using different levels of force [358].

2992 Safety

Adverse events were generally reported inconsistently and poorly in the 24 trials

- included in the Cochrane review [337, 338]. Two trials reported no adverse events
- 2995 [346, 359]. Six other trials reported adverse events including increased pain, increased

- rate of subsequent surgery, aggravation of neurological signs, aggravation of symptoms
- 2997 [337, 338]. The other sixteen trials did not mention adverse events.

2998 Costs

2999 We found no studies evaluating costs.

0000	O	• • • • • • • • • • •
3000	Summary o	revidence

- There is consistent evidence from multiple trials that continuous or intermittent traction are not associated with superior outcomes compared to placebo, sham, or other treatments for patients with low back pain of varying duration, either with or without sciatica (level of evidence: good).
- There is evidence from two lower-quality trials that autotraction is superior to
 placebo or sham therapies and one lower quality trial that autotraction is superior
 to mechanical traction (level of evidence: fair).
- Adverse events reported in the trials included aggravation of signs and
 symptoms and subsequent surgery, but were inconsistently and poorly reported
 (level of evidence: poor).
- 3011 **Recommendations and findings from other guidelines**
- The AHCPR guidelines recommend against traction for treatment of patients with
 acute low back problems (strength of evidence: B).
- The VA/DoD and UK RCGP also recommend against traction, but rate the 3015 strength of evidence differently (strength of evidence: C and ***, respectively).
- The European COST guidelines also recommend against traction for acute low
 back pain and found insufficient evidence to recommend traction for chronic low
 back pain.

3019 Ultrasound

- 3020 Results of search: systematic reviews
- 3021 We identified one higher-quality systematic review evaluating the effectiveness of
- 3022 therapeutic ultrasound in patients with low back pain [283]. It included one randomized
- trial [360] and one non-randomized study [361] (both rated lower-quality). Four other
- 3024 systematic reviews evaluated ultrasound therapy in patients with a variety of
- 3025 musculoskeletal conditions, but did not include any additional trials of low back pain
- 3026 [277, 362-364].
- 3027 Results of search: trials
- 3028 We identified no additional trials of therapeutic ultrasound.

- 3029 Efficacy of ultrasound versus sham or placebo
- 3030 One non-randomized study found that in patients with acute low back pain from a
- 3031 herniated disc, ultrasound ws superior to sham ultrasound or analgesics for the
- 3032 proportion of patient pain free (41% vs. 12% vs. 6.8%) [361]. Patients in all groups
- 3033 were also prescribed bed rest.
- 3034 In patients with chronic low back pain, one small (N=36) randomized trial found no
- 3035 difference in pain improvement after one month of therapy [360]. Functional status and 3036 other outcomes were not reported.
- 3037 Three systematic reviews found little evidence of beneficial effects with ultrasound
- 3038 relative to placebo for other musculoskeletal conditions, with the possible exceptions of
- 3039 single trials of lateral epicondylitis, carpal tunnel syndrome, and calcific tendinitis of the
- 3040 shoulder [277, 362, 364]
- 3041 Safety
- 3042 Adverse events were not reported in the two studies. None of the systematic reviews of
- 3043 therapeutic ultrasound for various musculoskeletal conditions assessed adverse events.
- 3044 There is one report of two patients with a herniated disc who had transiently increased
- 3045 radicular pain after application of therapeutic ultrasound [365].
- 3046 Costs
- 3047 We found no study evaluating costs.
- 3048 Summary of evidence
- There is insufficient evidence (single low-quality studies) to judge the efficacy of ultrasound for low back pain (level of insufficient: poor).
- 3051 **Recommendations and findings from other guidelines**
- The AHCPR guidelines found physical agents and modalities (including ultrasound) of insufficiently proven benefit to justify their cost in acute low back pain (strength of evidence: C).
- The VA/DoD and UK RCGP guidelines reached similar conclusions.
- The European COST guidelines found insufficient evidence to recommend
 ultrasound therapy for chronic low back pain.

- 3058 Other Non-invasive Interventions 3059 **Behavioral interventions** 3060 Results of search: systematic reviews 3061 We identified two recent, higher-quality systematic reviews evaluating the efficacy of 3062 behavioral interventions in patients with chronic low back pain [73, 305]. One was an 3063 update of an older (van Tulder 2000) Cochrane review (21 trials, 7 high guality) [73]. 3064 We excluded five other older systematic reviews [110, 132, 249, 251, 366]. 3065 Results of search: trials 3066 Several trials investigating interventions for identifying and treating psychosocial risk 3067 factors in patients with acute or subacute low back pain are discussed under section 3068 Key Question 1a. Efficacy of behavioral interventions versus wait list control 3069 3070 The Cochrane review [73] included four trials (one higher quality [367]) that found 3071 combined respondent-cognitive therapy moderately superior to wait list control for short-3072 term pain intensity (pooled effect size 0.59, 95% CI 0.10 to 1.09), but not for functional 3073 status (pooled effect size 0.31, 95% CI –0.20 to 0.82). It also included two lower-quality 3074 trials that found progressive relaxation associated with a large positive effect on short-3075 term pain (effect size 1.16, 95% CI 0.47 to 1.85) and behavioral outcomes (effect size 3076 1.31, 95% CI 0.61 to 2.01). Evidence regarding the effects of EMG biofeedback relative 3077 to wait list control was mixed: although three trials found a positive effect on pain 3078 intensity (effect size 0.84, 95% CI 0.32 to 1.35), a fourth trial found no differences. In 3079 addition, there were no differences between EMG biofeedback and wait list control for 3080 behavioral outcomes. There were also no differences between operant treatment and 3081 wait list controls for general functional status (two trials of behavioral outcomes).
 - The second systematic review (22 trials) also found both cognitive-behavioral and selfregulatory therapy (such as relaxation therapy) superior for pain intensity compared to wait list controls (effect size 0.62, 95% CI 0.25 to 0.98 and 0.75, 95% CI 0.35 to 1.15, respectively) [305]. Self-regulatory therapy was also superior to wait list controls for measures of depression (effect size 0.81, 95% CI 0.11 to 1.52).

3087 Efficacy of behavioral interventions versus other active interventions

- 3088 The Cochrane review [73] included one higher-quality trial [289] that found operant
- 3089 treatment in combination with a graded activity program associated with earlier return to
- 3090 work and reduced long-term sick leave compared to usual care in workers with
- 3091 subacute low back pain [289]. One lower-quality trial found no difference between
- 3092 behavioral treatment and exercise on pain intensity, functional status, and behavioral
- 3093 outcomes through 12 months [368].
- 3094 The other systematic review found no differences between behavioral therapy (including
- 3095 behavioral therapy as part of multidisciplinary treatment) and other active interventions
- 3096 (including physiotherapy and usual treatments) on pain intensity, pain interference,
- 3097 health care visits, or medication use [305]. However, behavioral therapy was
- 3098 associated with improved short- and long-term disability, with effect sizes of 0.36 (3
- 3099 trials, 95% CI 0.06 to 0.65) and 0.53 (4 trials, 95% CI 0.19 to 0.86), respectively.
- 3100 Comparative efficacy of different behavioral interventions
- 3101 Neither systematic review found clear differences in head-to-head comparisons of
- 3102 different types of behavioral therapy [73, 305]. In the Cochrane review, the best-studied
- 3103 comparisons were cognitive-behavioral versus operant therapy (three higher-quality
- trials [367, 369, 370]) and cognitive versus respondent therapy (three lower-quality trials
- 3105 [371-373]).
- 3106 Safety
- 3107 Safety was not assessed in any of the systematic reviews.
- 3108 Costs
- 3109 One trial comparing different operant interventions found no significant differences in
- 3110 costs or utilities [374].

3111 Summary of evidence

 There is consistent evidence from four RCTs (one higher quality) that cognitivebehavioral therapy is moderately more effective than wait list control for shortterm pain intensity in patients with chronic low back pain, though there were no significant differences on functional status and other outcomes (level of evidence: good).

3117 3118 3119	 Two lower-quality trials found progressive relaxation associated with large positive benefits relative to wait list control for pain intensity and behavioral outcomes in patients with chronic low back pain (level of evidence: fair).
3120 3121 3122	 Evidence on benefits associated with EMG biofeedback relative to wait list control is mixed, though three out of four trials demonstrated a moderate benefit on pain intensity in patients with chronic low back pain (level of evidence: fair).
3123 3124	 Operant therapy was not associated with any benefits relative to wait list controls in three trials of patients with chronic low back pain (level of evidence: good).
3125 3126 3127	 Behavioral interventions have not clearly been shown to be superior to other active interventions for most outcomes, though one systematic review found moderate benefits for short- and long-term disability (level of evidence: fair).
3128 3129	 There is no clear evidence from head-to-head comparisons that one behavioral intervention is superior to any other (level of evidence: fair to good).
3130	Recommendations and findings from other guidelines
3131 3132	 The AHCPR guidelines recommend against biofeedback in patients with acute low back problems (strength of evidence: C).
3133	 The Va/DoD guideline recommendations are similar.
3134 3135 3136	 The UK RCGP guidelines found conflicting evidence on the effectiveness of biofeedback for chronic low back problems, and no evidence on the effectiveness for acute low back problems (strength of evidence: *).
3137 3138 3139	 The European COST guidelines recommend against behavioural therapy for acute low back pain, but recommend behavioral therapy in patients with chronic low back pain.
3140	Massage
3141	Results of search: systematic reviews
3142	We identified one higher-quality Cochrane review of 9 trials (5 high quality) of massage
3143	for low back pain [375, 376]. One other recent, higher-quality systematic review came
3144	to similar conclusions as the Cochrane review [220]. We excluded two older systematic
3145	reviews [283, 377].

- 3146 Results of search: trials
- 3147 We did not search for additional trials.
- 3148 *Efficacy of massage versus placebo or sham massage.*
- 3149 The Cochrane review [375, 376] included one higher-quality sham-controlled trial of
- 3150 massage [378]. It found that in patients with subacute or chronic low back pain,

- 3151 massage was superior to sham laser for short- and long-term pain intensity
- 3152 (standardized mean difference –0.80, 95% CI –1.37 to –0.23 and –0.49, 95% CI –1.05
- to 0.06, respectively) and functional outcomes (SMD –1.06, 95% CI –1.65 to –0.47 and
- 3154 -0.96, 95% Cl -1.58 to -0.35).
- 3155 Efficacy of massage versus other active interventions
- 3156 The Cochrane review found massage inferior to manipulation in three trials (one higher
- 3157 quality) for immediate (after the first session) relief of pain and improvement in function
- 3158 in patients with chronic low back pain [375, 376]. The superiority of manipulation was
- 3159 maintained during the course of treatment for functional improvements but not for pain,
- and by the end of treatment through three weeks of follow-up, the effects of
- 3161 manipulation and massage were similar.
- 3162 In one higher-quality trial, massage was inferior to transcutaneous electrical stimulation
- 3163 for relieving pain and improving range of motion during the course of treatment [379]. In
- single trials, massage was equivalent to corsets [380, 381] and exercise [378], and
- 3165 moderately superior to relaxation therapy [382], acupuncture [223], and self-care
- 3166 education [223]. Nearly all of the trials only assessed outcomes during or shortly
- 3167 following (within one month) a course of treatment in patients with chronic low back
- 3168 pain. In the single trial (rated higher-quality) with extended follow-up, beneficial effects
- 3169 from massage relative to acupuncture and self-care education persisted for one year
- 3170 [223]. There was insufficient evidence to determine if massage is beneficial in patients
- 3171 with acute low back pain (one lower quality trial [383]), though there was moderate
- evidence of effectiveness from two trials [378, 380, 381] that included patients with
- 3173 subacute or chronic low back pain.
- 3174 Efficacy of different massage techniques
- 3175 The Cochrane review found no clear difference between results of trials of manual
- 3176 massage and those that used a mechanical device [375, 376]. One higher quality study
- 3177 [384] found acupuncture massage superior to classical (Swedish) massage for
- 3178 improvements in pain and function. The most significant benefits from massage were
- 3179 seen in trials that used a trained massage therapist with many years of experience or a
- 3180 licensed massage therapist [223, 378, 382]. No conclusions could be drawn regarding

3181 differential effects associated with the number or duration of massage sessions [375, 3182 376]. 3183 Safety 3184 No study assessed safety. 3185 Costs 3186 One trial found no significant differences (p=0.15) between HMO-related costs between 3187 massage (\$139), acupuncture (\$252), and a self-care education booklet (\$200) [223]. 3188 3189 Summary of evidence: 3190 Massage was superior to sham therapy in one higher quality trial of patients with 3191 subacute or chronic non-specific low back pain (level of evidence: fair). 3192 Massage was consistently inferior to spinal manipulation in three trials (one 3193 higher quality) up to one year after a course of treatment in patients with chronic low back pain (level of evidence: fair). 3194 3195 In single trials comparing massage to other interventions, massage was inferior 3196 to transcutaneous electrical stimulation, similar to exercise and corsets, and 3197 moderately superior to relaxation, acupuncture, and a self-care education book 3198 (level of evidence for each comparison: fair). 3199 A single trial found acupuncture massage superior to classical (Swedish) massage (level of evidence: fair). 3200 3201 There is insufficient evidence to judge the efficacy of massage in patients with • 3202 acute low back pain (one lower-quality trial) or in patients with sciatica (no trials 3203 specifically in this population) (level of evidence: poor). 3204 Recommendations and findings from other guidelines 3205 The AHCPR guidelines found physical agents and modalities (including 3206 massage) of insufficiently proven benefit to justify their cost (strength of 3207 evidence: C). 3208 The VA/DoD and UK RCGP guidelines reached similar conclusions. 3209 The European COST guidelines recommend against massage for acute low back 3210 pain and found insufficient evidence to recommend massage for chronic low 3211 back pain.

3212 Modified work

- 3213 Results of search: systematic reviews
- 3214 We identified one lower-quality systematic review on the effects of modified work (light
- 3215 duty) in workers with low back pain [385]. It included one lower-quality randomized trial
- 3216 (also reviewed in the section on multidisciplinary interventions) [307], and 12 higher-
- 3217 quality observational studies.
- 3218 Results of search: trials
- 3219 We did not identify any trials not included in the systematic review.
- 3220 Efficacy of modified work versus no modified work
- 3221 In the only randomized trial included in the systematic review, workers who received an
- 3222 occupational intervention had about half as many lost work days than those without (60
- and 67 versus 120 and 131) [307]. The occupational intervention involved a work site
- 3224 visit, ergonomic adjustments, and light duties if necessary. Results from several
- 3225 observational studies were consistent with these findings [385].
- 3226 Safety
- 3227 We found no studies on safety of modified work.
- 3228 Costs
- 3229 We found no studies evaluating costs.
- 3230 Summary of evidence
- There is consistent evidence from one lower-quality trial and observational studies that modified work can decrease time lost from work (level of evidence: fair).
- 3234 **Recommendations and findings from other guidelines**
- The AHCPR guidelines state that activity recommendations for the employed patient with acute low back symptoms need to consider the patient's age and general health, and the physical demands of required job tasks (strength of evidence: D).
- The VA/DoD guidelines are similar.
- The European COST guidelines state that temporary modified work (which may include ergonomic workplace adaptations) can be recommended, when needed, in order to facilitate earlier return to work for workers sicklisted due to low back pain (level B).

3244 Spa therapy

- 3245 Results of search: systematic reviews
- 3246 We identified no systematic reviews evaluating the efficacy of spa therapy (also referred
- 3247 to as spa therapy) in patients with low back pain
- 3248 Results of search: trials
- 3249 We identified five lower-quality trials of spa therapy, three in patients with chronic low
- back pain [386-388] and two in patients with subacute low back pain [359, 389]. All of
- 3251 the trials were conducted in Europe.

3252 Efficacy of spa therapy versus no spa therapy

- 3253 Four trials compared spa therapy to no spa therapy (Table 32) [359, 386-388]. In three
- 3254 trials of patients with chronic low back pain, balneotherapy was substantially superior to
- no balneotherapy for pain (improved by average of about 20 points compared to no
- 3256 balneotherapy) and analgesic intake at the end of a three-week course of treatment,
- 3257 with persistent benefits for up to 9 months. In two [387, 388] of the three [386] trials,
- 3258 there were also significant differences in measures of functional status or disability.
- 3259 In the single trial comparing spa therapy to no spa therapy in patients with subacute low
- back pain, there were no differences in pain outcomes either at the end of therapy or
- after one year [359]. Daily analgesics use significantly decreased in the spa therapy
- 3262 group but not in the control group.

Table 32. Trials of balneotherapy versus no balneotherapy

Author, year	Number of patients Duration of follow-up	Main results	Quality
Constant, 1998[387] (chronic LBP)	N=224 3 months	Balneotherapy vs. no balneotherapy (mean improvement from baseline at 3 months) Pain, VAS (0 to 100 scale): -37.6 vs14.2, p<0.0001 Overall patient evaluation (0 to 100 scale): +24.8 vs. +3.9, p<0.0001	4 or 5/11
Constant, 1995[388] (chronic LBP)	N=126 6 months	RDQ Score (0 to 24): -4.0 vs1.1, p<0.0001	5/11
Guillemin, 1994[386] (chronic LBP)	N=104 9 months	Balneotherapy vs. no balneotherapy (mean improvement from baseline at 9 months) Pain, VAS (0 to 100 scale): -34.4 vs. +7.1, p<0.0001 Waddell disability score: +0.09 vs. +0.18, NS	4/11
Konrad, 1992[359] (subacute or chronic LBP)	N=170 1 year	Balneotherapy vs. no balneotherapy (mean improvement from baseline at 1 year) Pain, VAS (0 to 100 scale): -13.9 vs6.6 (NS)	3/11

3264

3265 Efficacy of spa therapy versus other interventions

- 3266 One trial compared spa therapy plus exercise to exercise alone in patients with
- 3267 subacute or chronic (one to six month duration) low back pain (Table 33) [389]. It found
- 3268 no differences in pain scores through one month after a three-week course of treatment.
- 3269 A second trial compared balneotherapy to either underwater traction or underwater
- 3270 massage [359]. It found no differences in either pain scores or analgesic use through
- 3271 one year after a four-week course of therapy.
- 3272

Table 33. Trials of spa therapy versus other interventions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Yurtkuran, 1997[389] (subacute or chronic LBP)	N=50 7 week	Balneotherapy + exercise versus exercise alone (mean improvement from baseline at 1 month) Pain, VAS (0 to 10 scale): -2.95 vs1.35 (NS)	3 to 5/11
Konrad, 1992[359] (subacute)	N=170 1 year	Balneotherapy vs. underwater massage vs. underwater traction (mean improvement from baseline at 1 year) Pain, VAS (0 to 100 scale): -13.9 vs10.9 vs13.7 (NS)	3/11

3273

3274 Safety

3275 None of the trials reported adverse events.

3276	Costs
3277	We found no studies on costs.
3278 3279	Summary of evidence
3280 3281 3282	 Spa therapy was consistently and substantially superior to no spa therapy for pain in three lower-quality trials of patients (all conducted in Europe) with chronic low back pain up to nine months after a three-week course of treatment (level of evidence: fair).
3283 3284 3285	 Spa therapy was no better than no spa therapy for pain in one lower-quality RCT of patients with subacute or chronic low back pain, but associated with decreased analgesic use (level of evidence: poor).
3286 3287 3288	 Spa therapy was no better than underwater massage or underwater traction or when added to exercise therapy in patients with subacute or chronic low back pain in two lower-quality trials (level of evidence: poor).
3289	• There is no evidence for spa therapy in patients with acute low back pain.
3290	Recommendations and findings from other guidelines
3291	 None of the guidelines address spa therapy.
3292	Spinal manipulation
3293	Results of search: systematic reviews
3294	We identified a recent, higher-quality Cochrane review of spinal manipulation in patients
3295	with low back pain (39 trials, 11 rated higher-quality) [332, 333]. We also identified a
3296	recent technology report by the Canadian Coordinating Office for Health Technology
3297	Assessment (CCOHTA) that reviewed 14 published systematic reviews of spinal
3298	manipulation, including the Cochrane review [390]. It also reviewed two new RCTs and
3299	two non-randomized studies not in the Cochrane review. Five other recent, higher-
3300	quality systematic reviews also evaluated the efficacy of spinal manipulation [129, 220,
3301	391-393]. Six systematic reviews evaluated safety of spinal manipulation in randomized
3302	trials and observational studies [220, 394-398]. Because of the large number of
3303	systematic reviews, we excluded seven recent, lower-quality systematic reviews [129,
3304	282, 399-403]. We also excluded 23 older systematic reviews [110, 132, 250, 277, 404-
3305	422].

Results of search: trials
We included two large (N=681 and N=1334), recently published trials (the UK BEAM
Trial [284] and the UCLA Low Back Pain Study [423]) not included in the Cochrane
review.

3310 Efficacy of spinal manipulation versus sham, placebo, or therapies judged ineffective 3311 The Cochrane review included 14 trials of patients with acute low back pain that found 3312 spinal manipulative therapy modestly superior for short-term pain compared to sham 3313 therapy (average 10 mm difference on a 100 mm VAS) or therapies judged to be 3314 ineffective or harmful (traction, bed rest, home care, topical gel, no treatment, 3315 diathermy, and minimal massage) [332, 333]. Differences in functional outcomes did 3316 not reach statistical significance (2.8 mm difference on the RDQ Questionnare). In 3317 patients with chronic low back pain (11 trials), spinal manipulative therapy was also 3318 associated with modest improvements in short- or long-term pain and short-term 3319 function compared to sham manipulation (3 trials) or therapies judged to be ineffective 3320 or harmful (5 trials). Against sham manipulation, the differences in short- and long-term 3321 pain averaged 10 mm and 19 mm on a 100 mm VAS, and the differences for short-term 3322 function averaged 3.3 points on the RDQ Questionnaire. The conclusions were 3323 insensitive to the presence or absence of radiating pain, study quality, or the profession 3324 of the manipulator (chiropractor or other).

3325 A recent technology report by the Canadian Coordinating Office for Health Technology 3326 Assessment reviewed 14 published systematic reviews of spinal manipulation [390]. It 3327 concluded that the Cochrane review was the best available summary of clinical 3328 effectiveness because it received a high quality score, was published recently, and 3329 included the largest number of trials. The authors identified two additional randomized 3330 trials and two non-randomized trials that did not affect the overall conclusions. Four 3331 other recent systematic reviews also reported similar findings compared to the 3332 Cochrane review [129, 220, 391, 392]. Another higher-guality systematic review found 3333 that trials that allowed manual therapy providers to tailor their techniques to individual 3334 patients did not report better outcomes than trials that did not allow therapeutic 3335 discretion [393]. In fact, spinal manipulation was associated with better short-term 3336 outcomes in trials that didn't allow discretion, though long-term outcomes were similar.

- 3337 Efficacy of spinal manipulation versus usual care or other interventions
- 3338 The Cochrane review found that in patients with acute low back pain, spinal
- manipulative therapy had no clinically or statistically significant advantages over usual
- 3340 general practitioner care or analgesics (3 trials), physical therapy or exercises (5 trials),
- and back school (2 trials) [332, 333]. In patients with chronic low back pain, there were
- no differences between manipulation and general practitioner care or analgesics (6
- trials), physiotherapy or exercises (4 trials), and back school (3 trials).
- Two large, recently published trials reported results consistent with the conclusions of
 the Cochrane review. In patients with low back pain of unspecified duration, the UCLA
 Low Back Pain Study (rated higher-quality) found no differences in pain, functional
 status, or other outcomes between those randomized to chiropractic versus medical
- 3348 care (Table 34) [423]. The other trial found manipulation modestly superior to usual
- care for back-specific functional status, pain, and disability in patients with subacute orchronic low back pain, though beneficial effects were less after 12 months than after 3
- months [284]. There were no significant differences between manipulation andexercise, though trends favored manipulation.
- 3353

Table 34. Results of the UK BEAM Trial and the UCLA Low Back Pain Study

Author, year	Number of patients Duration of follow-up	Main results	Quality
UK BEAM Trial, 2004[284]	N=1334 12 months	Manipulation + exercise versus manipulation versus exercise (all results are net benefit relative to usual care at 12 months) RDQ Questionnaire (0 to 24 scale): 1.30 (95% CI 0.54 to 2.07) vs. 1.01 (95% CI 0.22 to 1.81) vs. 0.39 (95% CI - 0.41 to 1.19) Modified Von Korff pain score (0 to 100 scale): 6.71 (95% CI 2.47 to 10.95) vs. 5.87 (95% CI 1.58 to 10.17) vs. 4.90 (95% CI 0.30 to 9.50) Modified Von Korff disability score (0 to 100 scale): 6.71 (95% CI 2.62 to 10.80) vs. 5.65 (95% CI 1.57 to 9.72) vs. 4.56 (95% CI 0.34 to 8.78)	2 or 3/11
Hurwitz, 2002[423]	N=681 6 months	Chiropractic care vs. medical care (between-group difference in improvement from baseline at 6 months) Most severe pain (0 to 10): 0.27 (95% CI -0.32 to 0.86) Average pain: 0.22 (95% CI -0.25 to 0.69) RDQ score (0 to 24): 0.75 (95% CI -0.29 to 1.79)	8/11

3355 Safetv

3356 Six systematic reviews consistently found that serious adverse events such as 3357 worsening lumbar disc herniation or cauda equina syndrome from lumbar spinal 3358 manipulative therapy were very rare [220, 394-398]. One systematic review found no 3359 serious complications reported in over 70 controlled clinical trials [398]. Systematic 3360 reviews that included data from observational studies estimated risks for serious 3361 adverse events as lower than 1 in 1 million patient visits [394, 395]. One of the reasons 3362 serious adverse events are so rare may be patient selection: current guidelines 3363 recommend against spinal manipulation in patients with severe or progressive 3364 neurologic deficits.

3365 Costs

3366 In the UCLA Low Back Pain Study, costs were higher with chiropractic care relative to

3367 medical care (\$560 versus \$369, p<0.001) [424]. Because outcomes were very similar

3368 for the two interventions, this is essentially a cost-minimization analysis. In the UK

3369 BEAM Trial, manipulation was associated with an incremental cost-effectiveness of

£4800/QALY relative to best care and £2300/QALY relative to exercise [284]. Two 3370

3371 other trials comparing spinal manipulation to exercise therapy found similar costs and 3372 outcomes for the two interventions [296, 425, 426]. In one of the trials, chiropractic care 3373 was more costly then a self-care booklet (\$429 versus \$153), with only small differences

- 3374 in patient outcomes [296].
- 3375
- Summary of evidence
- 3376 Pooled evidence from many trials indicates that spinal manipulation is modestly • 3377 superior to sham, no treatment, or therapies thought to be ineffective or harmful, in patients with either acute or chronic low back pain (level of evidence: good). 3378
- 3379 There is also consistent evidence from multiple trials that spinal manipulation is • 3380 no more effective than other standard conservative interventions (level of 3381 evidence: good).
- 3382 In patients without severe or progressive neurologic deficits, serious adverse • 3383 events such as cauda equina syndrome or worsening lumbar disc herniation 3384 following lumbar spinal manipulation are very rare (level of evidence: good).
- 3385 Recommendations and findings from other guidelines
- 3386 The AHCPR guidelines found that manipulation can be helpful in patients with • acute low back problems without radiculopathy when used within the first month 3387 3388 of symptoms (strength of evidence: B).

3389	 The AHCPR guidelines found insufficient evidence to recommend manipulation
3390	in patients with radiculopathy (strength of evidence: C).
3391	 The AHCPR guidelines found that a trial of manipulation in patients without
3392	radiculopathy with symptoms longer than one month is probably safe, but
3393	efficacy unproven (strength of evidence: C).
3394	 The AHCPR guidelines recommended an appropriate diagnostic assessment to
3395	rule out serious neurologic conditions prior to initiating manipulation therapy
3396	when progressive or severe neurologic deficits are present (strength of evidence:
3397	D).
3398 3399	 The VA/DoD guidelines for manipulation are essentially identical to the AHCPR guidelines.
3400	 The UK RCGP guidelines found manipulation superior for short-term
3401	improvement in pain and activity levels and higher patient satisfaction compared
3402	to comparison treatments in patients with acute and subacute back pain (strength
3403	of evidence: **).
3404	 The UK RCGP guidelines found that the risks of manipulation for low back pain
3405	are very low, provided patients are selected and assessed properly and
3406	manipulation is performed by a trained therapist or practitioner (strength of
3407	evidence: **).
3408	 The UK RCGP guidelines found no firm evidence regarding what kind of
3409	manipulation is most effective, or optimum timing of manipulation (strength of
3410	evidence: *).
3411	 The UK RCGP guidelines recommend against manipulation under general
3412	anesthesia (strength of evidence: *).
3413	 The European COST guidelines recommend considering referral for spinal
3414	manipulation for patients with acute low back pain who are failing to return to
3415	normal activities, and a short-course of spinal manipulation/mobilization as a
3416	treatment option for chronic low back pain.
3417	Key Question 3a.
3418	Can decision tools predict which patients are more likely to respond to specific
3419	therapies like physical therapy or chiropractic?
3420	Results of search: systematic reviews

- 3420 Results of search: systematic reviews
- 3421 We identified no systematic review evaluating the usefulness of decision tools or clinical
- 3422 prediction rules for identifying patients more likely to respond to specific therapies.
- 3423 However, we found three systematic reviews evaluating the reliability and validity of

- 3424 physical exam maneuvers used to help determine if manipulative treatments are 3425 indicated, though clinical outcomes were not assessed [427-429].
- 3426 Results of search: trials
- 3427 We identified one higher-quality randomized trial that prospectively evaluated the
- 3428 usefulness of a clinical prediction rule for identifying patients more likely to respond to
- 3429 spinal manipulation in a randomized trial (Table 35) [430]. The prediction rule was
- 3430 based on a previous study that had identified five factors (symptom duration <15 days,
- 3431 Fear Avoidance Beliefs Questionnaire work subscale score <19, lumbar hypomobility,
- 3432 hip internal rotation range of motion >35 degrees, and no symptoms distal to the knee)
- 3433 associated with greater likelihood of success with spinal manipulation [431]. We also
- 3434 included one recent, small (N=54) observational study that derived a clinical prediction
- 3435 rule for identifying patients likely to benefit from a stabilization exercise program [432].
- 3436 Utility of clinical prediction rules for spinal manipulation
- 3437 The randomized trial by Childs et al allocated patients (n=131) with a median duration of
- 3438 27 days of low back pain to spinal manipulation or exercise therapy [430]. It applied a
- 3439 previously derived clinical prediction rule to all patients and prospectively evaluated
- 3440 whether outcomes from spinal manipulation depended on status according to the
- 3441 prediction rule. It found that treatment effects were greatest in the subgroup of patients
- 3442 who were positive on the rule (met at least 4 of 5 criteria) and received manipulation.
- 3443 Relative to patients who were negative on the rule and received exercise, odds of a
- 3444 successful outcome (improvement in Oswestry score at least 50%) in this subgroup was
- 3445 60.8 (95% CI 5.2 to 704.7), compared to 2.4 (95% CI 0.83 to 6.9) in those negative on
- 3446 the rule who received manipulation and 1.0 (CI 0.28 to 3.6) in those negative on the rule
- 3447 who received exercise. Patients positive on the rule who received manipulation had a
- 3448 92% chance of a successful outcome, with an associated number needed to treat for
- one successful outcome (relative to treatment with exercise) of 1.9 (95 % CI 1.4 to 3.5).

Table 35. Randomized trial evaluating decision tool for predicting success fromspinal manipulation

Author, year	Number of patients Duration of follow-up	Main results	Quality
Childs, 2004[430]	N=131 6 months	Manipulation + exercise vs. exercise alone "Success" at 4 weeks: 44/70 (63%) vs. 22/61 (36%) Likelihood of success at 4 weeks, relative to patients negative on rule who received exercise: Positive on rule and received manipulation OR 60.8 (5.2 to 704.7, p=0.002), negative on rule and received manipulation OR 2.4 (0.83 to 6.91), positive on rule and received exercise OR 1.0, 95% CI 0.28 to 3.6) Positive likelihood ratio for positive rule in manipulation group at predicting success at 1 week: 13.2 (3.4 to 52.1)	7/11

3452

The results of this trial are helpful for confirming the accuracy of the clinical prediction rule in a setting other than the one from which it was originally derived. One classification scheme categorizes clinical prediction rules validated in this manner as level 2 [433]. It does not meet criteria for a level 1 (highest classification) clinical prediction rule, which is defined as one that has been shown to affect clinician behavior

and improve outcomes.

3459 Three systematic reviews on the reliability and validity of manual spinal palpatory exam 3460 each found suboptimal evidence, poor reproducibility of examination findings, and 3461 uncertain validity [427-429]. One potential criticism of the prediction rule evaluated by 3462 Childs et al is that it may not be readily applied in everyday practice because it requires 3463 the clinician to perform spinal mobility and hip range of motion tests and also requires 3464 the patient to fill out a questionnaire (Fear-Avoidance Beliefs Questionnaire). The 3465 authors of the trial also developed a 'pragmatic' version of the prediction rule with two 3466 factors (duration <16 days and no symptoms extending distal to the knee) that also 3467 predicted outcomes with manipulation (positive likelihood ratio 7.2, 95% CI 3.2 to 16.1 in 3468 patients meeting both criteria) [434]. However, this variation on the prediction rule was 3469 developed retrospectively and needs to be prospectively validated.

3470 Exercise

3471 One study (N=54) prospectively derived a clinical prediction rule for determining which

3472 patients with low back pain will respond to a stabilization exercise program [435]. It

3473 found that presence of three or more of the following factors was associated with a

- 3474 greater likelihood of treatment success (positive likelihood ratio 4.0, 95% CI 1.6 to 10.0,
- 3475 negative likelihood radio 0.52, 95% CI 0.30 to 0.88): positive prone instability test,
- 3476 presence of aberrant movement, average straight leg raise test >91 degrees, or age
- 3477 <40 years. This prediction rule would be classified as level 4 (derived but not validated)
- 3478 [433].
- 3479 Safety
- 3480 No study evaluated safety.
- 3481 Summary of evidence
- A decision tool for identifying patients likely to benefit from spinal manipulation has been prospectively validated as highly predictive in a randomized trial. However, evidence of beneficial effects on clinical outcomes from applying the decision tool is not yet available. In addition, the tool may not be practical for use in many primary care settings, and a more pragmatic version has not yet been prospectively validated (level of evidence: fair).
- A decision tool for identifying patients likely to benefit from stabilization exercise
 has not yet been validated (level of evidence: poor).
- 3490 **Recommendations and findings from other guidelines**
- The UK RCGP guidelines found no firm evidence that it is possible to select which patients will respond to manipulation (strength of evidence: **).
- The European COST guidelines recommend against the use of spinal palpatory and range of motion tests to identify patients with manipulable lesions.
- 3495 Key Question 4.

3496 What is the value of different patient education or patient self-care methods for

3497 improving patient outcomes?

3498 Common goals of patient education and patient self-care methods for low back 3499 pain are to reduce fear of normal activity, encourage exercise, and promote self-3500 management of pain. A range of interventions have been defined as self-care for low 3501 back pain, including individual consultation with a professional or team of professionals, 3502 group treatment and/or education by professionals or trained lay leaders, group 3503 exercise classes, mini-back school and other approaches. We defined self-care as 3504 individual or group educational approaches that involve two sessions or fewer with a 3505 professional in a routine clinic visit and are readily implemented independently by

patients. We also review the efficacy of self-care groups led by non-medical laypersons.

3508 Self-care advice or education

3509 Bed rest

- 3510 Search results: systematic reviews
- 3511 We identified a recently, good-quality Cochrane review (11 trials, 6 meeting all quality
- 3512 criteria) evaluating advice to rest in bed in patients with low back pain [436, 437] that
- 3513 updated a previous Cochrane review [438] We excluded eight older systematic reviews
- 3514 [110, 132, 250, 281, 283, 439-441].
- 3515 Search results: trials
- 3516 We did not search for additional trials
- 3517 Efficacy of advice to rest in bed versus advice to remain active
- 3518 The Cochrane review included two-higher quality trials [286, 442] that found advice to
- 3519 rest in bed associated with inferior outcomes at 3 to 4 weeks (standardized mean
- difference for pain intensity 0.22, 95% CI 0.02 to 0.41 and for functional status 0.29,
- 3521 95% CI 0.09 to 0.49) and at 12 weeks (standardized mean difference for pain intensity
- 3522 0.25, 95% CI 0.05 to 0.45 and for functional status 0.24, 95% CI 0.04 to 0.44) [436,
- 437]. A standardized mean difference between 0.2 and 0.3 is roughly equivalent to 5 to
- 3524 7.5 on a 100-mm VAS pain scale and 1.2 to 1.8 points on the 24-point RDQ
- 3525 Questionnaire. Both trials also reported better sick-leave related outcomes in favor of
- advice to stay active and one trial [286] found no difference in satisfaction with care orcosts.
- In two higher quality RCTs of patients with sciatica, there was little or no difference
 between advice to stay active and advice to rest in bed for pain intensity or functional
 status, and sick leave [443, 444].
- 3531 Efficacy of advice to rest in bed versus other interventions
- 3532 The Cochrane review [436, 437] included two higher-quality trials that found that no
- 3533 significant differences in pain intensity or functional status between advice to rest in bed
- and exercises in patients with acute, non-specific low back pain [286, 445]. A third,
- 3535 lower quality trial found no difference on a combined pain, disability, and physical exam

- score between bed rest and manipulation, drug therapy, physiotherapy, back school, orplacebo [446].
- 3538 In patients with sciatica, one higher-quality trial found that physiotherapy was modestly
- 3539 superior (weighted mean difference 6.9 points on a 0 to 100 scale) to advice to rest in
- 3540 bed for functional status at four weeks, though the difference was no longer significant
- at 12 weeks [443]. There were no differences in pain intensity.
- 3542 Efficacy of different durations of bed rest
- 3543 The Cochrane review [436, 437] included two higher quality trials that found that shorter
- durations of bed rest (2 or 3 days) were associated with similar pain intensity compared
- to longer duration (7 days) in patients with acute [447] or mixed duration [448] low back
- pain. Benefits of shorter bed rest persisted through 12 weeks of follow-up in one trial,
- which also found shorter bed rest associated with fewer days off work (mean 3.1 days)
- 3548 compared to longer bed rest (mean 5.6 days) at 3 weeks [448].
- 3549 Safety
- One recent trial reported one case of pulmonary embolus in patients assigned to bed
- 3551 rest [443].
- 3552 Costs
- 3553 One trial found no significant differences in costs of health care and home help between 3554 bed rest and either exercise or usual activities (usual activities associated with more 3555 rapid recovery in this trial) [286].
- Summary of evidence 3556 3557 In two higher quality trials, advice to rest in bed was consistently associated with 3558 small but statistically inferior outcomes compared to advice to remain active in 3559 patients with acute nonspecific low back pain (level of evidence: good). 3560 Advice to rest in bed was consistently associated with similar outcomes • 3561 compared to physiotherapy/exercise in two higher quality trials of patients with 3562 acute nonspecific low back pain (level of evidence: good). 3563 There is insufficient evidence to accurately judge the efficacy of advice to rest in 3564 bed relative to interventions other than exercise (level of evidence: poor). 3565 In patients with sciatica, one higher quality trial found that physiotherapy was • 3566 associated with modestly superior functional status outcomes at 3 weeks

- 3567compared to advice to rest in bed, but this effect was no longer present after 123568weeks (level of evidence: good).
- Longer duration of bed rest was not associated with better outcomes compared to shorter duration, and increased the number of days off work in one higherquality trial (level of evidence: fair).
- There is no evidence to judge the efficacy of advice to rest in bed in patients with chronic low back pain.

3574 **Recommendations and findings from other guidelines**

- The AHCPR guidelines found that a gradual return to normal activities is more
 effective than prolonged bed rest for treating acute low back problems (strength
 of evidence: B).
- The AHCPR guidelines found that prolonged bed rest for more than 4 days may
 lead to debilitation and is not recommended for treating acute low back problems
 (strength of evidence: B).
- The AHCPR guidelines found that the majority of low back patients will not
 require bed rest, though bed rest for 2 to 4 days may be an option for patients
 with severe initial symptoms of primarily leg pain (strength of evidence: D).
- The VA/DoD and UK RCGP guidelines are similar to the AHCPR guidelines, but
 found stronger evidence that bed rest for 2-7 days is inferior to placebo or
 ordinary activity (strength of evidence: A and ***, respectively).
- The European COST Guidelines recommend against prescribing bed rest for acute nonspecific low back pain.
- 3589 Advice for activity
- 3590 In this section, we included trials evaluating advice for self-care given in a typical 3591 clinic visit or a clinic session lasting no longer than one hour.
- 3592 Search results: systematic reviews
- 3593 We identified one good-quality Cochrane review (4 trials) evaluating the efficacy of
- advice to stay active (maintaining usual activities as much as possible) [449, 450]. A
- 3595 recently updated Cochrane review of bed rest [436, 437] included two additional trials
- 3596 (both higher-quality) comparing bed rest to active to stay active [442, 443].
- 3597 Search results: trials
- 3598 We identified one additional higher-quality trial comparing advice to stay active versus
- 3599 exercise therapy [451]. We also found one lower-quality trial evaluating exercise advice

- versus usual care or a self-care book [452], and one lower-quality trial evaluatingexercises advice versus exercise [453, 454].
- 3602 Efficacy of advice to stay active versus advice to rest in bed
- 3603 Results of trials comparing advice to stay active with advice to rest in bed are discussed 3604 in the section on bed rest.
- 3605 Efficacy of advice to stay active versus other interventions
- 3606 The Cochrane review included one higher-quality trial [286] that found advice to stay
- 3607 active associated with similar improvements in pain intensity compared to an exercise
- 3608 program in patients with simple, acute low back pain [449, 450]. Short-term functional
- 3609 status initially favored advice to stay active (weighted mean difference on Oswestry
- 3610 questionnaire –8.6, 95% CI –13.9 to –3.3), but differences were no longer present after
- 3611 3 weeks. Average length of sick leave was lower in the advice to stay active group, but
- 3612 not statistically significant.
- 3613 A higher-quality trial not included in the Cochrane review found that in patients with
- 3614 nonspecific low back pain for more than six weeks, there were no differences between
- 3615 advice to stay active and usual physical therapy on pain or functional status through 12
- 3616 months, though perceived benefit was greater in the physical therapy group (Table 36)
- 3617 [451]. By contrast, one lower quality trial found that in patients with acute low back pain,
- 3618 a single back education session with advice to remain active (45 minutes) was
- associated with slower return from sick leave (22 vs.12, p<0.001), and fewer back pain
- 3620 recurrences in the first year and with longer follow-up (through five years) [453, 454]. A
- 3621 single higher-quality trial of patients with acute sciatica found no differences in pain or
- 3622 functional status between advice to stay active and physical therapy through 6 months
- 3623 of follow-up [443].
- 3624

able 36. Trials of advice to stay active vs. exercise therapy not included in Cochrane review

Author, year	Number of patients Duration of follow-up	Main results	Quality
Frost 2004[451] (nonspecific low back pain)	N=286 12 months	Advice to stay active vs. usual physical therapy Oswestry score (0 to 100 scale), mean change: -1.33 vs 2.65 at 2 months, -2.23 vs3.27 at 12 months (NS) RDQ Disability score (0 to 24 scale), mean change: -0.56 vs1.13 at 2 months, -0.99 vs1.36 at 12 months (NS) SF-36: No significant differences Perceived benefit (proportion reporting 'yes'): 60% vs. 77% at 2 months (p=0.002), 50% vs. 65% at 6 months (p=0.007) Perceived benefit (0 to 10 scale): 3.66 vs. 5.42 at 2 months (p<0.001); 4.13 vs. 5.02 at 12 months (p=0.011)	7/11
Stankovic, 1990, 1995[453, 454] (nonspecific low back pain)	N=100 5 years	Advice to stay active vs. McKenzie exercise Mean duration of sick leave: 22 vs. 12 days (p<0.001) Pain: decreased in exercise group (p<0.001), data not reported Recurrences: 74% (37/50) vs. 44% (22/50) after 1 year; 88% (37/42) vs. 64% (30/47) between 1 and 5 years (p<0.01) Sick leave between 1 and 5 years: 74% (31/42) vs. 51% (24/47) (p<0.03)	3/11
Hofstee, 2002[443] (sciatica)	N=167 6 months	Advice to stay active versus physiotherapy Pain VAS (0 to 100), mean difference in change from baseline: 0.8 (-8.2 to 9.8) at 1 month and -1.0 (-10.0 to 8.0) at 6 months (positive values favor physiotherapy) Quebec Disability Scale (0 to 100), mean difference in change from baseline: -0.5 (-6.3 to 5.3) at 1 month and - 0.7 (-8.4 to 6.9) at 6 months	6/11

3626

3627 Efficacy of exercise advice versus usual care or a self-care book

One lower-quality trial found advice for regular exercise superior to usual care for pain and function after one week in patients with low back pain for less than 3 months (Table 37) [452]. However, there were no differences after three weeks, when most patients reported resolved pain. Advice to exercise also improved patient satisfaction compared to usual care (p=0.03). There were no differences between advice to exercise and a self-care book. Adding a self-care education book to exercise advice did not improve outcomes compared to either alone.

Table 37. Trial of exercise advice vs. self-care book vs. usual care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Little 2001[452]	N=311 3 weeks	Self-care book vs. exercise advice vs. both vs. neither (control) (mean changes versus control) Pain/function scale (0 to 100): -8.7 vs -7.9 vs -0.1 at 1 week, -6.3 vs -1.4 vs -4.0 at 3 weeks (NS) Aberdeen pain and function scale (0 to 100): -3.8 vs -5.3 vs1.9 at 1 week (NS)	4/11

3636

- 3637 Safety
- 3638 No studies reporting safety associated with advice to stay active.
- 3639 Costs
- 3640 One of the trials included in the Cochrane review found no significant differences in
- 3641 costs of health care and home help between advice to remain active and either advice
- to rest in bed or an exercise program [286].

3643 Summary of evidence

- Advice to remain active was associated with similar effects on functional status or pain compared to exercise therapy in one higher-quality trial of patients with acute non-specific low back pain and one higher-quality trial of patients with symptoms for more than six weeks, but with slower return from sick leave and more back pain recurrences in one older, lower-quality trial (level of evidence: fair).
- Advice to remain active was not associated with clear benefits in a single, higher quality trial of patients with acute low back pain with sciatica (level of evidence:
 fair).
- Advice to exercise was superior to usual care in one lower-quality trial of patients
 with low back pain for less than 90 days. There were no differences between
 advice to exercise and a self-care book, and the combination did not improve
 outcomes (level of evidence: poor).
- See section on bed rest for summary of bed rest versus advice to remain active.

3658

Recommendations and findings from other guidelines

 The AHCPR guidelines recommend providing patients with acute low back pain accurate information about expectations for both rapid recovery and recurrent of symptoms based on the natural history of low back symptoms; safe and effect methods of symptom control; safe and reasonable activity modifications; best means of limiting recurrent low back problems; the lack of need for special

- investigations unless red flags are present; and effectiveness and risks of
 commonly available diagnostic methods and further treatment measures to be
 considered should symptoms persist (strength of evidence: B).
- The AHCPR guidelines suggest that patients with acute low back problems may be more comfortable if they temporarily limit or avoid specific activities known to increase mechanical stress on the spine, especially prolonged unsupported sitting, heavy lifting, and bending or twisting the back while lifting (strength of evidence: D).
- The AHCPR guidelines suggest considering the patients' age and general health, as well as the physical demands of required job tasks, when considering activity recommendations for employed workers with acute low back problems (strength of evidence: D).
- The VA/DoD and UK RCGP guidelines recommend an approach to patient advice and return to normal activity very similar to the AHCPR guidelines.
- The UK RCGP guidelines found stronger evidence than the AHCPR guidelines
 for advice to continue ordinary activity (strength of evidence: ***).
- The European COST guidelines recommend providing adequate information and reassurance to patients with acute low back pain. They also recommend advising patients to stay active and continue normal daily activities including work if possible.

3684 Self-care books

- 3685 Results of search: systematic reviews
- 3686 We identified no systematic reviews on the efficacy of self-care books for patients with
- 3687 low back pain.
- 3688 Results of search: trials

3689 We included eight trials (five-higher-quality [223, 296, 300, 455, 456]) on the efficacy of 3690 reading material (books, booklets, and leaflets) providing education and self-care advice 3691 for patients with low back pain) [452, 457, 458]. Although the specific content of self-3692 care books varied, in general they encourage return to normal activity, adoption of a 3693 fitness program, and appropriate lifestyle modification, and provide advice on coping 3694 strategies and managing flares. Four trials (one rated higher-guality [456]) compared a 3695 self-care book to usual care and three trials (all rated higher-quality [223, 296, 300]) 3696 compared a self-care book to another intervention. Two other trials compared different 3697 methods of providing information from a self-care book [455, 456]. Three trials

- 3698 evaluating the efficacy of a self-care book alone versus a self-care book combined with3699 other interventions are reviewed for Key Question 10.
- 3700 *Efficacy of self-care books versus usual care*
- 3701 Four trials (one rated higher-quality [456]) of patients with low back pain of acute and 3702 subacute or unspecified duration found no significant differences in pain or symptom 3703 bothersomeness scores with a self-care book versus usual care (Table 38) [452, 456, 3704 458, 459]. There were also no differences in functional status (Little 2001, Cherkin 3705 1996) and time lost from work (Hazard 2000, Cherkin 1996) in the trials that assessed 3706 these outcomes. Effects on health care use were mixed: one lower-quality trial found 3707 no difference between a self-care book and usual care on number of health care visits 3708 [457], but another found that fewer patients receiving a self-care book consulted for 3709 back pain over a one-year period [459]. Effects of self-care books on self-reported 3710 behaviors was mixed. One trial found that patients randomized to a self-care book were 3711 more likely to report recommended back care behaviors [459]. However, another trial 3712 found no difference between a self-care book and usual care in the proportion of 3713 patients who reported exercising, even though the self-care book group had higher 3714 scores on perceived knowledge [456].

Table 38.	. Trials of a self-care book versus ι	usual care
-----------	---------------------------------------	------------

Author, year Type of LBP	Number of patients Duration of follow-up	Main results	Quality
Roberts, 2002[458] Acute (not defined)	N=64 12 months	Self-care book vs. usual care: Aberdeen Low Back Pain Scale (0 to 100): 42.7 vs. 42.6 at 2 days, 11.0 vs. 8.1 at 1 year (NS)	4/11
Hazard, 2000[457] Not specified	N=1108 6 months	Self-care book vs. usual care Current pain severity, improvement in pain since maximum severity: no differences (data not reported) Number of health care visits: no differences (data not reported) Proportion not working at 6 months: 6.5% vs. 5.9% (p=0.84) Lost work days through 6 months: 19.1 vs. 18.1	5/11
Cherkin, 1996[456] Not specified	N=300 1 year	Self-care book vs. nurse education + self-care book vs. usual care (mean change from baseline) RDQ score (0 to 24 scale): -5.4 vs -5.2 vs -5.3 (NS) at 1 week Symptom bothersomeness score (0 to 10 scale): -3.3 vs -3.3 vs - 3.6 (NS) at 1 week Health care visits for low back pain: 45% vs. 46% vs. 47% in first 7 weeks after intervention (NS) Work loss days: 24% vs. 36% vs. 29% in first 7 weeks after intervention (NS)	6/11
Roland, 1989[459] Acute and chronic	N=936 1 year	Self-care book vs. usual care Patients initiating consultation for back pain: 23% vs 25% (NS) after 2 weeks, over 1 year: 35.6% vs. 42.2% (p<0.05) after 1 year Days certified sickness absence: 10.3 vs 10.1 (NS) Referral to hospital or to physiotherapy: 19.9% vs. 24.7% (p>0.05)	2/11

3716

3717 Efficacy of self-care books versus other interventions

3718 Four trials (three higher-quality [223, 296, 300]) compared a self-care book to other 3719 treatments (Table 39) [223, 296, 300, 452]. In one trial, patients with chronic low back 3720 pain reported lower functional status at 26 weeks with a self-care book compared to 3721 either yoga (difference of 3 to 4 points on the RDQ Questionnaire) or exercise therapy 3722 (difference of about 2 points on the RDQ) [300]. Yoga (but not exercise) was also 3723 associated with greater improvement in symptom bothersomeness scores at 26 weeks 3724 (about 2 points on a 0 to 10 scale) relative to the self-care book. Another trial found no 3725 significant differences between a self-care book and either chiropractic manipulation or 3726 physical therapy on symptom bothersomeness and RDQ scales, though trends favored 3727 the chiropractic intervention by about one point on both scales at 4 and 12 weeks [296]. 3728 A third higher-quality trial found massage, but not acupuncture, superior to a self-care 3729 book and videotapes at 10 weeks in patients with low back pain for at least one week

- 3730 (difference of about 1 point on a 0 to 10 symptom bothersomeness scale and 2.5 points
- on the RDQ score), though no differences between the self-care book and the other two
- interventions were observed after one year [223]. One lower-quality trial of patients with
- 3733 back pain for less than three months found no short-term differences on either a
- 3734 combined pain and function scale or the Aberdeen pain scale between a self-care book
- and physician advice to exercise [452].

Table 39. Trials comparing a self-care book to other interventions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Sherman, 2005[300]	N=101 26 weeks	Yoga vs. self-care book, mean differencesRDQ score (0 to 24 scale): -2.6 (-4.6 to -1.6) at 6 weeks, -3.6 (-5.4 to -1.8) at 26 weeksSymptom bothersomeness score (0 to 10 scale): -1.6 (-2.6 to -0.5) at 6 weeks, and -2.2 (-3.2 to -1.2) at 26weeksExercise vs self-care book, mean differences	7/11
		RDQ score (mean difference): -1.7 (-3.7 to 0.4) at 6 weeks, -2.1 (-4.1 to -0.1) at 26 weeks Symptom bothersomeness score: -0.9 (-1.9 to -0.1) at 6 weeks, -0.8 (-2.1 to 0.5) at 26 weeks	
		Yoga vs. exercise vs. self-care Visits to health care providers for low back pain: 4/34 (12%) vs 6/32 (19%) vs 9/29 (31%) at 26 weeks (NS) Medication use at week 26: 21% vs. 50% vs. 59% (p<0.05 for yoga vs. exercise or self-care) SF-36: No differences	
Little, 2001[452]	N=311 3 weeks	Self-care book vs exercise advice vs. both vs. neither (control) (mean changes versus control) Pain/function scale (0 to 100): -8.7 vs -7.9 vs -0.1 at 1 week, -6.3 vs -1.4 vs -4.0 at 3 weeks (NS) Aberdeen pain and function scale (0 to 100): -3.8 vs -5.3 vs1.9 at 1 week (NS)	4/11
Cherkin, 2001[223]	N=262 1 year	Self care book vs. acupuncture vs. massage Symptom bothersomeness (0 to 10 scale), mean scores: 4.6 vs. 4.0 vs. 3.6 at 10 weeks (p=0.01 for self care book versus massage, no other significant differences), 3.8 vs. 4.5 vs. 3.2 at 1 year (p=0.002 for acupuncture vs. massage, no other significant differences) RDQ score (0 to 24 scale), mean scores: 8.8 vs. 7.9 vs. 6.3 at 10 weeks (p<0.001 for self care book vs massage, p=0.01 for acupuncture vs. massage, p=0.75 for self care book vs. acupuncture), 6.4 vs. 8.0 vs. 6.8 at 1 year (p=0.05 for acupuncture vs. massage, no other significant differences) Provider visits: 1.5 vs.1.9 vs. 1.0 (p=0.17)	8/11
Cherkin, 1998[296]	N=323 2 years	Self-care book vs. chiropractic therapy vs. physical therapy Symptom bothersomeness (0 to 10 scale), mean scores: 3.1 vs. 1.9 vs.2.3 at 4 weeks (NS), 3.2 vs. 2.0 vs. 2.7 at 12 weeks (NS), no differences at 2 years RDQ score (0 to 24 scale), mean scores: 4.9 vs. 3.7 vs. 4.1 at 4 weeks (NS), 4.3 vs. 3.1 vs. 4.1 at 12 weeks (NS), no differences at 2 years Proportion reporting reduced activity in 11 months after intervention: 36% vs. 33% vs. 35% Proportion needing bed rest: 9% vs. 8% vs. 11% Proportion who missed work: 17% vs. 7% vs. 13% Visits for back pain in second year after intervention: 24% vs. 29% vs. 20% Total costs over 2 years: \$153 vs. \$429 vs. \$437	7/11

3737 Efficacy of different methods for providing information in self-care books 3738 One higher-quality trial found no differences in RDQ scores, symptom bothersomeness 3739 scores, days lost from work, or number of health care visits between a self-care book 3740 alone and a self-care book plus a 15-minute nurse education session and brief 3741 telephone follow-up in patients with back pain of unspecified duration (Table 40) [456]. 3742 However, patients in the nurse education group perceived themselves to be more 3743 knowledgeable and a higher proportion reported they had tried the exercises in the 3744 booklet (74% vs. 45%, p<0.001) in the first week after the intervention. A second higher 3745 guality trial found no differences in pain or functional status through one year in patients 3746 with low back pain of less than three months' duration randomized to an experimental 3747 back book (the Back Book, developed to accompany the UK's 1996 Royal College of 3748 General Practitioners guidelines) aimed at changing beliefs and behaviors, compared to 3749 a traditional self-care book mainly targeted at providing factual information [455]. 3750 However, patients randomized to the experimental book were more likely to report at 3751 least a 4-point reduction on a fear avoidance beliefs scale, and patients with high 3752 baseline fear avoidance beliefs were more likely to report improvements of at least three 3753 points on the RDQ score.

Author, year	Number of patients Duration of follow-up	Main results	Quality
Burton, 1999[455]	N=188 1 year	Experimental self-care book vs. traditional self-care book Pain at worst (0 to 100), mean scores: 53.9 vs. 53.9 at 2 weeks, 50.9 vs. 50.8 at 1 year (NS) RDQ scores: No significant differences, data not reported Fear avoidance beliefs score, >4 point improvement: RR 2.72 (1.57 to 4.72) at 2 weeks, RR 1.47 (1.02 to 2.11) at 1 year	7/11
Cherkin, 1996[456]	N=300 1 year	Self-care book vs. nurse education + self-care book vs. usual care (mean change from baseline) RDQ score (0 to 24 scale): -5.4 vs -5.2 vs -5.3 (NS) at 1 week Symptom bothersomeness score (0 to 10 scale): -3.3 vs - 3.3 vs -3.6 (NS) at 1 week Health care visits for low back pain: 45% vs. 46% vs. 47% in first 7 weeks after intervention (NS) Work loss days: 24% vs. 36% vs. 29% in first 7 weeks after intervention (NS)	6/11

54	Table 40. Trials evaluating different methods of providing information in a self-care book
----	--

- 3755 Safety
- 3756 Three trials providing information on adverse events reported none with a self-care book
- 3757 [223, 296, 300].
- 3758 Costs
- 3759 One trial estimated an average total cost (including the cost of the intervention and
- health care utilization) lower with a self-care book (\$153) compared to either
- 3761 chiropractic therapy or physical therapy (around \$430) [296]. Another trial found no
- 3762 significant differences in estimated costs between a self-care book (\$200), massage
- 3763 (\$139), and acupuncture (\$252) [223].
- 3764 Summary of evidence
- Four trials (one higher-quality) found no difference between a self-care book and usual care in pain or symptom bothersomeness scores (level of evidence: fair).
- In three higher-quality trials comparing a self-care book to other active
 interventions (yoga, acupuncture, exercise, massage, or manipulation), there
 were either no significant differences or the self-care book was modestly inferior
 on symptom bothersomeness scores and functional status. The largest
 differences were seen in single trials comparing a self-care book to yoga and a
 self-care book to massage (level of evidence: good).
- There was no difference between a self-care book and advice to exercise in one
 lower-quality trial (level of evidence: poor).
- Different methods for providing information in a self-care book were not associated with significant differences in pain or functional status, though a brief nurse education visit increased the proportion of patients who exercised in one higher-quality trial compared to providing the self-care book alone, and an experimental self care book targeted at changing beliefs and behaviors reduced fear avoidance beliefs more than a traditional self-care book in another higherquality trial (level of evidence: fair).
- 3782 **Recommendations and findings from other guidelines**
- None of the other guidelines specifically address self-care books. General
- 3784 recommendations on advice are listed in the bed rest section.
- 3785 E-mail discussion groups
- 3786 Results of search: systematic reviews
- 3787 We identified no relevant systematic reviews.

- 3788 Results of search: trials
- 3789 We identified one lower-quality trial that compared an e-mail discussion group versus
- usual care in patients with chronic low back pain [460].

3791 Efficacy of an e-mail discussion group versus usual care

- The trial found that participation in a closed, moderated e-mail discussion group, along with a self-care book and videotape was associated with greater improvements in pain (p=.045), back-specific functional status (p=.02), role function (p=.007) health distress (p=.001) after 12 months compared to usual care (Table 41) [460]. The differences on
- 3796 back specific functional status average about 1 point on the 24 point RDQ and for pain
- about 0.5 points on a 10 point scale. There were no differences in physician visits for
- back pain or average number of hospital days over a 12-month period.
- 3799

Table 41. Trial of e-mail discussion group versus usual care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Lorig, 2002[460]	N=580	E-mail discussion, book and video vs. usual care	
	12 months	(mean changes from baseline at 12 months)	
		RDQ (0 to 23): -2.77 vs -1.51 (p=.01)	
		Health distress (0 to 5): -0.92 vs -0.57 (p=.001)	
		Pain interference (0 to 10): -1.50 vs -1.02 (p=.05)	
		Role function (0 to 7): -0.830 vs -0.531(p=.007)	
		Physician visits for back in last 6 months: -1.54 vs -0.65 (NS)	2/11
		Chiropractor visits for back in last 6 months: -1.32 vs - 0.797 (NS)	
		Physical therapist visits for back in last 6 months: -1.99 vs -1.31 (NS)	
		Hospital days in recent 6 months: -0.198 vs 0.04 (NS)	

3800

3801 Safety

- 3802 Adverse events were not reported
- 3803 Costs
- 3804 We found no studies evaluating costs.

3805 Summary of evidence

 One lower-quality trial found an e-mail discussion group intervention plus a selfcare book and videotape superior to usual care for pain, disability, role function and health distress after one year in patients with chronic low back pain (level of evidence: poor).

3810 **Recommendations and findings from other guidelines**

None of the other guidelines specifically address e-mail discussion groups.
 General recommendations on advice are listed in the bed rest section.

3813 Self-care exercise videotape

- 3814 Results of search: systematic reviews
- 3815 We identified no relevant systematic reviews
- 3816 Results of search: trials
- 3817 We identified one lower-quality trial comparing a self-care exercise videotape to face-to-
- 3818 face instruction in patients with back pain of unspecified duration [461].
- 3819 Efficacy of self-care exercise videotape versus face-to-face advice
- 3820 The trial found no differences in RDQ scores after 4 to 6 weeks between a self-care
- 3821 exercise video (featuring either the treating physiotherapist or an anonymous
- 3822 physiotherapist) compared to face-to-face advice (Table 42) [461]. On one subscale of
- 3823 the SF-36 (pain), the self-care video group had greater improvements than the face-to-
- 3824 face advice group (p<0.005, data not reported).

3825

Table 42. Trial of e-mail discussion group versus usual care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Miller, 2004[461]	N=550 4-6 weeks	Self-care video with treating physiotherapist vs. self- care video with anonymout physiotherapist vs. face- to-face advice RDQ score (0 to 24), mean change: -3.58 vs -3.00 vs - 2.47. Neither video group improved more than the control (p=.06). SF36 pain subscale: Either video had greater improvement vs. control (p<0.005, data not reported)	3/11

3826

3827 Safety

- 3828 No trials assessed safety
- 3829 Costs
- 3830 We found no studies evaluating costs.

3831 Summary of evidence

One lower quality trial found no differences in functional status between
 videotaped exercise advice and face-to-face advice through 4 to 6 weeks in

patients with back pain of unspecified duration, but videotaped advice wassuperior for short-term pain (level of evidence: poor).

3836 **Recommendations and findings from other guidelines**

- None of the other guidelines specifically address videotaped exercise advice.
- 3838 General recommendations on advice are listed in the bed rest section.

3839 Advice to restrict early morning flexion

- 3840 Results of search: systematic reviews
- 3841 We identified no relevant systematic reviews.
- 3842 Results of search: trials
- 3843 We identified one lower-quality trial comparing advice to restrict early morning lumbar
- 3844 flexion with sham exercise advice in patients with chronic low back pain [462, 463].
- 3845 Efficacy of advice to restrict early morning flexion versus sham exercise advice
- 3846 The trial found a single 45-minute instructional session on restricting early morning
- 3847 flexion (with supplemental videotape and written instructions) superior to sham exercise
- 3848 advice for mean pain intensity, days with disability as well as medication use (Table 43)
- 3849 [462, 463]. However, large baseline differences between groups (baseline medication
- 3850 use and disability days two times higher in the sham exercise advice group) could
- 3851 invalidate these results.

3852

Table 43. Trial of advice to restrict early morning flexion versus sham exercise advice

Author, year	Number of patients Duration of follow-up	Main results	Quality
Snook, 1998[462, 463]	N=85 6 months	Advice to restrict early morning flexion vs. sham exercise advice (mean at 6 months) Pain intensity (0 to 10): 1.52 vs. 1.36 (p<0.05)	0/44
		Pain days: 102 vs. 150 Disability days: 3.0 vs. 10.7 Impariment days: 3.0 vs. 10.7 Medication days: 16.7 vs. 49.9	2/11

- 3854 Safety
- 3855 The trial did not report adverse events.
- 3856 *Costs*
- 3857 We found no studies evaluating costs.

3858 3859 3860 3861 3862 3863	 Summary of evidence One lower-quality trial found that patients with chronic low back pain who were given advice to restrict early morning flexion reported better outcomes related to pain intensity and disability compared to those given sham exercise advice, but marked baseline differences make these findings unreliable (level of evidence: poor).
3864	Recommendations and findings from other guidelines
3865 3866	 None of the other guidelines specifically address advice to restrict early morning flexion. General recommendations on advice are listed in the bed rest section.
3867	Lay-facilitated groups for self-care
3868	We defined lay leaders as non-professionals with or without training in self-care
3869	group facilitation or specific self-care approaches for low back pain management.
3870	Results of search: systematic reviews
3871	We identified no systematic reviews evaluating lay-facilitated groups for self-care in
3872	patients with low back pain.
3873	Results of search: trials
3874	We identified one lower-quality trial evaluating lay-facilitated self-care groups in patients
3875	invited to enroll 6 to 8 weeks after a low back pain visit with their primary care provider
3876	[464].
3877	Efficacy of lay-facilitated groups for self-care versus usual care
3878	The trial found that a four-session self-care group led by trained lay leaders and
3879	supplemented by a self-care book and videotapes was superior to usual care plus a
3880	self-care book on function at 6 and 12 months, though not at 3 months (Table 44) [464].
3881	In addition, a higher proportion of patients in the self-care group reported a $>50\%$
3882	reduction in RDQ Scores at 6 months. However, there was no difference between the
3883	groups in pain intensity.

3884

Table 44. Trial of lay-led self-care group versus usual care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Von Korff, 1998[464]	N=255 12 months	Lay-led group + self-care book vs usual care + self- care book RDQ Questionnaire (0 to 24), mean score: 6.56 vs 7.40 at 3 months (NS), 5.83 vs 7.23 at 6 months (p=0.007), 5.75 vs 6.75 at 12 months (p=0.092). >=50% decrease in RDQ score: 48% vs. 33% (p=0.02) at 6 months Pain intensity (0 to 10), mean score: 3.87 vs. 4.02 at 3 months, 3.22 vs. 3.79 at 12 months (NS)	5/11

- 3885
- 3886 Safety
- 3887 No studies assessed safety
- 3888 *Costs*
- 3889 A cost analysis based on the trial estimated a mean cost of \$9.70 per additional low-
- impact back day in the low-impact lay-led group relative to usual care [465].
- 3891 Summary of evidence
- A four-session lay-led self-care group was associated with greater improvements in functional status (but not pain intensity) compared to usual care after 6 to 12 months in one lower-quality trial of patients with subacute low back pain (level of evidence: poor).

3896 **Recommendations and findings from other guidelines**

- None of the guidelines addressed lay-led self-care groups.
- 3898 Self-help tools for back surgery decisions
- 3899 Results of search: systematic reviews

3900 We identified no systematic reviews evaluating tools for helping guide back surgery

- 3901 decisions.
- 3902 Results of search: trials
- 3903 We identified one higher-quality trial evaluating patient outcomes associated with a
- 3904 video and a self-care book for informing back surgery decisions versus a self-care book
- alone [466]. Another higher-quality trial also evaluated a video program for informing
- 3906 surgery decisions, but was excluded because it did not report relevant patient outcomes
- 3907 [467].

3908 Efficacy of a video plus self-care book for informing back surgery decisions versus a3909 self-care book alone

- 3910 The single trial reporting patient outcomes found no difference between an interactive
- 3911 video plus self-care book and a self-care book alone for function at 3 months or 1 year
- in potential back surgery candidates (Table 45) [466]. The video intervention was
- 3913 superior to the self-care book alone for the proportion of patients reporting 'extreme' or
- 3914 'quite a bit' of pain (28% versus 37%, p=0.04). However, no difference was found
- 3915 between the interventions for resolution of back or leg pain at 3 months or 1 year.
- 3916 There was no difference in the rate of patients undergoing surgery except for in those
- 3917 diagnosed with herniated disc, who were less likely to have surgery in the video arm
- 3918 (32% vs. 47%, p=0.05).

3919Table 45. Trial of interactive video + self-care book versus self-care book alone for informing3920surgical decisions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Deyo, 2000[466]	N=393 1 year	Videodisc program + booklet vs booklet alone RDQ Score: no differences between groups at 3 months or 1 year Back pain severity 'extreme' or 'quite a bit' at 1 year: 27.6% vs. 37.2% (p=0.04) Resolution of back or leg pain: no differences between groups at 3 months or 1 year Surgery rate: 26% vs 33% (p=0.08, NS). In those with herniated disks: 32% vs 47% (p=0.05) Health care utilization (Seattle patients only): Except for surgery data reported above, no differences between groups for number of physician visits, physical therapy, spine imaging, overall lab or pharmacy use, hospitizations for back pain. Satisfaction with treatment, decision-making process: no differences Satisfaction with amount of information received: 71.8% vs 57.1% (p=0.005)	7/11

3921

3922 Safety

- 3923 No study assessed safety.
- 3924 Costs
- 3925 We found no studies evaluating costs.

3926Summary of evidence

One higher-quality trial found no differences in function between an interactive video plus self-care book versus a self-care book alone for informing back surgery decisions even though a lower proportion of patients with herniated disc underwent surgery. The video was associated with a lower proportion of patients with severe pain at one year, though there was no difference in rates of resolution of back or leg pain (level of evidence: fair).

3933 **Recommendations and findings from other guidelines**

None of the other guidelines address tools to help patients with back care decisions.

3936 Self-care Interventions

3937 Lumbar supports

- 3938 Results of search: systematic reviews
- 3939 We identified one higher-quality Cochrane review (6 RCTs, 2 higher quality) evaluating
- the effectiveness of lumbar supports for the treatment of low back pain [468]. This
- 3941 updated an older Cochrane review [469]. We excluded four other older systematic
- 3942 reviews [249, 282, 440, 470].
- 3943 Results of search: trials
- 3944 We did not search for additional trials.
- 3945 Effectiveness of lumbar supports versus placebo
- 3946 The Cochrane review included one small (N=30), lower-quality trial that found a lumbar
- 3947 support superior to no intervention for improvement in pain in patients with low back
- 3948 pain of unspecified duration after 1 hour, 3 weeks, and 6 weeks [471].
- 3949 Effectiveness of lumbar supports versus other interventions

3950 Four trials [111, 349, 380, 381, 472] included in the Cochrane review found that lumbar

- 3951 supports are not more effective than other interventions in reducing pain, and conflicting
- 3952 evidence on their effects on functional outcomes, return to work, and overall
- improvement. In the only higher quality trial [380, 381], a lumbar support was superior
- to soft tissue massage in patients with subacute or chronic low back pain on the RDQ
- 3955 Questionnaire, but there were no significant differences on the ODQ or on outcomes
- 3956 related to pain relief. There were also no differences between a lumbar support and
- 3957 spinal manipulation or transcutaneous muscular stimulation. Two lower-quality trials

- also found no differences between lumbar supports and usual care (in patients with
- 3959 chronic low back pain [349]) or either spinal manipulation, physiotherapy, or
- acetaminophen (in patients with back pain of varying duration [111]). One other lower-
- 3961 quality trial found a lumbar support superior to advice on rest and lifestyle for pain relief,
- return to work, and overall improvement in patients with acute low back pain [472].
- 3963 Comparison of different types of lumbar supports
- 3964 The Cochrane review included one higher-quality trial that found that a lumbar support
- 3965 with a rigid insert was associated with significantly more global improvement than a
- 3966 lumbar support without a rigid insert [473].
- 3967 Safety
- 3968 No studies evaluated safety.
- 3969 Costs
- 3970 We found no studies evaluating costs.

3971 Summary of evidence

- There is insufficient evidence from one lower quality trial to determine whether
 lumbar supports are effective compared to no intervention (level of
 evidence: poor).
- There is conflicting evidence regarding the effectiveness of lumbar supports compared to other interventions (soft tissue massage, spinal manipulation, advice on lifestyle and bedrest, physiotherapy, acetaminophen, TENS, or usual care). Most comparisons were evaluated in only one lower-quality trial. The trials were mainly conducted in subjects with non-specific low back pain of varying or unspecified duration level of evidence: poor).
- One higher-quality trial found that a lumbar support with a rigid insert was
 associated with superior global assessment of outcomes compared to a support
 without a rigid insert (level of evidence: fair).

3984 **Recommendations and findings from other guidelines**

- The AHCPR guidelines found that lumbar corset and support belts had not been
 proven beneficial for treating patients with acute low back problems (strength of
 evidence: D).
- The VA/DoD and UK RCGP guidelines make similar recommendations.
- The European COST guidelines found insufficient evidence to recommend
 lumbar supports for nonspecific chronic low back pain.

3991 Mattresses

- 3992 Results of search: systematic reviews
- 3993 We identified no systematic reviews evaluating mattresses in patients with low back 3994 pain.
- ooo pain
- 3995 Results of search: trials
- 3996 We found two randomized [474, 475] and one quasi-randomized trial [476] evaluating
- 3997 effects of different mattresses on chronic low back pain. Only one was rated higher
- 3998 quality [474].

3999 Efficacy of different mattress types

4000 In the higher-guality RCT (N=313), patients randomized to a firm mattress were less 4001 likely to have improvement in pain related disability compared to those randomized to a 4002 medium-firm mattress after 90 days (68% vs. 82%, p=0.005) [474]. There were no 4003 differences in the proportion of patients with improvement in pain while lying in bed or 4004 on rising (Table 46). One of the other trials compared a soft interior sprung mattress to 4005 an isometric mattress [475] and the other compared four different mattresses 4006 (orthopedic hard, standard, waterbed, hybrid water-foam). However, we could not 4007 reliably interpret their results because of methodological flaws, use of unstandardized 4008 outcome measures, and poor reporting of outcomes [475, 476].

4009

Table 46. Trials of different mattresses in patients with low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Kovacs, 2003[474]	N=313 90 days	Firm versus medium-firm mattress Proportion with improvement in pain-related disability: 68% vs. 82%, p=0.005 Proportion with improvement while lying in bed: 78% vs. 83%, p=0.29 Proportion with improvement in pain on rising: 80% vs. 86%, p=0.20	11/11
Ahterton, 1983[475]	N=30 2 weeks followed by crossover	Isometric versus soft inferior sprung mattress Proportion reporting pain 'least': 40% (10/25) vs. 28% (7/25) Proportion reporting comfort 'best': 40% (10/25) vs. 52% (13/25)	4/11
Garfin, 1981[476]	N=15 2 weeks per intervention	Orthopedic hard mattress versus standard box spring and mattress versus water-filled mattress versus hybrid (combination water-foam) mattress Results not interpretable	0/11

- 4011 Safety
- 4012 The higher quality trial found that the firm mattress was associated with a higher
- 4013 proportion of patients with worsening of pain in bed (17% vs. 9.0%) and worsening of
- 4014 disability (24% vs. 9%) compared to the medium-firm mattress [474].
- 4015 Costs
- 4016 We found no studies evaluating costs.

4017 Summary of evidence

- One higher-quality trial found that a firm mattress was less likely to lead to
 improvement in pain related disability and worsen pain while in bed compared to
 a medium-firm mattress in patients with chronic low back pain. There were no
 differences in other pain outcomes (level of evidence: fair).
- 4022 There was insufficient evidence to judge the relative effectiveness of other 4023 mattress types (level of evidence: poor).
- 4024 **Recommendations and findings from other guidelines**
- None of the guidelines address the use of different mattresses.

4026 Superficial heat or cold

- 4027 Results of search: systematic reviews
- 4028 We identified one recent, good quality Cochrane review (9 trials, five rated higher
- 4029 quality) [477]. The same investigator led three of the trials [478-480]. We excluded one
- 4030 older systematic review that found no studies on superficial hot or cold [283].
- 4031 Results of search: trials
- 4032 We did not search for additional trials.
- 4033 Efficacy of heat wrap therapy versus placebo
- 4034 The Cochrane review [477] included two higher-quality trials [478, 480] that found heat
- 4035 wrap therapy more effective than placebo in patients with acute or subacute low back
- 4036 pain for short-term (5 days) pain relief (WMD 1.06 on a 0 to 5 scale, 95% CI 0.68 to
- 4037 1.45) and improvement in disability (WMD –2.10 on 0 to 24 RDQ Scale, 95% CI –3.19
- 4038 to -1.01). Another higher-quality trial [481] found that application of a heated blanket
- 4039 decreased acute low back pain immediately following application compared to a non-
- 4040 heated blanket (WMD –32.20 on a 0 to 100 scale, 95% CI –38.69 to –25.71).

- 4041 Efficacy of heat wrap therapy versus other interventions
- 4042 The Cochrane review included one higher-quality trial [479] that found heat wrap
- 4043 therapy superior to oral acetaminophen or ibuprofen for short-term pain relief
- 4044 (differences 0.68 and 0.49 points, respectively, on a 0 to 5 scale after 1 day and 0.66
- 4045 and 0.93 after 3 to 4 days) and improved function (difference 2 and 2.2 points after 4
- 4046 days) in patients with acute low back pain (p values <0.05 for all differences). Another
- 4047 higher-quality trial [482] found heat wrap therapy superior to an educational booklet for
- 4048 early pain relief (WMD 0.60 on a 0 to 5 scale, 95% CI 0.05 to 1.15 after 2 days and
- 4049 WMD 1.10, 95% CI 0.55 to 1.65 after 4 days) and improved function (WMD 0.40, 95%
- 4050 CI –1.15 to 0.95 after 2 days and WMD 0.30, 95% CI –0.41 to 1.01 after 4 days) in
- 4051 patients with subacute or acute low back pain, though the benefits were no longer
- 4052 present after a week. There were no significant differences between heat wrap therapy
- 4053 and McKenzie exercise.
- 4054 Efficacy of superficial cold versus placebo
- 4055 There were no trials comparing superficial cold to placebo or no cold.
- 4056 Efficacy of superficial cold versus other interventions
- 4057 The Cochrane review included one lower quality trial [483] that found found ice
- 4058 massage and transcutaneous electrical stimulation similar effective in reducing pain in
- 4059 patients with chronic low back pain.
- 4060 Efficacy of superficial heat versus superficial cold
- 4061 Two lower-quality, non-randomized trials [484, 485] included in the Cochrane review
- 4062 reported conflicting results for superficial heat versus cold in patients with back pain of
- 4063 varying duration. One found that hot packs and ice massage were not significantly
- 4064 different in patients with back pain of mixed duration and the other found ice massage
- 4065 superior to hot packs.
- 4066 Safety
- 4067 No serious adverse events were reported in the trials of heat wrap therapy, and mainly 4068 consisted of skin irritation or increased 'pinkness' [477].
- 4069 *Costs*
- 4070 One decision analysis compared the cost-effectiveness of heat wrap therapy relative to
- 4071 ibuprofen or acetaminophen in patients with acute low back pain [486]. It found that

4072 heat-wrap therapy dominated over both drugs (decreased costs and superior efficacy)
4073 and conclusions insensitive to changes in the parameters used. However, these results
4074 should be interpreted cautiously since the analysis used outcomes data from a single
4075 published trial [479].

1010	
4076	Summary
4077	 There is consistent evidence from three higher-quality trials that heat wrap
4078	therapy or a heated blanket is modestly superior to placebo or a non-heated
4079	blanket for short-term pain relief and back-specific functional status in patients
4080	with acute or subacute low back pain (level of evidence: good).
4081	 Heat wrap therapy was also modestly superior to analgesic medications for
4082	short-term pain relief in one higher-quality trial of patients with acute low back
4083	pain (level of evidence: fair).
4084	 Heat wrap therapy was superior to a self-care booklet, but not to exercise, in one
4085	higher-quality trial of patients with a mix of acute and subacute low back pain
4086	(level of evidence: fair).
4087	 There is insufficient evidence (one lower-quality trial) to determine the efficacy of
4088	superficial cold (level of evidence: poor).
4089	 There is conflicting evidence (two lower-quality, non-randomized trials) regarding
4090	the efficacy of superficial heat versus superficial cold (level of evidence: fair).
4091	Recommendations and findings from other guidelines
4092	 The AHCPR guidelines found physical agents and modalities (including
4093	superficial heat or cold) of insufficiently proven benefit to justify their cost for
4094	acute low back pain (strength of evidence: C). However, they suggested that
4095	self-application of heat or cold to the back could be taught to the patient as an
4096	option.
4097	 The VA/DoD and UK RCGP guidelines reached similar conclusions.
4098	 The European COST guidelines make no recommendation for superficial heat or
4099	cold for acute low back pain, but note that three trials came from one research
4100	group with potential conflict of interest.
4101 4102 4103	 The European COST guidelines found insufficient evidence to recommend superficial heat for chronic low back pain.

4103 Key Question 5.

- 4104 Does referral from primary care providers to back specialty providers affect
- 4105 patient outcomes? What are the outcomes for patients who are managed by
- 4106 different types of care providers or by multidisciplinary or interdisciplinary
- 4107 clinics?
- 4108 Results of search: systematic reviews
- 4109 We found no systematic review evaluating effects of referral by a primary care provider
- 4110 (defined here as a family practitioner, general internist, or general practitioner) to a non-
- 4111 surgical back specialist (defined here as a neurologist, rheumatologist, physiatrist,
- 4112 occupational medicine physician, neurologist, or pain physician) on patient outcomes.
- 4113 The efficacy of multidisciplinary rehabilitation, behavioral interventions, acupuncture,
- 4114 and spinal manipulation is reviewed for Key Question 3 and the efficacy of surgical and
- 4115 non-surgical invasive interventions for Key Questions 7 and 8. In general, trials focused
- 4116 on the intervention rather than the providing managing care, and did not specify whether
- 4117 patients were referred by a primary care provider, managed without a referral, or co-
- 4118 managed by multiple providers.
- 4119 Results of search: trials
- 4120 We found no trial evaluating the effects of referral from primary care providers to back
- 4121 specialty providers on patient outcomes. One recent large, higher-quality trial (the
- 4122 UCLA Low Back Pain Study) evaluated chiropractic versus medical care for patients
- 4123 with low back pain of unspecified duration (Table 47) [423]. We also identified one well-
- 4124 designed, prospective cohort study on outcomes of acute low back pain episodes in
- 4125 patients managed by different provider types [15].
- *Efficacy of referral to back specialty providers on patient outcomes from low back pain*The UCLA Low Back Pain Study (N=339) found no significant differences in pain or
 disability after 6 months in patients randomized to chiropractic care versus medical care
 without physical therapy, with specific interventions chosen at the discretion of the
 assigned providers [423]. Adding physical therapy to medical care was associated with
 a small but statistically significant benefit on disability scores (1.26 point difference on a
 0 to 24 scale, 95% CI 0.20 to 2.32).
- 4133

4133

Table 47. Results of UCLA Low Back Pain Study

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hurwitz, 2002[423]	N=681 6 months	Chiropractic care vs. medical care (mean difference in improvement from baseline at 6 months) Most severe pain (0 to 10): 0.27 (95% CI -0.32 to 0.86)	
		Average pain: 0.22 (95% CI -0.25 to 0.69) RDQ score (0 to 24): 0.75 (95% CI -0.29 to 1.79)	
		Medical care + physical thearpy vs. medical care Most severe pain: 0.27 (95% CI -0.34 to 0.88) Average pain: 0.35 (95% CI -0.12 to 0.82) RDQ score: 1.25 (95% CI 0.20 to 2.32)	8/11
		Chiropractic care + physical modalities vs. chiropractic care	
		Most severe pain: -0.02 (95% CI -0.63 to 0.59) Average pain: 0.10 (95% CI -0.37 to 0.57) RDQ score: -0.78 (95% CI -1.82 to 0.26)	

4134

4135 A well-designed prospective observational study from North Carolina found little 4136 difference in time to functional recovery, return to work, and complete in patients with 4137 acute back pain managed by primary care providers, chiropractors, or orthopedic 4138 surgeons [15]. Despite similar baseline pain and back-related disability, orthopedists 4139 were more likely to order CT or MRI of the spine compared to primary care providers 4140 (17% vs. 6-11%). Chiropractors saw patients an average of 9 to 13 visits for the acute 4141 back episode, compared to around 2 visits for primary care providers and orthopedists. 4142 Satisfaction with care was also greater with chiropractors than with the other providers. 4143 The mean cost per episode was higher for orthopedic or chiropractic care (\$611 to 4144 \$783, 1993 dollars) than with primary care providers (\$435 to \$508). An earlier 4145 observational study of 1020 back pain episodes from four states reported similar 4146 differences in patterns of care, though it did not assess patient outcomes or satisfaction 4147 [16]. A survey of physicians from the early 1990's also found that given the same 4148 clinical situations, use of diagnostic tests varied considerably among eight medical 4149 specialties (family practice, internal medicine, osteopathic general practice, physical 4150 medicine, rheumatology, neurology, orthopedic surgery, neurosurgery) [11]. 4151 Neurosurgeons and neurologists were more likely to order imaging studies, physiatrists 4152 and neurologists more likely to order electromyograms, and rheumatologists more likely 4153 to order laboratory tests.

4154 4155 4156 4157	 Summary of evidence There is no direct evidence on the effects of referral from primary care to back specialty providers on patient outcomes, though evidence on the effects of certain interventions offered by specialty providers is reviewed elsewhere.
4158 4159 4160 4161	 One recent large, high-quality trial found medical care and chiropractic care associated with similar patient outcomes. Observational data also suggests no significant differences for back pain episodes managed by different provider types, though patterns of care varied (level of evidence: fair).
4162	Recommendations and findings from other guidelines
4163 4164 4165	 All guidelines recommend considering referral to a back specialist if low back pain is not improving despite non-invasive, usual interventions (strength of evidence: not assessed).
4166 4167 4168 4169	 For active duty personnel who have not improved after 4 to 6 months, the VA/DoD guidelines specifically recommend consideration of referral to the Medical Evaluation Board for possible reclassification or discharge from service (strength of evidence: not assessed).
4170	Key Question 6.
4171	What is the diagnostic accuracy and potential harms associated with diagnostic

4172 tests for identifying patients who will benefit from invasive procedures such as

4173 provocative discography, diagnostic nerve blocks, or other similar tests? Does

4174 prior use of these tests improve outcomes from invasive procedures?

4175 **Provocative discography**

4176 The usefulness of provocative discography in patients with low back pain 4177 remains controversial [487]. Provocative discography, which involves the injection of 4178 radiographic contrast material into the nucleus of an intervertebral disc, is most 4179 commonly performed in patients with chronic low back pain in whom an invasive 4180 procedure for discogenic back pain is being considered. Much of the debate about 4181 provocative discography centers on whether it is accurate for identifying painful lumbar 4182 discs ('discogenic back pain'), the uncertain natural history of discogram-positive low back pain (in one retrospective study, 68% of un-operated patients improved [488]), and 4183 4184 whether use of provocative discography improves patient outcomes or leads to 4185 unnecessary and potentially harmful interventions. Many studies show good correlation 4186 between results of provocative discography and abnormalities on CT or MRI imaging 4187 [489, 490]. However, because the presence of radiographic degeneration or other

4188 abnormalities is not necessarily associated with patient symptoms, imaging is an
4189 inadequate reference standard for assessing diagnostic accuracy. However, no other
4190 reference standard for 'discogenic pain' has been available.

4191 We focused our review on several specific types of studies of provocative 4192 discography. First, we identified studies providing information on populations without 4193 serious back pain in which discography provokes a high rate of positive responses. 4194 Studies addressing this type of question—"Do test results in patients with the target 4195 disorder differ from those in normal people?"-have been categorized as the lowest 4196 level (Phase I) on a hierarchy of diagnostic research [491]. Because Phase II ("Are 4197 patients with certain test results more likely to have the target disorder than patients 4198 with other test results?") and Phase III ("Does the test result distinguish patients with 4199 and without the target disorder among patients in whom it is clinically reasonable to 4200 suspect that the disease is present?") studies cannot be reliably interpreted in the 4201 absence of an appropriate reference standard, we did not review the literature 4202 comparing provocative discography with CT or MRI imaging results. However, we 4203 searched for studies that evaluated accuracy of provocative discography using 4204 alternative reference standards. We also evaluated studies on the impact of 4205 provocative discography on patient outcomes. Such evidence addresses the highest 4206 level (Phase IV) question in the hierarchy of diagnostic research—"Do patients who 4207 undergo this diagnostic test fare better in their ultimate health outcomes than similar 4208 patients who are not tested?"

4209 Results of search: systematic reviews

4210 We identified two recent, lower-quality systematic reviews evaluating lumbar

4211 discography in patients with low back pain [489, 490]. We also included a systematic

- 4212 review evaluating the risk of discitis following discography [492].
- 4213 Results of search: additional studies
- 4214 We found seven studies published since 1990 (when the Walsh criteria were first
- 4215 introduced) evaluating rates of positive pain responses to provocative discography in
- 4216 patients without significant chronic back pain [493-499]. Four other studies evaluated
- 4217 factors associated with a higher likelihood for positive pain responses in patients with
- 4218 chronic low back pain [500-503]. We also found one recent study using a novel

reference standard to assess diagnostic accuracy of discography [504]. Finally, we
identified one study comparing surgical outcomes in patients selected by discography
versus those in whom discography was not performed [505]. We excluded two studies
from the 1960's reporting high rates of positive provocative discography because they

- 4223 used outdated techniques [506, 507].
- 4224 Rates of positive pain responses to provocative discography in patients without4225 significant back pain
- A study published by Walsh and colleagues in 1990 found that in ten asymptomatic,
 healthy young men undergoing provocative discography, none met criteria for a positive
 test [499]. By contrast, 6 of 7 (86%) of patients with low back pain for more than 6
 months had a positive test. A positive test by the 'Walsh criteria' was defined as an
 abnormal disc in conjunction with pain rated as more severe than moderate and pain-
- 4231 related behavior (at least two of the following: guard/brace/withdraw, rubbing, grimacing,
- 4232 sighing, or verbalizing).
- 4233 Carragee and colleagues subsequently conducted a series of studies evaluating the 4234 proportion of positive pain responses to provocative discography (as defined using 4235 Walsh criteria) in patients without serious back pain (or asymptomatic) (Table 48). They 4236 found that patients with somatization or abnormal psychometric testing had high rates of 4237 positive responses (70% to 83%), as did those who were disabled (86% or 5/6) or had 4238 an active worker's compensation or personal injury claim (89% or 8/9) [494, 495]. 4239 Patients with pain unrelated to the back also frequently had positive results (50% of 4/8 4240 following iliac crest harvest and 40% or 4/10 in those with neck pain following cervical 4241 surgery) [495, 496]. In patients with previous discectomy, positive pain responses were 4242 seen in 40% (8/20) of those with good surgical results [494].
- More recently, investigators have proposed adding pressure threshold criteria to the requirements for a positive response [508]. With this adaptation, pain that is only provoked with high injection pressures (which occurs in normal discs) is not considered a positive response. In one study, 0% (0/16) of asymptomatic volunteers had a positive response when incorporating pressure criteria, compared to a 35% (100/282) rate of positive discograms in patients with chronic low back pain [498]. In a re-analysis of data reported in earlier studies, Carragee and colleagues also reported no positive pain

- 4250 responses (0/10) in asymptomatic, low-risk patients without low back pain [497].
- 4251 However, 36% (5/14) of patients with back pain and either chronic pain or somatization,
- 4252 25% (5/20) of pain-free patients following disc surgery, and 28% (7/25) of patients with
- 4253 mild low back pain would still be classified as having positive tests.
- 4254 One limitation of this set of studies is small sample sizes, resulting in imprecise
- 4255 estimates. In addition, asymptomatic subjects in one study mainly consisted of
- 4256 physicians, which could limit the generalizability of results [509].

4257 4258

Table 48. Rates of positive pain responses to provocative discography in personswithout serious back pain

Author, year	Definition of positive pain response	Rates of positive pain responses	Quality
Carragee, 2006[497]	Walsh criteria, with added criteria of 'low pressure' response defined as pain provoked with static pressure of less than 22 psi	 A: No LBP, but with chronic pain or somatization: 36% (5/14); 30% (3/10) in patients with chronic pain and 50% (2/4) in patients with somatization B: No LBP, history of prior successful lumbar discectomy (n=20): 25% (5/20) C: Mild persistent low back pain but not seeking or receiving treatment for it (also s/p cervical surgery): 28% (7/25); 23% (3/13) in patients with no chronic pain and 33% (4/12) in patients with chronic pain D: No LBP, no chronic pain: 0% (0/10) 	8/9
Derby, 2005[498]	Negative discogram= no pain described as 'familiar', no pain >=6/10 at pressures <=50 psi above opening pressure and <=3.5 ml total injected volume	A: Asymptomatic volunteers: 0% (0/16) B: Chronic low back pain with unremitting pain despite conservative treatment: 35% (100/282) of discs positive	7/9
Carragee, 2002[493]	Walsh criteria	 A: Patients with mild persistent low back pain but not seeking or receiving treatment for it and s/p cervical spine surgery: 36% (9/25); 23% (3/13) in patients with good cervical surgery outcomes and 50% (6/12) in patients with worst cervical surgery outcomes B: Patients undergoing discography for consideration of surgery: 73% (38/52) In group A, 5/5 (100%) of patients with daily opioid had 	9/9
Carragee, 2000[494]	Walsh criteria	 A: No low back pain 2 to 10 years following successful lumbar disc surgery, no depression: 40% (8/20) B: Chronic persistent or recurrent low back and leg problems 14 months to 6 years following posterior discectomy: 63% (17/27); 43% (3/7) in patients with normal psychometric scores and 70% (14/20) in those with abnormal scores 	8/9
Carragee, 2000[495]	Walsh criteria	 A: No low back pain, status post cervical discectomy and/or fusion 2 to 4 years previously with good surgical outcomes: 10% (1/10) B: No low back pain, status post cervical discectomy and/or fusion 2 to 4 years previously with poor surgical outcomes: 40% (4/10) C: No low back pain, somatization disorder and chronic pain present: 83% (5/6) Disabled: 86% (5/6) 	8/9
Carragee, 1999[496]	Walsh criteria	Active worker's compensation or personal injury claim: 89% (8/9) A: No low back pain, status post iliac bone graft harvesting for reasons unrelated to lumbar spine: 50% (4/8)	7/9
Walsh, 1990[499]	Walsh criteria	A: Low back pain >6 months: 86% (6/7) B: No low back pain: 0% (0/10)	6/9

4259 Factors associated with higher rates of positive discography in patients with chronic low4260 back pain

4261 Two studies of patients with chronic low back pain reported higher rates of positive pain 4262 responses to provocative discography in patients with abnormal psychometric testing 4263 [500] or abnormal pain drawings (Table 49) [503]. Although one other study found no 4264 clear association between presence or absence of somatization disorder and positive 4265 pain responses to provocative discography, subjects appeared more highly selected as 4266 they had already undergone negative testing for facet joint mediated pain and an 4267 epidural steroid injection [502]. Another study reported positive pain responses in 38% 4268 (51/136) of un-operated discs in patients with chronic low back pain following lumbar 4269 surgery, though the rate was higher in previously operated discs (72% or 73/102) [501].

4270Table 49. Trials evaluating predictors of positive pain responses to provocative discography in4271patients with chronic back pain

Author, year	Definition of positive pain response	Rates of positive pain responses	Quality
Manchikanti, 2001[502]	NASS criteria	 A: Low back pain, negative testing for facet joint mediated pain and epidural steroids, with somatization disorder: 48% (12/25) B: Low back pain, negative testing for facet joint mediated pain and epidural steroids, without somatization disorder: 56% (14/25) 	5/9
Heggeness, 1997[501]	Reproduction of patient's typical pain pattern	A: Postoperative disks: 72% (73/102) B: Unoperated disks: 38% (51/136)	7/9
Block, 1996[500]	Similar or exact pain reproduction	 A: Low back pain, with at least 1 nondisrupted disc: 47% (34/72) Discordant pain response associated with higher scores on hysteria and hypochondriasis subscales of MMPI 	2/9
Ohnmeiss, 1995[503]	Similar or exact pain reproduction	 A: Low back pain with abnormal pain drawing: 50% (18/36) B: Low back pain with normal pain drawing: 12% (13/105) 	7/9

- 4273 Accuracy of provocative discography
- 4274 One recent, higher-quality prospective cohort study by Carragee and colleagues (2006)
- 4275 attempted to evaluate the positive predictive value of provocative discography by
- 4276 comparing the rate of successful surgical outcomes in patients with presumed
- 4277 discogenic pain by provocative discography relative to patients with single-level,
- 4278 unstable spondylolisthesis (a condition for which surgery is widely considered
- 4279 appropriate) (Table 50) [504]. Patients in the provocative discography group (N=32)

4280 were selected if they met low-pressure criteria for a positive response at a single level,

- 4281 failed conservative therapy, had negative facet joint and sacroiliac joint blocks, and had
- 4282 no other spinal or pelvic pathology or comorbidities associated with poorer surgical
- 4283 outcomes. Patients in the spondylolisthesis group (N=34) also had no comorbidities
- 4284 and had single-level Grade I or II isthmic spondylolisthesis of either L5-S1 or L4-L5 with
- 4285 radiologic segmental instability. Patients appeared well-matched on baseline
- 4286 demographics, pain scores, functional status, and other important covariates.
- 4287 The rate of highly successful outcomes two years following spinal fusion was 72%
- 4288 (23/32) in the spondylolisthesis group compared to 27% (8/30) in the positive
- 4289 discography group (p=0.0004). The proportion of patients who met criteria for minimal
- 4290 acceptable outcomes was 91% (29/32) in the spondylolisthesis group compared to 43%
- 4291 (13/30) in the positive discography group (assessed by blinded and independent
- 4292 observers). The "positive predictive value" (rate of success in the positive discography
- 4293 group relative to rate of success in the spondylolisthesis group) was 42% to 43% for
- 4294 both outcomes. Using the most favorable assumptions about dropouts (2 dropouts in
- 4295 discogenic pain group considered successes and 2 dropouts in spondylolisthesis group
- 4296 considered failures), the positive predictive value of discography would be 55% to 57%.

4297Table 50. Study evaluating rates of successful surgical outcomes in highly selected patients with4298positive discography relative to patients with isthmic spondylolisthesis

Author, year	Number of patients Duration of follow-up	Main results	Quality
Carragee, 2006[504]	N=66 2 years	Surgery for presumed discogenic pain (positive discography) vs. unstable single-level isthmic spondylolisthesis "Success" (pain VAS <=2/10, ODI<=15, no opioid or daily analgesic use, return to full employment): (27% (8/30) vs. 72% (23/32) Minimal acceptable outcome (pain VAS <4/10, ODI <30, no opioid use, return to at least partial employment): 43% (13/30) vs. 91% (29/32) Pain VAS <2 (0 to 10 scale): 30% (9/30) vs. 84% (27/32) ODI score <15: 33% (10/30) vs. 72% (23/32) No opioid or daily analgesic: 30% (9/30) vs. 88% (28/32) Working in usual occupation: 30% (9/30) vs. 81% (26/32) "Positive predictive value" (positive outcome in discography group relative to spondylolisthesis group: 42% for "success", 43% for minimal acceptable outcome	6/9

4299 Although this study met criteria for a higher-quality prospective cohort study, the 4300 reference standard is quite atypical because it involves a comparison to outcomes with 4301 the same procedure in another set of patients with a different underlying condition 4302 (rather than comparing results to a reference test in the same set of patients). 4303 Interpretation of 'positive predictive value' estimates from this study depend on the key 4304 assumption that surgery for 'true' discogenic pain should achieve similar outcomes as 4305 surgery (in a matched, but different set of patients) for unstable spondylolisthesis. A 4306 potential alternative interpretation of study results is that even though surgery for 4307 discogenic pain identified by provocative discography is associated with a lower rate of 4308 success compared to surgery for unstable spondylolisthesis in highly selected patients without comorbidities, this difference could reflect an imperfect treatment rather than an 4309 4310 incorrect diagnosis. On the other hand, it could also be argued that surgical removal of 4311 the disc and annulus (the presumed pain generators) should be the definitive treatment 4312 for discogenic pain.

- 4313 Effects of provocative discography on clinical outcomes
- 4314 One lower-quality observational study compared outcomes in patients selected for
- 4315 spinal fusion based on positive discography to those who underwent surgery without
- 4316 discography (Table 51)[505]. It was rated lower-quality because it used a historical
- 4317 control group, did not describe independent or blinded assessment of outcomes, and
- 4318 did not adjust for baseline differences or confounders. It found that after 2.4 to 2.8
- 4319 years of follow-up, there were no significant differences in rates of satisfactory
- 4320 outcomes (<40 on Oswestry scale), pain, or psychologic testing.
- 4321 4322

Table 51. Study of outcomes in patients selected for spinal fusion with or without provocativediscography

Author, year	Number of patients Duration of follow-up	Main results	Quality
Madan, 2002[505]	N=73 2.4 to 2.8 years	Discography vs. no discography "Excellent" or "good" ODI outcome: 81% vs. 76% "Excellent" ODI outcome: 62% vs. 58% ODI (mean scores): 34 vs. 34 Psychologic (mean scores): 22 vs. 15 Pain (VAS, 0-10): 4.2 vs. 4.4 Core set of surgical outcomes (range 10 to 50): 24 vs. 25	6/9

Two other retrospective cohort studies were excluded because they didn't compare
outcomes in patients who did and did not undergo discography prior to surgery. One
found successful surgery more likely in patients with positive discography and an
abnormal MRI compared to positive discography and a normal MRI (75% vs. 50%)
[510]. The other found success rates higher with abnormal discs and positive pain

- 4329 provocation compared to patients with abnormal discs and no pain provocation (88% vs.
- 4330 52%) [511]. Both studies failed to report independent or blinded assessment of
- 4331 outcomes and did not adjust for baseline differences or potential confounders.
- 4332 Safety
- 4333 The most common serious complication following discography is discitis. In one
- 4334 systematic review of observational studies, 12 cases of discitis occurred in 5,091
- 4335 patients (13,205 disc injections) undergoing discography without prophylactic antibiotics
- 4336 (mean 0.24% using the number of patients as the denominator and 0.09% using the
- 4337 number of disc injections as the denominator) [492]. In the single study of patients who
- 4338 received prophylactic antibiotics (200 patients, 435 discs), no cases were reported
- 4339 [512]. Other rare complications that have been reported after discography include disc
- 4340 herniation after injection, retroperitoneal hemorrhage, and dural penetration [492].
- 4341 Increased pain following the procedure is frequent but usually transient. However, one
- 4342 small study of patients without back pain who underwent discography reported
- 4343 persistent back pain one year after injection in 20-67% of those with chronic pain at
- 4344 other sites or with somatization [513]. Long-term effects have not been well-studied,
- though one small study (N=36) found no increase in degenerative disc changes 10 to 20
- 4346 years after discography [514].
- 4347 Costs
- 4348 We found no studies evaluating costs.
- 4349 Summary of evidence
- Positive responses to provocative discography were uncommon in small series of healthy, asymptomatic volunteers (level of evidence: fair).
- In patients without significant back pain, provocative discography was frequently associated with positive pain responses in small series of patients with chronic pain at other sites, those with somatization, those with previous disc surgery, and those disabled or seeking monetary compensation (level of evidence: fair).

4356 4357 4358	 Incorporating pressure criteria into the definition for a positive response did not eliminate positive results in high-risk sub-groups of patients without significant low back pain in one small study (level of evidence: fair).
4359 4360 4361	 Previous back surgery, chronic pain, and abnormal psychometric testing were also associated with increased rates of positive discography in small series of patients with chronic back pain (level of evidence: fair).
4362 4363 4364 4365 4366	 One higher-quality cohort study found that relative to the rate of successful surgery for single-level isthmic spondylolisthesis, the rate of successful surgery for presumed discogenic back pain (based on provocative discography) was 43- 44% in a highly selected population of patients without comorbidities (level of evidence: fair).
4367 4368 4369	 In one lower-quality observational study, surgery outcomes were similar with or without the use of provocative discography to select patients (level of evidence: poor).
4370 4371 4372	 Discitis appears rare with or without antibiotics. Other serious adverse events also appear rare. In one study, persistent pain was reported in patients with somatization or chronic pain at other sites (level of evidence: fair).
4373	Recommendations from other guidelines
4374 4375 4376	• The AHCPR guidelines recommend against discography in patients with acute low back pain because it is invasive and interpretation is equivocal (strength of evidence: C).
4377 4378 4379	 The AHCPR guidelines recommend against CT-discography over MRI or CT for assessing patients with suspected nerve root compression due to lumbar disc hernia (strength of evidence: C).
4380 4381	 The European COST guidelines recommend against discography for diagnosing discogenic pain.
4382	Diagnostic selective nerve root blocks
4383	Diagnostic selective nerve root blocks involve the injection of local anesthetic
4384	around spinal nerves under fluoroscopy. A positive response requires relief of usual
4385	symptoms. Results of selective nerve root blocks correlate well with radiologic or
4386	surgical evidence of nerve compression [515]. However, because nerve root
4387	compression can usually be assessed with non-invasive imaging, the main purposes of
4388	diagnostic nerve root blocks are to evaluate the appropriate target level for interventions
4389	when multiple nerve roots are involved and to confirm the diagnosis when imaging is
1000	and the sector of the discrete the termination of the termination of the termination of the termination of the

4390 equivocal or when there is discordance between clinical findings and imaging. No

- 4391 reference standard for evaluating the diagnostic accuracy of selective nerve root blocks
- 4392 for identifying "true" nerve root pain in these situations is available. We therefore
- 4393 focused our review on evidence evaluating whether selective nerve root blocks improve
- 4394 clinical outcomes (Phase 4 on the diagnostic research hierarchy [491]).
- 4395 Results of search: systematic reviews
- 4396 We identified one recent systematic review on the diagnostic accuracy of selective
- 4397 nerve root blocks [515]. However, it included no studies evaluating whether diagnostic
- 4398 selective nerve root blocks improve clinical outcomes in patients with suspected nerve
- 4399 root compression compared to relying only on imaging and other non-invasive
- 4400 diagnostic methods.
- 4401 Results of search: other studies
- 4402 We identified no relevant studies.
- 4403 Effects of selective nerve root blocks on clinical outcomes
- 4404 We could not assess the effects of selective nerve root blocks on clinical outcomes (no
- 4405 evidence).

4406 Summary of evidence

There are no studies evaluating the impact of diagnostic selective nerve root
 blocks on clinical outcomes relative to non-invasive methods alone for evaluating
 suspected nerve root compression.

4410 **Recommendations and findings from other guidelines**

• The other guidelines do not address diagnostic selective nerve root blocks.

4412 Diagnostic facet joint blocks

4413 Facet joint blocks involve the injection of local anesthetic into facet

4414 (zygapophysial) joints or around medial branches of the dorsal rami innervating the

- 4415 target joint under fluoroscopic guidance, in order to determine whether the facet joint is
- the source of low back pain. Like selective nerve root blocks, a positive response
- 4417 requires the relief of usual symptoms. Positive facet joint blocks have been reported in
- 4418 15% to 45% of patients in different populations with chronic low back pain [516]. Use of
- 4419 control blocks can reduce the rate of positive responses by up to 50% compared to
- 4420 relying on a single block. However, as in other invasive diagnostic procedures, no
- 4421 reference standard for facet joint pain is available for evaluating the diagnostic accuracy

- 4422 of facet joint blocks. Furthermore, results of facet joint blocks do not correlate well with
- findings on imaging studies. We therefore focused our review on evidence regardingthe effect of facet joint blocks on clinical outcomes.
- 4425 Results of search: systematic reviews
- 4426 We evaluated two recent systematic reviews evaluating the diagnostic utility or accuracy

4427 of facet joint blocks [516, 517]. Neither included any study evaluating the effect of facet

- 4428 joint blocks on clinical outcomes.
- 4429 Results of search: other studies
- 4430 We identified no relevant studies not included in the systematic reviews.
- 4431 Effects of facet joint blocks on clinical outcomes
- 4432 We could not assess the effects of facet joint blocks on clinical outcomes (no studies).

4433 Summary of evidence

- 4434
 4435
 There are no studies evaluating the impact of facet joint blocks on clinical outcomes in patients with prolonged non-specific low back pain.
- Evidence on interventions targeted at facet joint pain is outlined in Key Question
 7. In all trials of facet joint interventions, patients were enrolled based on positive
 diagnostic facet joint blocks.

4439 **Recommendations and findings from other guidelines**

The European COST guidelines recommend against facet joint blocks for the diagnosis of facet joint pain.

4442 Key Question 7.

- 4443 What is the effectiveness of injections (and different injection interventions) for
- 4444 non-specific low back pain, radicular low back pain, or spinal stenosis, and under
- 4445 what circumstances?
- 4446 Injections
- 4447 Chemonucleolysis
- 4448 Results of search: systematic reviews
- 4449 We identified one good-quality Cochrane review on the efficacy of chemonucleolysis (16
- trials) in patients with prolapsed lumbar disc [518]. It updated an earlier Cochrane
- 4451 review [519]. We excluded two other older systematic reviews [520, 521]

4452 Results of search: trials

- 4453 We identified two randomized trials of chemonucleolysis not included in the Cochrane
- review [455, 522]. One compared chemonucleolysis to spinal manipulation [455], and
- the other compared long-term outcomes of chemonucleolysis with chymopapain versus
- 4456 chemonucleolysis with collagenase [522].
- 4457 *Efficacy of chemonucleolysis versus placebo*
- 4458 The Cochrane review [518] included five generally higher-quality placebo-controlled
- trials comparing chemonucleolysis using chymopapain with placebo. A total of 446
- 4460 patients received chemonucleolysis. Chemonucleolysis was superior to placebo as

rated by patients (two trials, OR 0.24, 95% CI 0.12 to 0.49) and by surgeons or an

4462 independent observer (three trials, OR 0.40, 95% CI 0.21 to 0.75). Fewer patients

- 4463 proceeded to open discectomy following chemonucleolysis relative to placebo (OR 0.41,
- 4464 95% CI 0.25 to 0.68). One small, lower-quality trial found chemonucleolysis with
- 4465 collagenase superior to placebo [523].
- 4466 *Efficacy of chemonucleolysis versus standard discectomy*
- 4467 The Cochrane review also included five generally lower-quality trials (total number of
- 4468 subjects 680) comparing the efficacy of chemonucleolysis using chymopapain to
- 4469 standard surgical discectomy [518]. It found consistent trends towards poorer results
- 4470 with chemonucleolysis, though differences did not reach statistical significance. In
- addition, some between-study heterogeneity was present, and outcomes were
- 4472 inconsistently reported. At one year, patient-rated outcomes were worse in two trials
- 4473 (OR 0.61, 95% CI 0.30 to 1.24) and surgeon-rated outcomes in three trials (OR 0.37,
- 4474 95% CI 0.13 to 1.05). About 30% of patients receiving chemonucleolysis subsequently
- underwent disc surgery within two years (OR 0.07, 95% CI 0.02 to 0.18).
- 4476 *Efficacy of chemonucleolysis versus other interventions*
- 4477 One trial not included in the Cochrane review found no significant differences after one
- 4478 year between patients randomized to chymopapain chemonucleolysis or spinal
- 4479 manipulation, though short-term outcomes (through six weeks) favored manipulation
- 4480 (Table 52) [524].

4481Table 52. Trial of chemonucleolysis versus other interventions not included in systematic reviews

Author, year	Number of	Main results	Quality

	patients Duration of follow-up		
Burton,	N=40	Chemonucleolysis vs. manipulation (mean improvement from	
2000[524]	1 year	baseline at 12 months)	
		Leg pain (0 to 10): -1.38 vs1.87 (NS)	3/11
		Back pain (0 to 10): -1.18 vs1.52 (NS)	
		RDQ score: -4.68 vs6.03 (NS)	

4482

Three lower-quality trials comparing chemonucleolysis and intradiscal steroids were
reviewed in the section on intradiscal steroids [525, 526, 527]. None reported any
differences between interventions.

4486 Efficacy of different chemonucleolysis methods

4487 One trial included in the Cochrane review found no differences in outcomes between 4488 low dose and standard dose chymopapain chemonucleolysis [528]. Another trial found 4489 no differences between chemonucleolysis with chymopapain versus chemonucleolysis 4490 with collagenase [529]. One lower-quality trial not included in the Cochrane review 4491 evaluated long-term (five year) outcomes following chemonucleolysis with chymopapain 4492 or collagenase [522]. It found a greater proportion of "good" or "excellent" results in the 4493 chymopapain group (72% vs. 52%) using the McNab criteria, with much of the 4494 difference due to the proportion of patients proceeding to surgery (18% vs. 28%) and 4495 considered failures (Table 53). However, improvement in pain scores was similar 4496 across the two groups (-7.8 vs. -7.7 on a 10 point scale).

4497 4498

Table 53. Trials not included in systematic reviews on efficacy of differentchemonucleolysis methods

Author, year	Number of patients Duration of follow-up	Main results	Quality
Wittenberg, 2001[522]	N=66 5 years	Chemonucleolysis with chymopapain vs. collagenase "Good" or "excellent" result at 5 years (with patients requiring surgery considered poor results): 72% vs. 52% Leg pain score, mean improvement (0 to 10 scale): -7.6 vs7.7 Required surgery: 18% vs. 28%	5/11

4499 Safety

- 4500 Earlier trials reported allergic reactions in 1.5% to 2% of patients undergoing
- 4501 chemonucleolysis with chymopapain [523, 530, 531]. However, these may be
- 4502 underestimates, depending on how allergic reactions are assessed and defined, as one
- 4503 more recent trial reported that 12% of patient in the chymopapain arm experienced
- 4504 allergic reactions (flushing and itching), including one case of slight anaphylaxis [522].

APS Clinical Guidelines for the Management of Low Back Pain

4505 Rare serious complications that have been reported following chemonucleolysis include4506 lumbar subarachnoid hemorrhage and paraplegia [532, 533].

4507 Costs

- 4508 We identified two studies of costs associated with chemonucleolysis but excluded them
- 4509 because they used unreliable cost and outcomes data from a single observational study
- 4510 [534, 535].

4511 Summary of evidence

- 4512 Chemonucleolysis with chymopapain was consistently superior to placebo in five
 4513 higher-quality trials of patients with prolapsed lumbar disc (level of evidence:
 4514 good).
- 4515
 4516
 4516
 4517
 There is insufficient evidence to accurately judge the efficacy of chemonucleolysis with collagenase relative to placebo (one lower-quality trial) (level of evidence: poor).
- 4518
 Chemonucleolysis was consistently associated with trends towards worse outcomes relative to standard discectomy in five lower-quality trials, and led to subsequent surgery in about 30% of cases (level of evidence: fair).
- 4521
 Chemonucleolysis with chymopapain and intradiscal steroid injections were consistently associated with similar outcomes in three lower-quality trials (level of evidence: fair).
- One lower-quality trial found no differences between chemonucleolysis with
 chymopapain and spinal manipulation after one year, though manipulation was
 superior at short-term (through 6 weeks) follow-up (level of evidence: poor).
- Chemonucleolysis with chymopapain and collagenase were associated with
 similar pain outcomes in two lower-quality trials (one with five year follow-up), but
 chymopapain was associated with a trend towards reduced rate of subsequent
 surgery in one trial (level of evidence: fair).
- Chemonucleolysis with chymopapain is associated with mild allergic reactions in up to 12% of patients, though reporting of allergic reactions was suboptimal.
 Serious complications appear uncommon (level of evidence: poor).
- 4534 **Recommendations from other guidelines**
- The AHCPR guidelines recommend chymopapain as an acceptable treatment for patients with a herniated disc, severe, disabling sciatica, evidence of nerve root compromise, and persistence after at least one month of therapy, though it is less efficacious than standard or microdiscectomy. Testing patients for

4539 chymopapain allergic sensitivity could reduce the incidence of anaphylaxis4540 (strength of evidence: C).

4541 Epidural steroid injections

- 4542 Results of search: systematic reviews
- 4543 We identified one higher-quality Cochrane review that included eleven trials (five rated
- 4544 higher quality [350, 536-539]) of epidural steroids in patients with low back pain >1
- 4545 month and sciatica [540, 541]. We also identified one other recent higher-quality [129]
- 4546 and four lower-quality systematic reviews [542-545]. We excluded seven older
- 4547 systematic reviews [110, 249, 520, 546-549] and another systematic review [550] that
- 4548 has already been updated [542]. We also excluded four reviews that were not clearly
- 4549 systematic [548, 551-553].
- 4550 Results of search: trials
- 4551 We identified five recent trials of epidural steroids not included in any of the systematic
- 4552 reviews [554-558]. Four were rated higher-quality [554, 556-558]. One trial compared
- 4553 epidural steroid injection to placebo injection [556], three compared epidural steroid
- 4554 injection to other active interventions (discectomy [554], intrasmuscular steroid injection
- 4555 [557], adhesiolysis [559], and one compared the caudal approach to targeted steroid
- 4556 placement with spinal endoscopy [558].
- 4557 Efficacy of interlaminar or caudal epidural steroid versus placebo injection (saline or 4558 local anesthetic)
- The Cochrane review [540, 541] included four trials (two higher-quality [538, 560]) that found no differences between epidural steroid and placebo injections for short- (<6 weeks) or longer-term (>6 weeks) pain relief (4 trials, RR 0.93, 95% CI 0.79 to 1.09 and 3 trials, RR 0.92, 95% CI 0.76 to 1.11, respectively) in patients with low back pain and radicular symptoms of more than one month duration. The highest quality and largest
- 4564 (N=158) trial reported results very similar to the pooled estimates [560].
- Another systematic review, using different inclusion criteria, came to discordantconclusions [129]. Two [561, 562] of the four [350] trials in this review were not
- 4567 included in the Cochrane review because they evaluated patients with acute low back
- 4568 pain. The non-Cochrane review found epidural steroids superior to placebo injection for
- 4569 'improvement in symptoms' when restricting the analysis to trials with at least 20 patient
- 4570 in each arm (OR 2.2, 95% CI 1.04 to 4.7), with similar estimates after adding data from

4571 eight smaller trials. However, the results appeared sensitive to the inclusion of one trial
4572 of patients with acute low back pain [561] that reported an odds ratio of 6.8 (compared
4573 to odds ratios of 1.1 to 2.8 in the others).

4574 A third systematic review that included trials of back pain of any duration, with or without 4575 sciatica) found conflicting evidence from 15 trials (14 of patients with sciatica) regarding 4576 efficacy of epidural steroids relative to placebo, local anesthetic injection, or other 4577 control [544]. Epidural steroids were superior in eight trials but no better (inferior or no 4578 significant differences) in seven others. Among the five highest quality trials [350, 536, 4579 538, 560, 562], epidural steroids were superior in two [350, 536]. Two additional trials 4580 [563, 564] included in the most recent systematic review [542] both reported positive 4581 short-term (<6 weeks) results with epidural steroids, though only one of the trials [563] 4582 reported longer-term benefits.

One recent, large (N=228), high-quality trial not included in any of the systematic
reviews found no significant short- or long-term (one year) differences in any assessed
outcome (functional status, pain, requirement for surgery, and analgesics use) between
epidural steroid and epidural saline in patients with subacute or chronic sciatica (Table
54) [556].

4588	Table 54. Trial of epidural steroid versus epidural saline not included in systematic reviews
------	---

Author, year	Number of patients Duration of follow-up	Main results	Quality
Price, 2005[556]	N=228 1 year	Epidural steroid vs. epidural saline (all results at 52 weeks unless otherwise noted) Oswestry, proportion with >75% improvement: 12% vs. 4% at 3 weeks (p=0.016), 32%30 at 52 weeks (p=0.64) SF-36: No significant differences Leg pain, >50% improvement: 48% vs. 44% (NS) Back pain (VAS 0 to 100), mean improvement from baseline: -8 vs. –9 (NS) Required surgery: 13% vs. 13% Off work due to sciatica: 24% vs. 22%	10/11

- 4590 Nearly all of the trials included in the systematic reviews evaluated patients with
- 4591 sciatica. An exception was one lower-quality trial of patients with non-sciatic back pain
- 4592 that found no differences in pain and functional outcomes following epidural steroid
- 4593 injection versus intrathecal midazolam [565]. Another higher-quality trial (not included in

4594 any of the systematic reviews) found that in patients with spinal stenosis, epidural
4595 steroid and local anesthetic injections were both associated with improved walking
4596 distance at one week compared to epidural saline, though no beneficial effects were
4597 present for either at three months (Table 55) [566].

4598

Table 55. Trial of epidural steroids in patients with spinal stensois

Author, year	Number of patients Duration of follow-up	Main results	Quality
Fukusaki, ,	N=53	Epidural steroid vs. epidural local anesthetic vs. epidural	6/11
1988[566]	3 months	saline	
		Mean walking distance (m): 87 vs. 92 vs. 23 at week 1, 10 vs. 13	
		vs. 11 at 3 months (p<0.05 for epidural steroid and epidural local	
		anesthetic vs. saline at week 1 only)	

4599

4600 Efficacy of transforaminal epidural injection versus placebo injection

4601 Two recent systematic reviews specifically evaluated the efficacy of the more recently 4602 introduced transforaminal approach (using radiographic guidance), rather than the 4603 traditional interlaminar or caudal approaches, for administering epidural steroids [542, 4604 543]. Both included one higher-quality trial that found transforaminal epidural steroid 4605 injection superior to local anesthetic injection for the proportion of patients proceeding to 4606 surgery after a mean of 23 months (71% vs. 33%) [567]. Results were mixed from two 4607 other trials: transforaminal steroid injection was superior to saline for 'good' overall 4608 response at 3 months (54% vs. 40%) in one lower-quality trial [564], but no better at 12 4609 months in a higher-quality trial [568]. A fourth trial found no differences between 4610 transforaminal epidural injection with steroid versus hyaluronidase in patients with failed 4611 back surgery syndrome [569].

4612 Efficacy of epidural steroids versus local injections

4613 One higher-quality trial [350] included in the Cochrane review [540, 541] found no

4614 significant between epidural steroid injection and trigger point injection for the proportion

4615 of patients with sciatica who were recovered after one month (67% vs. 56%), though the

- 4616 epidural steroid was superior at three months. In a lower-quality trial included in two
- 4617 non-Cochrane systematic reviews [542, 543], both transforaminal and interlaminar
- 4618 epidural steroid injections were associated with a greater likelihood for a 'good' overall
- 4619 response at 3 months (68% and 53%, respectively) than paravertebral local anesthetic
- 4620 injections (26%), though it was not clear if the local anesthetic was administered at

- tender points [564]. Transforaminal epidural steroid injection was also superior to
- 4622 trigger point injection for the proportion of patients with a 'successful' outcome at 12 4623 months in one non-randomized study (84% vs. 48%) [570].
- 4624 Efficacy of epidural steroids versus other interventions
- 4625 One of the systematic reviews [544] included one small, lower-quality trial that found no
- 4626 differences between epidural steroid injection and dry needling of the interspinous
- 4627 ligament for the proportion of patients improved or cured according to clinician
- 4628 assessment (79% or 15/19 versus 83% or 10/12) [571].

4629 Three other recent trials not included in the systematic reviews also compared epidural 4630 steroid injection to other interventions (Table 56). One higher-quality trial found no 4631 significant difference in rates of subsequent surgery (41% vs. 31%) two years or longer 4632 following epidural steroid versus intramuscular steroid (methylprednisolone 80 mg) plus 4633 local anesthetic injection in patients with sciatica for at least six weeks [557]. Pain relief 4634 favored the epidural group at 35 days (p<0.004, other data not provided) but not at 4635 longer follow-up. In patients with a large herniated disc and no improvement for at least 4636 six weeks, one lower-guality trial found epidural steroid injection superior to discectomy 4637 for most short-term (1-3 months) outcomes, though significant benefits were no longer 4638 present for most outcomes by 2-3 years [554]. Results of this trial are difficult to 4639 interpret because about one-third of the patients assigned to epidural steroids crossed 4640 over to surgery, and no intention-to-treat results were presented. Among patients 4641 randomized to epidural steroids who did not cross over to surgery, 42% to 56% 4642 considered their treatment a success, compared to 92% to 98% in patients allocated 4643 surgery and 82% to 93% in patients who crossed over to surgery. A third trial found 4644 epidural steroid alone substantially inferior to adhesiolysis either with or without 4645 hypertonic saline for pain relief, functional status, opioid intake, and psychiatric outcome 4646 measures in patients with back pain for at least two years and no response to a 4647 previous epidural steroid [555]. However, even though this trial was rated higher-4648 guality, its reproducibility needs to be confirmed because of a very low response rate 4649 (>50% pain relief at 12 months) in the epidural steroid group (0%) and very high rates in 4650 the adhesiolysis groups (72% and 60%).

4651

Table 56. Additional trials of epidural steroids versus other interventions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Wilson-MacDonald, 2004[557]	N=93 2 years or longer	Epidural steroid versus intramuscular steroid plus local anesthetic Proportion of patients undergoing surgery after at least 2 years: 41% vs. 31%, p=0.45	7/11
Buttermann, 2004[554]	N=100 3 years	Epidural steroid versus discectomy Motor deficit: 72% vs. 38% at 1-3 months (p <0.05), 9% vs. 4% at 2-3 years (NS) Back pain, mean score (0 to 10 VAS): 3 vs. 2 at 1-3 months (p <0.05), 1.8 vs. 2.4 at 2-3 years (NS) Leg pain, mean score: 4.1 vs. 1.4 at 1-3 months (p <0.05), 0.8 vs. 1.5 at 2- 3years (NS) Oswestry, mean score: 34 vs. 22 at 1-3 months (p <0.05), 8 vs. 16 at 2-3 years (NS) Much less use of medication: 16% vs. 24% at 1-3 months, 57% vs. 32% at 2-3 years	3/11
Manchikanti, 2004[555]	N=75 12 months	Epidural steroid vs. adhesiolysis with hypertonic saline vs. adhesiolysis with isotonic saline Proportion with >50% pain relief at 12 months: 0% vs. 72% vs. 60% (p<0.001) ODI score at 12 months: 32 vs. 23 vs. 24 (p<0.001) VAS pain score (0 to 10) at 12 months: 7.7 vs. 4.6 vs. 5.2 Taking opioids: 52% vs. 16% vs. 16% (p<0.001)	8/11

4652

4653 Efficacy of different approaches for administering epidural steroids

4654 Four trials (none rated higher-quality) included in the systematic reviews [542, 543]

4655 compared different approaches for administering epidural steroids. Two trials [564, 572]

4656 found the transforaminal approach modestly superior to the interlaminar approach, but a

4657 third reported no differences in outcomes [573]. Radiologic confirmation of epidural

4658 placement with the interlaminar approach was either not reported or not performed in

4659 any trial. The fourth trial found no differences between the caudal and lumbar4660 interlaminar approaches [574].

4661 One higher-quality trial (not included in the systematic reviews) compared epidural

4662 steroid via the caudal approach versus targeted steroid placement during spinal

4663 endoscopy in patients with radicular back pain for at least six months, with needle

4664 placement confirmed by fluoroscopy for both methods (Table 57) [558]. It found no

4665 difference in any outcome between the two approaches.

4666 4667

Table 57. Trial of epidural steroid via caudal approach versus targeted placementduring spinal endoscopy

Author, year	Number of patients Duration of follow-up	Main results	Quality
Dashfield, 2005[558]	N=60 6 months	Epidural steroid via caudal approach versus targeted placement during spinal endoscopy Pain (VAS) mean improvement: -1.4 vs1.22 (NS) Present pain intensity, mean improvement: -0.8 vs1.0 (NS) Short-form McGill Pain Questionnaire (sensory), mean improvement: -2.3 vs. +0.5 (NS) Short-form McGill Pain Questionnaire (affective), mean improvement: 0 vs. 0 (NS) HAD-anxiety and -depression scales: no significant differences between groups	7/11

4668

4669 Safety

4670 Serious adverse events were rare in trials of epidural steroid injections, but adverse 4671 events were generally not well reported. One systematic review found that four of 15 4672 trials did not report adverse events, and another four reported no adverse events 4673 occurred [544]. Adverse events reported in the trials (typically transient and minor) 4674 included headache, nausea, irregular periods, pruritus, and increased sciatic pain. A 4675 recent, large (N=228), high-quality trial, reported post-injection headache in 3.3% 4676 (4/120) receiving epidural steroid, postdural puncture headache in 0.8% (1/120), nausea 4677 in 1.7% (2/120), and other adverse events in 4.2% (5/120) [556]. For the newer 4678 transforaminal approach, side effects were only reported in three of six trials [543]. One 4679 trial reported a 1.9% incidence of headache [564], one trial reported one episode of 4680 acute hypertension [573], and another reported one retroperitoneal bleed in a patient on 4681 anticoagulation [568]. Another trial found that all patients who underwent targeted 4682 placement of steroids during spinal endoscopy reported increased back pain, though no 4683 post-spinal headache, dural tap, or infection was observed [558]. Other adverse events 4684 associated with systemic corticosteroids include steroid myopathy, hyperglycemia, 4685 osteoporosis, avascular necrosis of bone, infection, and fluid retention.

4686 Costs

4687 One trial found no significant differences between transforaminal steroid and saline

4688 injections for cost per one response (\$3740 versus \$3629) [568]. However, a subgroup

4689 analysis suggested that the transforaminal steroid was more cost-effective for contained

4690 herniations (\$4432 versus \$17,098 per responder, p=0.0073) than for extrusions (\$7165 4691 versus \$2484, p=0.0058)

4692 Summary of evidence

- Evidence of beneficial effects following epidural steroid injections by interlaminar or caudal approaches in patients with sciatica is mixed, with some studies showing short-term benefits, but most trials (including two larger, high-quality trials) reporting no longer-term benefits. Most evidence is in patients with symptoms of at least one month's duration (level of evidence: fair).
- There is insufficient evidence (one lower-quality trial showing no benefit) to
 accurately judge the efficacy of epidural steroids in patients with low back pain
 without sciatica (level of evidence: fair).
- One higher-quality trial found that epidural steroids have no sustained effects on walking distance relative to a placebo injection in patients with spinal stenosis
 (level of evidence: fair).
- In one higher-quality randomized trial, epidural steroid injection was no better
 than trigger point injections at one month for overall outcomes, though modestly
 superior at three months. Other trials comparing epidural steroids and local
 injections were either not randomized or did not clearly inject tender points (level
 of evidence: fair).
- 4709 Epidural steroid injections were not clearly superior to intramuscular steroids for
 4710 long-term outcomes (level of evidence: fair).
- One higher-quality trial reported inferior outcomes with epidural steroid injection alone versus epidural adhesiolysis in patients with chronic back pain who previously failed an epidural injection, but reported high rates of response in the adhesiolysis group and unusually low rates in the epidural arm (0%) (level of evidence: fair).
- There is insufficient evidence (one lower-quality trial for each comparison) to accurately judge the relative efficacy of epidural steroids compared to dryneedling or discectomy (level of evidence: poor).
- 4719
 Several trials have found no clear differences between transforaminal and other approaches for administering epidural steroids, but lack of radiologic confirmation of epidural placement for the other approaches limits their interpretation (level of evidence: poor).
- One higher-quality trial found no differences between caudal epidural steroid and targeted steroid placement during spinal endoscopy, with needle placement confirmed by fluoroscopy for both methods (level of evidence: fair).

4700	
4726	Recommendations and findings from other guidelines
4727 4728	 The AHCPR guidelines found no evidence to support the use of invasive epidural injections of steroids, local anesthetics, and/or opioids as a treatment for acute
4729	low back pain without radiculography (strength of evidence: D).
4730	 The AHCPR guidelines recommend epidural steroids as an option for short-term
4731	relief of radicular pain after failure of conservative treatment and as a means of
4732	avoiding surgery (strength of evidence: C).
4733	The VA/DoD guidelines found limited evidence to support the use of epidural
4734	steroid injections for acute low back pain with nerve root pain and radicular
4735	neurologic deficit (strength of evidence: C).
4736	 The UK RCGP guidelines found that epidural steroids with or without local
4737	anesthetic appear to produce better short-term relief of acute low back pain with
4738	sciatica than comparison treatments (strength of evidence: **).
4739	The UK RCGP guidelines found limited evidence that epidural injections are not
4740	beneficial for acute low back pain without radiculopathy (strength of evidence: *).
4741	• The UK RCGP guidelines found that because of its invasive nature, epidural
4742	injections pose rare but serious potential risks (strength of evidence: **).
4743	The European COST guidelines recommend against epidural steroid injections
4744 4745	for acute nonspecific low back pain and found insufficient evidence to recommend epidural injections for chronic, nonspecific low back pain.
7775	
4746	Facet (zygapophysial) joint injections
4747	Results of search: systematic reviews
4748	One higher-quality Cochrane review (three trials, one higher quality [560]) evaluated the
4749	efficacy of facet joint injections in patients with chronic low back pain [540, 541]. We
4750	also identified two other recent systematic reviews [575, 576], neither of which identified
4751	any randomized trials not included in the Cochrane review, though both also included
4752	observational data.
4753	Results of search: trials
4754	We identified one lower-quality randomized trial not included in the systematic reviews
4755	that compared facet joint steroid injection versus medial branch block in patients with
4756	low back pain (duration of symptoms not specified) [577].

- 4757 Efficacy of facet joint injection versus control injection
- The lone high quality trial (N=101) included in the Cochrane review [540, 541] enrolled
- 4759 patients who responded to a single local anesthetic injection into the facet joint with

4761 patients randomized to steroid or saline either one or three months after the injection 4762 (RR 0.89, 95% CI 0.65 to 1.21 and RR 0.90, 95% CI 0.69 to 1.17, respectively). A 4763 higher proportion of patients in the corticosteroid injection group had marked or very 4764 marked improvement after six months (46% vs. 15%, p=0.002). There is no biologic 4765 explanation for a delayed benefit from steroids, which was attenuated after controlling 4766 for the increased use of co-interventions in the steroid group. The difference between 4767 groups in the proportion of patients with *sustained* improvement (improvement at one,

immediate pain relief [560]. There was no difference in the likelihood of pain relief in

- three, and six months) was not significant (22% vs. 10%, p=0.19), as half of the 22
- 4769 patients with improvement at 6 months had no benefits at earlier time periods. The
- 4770 second, lower-quality trial included in the Cochrane review found no difference in mean
- 4771 pain scores between steroid and/or bupivacaine injection compared to placebo [578].
- 4772 No diagnostic procedure was used to select patients for enrollment.
- 4773 The other two systematic reviews included several small (N<100), non-randomized
- 4774 studies (prospective or retrospective), most of which reported that around 50% of
- 4775 patients reported beneficial effects on pain through about three months, and the
- 4776 proportion reporting benefits decreasing with longer-term follow-up [575, 576].
- 4777 Efficacy of facet joint injection versus medial branch block
- 4778 One higher-quality trial included in the Cochrane review [540, 541] found facet joint
- 4779 injection with a steroid and local anesthetic not associated with superior pain relief
- 4780 compared to medial branch block of the posterior primary ramus after 1 to 3 months
- 4781 [579]. One lower-quality trial not included in the systematic reviews reported no benefit
- 4782 with either facet joint injection or medial branch block, but outcomes were reported
- 4783 using unconventional methods and difficult to interpret (paired sequential analysis)
- 4784 [577].

- 4785 Costs
- 4786 We found no studies evaluating costs.
- 4787 Safety
- 4788 No adverse events other than transient local pain at the injection sites were reported in
- 4789 the lone higher quality trial [560].

4790	Summary of evidence
4791	 Evidence from two randomized trials indicates that facet joint injections are not
4792	beneficial for short-term pain relief in patients with chronic low back pain, though
4793	there was a trend towards modestly superior sustained pain relief in the single
4794	higher-quality trial of patients with chronic low back pain (level of evidence: fair).
4795	 Two trials (one higher-quality) found no difference between facet joint injections
4796	and medial branch block.
4797	• There is no evidence on efficacy of facet joint injections for acute low back pain.
4798	Recommendations and findings from other guidelines
4799	 The AHCPR guidelines recommend against facet joint injections in patients with
4800	acute low back problems (strength of evidence: C).
4801	 The VA/DoD guideline recommendation is similar.
4802 4803 4804	• The UK RCGP guidelines found that facet joint injection do not produce pain relief or global improvement, with neither the type of agent injected nor the site of injection making a significant difference to outcomes (strength of evidence: *).
4805	 The UK RCGP guidelines also found no evidence on the efficacy of facet
4806	injections in acute low back problems (strength of evidence: *).
4807	Intradiscal steroid injections
4807	Intradiscal steroid injections
4808	Results of search: systematic reviews
	•
4808	Results of search: systematic reviews
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4813	Results of search: trials
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4813	Results of search: trials
4814	We identified three lower-quality RCTs and one non-randomized controlled trial
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4813	Results of search: trials
4814	We identified three lower-quality RCTs and one non-randomized controlled trial
4815	evaluating the efficacy of intradiscal steroid in patients with chronic discogenic low back
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4813	Results of search: trials
4814	We identified three lower-quality RCTs and one non-randomized controlled trial
4815	evaluating the efficacy of intradiscal steroid in patients with chronic discogenic low back
4816	pain [527, 580-582].
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4813	Results of search: trials
4814	We identified three lower-quality RCTs and one non-randomized controlled trial
4815	evaluating the efficacy of intradiscal steroid in patients with chronic discogenic low back
4816	pain [527, 580-582].
4817	Efficacy of intradiscal steroid versus control or no injection
4808	Results of search: systematic reviews
4809	We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid
4810	injections for patients with presumed chronic discogenic back pain. However, two RCTs
4811	comparing intradiscal steroids to chemonucleolysis with chymopapain were included in
4812	a good-quality Cochrane review of surgery for lumbar disc prolapse [519].
4813	Results of search: trials
4814	We identified three lower-quality RCTs and one non-randomized controlled trial
4815	evaluating the efficacy of intradiscal steroid in patients with chronic discogenic low back
4816	pain [527, 580-582].
4817	Efficacy of intradiscal steroid versus control or no injection
4818	In patients with MRI evidence of degenerative disc disease and positive discography,

4822 reporting longer-term outcomes, the median pain score was unchanged in both groups

4823 at one year [581]. A third trial found that in patients with degenerative disc disease who 4824 failed an epidural steroid injection, intradiscal steroid injection was superior to 4825 discography alone only in the subgroup of patients with inflammatory endplate changes 4826 on MRI [580]. However, changes in outcome scores and levels of statistical 4827 significance were poorly reported in this study. At 1-2 years, rates of 'success' (not 4828 clearly defined) in the subgroup with inflammatory endplate changes were 25% in 4829 patients randomized to discography plus intradiscal steroid, and 0% in the group 4830 randomized to discography alone. The proportion of patients who subsequently 4831 underwent fusion in this subgroup was 50% among those randomized to intradiscal 4832 steroid compared to 76% among those randomized to discography alone. Intradiscal 4833 steroid injection was also superior for functional status (ODI), though not for pain 4834 scores.

4835

Table 58. Trials of intradiscal steroids versus placebo injections

Author, year Khot, 2004[581]	Number of patients Duration of follow-up N=120 1 year	Main results Intradiscal methylprednisolone vs. intradiscal saline ODI, mean improvement (percent): 2.28 vs. 3.42 (p=0.71)	Quality 3 or
		VAS pain score (0 to 10), median change: 0 vs. 0 (p=0.72)	4/11
Buttermann, 2004[580]	N=171 1-2 years	Discography + intradiscal steroid vs. discography alone (estimated from graphs) Inflammatory end-plate changes present: Pain, mean improvement in VAS (0 to 10): -0.3 vs. +0.6 ODI (0 to 100), mean improvement: -18 vs. +9 "Success" (not defined): 10/40 (25%) vs. 0/38 (0%) Underwent fusion: 50% vs. 76% No inflammatory end-plate changes present: Pain, mean improvement in VAS: -1.2 vs. +0.6 ODI (0 to 100), mean improvement: -1 vs1 "Success" (not defined): 5/46 (11%) vs. 1/47 (2%) Underwent fusion: 78% vs. 89% Much less use of medication: 16% vs. 24% at 1-3 months, 57% vs. 32% at 2-3 years	4/11
Simmons, 1992[582]	N=25 10-14 days	Intradiscal methylprednisolone vs. intradiscal bupivicaine Proportion improved overall: 3/14 (21%) vs. 1/11 (9%) (NS) Proportion improved on VAS pain scale: 43% vs. 36% (NS) Proportion improved on ODI: 36% vs. 27% (NS)	5 or 6/11

- 4837 Efficacy of intradiscal steroid versus chemonucleolysis
- 4838 Two French-language trials [525, 526] included in the Cochrane review [518] found no
- 4839 differences between intradiscal steroid injection and chemonucleolysis in patients with
- 4840 sciatica (OR for failure or no improvement 1.20, 95% CI 0.61 to 2.38). One additional
- 4841 lower-quality, non-randomized controlled trial also reported similar rates of 'success'
- 4842 (defined as 'virtually pain-free') with intradiscal steroids or chemonucleolysis in patients
- 4843 with long-term back pain and sciatica unresponsive to conservative therapy (Table 59)
- 4844 [527].
- 4845

Table 59. Trial of intradiscal steroid versus chemonucleolysis

Author, year	Number of patients Duration of follow-up	Main results	Quality
Graham, 1975[527]	N=40	Intradiscal steroids vs. chemonucleolysis	4 or
	Not clear	"Success" (proportion virtually pain-free): 45% vs. 45%	5/11

4846 Safety

- 4847 None of the trials reported safety.
- 4848 Costs
- 4849 We found no studies evaluating costs.

4850 Summary of evidence

- There is consistent evidence from three low quality trials that intradiscal steroids are not associated with improved outcomes compared to control injections in patients with chronic low back pain with positive results on provocative discography (level of evidence: fair).
- One low quality trial found that intradiscal steroids are superior to discography
 alone in a selected subgroup of patients that failed epidural steroid injections and
 had inflammatory changes on MRI (level of evidence: poor).
- 4858
 4859
 4859
 4860
 4860
 4860
 4860
- None of the trials reported safety outcomes.

4862 **Recommendations and findings from other guidelines**

 4863
 The European COST guidelines recommend against intradiscal steroids for chronic low back pain. 4865 Local injections

- 4866 Results of search: systematic reviews
- 4867 We identified one higher-quality Cochrane review on the efficacy of local or trigger point
- 4868 injections (four relevant trials, one rated higher-quality [350] in patients with low back
- 4869 pain [540, 541]. Two other systematic reviews [542, 543] of epidural steroid injections
- 4870 included two trials (both lower-guality) comparing epidural steroids to local injections
- 4871 [564, 570].
- 4872 Results of search: trials
- 4873 We did not search for additional trials.
- 4874 Efficacy of trigger point injections versus saline injection
- 4875 The Cochrane review included three lower-quality trials that consistently found trigger
- 4876 point injections with a local anesthetic superior to saline injection for short-term pain
- 4877 relief in patients with subacute or chronic low back pain for short-term pain relief.
- 4878 However, the injections evaluated appeared to be heterogeneous: one evaluated an
- 4879 injection over the iliac crest [583], one evaluated injections over the iliolumbar ligament
- 4880 [584], and one evaluated trigger point injections [585]. A fourth trial compared trigger
- 4881 point injection to a single dry acupuncture needlestick, which we considered an active
- 4882 control (see below) [227]. Another trial included in the Cochrane review evaluated the
- 4883 efficacy of prolotherapy and is not discussed further here [586].
- 4884 Efficacy of trigger point injection versus other interventions
- 4885 The Cochrane review [540, 541] included one lower-quality trial that found a trigger
- 4886 point injection (with steroid, lidocaine, or both) inferior to a single dry acupuncture
- 4887 needelestick for achieving short-term improvement in pain scores, though the
- 4888 differences were not statistically significant (RR =0.64, 95% CI 0.35 to 1.16) [227].
- 4889 Evidence on the efficacy of trigger point injections versus epidural steroid injections is
- 4890 reviewed in the section on epidural steroids.
- 4891 Efficacy of trigger point injection with a local anesthetic versus a steroid
- 4892 The Cochrane reviewed included one higher-quality trial that found no difference
- 4893 between trigger point injection with a local anesthetic versus a local anesthetic plus a
- 4894 steroid [350].

4895 Safety 4896 One placebo-controlled trial reported no adverse events [585] and another didn't report 4897 adverse events [584]. In two other trials adverse events in patients receiving local 4898 injections included pain at the injection site, temporary paresthesia, and nausea (in both 4899 active and control injection groups) [227, 583]. 4900 Costs 4901 We identified no studies evaluating costs. 4902 Summary of evidence 4903 • There is consistent evidence from three lower quality trials that trigger point 4904 injection with a local anesthetic is superior to saline injection for short-term pain 4905 relief in patients with subacute or chronic low back pain (level of evidence: fair). 4906 There is no evidence on long-term pain relief. • 4907 One low-quality trial found trigger point injection inferior to a dry needle 4908 acupuncture stick (level of evidence: poor). 4909 • Using a steroid in place of a local anesthetic or adding a steroid to a local 4910 anesthetic did not result in superior outcomes in one higher-guality trial (level of 4911 evidence: fair). 4912 See section on epidural steroids for comparison between local injections and 4913 trigger point injections. 4914 Recommendations and findings from other guidelines 4915 The AHCPR guidelines recommend against invasive trigger point injections in the 4916 treatment of patients with acute low back problems (strength of evidence=C). 4917 The VA/DoD guideline recommendations are similar. • 4918 The UK RCGP guidelines found that studies of trigger point injections included • patients with chronic low back pain, and findings were equivocal, with little 4919 4920 evidence specifically in acute low back pain patients (strength of evidence: *). 4921 The European COST guidelines found insufficient evidence to recommend • 4922 trigger point injections for chronic low back pain. 4923 Prolotherapy 4924 Prolotherapy (also referred to as sclerotherapy) is a technique involving the 4925 repeated injection of irritants into ligaments and tendinous attachments in order to 4926 trigger an inflammatory response that will subsequently lead to the strengthening of 4927 ligaments and decrease in pain and disability. Prolotherapy injections are often

- 4928 supplemented by co-interventions such as trigger point injections, manipulation, and
- 4929 exercises that are thought to enhance the effectiveness of treatment. Anti-
- 4930 inflammatories are often discouraged because they are thought to potentially suppress
- 4931 the desired inflammatory response to the irritants.
- 4932 Results of search: systematic reviews
- 4933 We identified one recent, higher-quality Cochrane review (four trials, all higher quality)
- 4934 evaluating the efficacy of prolotherapy in patients with chronic low back pain [587].
- 4935 Results of search: trials
- 4936 We did not search for additional trials.
- 4937 Efficacy of prolotherapy versus control injections
- 4938 The Cochrane review included three higher-quality trials that evaluated the efficacy of 4939 prolotherapy versus control injections [588-590]. In the only trial to show a significant 4940 benefit with prolotherapy for the proportion of patients with short-term improvement in 4941 pain or disability (RR 1.47, 95% CI 1.04 to 2.06), both groups also received forceful 4942 manipulation, injection of gluteal tender points, flexion and extension exercises, and 4943 walking as co-interventions [589]. In the other two trials, there was no difference 4944 between prolotherapy and either saline or local anesthetic control injections for short- or 4945 long-term (up to 24 months) improvement in pain or disability [588, 590]. A fourth trial 4946 was included in the Cochrane review, but the effects of prolotherapy could not be 4947 determined because the prolotherapy group received strong manipulation and the
- 4948 control injection group only received light manipulation [586].
- 4949 Safety
- 4950 In three [586, 589, 590] of the four trials, nearly all participants had temporary increases
- 4951 in back pain and stiffness following injections. Post-injection headaches suggestive of
- 4952 lumbar puncture occurred in two to four percent of patients in two trials [589, 590].
- 4953 Other adverse events included postmenopausal spotting, leg pain (attributable to
- herniated disc), diarrhea, and other, generally transient symptoms, but there were no
- 4955 significant differences in any adverse event between treatment and control groups.
- 4956 *Costs*
- 4957 We found no studies evaluating costs.

4958	Summary of evidence
4959 4960 4961	 There is conflicting evidence on the efficacy of prolotherapy versus control injections for chronic low back pain from three higher-quality trials (level of evidence: fair).
4962	 There is no evidence in patients with acute low back pain.
4963 4964 4965	 Serious adverse events have not been reported following prolotherapy treatments, though nearly all patients report increases in back pain (level of evidence: fair).
4966	Recommendations and findings from other guidelines
4967 4968	 The AHCPR guidelines recommend against ligamentous and sclerosant injections for patient with acute low back problems (strength of evidence: C).
4969	 The VA/DoD and UK RCGP guideline recommendations are similar.
4970 4971	 The European COST guidelines recommend against injections of sclerosants (prolotherapy) for nonspecific chronic low back pain.
4972	Sacroiliac joint injection
4973	Results of search: systematic reviews
4974	We identified one lower-quality systematic review on sacroiliac joint injections [591]. It
4975	included only one small (N=24) trial of patients with low back pain not due to
4976	spondyloarthritis [592].
4977	Results of search: trials
4978	We identified no additional trials.
4979	Efficacy of sacroiliac joint injection versus control injection
4980	One small (N=24), higher-quality trial found a sacroiliac steroid injection superior to
4981	control (local anesthetic) injection for improvement in one-month pain scores in patients
4982	with chronic pain in the sacroiliac joint area and at least one positive physical exam

4983 finding (Table 60) [592].

4984

4984 4985

able 60. Trial on efficacy of sacroiliac joint injections in patients with suspected sacroiliac joint pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
· • •			Quality
Luukainen, 2002[592]	N=24	Sacroiliac joint steroid injection vs. control injection	
	1 month	VAS (0 to 100), improvement in median scores: -40 vs.	
		013, p=0.046	6/11
		Pain index (0 to 12), improvement in median scores: -3	
		vs. 0, p=0.017	

- 4986 Safety
- 4987 Adverse events were not reported in the trial.
- 4988 Costs
- 4989 We found no trials evaluating costs.
- 4990 Summary of evidence
- One higher-quality but very small trial found sacroiliac joint steroid injection
 superior to local anesthetic injection for short-term pain relief in patients thought
 to have non-spondylarthropathic sacroiliac pain (level of evidence: poor).

4994 **Recommendations and findings from other guidelines**

4995
 The European COST guidelines found insufficient evidence to recommend the use of corticosteroid injections for nonspecific chronic low back pain.

4997Botulinum toxin

- 4998 Results of search: systematic reviews
- 4999 We identified no systematic review evaluating the effectiveness of botulinum toxin for
- 5000 low back pain.
- 5001 Results of search: trials
- 5002 Two small studies (one higher-quality RCT [593] and one lower-quality, non-randomized
- 5003 trial [594]) evaluated botulinum toxin injections for chronic low back pain. We identified
- 5004 no trials evaluating the effectiveness of botulinum toxin for acute or subacute low back
- 5005 pain.
- 5006 Efficacy of botulinum toxin versus saline injection or no injection
- 5007 A small (N=31), higher-quality RCT found botulinum toxin A superior to saline injection
- 5008 for short-term pain relief (proportion of patients with >50% pain relief 73% vs. 25% at 3
- 5009 weeks, p=0.012, and 60% vs. 12.5% at 8 weeks, p=0.09), as well as for improvement in

- 5010 functional impairment (proportion with improvement in ODI score 67% vs. 19%,
- 5011 p=0.011) in patients with chronic low back pain who failed to respond to standard
- treatments (Table 61) [593]. However, 60% of patients with a response to botulinum
- 5013 toxin responded cessation of benefits after three to four months. A second, lower-
- 5014 quality non-randomized trial (N=19) found botulinum toxin superior to no injection for
- 5015 improvement in pain, though differences in functional status and work outcomes were
- 5016 not significant [594].
- 5017

Table 61. Trials of botulinum toxin versus saline injection or no injection

Author woor	Number of patients Duration of	Moin require	Quality
Author, year	follow-up N=19	Main results	Quality
Subin, 2003[594] (non-randomized study)	6-12 months	Botulinum toxin A vs. no treatment Pain, proportion improved on McGill-Melzack score: 78% (7/9) vs. 0% (0/10) (p<0.05) Disability, proportion improved on Oswestry score: 56% (5/9) vs. 10% (1/10) (NS) Proportion that missed work and were disabled: 11% (1/19) vs. 50% (5/10) (NS)	3/11
Foster, 2001[593] (randomized trial)	N=31 8 weeks	Botulinum toxin A vs. saline injection Degree of pain relief >50%: 73% (11/15) vs. 25% (4/16) at 3 weeks (p =0.012), 60% (9/15) vs. 12.5% (2/16) at 8 weeks (p =0.009) Oswestry score, proportion with improvement at 8 weeks: 67% (10/15) vs. 19% (3/14) (p =0.011) 6/10 responders in botulinum toxin A group reported cessation of analgesic effect after 3 to 4 months	9/11

5018

5019 Safety

5020 No side effects were reported in the single RCT [593]. However, a case of fatal

- anaphylaxis following injection of botulinum toxin A for chronic neck and back pain has
- 5022 been reported [595].
- 5023 Costs
- 5024 We identified no studies evaluating costs.

5025 Summary of evidence

- A single, small, higher-quality trial found botulinum toxin injection superior to
 saline injection for short-term pain relief and improvement in functional status in
 patients with chronic low back pain who failed to respond to standard treatments
 (level of evidence: fair).
- There is no evidence comparing botulinum toxin injection to other interventions.

- There is no evidence on effectiveness of botulinum toxin injection in patients with acute low back pain.
- There is insufficient evidence to judge safety of botulinum toxin in patients with low back pain, though one case of fatal anaphylaxis has been reported.

5035Radiofrequency Denervation, Intradiscal Electrothermal Therapy, and5036Percutaneous Intradiscal Radiofrequency Thermocoaglulation

5037 Radiofrequency denervation

- 5038 Results of search: systematic reviews
- 5039 We identified a recent, higher-quality Cochrane review (seven RCTs, six rated higher-
- 5040 quality) on efficacy of radiofrequency denervation in patients with chronic low back pain
- 5041 [596, 597]. We also identified three other systematic reviews, none of which identified
- additional trials not included in the Cochrane review [575, 576, 598]. We excluded one
- 5043 systematic review [599] because it has already been updated [575]. Another systematic
- 5044 review was excluded because it focussed on technical aspects and did not evaluate
- 5045 efficacy [600].
- 5046 Results of search: trials
- 5047 We identified three recent randomized trials not included in the systematic reviews.
- 5048 Two higher-quality trials evaluated the efficacy of radiofrequency denervation for facet
- 5049 joint [601] or radicular low back pain [602], and one lower-quality trial evaluated the
- 5050 efficacy of radiofrequency denervation for discogenic pain [603].
- 5051 Efficacy of radiofrequency denervation of the medial branch of the primary dosal ramus 5052 versus sham or placebo for facet joint pain
- 5053 The Cochrane review included three small (sample sizes 31 to 70) RCTs of patients
- 5054 with positive responses to facet joint testing (facet joint or dorsal ramus nerve block), all
- 5055 evaluating radiofrequency denervation of the medial branch of the primary dorsal rami
- 5056 [604-606]. The two higher-quality trials reported conflicting results [605, 606]. In one,
- 5057 patients randomized to radiofrequency denervation experienced greater improvement
- 5058 relative to patients randomized to sham on mean VAS pain scores (-2.4 vs. -0.4 on a 0
- to 10 scale, p<0.05) and Oswestry scores (-11.1 vs. +1.7, p<0.05) through 2 months
- 5060 (van Kleef 1999). In addition, a higher proportion of patients randomized to
- 5061 radiofrequency denervation reported at least a 2 point reduction in VAS pain score and
- 5062 greater than 50 percent improvement in global effect (67% vs. 37.5%, p=0.003). In the
- 5063 other high quality trial, the radiofrequency denervation group had greater improvement

in RDQ mean scores at four weeks compared to sham (-8.4 vs. -2.2, p=0.05), though
not in Oswestry or VAS pain scores [605]. At twelve weeks, the difference in RDQ
scores was no longer significant. Results of the third trial could not be reliably
interpreted because of low quality, including lack of intention-to-treat analysis [604].

5068 Two of the three non-Cochrane systematic reviews came to similar conclusions about 5069 uncertain benefits from radiofrequency denervation [576, 598]. The third systematic 5070 review [575] came to more optimistic conclusions regarding benefits of radiofrequency 5071 denervation, largely because it excluded the high-quality trial [605] with neutral findings 5072 because it used a single block to identify patients with facet joint pain. However, this 5073 leaves only a single small trial demonstrating short-term benefits [606]. In addition, 5074 even though this systematic review used a liberal definition for a 'positive' response (at 5075 least 50% of patients in observational studies reported some pain relief), half of the six 5076 observational studies included in this review reported 'negative' results.

5077 One higher-quality trial (N=82) of radiofrequency denervation in patients with positive 5078 facet joint testing has been published since the systematic review (Table 62) [601]. It 5079 found no differences between radiofrequency denervation and sham intervention for the 5080 proportion of patients with success (27.5% vs. 29.3%), VAS pain scores, or other 5081 outcomes after three months. About one-fifth of the 462 patients initially approached for 5082 possible inclusion were enrolled in this trial.

5083 Table 62. Additional trial of radiofrequency denervation in patients with positive facet joint testing

Author, year	Number of patients Duration of follow-up	Main results	Quality
Van Wijk, 2005[601]	N=81 3 months	Radiofrequency denervation vs. sham injection Clinical success (defined as at least 50% improvement in VAS-leg score, without drop in daily activities score or rise in analgesics rating scale, or improvement of at least 2% in VAS-leg score, daily activities score, and analgesic use score) at 3 months: 28% vs. 29% (p=0.86) Leg pain, change in VAS (0-10) score: -1.1 vs0.7 (NS) Back pain, change in VAS (0-10) score: -2.1 vs. 01.6 (NS) Change in daily activities: 1.5 vs. 0.9 (NS) Change in analgesics use: -0.1 vs0.2 (NS)	10/11

5084

- 5085 Efficacy of radiofrequency denervation of the ramus communicans nerve versus sham 5086 or placebo for discogenic
- 5087 One lower-quality trial of patients with positive discography who had failed IDET found
- 5088 radiofrequency neurotomy of the ramus communicans nerves associated with better
- 5089 mean VAS pain scores compared to lidocaine injection (3.8 vs. 6.3, p<0.05) as well as
- 5090 SF-36 bodily pain (43.7 vs. 32.4, p<0.05) and physical function (58.9 vs. 46.5, p<0.05)
- 5091 scores at 4 months (Table 63) [603].
- 5092

Table 63. Trial of radiofrequency denervation of the ramus communicans nerve

Author, year	Number of patients Duration of follow-up	Main results	Quality
Oh, 2004[603]	N=49 4 months	Radiofrequency denervation vs. lidocaine injectionPain, mean VAS (0-10) score at 4 months: 3.8 vs. 6.3(p<0.05)	5/11

- 5093
- 5094 *Efficacy of radiofrequency denervation versus sham or placebo for radicular low back* 5095 pain
- 5096 One higher-quality trial of patients with chronic (>6 months) radicular pain and a positive
- 5097 nerve block found no difference between radiofrequency denervation of the dorsal root
- 5098 ganglia and sham treatment for the proportion with clinical success (16% vs. 25%,
- 5099 p=0.43), SF-36 scores, or use of analgesics (Table 64) [602]. There was a trend
- 5100 towards a higher proportion of patients in the sham intervention group reporting >50%
- 5101 reduction in VAS-pain scores for the leg (21% vs. 42%, p=0.051). The population
- 5102 evaluated appeared to be highly selected (1001 approached and only 83 enrolled).

5103Table 64. Trial of radiofrequency denervation in patients with chronic radicular pain and positive5104nerve block

Author, year	Number of patients Duration of follow-up	Main results	Quality
Geurts,	N=83	Radiofrequency denervation vs. sham	
2003[602]	3 months	Clinical success (see definition in van Wijk above): 16% vs. 25% (p=0.43)	
		Leg pain, change in VAS (0-10) score: -0.7 vs2.0 (p=0.02)	9 or
		Back pain, change in VAS (0-10) score: -0.6 vs1.1 (p=0.32)	10/11
		Change in daily activities: -0.5 vs0.4 (p=0.85)	
		Change in analgesics use: 0.1 vs0.2 (p=0.23)	

5105 Safety

- 5106 None of the trials [604-606] included in the systematic reviews reported adverse events
- 5107 [596, 597]. In three other recent trials, adverse events were not reported [601], did not
- 5108 differ between treatment and sham [602], or consisted of one case of subjective mild
- 5109 lower limb weakness that resolved within two weeks [603].
- 5110 Costs
- 5111 We found no studies evaluating costs.

5112 Summary of evidence

- The evidence on the efficacy of radiofrequency denervation of the medial branch of the primary dorsal ramus in patients with a positive facet joint block is mixed, with two of three higher quality trials showing no benefits compared to sham or control injection, even in highly selected populations (level of evidence: fair).
- Radiofrequency denervation was not effective in one higher quality trial of highly
 selected patients with chronic radicular pain and a positive nerve block (level of
 evidence: fair).
- Radiofrequency denervation of the ramus communicans nerve was superior to
 sham in patients with positive discography in one lower-quality trial (level of
 evidence: poor).
- Adverse events were poorly reported, but serious adverse events have not yet
 been observed following radiofrequency denervation.

5125 **Recommendations and findings from other guidelines**

• The European COST guidelines found insufficient evidence to recommend 5127 radiofrequency denervation of dorsal root ganglion for chronic low back pain.

5128 Intradiscal electrothermal therapy (IDET)

- 5129 Results of search: systematic reviews
- 5130 We identified one recent, good-quality Cochrane review (two higher-quality trials [607,
- 5131 608]) of IDET for chronic low back pain [609, 610]. We also found two other systematic
- 5132 reviews that did not include any trials not included in the Cochrane review, but did
- 5133 review observational data [611, 612]. We considered IDET and a similar procedure,
- 5134 percutaneous intradiscal radiofrequency ablation, separately (see below). We excluded
- 5135 three other review articles that were not clearly systematic [613-615].
- 5136 Results of search: trials
- 5137 We did not search for additional trials.

- 5138 Efficacy of intradiscal electrothermal therapy versus sham
- 5139 The Cochrane review included two higher quality trials of IDET versus sham (N=57 and
- 5140 N=64) in patients with chronic low back pain and positive provocative lumbar
- 5141 discography that reported conflicting results [607, 608]. In one trial, patients
- 5142 randomized to IDET reported modestly superior improvements in mean VAS pain
- 5143 scores (0-10 scale, mean change 2.4 vs. 1.1, p=0.0045) and ODI scores (0 to 100
- 5144 scale, mean change 11 vs. 4, p=0.050), but no differences in SF-35 bodily pain or
- 5145 physical functioning subscales [608]. The proportion of patients with at least a two-point
- 5146 improvement in VAS pain scores was 56% (18/32) with IDET compared to 38% (9/24)
- 5147 with sham. The trial appeared to evaluate a highly selected subset of patients, as only
- 5148 64 patients from a potential cohort of 4253 were enrolled. By contrast, in the other trial,
- 5149 there were no differences between IDET and sham on the Low Back Pain Outcome
- 5150 Score, Oswestry Score, SF-36, or Zung Depression Index [607]. A third trial was
- 5151 excluded because it only compared two different durations of thermocoagulation, but
- 5152 found minimal improvement with either intensity of IDET [616].

5153 The two other systematic reviews did not identify any additional trials but also included 5154 observational studies. In the only controlled observational study, IDET was associated

5155 with better VAS pain scores at 3 months (3.5 vs. 8.0, p<0.0005) and 24 months (3.0 vs.

- 5156 7.5, p=0.028), as well as a higher proportion pain-free at 24 months (20% or 7/35 vs.
- 5157 0% or 0/17) [617].
- 5158 Safety
- 5159 Most studies of IDET reported transient and mild complications ranging in incidence
- 5160 from 0% (0/58) to 15% (5/33) [618]. These included increased radicular pain (5/33),
- 5161 paresthesias and numbress (2/79), and foot drop (1/79). In one study, one patient
- 5162 developed a CSF leak [619]. There have also been case reports of cauda equina
- 5163 syndrome and vertebral osteonecrosis [618].
- 5164 Costs
- 5165 We found no studies evaluating costs.

5166 Summary of evidence

• There is conflicting evidence from two higher-quality trials on the efficacy of IDET 5168 relative to sham in patients with chronic low back pain with positive provocative

- 5169discography. In the one trial reporting benefits from IDET, benefits were modest5170despite the evaluation of a highly selected population (level of evidence: fair).
- Complications associated with IDET were poorly reported but generally appeared
 mild or transient, though there are case reports of cauda equina syndrome and
 vertebral osteonecrosis after IDET (level of evidence: poor).
- 5174 **Recommendations and findings from other guidelines**
- The European COST guidelines found insufficient evidence to recommend IDET 5176 for nonspecific or 'discogenic' chronic low back pain.
- 5177 Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)
- 5178 Results of search: systematic reviews
- 5179 One higher-quality Cochrane review (one higher-quality trial [620]) evaluated the
- 5180 efficacy of PIRFT for chronic low back pain [609, 610]. We also identified two other
- 5181 systematic reviews, neither of which identified additional trials not included in the
- 5182 Cochrane review [611, 612].
- 5183 Results of search: trials
- 5184 We did not search for additional trials.
- 5185 Efficacy of PIRFT versus sham therapy for chronic low back pain
- 5186 The Cochrane review included one small (N=28) trial of discogenic low back pain
- 5187 (positive response to analgesic discography) [620]. It found no significant differences
- 5188 between radiofrequency denervation and sham therapy (two treatment successes in
- 5189 active treatment group and one in the sham group).
- 5190 Safety
- 5191 No adverse events were reported in the single published trial [620].
- 5192 Costs
- 5193 We found no studies evaluating costs.
- 5194 Summary of evidence
- One small, low-quality trial found no differences between PIRFT and sham in patients with a positive response to analgesic discography (level of evidence: 5197 poor).
- There is insufficient data to judge the safety of PIRFT.

- 5199 **Recommendations and findings from other guidelines**
- The European COST guidelines found insufficient evidence to recommend
 PIRFT for nonspecific or 'discogenic' chronic low back pain.

5202 Key Question 8.

5203What is the effectiveness of surgery (and different surgical interventions) for non-5204specific low back pain, radicular low back pain, or spinal stenosis, and under

- 5205 what circumstances?
- 5206 Results of search: systematic reviews

5207 We identified a recently updated (2005), higher-quality Cochrane review (31 trials) on 5208 the efficacy of surgery for degenerative lumbar spondylosis (defined by the authors of

- 5209 the review as degenerative conditions affecting the intervertebral discs, vertebrae,
- 5210 and/or associated joints, including associated instability, spinal stenosis, and/or
- 5211 degenerative spondylolisthesis) [609, 610]. Another higher-quality Cochrane review
- 5212 (last updated December 1999) evaluated the efficacy of surgery for lumbar disc
- 5213 prolapse (27 trials) [518]. Both Cochrane reviews noted numerous methodological
- 5214 shortcomings in nearly all of the included surgical trials (lack of blinded outcomes
- 5215 assessment, poorly described randomization techniques, poor allocation concealment,
- 5216 short duration of follow-up, absence of standardized clinical outcomes). Seven other
- 5217 systematic reviews addressing surgery for low back pain have been published since
- 5218 2000 [621-627], but only included one trial (published only as an abstract [628]) not
- 5219 already in the Cochrane reviews. We excluded five older systematic reviews [521, 629-
- 5220 632].
- 5221 Results of search: trials

5222 We identified one recent randomized trial (not included in the systematic reviews)

- 5223 comparing surgical stabilization with non-surgical management of chronic low back pain
- 5224 [633]. We also included three reports from two randomized trials on artificial disk
- 5225 replacement versus fusion for chronic low back pain [634-636]. Results of the
- 5226 multicenter Spine Patient Outcomes Research Trials (three concurrent randomized
- 5227 trials of patients with sciatica, spinal stenosis, or degenerative spondylolisthesis) have
- 5228 not yet been published [637].

DRAFT – for Peer Review only

APS Clinical Guidelines for the Management of Low Back Pain

5229 Efficacy of surgery versus non-surgical management

5230 Degenerative conditions of the lumbar spine (not including spinal stenosis)

5231 The Cochrane review of surgery for degenerative conditions [609, 610]included two 5232 higher quality trials [638-640] comparing surgery to non-surgical management in 5233 patients with chronic (>1 year) low back pain without neurological compromise (spinal 5234 stenosis or nerve root compression) (Table 65). In the larger (N=294), Swedish trial, 5235 independent assessors rated outcomes as 'excellent' or 'good' after 2 years in 46% of 5236 patients with chronic back pain randomized to fusion versus 18% in the usual care 5237 group (p<0.0001), and more of the surgical patients rated their results as 'better' or 5238 'much better' (63% vs. 29%, p<0.0001) [640]. The surgical patients also had 5239 significantly greater improvements in pain and disability scores, and a higher proportion 5240 back to work (36% vs. 13%, p=0.002). By contrast, the smaller Norwegian trial found no 5241 differences in any of the main outcomes after one year among chronic (>1 year) low 5242 back pain patients either with (N=60) or without (N=64) prior discectomy randomized to 5243 posterolateral fusion with transpedicular screws versus an educational intervention plus 5244 intensive exercise based on cognitive-behavioral principles [638, 639].

A recent, high-quality pragmatic trial compared spinal fusion (technique left to the discretion of the surgeon) to intensive multidisciplinary rehabilitation in patients with chronic low back pain considered candidates for surgical fusion (with or without sciatica) [633]. It found surgery associated with statistically greater improvements in Oswestry scores (mean difference between interventions -4.1, 95% Cl -9.1 to -0.1, p=0.045) that barely met predefined criteria for minimal clinically important difference. There were no differences in other outcomes, including SF-36 scores and the shuttle walking test.

5252

5252

Table 65. Trials of surgery versus non-surgical management of chronic low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Fairbank, 2005[633]	N=349 2 years	Surgery versus intensive rehabilitation ODI score, mean difference between interventions: -4.1 (- 9.1 to -0.1, p=0.045) SF-36: no differences	7/9
Brox, 2006[638]	N=60 (prior discectomy) 1 year	Surgery versus intensive rehabilitation ODI score, mean difference between interventions: -7.3 (- 17.3 to 2.7) Back pain, mean difference between interventions: -5.2 (- 18.0 to 7.6) Overall rating 'success': 50% vs. 48%, p=0.91	7/9
Brox, 2003[639]	N=64 (no prior discectomy) 1 year	Surgery versus intensive rehabilitation ODI score, mean difference between interventions: 2.3 (- 6.8 to 11.4) Back pain, mean difference between interventions: 8.6 (- 3.0 to 20.1) Overall rating 'success': 71% vs. 63%, p=0.59	8/9
Fritzell, 2001[640]	N=294 2 years	Surgery versus physical therapy Back pain VAS score, mean difference compared to baseline (0 to 100 scale): 21.0 vs. 4.3, p=0.0002 ODI score, mean: 11.6 vs. 2.8, p=0.015 Overall rating 'better' or 'much better': 63% vs. 29%, p<0.0001	8/9

5253

5254 One potential explanatory factor for the inconsistent results between trials is the non-5255 surgical treatment chosen as the comparator. In the Swedish trial, one of the criteria for

5256 enrollment was failure of non-surgical treatment, but the control group appeared to

5257 receive similar non-surgical treatments after randomization [640]. In the other trials, by 5258 contrast, non-surgical management consisted of intensive rehabilitation interventions

- 5259 incorporating cognitive behavioral components [303, 304], which might explain why they
- 5260 performed better relative to surgery.

5261 Spinal stenosis

The Cochrane review [609, 610] included a small (N=31), higher quality randomized trial 5262 5263 that found that the proportion of patients with an overall outcome rated 'good' was 5264 higher in patients randomized to initial surgical treatment (69% vs. 33% at 1 year, 92% 5265 vs. 47% at 4 years, 91% vs. 71% at 10 years) (Table 66) [641]. Interpretation of these 5266 results, however, is complicated by the fact that 10 of the 18 patients randomized to 5267 non-surgical treatment had subsequent surgery (none of the patients randomized to 5268 surgery underwent reoperation). In an observational cohort of patients evaluated 5269 alongside the randomized trial, the benefits of surgery also became attenuated over

time, with the overall outcome after 1 year judged 'good' in 89% of patients initially
receiving surgery vs. 64% initially receiving non-surgical management and 71% vs. 73%
after 10 years.

5273 Results of a recent, higher-quality, long-term (8 to 10 years) prospective observational 5274 study (N=148) of patients with spinal stenosis (the Maine Lumbar Spine Study) were 5275 consistent with the randomized trial [642]. It found that the proportion of patients with 5276 improvement in their predominant symptom was greater with initial surgery compared to 5277 non-surgical therapy after 1 and 4 years (55% vs. 28%, p=0.003 and 70% vs. 52%, 5278 p=0.05, respectively), but not after 8 to 10 years (54% vs. 42%, p=0.3) [642-644]. 5279 Satisfaction with current status was also similar with long-term follow-up (55% vs. 49%, 5280 p=0.5). However, back-related functional status persistently favored initial surgical 5281 treatment (mean change after 8 to 10 years -7.3 vs. -1.2 on modified RDQ scale, 5282 p=0.02). Among patients initially undergoing surgery, 23% underwent reoperation, and 5283 among patients initially receiving nonsurgical treatment, 39% subsequently underwent 5284 surgery.

5285 One other lower-quality RCT found that an interspinous spacer device was superior to 5286 non-surgical treatment (epidural injection, NSAIDs, analgesics, physical therapy) for the 5287 proportion of patients classified as treatment successes (59% vs. 12%, p<0.05) and on 5288 all SF-36 subscales after 1 year [645].

5289

Table 66. Trials of surgery versus non-surgical treatment for spinal stenosis

Author, year	Number of patients Duration of follow-up	Main results	Quality
Amundsen, 2000	N=31 10 years	Surgical decompression versus non-surgical treatment Proportion with 'good' results: 9/13 (69%) vs. 6/18 (33%) at 1 year; 11/12 (92%) vs. 8/17 (47%) at 4 years; 10/11 (91%) vs. 12/17 (71%) at 10 years (p values not reported)	6/9
Zucherman, 2004	N=200 1 year	Interspinous implant versus non-surgical treatment Treatment success: 59% vs. 12% (p<0.05)	3/9

5290 Isthmic spondylolisthesis

5291 One lower-quality trial included in the Cochrane review compared posterolateral fusion

to an exercise program and found that surgery was associated with less pain (mean

5293 score 37 vs. 56, p=0.002) and disability (mean Disability Rating Index 29 vs. 44,

p=0.004) and better patient-rated outcomes (74% vs. 43% better or much better) after 2
years in patients with lumbar isthmic spondylolisthesis and low back pain for at least
one year, though there were no significant difference in work-related outcomes (46% vs.
45% working) (Table 67) [646]. Outcomes associated with relief of sciatica from
foraminal stenosis (the generally accepted indication for surgery in patients with this
condition) were not reported.

5300

Table 67. Trial of surgery versus non-surgical treatment for isthmic spondylolisthesis

Author, year	Number of patients Duration of follow-up	Main results	Quality
Moller, 2000	N=114	Posterolateral fusion versus exercise program	
	2 years	Disability Rating Index, mean score: 29 vs. 44, p=0.004	
		Pain score, mean: 37 vs. 56, p=0.002	4/9
		Overall outcome 'much better' or 'better': 74% vs. 43% (p	
		not reported)	

5301

5302 Lumbar disc prolapse

5303 The Cochrane review of surgery for lumber disc prolapse [518] included one lower-

quality trial [647] comparing surgery to non-surgical treatment for lumbar disc prolapse

5305 in patients without definite indications for surgery that failed to improve with

5306 conservative management (Table 68). It found discectomy associated with a lower

5307 likelihood of poor results at 1 year (OR 0.38, 95% CI 0.14 to 0.99) but not after 4 or 10

5308 years (OR 1.21, 95% CI 0.42 to 3.45 and OR 1.21, 95% CI 0.29 to 5.10, respectively).

5309 However, one-quarter of the patients randomized to conservative management

5310 eventually underwent surgery.

5311

5311

Table 68. Trial of surgery versus non-surgical treatment for lumbar disc prolapse

Author, year	Number of patients Duration of follow-up	Main results	Quality
Weber, 1983	N=126 10 years	Surgery versus non-surgical treatment 'Good' result (patient completely satisfied): 36% (24/66) vs. 65% (39/60) at 1 year, 52% (34/66) vs. 70% (40/57) at four years, 56% (37/66) vs. 64% (35/55) at ten years 'Poor' or 'bad' result: 21% (14/66) vs. 8% (5/60) at 1 year, 12% (8/66) vs. 14% (8/57) at 4 years, 6% (4/66) vs. 7% (4/55) at 10 years Relapses: 24% (14/58) vs. 15% (8/54) after 0-4 years, 19% (11/58) vs. 27% (13/48) after 4 to 10 years Proportion with no low back pain: 58% (38/66) vs. 60% (36/60) at 4 years, 79% (52/66) vs. 84% (43/51) at 10 years Proportion with no radiating pain: 68% (45/66) vs. 98% (65/66) at 4 years, 76% (45/57) vs. 98% (54/55) at 10 years	4/10

5312

5313 A long-term, higher-quality prospective cohort study (the Maine Lumbar Spine Study) 5314 reported results consistent with the randomized trial [648]. Among 507 patients with 5315 sciatica due to a herniated disc, initial treatment with surgery was associated with 5316 greater likelihood for improvement in the predominant symptom (either back or leg pain) 5317 at 1 year compared to initial non-surgical treatment (71% vs. 43%, p<0.001), but the 5318 differences were attenuated after 5 years (70% vs. 56%, p<0.001) and no longer 5319 significant after 10 years (69% and 61%, p=0.20) [648-650]. Patients initially treated 5320 surgically were also more likely to report long-term resolution of low back and leg pain 5321 (56% vs. 40%, p=0.006) and greater improvements in the RDQ functional status scores. 5322 However, work and disability status were comparable between groups at all follow-up 5323 evaluations. About one-quarter of patients in either group underwent additional or 5324 subsequent back surgery. Another, lower-quality observational study (did not adjust for 5325 baseline differences or confounders) found that fewer patients (N=342) who initially 5326 underwent surgery reported their low back condition as unchanged or worse after 13 5327 years (19% vs. 41%), though similar proportions reported sciatica (67% vs. 68%) and 5328 being disabled due to a back problem (20% vs. 20%) [651]. There were also no 5329 differences in long-term functional status.

5330 Efficacy of surgery versus other interventions

5331 Lumbar disc prolapse

5332 The Cochrane review of surgery for lumbar disc prolapse included five lower-quality 5333 trials comparing standard surgical discectomy with chemonucleolysis using 5334 chymopapain [518]. Results from all trials generally favored surgery, though differences 5335 were not always statistically significant. The likelihood of subsequent surgery within two 5336 years was about 30% in the two years following chemonucleolysis and substantially 5337 more likely than following initial discectomy (5 trials, OR 0.07, 95% CI 0.02 to 0.18). 5338 Surgery was also associated with trends towards a lower proportion of patients 5339 reporting unchanged or worse condition (two trials, OR=0.61, 95% CI 0.30 to 1.24) and 5340 success at one year as rated by the surgeon at one year (three trials, OR=0.37, 95% CI 5341 0.13 to 1.05). By contrast, one lower-guality trial found percutaneous automated 5342 endoscopic discectomy associated with a greater likelihood of no success at one year 5343 compared to chemonuceolysis with chymopapain (OR 2.26, 95% CI 1.17 to 4.37) [652].

- 5344 One recent lower-quality trial not included in the systematic reviews compared
- 5345 discectomy to epidural steroid injection [554]. It found discectomy superior for short-
- term outcomes related to pain relief, functional status, motor deficits, and use of
- 5347 medications, though differences were no longer significant after 2-3 years of follow-up.
- 5348 This study is discussed in more detail in the section on epidural steroid injections. One
- 5349 other small (N=29) randomized trial [628] comparing laser discectomy to epidural
- 5350 steroids was included in a systematic review of laser discectomy [624], but has only
- 5351 been published as a conference abstract. It found no differences between interventions5352 for any outcome.

5353 *Efficacy of different surgical techniques*

5354 Degenerative conditions of the lumbar spine

The Cochrane review included 15 heterogeneous trials evaluating the efficacy of
different fusion techniques in patients with mixed degenerative conditions of the lumbar
spine [609, 610]. Instrumentation was associated with improved postero-lateral fusion
rates after an average of 28 months in eight trials (OR 0.43, 95% CI 0.21 to 0.91). The
pooled estimates for clinical outcomes also favored instrumentation (OR 0.49, 95% CI
0.28 to 0.84). However, excluding two lower-quality trials reporting unusually favorable

results (83% [653] and 93% [654]success with instrumented fusion) resulted in marginaland non-significant differences (74% vs. 66%).

The Cochrane review included four trials comparing various combinations of anterior,
posterior, or combined fusion that gave conflicting results on relative effectiveness.
Four other trials found that electrical stimulation (using heterogeneous methods)
increased fusion rates in non-instrumented fusion (OR 0.38, 95% CI 0.22 to 0.64) but
not in instrumented fusion (OR 0.59, 95% CI 0.15 to 2.30). In the three trials assessing
clinical outcomes, there were no differences in outcomes with or without electrical
stimulation [655-657].

5370 Artificial disk replacement versus fusion

5371 Three systematic reviews evaluated the efficacy of artificial disk replacement relative to

- 5372 fusion, but only included interim results from ongoing trials [609, 610, 622, 625]. Final
- 5373 results of one equivalence trial comparing the CHARITE Artificial Disc with anterior
- 5374 Iumbar interbody fusion using the BAK Interbody Fusion System (a technique no longer
- 5375 commonly used because of frequent failures [658]) for single-level degenerative disc
- 5376 disease from L4-S1 were published after the systematic reviews (Table 69) [634]. It
- 5377 found that total disc replacement was equivalent to fusion for a composite outcome of
- 5378 'clinical success' (>=25% improvement in ODI, no device failure, no major
- 5379 complications, and no neurologic deterioration) at 24 months in patients with
- 5380 symptomatic disc disease and positive discography who had failed at least six months
- of non-surgical treatment (57% vs. 46%, p<0.0001 for equivalence test). There were no
- 5382 differences in mean improvements in ODI scores (48.5 vs. 42.4, p=0.27 for difference)
- 5383 or visual analogue pain scores (40.6 vs. 34.1, p=0.11) at 24 months, though disk
- 5384 replacement was statistically superior at earlier evaluations. There were also no
- 5385 differences in rates of employment after 24 months.

5386

5386

Table 69. Completed trial of total disc replacement versus fusion

Author, year	Number of patients Duration of follow-up	Main results	Quality
Blumenthal, 2005[634]	N=304 24 months	Total disc replacement vs. fusion Clinical success: 117/205 (57%) vs. 46/99 (46%), p<0.0001 for equivalence >=25% improvement in Oswestry: 131/205 (64%) vs. 50/99 (50%) Length of hospitalization: 3.7 vs. 4.2 days, p=0.0039 ODI, mean improvement from baseline at 24 months: 49% vs. 42%, p<0.05 VAS for pain, mean improvement from baseline (0 to 100 scale): 40.6 vs. 34.1, p<0.05 Patient satisfaction rated as 'satisfied': 74% vs. 53%, p=0.0011 'Would have same treatment again': 70% vs. 50%, p=0.0062 Use of opioids: 148/205 (72%) vs. 85/99 (86%), p=0.0083 Employed at 24 months (percent increase): 9.2% vs. 7.4%, NS	6 or 7/10

5387

5388 Two other single center, interim reports from a multicenter trial comparing ProDisc-II

5389 artificial disc replacement to anterior discectomy and circumferential fusion have been

5390 published [635, 636]. Neither reported significant differences in pain relief or ODI

5391 Disability Index scores.

5392 Spinal stenosis

- 5393 The Cochrane review included one trial [659] of laminectomy versus multiple
- 5394 laminotomy for spinal stenosis that found no differences in clinical outcomes or
- 5395 spondylolisthesis progression, though confounding factors (including crossovers) may
- 5396 have affected results [609, 610]. Pooled results from three other small trials (total
- 5397 number of participants=139) also suggested no differences between postero-lateral
- 5398 fusion (with or without instrumentation) versus decompression alone for surgeon-rated
- 5399 outcomes (OR 0.44, 95% CI 0.13 to 1.48)

5400 Isthmic spondylolisthesis

- 5401 One trial found no difference between patients undergoing fusion alone versus fusion
- 5402 plus laminectomy and decompression for isthmic L5/S1 spondylolisthesis [660]. A
- 5403 systematic review of surgery for isthmic spondylolisthesis that combined data across
- 5404 randomized and non-randomized studies found the posterior approach associated with

5405 poorer success rates compared to anterior or combined approaches (75% versus 90% 5406 and 86%) [627].

5407 Lumbar disc prolapse

5408 The Cochrane review of surgery for lumbar disc prolapse included two trials [661, 662]

5409 that compared microdiscectomy to standard discectomy and reported similar clinical

5410 outcomes with either technique [609, 610]. There were also no differences in clinical 5411 outcomes in two trials comparing different types of interposition membranes [661, 662].

5412 A third trial reported better clinical outcomes after insertion of an antiadhesion barrier

5413 gel, but only published highly selected results [663].

5414 Two trials included in the Cochrane review reported conflicting results for automated 5415 percutaneous discectomy versus microdiscectomy, but aren't directly comparable 5416 because they evaluated different techniques. In one trial, which used modified forceps 5417 and an automated cutter with suction, clinical outcomes were comparable in patients 5418 randomized to automated percutaneous discectomy and microdiscectomy, but only 10% 5419 to 15% of patients needing surgical treatment were thought to be suitable for the former 5420 [664]. In the second trial, percutaneous discectomy using an automated suction 5421 nucleotome alone was associated with a lower rate of satisfactory results compared to

5422 microdiscectomy (29% vs. 80%) [665].

5423 The Cochrane review found no published trials of laser discectomy. Three other

5424 systematic reviews of laser discectomy (with [621] or without endoscopy [624]) and

5425 endoscopic laser foraminoplasty [623] identified a single trial [628], published as an

5426 abstract only, comparing laser lumbar discectomy versus epidural steroids (see

5427 discussion of surgery versus other interventions). No randomized trials evaluating

5428 efficacy of laser discectomy with endoscopy or endoscopic laser foraminoplasty were

5429 identified.

5430 Selection of patients for surgery

- 5431 Patients enrolled in surgical trials all had chronic pain for at least one year,
- 5432 unresponsive to standard non-surgical treatments. Exclusion criteria generally included
- 5433 any significant psychiatric or somatic illness and often included ongoing compensation
- 5434 issues or other chronic pain. Many of these exclusions are based on uncontrolled

- 5435 observational studies showing that surgical outcomes are poor in such patients [666,
- 5436 667]. In a recent randomized trial (the Swedish Lumbar Spine Study) of surgery versus
- 5437 non-surgical management of chronic low back pain, personality features and low disc
- 5438 height both predicted functional improvement after surgery, and low age and short sick
- 5439 leave predicted work resumption after surgery [668]. By contrast, the presence of
- 5440 depressive symptoms predicted functional improvement after non-surgical treatment.
- 5441 Safety
- 5442 An earlier systematic review that included observational data estimated an in-hospitality
- 5443 mortality rate of 0.2% after spine surgery [632]. Rates of other serious complications
- 5444 included 1.5% for deep wound infection, 1.6% for deep vein thrombosis, 2.2% for
- 5445 pulmonary embolus, and 2.8% for nerve injury (2.8%).
- 5446 No operative deaths were reported in any of the trials comparing surgery to non-surgical
- 5447 treatment. In two trials, early complication rates in the surgery group were 17% and
- 5448 18% [639, 640]. One of these studies, which evaluated different fusion techniques,
- 5449 found higher risks of complications with more technically difficult procedures [669]. The
- 5450 total complication rate after two years was 12% with posterolateral fusion, 22% with
- 5451 posterolateral fusion and instrumentation, and 40% with 360 degree fusion.
- In the only completed trial comparing total disc replacement to fusion, one death
 occurred among 205 patients randomized to total disc replacement (none in 99 patients
 randomized to fusion) [634]. There were no differences in rates of overall complications
 (p=0.6769). Major complications occurred in 1% with either total disc replacement or
 fusion.
- 5457 Costs
- 5458 Two trials of surgery versus non-surgical management of chronic low back pain
- 5459 conducted cost-effectiveness analyses. One study estimated an incremental cost-
- 5460 effectiveness ratio of £48,588/QALY for surgery relative to intensive rehabilitation [670].
- 5461 This estimate was sensitive to the proportion of patients in the rehabilitation group
- 5462 requiring surgery in the future. The other estimated incremental cost-effectiveness
- ratios for fusion relative to usual care of 2,600 (600-5,100) Swedish kroners per case of
- 5464 improvement, 5,200 (1,100-11,500) kroners per one point improvement on a 100 point

5465 pain scale, 11,300 (1,300-48,000) kroners per one point improvement on the ODI score, 5466 and 4,100 (100-21,400) kroners per patient returned to work [671]. There were no 5467 differences in costs associated with three different fusion techniques: posterolateral 5468 fusion, instrumented posterolateral fusion, and circumferential fusion with solid

- 5469 autogenous bone grafts.
- 5470 Another study estimated a cost-effectiveness ratio of \$12,000 to 33,900/QALY
- 5471 (depending on the cost of discectomy) for surgery for prolapsed disc relative to 5472 continued non-surgical management [672].
- 5473 A high-quality decision analysis estimated an incremental cost-effectiveness of
- 5474 \$56,500/QALY for laminectomy with noninstrumented fusion versus laminectomy
- 5475 without fusion in patients with degenerative spondylolisthesis and spinal stenosis [673].
- 5476 The cost-effectiveness ratio of instrumented fusion compared with noninstrumented
- 5477 fusion was \$3,112,800/QALY. However, this estimate was sensitive to the proportion of
- 5478 patients experiencing symptom relief after surgery, and could be as low as \$82,400 if
- 5479 the proportion of patients experiencing symptom relief was 90% with instrumented
- 5480 fusion and 80% with noninstrumented fusion. Estimated costs of laminectomy alone
- 5481 and noninstrumented and instrumented fusion were \$12,615, \$18,495, and \$25,914 in a
- 5482 study published in 1997 [674].
- 5483 One trial found similar costs for automated percutaneous lumbar discectomy and
- 5484 microdiscectomy for contained lumbar disc herniation (automated percutaneous lumbar
- 5485 discectomy associated with poorer outcomes) [675].
- 5486 Summary of evidence
- 5487
 - Non-specific, degenerative low back pain
- 5488 In patients with chronic low back pain due to other degenerative conditions, two 5489 high-guality trials indicate that spinal fusion surgery is no better than intensive 5490 rehabilitation plus a cognitive intervention, but a third trial found surgery superior 5491 to conventional physical therapy (level of evidence: fair).
- 5492 Evidence regarding the efficacy of instrumented versus non-instrumented fusion 5493 is inconsistent, though clinical outcomes are similar after excluding two lower-5494 guality trials reporting better outcomes and pooling data from the remaining five 5495 trials (level of evidence: fair).

5496	 Evidence regarding the efficacy of anterior, posterior, or combined fusion from
5497	four trials is inconsistent and does not permit reliable judgments about relative
5498	efficacy (level of evidence: fair).
5499	 Electrical stimulation may improve fusion rates in non-instrumented (but not
5500	instrumented) fusion, but didn't have a clear effect on clinical outcomes in three
5501	trials (level of evidence: fair).
5502 5503 5504 5505 5506	• Artificial disc replacement with the Charite artificial disc was equivalent to anterior interbody fusion with a stand-alone cage for a combined measure of success at 24 months in the only completed (higher-quality) trial. There were no differences in pain relief, functional status, of employment status at 24 months, though earlier results favored artificial disc replacement (level of evidence: fair).
5507	• Early complications following spine surgery occur in up to about 20% of patients.
5508	In-hospitality mortality after spine surgery occurs in about 0.2%, deep wound
5509	infection in 1.5%, deep vein thrombosis in 1.6%, pulmonary embolus in 2.2%,
5510	and nerve injury in 2.8% for nerve injury (level of evidence: fair).
5511	 Complications from spinal fusion were higher with more technically difficult
5512	methods in one trial (level of evidence: fair).
5513	 Rates of complications were similar after artificial disk replacement and fusion in
5514	one higher-quality trial (level of evidence: fair).
5515	 Trials of surgery versus non-surgical management generally included patients
5516	who did not have clear indications for surgery (such as progressive or severe
5517	neurologic deficits or severe, intractable pain), failed to improve after 6 months to
5518	2 years of conservative management, and had disease localized to L4-L5 and/or
5519	L5-S1.
5520 5521 5522 5523 5524 5525 5526	 Spinal stenosis, lumbar disc prolapse, and isthmic spondylolisthesis In patients with spinal stenosis and lumbar disc prolapse, consistent evidence from single RCTs and good-quality observational studies indicates that standard initial surgical therapy (decompression or discectomy, respectively) is associated with improved outcomes after one year compared to initial non-surgical therapy (or delayed surgery), but differences in outcomes are attenuated after 4 to 10 years of follow-up (level of evidence: fair).
5527	 There is insufficient evidence from single low quality trials to judge the efficacy of
5528	surgery versus non-surgical management for mild isthmic spondylolisthesis (level
5529	of evidence: poor).
5530	 There is insufficient evidence from one lower-quality trial to judge the efficacy of
5531	an interspinous spacer device for spinal stenosis (level of evidence: poor).
5532	 Standard discectomy was consistently superior to chemonucleolysis in five lower-
5533	quality trials (level of evidence: fair).

5534 There is insufficient evidence (one lower-quality trial) to accurately judge the 5535 relative efficacy of epidural steroids compared to discectomy (level of evidence: 5536 poor). 5537 In patients with spinal stenosis, one lower-quality trial found no differences • 5538 between laminectomy versus multiple laminotomy and three trials found no 5539 difference between postero-lateral fusion (with or without instrumentation) versus 5540 decompression alone (level of evidence: poor to fair). 5541 In patients with isthmic L5/S1 spondylolisthesis, one trial found no difference • between patients undergoing fusion alone versus fusion plus laminectomy and 5542 5543 decompression (level of evidence: fair). 5544 • In patients with lumbar prolapse, there are no clear differences between standard 5545 discectomy and microdiscectomy or discectomy using different interposition membranes (level of evidence: fair). 5546 5547 There is mixed evidence from two trials on the efficacy of automated • percutaneous discectomy versus microdiscectomy, with one trial reporting similar 5548 5549 outcomes and the other (using different techniques) poorer outcomes (level of 5550 evidence: poor). 5551 There is insufficient evidence to judge the efficacy of laser discectomy relative to other surgical methods (level of evidence: poor). 5552 Recommendations and findings from other guidelines 5553 5554 The AHCPR guidelines found that patients with acute low back pain who don't 5555 have findings suggestive of nerve root compression or positive red flags do not 5556 need surgical consultation for possible herniated lumbar disc (strength of 5557 evidence: D). 5558 The AHCPR guidelines recommend against spinal fusion for the treatment of low 5559 back problems during the first 3 months of symptoms (strength of evidence: C). The AHCPR guidelines recommend that spinal fusion be considered following 5560 5561 decompression at a level of increased motion due to degenerative 5562 spondylolisthesis (strength of evidence: C). 5563 The AHCPR guidelines recommend discussion further treatment options after 1 • 5564 month of conservative therapy in patients with sciatica, and consider referral to a 5565 specialist when all of the following are met: 1) sciatica is both severe and 5566 disabling, 2) symptoms of sciatic persist without improvement or with progression, 3) there is clinical evidence of nerve root compromise (strength of 5567 evidence: B). 5568 5569 The AHCPR guidelines found standard discectomy or microdiscectomy • 5570 appropriate for selected patients with herniated discs and nerve root dysfunction 5571 (strength of evidence: B).

- The AHCPR guidelines recommended against percutaneous discectomy in patients with lumbar disc herniation because of poor efficacy relative to chymopapain (strength of evidence: C).
- 5575 The AHCPR guidelines found that elderly patients with spinal stenosis who can 5576 adequately function can be managed without surgery, and surgery should 5577 normally not be considered in the first three months of symptoms. Decisions on 5578 treatment should take into account patient preferences, lifestyle, surgical risk, 5579 and co-morbid medical problems, and should not be based solely on imaging 5580 tests, but take into account degree of neurogenic claudication symptoms, 5581 associated limitations, and detectable neurologic compromise (strength of 5582 evidence: D).
- The European COST guidelines found insufficient evidence to recommend fusion surgery for chronic low back pain unless two years of all other recommended conservative treatments have failed and combined programs of cognitive interventions and exercises are not available in the given geographical area. It strongly recommends that only carefully selected patients with severe pain (and with maximum 2 affected levels) should be considered for fusion.
- 5589 Key Question 9.
- 5590 What is the effectiveness of other modalities (such as TENS or spinal cord
- 5591 stimulation) for non-specific low back pain, radicular low back pain, or spinal
- 5592 stenosis, and under what circumstances?
- 5593 Transcutaneous electrical nerve stimulation (TENS)
- 5594 Result of search: systematic reviews
- 5595 We identified one recent, higher-quality Cochrane review (two trials, one higher-quality
- 5596 [676]) on the efficacy of TENS versus sham TENS for chronic (>12 weeks) mechanical
- 5597 low back pain (with or without sciatica) [677]. This updated an earlier Cochrane review
- 5598 [678, 679]. Another higher-quality systematic review included four trials comparing
- 5599 TENS to acupuncture (discussed in the acupuncture section) [208]. We also included a
- 5600 systematic review that included two lower-quality trials of TENS versus other
- 5601 interventions for subacute (6 weeks to 3 months duration) low back pain [282]. We
- 5602 excluded four older systematic reviews [110, 283, 680, 681].
- 5603 Results of search: trials
- 5604 Three additional trials of TENS versus ice massage [483], TENS versus massage [379],
- and TENS versus traction [354] were previously discussed in the sections on massage,
- 5606 superficial heat or cold, and traction.

5607 *Efficacy of TENS versus sham TENS*

- 5608 The Cochrane review included one higher quality trial (n=145) [676] that found no
- 5609 differences between active and sham TENS for any measured outcome (including pain
- 5610 and functional status) after 4 weeks [677]. A smaller (n=30), fair-quality trial found that
- 5611 active TENS was associated with a greater reduction in pain over the 60-minute
- 5612 treatment session compared to sham TENS (weighted mean difference –33.62, 95% CI
- 5613 –52.27 to –13.97) [682]. Longer-term results and adverse events were not reported.
- 5614 A systematic review of interventions in subacute low back pain included one lower-
- 5615 quality trial that found that TENS plus acupuncture-like TENS was associated with
- 5616 similar outcomes as sham TENS, with both groups also receiving a rehabilitation
- 5617 intervention [683]. There was a greater likelihood of return to work with TENS at 5
- 5618 weeks (RR 2.0, 95% CI 0.7 to 5.9) but not at 6 months (RR 0.8, 95% CI 0.6 to 1.1).
- 5619 *Efficacy of TENS versus other interventions*
- 5620 A systematic review of acupuncture included four trials in patients with chronic low back
- 5621 pain that found no differences between acupuncture and TENS for short- (four trials,
- 5622 effect size 0.15, 95% CI –0.33 to 0.63) or long-term pain (two trials, effect size 0.32,
- 5623 95% CI –0.33 to 0.96) [208]. Results of studies comparing TENS to other interventions
- 5624 in patients with chronic low back pain are mixed: one lower-quality trial found traction
- 5625 superior to TENS [354], one higher-quality trial found TENS superior to massage [379],
- and one lower-quality trial found no differences between TENS and ice massage [483].
- 5627 A systematic review of interventions in subacute low back pain included one lower-
- 5628 quality trial [380, 381] that found spinal manipulation superior to TENS for pain (effect
- 5629 size 0.5, 95% CI 0.1 to 1.0) and disability (effect size 1.3, 95% CI 0.5 to 2.0) [282].
- 5630 Safety
- 5631 One third of patients with either active or sham TENS had minor skin irritation, with one 5632 patient (sham) discontinuing due to severe dermatitis [677]. The proportion of patients 5633 with skin irritation was similar in patients receiving active or sham TENS.
- 5634 Summary of evidence
- There is conflicting evidence regarding the efficacy of TENS versus sham TENS
 for patients with non-specific chronic low back pain, though the sole higher quality trial found no benefit (level of evidence: fair).

5638 5639	 There is consistent evidence from four trials that TENS is not superior to acupuncture in patients with chronic low back pain (level of evidence: fair). 				
5640 5641 5642 5643	 Evidence regarding the efficacy of TENS to other interventions in patients with chronic low back pain is limited to single trials of traction (traction superior), massage (TENS superior), and ice massage (no differences) (level of evidence: poor). 				
5644 5645 5646	 TENS was no better than sham TENS and inferior to spinal manipulation in two lower-quality trials of patients with subacute low back pain (level of evidence: fair). 				
5647 5648	 TENS is associated with skin irritation that is usually minor (level of evidence: fair). 				
5649	Recommendations and findings from other guidelines				
5650 5651	 The AHCPR guidelines recommend against TENS in patients with acute low back problems (strength of evidence: C). 				
5652	The VA/DoD guidelines are identical.				
5653 5654	 The UK RCGP found inconclusive evidence on the efficacy of TENS in patients with acute low back problems (strength of evidence: **). 				
5655 5656	 The European COST guidelines recommend against TENS for chronic low back pain. 				
5657	Percutaneous electrical nerve stimulation				
5658	Percutaneous electrical nerve stimulation (PENS) involves the insertion of				
5659	acupuncture-like needles and applying low-level electrical stimulation. It differs from				
5660	electroacupuncture in that the insertion points target dermatomal levels for local				
5661	pathology, rather than acupuncture points. However, there is some uncertainty over				
5662	whether PENS should be considered a novel therapy or a form of electroacupuncture				
5663	[684].				
5664	Results of search: systematic review				
5665	We identified no relevant systematic reviews.				
5666 5667	Results of search: trials We identified three trials of PENS in patients with chronic low back pain [685-687] and				

5667 We identified three trials of PENS in patients with chronic low back pain [685-687] and 5668 one trial in patients with sciatica [688]. All were rated lower quality.

- 5669 *Efficacy of PENS versus sham PENS*
- 5670 Two trials compared PENS to sham PENS in patients with chronic low back pain (Table
- 5671 70) [686, 687]. Both found PENS moderately superior to sham-PENS for pain
- 5672 outcomes at the end of treatment [686] and three months after a course of treatment
- 5673 [687]. One trial also found improvements in functional outcomes and quality of sleep at
- the end of treatment [686]. The other trial found no benefits on measures of depression
- 5675 or functional status three months after treatment. In both trials, the success of blinding
- 5676 was not assessed.
- 5677 A third trial compared PENS to sham PENS in patients with sciatica of at least 6 weeks
- 5678 duration. PENS was superior to sham PENS immediately after a two-week course of
- treatment for pain, functional status, and measures of sleep quality [688].
- 5680

Table 70. Trials of PENS versus sham PENS

	Number of patients Duration of		
Author, year	follow-up	Main results	Quality
Weiner, 2003[687]	N=34	PENS + physical therapy versus sham PENS +	
(non-sciatic low back	3 months	physical therapy (mean scores 3 months after treatment)	
pain)	after	McGill Pain Questionnaire: 6.19 vs. 11.82 (p=0.04)	3/11
	treatment	Multidimensional Pain Inventory Pain Inventory score:	3/11
		2.16 vs. 3.10 (p=0.003)	
		RDQ scale: 9.25 vs. 12.18 (p=0.26)	
Ghoname, 1999[686]	N=60	PENS vs. sham PENS (mean improvement from	
(not-sciatic low back pain)	At end of 2-	baseline)	
	week course	Pain (VAS 0 to 10): -2.9 vs0.2 (p<0.02 for PENS)	2/11
	of treatment	Level of activity (0 to 10): -2.3 vs0.2 (p<0.02 for PENS)	
		Quality of sleep (0 to 10): -2.4 vs. 0 (p<0.02 for PENS)	
Ghoname, 1999[688]	N=64	PENS vs. sham PENS	
(sciatica)	At end of 2-	Pain (VAS 0 to 10): -3.1 vs0.5 (p<0.01)	1/11
	week course	Level of activity (0 to 10): -2.4 vs0.5 (p<0.01)	1/11
	of treatment	Quality of sleep (0 to 10): -2.4 vs0.3 (p<0.01)	

5681

- 5682 Efficacy of PENS versus other interventions
- 5683 Two trials compared PENS to TENS [685, 686] in patients with chronic low back pain

5684 (Table 71). Both found PENS superior to TENS at the end of treatment for measures of

- 5685 pain and functional status, but the only trial that followed patients after the end of
- treatment found that benefits were no longer present after 1 to 2 months [685].
- 5687 One of these trials also compared PENS to a minimal exercise intervention (seated
- 5688 flexion and extension) [686]. PENS was superior to exercise on measures of pain and
- 5689 functional status at the end of a two-week course of treatment.

- 5690 One trial of patients with sciatica found PENS superior to TENS on measures of pain
- and functional status at the end of a two-week course of treatment [688].
- 5692

Table 71. Trials of PENS versus other interventions

Author year	Number of patients Duration of follow-up	Main results	Quality
Author, year	N=60	PENS vs. TENS	Quality
Yokoyama, 2004[685] (low back pain, presence or absence of sciatica not specified)	2 months after treatment	Pain (VAS pain scores): 32 vs. 48 at end of treatment (p<0.01), no differences 2 months after treatment Physical impairment (0 to 4 scale): difference between PENS and TENS significant at end of treatment but not 1 month after treatment (data not reported)	3/11
Ghoname, 1999[686] (non-sciatic low back pain)	N=60 At end of 2- week course of treatment	PENS vs. TENS vs. exercise, mean improvement from baseline Pain (VAS 0 to 10): -2.9 vs0.6 vs0.1 (p<0.02 for PENS vs. other interventions) Level of activity (0 to 10): -2.3 vs0.8 vs. 0 (p<0.02 for PENS vs. other interventions) Quality of sleep (0 to 10): -2.4 vs0.3 vs0.3 (p<0.02 for PENS vs. other interventions)	2/11
Ghoname, 1999[688] (sciatica)	N=64 At end of 2- week course of treatment	PENS vs. TENS , mean improvement from baseline Pain (VAS 0 to 10): -3.1 vs2.6 (p<0.01) Level of activity (0 to 10): -2.4 vs1.3 (p<0.01) Quality of sleep (0 to 10): -2.4 vs1.0 (p<0.01)	1/11

5693

5694 Safety

- 5695 None of the trials reported safety outcomes.
- 5696 Costs
- 5697 We found no studies evaluating costs.

5698 Summary of evidence

- PENS was superior to sham PENS in two lower-quality trials of patients with
 chronic low back pain for pain outcomes. In the only trial assessing outcomes
 after the end of treatment, pain benefits were present after two months, but there
 was no effect on functional outcomes (level of evidence: fair).
- PENS was superior to TENS and a minimal exercise intervention for pain and functional outcomes in one lower-quality trial of patients with chronic low back pain at the end of treatment, but in the only trial evaluating longer-term outcomes, no benefits were present after two months (level of evidence: poor).
- PENS was superior to sham PENS and TENS for pain and functional outcomes in one lower-quality trial of patients with sciatica, but outcomes were only assessed immediately after a two-week course of treatment (level of evidence: poor).

• There is insufficient evidence to accurately judge the safety of PENS.

5712 **Recommendations and findings from other guidelines**

• The European COST guidelines recommend considering PENS for patients with chronic nonspecific low back pain.

5715 Spinal cord stimulation

- 5716 Results of search: systematic reviews
- 5717 We identified one recent, fair-quality systematic review evaluating the efficacy of spinal
- 5718 cord stimulation in patients with chronic back and leg pain [689]. It found no trials of
- 5719 patients without failed back surgery syndrome, but reviewed 27 case series of patients
- 5720 with chronic back and leg pain (median quality score 1 on a 1 to 7 scale). Two other
- 5721 recent systematic reviews only included studies of patients with failed back surgery
- 5722 syndrome and are discussed in Key Question 11 [690, 691]. We excluded two older
- 5723 systematic reviews [692, 693].
- 5724 Results of search: trials
- 5725 We did not search for additional trials
- 5726 Efficacy of spinal cord stimulation
- 5727 The systematic review included 72 case series (mean duration of pain 6.5 years)
- 5728 reporting outcomes associated with spinal cord stimulation [689]. Twenty-seven studies
- 5729 were in patients with chronic back and leg pain. None of the studies prospectively
- 5730 studied consecutive patients using independently assessed and validated outcomes
- 5731 measures. Results were not reported separately for patients with chronic back and leg
- 5732 pain.

5733 Estimates from pooled case study data of the proportion of patients with greater than 5734 50% pain relief were 62% (95% CI 56-69%) following implantation and 48% (95% CI 43-5735 53%) during follow-up testing. The percentage of patients achieving pain relief was 15 5736 to 20% lower in studies rated higher quality (>3 on a 7 point scale), was reduced by 5% 5737 for every additional 10 months of follow-up, was increased by 10% for multicenter 5738 compared to single center studies, and was 20% higher for studies in patients with 5739 failed back surgery syndrome or chronic leg and back pain. The proportion of patients 5740 not requiring an analgesic after implantation was 53% (95% CI 48-56%), the proportion

returned to work 40% (95% CI 28-50%), and the proportion satisfied with the

5742 intervention 70% (95% CI 62-85%).

5743 Safety

- 5744 Only 18 of the 72 studies reported usable safety data [689]. Overall, 43% (48/112) of
- 5745 patients with chronic back and leg pain or failed back surgery syndrome experienced at
- 5746 least one complication with spinal cord stimulation. The most frequent complication was
- 5747 related to electrode or lead problems (27%). Other complications included infections
- 5748 (6%), generator problems (6%), extension cable problems (10%) and other issues (such
- 5749 as cerebrospinal fluid leak in 7%). No neurologic-related complications were reported.
- 5750 Costs
- 5751 We found no studies evaluating costs.

5752 Summary of evidence

- Low-quality evidence from multiple case series found that approximately half of patients with chronic back and leg pain or failed back surgery syndrome had decreased pain after spinal cord stimulator implantation, and 40% were returned to work. However, the lack of higher-quality evidence severely limits confidence in these estimates (level of evidence: poor).
- Spinal cord stimulation is associated with frequent complications, especially
 related to electrode or lead problems. Although most complications appear
 minor, infections (6% of complications) and cerebrospinal fluid leak (7%) have
 been reported (level of evidence: poor).
- 5762 **Recommendations and findings from other guidelines**
- The European guidelines found insufficient evidence to recommend spinal cord 5764 stimulation for chronic nonspecific low back pain.

5765 Key Question 10.

5766 Which combinations of therapies are effective for acute low back pain? Chronic

- 5767 low back pain?
- 5768 **Combinations of medications**
- 5769 Results of search: systematic reviews
- 5770 A Cochrane review of muscle relaxants included five trials (four higher-quality)
- 5771 evaluating the efficacy of muscle relaxants plus an analgesic versus an analgesic alone

- 5772 [163, 164]. We found no other systematic reviews evaluating the efficacy of one drug 5773 added to another relative to the other drug alone.
- 5774 Results of search: trials

5775 We identified one lower-quality trial evaluating the efficacy of opioids plus an NSAID

- 5776 versus an NSAID alone [182].
- 5777 Efficacy of a muscle relaxant plus an analgesic versus an analgesic alone
- 5778 The Cochrane review of muscle relaxants [163, 164] included three higher-quality trials
- 5779 [133, 694, 695] that consistently found tizanidine plus acetaminophen or NSAIDs
- 5780 superior to placebo plus acetaminophen or NSAIDs for short-term (up to one week) pain
- 5781 relief and decrease of muscle spasm in patients with acute low back pain. Another
- 5782 higher-quality trial included in the Cochrane review found no differences in global
- 5783 efficacy between orphenadrine plus acetaminophen compared to placebo plus
- 5784 acetaminophen, but the combination arm was associated with significantly fewer
- 5785 disability days [696]. One lower-quality trial found no difference in pain intensity or
- 5786 global efficacy between cyclobenzaprine plus an NSAID versus an NSAID alone,
- though effects on muscle spasm were superior [697].
- 5788 Efficacy of an opioids plus an NSAID versus an NSAID alone
- 5789 Naproxen was inferior to set-dose or titrated-dose opioid plus naproxen in one small
- 5790 N=36) lower-quality trial [182]. However, results are uninterpretable because the dose
- 5791 of naproxen was not specified and average doses not reported.
- 5792 Safety

5793 The Cochrane review found a higher risk of central nervous system adverse effects with 5794 the combination of a muscle relaxant plus an analgesic (4 trials, RR 2.44, 95% CI 1.05 5795 to 5.63), but a trend towards a lower risk of gastrointestinal adverse effects (RR 0.54, 5796 95% CI 0.26 to 1.14) [163, 164]. For overall adverse effects there was no significant 5797 difference (RR 1.34, 95% CI 0.67 to 2.67).

5798 Summary of evidence

There is consistent evidence from three higher-quality trials that tizanidine
 combined with acetaminophen or an NSAID is associated with greater short-term
 pain relief and decrease of muscle spasm in patients with acute low back pain
 (level of evidence: good).

- One higher-quality trial found no benefits from adding orphenadrine to
 acetaminophen in patients with acute low back pain, though the combination was
 associated with fewer disability days (level of evidence: fair).
- One lower-quality trial found no benefits from adding cyclobenzaprine to an
 NSAID in patients with acute low back pain (level of evidence: poor).
- There is insufficient evidence from one trial (doses unclear) to judge the efficacy 5809 of opioids plus an NSAID versus an NSAID alone (level of evidence: poor).
- Adding a muscle relaxant to acetaminophen or an NSAID was associated with an increased risk of central nervous system adverse effects (level of evidence: good).
- 5813 **Recommendations and findings from other guidelines**
- The AHCPR guidelines found no additional benefit from using muscle relaxants
 plus NSAIDs over using NSAIDs alone.
- The European COST guidelines recommend adding a short course of muscle
 relaxants on its own or added to NSAIDs in patients with acute low back pain, if
 acetaminophen or NSAIDs failed to reduce pain.
- 5819 Self-care advice combined with other interventions
- 5820 Results of search: systematic reviews
- 5821 We found no relevant systematic reviews.
- 5822 Results of search: trials
- 5823 We identified two trials (one higher-quality [698]) comparing a self-care book plus
- 5824 exercise to a self-care book alone [698, 699]. We also found a lower-quality trial
- 5825 compariing a self-care book plus interferential therapy to a self-care book alone [321].
- 5826 A fourth trial compared a self-care book plus exercise advice versus either alone [452].
- 5827 One other trial compared a self-care book to a self-care book plus nurse advice [456].
- 5828 Efficacy of a self-care book combined with other interventions
- 5829 One higher-quality trial of patients with low back pain for less than 6 weeks found that
- 5830 the a self-care book plus advice and immediate exercise therapy using a
- 5831 biopsychosocial approach was associated with more rapid improvements in function
- 5832 compared to a self-care book plus advice and waiting for 6 weeks to initiate therapy
- 5833 [698]. A lower-quality trial in patients off work for less than one year due to low back
- 5834 pain found that adding a brief exercise intervention to a self-care book and advice was
- 5835 associated with a quicker return to work compared to a self-care book and advice alone

5836 (20 versus 13 days, p=0.034) and greater improvement in pain scores through two 5837 months [699].

5838 One lower-quality trial was reviewed in more detail in the section on interferential

5839 therapy (Key Question 3) [321]. It found that the addition of interferential therapy

5840 applied to the paraspinal area to a self-care book was associated with greater

- 5841 improvement in functional status at three months compared to the self-care book alone,
- 5842 but baseline differences may invalidate these results.
- 5843 Two other trials evaluating the efficacy of a self-care book plus face-to-face advice with
- a self-care book alone were reviewed in the section on self-care interventions (Key
- 5845 Question 4). One higher-quality trial found that brief nurse-led education plus a self-
- 5846 care book was associated with a higher proportion of patients exercising and greater
- 5847 patient satisfaction than a self-care book alone [456]. However, there were no
- 5848 differences in pain or functional status. A lower-quality trial found that the combination
- 5849 of a self-care book and advice to exercise was not associated with improved outcomes 5850 relative to the self-care book alone [452].
- 5851 **Su**

Summary of evidence

- Two trials (one higher-quality) found that a self-care book plus advice plus
 exercise therapy was superior to the self-care book and advice alone. One trial
 was in patients with back pain for less than 6 weeks and the other in patients off
 work for less than one year due to back pain (level of evidence: fair).
- Two trials (one higher-quality) found that adding face-to-face advice to a self-care
 book did not improve patient outcomes, though one of the trials found that self reported exercise and patient satisfaction was higher (level of evidence: fair).
- There is insufficient evidence to judge the efficacy of a self-care book plus
 interferential therapy relative to a self-care book alone (one lower-quality trial)
 (level of evidence: poor).
- 5862 **Recommendations and findings from other guidelines**
- The other guidelines do not address this issue.

5864 Exercise combined with other interventions

- 5865 Results of search: systematic reviews
- 5866 We identified one good-quality Cochrane review [268, 269] and an associated meta-
- 5867 regression [293] evaluating the efficacy of exercise therapy plus other non-invasive
- 5868 interventions relative to exercise therapy alone in patients with chronic low back pain.
- 5869 Results of search: trials
- 5870 One recent, large, lower-quality trial (UK BEAM) not included in the Cochrane review
- 5871 evaluated the effects of exercise plus spinal manipulation versus spinal manipulation
- alone in patients with subacute or chronic low back pain [284].
- 5873 Efficacy of exercise therapy plus non-invasive treatments versus exercise alone
- 5874 The meta-regression performed in conjunction with the Cochrane review included 36
- 5875 groups receiving exercise plus another intervention and 36 groups receiving exercise
- 5876 alone [293]. In multivariate analyses, adding other non-invasive interventions had a
- 5877modest average additive effect compared to exercise therapy alone of 5.1 points (95%5878CI 3.6 to 7.1) for pain and 2.1 points (95% CI 0.7 to 3.7) for function (each on 100 point
- 5879 scales).

5880 Results of the recent, large (N=1334) UK BEAM trial were consistent with only modest 5881 additive benefits from adding exercise therapy (Table 72) [284]. At 12 months, the 5882 combination was associated with slightly greater (but non-significant) net improvements 5883 in RDQ scores (0 to 24 scale) than manipulation alone (net improvement relative to

- 5884 usual care 1.30 points, 95% CI 0.54 to 2.07 and 1.01 points, 95% CI 0.22 to 1.81,
- 5885 respectively). The difference between combination therapy and manipulation was
- 5886 similar at three months. There were also no significant differences on the modified Von
- 5887 Korff scale or SF-36, though results on the back beliefs and fear avoidance
- 5888 questionnaires favored combination therapy.

5889

5889

Table 72. Results of the UK BEAM Trial

Author, year	Number of patients Duration of follow-up	Main results	Quality
UK BEAM Trial, 2004	N=1334 12 months	Manipulation + exercise versus manipulation versus exercise versus usual care (all results are net benefit relative to usual care at 12 months) RDQ Questionnaire (0 to 24 scale): 1.30 (95% CI 0.54 to 2.07) vs. 1.01 (95% CI 0.22 to 1.81) vs. 0.39 (95% CI - 0.41 to 1.19) Modified Von Korff pain score (0 to 100 scale): 6.71 (95% CI 2.47 to 10.95) vs. 5.87 (95% CI 1.58 to 10.17) vs. 4.90 (95% CI 0.30 to 9.50) Modified Von Korff disability score (0 to 100 scale): 6.71 (95% CI 2.62 to 10.80) vs. 5.65 (95% CI 1.57 to 9.72) vs. 4.56 (95% CI 0.34 to 8.78)	2 or 3/11

5890

5891 Summary of evidence

The addition of exercise to other non-invasive interventions is associated with
 modest improvements in pain (about 5 points on a 100 point scale) and function
 (about 2 points on a 100 point scale) in a large meta-regression (level of
 evidence: good).

5896 **Recommendations and findings from other guidelines**

• The other guidelines don't address this issue.

5898 Acupuncture combined with other non-invasive interventions

- 5899 Results of search: systematic reviews
- 5900 We identified one good-quality Cochrane review of acupuncture for low back pain that
- 5901 evaluated the efficacy of acupuncture added to other non-invasive interventions for
- acute (one lower-quality trial) or chronic (four higher-quality trials) low back pain [209,
- 5903 210].
- 5904 Results of search: trials
- 5905 We did not search for additional trials
- 5906 Efficacy of acupuncture plus other non-invasive treatments versus the other treatment 5907 alone
- 5908 The Cochrane review included one lower-quality trial (N=100) that found the
- 5909 combination of acupuncture and moxibustion plus Chinese herbal medicine superior to
- 5910 Chinese herbal medicine alone for pain and function at long-term follow-up in patients
- 5911 with acute low back pain [700].

- 5912 The Cochrane review also included four higher-guality trials (N=289) of patients with 5913 chronic low back pain that found the addition of acupuncture to another intervention 5914 more effective than the other intervention alone (co-interventions included exercises, 5915 NSAIDs, aspirin, non-opioid analgesics, mud packs, infrared heat therapy, back care 5916 education, ergonomics, or behavioral modifications). In pooled analyses, the addition of 5917 acupuncture was associated with improvements in pain (two trials, standardized mean 5918 difference -0.76, 95% CI -1.14 to -0.38) and function (three trials, standardized mean 5919 difference -0.55, 955 CI -0.92 to -0.18) that persisted through 3 to 12 months of follow-5920 up [209, 210]. Despite the evaluation of different co-interventions, there was no
- 5921 between-study heterogeneity in the pooled analyses.
- 5922 Summary of evidence
- In four higher-quality trials, acupuncture was associated with moderate beneficial effects on pain and function through 12 months when combined with a variety of other non-invasive intervention compared to the other intervention alone (level of evidence: good).
- There is insufficient evidence to judge the effects of acupuncture added to other
 interventions in patients with acute low back pain (one lower-quality trial) (level of
 evidence: poor).
- 5930 **Recommendations and findings from other guidelines**
- The other guidelines don't address this issue.
- 5932 Spinal manipulation combined with other interventions
- 5933 Results of search: systematic reviews
- 5934 A recent, good-quality Cochrane review of spinal manipulation did not evaluate additive
- 5935 benefits of spinal manipulation to other non-invasive interventions [332, 333].
- 5936 Results of search: trials
- 5937 One recent, large trial that evaluated exercise therapy plus manipulation versus
- 5938 manipulation alone also evaluated exercise therapy alone [284]
- 5939 Efficacy of spinal manipulation plus exercise versus exercise alone
- 5940 Relative to usual care, the UK BEAM trial found that patients randomized to
- 5941 manipulation plus exercise improved RDQ scores (0 to 24 scale) after 12 months by an
- 5942 average of 1.30 points (95% CI 0.54 to 2.07) compared to 0.39 (-0.41 to 1.19) with
- 5943 exercise alone (see Table 72 above) [284]. The small difference in average effect

5944 (about one point) was not statistically significant. There were also no significant 5945 differences on other outcome measures including the Von Korff scale, back beliefs 5946 guestionnaire, fear avoidance beliefs guestionnaire, or SF-36. Another higher-guality 5947 trial found that the combination of manipulation and exercise and a brief intervention 5948 (physician consultation) was associated with modest long-term benefits on pain scores 5949 (average 6.3 point difference on a 100 point pain scale at 12 months and 2.4 point 5950 difference after 24 months) compared to physician consultation only in patients with 5951 chronic low back pain [266]. There were no differences on the ODI score or health-5952 related quality of life.

- 5953 Summary of evidence:
- Compared to exercise therapy alone, the addition of spinal manipulation was not associated with significant benefits in a recent, large, lower-quality trial (level of evidence: fair).
- The combination of spinal manipulation plus exercise and a brief intervention (physician consultation) was associated with modest long-term differences in pain but not function relative to physician consultation alone in one higher-quality trial (level of evidence: fair).
- 5961Recommendations and findings from other guidelines
- The other guidelines don't address this issue.

5963Massage combined with other interventions

- 5964 Results of search: systematic reviews
- 5965 We identified one recent, good-quality Cochrane review of massage therapy [375, 376]
- 5966 that included one higher-quality trial [378] of massage plus exercise and education
- 5967 versus exercise and education without massage.
- 5968 Results of search: trials
- 5969 We did not search for additional trials.
- 5970 Efficacy of massage plus exercise and education versus exercise and education without5971 massage
- 5972 In the one relevant trial included in the Cochrane review, combined treatment with
- 5973 massage, exercise and education was superior to exercise and education alone for pain
- 5974 (McGill Present Pain Intensity) and disability (RDQ score) in patients with subacute low
- 5975 back pain at one-month follow-up [378]. Mean Present Pain Intensity scores (0 to 5

scale) were 0.42 (95% CI 0.17 to 0.66) for the combination versus 1.33 (0.97 to 1.7) for
exercise and education alone, and mean RDQ scores (0 to 24 scale) 1.54 (95% CI 0.69
to 2.4) versus 5.71 (95% CI 3.5 to 7.9).

- 5979 Summary of evidence
- Compared to exercise and education alone, the addition of massage therapy was
 associated with moderate short-term benefits for pain and disability in patients
 with subacute low back pain.
- 5983 **Recommendations and findings from other guidelines**
- The other guidelines don't address this issue.

5985 Behavioral therapy combined with other interventions

- 5986 Results of search: systematic reviews
- 5987 We identified one recent, good-quality Cochrane review that included six lower-quality
- 5988 trials comparing behavioral treatment in addition to another treatment versus the other
- 5989 treatment alone [73].
- 5990 Results of search: trials
- 5991 We did not search for additional trials

5992 *Efficacy of behavioral therapy in addition to another intervention versus the other* 5993 *intervention alone*

- 5994 The Cochrane review included six trials that compared behavioral treatment combined 5995 with physiotherapy and back education, multidisciplinary treatment, inpatient pain 5996 management, various forms of medical treatment (pain medication, nerve blocks, or 5997 physical therapy), and exercise therapy [73]. In pooled analyses, adding behavioral 5998 therapy to other interventions was not associated with beneficial effects on long-term 5999 pain intensity (pooled effect size -0.24, 95% CI -0.64 to 0.16), generic functional status 6000 (pooled effect size 0.26, 95% CI -0.06 to 0.57), or behavioral outcomes (pooled effect 6001 size 0.32, 95% CI –0.06 to 0.71). There were also no differences on outcomes
- assessed at the end of treatment. Despite the evaluation of different co-interventions,little between-study heterogeneity was present.
- 6004 Summary of evidence
- Behavioral interventions were consistently ineffective for improving outcomes
 when added to a variety of other interventions in six lower-quality trials of patients
 with chronic low back pain. Diversity in both the behavioral and non-behavioral

- 6008 interventions may limit the generalizability of these findings (level of evidence: fair).
- 6010 **Recommendations and findings from other guidelines**
- The other guidelines don't address this issue.
- 6012 Traction combined with other interventions
- 6013 Results of search: systematic reviews
- 6014 We identified a recent, good-quality Cochrane review [337, 338] that included one
- 6015 lower-quality trial [701] comparing traction plus physical therapy to physical therapy
- 6016 alone.
- 6017 Results of search: trials
- 6018 We did not search for additional trials
- 6019 *Efficacy of traction plus physical therapy versus physical therapy alone*
- 6020 The small (N=42) trial included in the Cochrane review found no statistically significant
- 6021 differences between traction plus physical therapy and physical therapy alone for pain,
- 6022 functional status, global recovery, or satisfaction in patients with chronic low back pain
- 6023 with or without sciatica [701].
- 6024 Costs
- 6025 The UK BEAM Trial estimated a cost-effectiveness ratio of £3800/QALY for
- 6026 manipulation plus exercise relative to best care alone [284]. The cost-effectiveness of
- the combined treatment was superior to either manipulation or exercise alone
- 6028 (L4,800/QALY and 8,3800/QALY respectively, each relative to best care alone).
- The UCLA Low Back Pain Study found that the addition of physical modalities to chiropractic care associated with minimal additional average cost (\$579 vs. \$560) and no differences in outcomes. The addition of physical therapy to usual medical care was associated with substantially increased costs (\$760 vs. \$369) with clinically negligible benefits [424].
- 6034 Summary of evidence
- Traction plus physical therapy was no better than physical therapy alone in one
 small, lower-quality trial (level of evidence: poor).

6037 **Recommendations and findings from other guidelines**

• The other guidelines don't address this issue.

6039 Key Question 11.

6040 What are effective strategies for failed back surgery syndrome?

6041 Adhesiolysis

Adhesiolysis (also referred to as lysis of epidural adhesions, epidural neurolysis, and epidural neuroplasty) is a relatively new procedure whose purpose is to improve the application of drugs to target nerves and other tissues by removing scars and adhesions in the epidural space. Adhesiolysis can be performed percutaneously or with endoscopic guidance. It is typically reserved for patients with back pain refractory to other treatments, often in the post-surgical setting.

6048 Results of search: systematic reviews

- 6049 We identified one recent systematic review evaluating the effectiveness of adhesiolysis
- 6050 [702]. Although the literature search for this systematic review appeared
- 6051 comprehensive, it was rated poor-quality because it used inadequate methods to
- analyze and synthesize the results of included studies. For example, it classified one
- 6053 study as a randomized trial even though it clearly was non-randomized [703].
- 6054 Results of search: trials
- 6055 Because the literature search in the systematic review appeared adequate, we did not 6056 conduct a separate search. However, we independently abstracted and analyzed the 6057 three studies included in the systematic review [555, 703, 704]. Only one was rated 6058 higher-quality [555].

Efficacy of adhesiolysis with or without hypertonic saline versus other interventions 6059 6060 One higher quality trial (N=75) randomized patients with chronic back pain who failed to 6061 respond to conservative treatment (including epidural steroids) and had negative facet 6062 joint block testing to epidural steroid without adhesiolysis, adhesiolysis with normal 6063 saline, or adhesiolysis with hypertonic saline [555]. It found adhesiolysis with or without 6064 hypertonic saline associated with significantly greater likelihood for >50% pain relief 6065 compared to epidural steroid alone (72% and 60% vs. 0%, p<0.001) after 12 months. 6066 However, even though patients enrolled in this trial had failed a previous injection, the 6067 0% response rate with epidural steroids is still much lower than in other trials. For

- 6068 example, in a high quality trial of epidural steroids versus saline placebo, rates of
- 6069 improvement in pain were approximately 70% in both groups [537]. A second study
- 6070 comparing adhesiolysis to usual care was classified as a randomized trial by the
- 6071 systematic review [702], but was actually a non-randomized comparative study [703].
- 6072 Adhesiolysis was superior to usual care on most measured outcomes including pain,
- 6073 measures of functional status, and opioid intake.
- 6074

Table 73. Studies of adhesiolysis versus other interventions

Author, year	Number of patients Duration of follow-up	Main results	Quality
Manchikanti, 2004[555]	N=75	Adhesiolysis with hypertonic saline vs. adhesiolysis	
(randomized controlled trial)	12 months	with isotonic saline vs. epidural steroid Proportion with >50% pain relief at 12 months: 72% vs. 60% vs. 0% (p<0.001) ODI disability index score at 12 months: 23 vs. 24 vs. 32 (p<0.001) VAS pain score (0 to 10) at 12 months: 4.6 vs. 5.2 vs. 7.7 Taking opioids: 52% vs. 16% vs. 16% vs. 52% (p<0.001)	8/11
Manchikanti, 2001[703] (non-randomized comparative study)	N=45 18 months to 3 years	Adhesiolysis vs. usual care Average pain (0 to 10): 3.9 vs. 6.9 (p<0.06) Functional status (0 to 10): 5.3 vs. 4.3 (p<0.05) Opioid intake moderate or heavy: 74% vs. 80% Employed: 17% vs. 20%	1/11

6075

6076 Efficacy of adhesiolysis with hypertonic saline versus hyaluronidase versus isotonic 6077 saline

6078 The higher-quality trial found no significant differences in pain relief between patients

6079 randomized to adhesiolysis with hypertonic saline compared to adhesiolysis with

6080 isotonic saline (Table 73) [555]. One lower-quality trial found no significant differences

6081 between patients who underwent adhesiolysis with hypertonic saline alone versus

6082 adhesiolysis with hyaluronidase, hyaluronidase alone, or isotonic saline for pain relief or

6083 in the proportion of patients requiring additional treatments (Table 74) [704].

6084 Table 74. Trial of adhesiolysis with hypertonic saline versus hyaluronidase versus isotonic saline

Author, year	Number of patients Duration of follow-up	Main results	Quality
Heavner, 1999[704]	N=83 1 year	Adhesiolysis with hypertonic saline vs. hypertopnic saline + hyaluronidase vs. isotonic saline vs. isotonic saline + hyaluronidase No significant differences on McGill Questionnaire, VAS pain score, and percentage requiring additional treatments through 1 year (data only reported in graphs, raw data not provided)	2/11

6085

6086 Safety

The single higher-quality trial reported one subarachnoid block among 50 patients
undergoing adhesiolysis [555]. One lower-quality trial reported no adverse effects
among 59 patients [704]. A non-randomized comparative study reported one suspected
infection and minor complications (such as rash and itching) in 10% of patients [703]. In
other observational studies, subarachnoid puncture was reported in up to 9% of
procedures [705], suspected infection in up to 10% [705], and post dural headache in
14% [706].

- 6094 Costs
- 6095 We identified no studies evaluating costs.

6096 Summary of evidence

- Although one higher-quality trial found adhesiolysis markedly superior to epidural steroids for pain relief in patients with refractory back pain who failed a previous epidural steroid injection, confirmation of results by other trials is necessary because of the extremely low (0%) response rate in the epidural steroid group (level of evidence: fair).
- There is no clear evidence that use of hypertonic saline or hyaluronidase
 improves outcomes from adhesiolysis compared to using isotonic saline alone
 (level of evidence: fair).
- Adverse events were infrequent and usually minor in the trials, but were more
 common and included suspected infection, subarachnoid puncture, and postdural headache in up to 9-14% of patients in observational studies (level of
 evidence: fair).
- 6109 **Recommendations and findings from other guidelines**
- The other guidelines don't address this issue.

6111 Intrathecal therapy

- 6112 Results of search: systematic reviews
- 6113 We found no systematic reviews evaluating the efficacy of intrathecal delivery of opioids
- 6114 or other drugs in patients with low back pain.
- 6115 Results of search: trials
- 6116 We found no relevant trials.

6117 *Efficacy of intrathecal therapy*

- 6118 In the only comparative observational study, 27% of patients with failed back surgery 6119 syndrome who underwent implantation (N=23) had improvement in the ODI versus 12% 6120 in the usual care group (N=44) over a five-year period [707]. One prospective study of 6121 136 patients with chronic low back pain who had an intrathecal device implanted (76% 6122 with prior back surgery) found that pain scores had dropped by more than 47% at 12-6123 month follow-up [708]. In addition, more than 65% of implanted patients had 6124 improvements in ODI scores. Other data on efficacy of intrathecal therapy primarily 6125 comes from small case series of patients with cancer and non-cancer pain, with the 6126 proportion of patients with 'good or excellent' results ranging from 50% to close to 100% 6127 [709].
- 6128 Safety
- 6129 Complications with the intrathecal implant appear quite frequent. In one study, there
- 6130 was an average of 0.77 mean complications per implant (N=23). The most common
- 6131 complication was catheter-related and occurred in 26% (6/23). Other complications
- 6132 included pump flipping (22%) and infection (22%). One patient required pump
- 6133 explantation, and another developed late-onset meningitis after catheter replacement
- 6134 [707]. In another study, adverse events occurred in 23 of 136 (17%) patients after
- 6135 intrathecal pump implantation, with 21 (15%) requiring surgical correction [708].
- Adverse events included infection (12%), dislodgement or migration (1.5%), and
- 6137 cerebrospinal fluid leak (0.7%).
- 6138 Costs
- 6139 We identified two cost studies [710, 711]. Both estimated fewer costs with intrathecal
- 6140 morphine relative to medical management, but used poor-quality observational data for
- 6141 generate key parameters.

6142 Summary of evidence

- There is insufficient data to judge the efficacy of intrathecal therapy in patients
 with failed back surgery syndrome (limited observational studies only) (level of
 evidence: poor).
- Adverse events with intrathecal therapy appear to be frequent and often require
 surgery (level of evidence: poor).

- 6148 **Recommendations and findings from other guidelines**
- The other guidelines do not address this issue.

6150 Non-invasive interventions

- 6151 Results of search: systematic reviews
- 6152 We found no systematic reviews of non-invasive interventions in patients with failed
- 6153 back surgery syndrome.
- 6154 Results of search: trials
- 6155 We identified one lower-quality trial comparing the efficacy of low-tech exercise, hi-tech
- 6156 exercise, physical agents, manipulation, and no treatment in patients with chronic low
- 6157 back pain following L5 laminectomy [712].
- 6158 Efficacy of non-invasive interventions for failed back surgery syndrome
- 6159 The trial (N=250) found no significant differences in ODI scores at the end of an 8-week
- 6160 course of treatment of high-tech exercise (using specialized exercise equipment), low-
- 6161 tech exercise (using McKenzie and spinal stabilization training exercises), physical
- agents (hot packs, ultrasound, TENS), joint manipulation, and control, though trends
- 6163 favored the two exercise groups (Table 75) [712].

Table 75. Trial of efficacy of non-invasive interventions for failed back surgery syndrome

	Number of patients		
Author, year	Duration of follow-up	Main results	Quality
Timm,	N=250	Low-tech exercise vs. high-tech exercise vs. physical	
1994[712]	At end of 8 week	agents vs. manipulation vs. no treatment (at end of 8	
	course of treatment	week treatment session)	2/11
		ODI (0 to 100), mean improvement: -20.5 vs18.1 vs	
		0.14 vs3.8 vs0.18	

- 6165 Safety
- 6166 The trial did not assess safety.
- 6167 Costs
- 6168 No studies evaluated costs.

6169 Summary of evidence

- One lower-quality trial found no significant differences in immediate post-
- 6171 treatment ODI scores between exercise, physical agents, manipulation, and no 6172 treatment in patients with chronic low back pain following L5 laminectomy (level 6173 of evidence: poor).

- 6174 **Recommendations and findings from other guidelines**
- The other guidelines don't address this issue.

6176 Spinal cord stimulation

- 6177 Results of search: systematic reviews
- 6178 We identified three recent systematic reviews (all rated higher-quality) evaluating spinal
- 6179 cord stimulation for failed back surgery syndrome [689-691]. Only one higher-quality
- 6180 trial [713] and one low-quality, controlled observational study [714] were included in the
- 6181 reviews. Seventy-two other case series of spinal cord stimulation for chronic back and
- 6182 leg pain or failed back surgery syndrome were also included in one of the reviews [689];
- 6183 results are discussed in Key Question 9.
- 6184 Results of search: trials
- 6185 We did not search for additional trials

6186 Efficacy of spinal cord stimulation

- 6187 The single available RCT (N=50) found that patients randomized to spinal cord
- 6188 stimulation were more likely to report >50% pain relief compared to reoperation after 12
- 6189 months (38% or 9/24 vs. 12% or 3/26, p=0.0475) [713]. Patients randomized to spinal
- 6190 cord stimulation were also less likely to report an increase in opiate analgesia (13% vs.
- 6191 69%, p=0.0005). However, there was a crossover was high: five of 24 (21%) patients
- 6192 allocated to spinal cord stimulation and 14 of 26 (54%) allocated to reoperation received
- 6193 the other intervention. Analyzed by treatment received, the difference in the proportion
- of patients with >50% pain relief was not significant (45% or 15/33 vs. 18% or 3/17,
- 6195 p=0.0673). Three-year results were similar.
- 6196 In the only controlled observational study, patients with failed back surgery syndrome
- 6197 were allocated to spinal cord stimulation if they had persistent symptoms after six
- 6198 months of medical therapy, and continued medical therapy if they were successful
- 6199 [714]. Patients who remained on medical therapy reported similar overall improvements
- 6200 in pain compared to those receiving spinal cord stimulation, but reported superior
- 6201 improvements in disability score (17 versus 3 point improvement, p<0.05). However,
- 6202 these results are very difficult to interpret because patients with spinal cord stimulation
- 6203 were selected because of persistent symptoms.

6204 Safety

- 6205 The RCT reported four (17%) and six (26%) complications at 6 and 12 months following
- 6206 spinal cord stimulator implantation [713]. Long-term complications included one
- 6207 infection, two implantation generator pocket-related complications, and one defective
- 6208 lead. Safety results from non-randomized studies are discussed in Key Question 9.
- 6209 Costs
- 6210 One decision analysis found that the spinal cord stimulation dominated continued
- 6211 medical management over the lifetime of a patient with failed back surgery syndrome
- 6212 [715]. However, this study should be interpreted cautiously because it may have used
- 6213 indirect analyses (combining estimates from one trial of spinal cord stimulation versus
- 6214 surgery and one trial of surgery versus medical management) inappropriately to
- 6215 estimate effectiveness of spinal cord stimulation relative to continued medical
- 6216 management. Specifically, estimates for effectiveness of surgery relative to continued
- 6217 medical management were taken from the only trial showing a benefit from surgery
- 6218 [640]. Other cost studies also used unreliable data to estimates costs and outcomes
- 6219 [707, 716].
- 6220

Summary of evidence

- One small RCT found that spinal cord stimulation was associated with a higher
 likelihood of pain relief and lower likelihood of increase in opioid use in patients
 with failed back surgery syndrome, but results are difficult to interpret because of
 a high rate of crossovers (level of evidence: fair).
- Other evidence (low-quality observational data) is inadequate to make reliable judgments about efficacy.
- Long-term complications after spinal cord stimulation have not been well-studied,
 but include infection and generator or lead-associated problems.
- 6229 **Recommendations from other guidelines**
- The European COST guidelines found insufficient evidence to recommend spinal cord stimulation for patients with chronic low back pain.
- 6232

6232 Key Question 12.

6233 How effective are different methods of integrating and coordinating care in 6234 improving outcomes?

- 6235 Results of search: systematic reviews
- 6236 We identified no systematic reviews evaluating the efficacy of different methods of
- 6237 integrating or coordinating care in patients with low back pain.
- 6238 Results of search: trials
- 6239 We identified one lower-quality trial evaluating the efficacy of coordination of care
- 6240 relative to usual care in patients with back-pain associated disability [717]. One other
- 6241 low-quality trial evaluated the efficacy of integrated care between primary care and
- 6242 neurology via a psychiatrist liaison versus usual care in patients initially presenting with
- back pain of unspecified duration [718].

6244 Efficacy of coordinated or integrated care versus usual care

- 6245 One trial found that in workers receiving compensation for low back pain for 4 to 8 6246 weeks, coordination of primary health care was superior to usual care for functional 6247 status and disability after 6 months as measured by the ODI scale (average 9 point 6248 difference, p=0.02) and the Quebec Back Pain Disability Scale (average twelve point 6249 difference, p=0.01) (Table 76) [717]. Coordination of care was also associated with 6250 modestly quicker return to work (6.6 days, not significant). Patients randomized to 6251 coordinated care also used three times fewer specialized imaging tests (p < 0.01) and 6252 exercised twice as much (p<0.05) as controls. Two primary care physicians and a 6253 nurse performed the coordination of care intervention, which involved a complete 6254 examination, recommendations to the treating physician for clinical management 6255 consistent with guidelines, and support to carry out the recommendations.
- Another trial, which had numerous methodologic flaws (met 1 of 11 quality criteria) found that integration of care between a neurologist and primary care physician via a psychiatrist did not improve patient outcomes, satisfaction of general practitioners, or affect utilization of healthcare services relative to usual care in patients with low back pain of unspecified duration [718]. The protocol called for the psychiatrist, who did not see the patient, to facilitate communication between the primary care physician and neurologist through structured telephone communication, weekly communication, and

- 6263 development of a treatment plan of care. However, the protocol was only fully
- 6264 implemented in about one-quarter of the 50 patients randomized to the intervention
- 6265 group.
- 6266

Table 76. Trials of coordination of care

Author, year	Number of patients Duration of follow-up	Main results	Quality
Rossignol, 2000[717]	N=110 6 months	Coordination of care versus usual care Return to work by 6 months: 78% vs. 73% Time to return to work: average difference 6.6 days (NS) Pain, mean difference from baseline to 6 months: 22.9 vs. 12.8, p=0.1 Quebec Back Pain Disability Scale, mean difference from baseline to 6 months: 20.9 vs. 9.1, p=0.01 Owestry, mean difference from baseline to 6 months: 17.2 vs. 7.8, p=0.02 Dallas Pain Questionnaire, mean difference from baseline to 6 months: 25.9 vs. 11.7 (p=0.01)	5/11
Meeuwesen, 1996[718]	N=104 6 months	Integrated care versus usual care SCL-90 subscales, DSM-III-R somatoform disorders (DSM-SOM) scale: No differences between interventions Functional impairment scale (FBI), mean difference from baseline to 6 months: 1.6 vs. 0.9 (NS) General Health Questionnaire-28, mean difference from baseline to 6 months: 2.0 vs. 1.7 (NS) Satisfaction of general practitioners: no differences between interventions Medication use: no differences between interventions Diagnostic imaging: no differences between interventions	1/11

6267

6268 Safety

6269 No studies evaluated safety.

6270 Summary of evidence

- Coordination of care was superior to usual care for improving functional status and pain after 6 months while reducing use of specialized imaging tests in workers receiving short-term (4 to 8 weeks) compensation for low back pain in one lower quality trial (level of evidence: poor).
- There is insufficient evidence to judge the efficacy of coordination or integration
 of care in other (primary care) settings (one low quality trial) (level of evidence:
 poor).
- 6278 **Recommendations and findings of other guidelines**
- The other guidelines do not address this issue.

- 6280 Key Question 13.
- 6281 What interventions are effective for secondary prevention of LBP in patients who
- 6282 have had an episode of acute LBP, or prevention of flares of LBP in patients with
- 6283 chronic LBP?

6284 Back schools

- 6285 Results of search: systematic reviews
- 6286 A recent, good-quality Cochrane review of back schools (19 trials) included five trials
- 6287 (three higher-quality [255, 259, 260]) reporting recurrent low back pain episodes (or sick
- 6288 leave due to low back pain) as an outcome [237, 238]. This updated results from a
- 6289 previous Cochrane review [239]. Another recent, poor-quality systematic review did not
- 6290 include any trials of back schools reporting recurrence rates that weren't included in the
- 6291 Cochrane review [719].
- 6292 Results of search: trials
- 6293 We did not identify any additional relevant trials.

6294 Efficacy of back schools versus no back school, usual care, or placebo for preventing 6295 recurrent episodes of low back pain

6296 The Cochrane review included five trials comparing back schools to no treatment or 6297 usual care [237, 238]. Four trials were conducted in occupational settings and the fifth 6298 [255] in a mixed setting. Longer-term follow-up [258, 720] is available from two higher-6299 quality trials [255, 259]. One trial of 'mini' back school found no difference in the 6300 proportion of patients with subacute low back pain with one or more sick-leave 6301 recurrences randomized to back school versus usual care through five years of follow-6302 up (72% or 142/198 versus 74% or 118/160), though the proportion with two or more 6303 recurrences was lower in the back school group (35% or 69/198 vs. 46% or 74/160) 6304 [258, 259]. The other trial found that in patients with low back pain within the last year 6305 who had completed treatment and were no longer on sick leave, the mean number of 6306 low back pain recurrences decreased more with an intensive back school program than 6307 with no back school through three years (mean decrease 0.9 vs. 0.3 episodes/year, 6308 p<0.05) [255, 720]. On the other hand, three trials (one higher-guality) with shorter 6309 duration of follow-up (one year) reported no difference in low back pain recurrences with 6310 back school relative to usual care, placebo treatment, or wait-list control [253, 256, 260].

- 6311 Two of the trials included patients with back pain for less than three months, and the
- third [256] included patients with at least three episodes of low back pain annually.
- 6313 Efficacy of back schools versus exercise for preventing recurrent episodes of low back
- 6314 *pain*
- 6315 The Cochrane review included one lower-quality trial [256] that found back school
- 6316 associated with a higher incidence of low back pain episodes than biweekly calisthenics
- 6317 through 12 months in workers with frequent (at least three annually) low back pain
- episodes (mean number of painful months 7.3 vs. 4.5, p<0.05).
- 6319 Summary of evidence
- Evidence on the efficacy of back schools for preventing recurrent episodes of low back pain is mixed, which may be due in part to diversity between populations and interventions evaluated. One higher-quality trial found that an intensive back school intervention decreased recurrent episodes of low back pain more than no back school through three years of follow-up, but another evaluating a 'mini' back school found no clear effect. Three shorter-term (1 year) trials (one higher-6326 quality) also found no effect (level of evidence: fair).
- One lower-quality trial found back school inferior to calisthenic exercises for reducing low back pain episodes through 12 months (level of evidence: poor).
- 6329 **Recommendations and findings from other guidelines**
 - The VA/DoD guidelines found inconclusive evidence on the long term benefit of
 back schools (strength of evidence: A to B).
 - The UK RCGP guidelines found that group education based on the Swedish
 back school approach may be effective in occupational settings (strength of
 evidence: **).
 - The UK RCGP guidelines found that the efficacy of back schools in nonoccupational settings has not been demonstrated (strength of evidence: *).
 - 6337 The European COST guidelines recommend against back schools for acute low
 6338 back pain.
 - The European COST guidelines recommend considering back schools where
 information is consistent with evidence-based recommendations for short-term
 (<6 weeks) pain relief and improvements in functional status, but recommend
 against back schools for chronic low back pain when aiming for long-term effects
 (>12 months).

6344 Exercise

- 6345 Results of search: systematic reviews
- 6346 A recent, good-quality Cochrane review of exercise for low back pain did not include
- 6347 recurrences as an outcome [268, 269]. We identified one other recent systematic
- 6348 review of exercise that evaluated low back pain recurrences [719]. However, it was
- 6349 rated poor-quality because it did not assess quality of included trials and did not
- 6350 describe methods for synthesizing the evidence.
- 6351 Results of search: trials
- 6352 We identified three lower-quality trials that reported effects of exercise on recurrences of
- 6353 low back pain [453, 721, 722].

6354 *Efficacy of exercise versus no exercise for preventing recurrent episodes of low back* 6355 *pain*

- 6356 One trial found that a weekly, ongoing exercise program reduced the average number
- 6357 of low back pain episodes over a 1 $\frac{1}{2}$ year period by 0.27, compared to an average
- 6358 increase of 0.19 episodes in the no exercise group (Table 77) [721]. However, this
- 6359 study had numerous methodologic shortcomings including unclear randomization and
- 6360 allocation concealment methods, unclear use of blinded outcomes assessment, and
- 6361 lack of intention-to-treat analysis with high loss to follow-up.

6362 Table 77. Trial of exercise versus no exercise for preventing recurrent episodes of low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Kellett, 1991[721]	N=125 1.5 years	Exercise versus no exercise Mean episodes of low back pain in 1.5 years prior to intervention minus episodes during 1.5 years during intervention: 0.27 vs0.19 (p<0.05) Mean sick days in 1.5 years prior to intervention minus episodes during 1.5 years during intervention: 2.86 vs 1.63 (p<0.02)	1/11

6363

- 6364 *Efficacy of exercise versus education only for preventing recurrent episodes of low back* 6365 *pain*
- 6366 Two lower-quality trials both found that exercise reduced the number of back pain
- 6367 recurrences (Table 78) [453, 722]. In one trial of patients with a back pain episode who
- 6368 had completed treatment and sick leave, a course of McKenzie extension exercises was
- 6369 associated with fewer low back pain recurrences than back education only through one

6370 year follow-up (44% vs. 74%) [453]. The benefit persisted from one to five years follow-

- 6371 up (proportion of patients with recurrences 64% vs. 88%, p<0.01). In the other trial, a
- 6372 13-week course of a Mensendieck exercise program (incorporating exercises and
- 6373 education) was associated with fewer recurrences compared to information about the
- 6374 exercise program only during 12 months of follow-up (32% versus 57%, p<0.05) [722].

6375 Table 78. Trials of exercise versus education for preventing recurrent episodes of low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Soukup, 1999[722]	N=77 12 months	Mensendieck exercise program versus education only Low back pain recurrences during 12 month follow-up: 32% (11/34) vs. 57% (20/35) (p<0.05) Sick leave (mean days): 30 vs. 38 (NS) Pain, 0 to 100 scale: 26 vs. 32 (p=0.22)	3/11
Stankovic, 1995[453]	N=100 5 years	McKenzie exercise versus back education Recurrences: 44% (22/50) vs. 74% (37/50) after 1 year; 64% (30/47) vs. 88% (37/42) between 1 and 5 years (p<0.01) Sick leave between 1 and 5 years: 51% (24/47) vs. 74% (31/42) (p<0.03)	7/11

6376

6377 *Efficacy of exercise versus other interventions for preventing recurrences of low back* 6378 *pain*

6379 One higher-quality trial (reviewed in detail in the section on self-care books) found that

6380 approximately 50% of subjects randomized to exercise, manipulation, or a self-care

6381 book experienced a recurrence of low back pain during the first year after the

6382 intervention, and 70% during the second year [296]. There were no differences in the

6383 proportion of patients who sought care for back pain in the second year (20% vs. 29%

6384 vs. 24%, p=0.29).

- 6385 Summary of evidence
- There is consistent evidence from two lower-quality trials that an exercise
 program is superior to education only for reducing long-term low back pain
 recurrences (level of evidence: fair).
- There is insufficient evidence (one very low-quality trial) to judge the efficacy of
 an ongoing exercise program for reducing future episodes of low back pain (level
 of evidence: poor).

6392 **Recommendations and findings from other guidelines**

• The other guidelines don't address this issue.

6394 Lumbar supports

- 6395 Results of search: systematic reviews
- 6396 One recent, good-quality Cochrane review found no trials evaluating the efficacy of
- 6397 lumbar support for secondary prevention of low back pain [469].
- 6398 Results of search: trials
- 6399 We found no additional trials.
- 6400 Efficacy of lumbar supports for preventing recurrent episodes of low back pain
- 6401 There are no trials evaluating the efficacy of lumbar supports for prevention of low back
- 6402 pain recurrences. The Cochrane review found moderate evidence that lumbar supports
- are not more effective than other interventions or no treatment for primary prevention.
- 6404 Summary of evidence
- 6405
 No trials have evaluated the efficacy of lumbar supports for secondary prevention.

6407 **Recommendations and findings from other guidelines**

6408
 6409
 The European COST guidelines recommend against lumbar supports for prevention of low back pain.

6410 Advice to stay active

- 6411 Results of search: systematic reviews
- 6412 One recent, good-quality Cochrane review of advice to stay active included no trials
- 6413 reporting low back pain recurrences as an outcome [450].
- 6414 Results of search: trials
- 6415 We identified one higher-quality trial evaluating the effects of a multidisciplinary
- 6416 examination and advice to stay active on recurrent sick leave due to low back pain
- 6417 (Table 79) [262]. It was excluded from the Cochrane review because it didn't evaluate
- 6418 advice to stay active as a single intervention.
- 6419 Efficacy of advice to stay active for preventing recurrent episodes of low back pain
- 6420 One trial of patients on sick leave for 8 to 12 weeks due to low back pain found that a
- 6421 single visit to a spine clinic with examination by a physiatrist and physical therapist and
- 6422 advice on remaining active was associated with similar rates of recurrent episodes of
- 6423 low back pain compared to usual care through three years (62% vs. 61%, NS) [450].

- 6424 There were also no differences in the proportion off sick leave at 3 years, though the
- 6425 intervention group was superior at 1 year follow-up (OR 1.60, 95% CI 1.08 to 2.39).

6426Table 79. Trial of spine clinic exam and advice to stay active versus usual care for preventing6427recurrent episodes of low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Hagen, 2003[262]	N=510 3 years	Spine clinic exam and advice to stay active versus usual care New episodes of sick leave due to LBP (through 3 years): 62% (147/237) vs. 61% (135/220) (NS) LBP still present at 1 year: 47% vs. 52% (NS) On sick leave at 3 years: 64% vs. 62% (NS)	6/11

6428

- 6429 Summary of evidence
- One higher-quality trial found no difference in long-term (through 3 years)
 recurrences in patients on sick leave for low back pain randomized to a single
 spine clinic exam and advice to stay active versus usual care (level of evidence:
 fair).

6434 **Recommendations and findings from other guidelines**

6435 • Recommendations from other guidelines for advice are summarized in Key
 6436 Question 4.

6437 Early occupational medicine intervention

- 6438 Results of search: systematic reviews
- 6439 We identified no systematic reviews evaluating the effects of early interventions in
- 6440 preventing future episodes of low back pain.
- 6441 Results of search: trials
- 6442 We identified one higher-quality trial evaluating an early evaluation by an occupational
- 6443 physician in workers with low back pain [723].
- 6444 Efficacy of an early occupational medicine intervention versus usual care for preventing 6445 recurrent episodes of low back pain
- One trial of hospital workers on sick leave for at least 10 days due to low back pain
- 6447 found that early, routine management by occupational physicians trained in recent
- 6448 guidelines was associated with a greater likelihood of recurrent sick leave due to low
- back pain than usual management by the worker's supervisor for the first three months

(52% vs. 25%, hazard ratio 2.4, 95% Cl 1.2 to 4.7) (Table 80) [723]. However, there
were no differences in the amount of time until return to work (hazard ratio 1.3, 95% Cl
0.90 to 1.90) or other outcomes. A high rate of crossovers (24%) in the usual care
group and some deviation from the guidelines by the occupational medicine physicians
could have affected the results of this trial.

6455Table 80. Trial of early occupational medicine intervention versus usual care for preventing6456recurrent episodes of low back pain

Author, year	Number of patients Duration of follow-up	Main results	Quality
Verbeek, 2002[723]	N=120 12 months	Early intervention by an occupational physician versus no early intervention Time to return to work: 51 vs. 62 days (NS) Recurrence of sick leave in 1 year: 51% (26/51) vs. 25% (12/48) (p<0.05) Pain intensity (mean at 12 months, VAS 0 to 100): 24 vs. 30 (p=0.18) RDQ score (0 to 100): 20 vs. 21 (p=0.57)	6/11

6457 Summary of evidence

An early occupational medicine intervention was associated with a greater
 likelihood of lower back pain recurrences in one higher-quality trial (level of
 evidence: fair).

6461 **Recommendations and findings from other guidelines**

• The other guidelines don't address this issue.

6463 **Behavioral interventions, multidisciplinary rehabilitation, spinal manipulation,** 6464 **acupuncture, patient information or education**

- 6465 Results of search: systematic reviews
- 6466 Recent, good-quality Cochrane reviews of behavioral interventions [73], multidisciplinary
- rehabilitation [71, 72, 303, 304], or acupuncture [209, 210] included no other trials
- 6468 reporting rates of low back pain recurrences. One trial of spinal manipulation was
- 6469 discussed in the section on exercise therapy [296]. We found no systematic reviews on
- 6470 the effects of patient information or education on recurrent low back pain.
- 6471 Results of search: trials
- 6472 We found no additional relevant trials for any of these interventions.

6473 Summary of evidence

• There is no evidence on the effects of behavioral interventions, multidisciplinary disciplinary rehabilitation, and acupuncture on recurrent back pain episodes.

6476 Key Question 14.

6477 What is/are safe and effective strategies for managing low back pain during

6478 pregnancy and post-partum?

- 6479 We considered low back pain during pregnancy as separate from pelvic girdle
- 6480 pain (defined as pain experienced between the posterior iliac crest and the gluteal fold,
- 6481 particularly in the vicinity of the sacroiliac joints). The AHCPR, VA/DoD, UK RCGP, and

6482 European COST guidelines do not address low back pain in pregnancy, though the

6483 latter has developed a guideline on diagnosis and treatment of pelvic girdle pain [724].

6484 Acupuncture during pregnancy

- 6485 Results of search: systematic reviews
- 6486 A recent, higher-quality Cochrane review [209, 210] of acupuncture (reviewed earlier in
- 6487 this report) included one lower-quality trial [725] of acupuncture versus exercise in
- 6488 pregnant women. This trial was also included in a systematic review of physical therapy
- 6489 for pregnancy-related back pain [726].
- 6490 Results of search: trials
- 6491 We identified two lower-quality trials [727, 728] of acupuncture during pregnancy not
- 6492 included in the Cochrane review. Both compared acupuncture to usual care.
- 6493 Efficacy of acupuncture versus usual care
- 6494 Acupuncture was superior to usual care in pregnant women for pain relief in two lower-6495 quality trials (Table 81) [727, 728]. One found a higher proportion of patients reporting a 6496 >50% decrease in average pain intensity in the acupuncture group relative to usual care 6497 (78% vs. 15%, p<0.0001) [727]. The other reported decreased pain intensity in 60% of 6498 patients with acupuncture versus 14% with usual care (p<0.01) [728]. Both trials also 6499 found greater ability to perform activities with acupuncture, with increased capacity to 6500 perform general activities (p=0.01) [727] or decreased pain with activity (p<0.05) [728]. 6501 One trial reported less use of other therapies with acupuncture compared to usual care
- 6502 (p<0.01) [728]
- 6503

6503 Table 81. Trials of acupuncture versus usual care for low back pain during pregnancy

Author, year	Number of patients Duration of follow-up	Main results	Quality
Guerreiro da Silva,	N=61	Acupuncture vs. usual care	
2004[727]	8 weeks	Average pain (0 to 10), mean difference relative to baseline: -4.8 vs +0.3 (p<0.0001)	
		Average pain intensity decrease by > 50%: 78% (21/27) vs. 15% (5/34) (p<0.0001)	
		Medication use, median number of daily doses between initial and final interviews: 0.0 vs 2.0 (p=0.005)	3/11
		General activities functional status (0 to 10), median	
		difference relative to baseline: $-1.0 \text{ vs } 0.0 \text{ (p=0.01)}$ Ability to perform work (0 to 10): $0.0 \text{ vs } +1.0 \text{ (p<0.001)}$ Ability to walk (0 to 10): $0.0 \text{ vs } +2.0 \text{ (p<0.001)}$.	
Kvorning, 2004[728]	N=72	Acupuncture vs. usual care	
	From third trimester to	Pain intensity decreased: 60% vs. 14% (p<0.01) Decreased pain with activity: 43% vs. 9% (p<0.01)	4/11
	birth	Analgesic drug use: 0% (0/37) vs. 15% (5/34) (p<0.05)	

6504

6505 Efficacy of acupuncture versus exercise

Both systematic reviews included one lower-quality trial comparing acupuncture with

6507 physiotherapy that found acupuncture superior to exercise for mean pain scores after

treatment (difference of about 1.5 to 3 points on a 10 point VAS pain scale) [725].

6509 Acupuncture was also more effective than exercise for improving functional status for

6510 various activities as measured by the Disability Rating Index, and a higher proportion of

6511 patients reported 'excellent' or 'good' pain relief with acupuncture (96% or 27/28 versus

6512 178% or 14/18). However, there was a high drop-out rate in the exercise group (12/30)

and it is not clear how these patients were handled in the data analysis.

6514 Safety

None of the trials reported serious adverse effects in mothers or their infants following

acupuncture [725, 727, 728]. In one trial, two women had small bruises, 3 reported

6517 ecchymosis at one or two points and one experienced a higher level of pain for a few

hours after the first session [727]. In another trial, symptoms were reported in 38% of 37

- 6519 patients including local pain (n=6), heat or sweating (n=5), local hematoma (n=2),
- tiredness (n=2), nausea (n=2) and weakness (n=1) [728].
- 6521 Costs
- 6522 No studies evaluated costs

6523 Summary of evidence

Three lower-quality trials found acupuncture more effective than usual care (2
 trials) or exercise (1 trial) for improving pain and function in pregnant women with
 low back pain (level of evidence: fair).

6527 **Physical therapy during pregnancy**

- 6528 Results of search: systematic reviews
- 6529 We identified one higher-quality systematic review of exercise for back pain during
- 6530 pregnancy that included five trials [726]. Only one, a trial comparing water gymnastics
- to usual care, was rated higher-quality [729].
- 6532 Results of search: trials
- 6533 We identified two one additional trial (lower-quality) of a sitting pelvic tilt intervention
- 6534 [730]

6535 Efficacy of exercise versus usual care

- 6536 The systematic review included five trials of physical therapy (exercise, education,
- advice, or combination of these interventions) for back pain compared to usual care
- 6538 [726]. It did not attempt to pool trials because of diversity in the populations and6539 interventions studied.
- 6540 In the only higher-quality trial, water gymnastics was associated with decreased pain
- 6541 relative to usual care [729]. Pain intensity was lower in the water gymnastics group
- relative to the usual care group in the first postpartum week (p=0.034, data not
- 6543 reported). In addition, the water gymnastics group had less absence from work after 32
- 6544 weeks of pregnancy (OR 0.38, 95% CI 0.16-0.88).
- Two trials [731, 732] included in the systematic review [726] found individualized
- 6546 exercise superior to usual care for improving pain intensity. Group education or
- therapy, however, was superior to usual care in only one [733] of three [732, 734] trials.
- All of the trials were rated lower-quaity. The only trial with long-term (six years) follow-
- 6549 up found that back pain during pregnancy appeared to return to baseline levels soon
- 6550 after pregnancy [735].

6551 One lower-quality trial not included in the systematic review compared a sitting pelvic tilt

exercise to no exercise (Table 82) [730]. Those in the pelvic tilt intervention group had

less pain at day 56 versus usual care (2.03 vs. 7.49 on a 10 point VAS, p<0.001).

6554 6555

Table 82. Trial a sitting pelvic tilt interventions versus usual care for low back painduring pregnancy

Author, year	Number of patients Duration of follow-up	Main results	Quality
Suputtitada, 2002[730]	N=67 56 days	Sitting pelvic tilt exercise versus no exercise Pain (0 to 10), mean on day 56: 2.03 vs 7.49 (p<0.05) Labor onset at 37-38 weeks: 56% vs. 20% (p<0.05) Birth weight, mean: 3009g vs 3192g (p=0.018)	3/11

6556

6557 Efficacy of physical therapy versus other interventions

6558 One systematic review included a trial comparing physical therapy and acupuncture

6559 [725]. We reviewed this trial in the section on efficacy of acupuncture versus other

- 6560 interventions.
- 6561 Safety

In the trial of a sitting pelvic tilt exercise, labor onset was slightly earlier and birth weight

6563 slightly lower for those randomized to the pelvic tilt intervention, although there was no

6564 preterm labor or low birthweight [730]. Other trials did not report adverse events

- 6565 associated with exercise in pregnancy.
- 6566 *Costs*

6567 No studies evaluated costs.

6568 Summary of evidence

- One higher-quality trial found water gymnastics superior to usual care for treating
 back pain in pregnant women (level of evidence: fair).
- Individualized physiotherapy was superior to usual care in two lower-quality trials
 (level of evidence: fair).
- Evidence on efficacy of group education and exercise was mixed, with one of
 three lower-quality trials finding group education and exercise superior to usual
 care in only one of three lower-quality trials (level of evidence: poor).
- A pelvic tilt exercise was associated with decreased pain in one lower-quality trial of pregnant women with low back pain, but also with lower birthweight and earlier (full-term) onset of labor (level of evidence: poor)

6579 Massage during pregnancy

- 6580 Results of search: systematic reviews
- 6581 One higher-quality systematic review of physical therapy interventions [726] included
- one lower-quality trial of massage therapy versus progressive relaxation therapy [736].
- 6583 Results of search: trials
- 6584 We identified one lower-quality trial not included in the systematic review that evaluated
- 6585 the same interventions in depressed pregnant women [737].

6586 Efficacy of massage versus usual care

- 6587 In a trial of depressed pregnant women (N=84), mean pain intensity was significantly
- 6588 lower with massage than with usual care at the end of treatment relative to baseline, but
- the difference was only 0.6 point on a 10-point scale (Table 83) [737]. The pain score
- 6590 was unchanged in the usual care group. The statistical significance of between-group
- 6591 differences was not reported.

6592Table 83. Trial a massage versus progressive relaxation and usual care for low back pain in6593depressed pregnant women

Author, year	Number of patients Duration of follow-up	Main results	Quality
Field, 2004[737]	N=84 16 weeks	Massage vs. progressive relaxation vs. usual care Back pain (0 to 10), mean on last day: 2.9 vs. 4.0 vs. 2.6 Anxiety (0 to 80): 42 vs. 45 vs. 35 (between group differences not reported) Mood (0 to 60): 8.2 vs. 9.6 vs. 8.7 (between group differences not reported)	1/11

6594

6595 *Efficacy of massage versus progressive relaxation therapy*

6596 In a small (N=26) trial of non-depressed women included in the systematic review, there 6597 was less back pain intensity in the massage therapy group after treatment relative to 6598 baseline (4.6 vs. 3.8), but statistical significance of differences compared to the 6599 progressive relaxation therapy group (3.8 vs. 3.2) were not reported [736]. In a separate 6600 trial of depressed women, mean pain intensity was significantly lower at the end of 6601 treatment relative to baseline, but the difference was also small, averaging 0.6 points on 6602 a 10-point scale [737]. In the relaxation group, there was no change in pain intensity 6603 from baseline to end of treatment. Significance of between-group differences was not 6604 reported.

6605 Safety

- 6606 In a trial of depressed pregnant women, scores on the Obstetric Complications Scale
- 6607 were higher (superior) in the massage group relative to the relaxation group (102.1 vs.
- 6608 91.2), primarily related to decreased prematurity and low birthweight in the massage 6609 group [737].

6610 Summary of evidence

- Although two lower-quality trials found that massage therapy decreased pain
 scores in pregnant women, effects appeared modest and it was not clear if the
 differences were significant relative to usual care or progressive relaxation (level
 of evidence: poor).
- 6615 Supportive devices during pregnancy
- 6616 Results of search: systematic reviews
- 6617 A Cochrane review of interventions during pregnancy [738] included one lower-quality
- 6618 crossover trial (unclear if randomized) of the Ozzlo pillow (a wedge-shaped pillow
- 6619 designed to give support to pregnant women while lying on their side in bed) versus a
- 6620 standard pillow [739].
- 6621 Results of search: trials
- 6622 We found no additional trials
- 6623 Efficacy of supportive devices versus usual care
- 6624 The Ozzlo pillow was superior to a standard pillow for pain at night (median score 14 vs.
- 19, p=0.002) and during the day (19 vs. 25, p=0.02), though there was no effect on
- sleeping scores [739]. The pillow was rated as at least moderately useful by 47 of 92
- 6627 women using it versus 31 of 92 using the standard pillow (OR 0.32, 95% CI 0.18-0.58).
- 6628 Safety
- 6629 No side effects of the Ozzlo pillow were described.
- 6630 *Costs*
- 6631 We found no studies evaluating costs.

6632 Summary of evidence

There is insufficient evidence from one lower-quality trial to determine the
 efficacy of the Ozzlo pillow versus standard pillows in pregnant women with low
 back pain (level of evidence: poor).

6636 Key Question 15.

- 6637 What is the cost-effectiveness associated with different interventions or
- 6638 management strategies (such as care provided by different types of providers) for
- 6639 managing low back pain?

6640 We identified four recent systematic reviews evaluating cost-effectiveness 6641 studies of different interventions or management strategies in patients with low back 6642 pain [740-743]. All found few full cost-effectiveness or cost-utility analyses and 6643 important methodological deficiencies in the available cost studies, including inadequate 6644 methods for identifying, valuing, and analyzing costs, and lack of sensitivity analyses for 6645 evaluating the robustness of conclusions. In one systematic review, for example, 12 of 6646 the 17 included studies did not mention using the societal perspective to analyze costs 6647 [743]. All of the systematic reviews concluded that current economic analyses are 6648 insufficient for determining the most cost-effectiveness interventions. Individual cost 6649 studies are summarized separately elsewhere for each of the interventions reviewed in 6650 this report.

6651 Summary and Discussion

6652Specific findings from this evidence review are reported in the executive6653summary. We identified several key research gaps:

- Nearly all trials have been 'efficacy' trials conducted in ideal setting and selected populations, usually with short-term follow-up. More 'effectiveness' studies assessing long-term outcomes in less highly-selected populations are needed to help confirm the usefulness of interventions in real-world settings.
- For most interventions, data on harms are sparse, with disproportionate attention paid to benefits. Better assessment and reporting of harms (adhering to CONSORT recommendations [744]) would help provide a more balanced assessment of net benefits.
- Two higher-quality trials of low-intensity interventions for identifying and treating
 'yellow flags' (predictors of chronic disabling back pain) in patients with acute or
 subacute low back pain have not been shown to be beneficial. More research is
 needed on effective interventions for treating 'yellow flags' and on methods for
 identifying patients more likely to benefit from early interventions.
- The optimal use of combinations of medications has not been well studied. In
 addition, emerging data on potential cardiovascular risks with non-selective
 NSAIDs (and possibly acetaminophen) may alter risk-benefit assessments

- associated with different medications. There is also little evidence on long-term
 use of opioids for chronic low back pain, and evidence on abuse and addiction
 remains sparse.
- Decision tools for identifying patients more likely to benefit from certain interventions (such as manipulation or exercise) are promising but still in early stages of development. In addition, available tools include assessment of physical exam findings that many primary care clinicians are unfamiliar with or that have uncertain reliability and reproducibility. More research on decision tools that can be reliably used by most clinicians need to be developed and tested in clinical settings.
- Although concordant pain on provocative discography in selected patients is
 likely to have some diagnostic value, the use of discography to select patients for
 surgery or other invasive procedures has not been proven to improve clinical
 outcomes compared to non-invasive imaging. Clinical trials addressing this issue
 would be very helpful for resolving this long-standing controversy.
- Additional long-term trials with adequate follow-up and appropriate comparison interventions are required to further clarify the role of surgery in patients with chronic non-specific low back pain.
- Confirmatory trials and trials evaluating long-term outcomes associated with
 vertebral disc replacement are needed to help clarify its role as an option for
 surgical management.
- There is no evidence on optimal sequencing of interventions, and limited
 evidence on optimal combinations of interventions. In many cases, combinations
 of interventions were not much more effective than monotherapy, but more
 research is needed to clarify when and how treatments should be combined.
- High quality research on management of failed back surgery syndrome and back
 pain during pregnancy is lacking and provides little guidance for appropriate
 management in these populations.
- Few trials specifically evaluated patients with spinal stenosis, and it remains
 unclear if optimal non-surgical treatments for this condition are different than for
 patients with non-specific low back pain without spinal stenosis.
- Many interventions for low back pain appear to have similar effects on patient
 outcomes. Higher quality studies of cost-effectiveness could help clarify optimal
 choices between such interventions.

BIBLIOGRAPHY

- 1. Walker BF. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. Journal of Spine Disorders. 2000;13(3):205-217.
- 2. Hart LG, Deyo RA, Cherkin DC. Physician office visist for low back pain: Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine. 1995;20:11-19.
- 3. Carey TS, Evans AT, Hadler NM, et al. Acute severe low back pain: A population-based study of prevalence and care-seeking. Spine. 1996;221:339-344.
- 4. Pai S, Sundaram LJ. Low back pain: an economic assessment in the United States. Orthop Clin North Am. 2004;35:1-5.
- 5. Andersson GBJ. Epidemiological features of chronic low-back pain. Lancet. 1999;354:581-585.
- 6. Straus BN. Chronic pain of spinal origin: The costs of intervention. Spine. 2002;27:2614-2619.
- 7. Pengel LHM, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ. 2003;327:323-327.
- 8. Von Korff M, Saunders K. The course of back pain in primary care. Spine. 1996;21:2833-2839.
- 9. Hestbaek L, Leboeuf-Yde C, Manniche C. Low back pain: what is the long-term course? A review of studies of general patient populations. Eur Spine J. 2003;12:149-165.
- 10. Gatchel RJ, Polatin PB, Mayer TG. The dominant role of psychosocial risk factors in the development of chronic low back pain disability. Spine. 1995;20:2702-2709.
- 11. Cherkin DC, Deyo RA, Wheeler K, Ciol MA. Physician variation in diagnostic testing for low back pain. Who you see is what you get. Arthritis & Rheumatism. 1994;37:15-22.
- 12. Cherkin DC, Deyo RA, Wheeler K, Ciol MA. Physician views about treating low back pain: the results of a national survey. Spine. 1995;20:1-10.
- 13. Cherkin DC, Deyo RA, Loeser JD, Bush T, Waddell G. An international comparison of back surgery rates. Spine. 1994;19:1201-1206.
- 14. Volinn E, Mayer J, Diehr P, Van Koevering D, Connell FA, Loeser JD. Small area analysis of surgery for low-back pain. Spine. 1992;17:575-579.
- 15. Carey TS, Garrett J, Jackman A, McLaughlin C, Fryer J, Smucker DR. The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. N Engl J Med. 1995;333:913-917.
- 16. Shekelle PG, Markovich M, Louie R. Comparing the costs between provider types of episodes of back pain care. Spine. 1995;20:221-227.
- 17. Deyo RA. Fads in the treatment of low back pain. New England Journal of Medicine. 1991;325(14):1039-1040.
- 18. Deyo RA. Treatments for back pain: can we get past trivial effects? Annals of Internal Medicine. 2004;141:957-958.
- 19. Spitzer WO, LeBlanc FE, Dupuis M, et al. Scientific approach to the assessment and management of activity-related spinal disorders. A monograph for clinicians. Report of the Quebec Task Force on Spinal Disorders. Spine. 1987;12(Suppl 1):S1-S59.
- 20. Bigos SJ, Bowyer R, Braen R, et al. (AHCPR). Clinical Practice Guideline 14. Acute Low Back Problems in Adults. 1994.
- 21. Deyo RA. The messenger under attack--intimidation of researchers by special-interest groups. New England Journal of Medicine. 1997;336:1176-1180.
- 22. Koes B, van Tulder M, Ostelo R, Kim Burton A, Waddell G. Clinical guidelines for the management of low back pain in primary care: an international comparison. Spine. 2001;26(22):2504-13, discussion 2513-4.
- 23. Clancy CM, Cronin K. Evidence-based decision making: global evidence, local decisions. Health Affairs. 2005;24:151-162.
- 24. van Tulder MW, Tuut MK, Pennick V, Bombardier C, Assendelft WJJ. Quality of primary care guidelines for acute low back pain. Spine. 2004;29:E357-E362.

DRAFT – for Peer Review only

APS Clinical Guidelines for the Management of Low Back Pain

- 25. McGuirk B, King W, Govind J, Lowry J, Bogduk M. Safety, efficacy, and cost effectiveness of evidence-based guidelines for the management of acute low back pain in primary care. Spine. 2001;26:2615=2622.
- 26. Buchbinder R, Jolley D, Wyatt M. Population base intervention to change back pain beliefs and disability: three part evaluation. BMJ. 2001;322:1516-1520.
- 27. Goldberg HI, Deyo RA, Taylor VM, et al. Can evidence change the rate of back surgery? A randomized trial of community-based education. Effective Clinical Practice. 2001;4:95-104.
- 28. VA/DoD Evidence-Based Clinical Practice Guideline Working Group. Veterans Health Administration, Department of Veterans Affairs and Health Affairs, Department of Defense. *Low Back Pain or Sciatica in the Primary Care Setting*;1999.
- 29. Waddell G, McIntosh A, Hutchinson A, Feder G, Lewis M. Royal College of General Practitioners (London). *Clinical Guidelines for the Management of Acute Low Back Pain: Low Back Pain Evidence Review*,1996.
- 30. Airaksinen O, Brox J, Cedraschi C, et al. Chapter 4 European guidelines for the management of chronic nonspecific low back pain. European Spine Journal. 2006;15(Suppl 2):s192-s300.
- 31. Burton A, Balagué F, Cardon G, et al. Chapter 2 European guidelines for prevention in low back pain. European Spine Journal. 2006;15(Suppl 2):s136-s168.
- 32. van Tulder M, Becker A, Bekkering T, et al. Chapter 3 European guidelines for the management of acute nonspecific low back pain in primary care. European Spine Journal. 2006;15(Suppl 2):s169-s191.
- 33. Michel LJ, Wood R. Back pain in young athletes: significant differences from adults in causes and patterns. Archives of Pediatrics & Adolescent Medicine. 1995;149:15-18.
- 34. Combs JA, Caskey PM. Back pain in children and adolesecents: a retrospective review of 648 patients. Southern Medical Journal. 1997;90:789-792.
- 35. Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders: summary and general recommendations. Spine. 2000;25(24):2100-3103.
- 36. Deyo RA, Battie M, Beurskens AJHM, et al. Outcome measures for low back pain research: a proposal for standardized use. Spine. 15;23(18):2003-13.
- 37. Fairbank JCT, Pynsent PB. The Oswestry Disability Index. Spine. 2000;25:2940-2953.
- 38. Bombardier C, Hayden JA, Beaton DE. Minimal clinically important difference. Low back pain: outcome measures. J Rheumatol. 2001;28:431-438.
- 39. Ware JE. SF-36 health survey update. Spine. 2000;25:3130-3139.
- 40. Von Korff M, Jensen MP, Karoly P. Assessing global pain severity by self-report in clinical and health services research. Spine. 2000;25:3140-3151.
- 41. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8:283-291.
- 42. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. Journal of Clinical Epidemiology. 1991;44(11):1271-1278.
- 43. Furlan AD, Clarke J, Esmail R, Sinclair S, Irvin E, Bombardier C. A critical review of reviews on the treatment of chronic low back pain. Spine. 2001;26(7):E155-E162.
- 44. Jadad AR, McQuay HJ. Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. Journal of Clinical Epidemiology. 1996;49:235-243.
- 45. van Tulder M, Furlan AD, Bombardier C, Bouter L, the Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine. 2003;28(12):1290-1299.
- 46. Bombardier C, Esmail R, Nachemson AL, the Back Review Group Editorial Board. The Cochrane Collaboration Back Review Group for Spinal Disorders. Spine. 1997;22:837-840.
- 47. Bouter LM, Pennick V, Bombardier C, the Editorial Board of the Back Review Group. Cochrane Back Review Group. Spine. 2003;28:1215-1218.
- 48. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force. American Journal of Preventive Medicine. 2001;20(3S):21-35.

DRAFT – for Peer Review only

APS Clinical Guidelines for the Management of Low Back Pain

- 49. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061-1066.
- 50. Whiting P, Rutjes AWS, Reitsma JB, Glas AS, Bossuyt PMM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Annals of Internal Medicine. 2004;140:189-202.
- 51. Malmivaara A, Koes BW, Bouter LM, van Tulder MW. Applicability and clinical relevance of results in randomzied controlled trials. The Cochrane review on exercise therapy for low back pain as an example. Spine. 2006;31:1405-1409.
- 52. Deyo R, Diehl A. Cancer as a cause of back pain: frequency, clinical presentation, and diagnostic strategies. J Gen Intern Med. 1988;3(3):230-8.
- 53. Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med. 2002;137:586-597.
- 54. Devillé W, van der Windt D, Dzaferagic A, Bezemer P, Bouter L. The test of Lasegue: systematic review of the accuracy of diagnosing herniated discs. Spine. 2000;25(9):1140-7.
- 55. van den Hoogen HM, Koes BW, van Eijk JT, Bouter LM. On the accuracy of history, physical examination, and erythrocyte sedimentation rate in diagnosing low back pain in general practice. A criteria-based review of the literature. Spine. 1995;20(3):318-27.
- 56. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760-65.
- 57. Rebain R, Baxter D, McDonough S. A systematic review of the passive straight leg raising test as a diagnostic aid for low back pain. Spine. 2002;27(17):E388-E395.
- 58. Jarvik JG. Imaging of adults with low back pain in the primary care setting. Neuroimag Clin N Am. 2003;13:293-305.
- 59. Vroomen PC, de Krom MC, Knottnerus JA. Diagnostic value of history and physical examination in patients suspected of sciatica due to disc herniation: a systematic review. J Neurol. 1999;246:899-906.
- 60. Hudgins WR, Hudgins WR. Computer-aided diagnosis of lumbar disc herniation. Spine. 1983;8(6):604-15.
- 61. Hirsch C, Nachemson A. The reliability of lumbar disc surgery. Clin Orthop. 1963;29:189-195.
- 62. Crook J, Milner R, Schultz IZ, Stringer B. Determinants of Occupational Disability Following a Low Back Injury: A Critical Review of the Literature. Journal of Occupational Rehabilitation. 2002;12(4):277-95.
- 63. Dionne CE, Von Korff M, Koepsell TD, Deyo RA, Barlow WE, Checkoway H. Formal education and back pain: a review. J Epidemiol Comm Health. 2001;55(7):455-468.
- 64. Fayad F, Lefevre-Colau MM, Poiraudeau S, et al. Chronicity, recuurence, and return to work in low back pain: common prognostic factors. Annales de readaption et de medecine physique. 2004;47:179-189.
- 65. McIntosh G, Frank JW, Hogg-Johnson S, Hall H, Bombardier C. Low back pain prognosis: structured review of the literature. J Occup Rehab. 2000;10(2):101-115.
- 66. Pincus T, Burton AK, Vogel S, Field AP. A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine. 2002;27(5):E109-E120.
- 67. Shaw WS, Pransky G, Fitzgerald TE. Early prognosis for low back disability: intervention strategies for health care providers. Disability & Rehab. 2001;23(18):815-828.
- 68. Linton SJ. A review of psycholocial risk factors in back and neck pain. Spine. 2000;25:1148-1156.
- 69. Truchon M, Fillion L. Biopsychosocial determinants of chronic disability and low-back pain: a review. J Occup Rehab. 2000;10(2):117-142.
- 70. Borge JA, Leboef-Yde C, Lothe J. Prognostic vlaues of physical examination findings in patients with chronic low back pain treated conservatively: a systematic literature review. J Manipulative Physiol Ther. 2001;24(4):292-95.
- 71. Karjalainen K, Malmivaara A, van Tulder M, et al. Multidisciplinary biopsychosocial rehabilitation for subacute low back pain among working age adults.[update of Cochrane Database Syst Rev. 2000;(3):CD002193; PMID: 10908528]. Cochrane Database of Systematic Reviews. 2003(2).

DRAFT – for Peer Review only

APS Clinical Guidelines for the Management of Low Back Pain

- 72. Karjalainen K, Malmivaara M, van Tulder M, et al. Multidisciplinary biopsychosocial rehabilitation for subacute low-back pain among working age adults. Spine. 2001;26(3):262-269.
- 73. Ostelo RWJG, van Tulder MW, Vlaeyen JWS, Linton SJ, Morley SJ, Assendelft WJJ. Behavioural treatment for chronic low-back pain Cochrane Database of Systematic Reviews. 2005(1).
- 74. Schonstein E, Kenny D, Keating J, Koes B, Herbert RD. Physical conditioning programs for workers with back and neck pain: a cochrane systematic review. Spine. 2003;28(19):E391-5.
- 75. Schonstein E, Kenny DT, Keating J, Koes BW. Work conditioning, work hardening and functional restoration for workers with back and neck pain. Cochrane Database of Systematic Reviews. 2003(3).
- 76. Hay EM, Lewis M, Vohora K, et al. Comparison of physical treatments versus a brief painmanagement programme for back pain in primary care: a randomised clinical trial in physiotherapy practice. Lancet. 2005;365:2024-2030.
- 77. Jellema P, van der Windt D, van der Horst H, Twisk J, Stalman W, Bouter L. Should treatment of (sub)acute low back pain be aimed at psychosocial prognostic factors? Cluster randomised clinical trial in general practice. BMJ. 2005;331(7508):84.
- 78. Gatchel RJ, Polatin PB, Noe C, Gardea M, Pulliam C, Thompson J. Treatment- and costeffectiveness of early intervention for acute low-back pain patients: a one-year prospective study. Journal of Occupational Rehabilitation. 2003;13(1):1-9.
- 79. Von Korff M, Balderson BHK, Saunders K, et al. A trial of an activating intervention for chronic back pain in primary care and physical therapy settings. Pain. 2005;113(3):323-330.
- 80. George SZ, Fritz JM, Bialosky JE, Donald DA. The effect of a fear-avoidance-based physical therapy intervention for patients with acute low back pain: results of a randomized clinical trial. Spine. 2003;28(23):2551-60.
- 81. Jellema P, van der Windet DA, van der Horst HE, Blankenstein AH, Bouter LM, Stalman WA. Why is a treatment aimed at psychosocial factors not effective in patients with (sub)acute low back pain? Pain. 2005;118:350-359.
- 82. Jellema P, van der Horst HE, Vlaeyeyn JWS, Stalman WAB, Bouter LM, van der Windt DAWM. Predictors of outcome in patients with (sub)acute low back pain differ across treatment groups. Spine. 2006;31:1699-1705.
- van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Spinal radiographic findings and nonspecific low back pain: a systematic review of observational studies. Spine. 1997;22(4):427-434.
- 84. Lurie JD, Birkmeyer NJ, Weinstein JN. Rates of advanced spinal imaging and spine surgery. Spine. 2003;28(6):616-20.
- 85. Boos N, Lander PH. Clinical efficacy of imaging modalities in the diagnosis of low-back pain disorders. Eur Spine J. 1996;5(1):2-22.
- 86. Kardaun JW, Schipper J, Braakman R. CT, myelography, and phlebography in the detection of lumbar disk herniation: an analysis of the literature. American Journal of Neuroradiology. 1989;10(5):1111-22.
- 87. Kent DL, Haynor DR, Larson EB, Deyo RA. Diagnosis of lumbar spinal stenosis in adults: a metaanalysis of the accuracy of CT, MR, and myelography. Am J Roentgenol. 1992;158(5):1135-44.
- 88. Littenberg B, Siegel A, Tosteson AN, Mead T. Clinical efficacy of SPECT bone imaging for low back pain. Journal of Nuclear Medicine. 1995;36(9):1707-13.
- 89. Hoffman RM, Kent DL, Deyo RA. Diagnostic accuracy and clinical utility of thermography for lumbar radiculopathy. A meta-analysis. Spine. 1991;16(6):623-8.
- 90. Pullman SL, Goodin DS, Marquinez A, Tabbal S, Rubin M. Clinical utility of surface EMG: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2000;55(2):171-177.
- 91. Mohseni-Bandpei M. Application of surface electromyography in the assessment of low back pain: a literature review. Physical Therapy Reviews. 2000;5(2):93-105.

- Joines JD, McNutt RA, Carey TS, Deyo RA, Rouhani R. Finding cancer in primary care outpatients with low back pain: a comparison of diagnostic strategies. Journal of General Internal Medicine. 2001;16(1):14-23.
 Hollingworth W, Gray DT, Martin BI, Sullivan SD, Deyo RA, Jarvik JG. Rapid magnetic resonance
- 93. Hollingworth W, Gray DT, Martin BI, Sullivan SD, Deyo RA, Jarvik JG. Rapid magnetic resonance imaging for diagnosing cancer-related low back pain: A cost-effectiveness analysis. J Gen Intern Med. 2003;18:303-312.
- 94. Hanly JG, Barnes DC, Mitchell MJ, MacMillan L, Docherty P. Single photon emission computed tomography in the diagnosis of inflammatory spondyloarthropathies. J Rheumatol. 1993;20:2062-2068.
- 95. Marc V, Dromer C, Le Guennec P, Manelfe C, Fournie B. Magnetic resonance imaging and axial involvement in spondylarthropathies. Delineation of the spinal entheses. Rev Rhum Engl Ed. 1997;64:465-473.
- 96. Kerry S, Hilton S, Dundas D, Rink E, Oakeshott P. Radiography for low back pain: a randomised controlled trial and observational study in primary care. Br J Gen Pract. 2002;52(479):469-74.
- 97. Deyo RA, Diehl AK, Rosenthal M. Reducing roentgenography use. Can patient expectations be altered? Archives of Internal Medicine. 1987;147(1):141-5.
- 98. Kendrick D, Fielding K, Bentley E, Kerslake R, Miller P, Pringle M. Radiography of the lumbar spine in primary care patients with low back pain: randomised controlled trial. BMJ. 2001;322:400-405.
- 99. Gilbert FJ, Grant AM, Gillan MGC, et al. Low Back Pain: Influence of Early MR Imaging or CT on Treatment and Outcome Multicenter Randomized Trial. Radiology. 2004;231(2):343-351.
- 100. Modic MT, Obuchowski NA, Ross JS, et al. Acute Low Back Pain and Radiculopathy: MR Imaging Findings and Their Prognostic Role and Effect on Outcome. Radiology. 2005;237(2):597-604.
- 101. Jarvik JG, Hollingworth W, Martin B, et al. Rapid Magnetic Resonance Imaging vs Radiographs for Patients with Low Back Pain: A Randomized Controlled Trial. JAMA. 2003;289(21):2810-2818.
- 102. Jarvik JG, Maravilla KR, Haynor DR, Levitz M, Deyo RA. Rapid MR imaging versus plain radiography in patients with low back pain: initial results of a randomized study. Radiology. 1997;204(2):447-54.
- 103. Miller P, Kendrick D, Bentley E, Fielding K. Cost-effectiveness of lumbar spine radiography in primary care patients with low back pain. Spine. 2002;27(20):2291-7.
- 104. Liang M, Komaroff AL. Roentgenograms in primary care patients with acute low back pain. A cost-effectiveness analysis. Arch Intern Med. 1982;142:1108-1112.
- 105. Schnitzer TJ, Ferraro A, Hunsche E, Kong SX. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain & Sympt Mgmt. 2004;28(1):72-95.
- 106. van Tulder MW, Schotten RJPM, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs for low-back pain Cochrane Database of Systematic Reviews. 2000(2).
- 107. van Tulder MW, Schotten RJPM, Koes BW, Deyo RA. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration back review group. Spine. 2000;25(19):2501-2513.
- 108. Hickey RF, Hickey RF. Chronic low back pain: a comparison of diflunisal with paracetamol. New Zealand Medical Journal. 1982;95(707):312-4.
- 109. Deyo RA. Drug therapy for back pain: which drugs help which patients? Spine. 1996;21(24):2840-2849.
- 110. van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain: a systematic review of randomized controlled trials of the most common interventions. Spine. 1997;22(18):2128-2156.
- 111. Doran DM, Newell DJ, Doran DM, Newell DJ. Manipulation in treatment of low back pain: a multicentre study. British Medical Journal. 1975;2(5964):161-4.
- 112. Hackett GI, Seddon D, Kaminski D, Hackett GI, Seddon D, Kaminski D. Electroacupuncture compared with paracetamol for acute low back pain. Practitioner. 1988;232(1443):163-4.

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- 113. Milgrom C, Finestone A, Lev B, et al. Overexertional lumbar and thoracic back pain among recruits: a prospective study of risk factors and treatment regimens. Journal of Spinal Disorders. 1993;6(3):187-93.
- 114. Wiesel S, Cuckler J, Deluca F, Jones F, Zeide M, Rothman R. Acute low back pain: an objective analysis of conservative therapy. Spine 1980;5:324-330. Spine. 1980;5(4):324-30.
- 115. Evans DP, Burke MS, Newcombe RG, Evans DP, Burke MS, Newcombe RG. Medicines of choice in low back pain. Current Medical Research & Opinion. 1980;6(8):540-7.
- 116. Muckle DS. Flurbiprofen for the treatment of soft tissue trauma. American Journal of Medicine. 1986;80(3A):76-80.
- 117. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal anti-inflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis & Rheumatism. 2004;51(5):746-54.
- 118. Towheed TE, Judd MG, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews. 2005(3).
- 119. Wegman A, van der Windt D, van Tulder M, Stalman W, de Vries T. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. Journal of Rheumatology. 2004;31(2):344-54.
- 120. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Annals of the Rheumatic Diseases. 2004;63(8):901-7.
- 121. Stein D, Peri T, Edelstein E, et al. The efficacy of amitriptyline and acetaminophen in the management of acute low back pain. Psychosomatics. 1996;37(1):63-70.
- 122. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. American Journal of Epidemiology. 2004;159(1):23-31.
- 123. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis & Rheumatism. 2002;46(11):3046-3054.
- 124. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204-2208.
- 125. Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604-608.
- 126. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46:500-507.
- 127. McLaughlin JK, Lipworth L, Chow W-H, Blot WJ. Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney International. 1998;54:679-686.
- 128. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578-1587.
- 129. Vroomen P, de Krom M, Slofstra P, Knottnerus J. Conservative treatment of sciatica: a systematic review. J Spinal Disord. 2000;13(6):463-9.
- 130. Deyo RA. Conservative therapy for low back pain. Distinguishing useful from useless therapy. JAMA. 1983;250(8):1057-62.
- 131. Koes BW, Scholten RJPM, Mens JMA, Bouter LM. Efficacy of non-steriodal anti-inflammatory drugs for low back pain: a systematic review of randomized clinical trials. Ann Rheum Diseases. 1997;56(4):514-223.
- 132. van der Weide WE, Verbeek JH, van Tulder MW. Vocational outcome of intervention for low-back pain. Scandinavian Journal of Work, Environment & Health. 1997;23(3):165-78.
- Berry H, Hutchinson D. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. The Journal of International Medical Research. 1988;16:83-91.
- 134. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologi studies published in the 1990s. Arch Intern Med. 2000;160:2093-2099.

- 135. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570-576.
- 136. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-infalmmatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. . BMJ. 2006;332:1302-1308.
- 137. Food and Drug Administration. FDA Public Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatroy drugs (NSAIDS). 2006.
- 138. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine. 2000;343(21):1520-8.
- 139. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation. 2005;111:249.
- 140. Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial. Journal of Pain. 2003;4(6):307-15.
- 141. Chrubasik S, Kunzel O, model A, conradt C, Black A. Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology. 2001;40:1388-1393.
- 142. Chrubasik S, Model A, Black A, Pollak S. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology. 2003;42(1):141-8.
- 143. Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clinical Therapeutics. 2004;26(8):1249-60.
- 144. Katz N, Ju WD, Krupa DA, et al. Efficacy and safety of rofecoxib in patients with chronic low back pain: Results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine. 2003;28(9):851-858.
- 145. Katz N, Rodgers DB, Krupa D, Reicin A. Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials. Current Medical Research & Opinion. 2004;20(5):651-8.
- 146. Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scandinavian Journal of Rheumatology. 2004;33(4):257-66.
- 147. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine. 2000;25(12):1579-85.
- 148. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619.
- 149. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Research & Therapy. 2005;7:R644-R655.
- 150. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-55.
- 151. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287-1288.
- 152. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
- 153. Derry S, Loke YK. Risk of gastointestinal haemorrhage with long term use of aspirin: metaanalysis. BMJ. 2000;321:1183-1187.

- 154. Turner JA, Denny MC. Do antidepressant medications relieve chronic low back pain? J Family Pract. 1993;37(6):545-553.
- 155. Fishbain D. Evidence based data on pain relief with antidepressants. Ann Med. 2000;32(5):305-16.
- 156. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Archives of Internal Medicine. 2002;162(1):19-24.
- 157. Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003;28(22):2540-2545.
- 158. Schreiber S, Vinokur S, Shavelzon V, Pick CG, Zahavi E, Shir Y. A randomized trial of fluoxetine versus amitriptyline in musculo-skeletal pain. Israel Journal of Psychiatry & Related Sciences. 2001;38(2):88-94.
- 159. Goodkin K, Gullion CM. Antidepressants for the relief of chronic pain. Do they work? Ann Behav Med. 1989;11:83-131.
- 160. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992;49:205-219.
- 161. Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76(3):287-296.
- 162. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999;83(2):137-145.
- 163. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low-back pain Cochrane Database of Systematic Reviews. 2003(4).
- 164. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM, Cochrane Back Review G. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine. 2003;28(17):1978-92.
- 165. Moll W. Zur therapie akuter lumbovertebraler syndrome durch optimale medikamentose muskelrelaxation mittels diazepam. Med Welt. 1973;24:1747-1751.
- 166. Arbus L, Fajadet B, Aubert D, Morre M, Goldfinger E. Activity of tetrazepam in low back pain. Clinical Trials Journal. 1990;27(4):258-267.
- 167. Salzmann E, Pforringer W, Paal G, Gierend M. Treatment of chronic low-back syndrome with tetrazepam in a placebo controlled double-blinde trial. J Drug Dev. 1992;4:219-228.
- 168. Basmajian JV. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: two double-blind controlled clinical and laboratory studies. Archives of Physical Medicine & Rehabilitation. 1978;59(2):58-63.
- 169. Hennies OL. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin. Journal of International Medical Research. 1981;9(1):62-8.
- 170. Boyles W, Glassman J, Soyka J. Managemen of acute musculoskeeltal conditions: Thoracolumbar strain or sprain. A double-blind evaluationg comparing the efficacy and safety of carisoprodol with diazepam. Today's Therapeutic Trends. 1983;1:1-16.
- 171. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and posteherpetic neuralgia: a quantitative systematic review. Journal of Pain and Symptom Management. 2000;20(6):449-458.
- 172. Mellegers M, Furlan A, Mailis A. Gabapentin for Neuropathic Pain: Systematic Review of Controlled and Uncontrolled Literature. Clin J Pain. 2001;17(4):284-295.
- 173. McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomised, double-blind, placebo controlled study. Pain Clinic. 2001;13(2):103-107.
- 174. Yildirim K, Sisecioglu M, Karatay S, et al. The effectiveness of gabapentin in patients with chronic radiculopathy. The Pain Clinic. 2003;15(3):213-218.
- 175. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Archives of Internal Medicine. 2001;161(13):1613-20.
- 176. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. Journal of Pain and Symptom Management. 2004;28(2):140-175.

- 177. Bartleson JD. Evidence for and against the use of opioid analgesics for chornic nonmalignant low back pain: a review. Pain Medicine. 2002;3(3):260-271.
- 178. Brown RL, Fleming MF, Patterson JJ. Chronic opioid analgesic therapy for chronic low back pain. J Amer Board Family Prac. 1996;9(3):191-204.
- 179. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain:systematic revewi fo efficacy and safety. Pain. 2004;112:372-380.
- 180. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. Journal of Pain. 2005;6(1):21-8.
- 181. Baratta RR. A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome. Current Therapeutic Research, Clinical & Experimental. 1976;20(3):233-40.
- 182. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine. 1998;23(23):2591-600.
- 183. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opoiods naive patients with chronic low back pain. Spine. 2005;30:2484-2490.
- 184. Gostick N, Allen J, Cranfield R, et al. A comparison of the efficacy and adverse effects of controlled release dihydrocodeine and immediate release dihydrocodeine in the treatment of pain in osteoarthritis and chronic back pain. In: Twycross RG, ed. The Edinburgh Symposium on Pain Control and Medical Education; 1989:137-143.
- 185. Hale M, Speight K, Harsanyi Z, et al. Efficacy of 12 hourly controlled-release codeine compared with as required dosing of acetaminophen plus codeine in patients with chronic low back pain. Pain Research & Management. 1997;2(1):33-38.
- 186. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. The Clinical Journal of Pain. 1999;15(3):179-83.
- 187. Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? Journal of pain and symptom management. 1999;18(4):271-9.
- 188. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. Journal of Pain and Symptom Management. 2003;26(5):1026-1048.
- 189. Metscher B, Kubler U, Jahnel-Kracht H. [Dexketoprofen-trometamol and tramadol in acute lumbago]. Fortschritte der Medizin Originalien. 2001;118(4):147-51.
- 190. Muller FO, Odendaal CL, Muller FR, Raubenheimer J, Middle MV, Kummer M. Comparison of the efficacy and tolerability of a paracetamol/codeine fixed-dose combination with tramadol in patients with refractory chronic back pain. Arzneimittel Forschung. 1998;48(6):675-9.
- 191. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. The Journal of Rheumatology. 2000;27(3):772-8.
- 192. Sorge J, Stadler T. Comparison of the analgesic efficacy and tolerability of tramadol 100mg sustained-release tablets and tramadol 50mg capsules for the treatment of chronic low back pain. Clin Drug Invest. 1997;14(3):157-164.
- 193. Bamigbade TA, McCartney C, Paes M, Langford RM, Gallagher WJ. A randomised, double blind, crossover study comparing oral tramadol with oral co-proxamol for ther treatment of chronic back pain. 9th World congress on Pain; 1999.
- 194. Finckh A, Zufferey P, Schurch M, Balague F, Waldburger M, So A. Short-Term Efficacy of Intravenous Pulse Glucocorticoids in Acute Discogenic Sciatica. A Randomized Controlled Trial. Spine. 2006;31(4):377-381.
- 195. Haimovic IC, Beresford HR. Dexamethasone is not superior to placebo for treating lumbosacral radicular pain. Neurology. 1986;36:1593-1594.
- 196. Porsman O, Friis H. Prolapsed lumbar disc treated with intramuscularly administered dexamethasonephosphate. A prospectively planned, double-blind, controlled clinical trial in 52 patients. Scandinavian journal of rheumatology. 1979;8(3):142-4.

- 197. Friedman BW, Holden L, Esses D, et al. Parenteral corticosteroids are no better than placebo for emergency department pateitns with non-radicular low back pain. Acad Emerg Med. 2005;12(5 suppl 1):52.
- 198. Hofferberth B, Gottschaldt M, Grass H, Buttner K. [The usefulness of dexamethasonephosphate in the conservative treatment of lumbar pain--a double-blind study (author's transl)]. Arch Psychiatr Nervenkr. 1982;231:359-367.
- 199. Gagnier JJ, van Tulder MW, Berman B, Bombardier C. Herbal medicine for low back pain. Cochrane Database of Systematic Reviews. 2006(2).
- 200. Gagnier JJ, Chrubasik S, Manheimer E. *Harpgophytum procumbens* for osteoarthritis and low back pain: A systematic review. BMC Complement Altern Med. 2004;4:13.
- 201. Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind study. European Journal of Anaesthesiology. 1999;16:118-129.
- 202. Chrubasik S, Zimpfer CH, Schutt U, Ziegler R. Effectiveness of harpagophytum procumbens in the treatment of acute low back pain. Phytomedicine. 1996;3:1-10.
- 203. Chrubasik S, Eisenberg E, Balan E, Weinberger T, Luzzati R, Conradt C. Treatment of low back pain exacerbation with willow bark extract: A randomzied double-blind study. American Journal of Medicine. 2000;109:9-14.
- 204. Ginsberg F, Famaey JP. A double-blind study of topical massage with Rado-Salil Ointment in mechanical low back pain. The Journal of International Medical Research. 1987;15:148-153.
- 205. Keitel W, Frerick H, Kun U, Schmidt U, Kuhlmann M, Bredehoorst A. Capsicum pain plaster in c hronic non-specific low back pain. Arzneimtel Forschung. 2001;51.
- 206. Frerick H, Keitel W, Kuhn U, Schmidt S, Bredehorst A, Kuhlmann M. Topical treatment of chornic low back pain with a capsicum plaster. Pain. 2003;106:59-64.
- 207. Stam C, Bonnet MS, van Haselen RA. The efficacy and safety of a homeopathic gel in the treatment of acute low back pain: a multicentre, randomzied, double-blind comparative clinical trial. British Homeopathic Journal. 2001;90:21-28.
- 208. Manheimer E, White A, Berman B, Forys K, Ernst E. Meta-analysis: acupuncture for low back pain. Ann Intern Med. 2005;142:651-663.
- 209. Furlan AD, van Tulder MW, Cherkin DC, et al. Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of the cochrane collaboration. Spine. 2005;30(8):944-63.
- 210. Furlan AD, van Tulder MW, Cherkin DC, et al. Acupuncture and dry-needling for low back pain Cochrane Database of Systematic Reviews. 2005(1).
- 211. van Tulder MW, Cherkin DC, Berman B, Lao L, Koes BW. The effectiveness of acupuncture in the management of acute and chronic low back pain. A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 1999;24(11):1113-23.
- 212. Ernst E, White AR. Prospective studies of the safety of acupuncture: a systematic review. Am J Med. 2001;110:481-485.
- 213. ter Riet G, Kleijnen J, Knipschild P. Acupuncture and chronic pain: a criteria-based meta-analysis. J Clin Epidemiol. 1990;43(11):1191-9.
- 214. Strauss A. Acupuncture and the treatment of chronic low-back pain: a review of the literature. Chiropractic Journal of Australia. 1999;29:213.
- 215. Smith LA, Oldman AD, McQuay HJ, Moore RA. Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain. 2000;86(1-2):119-32.
- 216. Patel M. A meta-analysis of acupuncture for chronic pain. Int J Epidemiol. 1989;18:900-6.
- 217. Ezzo JM, Berman B, Hadhazy VA, Jadad AR, Lao L, Singh BB. Is acupuncture effective for the treatment of chronic pain? A systematic review. Pain. 2000;86:217-225.
- 218. Ernst E, White AR. Acupuncture for back pain: a meta-analysis of randomized controlled trials. Archives of Internal Medicine. 1998;158(20):2235-41.
- 219. Ernst E, White A. Life-threatening adverse reactions after acupuncture? A systematic review. Pain. 1997;71:123-126.

- 220. Cherkin DC, Sherman KJ, Deyo RA, Shekelle PG. A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain. Ann Intern Med. 2003;138(11):898-906.
- 221. Birch S, Hesselink JK, Jonkman FAM, Hekker TAM, Bos A. Clinical research on acupuncture: Part 1. What have reviews of the efficacy and safety of acupuncture told us so far? Journal of Alternative & Complementary Medicine. 2004;10:468-480.
- 222. Thomas K, MacPherson H, Ratcliffe J, et al. NHS R&D HTA Programme. Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain. Vol. 9; No. 32; 2005.
- 223. Cherkin DC, Eisenberg D, Sherman KJ, et al. Randomized trial comparing traditional Chinese medical acupuncture, therapeutic massage, and self-care education for chronic low back pain. Archives of internal medicine. 2001;161(8):1081-8.
- 224. Ceccherelli F, Rigoni MT, Gagliardi G, Ruzzane L. Comparison of superficial and deep acupuncture in the treatment of lumbar myofascial pain: a double-blind randomized controlled study. Clin J Pain. 2002;18(3):149-153.
- 225. Carlsson CP, Sjolund BH. Acupuncture for chronic low back pain: a randomized placebocontrolled study with long-term follow-up. Clin J Pain. 2001;17(4):296-305.
- 226. MacDonald AJ, Macrae KD, Master BR, Rubin AP. Superficial acupuncture in the relief of chronic low back pain. Ann Royal Coll Surg Engl. 1983;65:44-46.
- 227. Garvey TA, Marks MR, Wiesel SW. A prospective, randomized, double-blind evaluation of triggerpoint injection therapy for low-back pain. Spine. 1989;14:962-964.
- 228. Gunn CC, Milbrandt WE, Little AS, Mason KE. Dry needling of muscle motor points for chronic low-back pain: a randomized clinical trial with long-term follow-up. Spine. 1980;5:279-291.
- 229. Hsieh LL, Kuo CH, Lee LH, Yen AM, Chien KL, Chen TH. Treatment of low back pain by acupressure and physical therapy: randomised controlled trial. BMJ. 332(7543):696-700.
- 230. Hsieh LL-C, Kuo C-H, Yen M-F, Chen TH-H. A randomized controlled clinical trial for low back pain treated by acupressure and physical therapy. Preventive Medicine. 2004;39(1):168-176.
- 231. Urrutia G, Burton AK, Morral A, Bonfill X, Zanoli G. Neuroreflexotherapy for non-specific low-back pain Cochrane Database of Systematic Reviews. 2004(2).
- 232. Kovacs FM, Abraira V, Lopez-Abente G, F. P. [Neuro-reflexotherapy intervention in the treatment of non specified low back pain: a randomized, controlled, double-blind clinical trial]. Medicina Clinica. 1993;101(15):570-575.
- 233. Kovacs FM, Abraira V, Pozo F, et al. Local and remote sustained trigger point therapy for exacerbations of chronic low back pain. A randomized, double-blind, controlled, multicenter trial. Spine. 1997;22(7):786-797.
- 234. Kovacs FM, Llobera J, Abraira V, Lazaro P, Pozo F, Kleinbaum D. Effectiveness and costeffectiveness analysis of neuroreflexotherapy for subacute and chronic low back pain in routine general practice. Spine. 2002;27:1149-1159.
- 235. Forsell ZM. The back school. Spine. 1981;6:104-106.
- 236. Forssell ZM. The Swedish back school. Physiotherapy. 1980;66:112-114.
- 237. Heymans MW, van Tulder MW, Esmail R, Bombardier C, Koes BW. Back schools for nonspecific low back pain. A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 2005;2005:2153-2163.
- 238. Heymans MW, van Tulder MW, Esmail R, Bombardier C, Koes BW. Back schools for non-specific low-back pain. Cochrane Database of Systematic Reviews. 2004(4).
- 239. van Tulder MW, Esmail R, Bombardier C. Back schools for non-specific low-back pain. Cochrane Database of Systematic Reviews. 1999(3).
- 240. Maier-Riehle B, Harter M. The effects of back schools--a meta-analysis. International Journal of Rehabilitation Research. 2001;24(3):199-206.
- 241. Elders LAM, van der Beek AJ, Burdorf A, Elders LAM. Return to work after sickness absence due to back disorders a systematic review on intervention strategies. International Archives of Occupational and Environmental Health. 2000;73(5):339-348.

APS Clinical Guidelines for the Management of Low Back Pain

Di Fabio RP. Efficacy of comprehensive rehabilitation programs and back school for patients with 242. low back pain: a meta-analysis. Physical Therapy. 1995;75(10):865-78. 243. van der Hulst M, Vollenbroek-Hutten MMR, IJzerman MJ. A systematic review of sociodemographic, physical, and psychological predictors of multidisciplinary rehabilitation - or, back school treatment outcome in patients with chronic low back pain. Spine. 2005;30(7):813-825. 244. Cohen JE, Goel V, Frank JW, Bombardier C, Peloso P, Guillemin F. Group education interventions for people with low back pain: an overview of the literature. Spine. 1994:19(11):1214-1222. 245. Keijsers JFE, Bouter LM, Meertens RM. Validity and comparability of studies on the effects of back schools. Physiother Theory Pract. 1991;7(3):177-84. Koes BW, van Tulder MW, van der Windt WM, Bouter LM. The efficacy of back schools: a review 246. of randomized clinical trials. Journal of Clinical Epidemiology. 1994;47(8):851-62. 247. Linton SJ, Kamwendo K. Low back schools. A critical review. Phys Ther. 1987;67(9):1375-83. 248. Nentwig CG. [Effectiveness of the back school. A review of the results of evidence-based evaluation]. Der Orthopæde. 1999;28(11):958-965. Scheer S, Watanabe T, Radack K. Randomized controlled trials in industrial low back pain. Part 249. 3. Subacute/chronic pain interventions. Archives of Physical Medicine and Rehabilitation. 1997:78(4):414-423. 250. Scheer SJ, Radack K, O'Brien D, Jr. Randomized controlled trials in industrial low back pain relating to return to work. Part 1. Acute interventions. Archives of Physical Medicine & Rehabilitation. 1995;76(10):966-73. Turner JA. Educational and behavioral interventions for back pain in primary care. Spine. 251. 1996;21(24):2851-2859. 252. Lahad A, Malter AD, Berg AO, Deyo RA. The effectiveness of four interventions for the prevention of low back pain. JAMA. 1994;272(16):1286-91. 253. Bergquist-Ullman M, Larsson U. Acute low-back pain in industry. Acta Orthop Scand. 1977;170(Suppl):1-117. 254. Linton SJ, Bradley LA, Jensen IB, Spangfort E, Sundell L. The secondary prevention of low back pain: A controlled study with follow-up. Pain. 1989;36:197-207. Lonn JH, Glomsrod B, Soukup MG, Bo K, Larsen S. Active back school: Prophylactic 255. management for low back pain: A randomized controlled 1-year follow-up study. Spine. 1999;24:865-871. Donchin M, Woolf O, Kaplan L, Floman Y. Secondary prevention of low-back pain. A clinical trial. 256. Spine. 1990;15:1317-1320. 257. Lankhorst GJ, van der Stadt RJ, Vogelaar TW, van der Korst JK, Prevo AJH. The effect of the Swedish back school in chronic idiopathic low-back pain. Scand J Rehab Med. 1983:15:141-145. 258. Indahl A, Haldorsen EH, Holm S, Reikeras O, Ursin H. Five-year follow-up study of a controlled clinical trial using light mobilization and an informative approach to low back pain. Spine. 1998;23:2625-30. 259. Indahl A, Velund L, Reikeraas O. Good prognosis for low back pain when left untampered. A randomized clinical trial. Spine. 1995;20:473-477. 260. Leclaire R, Esdaile JM, Suissa S, Rossignol M, Proulx R, Dupuis M. Back school in a first episode of compensated acute low back pain: a clinictal trial to assess efficacy and prevent relapse. Arch Phys Med Rehabil. 1996;77:673-679. Lindequist SL, Lundberg B, Wikmark R, Bergstad B, Loof G, Ottermark AC. Information and 261. regime at low-back pain. Scand J Rehab Med. 1984;16:113-116. Molde Hagen E, Grasdal A, Eriksen HR. Does early intervention with a light mobilization program 262. reduce long-term sick leave for low back pain: A 3-year follow-up study. Spine. 2003;28(20):2309-2315. Karjalainen K, Malmivaara A, Mutanen P, Roine R, Hurri H, Pohjolainen T. Mini-intervention for 263. subacute low back pain: Two-year follow-up and modifiers of effectiveness. Spine. 2004;29(10):1069-1076.

- 264. Karjalainen K, Malmivaara A, Pohjolainen T, et al. Mini-intervention for subacute low back pain: A randomized controlled trial. Spine. 2003;28(6):533-540.
- 265. Niemisto L, Lahtinen-Suopanki T, Rissanen P, Lindgren KA, Sarna S, Hurri H. A randomized trial of combined manipulation, stabilizing exercises, and physician consultation compared to physician consultation alone for chronic low back pain. Spine. 2003;28(19):2185-91.
- 266. Niemisto L, Rissanen P, Sarna S, Lahtinen-Suopanki T, Lindgren KA, Hurri H. Cost-effectiveness of combined manipulation, stabilizing exercises, and physician consultation compared to physician consultation alone for chornic low back pain: a prospective randomized trial with 2-year follow-up. Spine. 2005;30:1109-1115.
- 267. Hagen, Molde E, Eriksen HR, Ursin H. Does early intervention with a light mobilization program reduce long-term sick leave for low back pain? Spine. 2000;25:1973-1976.
- 268. Hayden J, van Tulder M, Malmivaara A, Koes B. Exercise therapy for low-back pain Cochrane Database of Systematic Reviews. 2005(3).
- 269. Hayden JA, van Tulder MW, Malmivaara AV, Koes BW. Meta-analysis: exercise therapy for nonspecific low back pain. Ann Intern Med. 2005;142(9):765-75.
- 270. Kool J, de Bie R, Oesch P, Knusel O, van den Brandt P, Bachmann S. Exercise reduces sick leave in patients with non-acute non-specific low back pain: a meta-analysis. Journal of Rehabilitation Medicine. 2004;36(2):49-62.
- 271. McNeely ML, Torrance G, Magee D. A systematic review of physiotherapy for spondylolysis and spondylolisthesis. Manual Therapy 2003;8(2):80-9.
- 272. Liddle S, Baxter G, Gracey J. Exercise and chronic low back pain: what works? Pain. 2004;107(1-2):176-190.
- 273. Clare HA, Adams R, Maher CG. A systematic review of efficacy of McKenzie therapy for spinal pain. Australian Journal of Physiotherapy. 2004;50:2090-216.
- 274. van Tulder M, Malmivaara A, Esmail R, Koes B. Exercise therapy for low back pain: a systematic review within the framework of the Cochrane Collaboration back review group. Spine. 2000;25(21):2784-2796.
- 275. Cleland J, Schulte C, Durall C. The role of therapeutic exercise in treating instability-related lumbar spine pain: A systematic review. Journal of Back and Musculoskeletal Rehabilitation. 2002;16:105-115.
- 276. Colle F, Rannou F, Revel M, Fermanian J, Poiraudeau s. Impact of quality scales on levels of evidence inferred from a systematic review of exercise therapy and low back pain. Arch Phys Med Rehabil. 2002;83:1745-1752.
- 277. Beckerman H, Bouter LM, van der Heijden GJ, de Bie RA, Koes BW. Efficacy of physiotherapy for musculoskeletal disorders: what can we learn from research? Br J Gen Pract. 1993;43(367):73-7.
- 278. Faas A. Exercises: which ones are worth trying, for which patients, and when? Spine. 1996;21(24):2874-2879.
- 279. Hilde G, Bo K. Effect of exercise in the treatment of chronic low back pain: a systematic review, emphasising type and dose of exercise. Physical Therapy Reviews 1998;3(2):107-17.
- 280. Koes BW, Bouter LM, Beckerman H, van der heijden GJMG, Knipschild PG. Physiotherapy exercises and back pain: a blinded review. BMJ. 1991;302(June):1572-6.
- 281. Maher C, Latimer J, Refshauge K. Prescription of activity for low back pain: What works? Aust J Physiother. 1999;45(2):121-32.
- 282. Pengel HM, Maher CG, refshauge KM. Systematic review of conservative interventions for subacute low back pain. Clin Rehab. 2002;16:811-820.
- 283. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Physical Therapy. 2001;81(10):1641-74.
- 284. UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ. 2004;329(7479):1377,

- 285. Fritz JM, Delitto A, Erhard RE. Comparison of classification-based physical therapy with therapy based on clinical practice guidelines for patients with acute low back pain: a randomized clinical trial. Spine. 2003;28(13):1363-71.
- 286. Malmivaara A, Hakkinen U, Aro T, et al. The treatment of acute low back pain--bed rest, exercises, or ordinary activity? N Engl J Med. 1995;332:351-355.
- 287. Chok B, Lee RYW, Latimer J, Seang BT. Endurance training of the trunk extensor muscles in people with subacute low back pain. Phys Ther. 1999;79:1032-1042.
- 288. Staal JB, Hlobil H, Twisk JWR, Smid T, Koke AJA, Van Mechelen W. Graded Activity for Low Back Pain in Occupational Health Care: A Randomized, Controlled Trial. Annals of Internal Medicine. 2004;140(2):77-84+I24.
- 289. Lindstrom I. The effect of graded activity on patients with subacute low back pain: a randomized prospective clnical study with an operant-conditioning behavioural approach. Physical Therapy. 1992;72:279-293.
- 290. Moffett JK, Torgerson D, Bell-Syer S, et al. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences. BMJ. 1999;319:279-283.
- 291. O'Sullivan PB, Twomey LT, Allison GT. Evaluation of specific stabilizing exercise in the treatment of chronic low back pain with radiologic diagnosis of spondylolysis of spondylolisthesis. Spine. 1997;22(24):2959-2967.
- 292. Spratt KF, Weinstein JN, Lehmann TR, Woody J, Sayre H. Efficacy of flexion and extension treatments incorporating braces for low-back pain patients with retrodisplacement, spondylolisthesis, or normal sagittal translation. Spine. 1993;18(1839-1849).
- 293. Hayden JA, van Tulder MW, Tomlinson G. Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain. Ann Intern Med. 2005;142:776-85.
- 294. Rivero-Arias O, Gray A, Frost H, Lamb SE, Stewart-Brown S. Cost-utility analysis of physiotherapy treatment compared with physiotherapy advice in low back pain. Spine. 2006;31:1381-1387.
- 295. Seferlis T, Lindholm L, Nemeth G. Cost-minimisation analysis of three conservative treatment programmes in 180 patients sick-listed for acute low-back pain. Scand J Prim Health Care. 2000;18:53-57.
- 296. Cherkin DC, Deyo RA, Battie M, Street J, Barlow W. A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain. New Engl J Med. 1998;339(15):1021-9.
- 297. McIlveen B, Robertson VJ. A randomised controlled study of the outcome of hydrotherapy for subjects with low back or back and leg pain. Physiotherapy. 1998;84(1):17-26.
- 298. Sjogren T, Long N, Storay I, Smith J. Group hydrotherapy versus group land-based treatment for chronic low back pain. Physiotherapy research international : the journal for researchers and clinicians in physical therapy. 1997;2(4):212-22.
- 299. Yozbatiran N, Yildirim Y, Parlak B. Effects of fitness and aquafitness exercises on physical fitness in patients with chronic low back pain. The Pain Clinic. 2004;16(1):35-42.
- 300. Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA. Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain: A Randomized, Controlled Trial. Ann Intern Med. 2005;143(12):849-856.
- 301. Williams KA, Petronis J, Smith D, et al. Effect of lyengar yoga therapy for chronic low back pain. Pain. 2005;115(1-2):107-117.
- 302. Galantino ML, Bzdewka TM, Eissler-Russo JL, et al. The impact of modified Hatha yoga on chronic low back pain: a pilot study. Alternative Therapies in Health & Medicine. 2004;10(2):56-9.
- 303. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C. Multidisciplinary rehabilitation for chronic low back pain: systematic review. BMJ. 2001;322(7301):1511-6.
- 304. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C. Multidisciplinary biopsycho-social rehabilitation for chronic low-back pain Cochrane Database of Systematic Reviews. 2002(1).
- 305. Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of psychological interventions for chronic low back pain. Health Psychology. 2006:In press.

- 306. Tveito T, Hysing M, Eriksen H. Low back pain interventions at the workplace: a systematic literature review. Occup Med (Lond). 2004;54(1):3-13.
- 307. Loisel P, Abenhaim L, Durand P, et al. A population-based, randomized clinical trial on back pain management. Spine. 1997;22:2911-2918.
- 308. Bendix AF, Bendix T, Vaegtar KV, Lund C, Frolund L, Holm L. Multidisciplinary intensive treatment for chronic low back pain: a randomized, prospective study. Cleve Clinc J Med. 1996;63:62-69.
- 309. Bendix AF, Bendix T, Ostenfeld S, Bush E, Andersen. Active treatment programs for patients with chronic low back pain: a prospective, randomized, observer-blinded study. Eur Spine J. 1995;4:148-152.
- 310. Alaranta H, Rytokoski U, Rissanen A, et al. Intensive physical and psychosocial training program for patients with ch ronic low back pain. A controlled trial. Spine. 1994;19:1340-1349.
- 311. Mitchell RI, Carmen GM. The functional restoration approach to the treatment of chronic pain in patients with soft titssue and back injuries. Spine. 1994;19:633-642.
- 312. Loisel P, Lemaire J, Poitras S, et al. Cost-benefit and cost-effectiveness analysis of a disability prevention model for back pain management: a six year follow up study. Occupational & Environmental Medicine. 2002;59(12):807-15.
- 313. Skoen JS, Grasdal AL, Haldorsen EMH, Ursin H. Relative cost-effectiveness of extensive and light multidisciplinary treatment programs versus treatment as usual for patients with chronic low back pain on long-term sick leave. Spine. 2002;27:901-910.
- 314. Lechner DE. Work hardening and work conditioning interventions: do they affect disability? Physical Therapy. 1994;74(5):471-493.
- 315. Dettori JR, Bullock SH, Sutlive TG, Franklin RJ, Patience T. The effects of spinal flexion and extension exercises and their associated postures in patients with acute low back pain. Spine. 1995;20(21):2303-2312.
- 316. Faas A, van Eijk JTM, Chavannes AW, Gubbels JW. A randomized trial of exercise therapy in patients with acute low back pain: Efficacy on sickness absence. Spine. 1995;20(8):941-947.
- 317. Bendix AF, Bendix T, Lund C, Kirkbak S, Ostenfeld S. Comparison of three intensive programs fro chronic low back pain patients: a prospective, randomzied, observer-blinded study with one year follow-up. Scand J Rehab Med. 1997;29:81-89.
- 318. Bendix AF, Bendix T, Vaegter K, Busch E, Kirkbak S, Ostenfeld S. [Intensive work rehabilitation]. Videnskab og parksis. 1994;156:2388-2395.
- 319. Hurley DA, McDonough SM, Dempster M, Moore AP, Baxter GD. A randomized clinical trial of manipulative therapy and interferential therapy for acute low back pain. Spine. 2004;29(20):2207-2216.
- 320. Werners R, Pynsent PB, Bulstrode CJK. Randomized trial comparing interferential therpay with motorized lumbar traction and massage in the management of low back pain in a primary care setting. Spine. 1999;24(15):1579-1584.
- 321. Hurley DA, Minder PM, McDonough SM, Walsh DM, Moore AP, Baxter DG. Interferential therapy electrode placement technique in acute low back pain: a preliminary investigation. Archives of physical medicine and rehabilitation. 2001;82(4):485-93.
- 322. Basford JR, Sheffield CG, Harmsen WS. Laser therapy: a randomized, controlled trial of the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. Archives of physical medicine and rehabilitation. 1999;80(6):647-52.
- 323. Klein RG, Eek BC. Low-energy laser treatment and exercise for chronic low back pain: doubleblind controlled trial. Arch Phys Med Rehabil. 1990;71(1):34-7.
- 324. Soriano F, Rios R. Gallium arsenide laser treatment of chronic low back pain: a prospective, randomized and double blind study. Laser Therapy Vol. 1998;10:175-180.
- 325. Toya S, Motegi M, Inomata K, Ohshiro T, Maed T. Report on a computer-randomized double blind clinical trial to determine the effectiveness of the GaAlAs(830nm) diode laser for attenuation in selected pain groups. Laser Therapy. 1994;6:143-8.

- 326. Bjordal JM, Couppe C, Chow RT, Tuner J, Ljunggren EA. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Australian Journal of Physiotherapy. 2003;49(2):107-116.
- 327. Gam AN, Thorsen H, Lonnberg F. The effect of low-level laser therapy on musculoskeletal pain: A meta-analysis. Pain. 1993;52(1):63-66.
- 328. de Bie R. Efficacy of 904 nm laser therapy in musculoskeletal disorders. Physical Therapy Reviews. 1998;3:1-14.
- 329. Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ. Efficacy of low power laser therapy and exercise on pain and functions in chronic low back pain. Lasers in Surgery & Medicine. 2003;32(3):233-8.
- 330. Longo L, Tamburini A, Monti A, Cattaneo L, Sesti A. Treatment with 904 nm and 10 600 nm laser of acute lumbago: double blind control. . Laser Clinical Research 1988;3:16-20. 1988;3:16-20.
- 331. Monticone M, Barbarino A, Testi C, Arzano S, Moschi A, Negrini S. Symptomatic efficacy of stabilizing treatment versus laser therapy for sub-acute low back pain with positive tests for sacroiliac dysfunction: a randomised clinical controlled trial with 1 year follow-up. Europa Medicophysica. 2004;40(4):263-268.
- 332. Assendelft WJJ, Morton SC, Yu EI, Suttorp MJ, Shekelle PG. Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other therapies Annals of Internal Medicine. 2003;138(11):871-81.
- 333. Assendelft WJJ, Morton SC, Yu EI, Suttorp MJ, Shekelle PG. Spinal manipulative therapy for lowback pain Cochrane Database of Systematic Reviews. 2004(1).
- 334. Gibson T, Harkness J, Blagrave P, Grahame R, Woo P, Hills R. Controlled comparison of shortwave diathermy treatment with osteopathic treatment in non-specific low back pain. Lancet. 1985:1258-1261.
- 335. Sweetman BJ, Heinrich I, Anderson JAD. A randomzied controlled trial of exercises, short wave diathermy, and traction for low back pain, with evidence of diagnosis-related response to treatment. Journal of Orthopaedic Rheumatology. 1993;6:159-166.
- 336. Rasmussen GG. Manipulation in treatment of low back pain: a randomized clinical trial. Manuelle Medizin. 1979;1:8-10.
- 337. Clarke J, van Tulder M, Blomberg S, de Vet H, van der Heijden G, Bronfort G. Traction for low back pain with or without sciatica: an updated systematic review within the framework of the Cochrane Collaboration. Spine. 2006;31:1591-1599.
- 338. Clarke J, van Tulder M, Blomberg S, de Vet H, van der Heijden G, Bronfort G. Traction for lowback pain with or without sciatica. The Cochrane Database of Systematic Reviews 2005(4).
- 339. Harte A, Baxter G, Gracey J. The efficacy of traction for back pain. Arch Phys Med Rehabil 2003;84(10):1542-53.
- 340. van der Heijden GJ, Beurskens AJ, Koes BW, Assendelft WJ, de Vet HC, Bouter LM. The efficacy of traction for back and neck pain: a systematic, blinded review of randomized clinical trial methods. Physical Therapy. 1995;75(2):93-104.
- 341. Beurskens AJ, de Vet HC, van der Heijden GJ, et al. Efficacy of traction for non-specific low back pain: a randomised clinical trial. The Lancet. 1995;346(8990):1596-1600.
- 342. Beurskens AJP, de Vet HCP, Koke AJPT, et al. Efficacy of Traction for Nonspecific Low Back Pain: 12-Week and 6-Month Results of a Randomized Clinical Trial. Spine. 1997;22(23):2756-2762.
- 343. van der Heijden G, Beurskens A, Dirx M, Bouter L, Lindeman E. Efficacy of Lumbar Traction: A Randomised Clinical Trial. Physiotherapy. 1995;81(1):29-35.
- 344. Larsson U, Choler U, Lidstrom A, et al. Auto-traction for treatment of lumbago-sciatica. A multicentre controlled investigation. Acta Orthop Scand. 1980;81(5):791-8.
- 345. Lind G. Auto-traction, treatment of lowback pain and sciatica. An electromyographic, radiographic and clinical study (thesis). Linköping,Sweden: University of Linköping; 1974.
- 346. Walker L, Svenkerud T, Weber H. [Traksjonbehandling ved lumbago-ischias: en kontrollert undersolske med Spina-trac]. Fysioterapeuten. 1982;49:161-3, 177.

- Bihaug O. [Autotraksjon for ishialgpasienter: en kontollert sammenlikning mellom effekten av Auto-traksjon-B og isometriske ovelser ad modum Hume endall og enkins]. Fysioterapeuten. 1978;45:377-9.
- 348. Lidstrom A, Zachrisson M. Physical therapy on low back pain and sciatica. An attempt at evaluation. Scandinavian Journal of Rehabilitation Medicine. 1970;2(1):37-42.
- 349. Coxhead CE, Inskip H, Meade TW, North WR, Troup JD. Multi-centre trial of physiotherapy in the management of sciatic symptoms. Lancet. 1981;1(8229):1065-1068.
- 350. Mathews JA, Mills SB, Jenkins VM, et al. Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injection. Brit J Rheum. 1987;26:416-423.
- 351. Mathews W, Morkel M, Mathews J. Manipulation and traction for lumbago and sciatica: Physiotherapeutic techniques used in two controlled trials. Physiother Pract. 1988;4(4):201-6.
- 352. Weber H, Ljunggren A, Walker L. Traction therapy in patients with herniated lumbar intervertebral discs. J Oslo City Hosp. 1984;34:61-70.
- 353. Ljunggren A, Walker L, Weber H, Amundsen T. Manual traction versus isometric exercises in patients with herniated intervertebral. Physiotherapy Theory and Practice. 1992;8:207-13.
- 354. Sherry E, Kitchener P, Smart R. A prospective randomized controlled study of VAX-D and TENS for the treatment of chronic low back pain. Neurol Res. 2001;23(7):780-4.
- 355. Tesio L, Merlo A. Autotraction versus passive traction: an open controlled study in lumbar disc herniation. Arch Phys Med Rehabil. 1993;74(8):871-6.
- 356. Letchuman R, Deusinger R. Comparison of sacrospinalis myoelectric activity and pain levels in patients undergoing static and intermittent lumbar traction. Spine. 1993;18(10):1361-5.
- 357. Ljunggren A, Weber H, Larsen S. Autotraction versus manual traction in patients with prolapsed lumbar intervertebral discs. Scand J Rehabil Med. 1984;16(3):117-24.
- 358. Reust P, Chantraine A, Vischer T. [Traitment par tractions mécaniques des lombosciatalgies avec ou sans dé cit neurologique].Schweiz med Wschr 1988;118(8):271-4.
- 359. Konrad K, Tatrai T, Hunka A, Vereckei E, Korondi I. Controlled trial of balneotherapy in treatment of low back pain. Annals of the rheumatic diseases. 1992;51(6):820-2.
- 360. Roman MP. A clinical evaluation of ultrasound by use of a placebo technic. Phsy Ther Rev. 1960;40:649-652.
- 361. Nwuga VC. Ultrasound in treatment of back pain resulting from prolapsed intervertebral disc. Archives of physical medicine and rehabilitation. 1983;64(2):88-9.
- 362. van der Windt DAWM, van der Heijden GJMG, van den Berg SGM, ter Riet G, de Winter AF, Bouter LM. Ultrasound therapy for musculoskeletal disorders: a systematic review. Pain. 1999;81:257-271.
- 363. Robertson VJ, Baker KG. A review of therapeutic ultrasound: effectiveness studies. Physical Therapy. 2001;81:1339-1350.
- 364. Gam AN. Ultrasound therapy in musculoskeletal disorders: a meta-analysis. Pain. 1995;63:85-91.
- 365. Gnatz SM. Increased radicular pain due to therapeutic ultrasound applied to the back. Archives of Physical Medicine and Rehabilitation. 1989;70(6):493-494.
- 366. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1-13.
- 367. Turner JA, Clancy S. Comparison of operant behavioral and cognitive-behavioral group treatment for chronic low back pain. J Consult Clin Psychol. 1988;56:261-266.
- 368. Turner JA, Clancy S, McQuade KJ, Cardenas DD. Effectiveness of behavioral therapy for chronic low back pain: a component analysis. J Consult Clin Psychol. 1990;58:573-579.
- 369. van den Hout JHC, Vlaeyen JWS, Heuts PHTG, Zijlema JHL, Wijnen JAG. Secondary prevention of work-related disability in nonspecific low back pain: Does problem-solving therapy help? A randomized clinical trial. Clinical Journal of Pain. 2003;19(2):87-96.
- 370. Kole-Snijders AMJ, Vlaeyen JWS, Goossens MEJB. Chronic low back pain: what does cognitive coping skills training add to oepratn behavioral treatment? Results of a randomized clinical trial. J Consult Clin Psychol. 1999;67:931-944.

- 371. Turner JA, Jensen MP. Efficacy of cognitive therapy for chronic low back pain. Pain. 1993;52:169-177.
- 372. Turner JA. Comparison of group progressive-relaxation training and cognitive-behavioral group therapy for chronic low back pain. J Consult Clin Psychol. 1982;50:757-765.
- 373. Bru E, Mykletun R, Berge W, Svebak S. Effects of different psychological interventions on neck, shoulder and low back pain in female hospital staff. Psychology and Health. 1994;9:371-382.
- 374. Goossens MEJB, Rutten-Van Molken MPMH, Kole-Snijders AMJ, Vlaeyen JWS, van Breukelen GV, Leidl R. Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. Health Economics. 1998;7:39-51.
- 375. Furlan AD, Brosseau L, Imamura M, Irvin E. Massage for low-back pain Cochrane Database of Systematic Reviews. 2002(2).
- 376. Furlan AD, Brosseau L, Imamura M, Irvin E. Massage for low-back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 2002;27:1896-1910.
- 377. Ernst E. Massage therapy for low back pain: a systematic review. Journal of Pain and Symptom Management. 1999;17:65-69.
- 378. Preyde M. Effectiveness of massage therapy for subacute low-back pain: a randomized controlled trial. CMAJ. 2000;162:1815-1820.
- 379. Melzack R, Vetere P, Finch M. Transcutaneous electrical nerve stimulation for low back pain. A comparison of TENS and massage for pain and range of motion. Phys Ther. 1983;63:489-493.
- 380. Pope MH, Phillips RB, Haugh LD, Hsieh CY, MacDonald L, Haldeman S. A prospective randomized three-week trial of spinal manipulation, transcutaneous muscle stimulation, massage and corset in the treatment of subacute low back pain. Spine. 1994;19:2571-2577.
- 381. Hsieh CY, Phillips RB, Adams AH, Pope MH. Functional outcomes of low back pain: Comparison of four treatment groups in a randomized controlled trial. Journal of Manipulative & Physiological Therapeutics. 1992;15(1):4-9.
- 382. Hernandez-Reif M, field T, Krasnegor J, Theadston H. Lower back pain is reduced and range of motion increased after massage therapy. Int J Neurosci. 2001;106:131-145.
- 383. Godfrey CM, Morgan PP, Schatzker J. A randomzied trial of manipulation for low-back pain in a medical setting. Spine. 1984;9:301-304.
- 384. Franke A, Gebauer S, Franke K, Brockow T. Acupuncture massage vs Swedish massage and individual exercise vs group exercise in low back pain sufferes--a randomised controlled clinical trial in a 2 x 2 factorial trial design. Forschende Komplementarmedizin und Klassische Naturheilkunde. 2000;7:286-293.
- 385. Krause N, Dasinger L, Neuhauser F. Modified work and return to work: a review of the literature. J Occup Rehabil. 1998;8(2):113-39.
- 386. Guillemin F, Constant F, Collin JF, Boulange M. Short and long-term effect of spa therapy in chronic low back pain. British journal of rheumatology. 1994;33(2):148-51.
- 387. Constant F, Guillemin F, Collin JF, Boulange M. Use of spa therapy to improve the quality of life of chronic low back pain patients. Medical care. 1998;36(9):1309-14.
- 388. Constant F, Collin JF, Guillemin F, Boulange M. Effectiveness of spa therapy in chronic low back pain: a randomized clinical trial. The Journal of rheumatology. 1995;22(7):1315-20.
- 389. Yurtkuran M, Kahraman Z, Sivrioglu K, Afsin Y, Dogan M. Balneotherapy in Low Back Pain. European Journal of Physical Medicine and Rehabilitation. 1997;7(4):120-123.
- 390. Brown A, Angus A, Chen S, et al. Ottawa: Canadian Coordinating Office for Health Technology. *Costs and outcomes of chiropractic treatment for low back pain*. Technology Report No.: 56; 2005.
- 391. Ferreira ML, Ferreira PH, Latimer J, Herbert R, Maher CG. Efficacy of spinal manipulative therapy for low back pain of less than three months' duration. Journal of Manipulative & Physiological Therapeutics. 2003;26(9):593-601.
- 392. Ferreira ML, Ferreira PH, Latimer J, Herbert R, Maher CG. Does spinal manipulative therapy help people with chronic low back pain? Aust J Physiother. 2002;48:277-84.

- 393. Kent P, Marks D, Pearson W, Keating J. Does clinician treatment choice improve the outcomes of manual therapy for nonspecific low back pain: A meta-analysis. Journal of Manipulative & Physiological Therapeutics. 2005;28:312-322.
- 394. Stevinson C, Ernst E. Risks associated with spinal manipulation. The American Journal of Medicine. 2002;112(7):566-571.
- 395. Oliphant D. Safety of spinal manipulation in the treatment of lumbar disk herniations: a systematic review and risk assessment. Journal of Manipulative and Physiological Therapeutics 2004;27(3):197-210.
- 396. Meeker WC, Haldeman S. Chiropractic: A profession at the crossroads of mainstream and alternative medicine. Ann Intern med. 2002;136:216-227.
- 397. Assendelft WJJ, Bouter LM, Knipschild PG. Complications of spinal manipulation: a comprehensive review of the literature. J Family Pract. 1996;42(5):475-480.
- 398. Ernst E. Prospective investigations into the safey of spinal manipulation. Journal of Pain and Symptom Management. 2001;21(3):238-242.
- 399. Licciardone JC, Stoll ST, Fulda KG, et al. Osteopathic manipulative treatment for chronic low back pain: A randomized controlled trial. Spine. 2003;28(13):1355-1362.
- 400. Gay RE, Bronfort G, Evans RL. Distraction manipulation of the lumbar spine: A review of the literature. Journal of Manipulative & Physiological Therapeutics. 2005;28:266-273.
- 401. Ernst E, Canter P. Chiropractic spinal manipulation treatment for back pain? A systematic review of randomised clinical trials. Phys Ther Rev. 2003;8(2):85-91.
- 402. Bronfort G, Haas M, Evans R, Bouter L. Efficacy of spinal manipulation and mobilization for low back pain and neck pain: a systematic review and best evidence synthesis. The Spine Journal. 2004;4:335-56.
- 403. Avery S, O'Driscoll ML. Randomised controlled trials on the efficacy of spinal manipulation therapy in the treatment of low back pain. Physical Therapy Reviews. 2004;9:146-152.
- 404. Brox JI, Hagen KB, Juel NG, Storheim K. [Is exercise therapy and manipulation effective in low back pain?]. Tidsskrift for Den Norske Laegeforening. 1999;119(14):2042-2050.
- 405. Shekelle PG, Adams AH, Chassin MR, Hurwitz EL, Brook RH. Spinal manipulation for low-back pain. Ann Intern Med. 1992;117:590-598.
- 406. Ottenbacher K, DiFabio RP. Efficacy of spinal manipulation/mobilization therapy. A metaanalysis. Spine. 1985;10(9):833-7.
- 407. Mohseni-Bandpei M. Spinal manipulation in the treatment of low back pain: a review of the literature with particular emphasis on randomized controlled clinical trials. Phys Ther Rev. 1998;3:185-94.
- 408. Koes BW, Assendelft WJJ, van der Heijden GJMG, Bouter LM, Knipschild PG. Spinal manipulation and mobilisation for back and neck pain: a blinded review. BMJ. 1991;303(6813):1298-303.
- 409. Koes BW, Assendelft WJJ, van der Heijden GJMG, Bouter LM. Spinal manipulation for low back pain. An updated systematic review of randomized clinical trials. Spine. 1996;21(24):2860-2873.
- 410. Greenland S, Reisbord LS, Haldeman S, Buerger AA. Controlled clinical trials of manipulation: a review and a proposal. J Occup Med. 1980;22(10):670-6.
- 411. Ernst E, Harkness E. Spinal manipulation: a systematic review of sham-controlled, double-blind, randomized clinical trials. J Pain & Sympt Mgmt. 2001;22(4):879-889.
- 412. Ernst E. Does spinal manipulation have specific treatment effects? Family Prac. 2000;17(6):554-556.
- 413. Di Fabio RP. Clinical assessment of manipulation and mobilization of the lumbar spine. A critical review of the literature. Phys Ther. 1986;66(1):51-4.
- 414. Brunarski DJ. Clinical trials of spinal manipulation: a critical appraisal and review of the literature. J Manipulative Physiol Ther. 1984;7(4):243-9.
- 415. Bronfort G. Spinal manipulation. Current state of research and its indications. Neurologic Clinics of North America. 1999;17:91-111.

- 416. Assendelft WJJ, Koes BW, van der Heijden GJMG, Bouter LM. The efficacy of chiropractic manipulation for back pain: blinded review of relevant randomized clinical trials. J Manipulative Physiol Ther. 1992;15(8; Oct):487-94.
- 417. Assendelft WJJ, Koes BW, van der Heijden GJMG, Bouter LM. The effectiveness of chiropractic for treatment of low back pain: an update and attempt at statistical pooling. Journal of Manipulative & Physiological Therapeutics. 1996;19(8):499-507.
- 418. Assendelft WJJ, Koes BW, Knipschild PG, Bouter LM. The relationship between methodological quality and conclusions in reviews of spinal manipulation. JAMA. 1995;274(24):1942-8.
- 419. Pustaver M. Mechanical low back pain: etiology and conservative management. J Manipulative Physiol Ther. 1994;17`(6):376-84.
- 420. DiFabio RP. Efficacy of manual therapy. Phys Ther. 1992;72(12):853-864.
- 421. Anderson R, Meeker WC, Wirick BE, Mootz RD, Kirk DH, Adams A. A meta-analysis of clinical trials of spinal manipulation. J Manipulative Physiol Ther. 1992;15(3):181-94.
- 422. Abenhaim L, Bergeron AM. Twenty years of randomized clinical trials of manipulative therapy for back pain: a review. Clinical & Investigative Medicine(Medecine Clinique et Experimentale). 1992;15(6):527-35.
- 423. Hurwitz EL, Morgenstern H, Harber P, et al. A randomized trial of medical care with and without physical therapy and chiropractic care with and without physical modalities for patients with low back pain: 6-Month follow-up outcomes from the UCLA low back pain study. Spine. 2002;27(20):2193-2204.
- 424. Kominski GF, Heslin KC, Morgenstern H, Hurwitz EL, Harber PI. Economic evaluation of four treatments for low-back pain: results from a randomized controlled trial. Medical Care. 2005;43(5):428-35.
- 425. Skargren EI, Carlsson PG, Oberg BE. One-year follow-up comparison of the cost and effectiveness of chiropractic and physiotherapy as primary management for back pain: subgroup analysis, recurrence, and additional health care utilization. Spine. 1998;23(17):1875-1883.
- 426. Skargren EI, Oberg B, Carlsson PG, Gade M. Cost and effectiveness analysis of chiropractic and physiotherapy treatment for low back and neck pain: six-month follow-up. Spine. 1997;22(18):2167-2177.
- 427. Hestbrook L, Leboef-Yde C. Are chiropractic tests for the lumbo-pelvic spine reliable and valid? A systematic critical literary review. J Manipulative Physiol Ther. 2000;23(4):258-75.
- 428. Najm WI, Seffinger MA, Mishra SI, et al. Content validity of manual spinal palpatory exams a systematic review. BMC Complement Altern Med. 2003;3(1; May 7):1.
- 429. Seffinger MA, Najm WI, Mishra SI, et al. Reliability of spinal palpation for diagnosis of back and neck pain. Spine. 2004;29(19):E413-E425.
- 430. Childs JD, Fritz JM, Flynn TW, et al. A clinical prediction rule to identify patients with low back pain most likely to benefit from spinal manipulation: a validation study. Annals of Internal Medicine. 2004;141(12):920-8.
- 431. Flynn T, Fritz J, Whitman J, et al. A clinical prediction rule for classifying patients with low back pain who demonstrate short-term improvement with spinal manipulation. Spine. 2002;27(24):2835-43.
- 432. Fritz JM, Whitman JM, Childs JD. Lumbar spine segmental mobility assessment: An examination of validity for determining intervention strategies in patients with low back pain. Arch Phys Med Rehabil. 2005;86:1745-1752.
- 433. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users' guides to the medical literature: XXII: How to use articles about clinical decision rules. JAMA. 2000;284:279-284.
- 434. Fritz JM, Childs JD, Flynn TW. Pragmatic application of a clinical prediction rule in primary care to identify patients with low back pain with a good prognosis following a brief spinal manipulation intervention. BMC Family Practice. 2005;6:29.
- 435. Hicks GE, Fritz JM, Delitto A, Mishock J. Interrater reliability of clinical examination measures for identification of lumbar segmental instability. Archives of Physical Medicine & Rehabilitation. 2003;84(12):1858-64.

- 436. Hagen KB, Hilde G, Jamtvedt G, Winnem M. Bed rest for acute low-back pain and sciatica. Cochrane Database of Systematic Reviews. 2004(4).
- 437. Hagen KB, Jamtvedt G, Hilde G, Winnem MF. The updated Cochrane review of bed rest for low back pain and sciatica. Spine. 2005;30(5):542-546.
- 438. Hagen KB, Hilde G, Jamtvedt G. The Cochrane review of bed rest for acute low back pain and sciatica. Spine. 2000;25(22):2932-2939.
- 439. Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999;354(9186):1229-1233.
- 440. Koes BW. Efficacy of bed rest and orthoses for low back pain: A review of randomized clinical trials. Eur J Phys Med Rehabil. 1994;4:86-93.
- 441. Waddell G, Feder G, Lewis M. Systematic reviews of bed rest and advice to stay active for acute low back pain. Br J Gen Pract. 1997;47(423; Oct):647-52.
- 442. Rozenberg S, Delval C, Rezvani Y, al e. Bed rest or normal activity for patients with acute low back pain: a randomized controlled trial. Spine. 2002;27:1487-93.
- 443. Hofstee DJ, Gijtenbeek JMM, Hoogland PH, et al. Westeinde Sciatica Trial: randomized controlled study of bed rest and physiotherapy for acute sciatica. J Neurosurg: Spine. 2002;96:45-49.
- 444. Vroomen PCAJ, Marc CTFM, Wilmink JT, Kester ADM, Knottnerus JA. Lack of effectiveness of bed rest for sciatica. N Engl J Med. 1999;340:418-423.
- 445. Gilbert JR, Taylor DW, Hildebrand A, Evans C. Clinical trial of common treatments for low back pain in family practice. Br Med J Clin Res Ed. 1985;291:791-794.
- 446. Postacchini F, Facchini M, Palieri P. Efficacy of various forms of conservative treatment in low back pain: A comparative study. Neuro-Orthopedics. 1988;6:28-35.
- 447. Szpalski M, Hayez JP. How many days of bed rest for acute low back pain? Objective assessment of trunk function. Eur Spine J. 1992;1:29-31.
- 448. Deyo RA, Diehl AK, Rosenthal M. How many days of bed rest for acute low back pain? A randomized clinical trial. New England Journal of Medicine. 1986;315:1064-70.
- 449. Hagen KB, Hilde G, Jamtvedt G, Winnem M. The Cochrane review of advice to stay active as a single treatment for low back pain and sciatica. Spine. 2002;27(16):1736-1741.
- 450. Hilde G, Hagen KB, Jamtvedt G, Winnem M. Advice to stay active as a single treatment for lowback pain and sciatica. Cochrane Database of Systematic Reviews. 2002;2.
- 451. Frost H, Lamb SE, Doll HA, Carver PT, Stewart-Brown S. Randomised controlled trial of physiotherapy compared with advice for low back pain. British Medical Journal. 2004;329(7468):708-711.
- 452. Little P, Roberts L, Blowers H, et al. Should we give detailed advice and information booklets to patients with back pain? A randomized controlled factorial trial of a self-management booklet and doctor advice to take exercise for back pain. Spine. 2001;26(19):2065-72.
- 453. Stankovic R, Johnell O. Conservative treatment of acute low back pain. A 5-year follow-up study of two methods of treatment. Spine. 1995;20:469-472.
- 454. Stankovic R, Johnell O. Conservative treatment of acute low-back pain. A prospective randomized trial: McKenzie method of treatment versus patient education in "mini back school". 1990;Spine 15(2):120-3.
- 455. Burton, Waddell GT. Information and advice to patients with back pain does have a positive effect: an RCT of an educational booklet in primary care [Abstract]. Journal of Bone and Joint Surgery British Volume 1999;82(Suppl 1):3.
- 456. Cherkin DC, Deyo RA, Street JH, Hunt M, Barlow W. Pitfalls of patient education. Limited success of a program for back pain in primary care. Spine. 1996;21(3):345-55.
- 457. Hazard RG, Reid S, Haugh LD, McFarlane G. A controlled trial of an educational pamphlet to prevent disability after occupational low back injury. Spine. 2000;25(11):1419-23.
- 458. Roberts L, Little P, Chapman J, Cantrell T, Pickering R, Langridge J. The back home trial: general practitioner-supported leaflets may change back pain behavior. Spine. 2002;27(17):1821-8.

DRAFT – for Peer Review only APS Clinical Guidelines for the Management of Low Back Pain

- 459. Roland M, Dixon M. Randomized controlled trial of an educational booklet for patients presenting with back pain in general practice. The Journal of the Royal College of General Practitioners. 1989;39(323):244-6.
- 460. Lorig K, Laurent D, Deyo R. Can a back pain e-mail discussion group improve health status and lower health care costs? Arch Intern Med. 2002;162(7):792-6.
- 461. Miller JS, Stanley I, Moore K. Videotaped exercise instruction: A randomised controlled trial in musculoskeletal physiotherapy. Physiotherapy Theory and Practice. 2004;20(3):145-154.
- 462. Snook SH, Webster BS, McGorry RW. The reduction of chronic, nonspecific low back pain through the control of early morning lumbar flexion: 3-year follow-up. Journal of Occupational Rehabilitation. 2002;12(1):13-9.
- 463. Snook SH, Webster BS, McGorry RW, Fogleman MT, McCann KB. The reduction of chronic nonspecific low back pain through the control of early morning lumbar flexion. Spine. 1998;23(23):2601-2607.
- 464. Von Korff M, Moore JE, Lorig K, et al. A randomized trial of a lay person-led self-management group intervention for back pain patients in primary care. Spine. 1998;23(23):2608-15.
- 465. Strong LLMPH, Von Korff MS, Saunders KJD, Moore JEP. Cost-Effectiveness of Two Self-Care Interventions to Reduce Disability Associated With Back Pain. Spine. 2006;31(15):1639-1645.
- 466. Deyo RA, Cherkin DC, Weinstein J, Howe J, Ciol M, Mulley AG. Involving patients in clinical decisions: impact of an interactive video program on use of back surgery. Medical care. 2000;38(9):959-69.
- 467. Phelan EA, Deyo RA, Cherkin DC, et al. Helping patients decide about back surgery: a randomized trial of an interactive video program. Spine. 2001;26(2):206-11.
- 468. van Tulder M, Jellema P, van Poppel MNM, Nachemson AL, Bouter LM. Bed rest for acute lowback pain and sciatica. Cochrane Database of Systematic Reviews. 2000(3).
- 469. Jellema P, van Tulder M, van Poppel MNM, Nachemson AL, Bouter LM. Lumbar supports for prevention and treatment of low back pain. Spine. 2001;26(4):377-386.
- 470. van Poppel MN, de Looze MP, Koes BW, Smid T, Bouter LM. Mechanisms of action of lumbar supports: a systematic review. Spine. 2000;25(16):2103-13.
- 471. Penrose KW, Chook K, Stump JL. Acute and chronic effects of pneumatic lumbar suppor on muscular strength, flexibility, and functional impairment index. Sports Training Med Rehab. 1991;2:121-129.
- 472. Valle-Jones J, Walsh H, O'Hara J, O'Hara H, Davey N, Hopkin-Richards H. Controlled trial of a back support ('Lumbotrain') in patients with non-specific low back pain. Curr Med Res Opin. 1992;12(9):604-13. Links. 1992;12(9):604-13.
- 473. Million R, Nilsen K, Jayson M, Baker R. Evaluation of low back pain and assessment of lumbar corsets with and without back supports. Ann Rheum Dis. 1981;40(5):449-54.
- 474. Kovacs FM, Abraira V, Pena A, et al. Effect of firmness of mattress on chronic non-specific lowback pain: Randomised, double-blind, controlled, multicentre trial. Lancet. 2003;362(9396):1599-1604.
- 475. Atherton J, Clarke AK, Harrison RA, Maddison MC. Low back pain the use of the isometric mattress. Br J Occup Ther Vol. 1983;46:133-4.
- 476. Garfin SR, Pye SA. Bed design and its effect on chronic low back pain--a limited controlled trial. Pain. 1981;10(1):87-91.
- 477. French S, Cameron M, Walker B, Reggars J, Esterman A. Superficial heat or cold for low back pain. Cochrane Database of Systematic Reviews. 2006(1).
- 478. Nadler SF, Steiner DJ, Erasala GN, Hengehold DA, Abeln SB, Weingand KW. Continuous lowlevel heatwrap therapy for treating acute nonspecific low back pain. Archives of Physical Medicine & Rehabilitation. 2003;84(3):329-34.
- 479. Nadler SF, Steiner DJ, Erasala GN, et al. Continuous low-level heat wrap therapy provides more efficacy than Ibuprofen and acetaminophen for acute low back pain. Spine. 2002;27(10):1012-7.
- 480. Nadler SF, Steiner DJ, Petty SR, Erasala GN, Hengehold DA, Weingand KW. Overnight use of continuous low-level heatwrap therapy for relief of low back pain. Archives of Physical Medicine & Rehabilitation. 2003;84(3):335-42.

- 481. Nuhr M, Hoerauf K, Bertalanffy A, et al. Active warming during emergency transport relieves acute low back pain. Spine. 2004;29(14):1499-503.
- 482. Mayer JM, Ralph L, Look M, et al. Treating acute low back pain with continuous low-level heat wrap therapy and/or exercise: A randomized controlled trial. Spine Journal. 2005;5(4):395-403.
- 483. Melzack R, Jeans M, Stratford J, Monks R. Ice massage and transcutaneous electrical stimulation: comparison of treatment for low-back pain. Pain 1980;9(2):209-17.
- 484. Landen BR. Heat or cold for the relief of low back pain? Physical Therapy. 1967;47(12):1126-8.
- 485. Roberts D, Walls C, Carlile J, Wheaton C. Aronoff G, ed. Chapter 13, Evaluation and Treatment of Chronic Pain, in *Relief of chronic low back pain: heat versus cold*. 2nd edition ed. Baltimore: Urban & Schwarzenberg, 1992. Aronoff G, ed. Chapter 13, Evaluation and Treatment of Chronic Pain.
- 486. Lloyd A, Scott DA, Akehurst RL, Lurie-Luke E, Jessen G. Cost-effectiveness of low-level heat wrap therapy for low back pain. Value in Health. 2004;7(4):413-22.
- 487. Bogduk N, Modic MT. Lumbar discography. Spine. 1996;21(3):402-4.
- 488. Rhyne A, Smith S, Darden B, Wood K. Outcome of unoperated discogram-positive low back pain. Spine. 1995;20(18):1997-2000.
- 489. Cohen SP, Larkin TM, Barna SA, Palmer WE, Hecht AC, Stojanovic MP. Lumbar discography: A comprehensive review of outcome studies, diagnostic accuracy, and principles. Regional Anesthesia and Pain Medicine. 2005;30(2):163-183.
- 490. Shah R, Everett C, McKenzie-Brown A, Sehgal N. Discography as a Diagnostic Test for Spinal Pain: A Systematic and Narrative Review. An Invited Review. Pain Physician. 2005;8(2):187-209.
- 491. Sackett DL, Haynes RB. Evidence base of clinical diagnosis: The architecture of diagnostic research. BMJ. 2002;324(7336):539-541.
- 492. Willems P, Jacobs W, Duinkerke E, De Kleuver M. Discography as a Diagnostic Test for Spinal Pain: A Systematic and Narrative Review. An Invited Review. Spinal Disord Tech. 2004;17(3):243-7.
- 493. Carragee EJ, Alamin TF, Miller J, Grafe M. Provocative discography in volunteer subjects with mild persistent low back pain. Spine Journal: Official Journal of the North American Spine Society. 2002;2(1):25-34.
- 494. Carragee EJ, Chen Y, Tanner CM, Truong T, Lau E, Brito JL. Provocative discography in patients after limited lumbar discectomy: A controlled, randomized study of pain response in symptomatic and asymptomatic subjects. Spine. 2000;25(23):3065-71.
- 495. Carragee EJ, Tanner CM, Khurana S, et al. The rates of false-positive lumbar discography in select patients without low back symptoms. Spine. 2000;25(11):1373-80; discussion 1381.
- 496. Carragee EJ, Tanner CM, Yang B, Brito JL, Truong T. False-positive findings on lumbar discography. Reliability of subjective concordance assessment during provocative disc injection. Spine. 1999;24(23):2542-7.
- 497. Carragee EJMD, Alamin TFMD, Carragee JMMBA. Low-Pressure Positive Discography in Subjects Asymptomatic of Significant Low Back Pain Illness. Spine. 2006;31(5):505-509.
- 498. Derby R, Kim B-J, Lee S-H, Chen Y, Seo K-S, Aprill C. Comparison of discographic findings in asymptomatic subject discs and the negative discs of chronic LBP patients: Can discography distinguish asymptomatic discs among morphologically abnormal discs? Spine Journal. 2005;5(4):389-394.
- 499. Walsh TR, Weinstein JN, Spratt KF, Lehmann TR, Aprill C, Sayre H. Lumbar discography in normal subjects. A controlled, prospective study. Journal of Bone & Joint Surgery American Volume. 1990;72(7):1081-8.
- 500. Block AR, Vanharanta H, Ohnmeiss DD, et al. Discographic pain report. Influence of psychological factors. Spine. 1996;21(3):334-8.
- 501. Heggeness M, Watters W, Gray P. Discography of Lumbar Discs After Surgical Treatment for Disc Herniation. Spine. 1997;22(14):1606-1609.
- 502. Manchikanti L, Singh V, Pampati V, et al. Provocative Discography in Low Back Pain Patients With or Without Somatization Disorder. Pain Physician. 2001;4(32):227-39.

- Ohnmeiss D, Vanharanta H, Guyer R. The association between pain drawings and computed 503. tomographic/discographic pain responses. Spine. 1995;20(6):729-33. 504. Carragee EJ, Lincoln T, Parmar V, Alamin T. A gold standard evaluation of the "Discogenic Pain" diagnosis as determined by provocative discography. Spine. 2006 31(18): In Press. 505. Madan S, Gundanna M, Harley JM, Boeree NR, Sampson M. Does provocative discography screening of discogenic back pain improve surgical outcome? Journal of spinal disorders & techniques. 2002;15(3):245-51. 506. Holt EJ. The question of lumbar discography. J Bone Joint Surg Am. 1968;50(4):720-6. 507. Massie W, Stevens D. A critical evaluation of discography. J Bone Joint Surgery. 1967;49A:1243. 508. O'Neill C, Kurgansky M. Subgroups of Positive Discs on Discography. [Miscellaneous Article]. Spine. 2004;29(19):2134-9. Derby R, Lee S-H, Kim B-J, Chen Y, Aprill C, Bogduk N. Pressure-Controlled Lumbar 509. Discography in Volunteers Without Low Back Symptoms. Pain Medicine. 2005;6(3):213-221. 510. Gill K, Blumenthal S. Functional results after anterior lumbar fusion at L5-S1 in patients with normal and abnormal MRI scans. Spine. 1992;17(8):940-2. Colhoun E, McCall IW, Williams L, Cassar Pullicino VN. Provocation discography as a guide to 511. planning operations on the spine. Journal of Bone & Joint Surgery - British Volume. 1988:70(2):267-71. 512. Osti OL, Fraser RD, Vernon-Roberts B. Discitis after discography. The role of prophylactic antibiotics. J Bone Joint Surg (Br). 1990;72:271-274. 513. Carragee EJ, Chen Y, Tanner CM, Hayward C, Rossi M, Hagle C. Can discography cause longterm back symptoms in previously asymptomatic subjects? Spine. 2000;25(14):1803-8. 514. Flanagan MN, Chung BU. Roentgenographic changes in 188 patients 10-20 years after discography and chemonucleolysis. Spine. 1986;11:444-448. Everett C, Shah R, Sehgal N, McKenzie-Brown A. A Systematic Review of Diagnostic Utility of 515. Selective Nerve Root Blocks Pain Physician. 2005;8(2):225-33. 516. Sehgal N, V. R, Shah R, McKenzie-Brown A, Everett C. Diagnostic Utility of Facet (Zygapophysial) Joint Injections in Chronic Spinal Pain: A Systematic Review of Evidence Pain Physician. 2005;8(2):211-24. Boswell M, Singh V, Staats P, Hirsch J. Accuracy of Precision Diagnostic Blocks in the Diagnosis 517. of Chronic Spinal Pain of Facet or Zygapophysial Joint Origin. Pain Physician. 2003;6(4):449-56. 518. Gibson JNA, Grant IC, Waddell G. Surgery for lumbar disc prolapse. Cochrane Database of Systematic Reviews. 2000(3). Gibson JNA, Grant IC, Waddell G. The Cochrane review of surgery for lumbar disc prolapse and 519. degenerative lumbar spondylosis. Spine. 1999;24:1820-1832. Scheer S, Radack K, O'Brien D. Randomized controlled trials in industrial low back pain relating 520. to return to work. Part 2. Discogenic low back pain. Archives of Physical Medicine and Rehabilitation. 1996;77(11):1189-1197. Stevens C, Dubois R, Larequi-Lauber T, Vader J. Efficacy of lumbar discectomy and 521. percutaneous treatments for lumbar disc herniation. Soz Praventivmed. 1997;42(6):367-9. 522. Wittenberg RH, Oppel S, Rubenthaler FA, Steffen R. Five-year results from chemonucleolysis with chymopapain or collagenase. Spine. 2001;26:1835-1841. 523. Bromley JW, Varma AO, Santoro AJ, Cohen P, Jacobs R, Berger L. Double-blind evaluation of collagenase injections for herniated lumbar discs. Spine. 1984;9:486-488. 524. Burton AK, Tillotson KM, Cleary J. Single-blind randomised controlled trial of chemonucleolysis and manipulation in the treatment of symptomatic lumbar disc herniation. Eur Spine J. 2000:9:202-207. 525. Bontoux D, Alcalay M, Debiais F, et al. [Treatment of lumbar disk hernia by intra-disk injection of chymopapain or triamcinolone hexacetonide. Comparative study of 80 cases] Traitment des
 - hernies discales lombaires par injection intradiscale de chymopapain ou d'hexacetonide de triamcinolong. Etude comparee de 80 cas. Rev Rhum Mal Osteoartic. 1990;57:327-331.

- 526. Bourgeois P, Benoist M, Palazzo E, et al. [Multicenter randomized double-blind study of triamcinolone hexacetonide versus chymopapain in the treatment of disc lumbosciatica. Initial results at 6 months]. Rev Rhum Mal Osteoartic. 1988;55:767-769.
- 527. Graham C. Chemonucleolysis. A preliminary report on a double blind study comparing chemonucleolysis and intradiscal administration of hydrocortisone in the treatment of backache and sciatica. Orthop Clin North Am. 1975;6(1):259-63.
- 528. Benoist M, Bonneville JF, Lassale B, et al. A randomized, double-blind study to compare lowdose with standard-dose chymopapain in the treatment of herniated lumbar intervertebral discs. Spine. 1993;18:28-34.
- 529. Hedtmann A, Fett H, Steffen R, Kramer J. [Chemonucleolysis using chymoapain and collagnease. 3-year results of a prospective randomized study] Chemonukleolyse mit chymopapain und kollagenase. 3-jahres-ergebnisse einer prospektiv-randomisierten studie. Z Orthop Ihren Grenzgeb. 1992;130:36-44.
- 530. Day PL. Early, interim, and long-term observations on chemonucleolysis in 876 patients with special comments on the lateral approach. Clin Orthop. 1974;99:64.
- 531. Wiltse LL, Widell EH, Yuan HA. Chmopapain chemonucleolysis in lumbar disk disease. JAMA. 1975;231:474-479.
- 532. Agre K, Wilson rR, Brim M, McDermott DJ. Chymodiactin postmarketing surveillance: demographic and adverse experience data. Spine. 1984;9:479-486.
- 533. Brown MD, Tompkins JS. Chemonucleolysis (dscolysis) with collagenase. Spine. 1989;11:123-130.
- 534. Launois R, Henry B, Marty JR, et al. Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation: A cost and quality-of-life evaluation. PharmacoEconomics. 1994;6(5):453-463.
- 535. Ramirez LF, Javid MJ. Cost effectiveness of chemonucleolysis versus laminectomy in the treatment of herniated nucleus pulposus. Spine. 1985;10(4):363-367.
- 536. Breivik H, Hesla PE, Molnar I, Lind B. Treatment of chronic low back pain and sciatica: comparison of caudal epidural injections of bupivicainen and methylprednisolone with bupivicaine followed by saline. Adv Pain Res Ther. 1976;1:927-932.
- 537. Carette S, Leclaire R, Marcoux S, et al. Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. N Engl J Med. 1997;336:1634-1640.
- 538. Cuckler JM, Bernini PA, Wiesel SW, Booth RE, Rothman RH, Pickens GT. The use of epidural steroids in the treatment of lumbar radicular pain. J Bone Joint Surg 1985;67A:63-66.
- 539. Rogers P, Nash T, Schiller D, Norman J. Epidural steroids for sciatica. Pain Clin. 1992;5:67-72.
- 540. Nelemans P, deBie R, deVet H, Sturmans F. Injection therapy for subacute and chronic benign low back pain. Spine. 2001;26(5):501-515.
- 541. Nelemans PJ, de Bie RA, de Vet HCW, Sturmans F. Injection therapy for subacute and chronic benign low-back pain Cochrane Database of Systematic Reviews. 1999(4).
- 542. Abdi S, Datta S, Lucas L. Role of Epidural Steroids in the Management of Chronic Spinal Pain: A Systematic Review of Effectiveness and Complications A Systematic Review. Pain Physician. 2005;8(1):127-43.
- 543. DePalma MJ, Bhargava A, Slipman CW. A Critical Appraisal of the Evidence for Selective Nerve Root Injection in the Treatment of Lumbosacral Radiculopathy. Archives of Physical Medicine and Rehabilitation. 2005;86(7):1477-1483.
- 544. Koes B. Epidural steroid injections for low back pain and sciatica: an updated systematic review of randomized clinical trials. Pain Digest. 1999;9:241.
- 545. Tonkovich-Quaranta L, Winkler S. Use of epidural corticosteroids in low back pain. Ann Pharmacother. 2000;34(10):1165-1172.
- 546. Haselkorn JK. Epidural steroid injections and the management of sciatica: a meta-analysis (Abstract). Arch Phys Med Rehabil. 1995;76:1037.
- 547. Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of epidural steroid injections for low-back pain and sciatica: a systematic review of randomized clinical trials. Pain. 1995;63(3):279-88.

- 548. Rozenberg S, Dubourg G, Khalifa P, Paolozzi L, Maheu E, Ravaud P. Efficacy of epidural steroids in low back pain and sciatica. A critical appraisal by a French Task Force of randomized trials. Critical Analysis Group of the French Society for Rheumatology. Rev Rhum Engl Ed. 1999;66(2):79-85.
- 549. Watts RW, Silagy CA. A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica. Anaesth Intensive Care. 1995;23(5; Oct):564-9.
- 550. Boswell M, Hansen H, Trescot A, Hirsch J. Epidural steroids in the management of chronic spinal pain and radiculopathy. Pain Physician. 2003;6:319-334.
- 551. Cannon D, Aprill C. Lumbosacral epidural steroid injections. Arch Phys Med Rehabil. 2000;81(3 suppl 1):S87-S98.
- 552. Kepes ER, Duncalf D. Treatment of backache with spinal injections of local anesthetics, spinal and systemic steroids. A review. Pain. 1985;22(1):33-47.
- 553. Weinstein SM, Herring SA, Derby R, Weinstein SM, Herring SA, Derby R. Contemporary concepts in spine care. Epidural steroid injections. Spine. 1995;20(16):1842-6.
- 554. Buttermann GR, Buttermann GR. Treatment of lumbar disc herniation: epidural steroid injection compared with discectomy. A prospective, randomized study. Journal of Bone & Joint Surgery American Volume. 2004;86-A(4):670-9.
- 555. Manchikanti L, Rivera JJ, Pampati V, et al. One day lumbar epidural adhesiolysis and hypertonic saline neurolysis in treatment of chronic low back pain: a randomized, double-blind trial. Pain Physician. 2004;7:177-186.
- 556. Price C, Arden N, Coglan L, Rogers P. NHS R&D HTA Programme. *Cost effectiveness and safety of epidural steroids in the management of sciatica*. Health Technology Assessment. Vol. 9; No. 33 2005.
- 557. Wilson-MacDonald J, Burt G, Griffin D, Glynn C. Epidural steroid injection for nerve root compression. A randomised, controlled trial. The Journal of bone and joint surgery British volume. 2005;87(3):352-5.
- 558. Dashfield AK, Taylor MB, Cleaver JS, Farrow D. Comparison of caudal steroid epidural with targeted steroid placement during spinal endoscopy for chronic sciatica: a prospective, randomized, double-blind trial. Br. J. Anaesth. 2005;94(4):514-519.
- 559. Manchikanti L, Rivera JJ, Pampati V, et al. One day lumbar epidural adhesiolysis and hypertonic saline neurolysis in treatment of chronic low back pain: A randomized, double-blind trial. Pain Physician. 2004;7(2):177-186.
- 560. Carette S, Marcoux S, Truchon R, et al. A controlled trial of corticosteroid injections into facet joints for chronic low back pain. NEJM. 1991;325:1002-1007.
- 561. Dilke TFW, Burry HC, Grahame R. Extradural corticosteroid injectiosn in managment of lumbar nerve root compression. BMJ. 1973;2:635-637.
- 562. Snoek W, Weber H, Jorgensen BG. Double blind evaluation of extradural methyl prednisolone for herniated lumbar discs. Acta Orthop Scand. 1977;48:635-641.
- 563. Helsa PE, Breivik H. Epidural analgesia and epidural steroid injection for treatment of chronic low back pain and sciatica. Tidsskrift for Den Norske Laegeforening. 1979;21:511-513.
- 564. Kraemer J, Ludwig J, Bickert U, Owczarek V, Traupe M. Lumbar epidural perineural injection: a new technique. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 1997;6(5):357-61.
- 565. Serrao JM, Marks RL, Morley SJ, Goodchild CS. Intrathecal midazolam for the treatment of chronic mechanical low back pain: a controlled comparison with epidural steroid in a pilot study. Pain. 1992;48:5-12.
- 566. Fukusaki M, Kobayashi I, Hara T, Sumikawa K. Symptoms of spinal stenosis do not improve after epidural steroid injection. The Clinical journal of pain. 1998;14(2):148-51.
- 567. Riew KD, Yin Y, Gilula L, et al. The effect of nerve-root injections on the need for operative treatment of lumbar radicular pain. A prospective, randomized, controlled, double-blind study. The Journal of bone and joint surgery American volume. 2000;82-A(11):1589-93.

- 568. Karppinen J, Malmivaara A, Kurunlahti M, et al. Periradicular infiltration for sciatica: a randomized controlled trial. Spine. 2001;26(9):1059-67.
- 569. DeVulder J, Deene P, De Laat M, van Bastelaere M, Brusselmans G, Rolly G. Nerve root sleeve injectiosn in patients with failed back surgery syndrome: A comparison of three solutions. Clin J Pain. 1999;15:132-135.
- 570. Vad VB, Bhat AL, Lutz GE, Cammisa F. Transforaminal epidural steroid injections in lumbosacral radiculopathy: a prospective randomized study. Spine. 2002;27(1):11-6.
- 571. Klenerman L, Greenwood R, Davenport HT, White DC, Peskett S. Lumbar epidural injections in the treatment of sciatica. Brit J Rheum. 1984;23(1):35-38.
- 572. Thomas E, Cyteval C, Abiad L, Picot MC, Taourel P, Blotman F. Efficacy of transforaminal versus interspinous corticosteroid injectiosn in discal radiculalgia--a prospective, randomized, double-blind study. Clin Rheumatol. 2003;22:299-304.
- 573. Kolsi I, Delecrin J, Berthelot JM, Thomas L, Prost A, Maugars Y. Efficacy of nerve root versus interspinous injectiosn of glucocorticoids in the treatment of disk-related sciatica. A pilot, prospective, randomized, double-blind study. J Bone Spine. 2000;67:113-118.
- 574. McGregor AH, Anjarwalla NK, Stambach T. Does the method of injection alter the outcome of epidural injections? J Spinal Disord. 2001;14:507-510.
- 575. Boswell M, Colson J, Spillane W. Therapeutic facet joint interventions in chronic spinal pain: A systematic review of their role in chronic spinal pain management and complications. Pain Physician. 2005;8(1):101-14.
- 576. Slipman CW, Bhat AL, Gilchrist RV, Issac Z, Chou L, Lenrow DA. A critical review of the evidence for the use of zygapophysial injections and radiofrequency denervation in the treatment of low back pain. The Spine Journal. 2003;3(4):310-316.
- 577. Nash TP. Facet joints intra-articular steroids or nerve block? Pain Clinic. 1989;3(2):77-82.
- 578. Lilius G, Lassonen AM, Myllynen P, Harilainen A, Salo L. The lumbar facet joint s yndrome-significance of inappropriate signs. A randomized, placeocontrolled trial. French J Orthop Surg. 1989;3:479-486.
- 579. Marks RC, Houston T, Thulbourne T. Facet joint injection and facet nerve block: a randomised comparison in 86 patients with chornic low back pain. Pain. 1992;49:325-328.
- 580. Buttermann GR. The effect of spinal steroid injections for degenerative disc disease. Spine Journal: Official Journal of the North American Spine Society. 2004;4(5):495-505.
- 581. Khot A, Bowditch M, Powell J, Sharp D. The use of intradiscal steroid therapy for lumbar spinal discogenic pain: a randomized controlled trial. Spine. 2004;29(8):833-6.
- 582. Simmons JW, McMillin JN, Emery SF, Kimmich SJ. Intradiscal steroids. A prospective doubleblind clinical trial. Spine. 1992;17(6 Suppl).
- 583. Collee G, Dijkmans BAC, Vandenbroucke JP, Cats A. Iliac crest pain syndrome in low back pain. A double blind, randomized study of local injection therapy. J Rheumatol. 1991;18:1060-1063.
- 584. Sonne M, Chirstensen K, Hansen SE, Jensen EM. INjection of steroids and local anaesthetics as therapy for low-back pain. Scand J Rheum. 1985;14:343-345.
- 585. Hameroff SR, Crago BR, Blitt CD, Womble J, Kanel J. Comparison of bupivacaine, etidocaine, and saline for trigger-point therapy. Anaesthesia and Analgesia. 1981;60:752-755.
- 586. Ongley MJ, Klein RG, Dorman TA, Eek BC, Hubert LJ. A new approach to the treatment of chronic low back pain. Lancet. 1987;2(8551):143-146.
- 587. Yelland MJ, Del Mar C, Pirozzo S, Schoene ML, Vercoe P. Prolotherapy injections for chronic low-back pain Cochrane Database of Systematic Reviews. 2004(2).
- 588. Dechow E, Davies RK, Carr AJ, Thompson PW. A randomized, double-blind, placebo-controlled trial of sclerosing injections in patients with chronic low back pain. Rheumatology. 1999;38:1255-1259.
- 589. Klein RG, Eek BC, DeLong WB, Mooney V. A randomized double-blind trial of dextrose-glycerinephenol injectiosn for chronic low back pain. Journal of Spinal Disorders. 1993;6(1):23-33.
- 590. Yelland MJ, Glasziou PP, Bogduk N, Schluter PJ, McKernon M. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized trial. Spine. 2004;29(1):9-16.

- 591. McKenzie-Brown AM, Shah RV, Sehgal N, Everett Cr. A systematic review of sacroiliac joint interventions. Pain Physician. 2005;8:115-125.
- 592. Luukkainen RK, Wennerstrand PV, Kautiainen HH, Sanila MT, Asikainen EL. Efficacy of periarticular corticosteroid treatment of the sacroiliac join in non-spondyloarthropathic patients with chronic low back pain in the region of the sacroiliac joint. Clinical and Experimental Rheumatology. 2002;20:52-54.
- 593. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56(10):1290-3.
- 594. Subin B, Saleemi S, Morgan G, Zavisca F, Randall C. Treatment of Chronic Low Back Pain by Local Injection of Botulinum Toxin-A. The Internet Journal of Anesthesiology. 2003;6(2):1-8.
- 595. Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis? Journal of Forensic Sciences. 2005;50(1):169-72.
- 596. Niemisto L, Kalso E, Malmivaara A, Seitsalo S, Hurri H. Radiofrequency denervation for neck and back pain. A systematic review of randomized controlled trials. Cochrane Database of Systematic Reviews. 2003(1).
- 597. Niemisto L, Kalso E, Malmivaara A, Seitsalo S, Hurri H, Cochrane Collaboration Back Review G. Radiofrequency denervation for neck and back pain: a systematic review within the framework of the cochrane collaboration back review group. Spine. 2003;28(16):1877-88.
- 598. Geurts J, van Wijk R, Stolker R, Groen G. Efficacy of radiofrequency procedures for the treatment of spinal pain: a systematic review of randomized clinical trials. Reg Anesth Pain Med. 2001;26(5):394-400.
- 599. Manchikanti L, Singh V, Vilims B, Hansen H, Schultz D, Kloth D. Medial Branch Neurotomy in Management of Chronic Spinal Pain: Systematic Review of the Evidence 2002; 5(4):405-18. Pain Physician. 2002;5(4):405-18.
- 600. Hooten WM, Martin DP, Huntoon MA. Radiofrequency Neurotomy for Low Back Pain: Evidence-Based Procedural Guidelines. Pain Medicine. 2005;6(2):129-138.
- 601. van Wijk R, Geurts J, Wynne H, et al. Radiofrequency Denervation of Lumbar Facet Joints in the Treatment of Chronic Low Back Pain: A Randomized, Double-Blind, Sham Lesion-Controlled Trial. Clinical Journal of Pain July/August 2005;21(4). 2005;21(4):335-344.
- 602. Geurts J, van Wijk RM, Wynne HJ, et al. Radiofrequency lesioning of dorsal root ganglia for chronic lumbosacral radicular pain: a randomised, double-blind, controlled trial. The Lancet. 2003;361(9351):21-26.
- 603. Oh WS, Shim JC. A randomized controlled trial of radiofrequency denervation of the ramus communicans nerve for chronic discogenic low back pain. Clinical Journal of Pain. 2004;20(1):55-60.
- 604. Gallagher J, Petriccione D, Wedley J, et al. Radiofrequency facet joint denervation in the treatment of low back pain: A prospective controlled double-blind study to assess its efficacy Pain Clinic. 1994;7(3):193-98.
- 605. Leclaire R, Fortin L, Lambert R, Bergeron YM, Rossignol M. Radiofrequency facet joint denervation in the treatment of low back pain: a placeo-controlled clinical trial to assess efficacy. Spine. 2001;26(13):1411-1416.
- 606. van Kleef M, Barendse GA, Kessels AH, Voets HM, Weber WE, de Lange S. Randomized trial of radiofrequency lumbar facet denervation for chronic low back pain. Spine. 1999;24:1937-1942.
- 607. Freeman BJC, Fraser RD, Cain CMJ. A randomized, double-blind, controlled efficacy study: Intradiscal electrothermal therapy (IDET) versus placebo for the treatment of chronic discogenic low back pain. European Spine Journal. 2003;12:S23.
- 608. Pauza KJ, Howell S, Dreyfuss P, Peloza JH, Dawson K, Bogduk N. A randomized, placebocontrolled trial of intradiscal electrothermal therapy for the treatment of discogenic low back pain. Spine Journal: Official Journal of the North American Spine Society. 2004;4(1):27-35.
- 609. Gibson J, Waddell G. Surgery for Degenerative Lumbar Spondylosis: Updated Cochrane Review. Spine. 2005;30(20):2312-2320.
- 610. Gibson JNA, Waddell G, Grant IC. Surgery for degenerative lumbar spondylosis Cochrane Database of Systematic Reviews. 2005(4).

- 611. NICE. National Institute for Clinical Excellence. Interventional procedures overview of percutaneous intradiscal radiofrequency thermocoagulation for lower back pain. IP Guidance Number IPG081. 2004.
- 612. Samson D, Aronson N, Ziegler KM, Bonnell CJ, Gere MA. (Technology Evaluation Center, Blue Cross Blue Shield Association). Percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic low back pain. 2004.
- 613. Chou LH, Lew HL, Coelho PC, Slipman CW. Intradiscal electothermal annuloplasty. Am J Phys Med Rehabil. 2005;84:538-549.
- 614. Heary RF. Intradiscal electothermal annuloplasty: The IDET procedure. Journal of Spinal Disorders. 2001;14:353-360.
- 615. Wetzel FT, McNally TA, Phillips FM. Intradiscal electrothermal therapy used to manage chronic discogenic low back pain: New directions and interventions. Spine. 2002;27:2621-2626.
- 616. Ercelen O, Bulutcu E, Oktenoglu T, et al. Radiofrequency lesioning using two different time modalities for the treatment of lumbar discogenic pain: a randomized trial. Spine. 2003;28(17):1922-7.
- 617. Bogduk N, Karasek M. Two-year follow-up of a controlled trial of intradiscal electrothermal anuloplasty for chronic low back pain resulting from internal disc disruption. Spine Journal: Official Journal of the North American Spine Society. 2002;2(5):343-50.
- 618. NICE. (National Institute for Clinical Excellence). Interventional procedures overview of percutaneous intradiscal electrothermal therapy for lower back pain. 2004.
- 619. Gerszten PC, Welch WC, McGrath PM, Willis SL. A prospective outcomes study of patients undergoing intradiscal electrothermy (IDET) for chronic low back pain. Pain Physician. 2002;5(4):360-364.
- 620. Barendse GA, van Den Berg SG, Kessels AH, Weber WE, van Kleef M. Randomized controlled trial of percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic back pain. Spine. 2001;26(3):287-292.
- 621. Boult M, Fraser R, Jones N, et al. Percutaneous endoscopic laser discectomy. Aust N Z J Surg. 2000;70(7):475-9.
- 622. de Kleuver M, Oner F, Jacobs W. Total disc replacement for chronic low back pain: background and a systematic review of the literature. European Spine Journal. 2003;12(2):108-116.
- 623. NICE. National Institute for Clinical Excellence. Endoscopic laser foraminoplasty. IP Guidance Number IPG031 .2003.
- 624. NICE. National Institute for Clinical Excellence. Laser lumbar discectomy. IP Guidance Number IPG027.2003.
- 625. NICE. National Institute for Clinical Excellence. Prosthetic intervertebral disc replacement. IP Guidance Number IPG100. 2004.
- 626. Bono CMMD, Lee CKMD. Critical Analysis of Trends in Fusion for Degenerative Disc Disease Over the Past 20 Years: Influence of Technique on Fusion Rate and Clinical Outcome. Spine. 2004;29(4):455-463.
- 627. Kwon B, Hilibrand A, Malloy K, et al. A Critical Analysis of the Literature Regarding Surgical Approach and Outcome for Adult Low-Grade Isthmic Spondylolisthesis. Journal of Spinal Disorders & Techniques Latest Advances in Spinal Surgery. 2005;18(Supplement 1):S30-S40.
- 628. Livesey JPS. Laser discectomy versus lumbar epidural steroid injection: a randomised comparative study of two treatments for sciatica [Abstract]. Journal of Bone & Joint Surgery British Volume. 2000;82(Suppl 1):74.
- 629. Hoffman RM, Wheeler KJ, Deyo RA. Surgery for herniated lumbar discs: a literature syntehsis. J Gen Intern Med. 1993;8:487-96.
- 630. Mardjetko SM, Connolly PJ, Shott S. Degenerative lumbar spondylolisthesis. A meta-analysis of literature 1970-1993. Spine. 1994;19(20S):2256S-2265S.
- 631. Turner JA, Ersek M, Herron L, Deyo R. Surgery for lumbar spinal stenosis. Attempted metaanalysis of the literature. Spine. 1992;17(1):1-8.
- 632. Turner JA, Ersek M, Herron L, et al. Patient outcomes after lumbar spinal fusions. JAMA. 1992;268(7):907-911.

- 633. Fairbank J, Frost H, Wilson-MacDonald J, et al. Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilisation trial. BMJ. 2005;330(7502):1233.
- 634. Blumenthal SL, Ohnmeiss DD, Guyer RD, Hochschuler SH. Prospective study evaluating total disc replacement: preliminary results. Journal of Spinal Disorders & Techniques. 2003;16(5):450-4.
- 635. Delamarter RB, Bae HW, Pradhan BB. Clinical results of ProDisc-II lumbar total disc replacement: report from the United States clinical trial. Orthopedic Clinics of North America. 2005;36(3):301-13.
- 636. Zigler JE. Lumbar spine arthroplasty using the ProDisc II. The spine journal : official journal of the North American Spine Society. 2004;4(6 Supl):260S-267S.
- 637. Birkmeyer NJO, Weinstein JN, Tosteson ANA, et al. Design of the Spine Patient Outcomes Research Trial (SPORT). Spine. 2002;27(12):1361-1372.
- 638. Brox JI, Reikeras O, Nygaard O, et al. Lumbar instrumented fusion compared with cognitive intervention and exercises in patients with chronic back pain after previous surgery for disc herniation: A prospective randomized controlled study. Pain. 2006;122(1-2):145-155.
- 639. Brox JI, Sorensen R, Friis A, et al. Randomized clinical trial of lumbar instrumented fusion and cognitive intervention and exercises in patients with chronic low back pain and disc degeneration. Spine. 2003;28(17):1913-1921.
- 640. Fritzell PMD, Hagg OMD, Wessberg PMD, Nordwall AMDP, Swedish Lumbar Spine Study G. 2001 Volvo Award Winner in Clinical Studies: Lumbar Fusion Versus Nonsurgical Treatment for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial From the Swedish Lumbar Spine Study Group. Spine. 2001;26(23):2521-2532.
- 641. Amundsen TMD, Weber HMDD, Nordal HJMDD, Magnaes BMDD, Abdelnoor MMPHP, Lilleas FMD. Lumbar Spinal Stenosis: Conservative or Surgical Management? : A Prospective 10-Year Study. Spine. 2000;25(11):1424-1436.
- 642. Atlas SJMDMPH, Keller RBMD, Wu YAMPH, Deyo RAMDMPH, Singer DEMD. Long-Term Outcomes of Surgical and Nonsurgical Management of Lumbar Spinal Stenosis: 8 to 10 Year Results from the Maine Lumbar Spine Study. Spine. 2005;30(8):936-943.
- 643. Atlas S, Deyo R, Keller R, et al. The Maine Lumbar Spine Study, Part III: 1-Year Outcomes of Surgical and Nonsurgical Management of Lumbar Spinal Stenosis. Spine. 1996;21(15):1787-1794.
- 644. Atlas S, Keller R, Robson D, Deyo R, Singer D. Surgical and Nonsurgical Management of Lumbar Spinal Stenosis: Four-Year Outcomes From the Maine Lumbar Spine Study. Spine. 2000;25(5):556-562.
- 645. Zucherman JF, Hsu KY, Hartjen CA, et al. A prospective randomized multi-center study for the treatment of lumbar spinal stenosis with the X STOP interspinous implant: 1-year results. European Spine Journal. 2004;13(1):22-31.
- 646. Moller HMD, Hedlund RMDP. Surgery Versus Conservative Management in Adult Isthmic Spondylolisthesis: A Prospective Randomized Study: Part 1. Spine. 2000;25(13):1711-1715.
- 647. Weber H. Lumbar disc herniation. A controlled, prospective study with ten years of observation. Spine. 1983;8(2):131-40.
- 648. Atlas S, Keller R, Wu Y, Deyo R, Singer D. Long-Term Outcomes of Surgical and Nonsurgical Management of Sciatica Secondary to a Lumbar Disc Herniation: 10 Year Results from the Maine Lumbar Spine Study. Spine. 2005;30(8):927-935.
- 649. Atlas S, Deyo R, Keller R et al. The Maine Lumbar Spine Study, Part II: 1-Year Outcomes of Surgical and Nonsurgical Management of Sciatica. Spine. 1996;21(15):1777-1786.
- 650. Atlas S, Keller R, Chang YP, Deyo R, Singer D. Surgical and Nonsurgical Management of Sciatica Secondary to a Lumbar Disc Herniation: Five-Year Outcomes From the Maine Lumbar Spine Study. Spine. 2001;26(10):1179-1187.
- 651. Nykvist F, Hurme M, Alaranta H, Kaitsaari M. Severe sciatica: a 13-year follow-up of 342 patients. Eur Spine J. 1995;4(6):335-8.

652.	Revel M, Payan C, Vallee C, et al. Automated percutaneous lumbar discectomy versus
050	chemonucleolysis in the treatment of sciatica. A randomized multicenter trial. Spine. 1993;18:1-7.
653.	Bridwell KH, Sedgewick TA, O'Brien MF, Lenke LG, Baldus C. The role of fusion and
	instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord. 1993;6:461-472.
654.	Zdeblick TA. A prospective, randomized study of lumbar fusion. Preliminary results. Spine.
004.	1993;18:983-991.
655.	Goodwin CB, Brighton CT, Guyer RD, Johnson JR, Light KI, Yuan HA. A double-blind study of
	capacitively coupled electrical stimulation as an adjunt to lumbar spinal fusions. Spine.
	1999;24:1349-1357.
656.	Jenis LG, An HS, Stein R, Young B. Prospective comparison of the effect of direct current
	electrical stimulation and pulsed electromagnetic field on insturmented posterolateral lumbar
057	arthrodesis. Journal of Spien Disorders. 2000;13:290-296.
657.	Mooney V. A randomized double-blind prospective sutdy of the efficacy of pulsed electromagnetic
CE O	fields for interbody lumbar fusions. Spine. 1990;15:708-712.
658.	Mirza SKMDMPH. Point of View: Commentary on the Research Reports that Led to Food and Drug Administration Approval of an Artificial Disc. Spine. 2005;30(14):1561-1564.
659.	Postacchnini F, Cinotti G, Perugia D, Gumina S. The surgical treatment of central lumbar
000.	stenosis. J Bone Joint Surg. 1993;75-B:386-392.
660.	Carragee EJ. Single-level posterolateral arthrodesis, with or without posterior decompression, for
	the treatment of isthmis spondylolisthesis in adults. A prosepctive, randomised study. J Bone
	Joint Surg. 1997;79-A:1175-1180.
661.	Henriksen L, Schmidt V, Eskesen V, Jantzen E. A controlled study of microsurgical versus
	standard lumbar discectomy. Br J Neurosurg. 1996;10:289-293.
662.	Lagarrigue J, Chaynes P. Comparative study of disk surgery with or without microscopy. A
000	prospective study of 80 cases. Neurochirurgie. 1994;40(2):116-120.
663.	Geisler FH. [Prevention of peridural fibrosis: current methodologies]. Neurological Research.
664.	1999;21(Suppl 1):S9-S22. Mayer HM, Brock M. Percutaneous endoscopic discectomy: surgical technique and preliminary
004.	results compared to microsurgical discectomy. J Neurosurg. 1993;78:216-225.
665.	Chatterjee S, Foy PM, Findlay GF. Report of a controlled clinical trial comparing automated
	percutaneous lumbar discectomy and microdiscectomy in the treatment of contained lumbar disc
	herniation. Spine. 1995;20:734-738.
666.	Herron LD, Turner JA, Novell LA, Kreif SL. Patient selection for lumbar discectomy with a revised
	objective rating system. Clinical Orthopaedics & Related Research. 1996(325):148-155.
667.	Herron LD, Turner JA, Weiner P. Lumbar disc herniations: The predictive value of the Health
	Attribution Test (HAT) and the Minnesota Multiphasic Personality Inventory (MMPI). Journal of
<u></u>	Spinal Disorders. 1988;1(1):2-8.
668.	Hagg O, Fritzell P, Ekselius L, Nordwall A, Swedish Lumbar Spine S. Predictors of outcome in fusion surgery for chronic low back pain. A report from the Swedish Lumbar Spine Study.
	European Spine Journal. 2003;12(1):22-33.
669.	Fritzell P, Hagg O, Nordwall A, Swedish Lumbar Spine Study G. Complications in lumbar fusion
000.	surgery for chronic low back pain: comparison of three surgical techniques used in a prospective
	randomized study. A report from the Swedish Lumbar Spine Study Group. European Spine
	Journal. 2003;12(2):178-89.
670.	Rivero-Arias O, Campbell H, Gray A, Fairbank J, Frost H, Wilson-MacDonald J. Surgical
	stabilisation of the spine compared with a programme of intensive rehabilitation for the
	management of patients with chronic low back pain: cost utility analysis based on a randomised
	controlled trial. BMJ. 2005;330(7502):1239.
671.	Fritzell P, Hagg O, Jonsson D, Nordwall A, Swedish Lumbar Spine Study Group. Cost-
	effectiveness of lumbar fusion and nonsurgical treatment for chronic low back pain in the Swedish
	Lumbar Spine Study: a multicenter, randomized, controlled trial from the Swedish Lumbar Spine Study Group. Spine. 2004;29(4):421-34.
	Olday Oldap. Opine. 2007,23(7).721-07.

- 672. Malter AD, Larson EB, Urban N, Deyo RA. Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. Spine. 1996;21(9):1048-1054.
- 673. Kuntz KM, Snider RK, Weinstein JN, Pope MH, Katz JN. Cost-effectiveness of fusion with and without instrumentation for patients with degenerative spondylolisthesis and spinal stenosis. Spine. 2000;25:1132-1139.
- 674. Katz JN, Lipson SJ, Lew RA, et al. Lumbar laminectomy alone or with instrumented or noninstrumented arthrodesis in degenerative lumbar spinal stenosis: patient selection, costs, and surgical outcomes. Spine. 1997;22(10):1123-1131.
- 675. Stevenson RC, McCabe CJ, Findlay AM. An economic evaluation of a clinical trial to compare automated percutaneous lumbar discectomy with microdiscectomy in the treatment of contained lumbar disc herniation. Spine. 1995;20:739-742.
- 676. Deyo RA, Walsh NE, Martin DC, Schoenfeld LS, Ramamurthy S. A controlled trial of transcutaneous electrical nerve stimulation (TENS) and exercise for chronic low back pain. New England Journal of Medicine. 1990;322:1627-34.
- 677. Khadilkar A, Milne A, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain Cochrane Database of Systematic Reviews. 2005(3).
- 678. Brosseau L, Milne S, Robinson V, et al. Efficacy of the transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a meta-analysis. Spine. 2002;27(6):596-603.
- 679. Milne S, Welch V, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain Cochrane Database of Systematic Reviews. 2005(3).
- 680. Flowerdew M, Gadsby G. A review of the treatment of chronic low back pain with acupuncturelike transcutaneous electrical nerve stimulation and transcutaneous electrical nerve stimulation. Comp Ther Med. 1997;5(4):193-201.
- 681. Gadsby G, Flowerdew M. Nerve stimulation for low back pain--a review. Nursing Standard. 1997;11(43):32-3.
- 682. Cheing GL, Hui-Chan CW. Transcutaneous electrical nerve stimulation: nonparallel antinociceptive effects on chronic clinical pain and acute experimental pain. Archives of Physical Medicine & Rehabilitation. 1999;80(3):305-312.
- 683. Herman E, Williams RA, Stratford P, Fargas-Babjak A, Trott M. A randomized controlled trial of transcutaneous electrical nerve stimulation (CODETRON) to determine its benefits in a rehabilitation program for acute occupational low back pain. Spine. 1994;19:561-568.
- 684. Cummings M. Percutaneous electrical nerve stimulation--electroacupuncture by another name? A comparative review. Acupuncture in Medicine. 2001;2001:32-35.
- 685. Yokoyama M, Sun X, Oku S, et al. Comparison of percutaneous electrical nerve stimulation with transcutaneous electrical nerve stimulation for long-term pain relief in patients with chronic low back pain. Anesthesia and Analgesia. 2004;98(6):1552-1556.
- 686. Ghoname EA, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study. JAMA. 1999;281(9):818-823.
- 687. Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic low back pain in older adults. Journal of the American Geriatrics Society. 2003;51(5):599-608.
- 688. Ghoname eA, White PF, Ahmed HE, Hamza MA, Craig WF, Noe CE. Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica. Pain. 1999;83(2):193-199.
- 689. Taylor RS, Van Buyten J, Buscher E. Spinal cord stimulation for chronic back pain and leg pain and failed back surgery syndrome: a systematic review and analysis of progressive factors. Spine. 2005;30(1):152-160.
- 690. Mailis-Gagnon A, Furlan A, Sandoval J, Taylor R, Cochrane Pain Palliative Care and Supportive Care Group. Spinal cord stimulation for chronic pain. . Cochrane Database of Systematic Reviews. 2004(2).
- 691. Turner JA, Loeser JD, Deyo RA, Sanders SB. Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications. Pain. 2004;108(1-2):137-147.

- 692. Turner JA, Loeser JD, Bell KG. Spinal cord stimulation for chronic low back pain: a systematic literature synthesis. Neurosurgery. 1995;37(6):1088-95.
- 693. Wetzel FT, Hassenbusch S, Oakley JC, Willis KD, Simpson RK, Ross EL. Treatment of chronic pain in failed back surgery patients with spinal cord stimulation: a review of current literature and proposal for future investigation. Neuromodulation. 2000;3:59-74.
- 694. Corts Giner JR. Estudio DS 103-282: relajante muscular en lumbalgia aguda o lumbao (estudio doble ciego de tizanidina + paracetamol vs. placebo + paracetamol). Rev Esp de Cir Ost. 1989:119-124.
- 695. Sirdalud Ternelin Asia-Pacific Study Group. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus dicofenac in patients with painful muscle spasms. Current Therapeutic Research. 1998;59:13-22.
- 696. Tervo T, Petaja L, Lepisto P. A controlled clinical trial of a muscle relaxants analgesic combination in the treatment of acute lumbago. The British Journal of Clinical Practice. 1976;30:62-64.
- 697. Borenstein D, Lacks S, Wiesel S. Cyclobenzarpine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clinical Therapeutics. 1990;12:125-131.
- 698. Wand BM, Bird C, McAuley JH, Dore CJ, MacDowell M, De Souza LH. Early intervention for the management of acute low back pain: A single-blind randomized controlled trial of biopsychosocial education, manual therapy, and exercise. Spine. 2004;29(21):2350-2356.
- 699. Wright A, Lloyd-Davies A, Williams S, Ellis R, Strike P. Individual active treatment combined with group exercise for acute and subacute low back pain. Spine. 2005;30(11):1235-1241.
- 700. He RY. Clnical observation on treatment of lumbago due to cold-dampness by warm-acupuncture plus Chinese medicine. Chin Acupuncture Moxibustion. 1997;17:279-280.
- 701. Borman P, Keskin D, Bodur H. The efficacy of lumbar traction in the management of patients with low back pain. Rheumatology International. 2003;23(2):82-86.
- 702. Chopra P, Smith H, Deer T, Bowman R. Role of Adhesiolysis in the Management of Chronic Spinal Pain: A Systematic Review of Effectiveness and Complications. Pain Physician. 2005;8(1):87-100.
- 703. Manchikanti L, Pampati V, Fellows B, Rivera JJ, Beyer CD, Damron KS. Role of one day epidural adhesiolysis in management of chronic low back pain: A randomzied clinical trial. Pain Physician. 2001;4:153-166.
- 704. Heavner JE, Racz GB, Raj P. Percutaneous epidural neuroplasty. Prospective evaluation of 0.9% NaCl versus 10% NaCl with or without hyaluronidase. Reg Anesth Pain Med. 1999;24:202-207.
- 705. Manchikanti L, Pampati V, Bakhit CE, Pakanati RR. Non-endoscopic and endoscopic adhesiolysis in post lumbar laminectomy syndrome. A one-year outcome study and cost effective analysis. Pain Physician. 1999;2:52-58.
- 706. Geurts JW, Kallewaard JW, Richardson J, Groen GG. Targeted methylprednisolone acetate/hyaluronidase/clonidine injection after diagnostic epiduroscopy for chronic sciatica: a prospective, 1-year follow-up study. Reg Anesth Pain Med. 2002;27:343-352.
- 707. Kumar K, Malik S, Demeria D. Treatment of chronic pain with spinal cord stimulation versus alternative therapies: cost-effectiveness analysis. Neurosurgery. 2002;51:106-116.
- 708. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. Pain Medicine. 2004;5(1):6-13.
- 709. Prager JP. Neuraxial medication delivery: the development and maturity of a concept for treating chronic pain of spinal origin. Spine. 2002;27(22):2593-605; discussion 2606.
- 710. de Lissovoy G, Brown RE, Halpern M, Hassenbusch SJ, Ross E. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clinical Therapeutics. 1997;19(1):96-112.
- 711. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 1997;97:803-810.

- 712. Timm KE. A randomized-control study of active and passive treatments for chronic low back pain following L5 laminectomy. The Journal of orthopaedic and sports physical therapy. 1994;20(6):276-86.
- 713. North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005;56:98-107.
- 714. Dario A, Fortini G, Bertollo D, Bacuzzi A, Grizzetti C, Cuffari S. Treatment of failed back surgery syndrome. Neuromodulation. 2001;4:105-110.
- 715. Taylor RJ, Taylor RS. Spinal cord stimulation for failed back surgery syndrome: A decisionanalytic model and cost-effectiveness analysis. International Journal of Technology Assessment in Health Care. 2005;21(3):351-358.
- 716. Bell GK, Kidd D, North RB. Cost-effectiveness analysis of spinal cord stimulation in treatment of failed back surgery syndrome. Journal of Pain and Symptom Management. 1997;13(5):286-295.
- 717. Rossignol M, Abenhaim L, Seguin P, et al. Coordination of primary health care for back pain. A randomized controlled trial. Spine. 2000;25(2):251-8.
- 718. Meeuwesen L, Huyse FJ, Koopmans GT, Heimans JJ. Supervised integrated screening of lowback pain patients by a neurologist. A randomized clinical trial. General hospital psychiatry. 1996;18(6):385-94.
- 719. Linton SJ, van Tulder MW. Preventative interventions for back and neck pain problems. Spine. 2001;26(7):778-787.
- 720. Glomsrod B, Lonn JH, Soukup MG, Bo K, Larsen S. Active back school, prophylactic management for low back pain: Three-year follow-up of a randomized controlled trial. J Rehabil Med. 2001;33:26-30.
- 721. Kellett KM, Kellett DA, Nordholm LA. Effects of an exercise program on sick leave due to back pain. Physical Therapy. 1991;71:283-291.
- 722. Soukup MG, Glomsrod B, Lonn JH, Bo K, Larsen S. The effect of a Mensendieck exercise program as secondary prophylaxis for recurrent low back pain. Spine. 1999;24:1585-1592.
- 723. Verbeek JH, van der Weide WE, van Dijk FJ. Early occupational health management of patients with back pain: a randomized controlled trial. Spine. 2002;27(17):1844-51.
- 724. Vleeming A, Albert HB, Ostgaard HC, Stuge B, Sturesson B, On behalf of the Cost B. Working Group on Guidelines for the Management of Acute Low Back Pain in Primary Care. European Comission, Research Directorate-General, Cost Action B13. Low Back Pain: guidelines for its management. *European guidelines on the diagnosis and treatment of pelvic girdle pain*. 2004.
- 725. Wedenberg K, Moen B, Norling A. A prospective randomized study comparing acupuncture with physiotherapy for low-back and pelvic pain in pregnancy. Acta obstetricia et gynecologica Scandinavica. 2000;79(5):331-5.
- 726. Stuge B, Hilde G, Vollestad N. Physical therapy for pregnancy-related low back and pelvic pain: a systematic review. Acta Obstetricia et Gynecologica Scandinavica. 2003;82(11):983-990.
- 727. Guerreiro da Silva JB, Nakamura MU, Cordeiro JA, Kulay L, Jr. Acupuncture for low back pain in pregnancy--a prospective, quasi-randomised, controlled study. Acupuncture in Medicine. 2004;22(2):60-7.
- 728. Kvorning N, Holmberg C, Grennert L, Aberg A, Akeson J. Acupuncture relieves pelvic and lowback pain in late pregnancy. Acta Obstetricia et Gynecologica Scandinavica. 2004;83(3):246-50.
- 729. Kihlstrand M, Stenman B, Nilsson S, Axelsson O. Water-gymnastics reduced the intensity of back/low pain in pregnant women. Acta Obstetricia Gynecologica Scandinavica. 1999;78(3):180-185.
- 730. Suputtitada A, Wacharapreechanont T, Chaisayan P. Effect of the "sitting pelvic tilt exercise" during the third trimester in primigravidas on back pain. Journal of the Medical Association of Thailand = Chotmaihet thangphaet Vol. 2002;85(1).
- 731. Noren L, Ostgaard S, Nielsen TF, Ostgaard HC. Reduction of sick leave for lumbar bak and posterior pelvic pain in pregnancy. Spine. 1997;22:2157-2160.
- 732. Ostgaard HC, Zetherstrom G, Roos-Hansson E, Svanberg B. Reduction of back and posterior pelvic pain in pregnancy. Spine. 1994;19:894-900.

- 733. Mantle MJ, Holmes J, Currey HL. Backache in pregnancy II. Prophylactic influence of back care classes. Rheumatol Rehabil. 1981;20:227-232.
- 734. Dumas GA, Reid JG, Wolfe LA, Griffin MP. Exercise, posture, and back pain during pregnancy. Part 2. Exercise and back pain. Clin Biomechanics. 1995;10:104-109.
- 735. Ostgaard HC, Zetherstrom G, Roos-Hansson E. Back pain in relation to pregnancy: a 6-year follow-up. Spine. 1997;22(24):2945-50.
- 736. Field T, Hernandez-Reif M, Hart S, Theakston H, Schanberg S, Kuhn C. Pregnant women benefit from massage therapy. Journal of psychosomatic obstetrics and gynaecology. 1999;20(1):31-8.
- 737. Field T, Diego MA, Hernandex-Reif M, Schanberg S, Kuhn C. Massage therapy effects on depressed pregnant women. J Psychosom Obstet Gynecol. 2004;25:115-122.
- 738. Young G, Jewell D. Interventions for preventing and treating pelvic and back pain in pregnancy Cochrane Database of Systematic Reviews. 2005;1:1.
- 739. Thomas IL, Nicklin J, Pollock H, Faulkner K. Evaluation of a maternity cushion (Ozzlo pillow) for backache and insomnia in late pregnancy. Australian & New Zealand Journal of Obstetrics & Gynaecology. 1989;29(2):133-8.
- 740. Baldwin ML, Cote P, Frank JW, Johnson WG. Cost-effectiveness studies of medical and chiropractic care for occupational low back pain. a critical review of the literature. Spine Journal: Official Journal of the North American Spine Society. 2001;1(2):138-47.
- 741. Thomsen AB, Sorensen J, Sjogren P, Eriksen J. Economic evaluation of multidisciplinary pain management in chronic pain patients: a qualitative systematic review. Journal of Pain & Symptom Management. 2001;22(2):688-98.
- 742. Uhlig T, Finset A, Kvien TK. Effectiveness and cost-effectiveness of comprehensive rehabilitation programs. Current Opinion in Rheumatology. 2003;15(2):134-40.
- 743. van der Roer N, Goossens ME, Evers SM, et al. What is the most cost-effective treatment for patients with low back pain? A systematic review. Best Practice & Research in Clinical Rheumatology. 2005;19(4):671-84.
- 744. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.

APPENDIX 1

SEARCH STRATEGIES

Systematic Reviews

Database: Ovid MEDLINE(R) <1996 to July Week 2 2005> Search Strategy:

- 1 ((ache\$ or pain\$) adj2 (low back or lower back or lumbar)).mp. (6966)
- 2 lbp.mp. (941)
- 3 exp Back Pain/ (7424)
- 4 (1 or 2) and 3 (5305)
- 5 low back pain/ (5011)
- 6 4 or 5 (5305)
- 7 limit 6 to humans (5258)
- 8 limit 7 to "all adult (19 plus years)" (3381)
- 9 limit 8 to (guideline or meta analysis or randomized controlled trial) (406)
- 10 (20021\$ or 2003\$ or 2004\$ or 2005\$).ed. (1570361)
- 11 9 and 10 (157)
- 12 from 11 keep 1-157 (157)

Database: Ovid MEDLINE(R) <1996 to July Week 2 2005> Search Strategy:

- 1 ((ache\$ or pain\$) adj2 (low back or lower back or lumbar)).mp. (6966)
- 2 lbp.mp. (941)
- 3 exp Back Pain/ (7424)
- 4 (1 or 2) and 3 (5305)
- 5 low back pain/ (5011)
- 6 4 or 5 (5305)
- 7 limit 6 to humans (5258)
- 8 limit 7 to "all adult (19 plus years)" (3381)
- 9 limit 8 to (guideline or meta analysis or randomized controlled trial) (406)
- 10 exp Epidemiologic Studies/ (461334)
- 11 exp Evaluation Studies/ (236763)
- 12 Comparative Study/ (472223)
- 13 10 or 11 or 12 (1009798)
- 14 8 and 13 (1698)
- 15 14 not 9 (1424)
- 16 (20021\$ or 2003\$ or 2004\$ or 2005\$).ed. (1570361)
- 17 15 and 16 (571)
- 18 from 17 keep 1-571 (571)

APPENDIX 2

SEARCH STRATEGIES

Primary Studies: Opioids (Medline)

Database: Ovid MEDLINE(R) <1966 to September Week 3 2005> Search Strategy:

- 1 randomized controlled trial.pt. (206082)
- 2 controlled clinical trial.pt. (69290)
- 3 Randomized Controlled Trials/ (39086)
- 4 Random Allocation/ (53797)
- 5 Double-Blind Method/ (83140)
- 6 Single-Blind Method/ (9273)
- 7 1 or 2 or 3 or 4 or 5 or 6 (350538)
- 8 animal/ not human/ (2910356)
- 9 7 not 8 (330839)
- 10 clinical trial.pt. (414986)
- 11 exp clinical trials/ (169622)
- 12 (clinic\$ adj25 trial\$).tw. (113509)
- 13 ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (mask\$ or blind\$)).tw. (79708)
- 14 placebos/ (24013)
- 15 placebo\$.tw. (90652)
- 16 random\$.tw. (318251)
- 17 research design/ (41627)
- 18 (latin adj square).tw. (2204)
- 19 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (744979)
- 20 19 not 8 (691154)
- 21 20 not 9 (371148)
- 22 comparative study/ (1219518)
- 23 exp evaluation studies/ (532914)
- 24 follow-up studies/ (305506)
- 25 prospective studies/ (192151)
- 26 (control\$ or prospective\$ or volunteer\$).tw. (1568315)
- 27 cross-over studies/ (16591)
- 28 22 or 23 or 24 or 25 or 26 or 27 (3129575)
- 29 28 not 8 (2401820)
- 30 29 not (9 or 21) (1914642)
- 31 9 or 21 or 30 (2616629)
- 32 spine/ or coccyx/ or intervertebral disk/ or lumbar vertebrae/ or sacrum/ or spinal canal/ or exp back/ (52500)

33 (spine or coccyx or intervertebral disk\$ or lumbar vertebrae or sacrum or spinal canal or back).tw. (104057)

34 spinal diseases/ or intervertebral disk displacement/ or spinal curvatures/ or kyphosis/ or lordosis/ or scoliosis/ or spinal osteophytosis/ or hyperostosis, diffuse idiopathic skeletal/ or spinal stenosis/ or spondylitis/ or spondylolisthesis/ or spondylolysis/ (39342)

35 (spinal disease\$ or spinal curvatur\$ or kyphosis or lordosis or scoliosis or spinal osteophytosis or hyperostosis or spinal stenosis or spondyliti\$ or spondylolisthesis or spondylolysis).tw. (22739)

36 exp BACK INJURIES/ or ((back or lumbar or sacrum or sacral) adj2 (wound\$ or injur\$ or trauma\$)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (12333)

37 34 or 35 or 36 (60094)

exp pain/ or pain\$.mp. or ache.mp. or aches.mp. or aching.mp. or ached.mp.
 [mp=title, original title, abstract, name of substance word, subject heading word]
 (326880)

39 (32 or 33) and 38 (27047)

40 exp back pain/ or ((back or lumbar or sacrum or sacral) adj2 (pain\$ or ache\$ or aching)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (22849)

- 41 37 or 39 or 40 (82140)
- 42 Opioid\$.mp. or exp Narcotics/ or narcotic\$.mp. (103374)
- 43 41 and 42 (1117)
- 44 31 and 43 (568)
- 45 from 44 keep 1-568 (568)

SEARCH STRATEGIES

Primary Studies: Self-care (Cochrane)

Database: EBM Reviews - Cochrane Central Register of Controlled Trials <1st Quarter 2006>

Search Strategy:

1 spine/ or coccyx/ or intervertebral disk/ or lumbar vertebrae/ or sacrum/ or spinal canal/ or exp back/ (1443)

2 (spine or coccyx or intervertebral disk\$ or lumbar vertebrae or sacrum or spinal canal or back).tw. (5300)

3 spinal diseases/ or intervertebral disk displacement/ or spinal curvatures/ or kyphosis/ or lordosis/ or scoliosis/ or spinal osteophytosis/ or hyperostosis, diffuse idiopathic skeletal/ or spinal stenosis/ or spondylitis/ or spondylolisthesis/ or spondylolysis/ (646)

4 (spinal disease\$ or spinal curvatur\$ or kyphosis or lordosis or scoliosis or spinal osteophytosis or hyperostosis or spinal stenosis or spondyliti\$ or spondylolisthesis or spondylolysis).tw. (617)

5 exp BACK INJURIES/ or ((back or lumbar or sacrum or sacral) adj2 (wound\$ or injur\$ or trauma\$)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (359)

6 3 or 4 or 5 (1421)

7 exp pain/ or pain\$.mp. or ache.mp. or aches.mp. or aching.mp. or ached.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (38262)

8 (1 or 2) and 7 (2534)

9 exp back pain/ or ((back or lumbar or sacrum or sacral) adj2 (pain\$ or ache\$ or aching)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (2248)

10 6 or 8 or 9 (3809)

11 ((self or selves or themsel\$) adj3 (care or look after)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (1288)

12 (patient\$ adj3 (informed or information or informing or educat\$ or teach\$ or learn\$)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (6090)

13 11 or 12 (6885)

14 10 and 13 (157)

15 from 14 keep 1-157 (157)

SEARCH STRATEGIES

Primary Studies: Imaging (Medline)

Database: Ovid MEDLINE(R) <1966 to March Week 3 2006> Search Strategy:

1 spine/ or coccyx/ or intervertebral disk/ or lumbar vertebrae/ or sacrum/ or spinal canal/ or exp back/ (53119)

2 (spine or coccyx or intervertebral disk\$ or lumbar vertebrae or sacrum or spinal canal or back).tw. (107146)

3 spinal diseases/ or intervertebral disk displacement/ or spinal curvatures/ or kyphosis/ or lordosis/ or scoliosis/ or spinal osteophytosis/ or hyperostosis, diffuse idiopathic skeletal/ or spinal stenosis/ or spondylitis/ or spondylolisthesis/ or spondylolysis/ (39393)

4 (spinal disease\$ or spinal curvatur\$ or kyphosis or lordosis or scoliosis or spinal osteophytosis or hyperostosis or spinal stenosis or spondyliti\$ or spondylolisthesis or spondylolysis).tw. (22894)

5 exp BACK INJURIES/ or ((back or lumbar or sacrum or sacral) adj2 (wound\$ or injur\$ or trauma\$)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (12157)

6 3 or 4 or 5 (60147)

7 exp pain/ or pain\$.mp. or ache.mp. or aches.mp. or aching.mp. or ached.mp. [mp=title, original title, abstract, name of substance word, subject heading word] (337357)

8 (1 or 2) and 7 (27925)

9 exp back pain/ or ((back or lumbar or sacrum or sacral) adj2 (pain\$ or ache\$ or aching)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (22711)

10 6 or 8 or 9 (82897)

11 exp Magnetic Resonance Imaging/ (146646)

- 12 exp Tomography, X-Ray Computed/ (167684)
- 13 exp Radiography/ (395689)
- 14 13 not 12 (228005)
- 15 exp Myelography/ (7132)
- 16 11 and 12 (32679)
- 17 10 and 16 (2109)
- 18 11 and 14 (7916)
- 19 10 and 18 (276)
- 20 11 and 15 (892)
- 21 10 and 20 (468)
- 22 12 and 15 (2081)
- 23 10 and 22 (1014)
- 24 14 and 15 (5051)
- 25 10 and 24 (1894)

- 26 17 or 19 or 21 or 23 or 25 (4825)
- 27 limit 26 to randomized controlled trial (31)
- 28 exp "sensitivity and specificity"/ (198840)
- 29 26 and 28 (159)
- 30 "reproducibility of results"/ (117278)
- 31 26 and 30 (40)
- 32 exp Diagnostic Errors/ (62684)
- 33 26 and 32 (118)
- 34 29 or 31 or 33 (284)
- 35 random\$.mp. (443760)
- 36 26 and 35 (61)
- 37 27 or 34 or 36 (338)
- 38 limit 37 to humans (328)
- 39 limit 38 to english language (265)
- 40 limit 38 to abstracts (276)
- 41 39 or 40 (315)
- 42 from 41 keep 1-315 (315

APPENDIX 3

QUALITY RATING SYSTEMS

Systematic Reviews

Criteria for Assess	ing Scientific Quality of Research Reviews*
Criteria	Operationalization of Criteria
 Were the search methods reported? Were the search methods used to find evidence (original research) on the primary questions stated? "Yes" if the review states the databases used, date of most recent searches, and some mention of search terms. 	The purpose of this index is to evaluate the scientific quality (i.e. adherence to scientific principles) of research overviews (review articles) published in the medical literature. It is not intended to measure literary quality, importance, relevance, originality, or other attributes of overviews.
 2. Was the search comprehensive? Was the search for evidence reasonably comprehensive? "Yes" if the review searches at least 2 databases and looks at other sources (such as reference lists, hand searches, queries experts). 3. Were the inclusion criteria reported? Were the criteria used for deciding which studies to include in the overview reported? 4. Was selection bias avoided? Was bias in the selection of studies avoided? 	The index is for assessing overviews of primary ("original") research on pragmatic questions regarding causation, diagnosis, prognosis, therapy, or prevention. A research overview is a survey of research. The same principles that apply to epidemiological surveys apply to overviews: a question must be clearly specified, a target population identified and accessed, appropriate information obtained from that population in an unbiased fashion, and conclusions derived, sometimes with the help of formal statistical analysis, as is done in "meta-analyses". The fundamental difference between overviews and epidemiological studies is the unit of analysis, not the scientific issues that the questions in this index address.
 "Yes" if the review reports how many studies were identified by searches, numbers excluded, and gives appropriate reasons for excluding them (usually because of pre-defined inclusion/exclusion criteria). 5. Were the validity criteria reported? Were the criteria used for assessing the validity of the included studies reported? 	Since most published overviews do not include a methods section, it is difficult to answer some of the questions in the index. Base your answers, as much as possible, on information provided in the overview. If the methods that were used are reported incompletely relative to a specific question, score it as "can't tell", unless there is information in the overview to suggest either the criterion was or was not met.

APS Clinical Guidelines for the Management of Low Back Pain

Criteria for Assess	sing Scientific Quality of Research Reviews*
Criteria	Operationalization of Criteria
 6. Was validity assessed appropriately? Was the validity of all the studies referred to in the text assessed using appropriate criteria (either in selecting studies for inclusion or in analyzing the studies that are cited)? "Yes" if the review reports validity assessment and did some type of analysis with it (e.g. sensitivity analysis of results according to quality ratings, excluded low-quality studies, etc.) 	
 7. Were the methods used to combine studies reported? Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported? "Yes" for studies that did qualitative analysis if there is some mention that quantitative analysis was not possible and reasons that it could not be done, or if 'best evidence' or some other grading of evidence scheme used. 8. Were the findings combined appropriately? Were the findings of the relevant studies combined appropriately relative to the primary question the overview addresses? "Yes" if the review performs a test for heterogeneity before pooling, does appropriate subgroup testing, appropriate sensitivity analysis, or other such analysis. 	 For Question 8, if not attempt has been made to combine findings, and no statement is made regarding the inappropriateness of combining findings, check "No". if a summary (general) estimate is given anywhere in the abstract, the discussion, or the summary section of the paper, and it is not reported how that estimate was derived, mark "No" even if there is a statement regarding the limitations of combining the findings of the studies reviewed. If in doubt, mark "Can't tell". For an overview to be scored as "Yes" in Question 9, data (not just citations) must be reported that support the main conclusions regarding the primary question(s) that the overview addresses. The score for Question 10, the overall scientific quality, should be based on your
 9. Were the conclusions supported by the reported data? Were the conclusions made by the author(s) supported by the data and/or analysis reported in the overview? 	on the preceding questions, a review is likely to have minor flaws at best and it is
10. What was the overall scientific quality of the overview? How would you rate the scientific quality of this overview?	difficult to rule out major flaws (i.e. a score of 4 or lower). If the "No" option is used on Question 2, 4, 6 or 8, the review is likely to have major flaws (i.e. a score of 3 or less, depending on the number and degree of the flaws).
Scoring	Each Question is scored as Yes, Partially/Can't tell or No
Extensive Flaws Major Flaws	Minor Flaws Minimal Flaws
1 2 3	4 5 6 7

*Table created using information from Oxman & Guyatt, J Clin Epidemiol. 1991;44(11):1271-8 and Furlan, Clarke, et al., Spine. 2001 Apr 1;26(7):E155-62.

APPENDIX 4

QUALITY RATING SYSTEMS

Primary Studies

Criter	ia List for the Methodological Quality Assessment	
Criteria	Operationalization of Criteria	Score
A. Was the method of randomization adequate?	A random (unpredictable) assignment sequence. An example of adequate methods is a computer generated random number table and use of sealed opaque envelopes. Methods of allocation using DOB, date of admission, hospital numbers, or alternation should not be regarded as appropriate.	Yes/No/Don't Know
B. Was the treatment allocation concealed?	Assignment generated by an independent person not responsible for determining the eligibility of the patients. This person has no information about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the patient.	
 C. Were the groups similar at baseline regarding the most important prognostic factors? "Yes", if at least one of the following: Age & gender Description of type of pain Intensity, duration or severity of pain 	In order to receive a "yes", groups have to be similar in baseline regading demographic factors, duration or severity of complaints, percentage of patients with neurologic symptoms, and value of main outcome measure(s).	
 D. Was the patient blinded to the intervention? E. Was the care provider blinded to the intervention? F. Was the outcome assessor blinded to the intervention? 	The reviewer determines if enough information about the blinding is given in order to score a "yes": Use the author's statement on blinding, unless there is a differing statement/reason not to (no need for explicit information on blinding).	
G. Were cointerventions avoided or similar?	Cointerventions should either be avoided in the trial design or similar between the index and control groups.	
H. Was the compliance acceptable in all groups?	The reviewer determines if the compliance to the interventions is acceptable, based on the reported intensity, duration, number and frequency of sessions for both the index intervention and control intervention(s).	

Criter	ia List for the Methodological Quality Assessment	
Criteria	Operationalization of Criteria	Score
I. Was the drop-out rate described and	The number of participants who are included in the study but did not	
acceptable?	complete the observation period or were not included in the analysis	
>= 85% drop out rate = acceptable.	must be described and reasons given. If the percentage of withdrawals	
	and drop-outs does not exceed 15% and does not lead to substantial	
	bias, a "yes" is scored.	
J. Was the timing of the outcome assessment	Timing of outcome assessment should be identical for all intervention	
in all groups similar?	groups and for all important outcome assessments.	
K. Did the analysis include an intention-to-treat	All randomized patients are reported/analyzed in the group they were	Yes/No/Don't Know
analysis?	allocated to by randomization for the most important moments of effect	
OK if less than 5% of no-treatment excluded.	measurement (minus missing values) irrespective of noncompliance and	
	cointerventions.	
	(n=11) that refer to characteristics of the study that might be related to select	
	I), attrition bias (criteria I and K and detection bias (criteria f and J). The inte	rnal validity criteria
should be used to define methodologic quality in	the meta-analysis.	

APS Clinical Guidelines for the Management of Low Back Pain

* Table created using information from van Tulder, Furlan, Bombardier, Bouter, and Editorial Board of the Cochrane Collaboration Back Review Group. Spine. 2003;28(12):121290-9.

APPENDIX 5

LIST OF INCLUDED SYSTEMATIC REVIEWS

ACETAMINOPHEN
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
SRs comparing acetaminophen to NSAIDs
Van Tulder, 2000
Nonsteroidal anti-inflammatory drugs for low back pain. A systematic review within the framework of the
Cochrane Collaboration Back Review Group (also published as a Cochrane review)
ACUPUNCTURE
Furlan, 2005
Acupuncture and dry-needling for low back pain: An updated systematic review within the framework of
the Cochrane collaboration
Manheimer, 2005
Meta-analysis: Acupuncture for low back pain
ANTIDEPRESSANTS
Fishbain, 2000
Evidence-based data on pain relief with antidepressants
Salerno, 2002
The effect of antidepressant treatment on chronic back pain
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
Staiger, 2003
Systematic review of antidepressants in the treatment of chronic low back pain
BACK SCHOOLS
DiFabio, 1995
Efficacy of comprehensive rehabilitation programs and back school for patients with low back pain: A
meta-analysis
Elders, 2000
Return to work after sickness absence due to back disordersa systematic review on intervention
strategies
Heymans, 2005 (update of van Tulder, 1999)
Back schools for non-specific low-back pain. A systematic review within the framework of the Cochrane
Collaboration Back Review Group
(also published as a Cochrane review).
Linton, 2001
Preventive interventions for back and neck pain problems. What is the evidence?
Maier-Riehle, 2001
The effects of back schools - a meta-analysis
BED REST
Hagen, 2002
The Cochrane review of advice to stay active as a single treatment for low back pain and sciatica
Hagen, 2004
Bed rest for acute low-back pain and sciatica
Hagen, 2005
The Updated Cochrane review of bed rest for low back pain and sciatica

BEHAVIORAL
Assendelft, 2003
Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other
therapies
Assendelft, 2004
Spinal manipulative therapy for low-back pain
Furlan, 2005
Acupuncture and dry-needling for low back pain
Furlan, 2005
Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of
the cochrane collaboration
Guzman, 2001
Multidisciplinary rehabilitation for chronic low back pain: systematic review
Guzman, 2002
Multidisciplinary bio-psycho-social rehabilitation for chronic low-back pain
Hoffman, 2006 (in press)
Meta-analysis of psychological interventions for chronic low back pain
Karjalainen, 2001
Multidisciplinary biopsychosocial rehabilitation for subacute low-back pain among working age adults
Karjalainen, 2003
Multidisciplinary biopsychosocial rehabilitation for subacute low back pain among working age adults
(update)
Ostelo, 2005
Behavioural treatment for chronic low-back pain
Previously published in Spine (van Tulder et al 2000)
BENZODIAZEPENES
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
van Tulder, 2003 (#198)
Muscle relaxants for non-specific low-back pain
COST EFFECTIVENESS/MANAGEMENT STRATEGIES
Baldwin, 2001
Cost-effectiveness studies of medical and chiropractic care for occupational low back pain. A critical
review of the literature
Thomsen, 2001
Economic evaluation of multidisciplinary pain management in chronic pain patients: A qualitative
systematic review
Uhlig, 2003
Effectiveness and cost-effectiveness of comprehensive rehabilitation programs
van der Roer, 2005
What is the most cost-effective treatment for patients with low back pain? A systematic review
DECISION TOOLS
We identified no systematic review evaluating the usefulness of decision tools or clinical prediction rules
for identifying patients more likely to respond to specific therapies. However, we found three systematic
reviews evaluating the reliability and validity of physical exam maneuvers used to help determine if
manipulative treatments are indicated, though clinical outcomes were not assessed.
Hestbrook, 2000
Are chiropractic tests for the lumbo-pelvic spine reliable and valid? A systematic critical literary review
Najm, 2003
Content validity of manual spinal palpatory exams - a systematic review
Seffinger, 2004 #262
Reliability of spinal palpation for diagnosis of back and neck pain

DIAGNOSIS—INVASIVE TESTING
Diagnostic Nerve Blocks
Everett, 2005
A Systematic Review of Diagnostic Utility of Selective Nerve Root Blocks
DISCOGRAPHY
Cohen, 2005
Lumbar discography: A comprehensive review of outcome studies, diagnostic accuracy, and principles
Shah, 2005
Discography as a Diagnostic Test for Spinal Pain: A Systematic and Narrative Review
Willems, 2004
Lumbar discography: should we use prophylactic antibiotics? A study of 435 consecutive discograms and
a systematic review of the literature
EXERCISE
Clare, 2004 #3441
A systematic review of efficacy of McKenzie therapy for spinal pain
Hayden, 2005
Exercise therapy for low-back pain
Hayden, 2005
Meta-analysis: exercise therapy for nonspecific low back pain
Hayden, 2005 (303)
Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain
Kool, 2004
Exercise reduces sick leave in patients with non-acute non-specific low back pain: a meta-analysis
Liddle, 2004 #354
Exercise and chronic low back pain: what works?
Linton, 2001
Occupational psychological factors increase the risk for back pain: a systematic review
McNeely, 2003 #3173
A systematic review of physiotherapy for spondylolysis and spondylolisthesis
FAILED SUREGERY SYNDROMES
Adhesiolysis
Chopra 2005
Role of adhesiolysis in the management of chronic spinal pain: a systematic review of effectiveness and
complications
Spincal Cord Stimulation
Maillis-Gagnon, 2004
Spinal cord stimulation for chronic pain
Taylor, 2005
Spinal cord stimulation for chronic back pain and leg pain and failed back surgery syndrome: a
systematic review and analysis of progressive factors
Turner, 2004
Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain
syndrome: a systematic review of effectiveness and complications
HERBAL THERAPY
Gagnier, 2006
Herbal medicine for low back pain
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
IDET
Gibson, 2005
Surgery for degenerative lumbar spondylosis
ourgery for degenerative lumbar spondylosis

Surgery for Degenerative Lumbar Spondylosis: Updated Cochrane Review
NICE, 2004 #3749
Interventional procedures overview of percutaneous intradiscal radiofrequency thermocoagulation for
lower back pain
Samson, 2004
Percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic low back pain
IMAGING
Plain Radiography
Jarvik, 2002
Diagnostic evaluation of low back pain with emphasis on imaging
Lurie, 2003
Rates of advanced spinal imaging and spine surgery
van Tulder, 1997
Spinal radiographic findings and nonspecific low back pain: a systematic review of observational studies
INJECTIONS
Chemonucleolysis
Gibson, 2000
Surgery for lumbar disc prolapse
Epidural steroid injections
Abdi, 2005
role of epidural steroids in the management of chronic spinal pain: a systematic Review of effectiveness
and complications - a systematic review
DePalma, 2005
A critical appraisal of the evidence for selective nerve root injection in the treatment of lumbosacral
radiculopathy
Koes, 1999
Epidural steroid injections for low back pain and sciatica: an updated systematic review of randomized
clinical trials
Nelemans, 1999
Injection therapy for subacute and chronic benign low-back pain
Nelemans, 2001
Injection therapy for subacute and chronic benign low back pain (update)
Tonkovich-Quaranta, 2000
Use of epidural corticosteroids in low back pain
Vroomen, 2000
,
Conservative treatment of sciatica: a systematic review
Facet (zygapophysial) joint injections
Boswell, 2005
Therapeutic facet joint interventions in chronic spinal pain: A systematic review of their role in chronic
spinal pain management and complications
Nelemans, 1999
Injection therapy for subacute and chronic benign low-back pain
Nelemans, 2001
Injection therapy for subacute and chronic benign low back pain (update)
Slipman, 2003
A critical review of the evidence for the use of zygapophysial injections and radiofrequency denervation
in the treatment of low back pain
Intradiscal steroid injections
We found no systematic reviews specifically evaluating the efficacy of intradiscal steroid injections for
patients with presumed chronic discogenic back pain, however, two RCTs comparing intradiscal steroids
to chemonucleolysis with chymopapain were included in a good-quality Cochrane review of surgery for
lumbar disc prolapse.
Gibson, 1999

The Cochrane review of surgery for lumbar disc prolapse and degenerative lumbar spondylosis
Local Injections
Kraemer, 1997
Lumbar epidural perineural injection: a new technique
Nelemans, 1999
Injection therapy for subacute and chronic benign low-back pain
Nelemans, 2001
Injection therapy for subacute and chronic benign low back pain (update)
Prolotherapy
Yelland, 2004
Prolotherapy injections for chronic low-back pain
Sacroiliac joint injections
McKenzie-Brown, 2005
A systematic review of sacroiliac joint interventions
MASSAGE
Furlan, 2002
Massage for low-back pain
Furlan, 2002
Massage for low-back pain: a systematic review within the framework of the Cochrane Collaboration
Back Review Group
MODIFIED WORK
Krause, 1998
Modified work and return to work: a review of the literature
MULTIDISCIPLINARY
Multidisciplinary rehabilitation
Guzman, 2001
Multidisciplinary rehabilitation for chronic low back pain: systematic review
Guzman, 2002
Multidisciplinary bio-psycho-social rehabilitation for chronic low-back pain
Hoffman, 2006
Meta-analysis of psychological interventions for chronic low back pain
Karjalainen, 2001
Multidisciplinary biopsychosocial rehabilitation for subacute low-back pain among working age adults
Karjalainen, 2003
Multidisciplinary biopsychosocial rehabilitation for subacute low back pain among working age adults
(update)
Physical conditioning
Schonstein, 2003
Physical conditioning programs for workers with back and neck pain: a cochrane systematic review
Schonstein, 2003
Work conditioning, work hardening and functional restoration for workers with back and neck pain
MUSCLE RELAXANTS
Browning, 2001
Cyclobenzaprine and back pain: a meta-analysis
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
Van Tulder, 2003
Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the
Cochrane collaboration
Van Tulder, 2003
Muscle relaxants for non-specific low-back pain
Vroomen, 2000

Conservative treatment of sciatica: a systematic review
NEUROREFLEXOTHERAPY
Urrutia, 2004
Neuroreflexotherapy for non-specific low-back pain
NSAIDS
Non-steroidal NSAIDs
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
Van Tulder, 2000
Non-steroidal anti-inflammatory drugs for low-back pain
Van Tulder, 2000
Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the
Cochrane Collaboration back review group
Vroomen, 2000
Conservative treatment of sciatica: a systematic review
OPIOIDS
Schnitzer, 2004
A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back
pain
van Tulder, 1997
Conservative treatment of acute and chronic nonspecific low back pain: a systematic review of
randomized controlled trials of the most common interventions
Percutaneous intradiscal radiofrequency thermocoagulation (PENS)
Gibson, 2005
The cochrane review of surgery for lumbar disc prolapse and degenerative lumbar spondylosis
surgery for degenerative lumbar spondylosis: updated cochrane review
NICE, 2004 3749
Interventional procedures overview of percutaneous intradiscal radiofrequency thermocoagulation for
lower back pain
Samson, 2004
Percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic low back pain
PREGNANCY
Stuge, 2003
Physical therapy for pregnancy-related low back and pelvic pain: a systematic review
Young, 2005
Interventions for preventing and treating pelvic and back pain in pregnancy
Boswell, 2005
Therapeutic facet joint interventions in chronic spinal pain: A systematic review of their role in chronic
spinal pain management and complications
Geurts, 2001
Efficacy of radiofrequency procedures for the treatment of spinal pain: a systematic review of randomized
clinical trials
Niemisto, 2003
Radiofrequency denervation for neck and back pain. a systematic review of randomized controlled trials
Radiofrequency denervation for neck and back pain: a systematic review within the framework of the
Cochrane collaboration back review group
Slipman, 2003
A critical review of the evidence for the use of zygapophysial injections and radiofrequency denervation
in the treatment of low back pain
RED FLAGS
Crook, 2002

Determinants of occupational disability following a low back Injury: a critical review of the literature
Devillé, 2000
The test of Lasegue: systematic review of the accuracy of diagnosing herniated discs
Dionne, 2001
Formal education and back pain: a review
Fayad, 2004
Chronicity, recuurence, and return to work in low back pain: common prognostic factors
Jarvik, 2002
Diagnostic evaluation of low back pain with emphasis on imaging
Linton, 2000
A review of psycholocial risk factors in back and neck pain
McIntosh, 2000
Low back pain prognosis: structured review of the literature
Pengel, 2003
Acute low back pain: systematic review of its prognosis
Pincus, 2002
A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of
low back pain
Shaw, 2001
Early prognosis for low back disability: intervention strategies for health care providers
Truchon, 2000
Biopsychosocial determinants of chronic disability and low-back pain: a review
van den Hoogen, 1995
On the accuracy of history, physical examination, and erythrocyte sedimentation rate in diagnosing low
back pain in general practice. A criteria-based review of the literature
SELF-CARE
Advice for activity
Hagen, 2002
The Cochrane review of advice to stay active as a single treatment for low back pain and sciatica
Hilde, 2002
Advice to stay active as a single treatment for low-back pain and sciatica
Bed Rest
Hagen, 2004
Bed rest for acute low-back pain and sciatica (update)
Self-care interventions
van Tulder, 2000 Red roet fer ooute low beek pein and existing
Bed rest for acute low-back pain and sciatica
Superficial heat or cold
French, 2006
Superficial heat or cold for low back pain
SHORT WAVE DIATHERMY
We identified no systematic review of short-wave diathermy, however, a good-quality Cochrane review of
spinal manipulation: Assendelft, 2003 and Assendelft, 2004 (update) included two trials comparing short-
wave diathermy to sham diathermy or manipulation.
SPINAL CORD STIMULATION
Maillis-Gagnon, 2004
Spinal cord stimulation for chronic pain
Taylor, 2005
Spinal cord stimulation for failed back surgery syndrome: A decision-analytic model and cost-
effectiveness analysis
Turner, 2004 #269
Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain
syndrome: a systematic review of effectiveness and complications

PINAL MANIPULATION ssendelft, 1996 omplications of spinal manipulation: a comprehensive review of the literature ssendelft, 2003 pinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other erapies ssendelft, 2004
omplications of spinal manipulation: a comprehensive review of the literature ssendelft, 2003 pinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other erapies ssendelft, 2004
ssendelft, 2003 pinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other erapies ssendelft, 2004
pinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other erapies sendelft, 2004
erapies ssendelft, 2004
ssendelft, 2004
pinal manipulative therapy for low-back pain
rown, 2005
osts and outcomes of chiropractic treatment for low back pain - Technology Report No 56
herkin, 2003
review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and
pinal manipulation for back pain
rnst, 2001
rospective investigations into the safey of spinal manipulation
erreira, 2002
oes spinal manipulative therapy help people with chronic low back pain?
erreira, 2003
fficacy of spinal manipulative therapy for low back pain of less than three months duration
ent, 2005
linical rule predicts patients likely to benefit from spinal manipulation
eeker, 2002
hiropractic: A profession at the crossroads of mainstream and alternative medicine
liphant, 2004
afety of spinal manipulation in the treatment of lumbar disk herniations: a systematic review and risk
ssessment
tevenson, 2002
isks associated with spinal manipulation
roomen, 2000
onservative treatment of sciatica: a systematic review
URGERY
ono, 2004
ritical analysis of trends in fusion for degenerative disc disease over the past 20 years: influence of
chnique on fusion rate and clinical outcome
oult, 2000
ercutaneous endoscopic laser discectomy
e Kleuver, 2003
otal disc replacement for chronic low back pain: background and a systematic review of the literature
ibson, 2000
,
urgery for lumbar disc prolapse ibson, 2005
urgery for degenerative lumbar spondylosis
urgery for degenerative lumbar spondylosis: updated cochrane review won, 2005 #3164
critical analysis of the literature regarding surgical approach and outcome for adult low-grade isthmic
bondylolisthesis
ICE, 2003
ndoscopic laser foraminoplasty
aser lumbar discectomy
ICE, 2004
rosthetic intervertebral disc replacement

TENS
Khadilkar, 2005
Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain
Manheimer, 2005
Meta-analysis: acupuncture for low back pain
Pengel, 2002
Systematic review of conservative interventions for subacute low back pain
TRACTION
Clarke, 2006
Traction for low back pain with or without sciatica: an updated systematic review within the framework of
the Cochrane Collaboration
Clarke, 2005
Traction for low-back pain with or without sciatica
ULTRASOUND
Beckerman, 1993
Efficacy of physiotherapy for musculoskeletal disorders: what can we learn from research?
Gam, 1995
Ultrasound therapy in musculoskeletal disorders: a meta-analysis
Philadelphia Panel, 2001
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for
low back pain
Robertson, 2001
A review of therapeutic ultrasound: effectiveness studies
van der Windt, 1999
Ultrasound therapy for musculoskeletal disorders: a systematic review
YELLOW FLAGS
No systematic reviews evaluated the effects of interventions targeted at identification and treatment of
yellow flags; several evaluated interventions addressing psychological issues, identification of yellow
flags was not the main goal of therapy.
Karjalainen, 2001
Multidisciplinary biopsychosocial rehabilitation for subacute low-back pain among working age adults
Karjalainen, 2003
Multidisciplinary biopsychosocial rehabilitation for subacute low back pain among working age adults
(update)
Östelo, 2005
Behavioural treatment for chronic low-back pain
Schonstein, 2003
Work conditioning, work hardening and functional restoration for workers with back and neck pain
Schonstein, 2003
Physical conditioning programs for workers with back and neck pain: a cochrane systematic review



NORTH AMERICAN SPINE SOCIETY

8320 ST. MORITZ DR., SPRING GROVE, IL 60081 877-SPINEDR (815) 675-0021 FAX (815) 675-3137 WWW.SPINE.ORG

August 14, 2006

Richard Ellenbogen, MD President Congress of Neurological Surgeons 10 North Martingale Rd., Ste. 190 Schaumburg, IL 60173

Subject: Spine Clinical Guideline Collaboration Invitation

Dear Dr. Ellenbogen:

Per previous correspondence, NASS would like to invite the Congress of Neurological Surgeons to join us in the collaborative development of evidence-based clinical guidelines and performance measures. As a multidisciplinary society, it is our sincere belief that multispecialty collaborative efforts to develop these tools can only lead to stronger documents and measures, better patient care and stronger bonds between specialties relative to quality of care. Currently six societies have expressed interest in this project: American Academy of Physical Medicine and Rehabilitation, American Academy of Orthopaedic Surgeons, America Academy of Family Physicians, American Society of Spine Radiology, International Spinal Injection Society and the American Academy of Pain Medicine. It is anticipated that any clinical guidelines written will be followed by the development of corresponding performance measures through the AMA Physician Consortium for Performance Improvement. Since all affected specialties will come to the table for the development of spinerelated performance measures at the Consortium, it can only be beneficial to be in agreement in advance.

A planning meeting is scheduled for October 13, 2006 in Chicago, Illinois to discuss this project and begin negotiation of the project terms. The terms are to be determined in a democratic manner with equal representation by each group. All terms (development methodology, publication and ownership) will be decided by the group, with each society (at a later date) being given the opportunity to opt-in or out. Terms will not be determined in advance. However, we are providing you with some of our previously used guidelines' materials for reference and a meeting agenda.

Each society is invited to send two physician representatives and one staff representative to this meeting at their own expense. Further details regarding the meeting (location, time, local hotels, etc.) will be forwarded in the near future. In the interest of strong collaborative medicine, we would invite you to consider our invitation and RSVP with your participation and representatives' names by September 1, 2006 to Pam Hayden, Director of Research at 815.675.0021 or hayden@spine.org. We look forward to working with you on the advancement of spine care in the best interests of all our patients.

Best wishes,

Joel Press, MD 2006 NASS President

cc. Dan Resnick, MD Paul Matz, MD Charlie Branch, MD Katie Orrico

Rich D. Dyn, mo

Richard Guyer, MD 2007 NASS President



NORTH AMERICAN SPINE SOCIETY

8320 ST. MORITZ DR., SPRING GROVE, IL 60081 877-SPINEDR (815) 675-0021 FAX (815) 675-3137 WWW.SPINE.ORG

Agenda Spine Clinical Guideline Collaborative Project October 13, 2006

Attendees:

<u>Vision</u> :	NASS envisions collaborative, broad spectrum spine guidelines that will be widely accepted due to their multispecialty and evidence-based nature.
<u>Belief</u> :	Multispecialty collaborative efforts to develop guidelines lead to stronger documents and performance measures, better patient care and stronger bonds between specialties.
<u>Belief</u> :	All issues regarding collaboration should be negotiated and agreed upon upfront by all participating societies.
<u>Belief</u> :	Up until the collaborative project terms are finalized and signed off on by all groups, anyone can opt out.

Collaboration Terms and Issues for Discussion

- I. General Issues Relative to Collaborative Works
 - A. All organizations must be prepared to deal with the politics inherent in working with multiple organizations with differing expectations.
 - B. Process/terms will be outlined in advance and agreed upon in writing by participating societies.
 - C. Transparent negotiations with clear expectations and written agreements.
 - D. Any work products/text/etc. brought to the collaborative are shared with the understanding that they may become a part of the clinical guideline developed and submitted with the understanding that the item is shared without condition.
- II. Development Process
 - A. Broad multidisciplinary representation, with equal representation from each society.
 - B. Thorough & realistic timeframe
 - C. Scope: primary care, musculoskeletal care and spine specialists
 - D. Transparency
 - E. Topics
 - F. Methodology
 - 1. Input by all participating societies on methodology
 - 2. All societies are responsible for ensuring compliance to chosen methodology
 - 3. Evidence-based, with rated literature and graded recommendations
 - 4. Agreed upon levels of evidence and grades of recommendation
 - 5. Clearly identified expert consensus where literature is lacking
 - 6. Agreement on literature search protocol and inclusion/exclusion criteria
 - 7. EBM training of representatives
 - G. Format
 - H. Openly stated and documented disclosure
- III. Resource Allocation/Commitment
 - A. Since guideline development will be a long-term proposition (potentially several years for multiple topics), resource allocation issues must be addressed in advance. All resource allocations shall be for the guideline development only.
 - 1. Indirect costs
 - a. Volunteer time
 - b. Staff time
 - 2. Direct Costs
 - a. Travel expenses
 - b. Literature searches/article retrieval
 - c. Meetings expense
 - d. Volunteer training
 - e. Promotion
 - 3. Walk-Away Terms

If any society chooses to walk away after agreeing in writing to the terms of collaboration and prior to the completion of any guideline, any resources allocated will be forfeited and they shall give up any right to the publication.

- B. Multi-year commitments from all participating societies
 - 1. Support guideline's evidence-based conclusions & recommendations
 - 2. Acknowledge & support changes in practices supported by strong evidence even if the evidence doesn't support current practice or trends.

- IV. Approval/Endorsement
 - A. All societies will be given an opportunity for review and formal endorsement prior to publication.
 - B. No revision of content by individual society boards or committees; more evidence or comments may be submitted to the collaborative for review. Comments and responses will be documented. If changes are made based on comments, guidelines will be resubmitted for final review/endorsement.
- V. Publication, Use, Distribution, Copyright, Recognition and Revenue
 - A. All participating societies should:
 - 1. Have joint copyright permanently? Or for a predetermined timeframe?
 - 2. Be recognized as authors in an equitable manner
 - 3. Be provided with a final electronic copy of the guideline in a standard publishing software to be published, distributed and marketed at their own expense, in a format of their choosing
 - 4. Not make any changes to the document and should represent it as work of the collaborative at all times
 - 5. Be invited to participate in any revision process
 - 6. Recognize that all terms apply on guideline by guideline basis and agreements will be signed on a guideline by guideline basis
 - B. Marketing/Distribution
 - 1. Participating societies may distribute and use the guidelines as they see fit, at their own expense, retaining their own profits. Derivative products are acceptable at individual society expense as long as they accurately represent the content of the guideline and are acknowledged as the work of the authoring society, not the collaborative.
 - 2. The collaborative shall predetermine some mutually beneficial venues for promotion and submission of the guidelines (eg, National Guidelines Clearinghouse) to eliminate any duplication of effort between societies. In the event that new opportunities for same types of promotion arise, the collaborative should submit the guidelines jointly.
 - 3. Standard, agreed upon marketing verbiage and appearance shall be provided to all the participating societies in order encourage promotion of a consistent message about the guidelines and represent the collaborative well.
 - 4. All societies should agree on pricing.
 - a. Same price for all?
 - b. One copy free to members and charge for additional copies to members, with all nonmembers being charged?
 - c. Will guidelines be available on members' only sides of web sites? Read-only or in electronically downloadable form?
 - C. Performance Measures
 - All societies should agree that the guidelines will be used to develop performance measures using appropriately qualified methodologists. Optimally, it is proposed that the collaborative will approach the AMA Physician Consortium for Performance Improvement enmasse in this endeavor.

Tentative Timeline for Collaborative Guideline Development-Topic 1 *We recognize this timetable makes certain assumptions and is somewhat aggressive. It is based on a desire to complete a collaborative guideline by December 2007, as well as our most recent experiences in guideline development. Times can be adjusted as necessary.

August 2006	Invitations Sent to All Organizations
October 2006	Meeting With All Interested Organizations To Discuss/Negotiate Terms and
	Process (October 13, 2006)
	Documentation Of Agreed Upon Terms From The Meeting Is Distributed
	To All Organizations For Review
November 2006	All Organizations Sign Off on Project Terms and Opt-in or Out (Including
	Topic Selection)
	Identification of All Guideline Development Participants (Content
	Participants and Staff)
By December 15, 2006	Identified Content Participants Signed Up for EBM Training
February 15, 2007	All Participants Complete EBM Training
February 28, 2007	Conference Call to Identify Clinical Questions and Discuss Work Group
	Formations
March 15, 2007	Master List of Clinical Questions Completed
	Work Group Chairs Identified and Member Assignments Finalized
March 30, 2007	Identification of Search Terms and Parameters
April 15, 2007	Searches Conducted
May 1, 2007	Review of Search Results/Identification of Literature To Review
June 1, 2007	Evidence Analysis Begins
1 0007	Creation of Guideline Template (Staff)
August 1, 2007	Meeting to Formulate Evidence-based Recommendations and
<u>C</u> i l 1.0007	Incorporation of Expert Consensus
September 1, 2007	Submission of Draft Guidelines for Review/Comment to Each Organization
October 1, 2007	Re-Submission to Each Organization of Any Necessary Revisions
November 1, 2007	Formal Endorsement or Opt-Out by All Organizations Due
November 30, 2007	Distribution of Finalized Guideline to All Organizations
December 2007	Presentation of Guideline to the AMA Consortium for Development of
	Performance Measures
	(NASS, AAOS, AANS serve as co-joint lead organizations in the
	development of any spine measures at the Consortium).
	development of any spine measures at the consolituting.



EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES

NASS GUIDELINE DEVELOPMENT METHODOLOGY 2006

GUIDELINE DEVELOPMENT METHODOLOGY 2006

BACKGROUND

Through objective evaluation of the evidence and transparency in the process of making recommendations, it is NASS' goal to develop evidence-based clinical practice guidelines for the diagnosis and treatment of adult patients with back pain. These guidelines are developed for educational purposes to assist practitioners in their clinical decision-making processes. It is anticipated that where evidence is very strong in support of recommendations, these recommendations will be operationalized into performance measures.

Levels of Evidence and Grades of Recommendation

NASS has adopted standardized levels of evidence and grades of recommendation (*Attachments 1 and 2*) to assist practitioners in easily understanding the strength of the evidence and recommendations within the guidelines. These levels of evidence and grades of recommendation have also been adopted by the Journal of Bone and Joint Surgery, the American Academy of Orthopaedic Surgeons, Clinical Orthopaedics and Related Research and the Pediatric Orthopaedic Society of North America.

Evidence Analysis Training of All NASS Guideline Developers

NASS has initiated, in conjunction with the University of Alberta's Centre for Health Evidence, an online training program geared towards educating guideline developers about evidence analysis and guideline development. All volunteers participating in guideline development for NASS must complete the training prior to participating in the guideline development program at NASS. This training includes a series of readings and exercises, or interactivities, to prepare guideline developers for systematically evaluating literature and developing evidence-based guidelines. The online course takes approximately 15-30 hours to complete, and participants are awarded CME credit upon completion of the course.

Disclosure of Potential Conflicts of Interest

All participants involved in guideline development will disclose potential conflicts of interest to their colleagues and their potential conflicts will be documented for future reference. They will not be published in any guideline, but kept on file in the case a question arises. Participants will be requested to update their disclosures regularly throughout the guideline development process.

Multidisciplinary Collaboration

With the goal of ensuring the best possible care for adult patients suffering with back pain, NASS is committed to multidisciplinary involvement in the process of guideline and performance measure development. To this end, NASS will ensure that representatives from medical, interventional and surgical spine specialties participate in the development and review of all NASS guidelines. It is also important that primary care providers and musculoskeletal specialists who care for patients with back pain are represented in the development and review of guidelines that address treatment by first contact physicians. To ensure broad-based representation, NASS has invited and welcomes input from other societies and specialities.

Any societies who wish to collaborate in guideline development with NASS must identify qualified representatives who are willing to complete the online training program in evidence analysis and guideline development prior to participating in the development process. NASS acknowledges that many issues will need to be discussed with societies interested in collaboration prior to embarking upon a collaborative effort. Agreements will need to be negotiated about financial support and resource allocation, the development process, the review and approval process, copyright issues, publication and use of the guidelines, etc. As societies agree to become involved, their designated representatives will be rolled into the training component, and once the training is completed they will be full participants in the guideline development project.

With broad-based representation and buy-in on the development of evidence-based guidelines for the diagnosis and treatment of back pain, the goal of increasing the implementation of evidence-based recommendations can be realized. With the push for development of performance measures to meet the prospect of pay-for-performance programs, it is becoming increasing important that providers develop the measures upon which they will be held accountable. Once the guidelines are completed, it is anticipated that all specialties will work together, in collaboration with either the AMA Physician's Consortium for Performance Improvement or others appropriately trained in evidence-based performance measure development, to develop evidence-based performance measures for the diagnosis and treatment of back pain. If all those who care for patients with back pain can collaborate on the development of evidence-based guidelines, and then upon the resulting performance measures, eventual implementation of any pay-for-performance or quality improvement program will be greatly facilitated.

Once a topic has been identified, the following steps are implemented:

Step 1: Identification of Clinical Questions

Trained guideline participants are asked to submit a list of clinical questions that the guideline should address. The list is compiled into a master list, which is then circulated to each member with a request that they independently rank the questions in order of importance for consideration in the guideline. The most highly ranked questions, as determined by the participants, will serve to focus the guideline.

Step 2: Identification of Work Groups

Multidisciplinary teams are assigned to work groups and assigned specific clinical questions to address. Because NASS is comprised of surgical, medical and interventional specialists, it is imperative to the guideline development process that a cross-section of NASS membership is represented on each group. This also helps to ensure that the potential for inadvertent biases in evaluating the literature and formulating recommendations are minimized.

Step 3: Identification of Search Terms and Parameters

One of the most crucial elements of evidence analysis to support development of recommendations for appropriate clinical care is the comprehensive literature search. Thorough assessment of the literature is the basis for the review of existing evidence and the formulation of evidence-based recommendations. In order to ensure a thorough literature search, NASS has instituted a Literature Search Protocol (*Attachment 3*) which will be followed to identify literature for evaluation in guideline development. In keeping with the Literature Search Protocol, work group members will identify appropriate search terms and parameters to direct the literature search.

Step 4: Completion of the Literature Search

Once each work group identifies search terms/parameters, the literature search will be implemented by a medical/research librarian, consistent with the Literature Search Protocol.

Step 5: Review of Search Results/Identification of Literature to Review It is at this point that members will review abstracts yielded from the literature search and identify the literature they will review in order to address the clinical questions, in accordance with the Literature Search Protocol. Members will strive to identify the best research evidence available to answer the targeted clinical questions. That is, if Level I, II, and/or III literature is available to answer specific questions, the work group will not be required to review Level IV or V studies.

***** Step 6: Evidence Analysis

Each member will develop their own evidentiary table summarizing study conclusions, strengths and weaknesses, and identifying levels of evidence. In order to systematically control for potential biases, two work group members will review each article selected, and independently assign levels of evidence to the literature using the NASS levels of evidence (*Attachment 1*). Any discrepancies in scoring will be addressed by the two reviewers, and where consensus cannot be reached by two reviewers, another work group member will be assigned to review the article and assign a level of evidence (without knowledge of the other scores identified).Gaps in the evidence should also be documented to educate guideline readers about where evidence is lacking and help guide further needed research by NASS and other societies.

 Step 7: Formulation of Evidence-Based Recommendations and Incorporation of Expert Consensus

Two- or three-day meetings of the work groups will be scheduled to discuss the evidence-based answers to the clinical questions, the grades of recommendations (*Attachment 2*), and the incorporation of expert consensus. Expert consensus will be used only where evidence is lacking and the work group deems a recommendation is warranted. Transparency in the incorporation of consensus is crucial, and any consensus-based recommendations made in the guidelines will very clearly indicate that the evidence is insufficient to make a recommendation and that the recommendation is based only on expert consensus. The work groups will develop a preliminary draft of their guidelines.

Step 8: Submission of the Draft Guidelines for Review/Comment

Guidelines will be submitted to the full Guidelines Committee, the Clinical Care Council Director and, later, the Advisory Panel for review and comment. The Advisory Panel is comprised of representatives from physical medicine and rehab, pain medicine/management, orthopedic surgery, neurosurgery, anesthesiology, rheumatology, psychology/psychiatry and family practice. In addition, the guidelines will be submitted to participating societies for review and comment. *Revisions to recommendations will be considered for incorporation only when substantiated by a preponderance of appropriate level evidence.*

Step 9: Submission for Board Approval

Once any evidence-based revisions are incorporated, the drafts will be prepared for NASS Board review and approval. *Edits and revisions to recommendations and any other content will be considered for incorporation only when substantiated by a preponderance of appropriate level evidence.*

Step 10: Submission for Endorsement, Publication and NGC Inclusion Once approved by the NASS Board, the guidelines will be published, submitted for endorsement to all appropriate societies, and submitted for inclusion in the National Guidelines Clearinghouse (NGC). Given that societies participating in the development of guidelines will have had an opportunity to review/comment, the final society review is for endorsement of the guidelines as submitted for consideration. No revisions will be made at this point in the process, but comments will be saved for the next iterations.

Step 11: Identification and Development of Performance Measures

Once the guidelines are finalized, the recommendations will be reviewed by a group experienced in performance measure development (eg, the AMA Physician's Consortium for Performance Improvement) to identify those recommendations rigorous enough for measure development. All relevant medical specialties involved in the guideline development and at the Consortium will be invited to collaborate in the development of evidence-based performance measures related to spine care.

ATTACHMENT 1

Levels of Evidence For Primary Research Question¹

		Types o	f Studies	
	Therapeutic Studies – Investigating the results of treatment	Prognostic Studies – Investigating the effect of a patient characteristic on the outcome of disease	Diagnostic Studies – Investigating a diagnostic test	Economic and Decision Analyses – Developing an economic or decision model
Level I	 High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals Systematic Review² of Level I RCTs (and study results were homogenous³) 	 High quality prospective study⁴ (all patients were enrolled at the same point in their disease with ≥ 80% follow- up of enrolled patients) Systematic review² of Level I studies 	 Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference "gold" standard) Systematic review² of Level I studies 	 Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses Systematic review² of Level I studies
Level II	 Lesser quality RCT (e.g. < 80% follow- up, no blinding, or improper randomization) Prospective⁴ comparative study⁵ Systematic review² of Level II studies or Level 1 studies with inconsistent results 	 Retrospective⁶ study Untreated controls from an RCT Lesser quality prospective study (e.g. patients enrolled at different points in their disease or <80% follow-up.) Systematic review² of Level II studies 	 Development of diagnostic criteria on consecutive patients (with universally applied reference "gold" standard) Systematic review² of Level II studies 	 Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses Systematic review² of Level II studies
Level III	 Case control study⁷ Retrospective⁶ comparative study⁵ Systematic review² of Level III studies 	• Case control study ⁷	 Study of non- consecutive patients; without consistently applied reference "gold" standard Systematic review² of Level III studies 	 Analyses based on limited alternatives and costs; and poor estimates Systematic review² of Level III studies
Level IV	Case Series ⁸	Case series	 Case-control study Poor reference standard 	• Analyses with no sensitivity analyses
Level V	Expert Opinion	Expert Opinion	Expert Opinion	Expert Opinion

- 1. A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.
- 2. A combination of results from two or more prior studies.
- 3. Studies provided consistent results.
- 4. Study was started before the first patient enrolled.
- 5. Patients treated one way (e.g. cemented hip arthroplasty) compared with a group of patients treated in another way (e.g. uncemented hip arthroplasty) at the same institution.
- 6. The study was started after the first patient enrolled.
- 7. Patients identified for the study based on their outcome, called "cases"; e.g. failed total arthroplasty, are compared to those who did not have outcome, called "controls"; e.g. successful total hip arthroplasty.
- 8. Patients treated one way with no comparison group of patients treated in another way.

Grades of Recommendation for Summaries or Reviews of Studies

- A: Good evidence (Level I Studies with consistent finding) for or against recommending intervention.
- B: Fair evidence (Level II or III Studies with consistent findings) for or against recommending intervention.
- C: Poor quality evidence (Level IV or V Studies) for or against recommending intervention.
- I: There is insufficient or conflicting evidence not allowing a recommendation for or against intervention.

Protocol for NASS Literature Searches

One of the most crucial elements of evidence analysis to support development of recommendations for appropriate clinical care or use of new technologies is the comprehensive literature search. Thorough assessment of the literature is the basis for the review of existing evidence, which will be instrumental to these activities.

Background

It has become apparent that the number of literature searches being conducted at NASS is increasing and that they are not necessarily conducted in a consistent manner between committees/projects. Since the quality of a literature search directly affects the quality of recommendations made, a comparative literature search was undertaken to help NASS refine the process and make recommendations about how to conduct future literature searches on a NASS-wide basis.

In November-December 2004, NASS conducted a trial-run at new technology assessment. As part of the analysis of that pilot process, the same literature searches were conducted by both an experienced NASS member and a medical librarian for comparison purposes. After reviewing the results of that experiment and the different strategies employed for both searches, it was the recommendation of NASS Research staff that a protocol be developed to ensure that all future NASS searches be conducted consistently to yield the most comprehensive results. While it is recognized that some searches occur outside the Research and Clinical Care Councils, it is important that all searches conducted at NASS employ a solid search strategy, regardless of the source of the request. To this end, this protocol has been developed and NASS-wide implementation is recommended.

Protocol for NASS Literature Searches

The NASS Research Department has a relationship with Northwestern University's Galter Health Sciences Library. When it is determined that a literature search is needed, NASS research staff will work with the requesting parties and Galter to run a comprehensive search employing *at a minimum* the following search techniques:

- 1. A preliminary search of the evidence will be conducted using the following clearly defined search parameters (as determined by the content experts). The following parameters are to be provided to research staff to facilitate this search.
 - Time frames for search;
 - Foreign and/or English language;
 - Order of results (chronological, by journal, etc.);
 - Key search terms and connectors, with or without MeSH terms to be employed;
 - Age range;

Must answer the following questions:

- Should duplicates be eliminated between searches?
- Should searches be separated by term or as one large package?
- Should human studies, animal studies or cadaver studies be included?

This preliminary search should encompass a search of the Cochrane database when access is available.

- 2. Search results with abstracts will be compiled by Galter in Endnote software. Galter typically responds to requests and completes the searches within 2-5 days. Results will be forwarded to the Research staff, who will share it with the appropriate NASS staff member or requesting party(ies). (Research staff has access to Endnote software and will maintain a database of search results for future use/documentation.)
- 3. NASS staff shares the search results with an appropriate content expert (NASS Committee member or other) to assess relevance of articles and identify appropriate articles to review and on which to run a "related articles" search.
- 4. Based on content expert's review, NASS Research staff will then coordinate with the Galter medical librarian the second level searching to identify relevant "related articles."
- 5. Galter will forward results to Research staff to again share with appropriate NASS staff member.
- 6. NASS staff shares related articles search results with an appropriate content expert (NASS Committee member or other) to assess relevance of this second set of articles, and identify appropriate articles to review and on which to run a second "related articles" search.
- 7. NASS Research staff will work with Galter library to obtain the 2nd related articles search results and any necessary full-text articles for review.
- 8. NASS members reviewing full-text articles should also review the references at the end of each article to identify additional articles which should be reviewed, but may have been missed in the search.

Protocol for Expedited Searches

Numbers 1,2 and $\overline{3}$ should minimally be followed for any necessary expedited search. Following #3, depending on the time frame allowed, deeper searching may be conducted as described by the full protocol or request of full-text articles may occur. If full-text articles are requested, #8 should also be included. Use of the expedited protocol or any deviation from the full protocol should be documented with explanation.

Following these protocols will help ensure that NASS recommendations are (1) based on a thorough review of relevant literature; (2) are truly based on a uniform, comprehensive search strategy; and (3) represent the current best research evidence available. Research staff will maintain a search history in Endnote, for future use or reference.

Dear Colleague,

On behalf of the AANS/CNS Joint Section on Spine & Peripheral Nerves we would like to thank you for presenting your research at the annual meeting in Orlando, Florida. The 2006 meeting was a great success, due in large part to the outstanding quality of your podium presentation.

Following the 2005 meeting last year, solicitations were made for oral presenters to submit manuscripts to the *Journal of Neurosurgery: Spine*. This resulted in the expeditious publication of many high-quality papers. This year we would like to again invite authors of oral presentations to submit their manuscripts for possible publication to the *Journal of Neurosurgery: Spine*.

As you know, the *Journal of Neurosurgery: Spine* is a peer-reviewed monthly publication, and all papers submitted must undergo a rigorous peer-review process. However, based on the high quality of the presentations at the 2006 Section Meeting we encourage you to submit your work. Author guidelines can be found on the Journal's website http://manuscript.thejns-net.org_under View instructions & Forms. Please include a statement in your cover letter this material was presented at the 2006 Spine Section meeting.

Thank you once again for your participation in Orlando, and we look forward to seeing you in Phoenix in 2007!

Sincerely,

Robert Heary, MD Immediate Past-Chairman

Michael Groff, MD Annual Meeting Chairman

Mark McLaughlin, MD Scientific Program Chairman

Michael Y Wang, MD Publications Committee Chairman

SP Section Membership Report

sjmtember 18, 2006

		Count
P Member Type		
irrent Members		
SP01S	Spine Section Active Member	1,041
SP15D	Spine Section Associate Member	9
SP25S	Spine Section Senior Member	198
SP40S	Spine Section International Member	46
SP45D	Spine Section Honorary Member	1
SP60D	Spine Section Adjunct Member	21
SP60P	Spine Section Pending Adjunct Member	3
SP65R	Spine Section Resident Member	120
		1,439
esigned, Deceased, o	or Suspended Members - 2006	
SP96S	Spine Section Suspended Member	21
SP97S	Spine Section Resigned Member	10
SP98S	Spine Section Deceased Member	9

Member ID	Name	AANS Member Type	CNS Member Type				
			Inv #	Batch	Inv Amt	Amt Paid	Amt Du
n: Spine S	ection						
59709	Moustapha Abou-Samra MD	A01S	CN01S				
			5-000130393	SP051219DU01	50.00	0.00	50.0
121910	Bret B. Abshire MD	A01S					
			5-000130066	SP051219DU01	50.00	0.00	50.0
96107	Maged Lotfy Abu-Assal MD	A01S					
			5-000130007	SP051219DU01	50.00	0.00	50.0
117649	Mark S. Adams MD	A01S					
	Mark 5. Adams MD	1015	5-000130061	SP051219DU01	50.00	0.00	50.0
102026		4.010	CNALC				
103026	James M. Alvis MD FACS	A01S	CN01S 5-000130663	SP051219DU01	50.00	0.00	50.0
				51 00 121/2 001	20100	0.00	001
102033	Ely Ashkenazi MD	C99S	CN05S	CD071010D101	50.00	0.00	
			5-000130985	SP051219DU01	50.00	0.00	50.
120391	Koang Hum Bak MD	A40S					
			5-000111729	SP041220DU01	50.00 50.00	0.00 0.00	50.
			5-000130108	SP051219DU01	30.00	0.00	50.
104371	William B. Betts MD	A01S					
			5-000111662 5-000130033	SP041220DU01 SP051219DU01	50.00 50.00	0.00 0.00	50. 50.
				51 05 121 / 15 0 001	20.00	0.00	20.
136815	Kenneth C. Brewington II MD	D A01S	CN01S		50.00	0.00	50
			5-000130876	SP051219DU01	50.00	0.00	50.
59022	Leonard A. Bruno MD	A01S	CN01S				
			5-000130375	SP051219DU01	50.00	0.00	50.
50611	Kim J. Burchiel MD FACS	A01S	CN01S				
			5-000111941	SP041220DU01	50.00	0.00	50.
			5-000130304	SP051219DU01	50.00	0.00	50.
50807	Carlos A. Carrion MD	C99S	CN01S				
			5-000130941	SP051219DU01	50.00	0.00	50.
96156	Richard L. Carter MD FACS	A01S	CN01S				
			5-000130582	SP051219DU01	50.00	0.00	50.
98017	W. Bruce Cherny MD	A01S	CN01S				
	-		5-000112242	SP041220DU01	50.00	0.00	50.
			5-000130591	SP051219DU01	50.00	0.00	50.

Member ID	Name	AANS Member Type	CNS Member Type				
			Inv #	Batch	Inv Amt	Amt Paid	Amt Du
415100	Bo-Young Cho	X99D					
			5-000131010	SP051219DU01	50.00	0.00	50.0
106551	Kyung Gi Cho MD	A40S					
			5-000130105	SP051219DU01	50.00	0.00	50.0
105968	Tanvir F. Choudhri MD	A60S					
			5-000111737	SP041220DU01	50.00	0.00	50.0
			5-000130116	SP051219DU01	50.00	0.00	50.0
96164	Geoffrey P. Cole MD	A01S	CN01S				
			5-000112234	SP041220DU01	50.00	0.00	50.0
			5-000130583	SP051219DU01	50.00	0.00	50.0
90092	George R. Cybulski MD FAC	C A01S	CN01S				
			5-000112067	SP041220DU01	50.00	0.00	50.0
			5-000130420	SP051219DU01	50.00	0.00	50.0
3202	David F. Dean MD	A01S	CN97S				
			5-000111786	SP041220DU01	50.00	0.00	50.0
			5-000130156	SP051219DU01	50.00	0.00	50.0
105038	Mohamed Nagy El Wany MI	D C99S	CN05S				
			5-000112609	SP041220DU01	50.00	0.00	50.0
			5-000130987	SP051219DU01	50.00	0.00	50.0
161845	Ghasem E. Eshaghi MD	C99S	CN01S				
			5-000130836	SP051219DU01	50.00	0.00	50.0
123026	Frank Feigenbaum MD	A01S					
			5-000130069	SP051219DU01	50.00	0.00	50.0
90934	Aaron G. Filler MD PhD	A01S	CN01S				
			5-000130544	SP051219DU01	50.00	0.00	50.0
10216	S. Sam Finn MD	A01S	CN97S				
			5-000111820	SP041220DU01	50.00	0.00	50.0
			5-000130189	SP051219DU01	50.00	0.00	50.0
419676	Shee Yan Fong FRCS	X99D					
			5-000131012	SP051219DU01	50.00	0.00	50.0
22	Modesto Fontanez MD JD FA	A A01S	CN01S				
			5-000130128	SP051219DU01	50.00	0.00	50.0
97345	Joel Ira Franck MD PA	A01S	CN01S				
			5-000130588	SP051219DU01	50.00	0.00	50.0

Member		AANS Member	CNS				
ID	Name	Туре	Member Type Inv #	Batch	Inv Amt	Amt Paid	Amt Du
130218	Bruce M. Frankel MD	A60S	CN01S				
		11000	5-000130871	SP051219DU01	50.00	0.00	50.00
90575	Marvin E. Friedlander MD F.	A A01S	CN01S				
			5-000112138	SP041220DU01	50.00	0.00	50.00
			5-000131046	SP051219DU01	50.00	0.00	50.00
95126	Paul A. Grabb MD	A01S	CN01S				
			5-000130570	SP051219DU01	50.00	0.00	50.00
90082	John Peter Gruen MD	A01S	CN01S				
			5-000130416	SP051219DU01	50.00	0.00	50.00
52431	L. N. Hopkins III MD	A01S	CN01S				
			5-000130324	SP051219DU01	50.00	0.00	50.0
6429	Herman Hugenholtz MD	C99S	CN01S				
			5-000130975	SP051219DU01	50.00	0.00	50.0
52589	Abelardo D. Inoa MD	C99S	CN01S				
			5-000112567	SP041220DU01	50.00	0.00	50.0
			5-000130947	SP051219DU01	50.00	0.00	50.0
130258	Terrence D. Julien MD	C99S	CN65T				
			5-000130972	SP051219DU01	50.00	0.00	50.0
401601	Dimitrios Kafritsas	X99D					
			5-000131008	SP051219DU01	50.00	0.00	50.0
98236	Phillip Kissel MD	A01S	CN01S				
			5-000130619	SP051219DU01	50.00	0.00	50.0
119015	Joseph L. Koen MD	A01S					
			5-000111743	SP041220DU01	50.00	0.00	50.0
			5-000130064	SP051219DU01	50.00	0.00	50.0
101140	Tadashi Kojima MD	C99S	CN05S				
			5-000112606	SP041220DU01	50.00	0.00	50.0
			5-000130984	SP051219DU01	50.00	0.00	50.0
7708	Vijay S. Kumar MD	A40S	CN01S				
			5-000112387	SP041220DU01	50.00	0.00	50.0
			5-000130838	SP051219DU01	50.00	0.00	50.0
106784	Giuseppe Lanzino MD	A60S	CN01S				
			5-000130852	SP051219DU01	50.00	0.00	50.0
51111	Bothwell Graves Lee MD	A01S	CN01S				

Member ID	Name	AANS Member Type	CNS Member Type				
	name	Type	Inv #	Batch	Inv Amt	Amt Paid	Amt Du
			5-000131043	SP051219DU01	50.00	0.00	50.00
90836	Sean Raymond Logan MD	A01S	CN01S				
			5-000130530	SP051219DU01	50.00	0.00	50.00
150202	Rafael A. Lopez MD	X99D					
			5-000131006	SP051219DU01	50.00	0.00	50.00
53157	Gary J. Lustgarten MD	C99S	CN01S				
			5-000112669	SP041220DU01	50.00	0.00	50.0
			5-000130948	SP051219DU01	50.00	0.00	50.0
101376	Philip J. Marra MD	A01S	CN97S				
			5-000130630	SP051219DU01	50.00	0.00	50.0
53462	Jay D. Miller MD	A01S					
			5-000111593	SP041220DU01	50.00	0.00	50.0
			5-000129966	SP051219DU01	50.00	0.00	50.0
50293	Daniel W. Moore MD FACS	A01S	CN01S				
			5-000130293	SP051219DU01	50.00	0.00	50.0
16585	John Innis Moseley MD	A01S					
			5-000129955	SP051219DU01	50.00	0.00	50.0
152306	Jaime H. Nieto MD	C99S	CN01S				
			5-000112594	SP041220DU01	50.00	0.00	50.0
			5-000130974	SP051219DU01	50.00	0.00	50.0
135940	Robert T. Numoto MD	C99S	CN05S				
			5-000130995	SP051219DU01	50.00	0.00	50.0
62389	Hirohisa Ono MD	A01S					
			5-000129972	SP051219DU01	50.00	0.00	50.0
97980	Jeffrey H. Oppenheimer MD	A01S	CN01S				
			5-000130589	SP051219DU01	50.00	0.00	50.0
59279	A. E. Oygar MD	A01S	CN01S				
			5-000130380	SP051219DU01	50.00	0.00	50.0
113664	Jung Yul Park MD PhD	A40S	CN05S				
			5-000130843	SP051219DU01	50.00	0.00	50.0
102513	John Bruce Payne DO	A01S					
			5-000111652	SP041220DU01	50.00	0.00	50.0
			5-000130023	SP051219DU01	50.00	0.00	50.0

Member ID	A	ANS Member Type	CNS Member Type Inv #	Batch	Inv Amt	Amt Paid	Amt Du
58776	David Buenor O. Puplampu M	T01S	CN01S				
38770	David Duchor O. 1 upranipu W	1015	5-000112666	SP041220DU01	50.00	0.00	50.00
			5-000131063	SP051219DU01	50.00	0.00	50.0
154784	Alfredo Quinones-Hinojosa M	A60S	CN65R				
			5-000130851	SP051219DU01	50.00	0.00	50.0
102935	Paul K. Ratzker MD	A01S					
			5-000130026	SP051219DU01	50.00	0.00	50.0
117630	Michael J. Rauzzino MD	A01S					
			5-000111740	SP041220DU01	50.00	0.00	50.0
			5-000130060	SP051219DU01	50.00	0.00	50.0
50073	Gary L. Rea MD	A01S	CN01S				
			5-000130271	SP051219DU01	50.00	0.00	50.0
101367	Robert L. Remondino MD	A01S					
			5-000111649	SP041220DU01	50.00	0.00	50.0
			5-000130020	SP051219DU01	50.00	0.00	50.0
161534	Ayman M. Salem MD	A60S	CN65T				
			5-000130922	SP051219DU01	50.00	0.00	50.0
407325	Dino Samartzis BS	C99S	CN20S				
			5-000112622	SP041220DU01	50.00	0.00	50.0
			5-000131001	SP051219DU01	50.00	0.00	50.0
152106	Alan M. Scarrow MD JD	A60S	CN01S				
			5-000130909	SP051219DU01	50.00	0.00	50.0
91770	Itzhack Shacked MD	A40S					
			5-000111724	SP041220DU01	50.00	0.00	50.0
			5-000131054	SP051219DU01	50.00	0.00	50.0
90553	Bryson Swain Smith MD	A01S	CN01S	GD051010D101	5 0.00	0.00	5 0 (
			5-000130486	SP051219DU01	50.00	0.00	50.0
95102	Richard A. Stea MD	A01P	F 000101010	CD051010D101	50 .00	0.00	
			5-000131018	SP051219DU01	50.00	0.00	50.0
50318	Mark Stern MD	A01S	CN01S				
			5-000130298	SP051219DU01	50.00	0.00	50.0
100806	Jung-Keun Suh MD PhD	A40S					
			5-000130104	SP051219DU01	50.00	0.00	50.0
102795	Mitchell L. Supler MD	A01S	CN01S				

Printed: 9/18/2006 11:10:44AMsjm Page 6 of 6 Member AANS Member CNS ID Туре Member Type Name Inv # Batch Inv Amt Amt Paid Amt Due 5-000130641 SP051219DU01 50.00 0.00 50.00 CN05S 161272 Leonello Tacconi MD FRCS A40S 5-000130849 SP051219DU01 50.00 0.00 50.00 CN01S 130182 Richard J. Teff MD A06S 5-000112396 SP041220DU01 50.00 0.00 50.00 5-000130773 SP051219DU01 50.00 0.00 50.00 98260 X99S CN01S Larry L. Teuber MD 5-000131058 0.00 SP051219DU01 50.00 50.00 Robert E. Tibbs Jr. MD A01S CN01S 135968 5-000130753 SP051219DU01 50.00 0.00 50.00 Robert L. Tiel MD A01S CN01S 105055 5-000130681 SP051219DU01 50.00 0.00 50.00 157292 Daniel J. Tomes MD A60S CN65T 5-000130915 SP051219DU01 50.00 0.00 50.00 55327 Raul A. Vernal MD C99S CN01S 5-000130954 SP051219DU01 50.00 0.00 50.00 120085 Beverly C. Walters MD A01S CN01S 5-000130718 SP051219DU01 50.00 0.00 50.00 50172 Melvin D. Whitfield MD FAC A01S CN01S 5-000111917 SP041220DU01 50.00 0.00 50.00 5-000131042 SP051219DU01 50.00 0.00 50.00 408696 Diana B. Wiseman MD A06S 5-000130085 SP051219DU01 50.00 0.00 50.00 102927 Peter A. Zahos MD FACS A01S CN01S 5-000130655 SP051219DU01 50.00 0.00 50.00 98285 A01S Luis Manuel Zavala MD 5-000130016 SP051219DU01 50.00 0.00 50.00 104034 CN01S Christian G. Zimmerman MD A01S 50.00 0.00 50.00 5-000130675 SP051219DU01 **Totals for Section: Spine Section** 111 \$5,550.00 \$0.00 \$5,550.00



5550 Meadowbrook Drive Rolling Meadows, IL 60008

member services: 888.566.AANS **phone:** 847.378.0500 **fax:** 847.378.0600 **web:** www.AANS.org www.NeurosurgeryToday.org

2006-2007 Board of Directors

President Donald O. Quest doq1@columbia.edu

President-Elect Jon H. Robertson jrobertson@semmes-murphey.com

> Vice-President Arthur L. Day aday1@partners.org

Secretary James T. Rutka james.rutka@sickkids.ca

> Treasurer James R. Bean jbeanlex@aol.com

Past President Fremont P. Wirth

Directors-at-Large William T. Couldwell Robert E. Harbaugh Christopher M. Loftus Warren R. Selman Troy M. Tippett

Regional Directors NE: Stephen T. Onesti NW: Jeffrey W. Cozzens SE: R. Patrick Jacob SW: Edie E. Zusman

> Historian Eugene S. Flamm

Executive Director Thomas A. Marshall tam@aans.org



August 31, 2006

Debbie Katsarelis Staff Liaison Society of Interventional Radiology 3975 Fair Ridge Drive Suite 400 North Fairfax, Virginia 22033

RE: Vertebroplasty Position Statement

Dear Ms. Katsarelis,

Thank you for giving the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) the opportunity to review the draft "Position Statement on Percutaneous Vertebral Augmentation". We have circulated this among our spine and endovascular neurosurgeons, and reached consensus that this is a very well written document that generally arrives at the appropriate conclusions.

The AANS/CNS Cerebrovascular Section and the AANS/CNS Joint Section on Diseases on Disorders of the Spine and Peripheral Nerves have recommended that the AANS endorse this position statement subject to you making several editorial changes that we believe would strengthen the document.

- There are a number of places in the document that seem to inappropriately favor vertebroplasty over kyphoplasty, primarily because of the increased costs associated with kyphoplasty. While we appreciate that kyphoplasty may be more expensive, the AANS and CNS believe that both procedures are equally beneficial for those patients in need of this therapy and both should be fully covered by Medicare. The document should therefore be edited to eliminate any potential bias against kyphoplasty.
- The introductory comments on pages 3-4 of the attached .pdf file should describe the procedure as percutaneous vertebral augmentation, regardless of whether vertebroplasty or kyphoplasty is performed.
- Using the introductory paragraphs to establish the position that percutaneous vertebral augmentation is a valid, safe, and beneficial therapy, in a generic, non-technique specific way, is a much stronger introduction. Since this is the message conveyed at the conclusion of the document, it seems appropriate to state this conclusion at the beginning of the document as well.

Debbie Katsarelis Vertebroplasty Position Statement August 31, 2006 Page 2 of 2

• The description of the differences between vertebroplasty and kyphoplasty should appear later in the document. Since the description of kyphoplasty appears on page 12 of the attached .pdf file, perhaps this would be a more appropriate position for the statements of comparison or contrast that are currently expressed in the introductory paragraphs on pages 3-4.

Again, thank you for soliciting our feedback. We hope you will consider making our suggested changes so the AANS can be listed as an endorsing organization. Please let me know if you need additional information or clarification on any of our suggestions.

Sincerely,

Donald O. Quest, MD President

cc: J. Kevin McGraw, MD Charles Branch, MD Gregory Thompson, MD

Staff Contact

Katie O. Orrico, Director AANS/CNS Washington Office 725 15th Street, NW Suite 800 Washington, DC 20005 Phone: 202-628-2072 Fax: 202-628-5264 Email: korrico@neurosurgery.org September 19, 2006 FDA Panel on Orthopedic and Rehabilitation Devices Gaithersburg, Maryland

Dr. Mabrey,

Ladies and Gentlemen:

Good morning. Thank you for this opportunity to speak. I will begin with an introduction and disclosure. My name is Charles L. Branch, Jr. and I am neurosurgeon certified by the American Board of Neurological Surgery and licensed by and practicing in the State of North Carolina where I am the Professor and Chair of the Department of Neurosurgery at the Wake Forest University School of Medicine in Winston-Salem. I have a long standing subspecialty interest in the field of spinal surgery. This morning I represent the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS) as the Chair of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves. I disclose that my travel expense to this presentation is funded by the AANS and CNS. I also disclose that I am a consultant to Medtronic and receive compensation for consulting service but will not personally benefit financially from any decision made by this panel today. I have not participated as an investigator or reviewer of the device being considered today. Neither I nor my family directly own stock in Medtronic nor are we directors on any of its Boards. The American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS) and the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves support the FDA Orthopaedic and Rehabilitation Devices Panel's serious and favorable consideration of cervical disc arthroplasty technology.

During the most recent 4-5 years, the concept of cervical disc arthroplasty has been presented and debated in a variety of scientific forums sponsored by the AANS and CNS and the Section on Spinal Disorders including the Annual Scientific Meetings. In these same forums, the distinct difference or uniqueness of the cervical spine as opposed to the lumbar spine has been articulated and deliberated. Conceptually, cervical disc arthroplasty or disc replacement technology has been embraced as a potential advance in patient care pending further experience and understanding of the safety and long term effectiveness of this technology to preserve normal or near normal motion in one or multiple segments of the cervical spine. For the treatment of symptomatic cervical disc degeneration, this technology would appear to have value in the relief of symptoms and added value in the prevention of adjacent level degeneration.

In our scientific forums, reported experience with cervical artificial disc technology both domestic and international has shown this to be safe, durable, and effective both with respect to preservation of motion and relief of radicular symptoms, at least comparable to the currently standard treatment of anterior cervical discectomy and fusion.

Should the Panel find that the PMA study data validates that the device under review is in fact safe and effective, then Neurosurgery strongly supports a recommendation for approval by the FDA so that as physicians we may gain a greater experience and we anticipate that our patients may benefit from a broader application of this technology. Again, thank you for considering our views on this issue.

Charles L. Branch, Jr. MD

Chair

AANS/CNS Section on Disorders of the Spine and Peripheral Nerves

AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS THOMAS A. MARSHALL, *Executive Director* 5550 Meadowbrook Drive Rolling Meadows, IL 60008 Phone: 888-566-AANS Fax: 847-378-0600 info@aans.org





CONGRESS OF NEUROLOGICAL SURGEONS LAURIE BEHNCKE, *Executive Director* 10 North Martingale Road, Suite 190 Schaumburg, IL 60173 Phone: 877-517-1CNS FAX: 847-240-0804 info@1CNS.org

> President RICHARD G. ELLENBOGEN, MD University of Washington Seattle, Washington

President DONALD O. QUEST, MD Columbia University New York, New York

May 5, 2006

Food and Drug Administration Division of Dockets Management HFA-305 5630 Fishers Lane, Room 1601 Rockville, MD 20852

Dear Sir or Madame:

RE: Orthopedic Devices: Reclassification of the Intervertebral Body Fusion Device. Docket No. 2006N--0019

On behalf of the American Association of Neurological Surgeons (AANS), we appreciate the opportunity to comment on the above referenced notice, which was published in the *Federal Register* on February 9, 2006.

We support the FDA proposal to reclassify intervertebral body fusion devices that contain bone grafting material from class III to class II. We believe that these devices are safe and effective when implanted by appropriately trained surgeons in carefully selected patients.

With regard to the proposal to retain intervertebral body fusion devices containing therapeutic biologic (e.g. bone morphogenic protein) in class III, we would suggest that the device itself is not substantially different than the device used for the bone grafting material and would recommend de-linking the device from the material placed in the device. In other words, we feel the "cage" itself should be reclassified to class II even if the FDA believes that the therapeutic biologic should remain in class III.

Thank you for your time and attention.

Sincerely,

Donald O. Quest, MD, President American Association of Neurological Surgeons

Washington Office Contact

Catherine Jeakle Hill, Senior Manager for Regulatory Affairs AANS/CNS Washington Office 725 15th Street, NW, Suite 800 Washington, DC 20005 Office: 202-628-2072 Email: chill@neurosurgery.org

Tuil G. Ellerboy

Richard G. Ellenbogen, MD, President Congress of Neurological Surgeons

WASHINGTON OFFICE KATIE O. ORRICO, Director

725 Fifteenth Street, NW, Suite 800 Phone: 202-628-2072 Fax: 202-628-5264

Washington, DC 20005 E-mail: korrico@neurosurgery.org AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS THOMAS A. MARSHALL, *Executive Director* 5550 Meadowbrook Drive Rolling Meadows, IL 60008 Phone: 888-566-AANS Fax: 847-378-0600 info@aans.org





CONGRESS OF NEUROLOGICAL SURGEONS LAURIE BEHNCKE, *Executive Director* 10 North Martingale Road, Suite 190 Schaumburg, IL 60173 Phone: 877-517-1CNS FAX: 847-240-0804 info@1CNS.org

> President RICHARD G. ELLENBOGEN, MD University of Washington Seattle, Washington

President DONALD O. QUEST, MD Columbia University New York, New York

September 8, 2006

Mark Melkerson, Deputy Director Division of General, Restorative, and Neurological Devices FDA Center for Devices and Radiological Health Room 350C, Mail stop HFZ 410 Rockville, MD 20850

> RE: September 19, 2006, Orthopaedic and Rehabilitation Panel Consideration of Cervical Disc Prosthesis

Dear Mr. Melkerson:

The American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS) and the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves support the FDA Orthopaedic and Rehabilitation Devices Panel Panel's serious and favorable consideration of cervical disc arthroplasty technology.

The potential for treatment of pathology with preservation of motion in symptomatic cervical disc degeneration appears to have value in the relief of symptoms and in the prevention of adjacent level degeneration. Reported experience with the cervical artificial disc has shown this to be safe, durable, and effective both with respect to preservation of motion and relief of radicular symptoms, at least comparable to the currently standard treatment of anterior cervical discectomy and fusion. Should the Panel find that the IDE study data validates that the device under review is in fact safe and effective, then Neurosurgery strongly supports its approval by the FDA so that patients may benefit from a broader application of this technology.

The AANS and CNS intend to have a representative present our views at the September 19 panel meeting and we will inform you who that individual is as soon as possible.

In the meantime, thank you for considering our views on this issue.

Sincerely,

Donald O. Quest, MD, President American Association of Neurological Surgeons

<u>Staff Contact</u> Catherine Jeakle Hill, Senior Manager for Regulatory Affairs AANS/CNS Washington Office Email: chill@neurosurgery.org

il G. allerboy

Richard G. Ellenbogen, MD, President Congress of Neurological Surgeons

WASHINGTON OFFICE KATIE O. ORRICO, *Director*

725 Fifteenth Street, NW, Suite 800 Phone: 202-628-2072 Fax: 202-628-5264 Washington, DC 20005 E-mail: korrico@neurosurgery.org



 3975 Fair Ridge Drive Suite 400 North Fairfax, Virginia 22033
 703.691.1805 Www.SIRweb.org
 Thomas A. Marshal Executive Director American Association of Neurological Surgeons 5550 Meadowbrook Drive Rolling Meadows, Illinois 60008-3852

RE: Vertebroplasty Position Statement

Dear Mr. Marshal,

The Society of Interventional Radiology would like to know if AANS would like to endorse this position statement: "Position Statement on Percutaneous Vertebral Augmentation".

1

This statement is an adaptation of a position statement sent to the Medicare Coverage Advisory Committee on May 3, 2005 with supporting information on the issues surrounding percutaneous vertebroplasty and kyphoplasty in the treatment of painful vertebral body compression fractures. Vertebroplasty is a medically appropriate therapy for treatment of painful vertebral compression fractures refractory to medical therapy and it is the recommendation of the ASITN, ASNR, and SIR that CMS continue to cover the procedure for the medical indications outlined in the published standards.

CMS communicated back that the available evidence was not sufficient to permit conclusions of the effect of percutaneous vertebroplasty (PVP) on health outcomes. The published evidence describing the outcomes of vertebroplasty consisted mostly of uncontrolled studies. These uncontrolled studies were mostly retrospective and enrolled heterogeneous patient populations. Such studies could not eliminate placebo and natural history effects as explanations for the apparent effectiveness of PVP.

The purpose of the enclosed statement is to give members useful information should they need to appeal an insurer's denial of payment for vertebral augmentation procedures. With your endorsement, we can strengthen consensus and make the position statement even stronger.

Enclosed is a Confidential Draft for your review. Please acknowledge intent by August 31, 2006.

If you have any questions please do not hesitate to email <u>debbie@sirweb.org</u>. Thank you in advance for your immediate reply.

Sincerely,

Debbie Katsarelis SIR Staff Liaison

	CONFIDENTIAL DOCUMENT – NOT FOR DISTRIBUTION
1	
2	
3	
4	
5	
6	
7	Position Statement on Percutaneous Vertebral
8	Augmentation: A consensus statement developed by the
9	American Society of Interventional and Therapeutic
10	Neuroradiology
11	American Society of Neuroradiology
12	Society of Interventional Radiology
13 14	Mary E. Jensen, MD, J. Kevin McGraw, MD, John F. Cardella, MD, Joshua A.
15	Hirsch, MD, Patrick A. Turski, MD
16	
17	
18	
19	
20	
21	
22	
23 24	
24 25	

,

l C

.

•

26 27

28 It is the position of the Societies that percutaneous vertebroplasty is a 29 safe, efficacious and durable procedure in appropriate patients with 30 symptomatic osteoporotic and neoplastic fractures, when performed in a manner 1,2 in accordance with published standards. This procedure is offered only when 31 32 traditional medical therapy has not provided pain relief or pain is significantly 3-17 18,19 altering the patient's lifestyle. Multiple case series, retrospective 33 and 20-23 have shown statistically significant 34 prospective non-randomized studies 35 improvement in pain and function, particularly ambulation, and these results have been confirmed in a prospective study using a control group, and a 36 prospective randomized control study . The benefits of vertebroplasty far 37 38 outweigh its risks and the risks of conservative therapy, and the success rate is 39 consistently high. This procedure is cost effective by producing immediate 40 improvement in a patient's quality of life, primarily through the alleviation of 41 pain and rapid return to ambulation. In addition to reducing the need for costly 42 skilled care, expensive drugs, or orthopedic devices, a return to ambulation is known to reduce adverse outcomes in elderly patients confined to bed . It is 43 44 the opinion of the ASITN, ASNR, and SIR that vertebroplasty is a medically appropriate therapy for treatment of painful vertebral compression fractures 45 refractory to medical therapy when performed for the medical indications 46 outlined in the published standards . 47

48	Kyphoplasty has been introduced as an alternative approach . It is
49	quite similar to vertebroplasty, and has been referred to as "balloon-assisted
50	vertebroplasty." Kyphoplasty entails the inflation of a percutaneously delivered
51	balloon in the vertebral body, followed by the percutaneous injection of bone
52	cement into the cavity created by the balloon. The balloon is intended to restore
53	the vertebral body height in addition to creating the cavity .
54	After reviewing the published literature on kyphoplasty, the Societies
55	have determined that the clinical response rate in individuals treated with
56	kyphoplasty is equivalent to that seen in patients treated with vertebroplasty.
57	There is no proven advantage of kyphoplasty relative to vertebroplasty with
58	27-44 regard to pain relief, vertebral height restoration, and complication rate
59	Because of additional equipment, anesthesia, and hospital costs, kyphoplasty is
60	approximately 2.5 times more expensive than vertebroplasty. It is possible that
61	certain subgroups of patients may derive more benefit from one particular
62	45 procedure 5 . Features that might affect choice of procedure include degree of
63	compression deformity, age of the fracture, and the presence of neoplastic
64	involvement, but the benefits of kyphoplasty relative to vertebroplasty in such
65	subgroups currently remain totally undefined. With the considerable added
66	financial expense of kyphoplasty, a significant clinical benefit over
67	vertebroplasty would have to be proven to justify this cost. A convincing
68	benefit to kyphoplasty relative to vertebroplasty can only be proven by
69	comparing outcomes from both procedures in a prospective, randomized study.
70	The Societies recognize, however, that performance of kyphoplasty instead of

CONFIDENTIAL DOCUMENT – NOT FOR DISTRIBUTION 71 vertebroplasty may be due to operator experience or preference. Since the 72 clinical outcomes studies show the same benefit as vertebroplasty in patient 73 pain relief and mobility at similar complication rates, it is the Societies' position 74 that kyphoplasty should be considered an alternative procedure to 75 vertebroplasty. 76 RATIONALE 77 78 Vertebral Augmentation versus Traditional Conservative Management 79 80 Although "conservative" implies "safe," conservative therapy is neither 46-48 81 benign nor risk-free, and its complications are well documented 82 Conservative treatment of painful vertebral compression fractures usually 83 consists of bed rest, bracing and narcotic analgesia. In a recent prospective 84 study of 498 hospitalized patients age 70 or older, low mobility (defined as bed 85 rest or ability to transfer to chair) or intermediate mobility (defined as 86 ambulation one to two times with total assistance) were independent predictors 87 of the following poor hospital outcomes at discharge: a) decline in activities of 88 daily living (ADLs), b) new institutionalization, and c) death when compared to 89 high mobility (defined as ambulation two or more times with partial or no assistance). The contribution of low mobility to these outcomes remained 90 91 statistically significant in multivariate analyses even after controlling for 92 multiple variables including age, sex, severity of illness and comorbitidies. In 93 short, conservative treatment leads to adverse outcomes associated with low

94 mobility and bed rest, which may be viewed as iatrogenic events leading to

95 complications such as functional decline.

96	As previously mentioned, conservative treatment often includes
97	immobilization with bed rest. During bed rest virtually every organ system is
98	adversely affected and these effects tend to be more pronounced in older
99	patients who have less reserve than younger patients. Bone density declines
100	approximately 2% per week, a serious concern in patients already suffering
101	from osteoporosis and these patients are unlikely to ever regain the lost bone
102	49 mass 30 . Bone loss tends to occur in stages with the most dramatic changes
103	occurring in the first twelve weeks of immobilization.
104	Muscle strength declines 1-3% per day or 10-15% per week $\overset{46}{}$. Nearly
105	half of normal strength is lost within 3 to 5 weeks of immobilization and the
106	rate of recovery from disuse weakness is slower than the rate of loss. Complete
107	rest results in decreased endurance, which leads to a sense of fatigue and
108	reduced patient motivation, setting up a vicious circle of greater inactivity.
109	Ligament complexes are also affected by immobilization, leading to
110	contractures, which are more prone to occur in frail, elderly individuals.
111	Muscles that cross two joints, such as the back muscles, are particularly at risk
112	of shortening during immobilization. There is abundant evidence that shows
113	early active mobilization after initial stabilization—a benefit of vertebral
114	augmentation is the key to contracture prevention.
115	Early mobilization also leads to the prevention of pressure sores, the
116	prevalence of which tends to increase significantly with age. Patients older than

117	70 years have more than 70% of all pressure sores and get them within two
118	weeks of admission to the hospital. Once decubitus ulcers occur, nursing costs
119	can increase by as much as 50% with the total cost of treatment per ulcer
120	estimated between \$15,000 and \$20,000. Complications often develop with
121	pressure sores. Infection is the most common complication and leads to
122	septicemia, osteomyelitis, anemia and protein loss through chronic discharge.
123	Cardiovascular effects include increased heart rate, shorter diastolic
124	times and reduced coronary blood flow. Cardiac output, stroke volume and left
125	ventricular function decline overall. In the elderly, orthostatic hypotension
126	occurs within the first three weeks of bed rest. This, along with the elevated
127	heart rate, leads to diminished diastolic ventricular filling and a decline in
128	cerebral perfusion. Depending on the length of bed rest it may take 20-72 days
129	to restore pre-bed rest cardiac function .
	46
129	to restore pre-bed rest cardiac function .
129 130	to restore pre-bed rest cardiac function . In patients at bed rest the incidence of deep vein thrombosis is 61% with
129 130 131	 to restore pre-bed rest cardiac function ⁴⁶. In patients at bed rest the incidence of deep vein thrombosis is 61% with proximal DVT occurring in 29%. Pulmonary embolism is seen in 2-12% of ⁴⁹
129 130 131 132	to restore pre-bed rest cardiac function $\frac{46}{2}$. In patients at bed rest the incidence of deep vein thrombosis is 61% with proximal DVT occurring in 29%. Pulmonary embolism is seen in 2-12% of patients and is fatal in 0.5-10% A restrictive impairment, an overall decrease
129 130 131 132 133	to restore pre-bed rest cardiac function $\frac{46}{100}$. In patients at bed rest the incidence of deep vein thrombosis is 61% with proximal DVT occurring in 29%. Pulmonary embolism is seen in 2-12% of patients and is fatal in 0.5-10% A restrictive impairment, an overall decrease in muscle strength, deconditioning of respiratory muscles, and failure to fully
 129 130 131 132 133 134 	to restore pre-bed rest cardiac function $\frac{46}{100}$. In patients at bed rest the incidence of deep vein thrombosis is 61% with proximal DVT occurring in 29%. Pulmonary embolism is seen in 2-12% of patients and is fatal in 0.5-10% $\frac{49}{1000000000000000000000000000000000000$
 129 130 131 132 133 134 135 	 ⁴⁶ to restore pre-bed rest cardiac function ⁴. In patients at bed rest the incidence of deep vein thrombosis is 61% with proximal DVT occurring in 29%. Pulmonary embolism is seen in 2-12% of patients and is fatal in 0.5-10% ⁴⁹. A restrictive impairment, an overall decrease in muscle strength, deconditioning of respiratory muscles, and failure to fully expand the chest wall results in a 25% to 50% decrease in respiratory capacity ⁴⁷. The lungs also suffer from decreased ciliary clearance, less effective
 129 130 131 132 133 134 135 136 	to restore pre-bed rest cardiac function 46 . In patients at bed rest the incidence of deep vein thrombosis is 61% with proximal DVT occurring in 29%. Pulmonary embolism is seen in 2-12% of patients and is fatal in 0.5-10% 49 . A restrictive impairment, an overall decrease in muscle strength, deconditioning of respiratory muscles, and failure to fully expand the chest wall results in a 25% to 50% decrease in respiratory capacity 47 . The lungs also suffer from decreased ciliary clearance, less effective coughing, atelectasis, and a predilection for pneumonia. Gastrointestinal

140	diabetes . Patients are at increased risk of genitourinary calculus formation,
141	incontinence, urinary tract infections and urosepsis. Even the central nervous
142	system is not immune; patients at bed rest exhibit higher levels of anxiety,
143	depression, insomnia, pain intolerance, sensory deprivation and balance
144	problems.
145	Narcotic analgesia is commonly used in conjunction with bed rest in the
146	48,50 treatment of acute and chronic non-malignant musculoskeletal pain
147	Adverse drug reactions (ADRs) have been seen in over 70% of individuals
148	treated with opioids 48 , and although the majority of side effects are minor, the
149	elderly are more likely to suffer severe ADR such as confusion. In one study ,
150	severe ADRs occurred in over 10% of patients. A multivariate analysis of the
151	findings showed that the only factor associated with severe ADRs was
152	advancing age.
153	Vertebroplasty has consistently shown immediate and considerable
154	improvement in pain and patient mobility following treatment . In a recent
155	study of 79 consecutive patients with osteoporotic compression fractures 24 , of
156	whom 55 (70%) were treated with vertebroplasty and 24 (30%) were treated
157	with conservative therapy, the vertebroplasty group showed statistically
158	significant reduction in pain and improvement in physical functioning at 24
159	hours over the conservative treatment group. In addition, 24% of the
160	vertebroplasty patients were able to cease all analgesia after 24 hours compared
161	to none in the conservative treatment group. These markedly different clinical

.

162 outcomes at 24 hours to one week represent the enormous benefit of

163 vertebroplasty over conservative therapy in terms of early mobilization, even

- 164 though at 6 weeks, 6 months and 12 months the clinical outcomes were the
- 165 same in the two groups.

166	In a trial of vertebroplasty versus best medical therapy 25 , 40 patients
167	with acute (symptomatic for six weeks or less) osteoporotic compression
168	fractures were randomized to vertebroplasty or conservative therapy, with
169	crossover for the medically treated group allowed at six weeks. The
170	vertebroplasty group showed statistically significant improvement in pain and
171	mobility and reduction in medication use immediately after vertebroplasty.
172	None of the patients randomized to medical therapy showed significant
173	improvement, and 16 of the 19 patients were offered vertebroplasty. This post-
174	medical therapy vertebroplasty group also showed statistically significant
175	improvement in all three parameters immediately following the procedure. At
176	12 weeks, both groups showed statistically significant durability of the
177	therapeutic response. ²⁵
178	It is well documented that the natural history of healing compression
179	fractures is comprised of gradual improvement in pain over two to twelve
180	^{51,52} weeks with variable return of function . What is not described as "natural
181	history" is sudden improvement in pain and return in function the hallmark
182	picture of a positive therapeutic response with vertebroplasty. Most of the
183	patients enrolled in the initial vertebroplasty studies did not undergo treatment

184 until all non-invasive therapies had been exhausted. These patients acted as

185	their own internal controls, as vertebroplasty was performed at a point in their
186	clinical course where if improvement associated with healing were to occur it
187	should have happened. It is therefore unlikely that the rapid, marked
188	improvement in clinical findings following vertebroplasty was associated with
189	the natural course of the disease.
190	It may also be argued that patients treated medically are just as likely to
191	have a long-term positive outcome similar to that of the vertebroplasty treated
192	population, a finding noted in the Diamond study ²⁴ . However, equality in long-
193	term outcomes does not negate the early positive effects of a successful
194	vertebroplasty. The potential complications associated with conservative
195	therapy are most likely to happen early in the course of a patient's
196	immobilization, leading to physiological losses from which the patient may not
197	recover, or resulting in adverse outcomes as seen in the Brown study.
197 198	
	recover, or resulting in adverse outcomes as seen in the Brown study .
198	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in
198 199	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in vertebroplasty are due to the placebo effect. Vertebroplasty reports have
198 199 200	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in vertebroplasty are due to the placebo effect. Vertebroplasty reports have consistently shown positive responses in the 80% to 90% range for osteoporotic
198 199 200 201	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in vertebroplasty are due to the placebo effect. Vertebroplasty reports have consistently shown positive responses in the 80% to 90% range for osteoporotic fractures, regardless of cohort demographics, etiology of osteoporosis,
198 199 200 201 202	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in vertebroplasty are due to the placebo effect. Vertebroplasty reports have consistently shown positive responses in the 80% to 90% range for osteoporotic fractures, regardless of cohort demographics, etiology of osteoporosis, geographic location, or type of institution (community practice versus academic
 198 199 200 201 202 203 	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in vertebroplasty are due to the placebo effect. Vertebroplasty reports have consistently shown positive responses in the 80% to 90% range for osteoporotic fractures, regardless of cohort demographics, etiology of osteoporosis, geographic location, or type of institution (community practice versus academic setting). The question would be laid to rest with the completion of a sham trial.
 198 199 200 201 202 203 204 	recover, or resulting in adverse outcomes as seen in the Brown study . Another consideration is that the positive outcomes seen in vertebroplasty are due to the placebo effect. Vertebroplasty reports have consistently shown positive responses in the 80% to 90% range for osteoporotic fractures, regardless of cohort demographics, etiology of osteoporosis, geographic location, or type of institution (community practice versus academic setting). The question would be laid to rest with the completion of a sham trial. A feasibility study reported in an abstract by Kallmes et al. ⁵³ showed that

sham procedure trial. A total of 150 patients are to be studied, but the trial hasbeen hampered by enrollment difficulties.

210 Over 450 papers concerning vertebroplasty have been published in the 211 last 20 years. Among these papers, about one hundred studies address the 212 clinical outcomes of patients treated with percutaneous vertebroplasty. Without 213 exception, these reports describe vertebroplasty as a successful therapy for the 214 relief of the pain associated with vertebral compression fractures caused by 215 either osteoporosis or tumor involvement. The earliest literature consisted of 216 small, retrospective, uncontrolled case series introducing the technique, and described excellent results for the patients involved $\overset{3-8}{}$. Since that time, larger 217 9-19 218 case series have been published . Literature reviews on the efficacy of 219 vertebroplasty have concluded that the procedure, when used in the setting of 220 osteroporotic compression fractures, results in substantial and immediate pain 54-57 relief, improved functional status, and minimal short-term complications 221 222 , including unrandomized and randomized controlled Prospective reports 24,25 also show overwhelming positive responses. The Societies conclude 223 studies 224 that the evidence supports the statement that vertebroplasty is efficacious in the 225 relief of pain and improvement of mobility associated with acute and subacute 17 58 226 compression fractures. Two studies show similar results in chronic 227 fractures up to two years in age. 228 Given the currently available scientific data, the Societies believe that

229 vertebroplasty has been shown to be more effective than continued medical

.

230	treatment in patients with painful VCFs who have failed conservative therapy.
231	To deny a patient vertebroplasty in favor of "more of the same" increases the
232	chance of an adverse outcome associated with low mobility and complications
233	associated with bed rest and narcotic analgesia.
234	As vertebroplasty utilization became widespread, kyphoplasty was
235	introduced as an alternative approach. Kyphoplasty entails inflation of a
236	percutaneously delivered balloon in the vertebral body, followed by the
237	percutaneous injection of bone cement into the cavity created by the balloon.
238	Kyphoplasty is quite similar to vertebroplasty, differing only in the use of the
239	balloon. Indeed, kyphoplasty has been referred to as "balloon assisted
240	vertebroplasty". The balloon ,in theory, is intended to restore the vertebral
241	body height while creating a cavity to be filled with bone cement 27 . The
242	balloon, the KyphX Inflatable Bone Tamp, is manufactured by Kyphon, Inc.
243	(Sunnyvale, CA), and has been approved by the United States Food and Drug
244	Administration for use as a bone tamp for the reduction of fractures, and/or the
245	creation of a void in cancellous bone.
246	The clinical outcomes data is not as extensive as vertebroplasty.
247	However, the available data describes treatment of osteoporotic and some
248	neoplastic fractures and has some prospective non-randomized data with
249	one report including a control group of patients given conservative therapy.
250	Currently, there has been no comparison of kyphoplasty to vertebroplasty. As
251	with vertebroplasty, the kyphoplasty reports show substantial pain relief and
252	improved mobility in the great majority of patients who have failed

	CONFIDENTIAL DOCUMENT – NOT FOR DISTRIBUTION
253	conservative therapy. Given the similarity of the two techniques and their
254	outcomes, the Societies are confident that kyphoplasty is effective in
255	substantially reducing pain and improving mobility in affected patients who
256	have failed conservative therapy.
257 258	
259	Quality of Life
260	Not only has vertebroplasty been shown to decrease pain and improve
261	mobility, it also has a positive impact on patients' quality of life. In a recent
262	study, forty-six consecutive patients underwent vertebropasty. At the time of
263	enrollment, all patients completed the Osteoporosis Quality of Life
264	Questionnaire, a validated thirty-item, five domain, 7-point response-option
265	instrument. All five domains of the questionnaire were improved at two weeks
266	post procedure and remained improved at each evaluation point through six
267	59 months . Similar quality of life improvements have been shown for
268	kyphoplasty ⁶⁸ .
269 270	Complications
271	The complication rate for Vertebroplasty is exceeding low but
272	complications nevertheless do occur. The primary cause of a symptomatic
273	vertebroplasty complication is leakage of polymethylmethacrylate (PMMA)
274	into adjacent structures, although the vast majority of such leaks are completely
275	asymptomatic This leakage can occur through fracture lines, areas of cortical
276	destruction, along the needle track, or into the epidural and paravertebral

277	9,60 venous complexes . Acrylic material that has leaked from the vertebral body
278	may cause spinal cord or nerve root compression, with resultant worsening pain
279	and/or neurological dysfunction. Migration of small amounts of PMMA
280	through the epidural or paravertebral venous system to the pulmonary
281	vasculature is virtually always clinically insignificant, but rare cases of
282	⁶¹ symptomatic pulmonary embolus have been reported .
283	Perivertebral acrylic is usually asymptomatic, although dysphagia from
284	esophageal compression after a cervical vertebroplasty has occurred $\overset{10}{}$. Other
285	complications that have occurred, as reported in the literature or through
286	personal knowledge, include fracture of the transverse process or pedicle,
287	paravertebral hematoma, epidural abscess, pneumothrax, CSF leak, seizure or
288	respiratory arrest from oversedation, and death. Severely osteoporotic patients
289	may sustain rib fractures or sternal fractures from lying prone on the
290	procedure table.
291	Hemodynamic compromise has been associated with packing of the
292	acetabulum with PMMA during hip replacement surgery. Transient systemic
293	
<u> </u>	hypotension during acrylic injection in vertebroplasty has been reported 62 , but a
294	
	hypotension during acrylic injection in vertebroplasty has been reported, but a
294	hypotension during acrylic injection in vertebroplasty has been reported, but a large retrospective study of the cardiovascular effects of PMMA in
294 295	hypotension during acrylic injection in vertebroplasty has been reported , but a large retrospective study of the cardiovascular effects of PMMA in vertebroplasty patients found no generalized association between acrylic

299	CONFIDENTIAL DOCUMENT – NOT FOR DISTRIBUTION this phenomenon and its possibility appears unlikely based upon in vitro tests,
300	which showed no significant temperature rise in the spinal canal with
500	64
301	vertebroplasty $\frac{64}{10}$, and in vivo animal experiments, which showed no spinal cord
302	damage from PMMA located adjacent to the dural sac in dogs .
303	More often than not, PMMA leakage is asymptomatic, even in
304	malignant lesions. Cotten et al demonstrated acrylic leaks by computed
305	tomography, both venous and cortical, in 29 out of 40 patients with osteolytic
306	metastases or myeloma. Most of these leaks were asymptomatic, but two of
307	eight foraminal leaks produced nerve root compression that required
308	decompressive surgery. In a later series, Cotten et al reported one patient out
309	of 258 treated who experienced spinal cord compression that required surgery.
310	Of 13 patients with radicular pain, only three required surgical decompression,
311	while ten responded to local anesthetic infiltration or medical therapy.
312	Deramond et al noted a single transient neurologic complication in 80 patients
313	with osteoporotic fractures. Review of all major vertebroplasty series shows
314	that the complication rate ranges from 1% to 10%; Murphy and Deramond 66
315	divide it further into 1.3% for osteoporosis, 2.5% for hemangiomas and 10% for
316	neoplastic disease. Fortunately, most patients with radicular symptoms respond
317	to anti-inflammatory or narcotic analgesics or local anesthetic infiltration, while
318	surgical intervention is required only in a minority of cases. Complications are
319	most likely to occur during or immediately after treatment. In two long-term
320	studies, no complications were found in patients followed at 48 months ¹⁹ and 5

321	years . A difference in complication rates between acute and chronic fractures
322	has not been reported.

323	The issue of increased risk for fracture at an adjacent level has been
324	raised in the literature. Grados and colleagues found a slight, but statistically
325	significant, increased risk of vertebral fracture in the vicinity of a cemented
326	vertebra when compared to a vertebral fracture in the vicinity of an uncemented
327	fracture. However, new fractures following vertebroplasty may actually
328	represent the natural history of osteoporosis rather than a complication of the
329	procedure and further study is necessary.
330	Complications associated with kyphoplasty are similar to those seen in
331	vertebroplasty. Six major complications in 531 patients (1.1%) treated with
332	kyphoplasty were reported in a multicenter collection of patients, four of which
333	were neurological complications 40 . This complication rate is similar to the 1.3%
334	66 complication rate seen in vertebroplasty for osteoporotic fractures 66 .
335	In summary, clinically significant complications for vertebroplasty
336	remain small and are most significant in the treatment of malignant disease.
337	Most respond to short-term medical therapy and surgery is usually not required.
338	The societies recommends that all practitioners incorporate indicator thresholds
339	into one's quality improvement program to identify potential problems. As
340	serious complications of vertebroplasty are infrequent, a review is
341	recommended for all instances of death, infection, and symptomatic pulmonary
342	embolus. Recommended thresholds for complications can be found in The
343	American College of Radiology's "Standards for the Performance of

Percutaneous Vertebroplasty" document and the Society of Interventional 344 345 Radiology's "Quality Improvement Guidelines for Percutaneous Vertebroplasty" document. The Societies are very confident in the validity of 346 347 the abovementioned complication data. 348 349 **CONCLUSION** 350 It is the position of the ASITN, ASNR, and SIR that vertebral 351 augmentation with Vertebroplasty or Kyphoplasty is a medically appropriate 352 therapy for treatment of painful vertebral compression fractures refractory to 353 medical therapy when performed for the medical indications outlined in the published standards . We believe vertebral augmentation with vertebroplasty 354 355 or kyphoplasty is established therapy and should be reimbursed by payors as a 356 safe and effective treatment for painful compression fractures. 357 358 359 REFERENCES 360 361 1. Barr JD, Mathis JM, Barr MS, et al. Standard for the performance of 362 percutaneous vertebroplasty. In: American College of Radiology Standards 363 2000–2001. Reston, VA: American College of Radiology, 2000; 441-448. 364 365 366 2. McGraw JK, Cardella JC, Barr JD, et al. Quality improvement guidelines for 367 percutaneous vertebroplasty. J Vasc Interv Radiol; July; 14(7):827-31, 2003.

368 369	
370	3. Galibert P, Deramond H, Rosat P, Le Gars D. Note préliminaire sur le
371	traitement des angiomes vertébraux par vertebroplastie percutanée.
372	Neurochirurgie 33:166-168, 1987.
373	
374	4. Kaemmerlen P, Thiesse P, Bouvard H, et al: Vertébroplastie percutanée dans
375	le traitement des métastases. Technique et résultats. J Radiol 70:557-562,
376	1989.
377	
378	5. Nguyen JP, Djindjian M, Pavlovitch JM, Badiane S: Vertebral hemangioma
379	with neurologic signs. Therapeutic results. Survey of the French Society of
380	Neurosurgery. Neurochirurgie 35:299-303, 305-308, 1989.
381	
382	6. Deramond H, Darrason R, Galibert P. Percutaneous vertebroplasty with
383	acrylic cement in the treatment of aggressive spinal angiomas. Rachis 1: 143-
384	153,1989.
385	
386	7. Debussche-Depriester C, Deramond H, Fardellone P, et al: Percutaneous
387	vertebroplasty with acrylic cement in the treatment of osteoporotic vertebral
388	crush fracture syndrome. Neuroradiology 33 (Suppl):149-152, 1991.
389	
390	8. Gangi A, Kastler BA, Dietemann JL. Percutaneous vertebroplasty guided by
391	a combination of CT and fluoroscopy. AJNR Am J Neuroradiol 15:83-86,

- 392 1994.

394	9. Cotten A, Dewatre F, Cortet B, et al. Percutaneous vertebroplasty for
395	osteolytic metastases and myeloma: effects of the percentage of lesion filling
396	and the leakage of methyl methacrylate at clinical follow-up. Radiology
397	200:525-530, 1996.
398	
399	10. Weill A, Chiras J, Simon J, et al. Spinal metastases: indications for and
400	results of percutaneous injection of acrylic cement. Radiology 199:241-247,
401	1996.
402	
403	11. Jensen ME, Evans AE, Mathis JM et al: Percutaneous
404	polymethylmethacrylate vertebroplasty in the treatment of osteoporotic
405	vertebral body compression fractures: technical aspects. AJNR Am J
406	Neuroradiol 18:1897-1904, 1997.
407	
408	12. Deramond H, Depriester C, Galibert P, Le Gars D: Percutaneous
409	vertebroplasty with polymethylmethacrylate. Technique, indications and
410	results. Radiologic Clinics of North America 36:533-546, 1998.
411	
412	13. Cotten A, Boutry N, Cortet B, et al: Percutaneous vertebroplasty: state of
413	the art. Radiographics 18:311-320, 1998.
414	
415	14. Gangi A, Guth S, Imbert JP, et al. Percutaneous vertebroplasty:

- 416 indications, technique, and results. Radiographics 23:e10, 2002.
- 417
- 418 15. Barr JD, Barr MS, Lemley TJ, Mc Cann RM. Percutaneous vertebroplasty
- 419 for pain relief and spinal stabilization. Spine 2000;25: 923-928.
- 420
- 421 16. Martin JB, Jean B, Sugiu K, et al. Vertebroplasty: clinical experience and
 422 follow-up results. Bone 1999;25: 11S-15S.
- 423
- 424 17. Kaufmann TJ, Jensen ME, Schweickert PA, et al. Age of fracture and
- 425 clinical outcomes of percutaneous vertebroplasty. AJNR Am J Neuroradiol
- 426 22:1860-1863, 2001.
- 427
- 428 18. Evans AJ, Jensen ME, Kip KE, et al. Vertebral compression fractures: pain
- 429 reduction and improvement in functional mobility after percutaneous
- 430 polymethylmethacrylate vertebroplasty retrospective report of 245 cases.
- 431 Radiology 226:366-72, 2003.
- 432
- 433 19. Grados F, Depriester C, Cayrolle G, et al. Long-term observations of
- 434 vertebral osteoporotic fractures treated by percutaneous vertebroplasty.
- 435 Rheumatology (Oxford) 39:1410-1414, 2000.
- 436
- 437 20. Cortet B, Cotten A, Boutry N, Flipo RM et al: Percutaneous vertebroplasty
- 438 in the treatment of osteoporotic vertebral compression fractures: an open
- 439 prospective study. J Rheumatol 26:2222-2228, 1999.

- 440
- 441 21. Heini PF, Walchli B, Berlemann U. Percutaneous transpedicular
- 442 vertebroplasty with PMMA: operative technique and early results. A
- 443 prospective study for the treatment of osteoporotic compression fractures.
- 444 European Spine Journal 2000;9: 445-450.
- 445
- 446 22. McGraw JK, Lippert JA, Minkus KD, et al. Prospective evaluation of pain
- 447 relief in 100 patients undergoing percutaneous vertebroplasty: results and
- 448 follow-up. J Vasc Interv Radiol 13(9 Pt 1):883-6, 2002.
- 449
- 450 23. Zoarski GH, Snow P, Olan WJ, et al. Percutaneous vertebroplasty for
- 451 osteoporotic compression fractures: quantitative prospective evaluation of long-
- 452 term outcomes. J Vasc Interv Radiol 13(2 Pt 1):139-48, 2002.
- 453
- 454 24. Diamond TH, Champion B, Clark WA. Management of acute osteoporotic
- 455 vertebral fractures: a non-randomized trial comparing percutaneous
- 456 vertebroplasty with conservative therapy. Am J Med 114:257-265, 2003.
- 457
- 458 25. Do HM, Marcellus ML, Weir RU, Marks MP. Percutaneous vertebroplasty
- 459 versus medical therapy for treatment of acute vertebral body compression
- 460 fractures: a prospective randomized study. Proceedings of the ASNR, 2002
- and Proceedings of the AUR, 2002.
- 462

463 26. Brown CJ, Friedkin RJ, Inouye SK. Prevalence and outcomes of low

464	mobility in hospitalized older patients.	J Am Geriart Soc 1263-1270, 2004.
465		

466 27. Lieberman IH, Dudeney S, Reinhardt MK, Bell G. Initial outcome and

467 efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral

468 compression fractures. Spine 26:1631-8, 2001.

469

470 28. Coumans JV, Reinhardt MK, Lieberman IH. Kyphoplasty for vertebral

471 compression fractures: 1-year clinical outcomes from a prospective study. J

472 Neurosurg Spine 2003;99(1):44-50.

473

474 29. Theodorou DJ, Theodorou SJ, Duncan TD, et al. Percutaneous balloon

475 kyphoplasty for the correction of spinal deformity in painful vertebral body

476 compression fractures. Clin Imaging 2002;26(1):1-5.

477

478 30. Feltes C, Fountas KN, Machinis T, et al. Immediate and early postoperative

479 pain relief after kyphoplasty without significant restoration of vertebral body

480 height in acute osteoporotic vertebral fractures. Neurosurg Focus 2005;18(3):e5.

481

482 31. Kasperk C, Hillmeier J, Noldge G, et al. Treatment of painful vertebral

483 fractures by kyphoplasty in patients with primary osteoporosis: a prospective

484 nonrandomized controlled study. J Bone Miner Res 2005;20(4):604-12.

485

486 32. Ledlie JT, Renfro M. Balloon kyphoplasty: one-year outcomes in vertebral
487 body height restoration, chronic pain, and activity levels. J Neurosurg 98:36-

- 488 42, 2003.
- 489
- 490 33. Gaitanis IN, Hadjipavlou AG, Katonis PG, et al. Balloon kyphoplasty for
- 491 the treatment of pathological vertebral compressive fractures. Eur Spine J
- 492 2005;14(3):250-60.
- 493
- 494 34. Berlemann U, Franz T, Orler R, Heini PF. Kyphoplasty for treatment of
- 495 osteoporotic vertebral fractures: a prospective non-randomized study. Eur Spine
- 496 J 2004;13(6):496-501.
- 497
- 498 35. Crandall D, Slaughter D, Hankins PJ, et al. Acute versus chronic vertebral
- 499 compression fractures treated with kyphoplasty: early results. Spine J
- 500 2004;4(4):418-24.
- 501
- 502 36. Rhyne A, 3rd, Banit D, Laxer E, et al. Kyphoplasty: report of eighty-two
- 503 thoracolumbar osteoporotic vertebral fractures. J Orthop Trauma
- 504 2004;18(5):294-9.
- 505
- 506 37. Phillips FM, Ho E, Campbell-Hupp M, et al. Early radiographic and
- 507 clinical results of balloon kyphoplasty for the treatment of osteoporotic
- vertebral compression fractures. Spine 2003;28(19):2260-5; discussion 2265-7.
- 509
- 510 38. Lane JM, Hong R, Koob J, et al. Kyphoplasty enhances function and
- 511 structural alignment in multiple myeloma. Clin Orthop Relat Res 2004(426):49-

- 512 53.
- 513
- 514 39. Choe du H, Marom EM, Ahrar K, et al. Pulmonary embolism of
- 515 polymethyl methacrylate during percutaneous vertebroplasty and kyphoplasty.
- 516 AJR Am J Roentgenol 2004;183(4):1097-102.
- 517
- 518 40. Garfin SR, Reilley MA. Minimally invasive treatment of osteoporotic
- 519 vertebral body compression fractures. Spine J 2002;2(1):76-80.
- 520
- 521 41. Nussbaum DA, Gailloud P, Murphy K. A review of complications
- 522 associated with vertebroplasty and kyphoplasty as reported to the food and drug
- 523 administration medical device related web site. J Vasc Interv Radiol
- 524 2004;15(11):1185-92.
- 525
- 526 42. Fribourg D, Tang C, Sra P, et al. Incidence of subsequent vertebral fracture

527 after kyphoplasty. Spine 2004;29(20):2270-6; discussion 2277.

528

529 43. Harrop JS, Prpa B, Reinhardt MK, Lieberman I. Primary and secondary

- 530 osteoporosis' incidence of subsequent vertebral compression fractures after
- 531 kyphoplasty. Spine 2004;29(19):2120-5.
- 532

533 44. Majd ME, Farley S, Holt RT. Preliminary outcomes and efficacy of the

- 534 first 360 consecutive kyphoplasties for the treatment of painful osteoporotic
- 535 vertebral compression fractures. Spine J. 2005 May-Jun;5(3):244-55.

	CONFIDENTIAL DOCUMENT – NOT FOR DISTRIBUTION
536	
537	45. Myers ME. Vertebroplasty and kyphoplasty: is one of these procedures the
538	best choice for all patients? AJNR Am J Neuroradiol 2004;25(7):1297.
539	
540	46. Dittmer DK, Teasell R. Complications of immobilization and bed rest.
541	Part 1: Musculoskeletal and cardiovascular complications. Can Fam Physician
542	39:1428-1432, 1435-1437, 1993.
543	
544	47. Teasell R, Dittmer DK. Complications of immobilization and bed rest.
545	Part 2: Other complications. Can Fam Physician 39:1440-1442, 1445-1447,
546	1993.
547	
548	48. Cherasse A, Muller G, Ornetti P, et al. Tolerability of opioids in patients
549	with acute pain due to nonmalignant musculoskeletal disease. A hospital-based
550	observational study. Joint Bone Spine 71:572-6, 2004.
551	
552	49. Babayev M, Lachmann E, Nagler W. The controversy surrounding sacral
553	insufficiency fractures: to ambulate or not to ambulate? Am J Phys Med
554	Rehabil 79:404-9, 2000.
555	
556	50. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices
557	regarding the long-term prescribing of opioids for non-cancer pain. Pain
558	59:201-8, 1994.

560	51. Patel U, Skingle S, Campbell GA, et al: Clinical profile of acute vertebral
561	compression fractures in osteoporosis. Br J of Rheumatology 30:418-421,
562	1991.
563	
564	52. Silverman SL: The clinical consequences of vertebral compression fracture.
565	Bone 13:S27-31, 1992.
566	
567	53. Kallmes DF, Jensen ME, Marx WF, et al. A pilot study for a sham-
568	controlled, randomized, prospective, crossover trial of percutaneous
569	vertebroplasty. ASNR annual meeting, Vancouver, BC, 13-17 May 02.
570	
571	54. Garfin SR, Yuan HA, Reiley MA. New technologies in spine: kyphoplasty
572	and vertebroplasty for the treatment of painful osteoporotic compression
573	fractures. Spine 26: 1511-1515, 2001.
574	
575	55. Watts NB, Harris ST, Genant HK. Treatment of painful osteoporotic
576	vertebral fractures with percutaneous vertebroplasty or kyphoplasty.
577	Osteoporos Int 12:429-37 2001.
578	
579	56. Levine SA, Perin LA, Hayes D, Hayes WS. An evidence-based evaluation
580	of percutaneous vertebroplasty. Managed Care 9: 56-60, 63, 2000.
581	
582	57. Murphy, KJ, Lin, DD. Vertebroplasty: A Simple Solution to a Difficult
583	Problem. J Clin Densitometry 4:185-187,2001.

584	
585	58. Brown DB, Gilula LA, Sehgal M, Shimony JS Treatment of chronic
586	symptomatic vertebral compression fractures with percutaneous vertebroplasty.
587	AJR Am J Roentgenol 182:319-22, 2004.
588	
589	59. McKiernan F, Faciszewski T, Jensen R. Quality of life following
590	vertebroplasty. J Bone Joint Surg Am. 2004 Dec;86-A(12):2600-6.
591	
592	60. Jensen ME, Dion JE. Percutaneous vertebroplasty in osteoporotic
593	compression fractures. Neuroimaging Clin N Am 10:547-568, 2000. [Review]
594	
595	61. Padovani B, Kasriel O, Brunner P, Peretti-Viton, P: Pulmonary embolism
596	caused by acrylic cement: a rare complication of percutaneous vertebroplasty.
597	AJNR Am J Neuroradiol 20:375-377, 1999.
598	
599	62. Vasconcelos C, Gailloud P, Martin JB, Murphy KJ. Transient arterial
600	hypotension induced by polymethylmethacrylate injection during percutaneous
601	vertebroplasty. J Vasc Interv Radiol 12:1001-1002, 2001.
602	
603	63. Kaufinann TJ, Jensen ME, Ford G, et al. Cardiovascular effects of
604	polymethylmethacrylate use in percutaneous vertebroplasty. AJNR Am J
605	Neuroradiol 23:601-604, 2002.
606	

607 64. Deramond H, Wright NT, Belkoff SM. Temperature elevation caused by

	CONFIDENTIAL DOCUMENT – NOT FOR DISTRIBUTION
608	bone cement polymerization during vertebroplasty. Bone 25(2 Suppl):17S-21S,
609	1999.
610	
611	65. Wang GW, Wilson CS, Hubbard SL, et al: Safety of anterior cement
612	fixation in the cervical spine: in vivo study of dog spine. South Med J 77:178-
613	179, 1984.
614	
615	66. Murphy KJ, Deramond H: Percutaneous vertebroplasty in benign and
616	malignant disease. Neuroimaging Clinics of North Am 10:535-545, 2000.
617	
618	67. Perez-Higueras A, Alvarez L, Rossi RE et al. Percutaneous vertebroplasty:
619	long-term clinical and radiological outcome. Neuroradiology. 2002
620	Nov;44(11):950-4. Epub 2002 Oct 3.
621 622	68. Ledlie JT and Renfro MB. Kyphoplasty treatment of vertebral fractures:
623	2-year outcomes show sustained benefits. Spine. 2006 Jan1;31(1):65-6.
624 625	
626	
627	
628	

NREF-AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves Young Clinician Investigator Award (SS-YCI)

The Joint Section on Disorders of the Spine and Peripheral Nerves (the "Section") wishes to provide the **Neurosurgery Research and Education Foundation** (**NREF**) (the "Institution") with an endowment totaling \$500,000, which should be apportioned as follows: \$400,000 in a permanent endowment and \$100,000 to be distributed over five (5) years in order to bring the income generated from the endowment to a full YCI award of \$40,000 (the "Grant").

It is understood that at the end of five (5) years, if funds are available, the Section will replenish the \$100,000 portion of this Grant, which will be distributed over the next five (5) years pursuant to this Agreement.

The purpose of this agreement is to set forth the terms and conditions pursuant to which the Section shall provide the Grant to the Institution.

Scope of Grant Support

- 1. Potential grant recipients will apply to the Institution between July 1st and June 30th of said year.
- 1.2 The Scientific Advisory Committee of NREF will review all applications and will render its recommendations to the NREF Executive Council (EC). The NREF EC will make the decision and will forward its selection(s) onto the Section.
- 1.3 The Section's designated grant will be available only for applications dealing with topics related to spine and/or peripheral nerve. For the AANS/CNS Joint Spine Section Young Clinician Investigator Award (SS-YCI), the NREF SAC shall review, score and rank only those applications that meet the aforementioned requirements.

Terms and Conditions

- 1. The Grant shall be used by the Institution to support an endowment and an annual AANS/CNS Joint Spine Section Young Clinician Investigator Award (SS-YCI).
- 2. The Institution and Section acknowledge and agree that the Institution shall have sole and complete control over the review and selection process for the Grant (see 1.1 to 1.4 above for more detail).
- 3. The Institution shall remit to the Section a detailed accounting of the manner in which the Grant proceeds were disseminated to the beneficiaries and otherwise expended. Additionally, as requested by the Section, the Institution shall permit the Section to review accounting records, which are related to the Grant.
- 4. The Institution and Section acknowledge and agree that the Grant has not been determined in a manner which takes into account the volume or value of business otherwise generated between the Institution and the Section and shall not obligate the Institution to purchase, use, recommend, or arrange for the use of any product of or service provided by the Section.
- 5. The Institution or the Section in the event of a material breach may immediately terminate this agreement by the other, which breach is not cured by said party within thirty (30) days after written notice thereof from the other. In the event that this agreement is terminated by the Section for cause, as provided in this paragraph, and the termination is approved by the Section's two parent organizations (AANS and CNS), the Institution shall immediately return

to the Section the endowment funds and any remaining funds in the pay-down portion of the grant that has not been expended as of the effective date of the termination.

6. The Institution and Section agree that this agreement shall be governed by and interpreted under the laws of the State of Illinois. Any controversy or claim arising out of or relating to this agreement or the validity, inducement in accordance with the Commercial Arbitration Rules of the American Arbitration Association ("AAA") then pertaining. The Institution and Section hereby consent to the jurisdiction of the federal district court for the Northern District of Illinois and the entry of judgment on any award rendered hereunder. The Institution and Section further agree that this agreement sets forth the entire understanding regarding the subject matter hereof, supercedes all prior agreements or understandings, whether written or oral, between the Institution and Section.

If the terms of this agreement are acceptable to the Section, please acknowledge the Section's agreement to the terms of this agreement by countersigning the attached three (3) copies and returning one (2) copies to AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves c/o Michele S. Gregory, Director of Development, AANS, 5550 Meadowbrook Drive, Rolling Meadows, IL 60008. Should there be any questions or a need for clarification, please contact the AANS at (847) 378-0500.

AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves

By:	
	Thomas A. Marshall, AANS Executive Director
Date:	
Agreed and ac	knowledged this day of
(Signature)	
By:	Laurie Behncke, CNS Executive Director
Date:	
Agreed and ac	knowledged this day of
(Signature)	
By:	Ronald W. Engelbreit, CPA
Date:	
Agreed and ac	knowledged this day of

(Signature)

Results of Spine executive Committee Vote on NREF Contribution

Total Votes: 14

Yes: 11 No: 2 Abstain: 3 September 23, 2006

Dr. Marty Weiss Chair NREF Executive Council

Dear Marty,

I am delighted to report to you that the Executive Committee of the Section on Disorders of the Spine and Peripheral Nerves has voted to approve the establishment and funding of the Young Clinician Investigator Award for Spine through the NREF.

The details of this proposal are described in the revised document from Michele Gregory dated July 14, 2006, also attached to the electronic transmission of this document. We understand that upon this directive that appropriate signatures from the parent organizations will memorialize this decision and initiate the transfer of funds from the long term investment pool of the Section, the details of which will be determined by Mr. Engelbreit, AANS Treasurer and Dr. Wolfla, Section Treasurer.

It is our pleasure to participate in this very significant way in the NREF. We appreciate and understand that the NREF Executive Council will receive nominations from the Section and include a qualified member or members of our Section on the Council so that the true breadth of Neurosurgery will be represented in this important research enterprise. We also appreciate and understand that the NREF Scientific Advisory Committee has accepted our nomination of Dr. Jim Guest to that committee and will maintain a qualified member or members of the Section on that committee as well.

The Section leadership recognizes the great value of a Neurosurgery research initiative, and the great value of the subspecialty area of Spine to Neurosurgery and visa versa. We also recognize that in some areas, spinal research in Neurosurgery has been limited and it is our intent with this and other initiatives to grow our research base and our participation in Neurosurgery research leadership.

Thank you and Michele for your efforts to make this particular iniative successful. I personally look forward to continuing our work together in the future.

With kindest regards,

Charles L. Branch, Jr., M.D. Chairperson AANS/CNS Section on disorders of the Spine and Peripheral Nerves

Cc: Michele Gregory Don Quest Tom Marshall Rich Ellenbogen Laurie Behncke Joe Alexander Dan Resnick Chris Wolfla

Clinical Trials Committee Proposal

Problem:

There are many questions in spine surgery for which good-quality clinical trial evidence is not available, and too few investigatorinitiated clinical trials in spine surgery; most current trials are industry sponsored. Most spine surgeons recognize that we need more class I evidence on many questions, but few neurosurgeons are trained in clinical trial methods or design. Compounding these problems, funding clinical trials is becoming an increasingly difficult challenge. Failure to correct these problems, however, will result in industry driving the field as opposed to spine surgeons, who should be in the saddle to push the field forward (with help from industrial partners as necessary).

Objectives:

- 1) To encourage more investigator-initiated clinical trials in spine and develop strategies for team building and funding.
- 2) To increase appreciation and disseminate information on ongoing clinical trials.

Background:

I have personally designed 2 multicenter clinical trials in spine surgery. The SLIP study is a multi-center prospective randomized clinical trial which tests whether adding fusion to a decompressive laminectomy improves outcomes for the surgical management of spinal stenosis with a grade I spondylolisthesis. Preliminary data for the trial has been published in *JNS (Spine)*. We have 80 patients accrued to date from 5 centers. Grant support for this trial is \$250,000, of which \$185,000 has been disbursed to date. The second study, the CSM trial, is just getting off the ground. This study tests whether anterior or posterior approaches for decompression of cervical spondylotic myelopathy will provide better results. This study is funded to date at \$470,000. Preliminary results from the design process of the CSM trial have included a survey of the CSRS membership to define entry criteria for the trial; a manuscript on the analysis of the survey has been resubmitted after revision to *Spine*.

Specific Goals:

1) To encourage more investigator-initiated clinical trials in spine and develop strategies for team building and funding.

- Provide guidelines on the section website for designing a clinical trial including NIH-guidelines
 (<u>http://www.clinicaltrials.gov/ct/show/NCT00109213</u> the SLIP study, for example, is registered with the NIH site)
- Keep an interactive forum on the website for potential investigators to join with those at other centers to create multi-center collaborative efforts. Provide useful information on the section website or as a newsletter to section members on funding mechanisms (such as the newly created NIH R34 mechanism) and resources for designing clinical trials (i.e. dates of American College of Surgeons Clinical Trials courses, relevant papers, books, etc).
- Work closely with the Outcomes Committee (Mike Kaiser, MD, Chairman – where I am also a member) to help trialists to identify appropriate outcomes measures when designing their trials.

2) To increase appreciation and disseminate information on ongoing clinical trials

- To create a team award for the best clinical trial proposal that would by design involve at least 3 centers. This would be a great lesson in team building and we would reward all who collaborated (up to 5 people). I am certain I can create support for this from Foundations that support my work. I'd target \$750/ resident.
- To organize a time at the AANS, Congress, or spine section meeting for getting '2 minute updates' on current trials including those ongoing in Europe. The tumor section is doing this at the April AANS meeting and it allows investigators the opportunity to 'advertise' their trials in a national forum and gain recognition for being involved in long-term projects. In addition, we could have guest speakers address funding mechanisms for neurosurgical research. For example, the tumor section held a roundtable discussion with invited NIH speakers at the Congress '05 meeting regarding funding opportunities.

Thanks,

Zo Ghogawala

Charlie, Dan and Chris:

Bill Krauss and Brad Currier are at Mayo and are putting together a meeting--see below. Do we have a policy about our section mailing list for activities like this--I can't recall if we do. If not, I would suggest that legitimate educational meetings run by true non-profits like universities (not companies, or company-sponsored entities or meetings) could use our list for free. Profit-based entities, or meetings with major corporate support, could potentially use it for a fee that we could establish. Either type would have to be for activities that would not conflict with our section's annual meeting or significant activities of our parent organizations.

If such a policy does not exist, I would suggest that we allow Mayo to use the list for this purpose. I would further suggest that we put this on the agenda for the Exec Committee next month. Requests could be handled by the education committee person based on guidelines that we set up, with uncertain cases referred for wider ex-comm input.

Joe

Dan,

As the liason member to and from the SRS from the Spine Section Exec, I have two items that the SRS has asked for review and possible support from the Section.

1. From the SRS Education Committee:

The SRS has developed a suggested curriculum for spinal deformity fellowship. This is not meant as a mandate or to suggest practice restriction. It is also not intended to be a step into sub specialty certification. It is simply meant to be a recommendation of what should be included in any fellowship that is to train fellows in spinal deformity surgery as a primary goal. If supported by other societies, such as ours that train spine surgeons for all types of spine practice, the SRS will send the curriculum to all of those societies for distribution.

My assistant will attach the curriculum document and cover letter from it's Chair, Jim Olgilvie.

I strongly encourage the Section to issue a letter in support of this and send it along to the AANS, CNS and SNS executive coimmittees. This document will provide a template to optimize and codify training in fellowships dealing with spinal deformity. It can also serve as a model for other fellowships. All to often, the curriculum and quality of fellowship training is poorly defined. Developing nonrestrictive fellowship curriculum guidelines would go a long way to standardizing acceptable education parameters. This is in the interest of our specialty, it's fellows and society. Standardized curriculum development is fast becoming a norm and it would be good to get ahead of the curve on this one.

The SRS has reached out to work with organized neurosurgery as colleagues. They are the first to change by-laws to allow both specialties to belong to one organization (NASS is a big tent by definition). They included neurosurgical input on the education committee to draft the curriculum. I believe that the Section's cooperation will help foster collaborative work in spine education between organized neurosurgery and orthopedic surgery. This will improve training and education for all.

2. From the SRS Advocacy Committee

The SRS asks for a letter of support from the Spine Section to allow spine surgeons to practice in their area of training regardless of specialty.

This seemingly straight forward issue arises from an issue of professional discrimination in Turkey. In Turkey, there is an SRS member, Dr. Aydinli, who is an Orthopedic surgeon who is extensively trained in spine surgery. This includes deformity, degenerative reconstruction and decompression. He is being prevented from performing decompressive and degenerative spine procedures by the Department of neurosurgery at his hospital as this is the "purvue" of neurosurgery and orthopedics should not perform them. This of course is blatant prejudice based on turf and practice protection, not qualification. It is the type of behavior that is unprofessional and embarrassing to our field. Fortunately, it is rapidly evaporating in the U.S. While the Section cannot dictate a hospital policy in Turkey, we can make the stance a bit less tenable by joining the SRS in condemming restrictive behavior that arises from specialty self interest rather than training and education. If we fail to do this, we will fail to stand for the high road principles of justice. On the low road of self interest, failure to do this could re-ignite inter specialty rivalry and organized orthopedics taking the stance that they are the only ones qualified to do reconstruction and deformity. That neurosurgery is for decompression alone. I strongly recommend that we join the SRS on the high road. They have demonstrated their willingness to support neurosurgeons as spine surgeons. We should return this favor.

Please let me know if there are any questions or additional documentation needed from me.

See you at the CNS.

Sincerely, Steve Ondra

Spine Deformity Educational Curriculum

Definition: Spine deformity is any condition in which the posture and/or spinal contour is the primary abnormality determining the treatment strategy.

Educational curriculum: The Spinal Deformity Educational Curriculum is a suggested ideal format for educational planning. It is recognized that some educational programs/fellowships may not incorporate all aspects of the curriculum.

I.	Suggested Topics for Didactic Presentation:
	Clinical biomechanics of the spine
	Pain management
	Nutritional
	Spinal radiology
	Spine embryology, growth, development and genetics
	Pediatric and adult reading list – (determined by each site)
	Principles of evidence-based medicine

II. The fellowship curriculum for spine deformity should include exposure to and familiarity with the pathogenesis, treatment principles, and surgical decision making, but not necessarily a comprehensive surgical experience in the following diagnoses:

 a. Scoliosis: idiopathic, neuromuscular (cerebral palsy, muscular dystrophies, myelodysplasia, etc), congenital, degenerative, syndromic (neurofibromatosis, osteogenesis imperfecta, mucopolysaccharidoses, Down, etc.), pathologic, traumatic, iatrogenic, post-infectious, metabolic, and other etiologies

- b. Sagittal plane deformity: Scheuermann's, post-laminectomy, neuromuscular, degenerative, traumatic, pathologic, congenital, neoplastic, and other etiologies
- c. Spondylolisthesis

III. The fellowship curriculum for spine deformity should include exposure to and familiarity with the following non-operative spinal deformity evaluation and treatment methods:

- a. Orthotic and cast treatment options for spinal deformity
- b. Awareness of long term consequences of treatment and non-treatment options
- c. Knowledge of appropriate referral patterns for specialized care in ICU, nephrology, metabolic disorders, developmental pediatrics, pulmonology, genetics, and other specialties that relate to spinal deformity care.
- d. Knowledge of appropriate diagnostic evaluations for patients with spinal deformity

IV. The fellowship curriculum for spine deformity should include exposure to and/or familiarity with the surgical approaches listed below, performed either with an attending spinal deformity surgeon or

access surgeon:

- a. Anterior, including extracavitary
 - i. cervical including cervicothoracic junction
 - ii. thoracic
 - iii. lumbar
- b. Posterior
 - i. midline including cervico-occipital
 - ii. transpedicular
 - iii. posterior lateral (TLIF, costotransversectomy)

iv. sacropelvic exposure

- c. Techniques of bone graft harvesting
- d. Techniques of thoracoplasty

V. The fellowship curriculum for spine deformity should include exposure to and/or familiarity with the following surgical intra-operative spinal deformity correction techniques, decision making and post operative management:

a. Instrumentation

i. spinal fixation with hook, screw and wire anchorage for the posterior occipital, cervical, thoracic, lumbar regions of the spine

- ii. sacral and iliac fixation
- iii. anterior fixation with plate and/or rod systems cervical, thoracic and lumbar regions of the spine
- iv. anterior column structural support, intradiscal and corpectomy
- v. Techniques appropriate for the immature, deformed spine (growth rods, VEPTR, stapling, etc.)
- b. Osteotomies
 - i. Smith-Petersen
 - ii. Pedicle subtraction
 - iii. Vertebral body resection
- c. Principles of and indication for neuromonitoring
 - i. SSEP
 - ii. MEP
 - iii. Evoked EMG